<SEC-DOCUMENT>0001117480-23-000018.txt : 20230504
<SEC-HEADER>0001117480-23-000018.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504083039
ACCESSION NUMBER:		0001117480-23-000018
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHIMERIX INC
		CENTRAL INDEX KEY:			0001117480
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330903395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35867
		FILM NUMBER:		23886693

	BUSINESS ADDRESS:	
		STREET 1:		2505 MERIDIAN PARKWAY, SUITE 100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		919.806.1074

	MAIL ADDRESS:	
		STREET 1:		2505 MERIDIAN PARKWAY, SUITE 100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cmrx-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:bd8f579e-4e63-4bef-9c1c-fca25009f3d7,g:bc09e6ba-bd4a-4780-8a45-ad8ddbcdd46a,d:4446784166784bc6ab6a1471468846ff--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:cmrx="http://www.chimerix.com/20230331" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cmrx-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80L2ZyYWc6M2ZiMDYxNmY0ZTM1NDFhZjg4YTUyMTkwYzg1N2UxYzYvdGFibGU6MDQ2NDcxYWI5MmRjNDJkNTgyZmRmYmQyMjIxYzRmMzcvdGFibGVyYW5nZTowNDY0NzFhYjkyZGM0MmQ1ODJmZGZiZDIyMjFjNGYzN180LTEtMS0xLTU3Njc4_34b040f1-3e5a-43d5-b048-815a472cd286">false</ix:nonNumeric><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80L2ZyYWc6M2ZiMDYxNmY0ZTM1NDFhZjg4YTUyMTkwYzg1N2UxYzYvdGFibGU6MDQ2NDcxYWI5MmRjNDJkNTgyZmRmYmQyMjIxYzRmMzcvdGFibGVyYW5nZTowNDY0NzFhYjkyZGM0MmQ1ODJmZGZiZDIyMjFjNGYzN181LTEtMS0xLTU3Njc4_7e37088d-418c-4107-a76c-e5546cd4a952">2023</ix:nonNumeric><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80L2ZyYWc6M2ZiMDYxNmY0ZTM1NDFhZjg4YTUyMTkwYzg1N2UxYzYvdGFibGU6MDQ2NDcxYWI5MmRjNDJkNTgyZmRmYmQyMjIxYzRmMzcvdGFibGVyYW5nZTowNDY0NzFhYjkyZGM0MmQ1ODJmZGZiZDIyMjFjNGYzN182LTEtMS0xLTU3Njc4_820f624a-8f79-4241-a116-75e8ba53e8bd">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80L2ZyYWc6M2ZiMDYxNmY0ZTM1NDFhZjg4YTUyMTkwYzg1N2UxYzYvdGFibGU6MDQ2NDcxYWI5MmRjNDJkNTgyZmRmYmQyMjIxYzRmMzcvdGFibGVyYW5nZTowNDY0NzFhYjkyZGM0MmQ1ODJmZGZiZDIyMjFjNGYzN183LTEtMS0xLTU3Njc4_d09b8a3d-46b4-442b-ae8f-eab4808c4952">0001117480</ix:nonNumeric><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80L2ZyYWc6M2ZiMDYxNmY0ZTM1NDFhZjg4YTUyMTkwYzg1N2UxYzYvdGFibGU6MDQ2NDcxYWI5MmRjNDJkNTgyZmRmYmQyMjIxYzRmMzcvdGFibGVyYW5nZTowNDY0NzFhYjkyZGM0MmQ1ODJmZGZiZDIyMjFjNGYzN184LTEtMS0xLTU3Njc4_fb079328-d44c-40e9-bdc4-0b486cffb23d">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfNC0wLTEtMS01NzY3OA_f81a58fa-8b97-4a63-b960-98a6f8393ce5">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cmrx-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00ca283eef774858b67f6475ece947f1_I20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i040b1a26f397449cbae5cbdc11f92d47_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ifd4275020e18400eb3bcc3b3b804d073_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:ContractAndGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1946ece09c904951861cbc7bb236f26e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:ContractAndGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2cbb7f16c184e0ca3be6befb0a3c161_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6258f7ba70a2429d893b0989f0d4e545_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4f4cba41ac745a2873593ff4a0af42c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78825b0461dd42a184dfa832830bb172_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee7e43b8df1e40e2838c78908a8c90a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea3aca87c515473fb5fb58cb32a3ecaf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88f8447d733347d58c5c02338a641fca_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16d995cc04da4cafbe2ba9be78b1c72b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaea1f9ee2956448baa9ee91273abae28_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dab6564bb614134994df6db247ed37a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0a1f31f73c41a7a5ec947966979961_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f11fe9d82e47fd898e0f573563fa9b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1f10aa7207a45ec828484d3d85f7316_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03c8e1a7f33e40d49435c773a7314a83_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84561bae0aa74e99990371324cca219c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d07e6b250054a5da85d70f2553d7020_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28c9d91d02cb4b33936d8547b6f48fc3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i796ee983b1a3444ba7cc01d9c90293e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de410df18e74128ab476b930f4658bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if412d998e56846989f5ae6842d1e08f4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44a6ce80a0054a1c81b01150954b377c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5a7585076314ed6a713d0ca7be1cc36_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5551887562a49f8bc19f22a00cfe692_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5542e921d03d486d97066d5da0dd33dd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd9e7194f06647efb45e1a08985ba180_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6877193126b044118b28af082201f8d3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e69b868007a4b97aafa93214a71b658_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c9fa7eab31843dd898750d8c76cfcf9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1192c9f83b36465e8f80e3685ed58c8b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ffd7159be8e43f19e53d050ecbf41ae_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20743e8f7f174eeeadbd88e1c7f0cc12_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20f3f186e36448f5b3a63b9e3b863269_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i804d7d03889847d5ae48e5ad93dbb50f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i887daef78c58443e893277334452edbc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ade65735c9545f2a12dec9f4312f6cd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7c60bf2d7ba4e96bf4498b8f2014d16_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib107a3ac2180405c9d10f438e8b18db3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id189accf19a84607a3af2777ead773ad_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic51cb125601349b8b451af99cb1a781a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39e8a7b56d01472097cdbcd15bfb49c6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0c0f4bcdd5c402e9040e2f3d650afb7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5037b9b3c73466389a40771e5177e59_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifedf03aebe3b4bc78bfbfef940377a97_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ff2067d964e4f6eb5c4572c7df44ff5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5a617b479c5421ab4085ecb7805f41b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b72ea3730984bc299a26ec655d2be77_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i550880ea43424204a2167a6dad7fc32f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9aa19420d064b6ea99c0aef9e593870_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15168c3e9c9e45d884e1da247a40b7ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e929ebf603643be9d50f1d1c81d5553_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia11f96247a744891aedb33da4b10f863_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i826e3ed6eed14f59899dfce3d3fb5ed5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41d1ac0e92874f2ab60e2efbc7472cb3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff7a494199b34fe38f094bf02e43219e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id99c937daad4485a99236d4462f4fe95_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie06e373167d2401d87352019c0070854_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if67b2ed977af4ca5be169e787fd04e24_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic01dbb19691142bcaf240d5503fa85ce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i216aa5360f47421dad09d1e2fe063cd9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfbc49f108964d9586b1fe78301cede3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65078142e8c646429535c348eb43e549_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73233ee3c3004e849b476b2a2bdd672d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea8cb0da69264659b6fb1593ca7975a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95a0ab613b064db9811414440e1df09c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i830e14896ae3418090aea88e6361ccff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bb926ac6f54414ab15657d5d02f6bef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff79739385f045859d1ea7c0fd2a699e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b68c3a79434ad59d870f352df7ab52_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9612d95ff6e485ab93759b9c6a1bc22_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cdfd50074bb4f2780f387ee055c71f1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i229430736baa458696f8be14caad07c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i843f7d4691c94406bd8946f2730515ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d0bbe7e74a49d99423e480deb74908_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0b110316ee84c4196d882c915b7f130_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fff5d25cf6449308bcbf75364001e45_D20220131-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f1afc1bd8bb425d867be35c0e46ed08_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80ced39ca26c4f13818bb6d006095818_D20220131-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="installment"><xbrli:measure>cmrx:installment</xbrli:measure></xbrli:unit><xbrli:context id="id5258aa58e96454ba7f47be820e18166_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39fee762c2014475826a3d701b15814d_D20220926-20220926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBioSolutionsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-26</xbrli:startDate><xbrli:endDate>2022-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide975e55e26c4a95b067825a19f1af74_I20220926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBioSolutionsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4febe75fb14447a39e9fe6f7451fff6c_I20220926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBioSolutionsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="treatment"><xbrli:measure>cmrx:treatment</xbrli:measure></xbrli:unit><xbrli:context id="i49c5bcc0f6e3428b874169048e2386a2_I20220926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBioSolutionsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cmrx:NonUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibef35d312f6649c48ca5770e34d07f53_I20220926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBioSolutionsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5668b209a8cf48ffac44b53d2385eeb5_I20220926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:SymBioPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae67a95e48a4514b6b62802563f5af0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBiodefenseOperationsLansingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66e19cf7c3a84bd69adc584ad7985cb2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cmrx:OncoceuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec10cd07bccf4bdea2cab77c4d8be033_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cmrx:OncoceuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aced1df796f4e5d948dedb09bb1dc06_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cmrx:OncoceuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica04db5e597f4a148bb1cd8f8e4c8b48_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:OharaPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic046decd305e415f9bdb56550cc8bda5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:OharaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94ca8168a35a4764b28df995a789e4a5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:OharaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d6a71fabac4ccbb276c7996d4a8257_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cmrx:PublicHealthAgencyOfCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07e0fd7ae2114d36b0896130bfc39369_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cmrx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i81f288735d374f28b4bc08d750b772c0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60cc7c18a97a43f2bc365519b6490b77_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26c7e37b1d0940819ffe67431c0d8379_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb7c6239239c4da7a999932e68f2b1d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5b23ee2279148de946ebbc12395a903_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>cmrx:security</xbrli:measure></xbrli:unit><xbrli:context id="i9517f9ec839e440d95427249384ef67c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:BARDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:RefundableAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i342138d95ca84510be429a8206bf6d91_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:BARDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:RefundableAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf6d919a74434c88a93c3c9563ebfc77_I20200810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmrx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d40a540d19e49cd84414a5e1c507455_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmrx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c9f154273194565a27c741f7878e0e3_D20230101-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i431035fe4c0e4c04baad526438084c5b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if122bfed225d4e6b9ea7dabd81e702ef_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a68a6a0ea9447b09e9381db440aee36_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0396b8eb64340e7b468fbedd1556a7c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11ef95703d59450f84bcac3c8c1fe127_D20230101-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idff0b85443fb4b408cf3cd0b099f45c4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6085f06cabc84a509e0e944fb745eeb7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i524f8a9b49ff48159693771c90e88f29_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib125a1468b8f4d2e8c10c699c34bc410_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic212316462214f758bddf2408b982c40_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i707d882d90674ded914e0c24595f4781_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0ee769ecce64f21994ca9ced836dbaa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iada28bd88d134a9886cbbb069ddd2f51_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cmrx:IndependentMembersOfBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e1bad3a6f1a46cc92694fa22413949c_D20230101-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87dd3af02ad441ce9c3886a519178bc9_I20220826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:BARDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d079805c3384255aaa8160de0eddece_D20220826-20220826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:BARDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-26</xbrli:startDate><xbrli:endDate>2022-08-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c153c1c04674d08b3b67fbf5f6520f6_D20220826-20220826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:BARDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-26</xbrli:startDate><xbrli:endDate>2022-08-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0c3ebb768e14ba1adac8fecc4608694_I20220826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:BARDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb56f621902543d18de68b58f4527963_I20220826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:NationalStockpileMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2bf6b11e1724d84ba0bcc3f1428cc8e_I20220826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:ExpenseReimbursementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:NationalStockpileMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dda99b1defa4528b1254af85ee9ca46_I20220826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:BARDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i069e85b680a44fffa3ee317f7da6fae3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBioSolutionsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBioSolutionsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-26</xbrli:startDate><xbrli:endDate>2022-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dc7c0b07dc840118483ece5d0ba3401_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cmrx:PurchaserMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib85fa50450aa424aafb519800af6ba59_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cmrx:PurchaserMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib699e30492f44e8a804263792c19142f_D20220623-20220623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cmrx:PurchaserMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-23</xbrli:startDate><xbrli:endDate>2022-06-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a47e7a6ffe740b1ab49e33529826b16_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cmrx:PurchaserMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i041e87dc76b7486fad7182d5c433de1d_I20220623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cmrx:PublicHealthAgencyOfCanadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i7858fb7e8acd42509124fae89e255dca_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cmrx:PublicHealthAgencyOfCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21532ae17c8540b2814f9047fab955e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cmrx:OncoceuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:SanjiuMedicalPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if82f3e05482f40578ab012f41b08b052_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bb99da3a7e24972a69174d9a86c03d0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6f299962fcf4e829643ecd56dc9183d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5109aa96790c4d84b6c1982ac5f7ba63_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d7df4ccac55457db9fc511a4813ea18_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80f398e930dd4c1195d38e4f087c0836_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6405e9f8e2e42febb0630cc3f4b70cf_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>cmrx:employee</xbrli:measure></xbrli:unit><xbrli:context id="i8bc40ecede3346368c17697b995b6608_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01d7ce8ff73a42f8bc6ebe1f484b504b_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3b15fe0b2c840688dc4fc6ff3dc199f_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001117480</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4446784166784bc6ab6a1471468846ff_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTkw_1fc814f2-cd8f-4987-943b-84510501c587">10-Q</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:3.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6ZDIyMmU0YTI4MTEwNDRiZWEzY2M4MTIwMThlMGIxMTEvdGFibGVyYW5nZTpkMjIyZTRhMjgxMTA0NGJlYTNjYzgxMjAxOGUwYjExMV8wLTAtMS0xLTU3Njc4_cb315ad8-c3b3-4fe8-86f6-2e34805fb8b0">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xMzc_93e73736-3a09-4567-918d-1d54322dc702">March 31, 2023</ix:nonNumeric> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:3.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6ZTRmMzI3NThiNDVlNGQ2N2I4NzU0YTMzNWYwY2MxMGIvdGFibGVyYW5nZTplNGYzMjc1OGI0NWU0ZDY3Yjg3NTRhMzM1ZjBjYzEwYl8wLTAtMS0xLTU3Njc4_bea201b3-60b0-4873-81e6-7f6907244bb9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTkx_accc56a2-6bef-4958-b823-5160bc6607bd">001-35867</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTky_d75c3963-c46b-4af3-bad6-3e0c6c62713c">CHIMERIX,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)&#160;&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NzRiMjgwOWI2NTVhNGNjNWFjMmFlMjM2MWJjM2NmODYvdGFibGVyYW5nZTo3NGIyODA5YjY1NWE0Y2M1YWMyYWUyMzYxYmMzY2Y4Nl8wLTAtMS0xLTU3Njc4_f3bddd9b-9385-4650-8cf8-73cba6a860fa">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NzRiMjgwOWI2NTVhNGNjNWFjMmFlMjM2MWJjM2NmODYvdGFibGVyYW5nZTo3NGIyODA5YjY1NWE0Y2M1YWMyYWUyMzYxYmMzY2Y4Nl8wLTItMS0xLTU3Njc4_500caf85-73eb-4a2b-8c6a-384e8df52185">33-0903395</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NzRiMjgwOWI2NTVhNGNjNWFjMmFlMjM2MWJjM2NmODYvdGFibGVyYW5nZTo3NGIyODA5YjY1NWE0Y2M1YWMyYWUyMzYxYmMzY2Y4Nl8zLTAtMS0xLTU3Njc4L3RleHRyZWdpb246OGQwNzk1MTIwMDVmNDcxNmE2ZjA3ZDljNTQ3ZGFlZjFfNA_1438394c-77ea-4a05-942c-8b3b7ada2f65">2505 Meridian Parkway</ix:nonNumeric>, <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NzRiMjgwOWI2NTVhNGNjNWFjMmFlMjM2MWJjM2NmODYvdGFibGVyYW5nZTo3NGIyODA5YjY1NWE0Y2M1YWMyYWUyMzYxYmMzY2Y4Nl8zLTAtMS0xLTU3Njc4L3RleHRyZWdpb246OGQwNzk1MTIwMDVmNDcxNmE2ZjA3ZDljNTQ3ZGFlZjFfOA_9c867475-b8ec-4469-a7b6-ad635a60ca98">Suite&#160;100</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NzRiMjgwOWI2NTVhNGNjNWFjMmFlMjM2MWJjM2NmODYvdGFibGVyYW5nZTo3NGIyODA5YjY1NWE0Y2M1YWMyYWUyMzYxYmMzY2Y4Nl80LTAtMS0xLTU3Njc4L3RleHRyZWdpb246ZjE1ZTYyMDlkMTJlNDdkNDlkY2E3YWYzMmRiYWIxMWZfNA_5e4ef440-b859-4d77-9845-22720d5ef526">Durham</ix:nonNumeric>, <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NzRiMjgwOWI2NTVhNGNjNWFjMmFlMjM2MWJjM2NmODYvdGFibGVyYW5nZTo3NGIyODA5YjY1NWE0Y2M1YWMyYWUyMzYxYmMzY2Y4Nl80LTAtMS0xLTU3Njc4L3RleHRyZWdpb246ZjE1ZTYyMDlkMTJlNDdkNDlkY2E3YWYzMmRiYWIxMWZfOA_a7d1eb6d-b947-4508-80e7-18a3679610fe">North Carolina</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NzRiMjgwOWI2NTVhNGNjNWFjMmFlMjM2MWJjM2NmODYvdGFibGVyYW5nZTo3NGIyODA5YjY1NWE0Y2M1YWMyYWUyMzYxYmMzY2Y4Nl80LTItMS0xLTU3Njc4_a5034790-4d75-40bb-ad7c-3dfab2a42fb0">27713</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8zMzI_34a236cb-f717-4417-9eb2-8bfba5a256ac">919</ix:nonNumeric>) <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTk0_3969d143-28d3-46a2-b00c-5a36a92d28fa">806-1074</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number,&#160;Including Area Code)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NWQ4YzJhYjU5N2YyNDExMzg2MWQwNjliNmNjMDI3MDEvdGFibGVyYW5nZTo1ZDhjMmFiNTk3ZjI0MTEzODYxZDA2OWI2Y2MwMjcwMV8xLTAtMS0xLTU3Njc4_629b4ea5-740e-4ffb-811d-e4121133a97b">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NWQ4YzJhYjU5N2YyNDExMzg2MWQwNjliNmNjMDI3MDEvdGFibGVyYW5nZTo1ZDhjMmFiNTk3ZjI0MTEzODYxZDA2OWI2Y2MwMjcwMV8xLTEtMS0xLTU3Njc4_6cda7983-e2fa-4a81-8c3b-c9c526a38641">CMRX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NWQ4YzJhYjU5N2YyNDExMzg2MWQwNjliNmNjMDI3MDEvdGFibGVyYW5nZTo1ZDhjMmFiNTk3ZjI0MTEzODYxZDA2OWI2Y2MwMjcwMV8xLTItMS0xLTU3Njc4_0859f25b-172d-4789-a5e1-18f4a3699bcc">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;<ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTk1_20341a07-9331-48a8-9b9b-0b19371468cb">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;<ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTg4_33304586-3a45-4e3e-a422-2ed397cc9f26">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </span></div><div style="margin-top:5pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6OTI3ODlhMTk4NzlmNDQ4ZDljNGMwYmFjMzIyMWM4ODUvdGFibGVyYW5nZTo5Mjc4OWExOTg3OWY0NDhkOWM0YzBiYWMzMjIxYzg4NV8xLTAtMS0xLTU3Njc4L3RleHRyZWdpb246NTljZTE4NGNlMzdhNGI0NThkN2VkMTc5MmE2ZDVkNmVfNA_9730d6fc-63cb-4a1d-8125-b5454980a537">Non-accelerated filer</ix:nonNumeric>&#160;&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company&#160;<ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6OTI3ODlhMTk4NzlmNDQ4ZDljNGMwYmFjMzIyMWM4ODUvdGFibGVyYW5nZTo5Mjc4OWExOTg3OWY0NDhkOWM0YzBiYWMzMjIxYzg4NV8xLTItMS0xLTU3Njc4L3RleHRyZWdpb246MTk4YjQwZjUxMzZmNGZiZmEwODI4ZDBjODAzNDBmNzJfMzA_5719366f-5ebb-42ec-875b-a7f0307d795b">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company&#160;<ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6OTI3ODlhMTk4NzlmNDQ4ZDljNGMwYmFjMzIyMWM4ODUvdGFibGVyYW5nZTo5Mjc4OWExOTg3OWY0NDhkOWM0YzBiYWMzMjIxYzg4NV8yLTItMS0xLTU3Njc4L3RleHRyZWdpb246NGFkMWEwOGFhN2VlNGUxNTkxM2UxMDliZDQ3YmY2ZmVfMjg_224aff02-12ff-4fa8-95d2-a576ff98d114">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTg5_e95e35b6-1c2e-4503-904b-53be34aecb16">x</ix:nonNumeric></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;28, 2023, the number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, was <ix:nonFraction unitRef="shares" contextRef="i00ca283eef774858b67f6475ece947f1_I20230428" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTg2_f434ad56-172e-45f8-abfe-92311de5f7ba">88,583,567</ix:nonFraction>.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4446784166784bc6ab6a1471468846ff_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIMERIX, INC.</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;10-Q FOR THE QUARTER ENDED MARCH&#160;31, 2023 </span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_10">Part&#160;I &#8212; Financial Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_10">Item 1. Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_10">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_13">Consolidated Balance Sheets as of March 31, 2023 and December&#160;31, 2022 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_13">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_16">Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three Months Ended March 31, 2023 and 2022 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_16">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_19">Consolidated Statements of Stockholders' Equity (Deficit) for the Three Months Ended March 31, 2023 and 2022 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_19">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_25">Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and 2022 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_25">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_28">Notes to the Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_28">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_58">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_58">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_79">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_79">29</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_82">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_82">29</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_85">Part&#160;II &#8212; Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_88">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_88">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_91">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_91">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_94">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_94">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_97">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_97">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_100">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_100">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_103">Item 5. Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_103">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_106">Item 6. Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_106">60</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_109">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4446784166784bc6ab6a1471468846ff_109">61</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Unless otherwise mentioned or unless the context indicates otherwise, as used in this prospectus, the terms &#8220;Chimerix,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Chimerix, Inc., a Delaware corporation. We have obtained a registered trademark for Chimerix&#174; in the United States. All other trademarks or trade names referred to in this Quarterly Report on Form 10-Q are the property of their respective owners.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i4446784166784bc6ab6a1471468846ff_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4446784166784bc6ab6a1471468846ff_13"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIMERIX, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMy0yLTEtMS01NzY3OA_2ca9d13b-8a62-41ca-8c02-456a6d76da22">15,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMy00LTEtMS01NzY3OA_42f61638-12c8-4f37-925c-b638af0b4104">25,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments, available-for-sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfNC0yLTEtMS01NzY3OA_850acd71-6ef7-424f-92ca-b8e913c6e4a8">198,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfNC00LTEtMS01NzY3OA_b37c8ade-e5a3-4211-9ec6-89746a80efed">191,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfNS0yLTEtMS01NzY3OA_aba5b69b-e7c7-4dea-b6cf-10d96a0c0201">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfNS00LTEtMS01NzY3OA_87245bcd-65af-4d22-8d4a-1c758f39dff4">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfNy0yLTEtMS01NzY3OA_17cc5839-ac4a-4430-aae6-03f4b2756696">9,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfNy00LTEtMS01NzY3OA_05b06319-8a82-4c8c-8f8d-a19315d0e563">9,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfOC0yLTEtMS01NzY3OA_5f501abe-0a70-42e3-8ed1-0773150fc085">224,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfOC00LTEtMS01NzY3OA_dacf0b5b-ed32-407b-900b-ceac5ea5054e">228,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfOS0yLTEtMS01NzY3OA_d5de335b-5fc8-4ef7-a93c-1ae8e776d1c4">31,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfOS00LTEtMS01NzY3OA_4c3dee56-7f93-44c5-b977-8efb9160b705">48,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTAtMi0xLTEtNTc2Nzg_158fbdc7-a731-438b-bd8b-394bf9cf6a47">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTAtNC0xLTEtNTc2Nzg_518d8828-81c7-40ec-8e5f-12483422e741">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTEtMi0xLTEtNTc2Nzg_c08be86d-007b-46fa-b801-bc13fdb721e7">1,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTEtNC0xLTEtNTc2Nzg_ca239b36-74d9-4c2e-92db-200b840d2546">1,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTItMi0xLTEtNTc2Nzg_bd720ea7-5382-46c5-9667-39c81d3b72ab">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTItNC0xLTEtNTc2Nzg_f3aeb6ba-fe26-4221-9453-5e2ee8b87606">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTMtMi0xLTEtNTc2Nzg_2733e723-62dd-49ef-a0ec-42792a168757">258,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTMtNC0xLTEtNTc2Nzg_75338131-3a5c-4a0e-9765-68538a11895d">279,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTctMi0xLTEtNTc2Nzg_8b1ebc9e-851b-453a-980d-62ee86e8b9d4">2,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTctNC0xLTEtNTc2Nzg_60bfbcbe-a273-42e7-8186-8c4b530f42f2">3,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTgtMi0xLTEtNTc2Nzg_002b9155-1bc3-4197-8340-589241685598">13,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTgtNC0xLTEtNTc2Nzg_7eda4f01-87d3-4d6c-ae17-dafc3d0740dd">17,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjEtMi0xLTEtNTc2Nzg_fee88dd9-c125-4377-86d0-5e68308bb385">16,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjEtNC0xLTEtNTc2Nzg_fe2b9d4a-b9a5-4f1b-97f6-e986f7ca402a">20,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="cmrx:LoanFeesLiabilityNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjItMi0xLTEtNTc2Nzg_a42f6a02-2472-4038-9176-68a635c44b14">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="cmrx:LoanFeesLiabilityNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjItNC0xLTEtNTc2Nzg_8061af71-920f-4345-9d09-c27ba888ac81">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease-related obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjMtMi0xLTEtNTc2Nzg_ba4a5038-3f39-45e4-b16a-0decbc78d615">1,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjMtNC0xLTEtNTc2Nzg_6f7fcc1b-8c9a-4e7c-bf71-0f1506babdcf">1,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjQtMi0xLTEtNTc2Nzg_93e13c97-0722-48e5-b4e1-fc0a11d93e05">18,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjQtNC0xLTEtNTc2Nzg_8dcae06f-d9bb-4014-b14f-729114f8e971">22,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF8yMQ_6e35e955-e389-4d12-a49a-d5e559ffc31d"><ix:nonFraction unitRef="usdPerShare" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF8yMQ_9d9ed04e-24c8-4210-9543-d071cb65d552">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF8zNQ_55384b2e-e33c-4cdc-946f-516b0760d6e4"><ix:nonFraction unitRef="shares" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF8zNQ_b1810015-4975-493c-b28b-2cff5ab81b41">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF83MA_5d25123f-4c75-413f-820e-d340bd8297c6"><ix:nonFraction unitRef="shares" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF83MA_d8b3a860-c091-459b-812b-55dbd0d9f621"><ix:nonFraction unitRef="shares" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF83MA_da847bdc-1c31-4880-94c8-863fa1bcd9a8"><ix:nonFraction unitRef="shares" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF83MA_e8f84e54-87ca-461b-989c-a6889bb665c3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMi0xLTEtNTc2Nzg_590e5c4e-20a9-408f-a1fe-1895cdeacb5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctNC0xLTEtNTc2Nzg_35b37d23-6577-4ea5-bab6-709a184d312d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV8xOA_a416b9e3-e118-4550-a25c-d47c1bb2abca"><ix:nonFraction unitRef="usdPerShare" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV8xOA_fd181bea-8123-4eb1-abfb-34331a59c142">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV8zMg_07809c3a-ba58-4984-bb25-d74cc993a64b"><ix:nonFraction unitRef="shares" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV8zMg_cfdb7c13-2d91-4857-a3de-dd0efff1c583">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV82Nw_01571cb4-16f8-4a13-9228-e8e4b202af62"><ix:nonFraction unitRef="shares" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV82Nw_8141010e-23b6-4c91-831f-1fd4928e785d">88,583,567</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV83NA_3bb2d28e-8b7d-46af-946e-c446afee037f"><ix:nonFraction unitRef="shares" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV83NA_e75ca9e7-9eab-4655-b2b0-49f663ca84ed">88,054,127</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMi0xLTEtNTc2Nzg_91565acd-a684-46dc-bbde-2913285b5d53">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtNC0xLTEtNTc2Nzg_adb8039e-bc8f-481e-a9bb-a5bdf5886b91">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjktMi0xLTEtNTc2Nzg_e07c46ca-5106-4944-a6bc-8a9f7b2e80a0">975,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjktNC0xLTEtNTc2Nzg_7cc33eaf-4c0a-496f-8489-5bd59dd94cae">970,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzAtMi0xLTEtNTc2Nzg_7a97e458-98d4-400e-9905-f1dcb0c4fc9d">231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzAtNC0xLTEtNTc2Nzg_75396688-9b3e-422d-8d08-0bdd1b0cfc08">337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzEtMi0xLTEtNTc2Nzg_23852491-88ce-4b00-bb8c-ca599c0ee989">734,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzEtNC0xLTEtNTc2Nzg_98d89fae-08cc-44d0-ab4a-c714f4896352">713,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzItMi0xLTEtNTc2Nzg_0a9cee6d-6b2a-41ca-8b16-50d016eb809c">240,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzItNC0xLTEtNTc2Nzg_ecd7d169-7a36-4861-b99a-d7f5c2b69551">256,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzMtMi0xLTEtNTc2Nzg_d94b3314-e50e-470c-a8e3-df4f69c99987">258,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzMtNC0xLTEtNTc2Nzg_b20c4423-dc93-40b1-8f8b-3017af2f2d1d">279,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i4446784166784bc6ab6a1471468846ff_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIMERIX, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 66.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract and grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4275020e18400eb3bcc3b3b804d073_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNC0yLTEtMS01NzY3OA_2a659d38-64b1-449e-8411-a4a42fb2d258">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1946ece09c904951861cbc7bb236f26e_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNC00LTEtMS01NzY3OA_8c34b56b-f0b4-4f0f-aaaa-86d4fca1a144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2cbb7f16c184e0ca3be6befb0a3c161_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNS0yLTEtMS01NzY3OA_62506264-5c2a-4722-bf98-21a2b4ae6500">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6258f7ba70a2429d893b0989f0d4e545_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNS00LTEtMS01NzY3OA_d4e27c88-7b54-43cd-8b6c-bacdcde65731">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNi0yLTEtMS01NzY3OA_de5542db-a71f-46d8-a533-45049a6c48f0">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNi00LTEtMS01NzY3OA_2c18373d-b730-46f1-becb-067ecdbab652">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNy0yLTEtMS01NzY3OA_838a4fa4-b337-4a67-903a-0ceeb2aac652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNy00LTEtMS01NzY3OA_5242fba7-790c-4ae6-8298-bea3582bf3a2">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfOC0yLTEtMS01NzY3OA_1dff1ebb-b719-4ea5-93a9-03551dcfd218">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfOC00LTEtMS01NzY3OA_9d110c12-fb12-41a2-8d93-35ad00f0d3c4">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTAtMi0xLTEtNTc2Nzg_592f7ead-0d0f-4c01-8ed9-8d7d921e3e7d">18,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTAtNC0xLTEtNTc2Nzg_9713037b-266f-452f-ba63-31ecd37a1cf2">19,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTEtMi0xLTEtNTc2Nzg_582c0643-f255-4353-b9b7-689aed7d264a">5,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTEtNC0xLTEtNTc2Nzg_b8f1d565-1a1a-493b-acfd-c7b0a47e4b76">5,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTMtMi0xLTEtNTc2Nzg_eda00beb-665f-46a2-b163-ce903768eeed">24,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTMtNC0xLTEtNTc2Nzg_f7e2b21a-7631-4779-b57b-49dfc9141554">24,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTQtMi0xLTEtNTc2Nzg_f9a0e62a-98de-488b-898e-006de9aaa64a">24,218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTQtNC0xLTEtNTc2Nzg_bd6d98d0-5ea3-4187-b741-ed8619a2a906">24,771</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income and other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTctMi0xLTEtNTc2Nzg_d7641584-ba34-4706-84db-c2f14204cef8">2,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTctNC0xLTEtNTc2Nzg_8baa6131-2571-434e-9de8-29d0b561958b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjEtMi0xLTEtNTc2Nzg_28a1a8c8-8db1-4657-a527-9aa4416ab8a9">21,372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjEtNC0xLTEtNTc2Nzg_28764e30-c18c-4ed5-8003-b6a4322917b3">24,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on debt investments, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjMtMi0xLTEtNTc2Nzg_649ae1aa-d6e0-4ea5-8736-daddc130dbc8">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjMtNC0xLTEtNTc2Nzg_b45249e5-e4fa-4ea0-9e46-571f6f7e167a">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjQtMi0xLTEtNTc2Nzg_ce920f90-f350-4070-9352-380089f61404">21,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjQtNC0xLTEtNTc2Nzg_d810b5e7-a40d-4a24-9b25-b7c297718d90">24,819</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per share information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjYtMi0xLTEtNTc2Nzg_3f5d9fda-5cb3-448f-a224-3ce4fb1a5f4c"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjYtMi0xLTEtNTc2Nzg_63a4d5eb-d4e9-418f-b5c5-9cc1baf9158f">0.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjYtNC0xLTEtNTc2Nzg_bb123421-bafb-46d6-99cd-513ba05ce289"><ix:nonFraction unitRef="usdPerShare" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjYtNC0xLTEtNTc2Nzg_eab7f8ef-1e4b-466e-9f6b-c54f790d1a16">0.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjktMi0xLTEtNTc2Nzg_524127b3-b663-4c63-987a-e816fdc1c01d"><ix:nonFraction unitRef="shares" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjktMi0xLTEtNTc2Nzg_cd817d03-2a27-4c5e-a06b-af7ef99d93d2">88,294,624</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjktNC0xLTEtNTc2Nzg_dbc9ac26-f965-41ce-97c1-5c9a5469f964"><ix:nonFraction unitRef="shares" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjktNC0xLTEtNTc2Nzg_fcdd3845-9199-445c-8726-c629a9067b34">87,088,804</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i4446784166784bc6ab6a1471468846ff_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIMERIX, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in&#160;Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated&#160;Other<br/>Comprehensive<br/>Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;<br/>Stockholders&#8217;<br/>Equity&#160;(Deficit)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4f4cba41ac745a2873593ff4a0af42c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMi0xLTEtMS01NzY3OA_6153deea-3331-4821-a991-79e174ada623">88,054,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4f4cba41ac745a2873593ff4a0af42c_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMi0zLTEtMS01NzY3OA_f470e7c1-7ce8-455a-951c-fe8ec359933b">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78825b0461dd42a184dfa832830bb172_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMi01LTEtMS01NzY3OA_b84211e7-a3ac-4dc7-aafd-bd352338e89b">970,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee7e43b8df1e40e2838c78908a8c90a6_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMi03LTEtMS01NzY3OA_e9275a49-2dfd-4a26-b065-b44e2947630a">337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea3aca87c515473fb5fb58cb32a3ecaf_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMi05LTEtMS01NzY3OA_b53271a2-5450-4c41-8c3d-bad877483a3a">713,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMi0xMS0xLTEtNTc2Nzg_5e931020-224f-43e8-9a48-07b5aa13743f">256,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f8447d733347d58c5c02338a641fca_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMy01LTEtMS01NzY3OA_765503c2-c012-4004-bb76-bba188271a6e">4,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMy0xMS0xLTEtNTc2Nzg_9d551830-0104-4397-9f8e-fc9911b1c334">4,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock purchase plan purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16d995cc04da4cafbe2ba9be78b1c72b_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfNS0xLTEtMS01NzY3OA_b314f70a-28d3-4a10-b742-9c6b8f13eae3">308,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d995cc04da4cafbe2ba9be78b1c72b_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfNS0zLTEtMS01NzY3OA_cd2df34a-cf30-46a7-a4ec-23da68b981fd">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f8447d733347d58c5c02338a641fca_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfNS01LTEtMS01NzY3OA_70847b51-f5dc-4bbc-ba6b-b454c114ce77">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfNS0xMS0xLTEtNTc2Nzg_d8945224-8fea-49d0-a906-854cdfcf5e11">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSU stock issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16d995cc04da4cafbe2ba9be78b1c72b_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfNi0xLTEtMS01NzY3OA_28963a02-a4fb-4b11-ae6a-423423775097">221,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on investments, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea1f9ee2956448baa9ee91273abae28_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTAtNy0xLTEtNTc2Nzg_33462300-7186-4499-9d0b-a5d7391382ad">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTAtMTEtMS0xLTU3Njc4_7c4dcd72-e73e-4f86-9f09-e6f01f6c4db5">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dab6564bb614134994df6db247ed37a_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTEtOS0xLTEtNTc2Nzg_03cf1fab-88b4-4127-b2d7-245e5a99ff4b">21,372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTEtMTEtMS0xLTU3Njc4_068f66f9-311c-42c3-a520-44fd67c907fd">21,372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTItMTEtMS0xLTU3Njc4_ac506b4d-954d-40e3-bed3-67017e78edbf">21,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd0a1f31f73c41a7a5ec947966979961_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTMtMS0xLTEtNTc2Nzg_51f49506-2e29-4882-a215-5f0708ee535f">88,583,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0a1f31f73c41a7a5ec947966979961_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTMtMy0xLTEtNTc2Nzg_a7c290be-48d4-4dcd-af62-4108bd3dff2c">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f11fe9d82e47fd898e0f573563fa9b_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTMtNS0xLTEtNTc2Nzg_5008a90b-dab3-4c18-a503-f986483fc1c1">975,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1f10aa7207a45ec828484d3d85f7316_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTMtNy0xLTEtNTc2Nzg_2ac9ae7b-c17c-4cdd-8b7d-13a77effc094">231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03c8e1a7f33e40d49435c773a7314a83_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTMtOS0xLTEtNTc2Nzg_718da81f-b532-4ba9-bfc3-a42923d0eaa6">734,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTMtMTEtMS0xLTU3Njc4_a94e436f-8237-4ca5-a903-be343cf69477">240,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div id="i4446784166784bc6ab6a1471468846ff_22"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in&#160;Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated&#160;Other<br/>Comprehensive<br/>Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;<br/>Stockholders&#8217;<br/>Equity&#160;(Deficit)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84561bae0aa74e99990371324cca219c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMi0xLTEtMS01NzY3OA_aad25472-93be-442c-bf69-cb217a37de51">86,884,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84561bae0aa74e99990371324cca219c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMi0zLTEtMS01NzY3OA_c865a15f-2cd1-40aa-a006-641ed7a8def5">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d07e6b250054a5da85d70f2553d7020_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMi01LTEtMS01NzY3OA_a3150805-0fa3-44e9-8c87-262ca1a07bbd">953,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28c9d91d02cb4b33936d8547b6f48fc3_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMi03LTEtMS01NzY3OA_9abd0546-61f5-41f6-8f8e-1d002a592ba8">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i796ee983b1a3444ba7cc01d9c90293e1_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMi05LTEtMS01NzY3OA_5045cecc-52d6-46f2-a97d-0891d8863b14">885,596</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de410df18e74128ab476b930f4658bc_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMi0xMS0xLTEtNTc2Nzg_9e6b8334-c56a-4c06-84e1-367007db0221">68,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if412d998e56846989f5ae6842d1e08f4_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMy01LTEtMS01NzY3OA_fb863cd8-9446-4625-8c47-41aec82be020">3,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMy0xMS0xLTEtNTc2Nzg_38180e6d-531e-4746-9552-aa38ceb3bd12">3,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44a6ce80a0054a1c81b01150954b377c_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfNC0xLTEtMS01NzY3OA_a8fa2591-1a6a-47d8-a72e-873d6261e1bc">34,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if412d998e56846989f5ae6842d1e08f4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfNC01LTEtMS01NzY3OA_835ffbd7-3b5a-4769-aff5-9427fb155d43">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfNC0xMS0xLTEtNTc2Nzg_5a8dfd7e-b8bc-4d11-8534-3a69867b009c">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock purchase plan purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44a6ce80a0054a1c81b01150954b377c_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfNS0xLTEtMS01NzY3OA_c597a0c7-fe6b-4763-bc78-5616ad9a7835">383,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if412d998e56846989f5ae6842d1e08f4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfNS01LTEtMS01NzY3OA_9ba0dd17-00ee-46ea-a053-f7b93e4a20e6">555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfNS0xMS0xLTEtNTc2Nzg_0aeb2bb9-e15c-4e9b-83ef-005a271ec9f4">555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSU stock issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44a6ce80a0054a1c81b01150954b377c_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfNi0xLTEtMS01NzY3OA_18d25386-edb8-4c15-a85e-47b04865f66b">133,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on investments, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5a7585076314ed6a713d0ca7be1cc36_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTAtNy0xLTEtNTc2Nzg_b78e5116-f395-4de5-b502-e9ff6c932560">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTAtMTEtMS0xLTU3Njc4_908dc25a-097e-4650-9d82-8fb161b6a83c">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5551887562a49f8bc19f22a00cfe692_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTEtOS0xLTEtNTc2Nzg_2b619cae-fd7b-4824-9e1d-da5f6e57d368">24,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTEtMTEtMS0xLTU3Njc4_c3ea1be8-1b49-455b-b4e0-77d61b7ac6bf">24,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTItMTEtMS0xLTU3Njc4_cebd7dc4-7a72-4b3f-9b44-0c83ea1917d8">24,819</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5542e921d03d486d97066d5da0dd33dd_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTMtMS0xLTEtNTc2Nzg_d0ce03c8-88d8-41c8-9b41-6063a8f68552">87,436,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5542e921d03d486d97066d5da0dd33dd_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTMtMy0xLTEtNTc2Nzg_6a055bfb-c2dd-4def-8ea7-c7a9b9e1441f">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9e7194f06647efb45e1a08985ba180_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTMtNS0xLTEtNTc2Nzg_88169bd4-634b-447d-8452-38151c5a3aed">958,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6877193126b044118b28af082201f8d3_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTMtNy0xLTEtNTc2Nzg_8a0b019f-d1a0-45f9-9881-90cd10a02c29">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e69b868007a4b97aafa93214a71b658_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTMtOS0xLTEtNTc2Nzg_b3bc7520-c4b7-4881-8bab-9d59d2594f4f">910,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9fa7eab31843dd898750d8c76cfcf9_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTMtMTEtMS0xLTU3Njc4_63996401-b5c2-4ec0-ab83-4bdf922e86c6">47,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i4446784166784bc6ab6a1471468846ff_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIMERIX, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMy0yLTEtMS01NzY3OA_c341df24-2822-48bd-9d9a-b2009cf3b06a">21,372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMy00LTEtMS01NzY3OA_21cd03cc-9b09-4f21-8d8d-49f6a6c2bf42">24,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash used in operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNS0yLTEtMS01NzY3OA_cd67d46c-209b-4297-98df-cfc82d3720bc">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNS00LTEtMS01NzY3OA_ebbbf163-20ce-46c8-80dd-bb77ef8a1146">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNi0yLTEtMS01NzY3OA_a8e02682-993b-4b76-90a1-6efc1d450b64">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNi00LTEtMS01NzY3OA_8f8fdc8b-1b10-4b35-90db-5a24c2ac0bc7">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discount/premium on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNy0yLTEtMS01NzY3OA_7c8000f6-59ce-42a6-a6b3-cf106bdf1c12">2,096</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNy00LTEtMS01NzY3OA_cb66138b-cb43-49b3-aee7-f7071eb33e9a">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfOC0yLTEtMS01NzY3OA_ae9ff67c-6c41-4835-b175-d2224c16054c">4,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfOC00LTEtMS01NzY3OA_2075a33f-0b1c-40a9-b70e-342147b5bebf">3,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTMtMi0xLTEtNTc2Nzg_404780c5-150c-4f5a-a60c-113a223725c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTMtNC0xLTEtNTc2Nzg_b0e97684-3004-4e13-833e-d75b0af65d71">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease-related amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" sign="-" name="cmrx:OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTUtMi0xLTEtNTc2Nzg_cd6662e8-a74a-495d-ba12-a00ee35b4960">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="cmrx:OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTUtNC0xLTEtNTc2Nzg_36c95fb7-948a-49c5-9b43-47f83c12e8dc">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTctMi0xLTEtNTc2Nzg_b2f13f7d-9fbb-41fa-9a59-467a0162f371">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTctNC0xLTEtNTc2Nzg_d0b74482-130b-4791-91fa-6535138322c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTgtMi0xLTEtNTc2Nzg_affe98cb-2a50-4a28-90ad-62e0177918e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTgtNC0xLTEtNTc2Nzg_258c685d-da57-44ee-aeaf-38c10341dba9">646</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTktMi0xLTEtNTc2Nzg_1f54fe58-b728-42be-939e-ff59486b58fb">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTktNC0xLTEtNTc2Nzg_c481b8a0-43b6-4424-88a1-3bc1c5f5c015">1,002</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjAtMi0xLTEtNTc2Nzg_933644de-e238-4c98-a596-c0d061b4d409">4,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjAtNC0xLTEtNTc2Nzg_5e0374ed-5da7-4014-92d3-433c1deb2ee3">912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjItMi0xLTEtNTc2Nzg_ef685d28-f713-4b36-bf29-59d606c6f5bb">22,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjItNC0xLTEtNTc2Nzg_351bf248-c94c-4118-8fc4-0f91d0354d5e">23,447</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjUtMi0xLTEtNTc2Nzg_cd215f5d-5a3a-461c-bb2a-76793d11a054">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjUtNC0xLTEtNTc2Nzg_0134532e-a222-48f3-a24e-f23bacfe1c7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjctMi0xLTEtNTc2Nzg_b4cf8b84-653d-4f73-b008-652a53091ee6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjctNC0xLTEtNTc2Nzg_c0791c65-a922-48f6-a151-82273fd408a3">5,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjgtMi0xLTEtNTc2Nzg_2062f754-3353-4f08-891f-052b61445c34">6,803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjgtNC0xLTEtNTc2Nzg_4b3bb545-8164-41dd-9f1d-e4adbae427c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjktMi0xLTEtNTc2Nzg_90ea7ff2-d2dd-4243-aa7f-3bd28958283c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjktNC0xLTEtNTc2Nzg_2e32ba86-8980-479b-88fc-0635a69a7c01">7,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzAtMi0xLTEtNTc2Nzg_2fab5c3b-6521-4fb9-ac81-4e3703e425f4">19,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzAtNC0xLTEtNTc2Nzg_8128142d-4851-42c4-be18-ba5ee0981386">51,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzMtMi0xLTEtNTc2Nzg_988045c4-9f37-44b3-ab7e-790f0e1ddad9">12,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzMtNC0xLTEtNTc2Nzg_16316b57-e741-48bb-b729-a7d2791a8793">53,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzYtMi0xLTEtNTc2Nzg_01e22f0b-52c4-421f-ba86-6c96ddff49b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzYtNC0xLTEtNTc2Nzg_8db70fcd-35cd-4e5b-9f1c-299a8279c4b0">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzctMi0xLTEtNTc2Nzg_01ece5ec-3edb-4d42-8c68-c97e1353f6e8">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzctNC0xLTEtNTc2Nzg_033b0ab3-d3fc-426c-947c-06aab7afa30d">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzktMi0xLTEtNTc2Nzg_a4ad8542-d497-4d54-9f99-2b694eb395ee">157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzktNC0xLTEtNTc2Nzg_e8ac67b6-92a1-4d51-9da9-8d506e30d9af">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of note payable related to asset acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDAtMi0xLTEtNTc2Nzg_874d8e45-46da-4ed5-8a6d-3183850293ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDAtNC0xLTEtNTc2Nzg_a21aa608-7a46-4b6e-8fec-14726f86c531">14,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDEtMi0xLTEtNTc2Nzg_11760136-cb87-41c5-a2a6-1073fea1aac5">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDEtNC0xLTEtNTc2Nzg_2c6982d2-fa1a-4eb5-8346-0b746afeb4b4">13,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDItMi0xLTEtNTc2Nzg_621ac78e-104b-44b9-b86b-f96a7c288e09">9,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDItNC0xLTEtNTc2Nzg_b24e218d-3b89-431f-a308-1945f91f4564">16,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDQtMi0xLTEtNTc2Nzg_ed95d22a-3901-4935-ae9c-728fe535c69a">25,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de410df18e74128ab476b930f4658bc_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDQtNC0xLTEtNTc2Nzg_80203605-4f7d-4759-ab75-63e1470ea5f6">15,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDUtMi0xLTEtNTc2Nzg_fa8b7473-5c23-45da-94f5-4f97bada81fc">15,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9fa7eab31843dd898750d8c76cfcf9_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDUtNC0xLTEtNTc2Nzg_baec640d-bd0a-4360-866a-180bbdb65f8e">31,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.&#160;</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i4446784166784bc6ab6a1471468846ff_28"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIMERIX, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4446784166784bc6ab6a1471468846ff_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0Nzc_39212364-e523-43ea-9e6b-c7a1f311345d" continuedAt="i99965a3e875c4a9ca3a4987702aa88f0" escape="true">The Business and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i99965a3e875c4a9ca3a4987702aa88f0" continuedAt="idfe9c0c85faf485ea300b4d6ccebc44b"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chimerix is a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0OTI_aaf58cc5-514d-4308-850b-69bd04203442" continuedAt="i8a2fbf1599884b03a4ac4edad345d50e" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8a2fbf1599884b03a4ac4edad345d50e">The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December&#160;31, 2022.&#160;In the opinion of the Company&#8217;s management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of its financial position, operating results and cash flows for the periods presented have been included.&#160;Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the full year, for any other interim period or for any future year.</ix:continuation>&#160;</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0NDg_6d75765a-cd12-4359-a505-d6b3b1d43bfc" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of certain financial instruments, including accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of such instruments.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For assets and liabilities recorded at fair value, it is the Company&#8217;s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates and are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, fair value measurements cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the calculated current or future fair values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The determination of where an asset or liability falls in the hierarchy requires significant judgment. These levels are:</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.</span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and models for which all significant inputs are observable, either directly or indirectly.</span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There was no material re-measurement to fair value of financial assets and liabilities that are not measured at fair value on a recurring basis. For additional information regarding the Company&#8217;s investments, please refer to Note 2, &#8220;Investments.&#8221;</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idfe9c0c85faf485ea300b4d6ccebc44b" continuedAt="i18c0789b2add4b48b0832076e5237077"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0ODM_15e3250e-a530-4ec3-b107-119aaace8043" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below are tables that present information about certain assets measured at fair value on a recurring basis (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets<br/>for&#160;Identical&#160;Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="18" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1192c9f83b36465e8f80e3685ed58c8b_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNC0xLTEtMS01NzY3OA_ad9e26ec-a91b-4d86-8b2b-a56bf1550910">13,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ffd7159be8e43f19e53d050ecbf41ae_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNC0zLTEtMS01NzY3OA_912c1422-915b-436c-aae3-31d895751890">13,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20743e8f7f174eeeadbd88e1c7f0cc12_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNC01LTEtMS01NzY3OA_ce551013-36fb-402b-b5c2-72468c1b9baa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f3f186e36448f5b3a63b9e3b863269_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNC03LTEtMS01NzY3OA_5b692765-2d93-4572-9003-e58d960ef9f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i804d7d03889847d5ae48e5ad93dbb50f_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfOS0xLTEtMS01NzY3OA_b723e719-b9d1-42c3-868d-d00b2d232c3e">13,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887daef78c58443e893277334452edbc_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfOS0zLTEtMS01NzY3OA_a5efc4d8-ee3d-404e-a972-203507a60ffc">13,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ade65735c9545f2a12dec9f4312f6cd_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfOS01LTEtMS01NzY3OA_21aceab3-f714-454b-930f-528b0c54977f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c60bf2d7ba4e96bf4498b8f2014d16_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfOS03LTEtMS01NzY3OA_b4a3b552-33ec-4bfb-bd8d-f327f91609a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib107a3ac2180405c9d10f438e8b18db3_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTItMS0xLTEtNTc2Nzg_998ccc8c-95f1-43ad-b0a5-bcf98e31f3be">60,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id189accf19a84607a3af2777ead773ad_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTItMy0xLTEtNTc2Nzg_368d88ec-257f-4ed0-90da-13de65ed19a3">26,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic51cb125601349b8b451af99cb1a781a_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTItNS0xLTEtNTc2Nzg_e86f5ddf-0dd9-415b-ae45-1ce3c28f1b13">34,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e8a7b56d01472097cdbcd15bfb49c6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTItNy0xLTEtNTc2Nzg_c305d262-09b2-4158-91e9-625810c4fb56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0c0f4bcdd5c402e9040e2f3d650afb7_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTQtMS0xLTEtNTc2Nzg_7d8c9c09-5570-4c64-ab2c-33c437810983">115,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5037b9b3c73466389a40771e5177e59_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTQtMy0xLTEtNTc2Nzg_40abfcb8-b285-4d4d-a20a-dcc4cbe30613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedf03aebe3b4bc78bfbfef940377a97_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTQtNS0xLTEtNTc2Nzg_a9df39eb-72a7-47ee-be4f-bb4d39fe817f">115,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff2067d964e4f6eb5c4572c7df44ff5_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTQtNy0xLTEtNTc2Nzg_4c46c8c0-f21e-45fe-9027-d58368a63aba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5a617b479c5421ab4085ecb7805f41b_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTUtMS0xLTEtNTc2Nzg_58399088-d21c-4554-891b-9beadebd5b9f">23,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b72ea3730984bc299a26ec655d2be77_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTUtMy0xLTEtNTc2Nzg_9340258d-b6ec-4db7-a7d6-094f5d68c264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i550880ea43424204a2167a6dad7fc32f_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTUtNS0xLTEtNTc2Nzg_59254bcf-5bb6-428d-9e4d-56e5e6b8d4ff">23,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9aa19420d064b6ea99c0aef9e593870_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTUtNy0xLTEtNTc2Nzg_3b1a0fdc-e684-431c-b99b-284aeba33347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i804d7d03889847d5ae48e5ad93dbb50f_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTYtMS0xLTEtNTc2Nzg_28c4764d-f7aa-47ab-9027-79b4bce6ac47">198,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887daef78c58443e893277334452edbc_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTYtMy0xLTEtNTc2Nzg_2ab7ad89-0250-4950-8f3c-d345b5420ae3">26,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ade65735c9545f2a12dec9f4312f6cd_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTYtNS0xLTEtNTc2Nzg_cdb722a6-95ae-4746-9557-ca955d9e0a96">172,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c60bf2d7ba4e96bf4498b8f2014d16_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTYtNy0xLTEtNTc2Nzg_a49fdd9a-e537-4f06-aa48-2b54ef456ca2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib107a3ac2180405c9d10f438e8b18db3_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTktMS0xLTEtNTc2Nzg_9a624034-a6dd-4f25-99b9-f04215807187">31,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id189accf19a84607a3af2777ead773ad_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTktMy0xLTEtNTc2Nzg_2c186d77-cee5-41fa-8688-6efef448fced">10,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic51cb125601349b8b451af99cb1a781a_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTktNS0xLTEtNTc2Nzg_ff98b07f-098d-4671-852c-924dd4e43be6">21,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e8a7b56d01472097cdbcd15bfb49c6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTktNy0xLTEtNTc2Nzg_6eabfd3a-4c74-4ec9-85cb-11c77e4e4d20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total long-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i804d7d03889847d5ae48e5ad93dbb50f_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjAtMS0xLTEtNTc2Nzg_ede7f3b7-e17d-409f-8d39-ecad718a86f4">31,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887daef78c58443e893277334452edbc_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjAtMy0xLTEtNTc2Nzg_d5106be5-c438-4d2c-b712-20fc80279b1f">10,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ade65735c9545f2a12dec9f4312f6cd_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjAtNS0xLTEtNTc2Nzg_5550e16b-a276-43ef-acbc-750d01bf24d6">21,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c60bf2d7ba4e96bf4498b8f2014d16_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjAtNy0xLTEtNTc2Nzg_8953f10e-e864-4e6f-89f1-b3a6ff1bb63e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i804d7d03889847d5ae48e5ad93dbb50f_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjEtMS0xLTEtNTc2Nzg_98be16c7-a528-4530-88dd-a9744d5777eb">243,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887daef78c58443e893277334452edbc_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjEtMy0xLTEtNTc2Nzg_42159dff-3ac1-4c48-92bc-025b7bbd5427">50,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ade65735c9545f2a12dec9f4312f6cd_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjEtNS0xLTEtNTc2Nzg_e9ad6493-31aa-4f42-91ae-f9f74e725ebe">193,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c60bf2d7ba4e96bf4498b8f2014d16_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjEtNy0xLTEtNTc2Nzg_b85b345c-27a3-43fb-a123-6852756b4381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets<br/>for&#160;Identical&#160;Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15168c3e9c9e45d884e1da247a40b7ec_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjctMS0xLTEtNTc2Nzg_dd24e4c9-8bfd-43e5-b4c8-af0f3862c504">17,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e929ebf603643be9d50f1d1c81d5553_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjctMy0xLTEtNTc2Nzg_d53cd4dc-cc09-4ebe-b305-dc81e4d85ad0">17,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11f96247a744891aedb33da4b10f863_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjctNS0xLTEtNTc2Nzg_fac9eee5-cf95-4b9e-a825-979934038885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i826e3ed6eed14f59899dfce3d3fb5ed5_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjctNy0xLTEtNTc2Nzg_fe5b0b23-028b-454e-b681-7ebee92def29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41d1ac0e92874f2ab60e2efbc7472cb3_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjktMS0xLTEtNTc2Nzg_84abfcaa-eb49-4b7c-a1aa-e19b9ef8bb00">4,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7a494199b34fe38f094bf02e43219e_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjktMy0xLTEtNTc2Nzg_0d79ace5-9abd-4fc0-9670-67fca89e3df2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99c937daad4485a99236d4462f4fe95_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjktNS0xLTEtNTc2Nzg_1f9d16d5-2215-49ce-a118-2716915c9d68">4,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06e373167d2401d87352019c0070854_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjktNy0xLTEtNTc2Nzg_6833cf19-5e2f-4035-8267-73d9b7d8e3cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67b2ed977af4ca5be169e787fd04e24_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzEtMS0xLTEtNTc2Nzg_0186dda4-421d-472f-84e0-39f04ce049a0">22,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic01dbb19691142bcaf240d5503fa85ce_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzEtMy0xLTEtNTc2Nzg_f81772cc-dbb1-4894-8e8b-46be01471839">17,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i216aa5360f47421dad09d1e2fe063cd9_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzEtNS0xLTEtNTc2Nzg_9c3b4198-15ab-4dcd-859a-d0afdf587d2c">4,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbc49f108964d9586b1fe78301cede3_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzEtNy0xLTEtNTc2Nzg_d1be3403-e02a-4317-8fd5-1215e9296be0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65078142e8c646429535c348eb43e549_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzQtMS0xLTEtNTc2Nzg_f42e1ab2-e60a-49f9-94c5-e8f2f5ab387c">38,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73233ee3c3004e849b476b2a2bdd672d_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzQtMy0xLTEtNTc2Nzg_33629e72-4a8e-4ba4-82a1-4f11264d92dd">25,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8cb0da69264659b6fb1593ca7975a3_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzQtNS0xLTEtNTc2Nzg_0da34720-3390-4304-986a-ec9da0832e2a">12,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a0ab613b064db9811414440e1df09c_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzQtNy0xLTEtNTc2Nzg_d0b69d22-0e07-4764-a0c4-bca4dbd077e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830e14896ae3418090aea88e6361ccff_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzYtMS0xLTEtNTc2Nzg_1ff8a5aa-24e6-44e6-a76d-299bc25750f1">127,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb926ac6f54414ab15657d5d02f6bef_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzYtMy0xLTEtNTc2Nzg_f50073ae-4b6f-41df-a164-e5696064ea6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff79739385f045859d1ea7c0fd2a699e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzYtNS0xLTEtNTc2Nzg_3f253d3c-4a2d-4d7f-a8d2-ff0a843f25a5">127,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b68c3a79434ad59d870f352df7ab52_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzYtNy0xLTEtNTc2Nzg_ad0bc65c-cb30-416d-95e0-6eb973a20ed8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9612d95ff6e485ab93759b9c6a1bc22_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzctMS0xLTEtNTc2Nzg_561eacd9-8bf4-4b34-8856-86e37aba49a4">25,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cdfd50074bb4f2780f387ee055c71f1_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzctMy0xLTEtNTc2Nzg_9f3fcba5-5f5d-435e-bf7d-e343799586cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229430736baa458696f8be14caad07c2_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzctNS0xLTEtNTc2Nzg_575f6b46-e9f2-4d83-8929-e35a98a2b9ed">25,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i843f7d4691c94406bd8946f2730515ba_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzctNy0xLTEtNTc2Nzg_16d011e8-75c7-4bcb-a54d-aee9323edc71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67b2ed977af4ca5be169e787fd04e24_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzgtMS0xLTEtNTc2Nzg_58daa351-9e8c-42ee-8749-49cb60a7949d">191,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic01dbb19691142bcaf240d5503fa85ce_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzgtMy0xLTEtNTc2Nzg_f0a37326-3d65-433f-bf81-471b97f64c9a">25,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i216aa5360f47421dad09d1e2fe063cd9_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzgtNS0xLTEtNTc2Nzg_30385fce-e73d-4a58-a907-079700802a52">166,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbc49f108964d9586b1fe78301cede3_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzgtNy0xLTEtNTc2Nzg_5317e767-941b-4be8-be33-7fad0b1c719b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65078142e8c646429535c348eb43e549_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDEtMS0xLTEtNTc2Nzg_4fae78c6-5a84-4e11-a456-47a2def97b9c">48,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73233ee3c3004e849b476b2a2bdd672d_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDEtMy0xLTEtNTc2Nzg_a61c86a7-fd9e-42e4-b3a7-39ab53f08017">11,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8cb0da69264659b6fb1593ca7975a3_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDEtNS0xLTEtNTc2Nzg_5410e054-1dee-4a27-b28f-2032ca59c7f8">36,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a0ab613b064db9811414440e1df09c_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDEtNy0xLTEtNTc2Nzg_65bc9ebc-46d6-49ad-ae14-cb3d9e3b38a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total long-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67b2ed977af4ca5be169e787fd04e24_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDMtMS0xLTEtNTc2Nzg_e372736c-6070-435e-9d76-6295b1b90fc0">48,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic01dbb19691142bcaf240d5503fa85ce_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDMtMy0xLTEtNTc2Nzg_662ca35c-dc57-4fca-a5a2-22c82d947101">11,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i216aa5360f47421dad09d1e2fe063cd9_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDMtNS0xLTEtNTc2Nzg_8452b90d-336c-42f6-a748-2584bf7d176b">36,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbc49f108964d9586b1fe78301cede3_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDMtNy0xLTEtNTc2Nzg_4975c97e-7dba-492e-ba9c-b90a2704054f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67b2ed977af4ca5be169e787fd04e24_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDQtMS0xLTEtNTc2Nzg_3bab8ea1-ed95-4fd7-9cf4-1b98db8e65d8">262,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic01dbb19691142bcaf240d5503fa85ce_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDQtMy0xLTEtNTc2Nzg_557a434b-4adc-4a51-9d36-35674d4a54cb">54,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i216aa5360f47421dad09d1e2fe063cd9_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDQtNS0xLTEtNTc2Nzg_df56169c-c441-4e0b-a76d-24d56102f5e9">208,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbc49f108964d9586b1fe78301cede3_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDQtNy0xLTEtNTc2Nzg_9be4aefd-82f0-41f6-b8b7-ec97d9c12030">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0NTk_0843c488-5f2e-4e02-9668-8c944f19e155" continuedAt="i9613ce9ea85b49c3844052b2d277dd40" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. The Company begins capitalization of these inventory related costs once regulatory approval is obtained. The Company primarily uses actual costs to determine its cost basis for inventories. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 15, 2022, we entered into an Asset Purchase Agreement (the Asset Purchase Agreement) with an affiliate of Emergent BioSolutions Inc. (Emergent BioSolutions) for the sale of our exclusive worldwide rights to brincidofovir, including </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i18c0789b2add4b48b0832076e5237077" continuedAt="i1d6d8511951841d2b31d4f3a945d2bfe"><ix:continuation id="i9613ce9ea85b49c3844052b2d277dd40"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TEMBEXA&#174; and specified related assets (the Asset Sale). On September 26, 2022, we closed the Asset Sale with Emergent Biodefense Operations Lansing LLC (Emergent), an affiliate of Emergent BioSolutions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale of TEMBEXA to Emergent, the Company&#8217;s inventory consisted of TEMBEXA, which was being manufactured for the treatment of smallpox for potential delivery to the Strategic National Stockpile (SNS) for the U.S. government and to other government agencies. TEMBEXA was approved by the FDA on June 4, 2021, at which time the Company began to capitalize inventory costs associated with TEMBEXA. Prior to FDA approval of TEMBEXA, all costs related to the manufacturing of TEMBEXA were charged to research and development expense in the period incurred as there was no alternative future use.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company valued its inventories at the lower of cost or estimated net realizable value. The Company determined the cost of its inventories, which included amounts related to materials, manufacturing costs, shipping and handling costs on a first-in, first-out (FIFO) basis. Work-in-process included all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods included packaged and labelled products. Title to all inventory was transferred to Emergent upon the close of the Asset Sale.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Retention Credit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) passed by the United States Congress and signed by the President, the Company was eligible for a refundable employee retention credit subject to certain criteria. The Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i18d0bbe7e74a49d99423e480deb74908_D20220701-20220930" decimals="-5" name="cmrx:EmployeeRetentionCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNzc3Ng_59755d32-14af-4c70-a945-838b5b1f9a42">2.0</ix:nonFraction>&#160;million employee retention credit during the three months ended September 30, 2022 related to labor costs recognized during 2020 and 2021, which is recorded in prepaid expenses and other current assets. For the three months ended September 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="ic0b110316ee84c4196d882c915b7f130_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfODAwNw_3b2d0ece-67f4-48e1-8dc1-d433269281ee">1.5</ix:nonFraction>&#160;million was recorded as a reduction to research and development expenses and $<ix:nonFraction unitRef="usd" contextRef="ic0b110316ee84c4196d882c915b7f130_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfODA3OA_846b560a-7837-4ae9-ba3f-f7d8d19c3e6c">0.5</ix:nonFraction>&#160;million was recorded as a reduction to general and administrative expenses. The Company has filed for refunds of the employee retention credits and as of the date of this Quarterly Report on Form 10-Q, it has received $<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIncomeTaxRefunds" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODQzMjcy_60c8dac1-5fa2-4122-9535-af0df8ad5a90">27,000</ix:nonFraction> of refunds and cannot reasonably estimate when it will receive any or all of the remaining refunds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Loan Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022 (the Effective Date), the Company entered into a Loan and Security Agreement (the Loan Agreement), by and between the Company, as borrower, and Silicon Valley Bank, now a division of First-Citizens Bank &amp; Trust Company, as the lender (the Lender). The Loan Agreement provides for a <ix:nonNumeric contextRef="i3fff5d25cf6449308bcbf75364001e45_D20220131-20220131" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0NTE_14f52841-3987-4e40-96f5-1c59a0bc0a78">four-year</ix:nonNumeric> secured revolving loan facility (the Credit Facility) in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i5f1afc1bd8bb425d867be35c0e46ed08_I20220131" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfODc2MA_089e9d6d-ccb8-4dce-ad9f-1d030e28cae7">50.0</ix:nonFraction>&#160;million. Proceeds from the Credit Facility may be used for working capital and general corporate purposes. The Company has no obligation to draw down any amount under the Credit Facility, and has not drawn down any amount as of March&#160;31, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, in connection with the Asset Sale, the Lender and the Company agreed to suspend the availability of future advances under the Loan Agreement until such time the parties mutually agree to amend the Loan Agreement to, among other things, adjust the borrowing base and reset the covenants. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Facility accrue interest at a floating per annum rate of the greater of (i) <ix:nonFraction unitRef="number" contextRef="i80ced39ca26c4f13818bb6d006095818_D20220131-20220131" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfOTA5Mw_5a2b4b4a-36df-4dc4-87d2-d7f3403f7572">1.50</ix:nonFraction>% above the Prime Rate (as defined below) and (ii) <ix:nonFraction unitRef="number" contextRef="i5f1afc1bd8bb425d867be35c0e46ed08_I20220131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfOTE0NQ_ee578b71-f364-41bf-95fb-916f0edc9db0">4.75</ix:nonFraction>%. Prime Rate is defined as the rate of interest per annum published in The Wall Street Journal or any successor publication thereto as the &#8220;Prime Rate&#8221;. If such rate of interest from The Wall Street Journal becomes unavailable, the &#8220;Prime Rate&#8221; shall mean the rate of interest per annum announced by the Lender as its prime rate in effect. In each case, in the event such prime rate is less than zero, such rate shall be deemed to be zero for purposes of the Loan Agreement. The Company must also pay an unused line fee equal to <ix:nonFraction unitRef="number" contextRef="i3fff5d25cf6449308bcbf75364001e45_D20220131-20220131" decimals="4" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfOTY3Ng_dfa36a2c-60d7-4a21-82f9-1ff6744e01dc">0.25</ix:nonFraction>% per annum on the unused portion of the Credit Facility, payable quarterly in arrears. Upon the termination of the Loan Agreement for any reason prior to the Maturity Date, the Company will be required to pay to the Lender an early termination fee of $<ix:nonFraction unitRef="usd" contextRef="i3fff5d25cf6449308bcbf75364001e45_D20220131-20220131" decimals="-5" name="cmrx:DebtInstrumentEarlyTerminationFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfOTkyOQ_6b62163b-b959-483d-84c9-a2a32cd5d128">0.5</ix:nonFraction>&#160;million. The Loan Agreement also requires the Company to pay the Lender a non-refundable commitment fee of $<ix:nonFraction unitRef="usd" contextRef="i3fff5d25cf6449308bcbf75364001e45_D20220131-20220131" decimals="-5" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTAwMzE_93092901-2ef6-4294-8511-21a0175cd567">0.5</ix:nonFraction>&#160;million, payable in <ix:nonFraction unitRef="installment" contextRef="i5f1afc1bd8bb425d867be35c0e46ed08_I20220131" decimals="INF" name="cmrx:DebtInstrumentNumberOfInstallmentPayments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTAwNDY_7d4a94ad-54d4-493c-847a-41800c54bbde">four</ix:nonFraction> equal installments beginning on the Effective Date and each anniversary of the Effective Date thereafter until January 31, 2025. As of March&#160;31, 2023, the Company has recorded current deferred loan costs of $<ix:nonFraction unitRef="usd" contextRef="id5258aa58e96454ba7f47be820e18166_I20230331" decimals="-5" name="us-gaap:DeferredCostsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTAyNDQ_3e62fb3c-245b-4c26-a688-bc4f18c9e6e2">0.1</ix:nonFraction>&#160;million in prepaid expenses and other current assets and non-current deferred loan costs of $<ix:nonFraction unitRef="usd" contextRef="id5258aa58e96454ba7f47be820e18166_I20230331" decimals="-5" name="us-gaap:DeferredCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTAzMzE_6a105043-b069-47ba-af9a-59871d013ed6">0.3</ix:nonFraction>&#160;million in other long-term assets on the Consolidated Balance Sheets. As of March&#160;31, 2023, the Company has recorded a current loan fee liability of $<ix:nonFraction unitRef="usd" contextRef="id5258aa58e96454ba7f47be820e18166_I20230331" decimals="-5" name="cmrx:LoanFeesLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTA0NjM_87135ace-77ff-4c1c-87ec-142e17e8cb77">0.2</ix:nonFraction>&#160;million in accrued liabilities and a non-current loan fee liability of $<ix:nonFraction unitRef="usd" contextRef="id5258aa58e96454ba7f47be820e18166_I20230331" decimals="-5" name="cmrx:LoanFeesLiabilityNonCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTA1Mjk_aeae8149-a7de-4139-ab97-8dbf7c9b4d9f">0.1</ix:nonFraction>&#160;million in loan fees on the Consolidated Balance Sheets. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1d6d8511951841d2b31d4f3a945d2bfe" continuedAt="i58244db7dae449ddbc919526438ff7c8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0ODA_66e8e767-0aaf-4564-9989-9d4d20955dff" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="cmrx:AccruedDevelopmentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfMS0xLTEtMS01NzY3OA_d6d17dd9-dce2-4fa5-94b7-86156f009cb2">7,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="cmrx:AccruedDevelopmentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfMS0zLTEtMS01NzY3OA_a6a812a2-e2f1-4376-a8cc-4f129fa433f1">6,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:AccruedSalariesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfMi0xLTEtMS01NzY3OA_686d92a5-9bc3-4722-99f6-4df01318bd07">3,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:AccruedSalariesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfMi0zLTEtMS01NzY3OA_57332938-7a7e-485e-96b2-dc34a88b977a">6,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfNS0xLTEtMS01NzY3OA_f2986dbc-647e-4078-914c-9343162d83f9">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfNS0zLTEtMS01NzY3OA_74cfbdde-4aff-4c05-b5ae-8861e1bb3efe">4,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfNi0xLTEtMS01NzY3OA_f332bcdb-2f41-4b35-9af7-d14717adf604">13,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfNi0zLTEtMS01NzY3OA_0cae9acd-0ebb-485a-b02a-d2b76c75954d">17,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0ODQ_7e05a350-674a-49a6-a5b0-5c45c883f7fe" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Policy</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s revenues generally consist of  (i) contract and grant revenue&#8212;revenue generated under federal and private foundation grants and contracts, (ii) licensing revenue&#8212;revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements (iii) royalty revenue&#8212;revenue related to sales of TEMBEXA made by Emergent after the Asset Sale, and (iv) procurement revenue&#8212;revenue related to sales of TEMBEXA prior to the Asset Sale. Revenue is recognized in accordance with the criteria outlined in Accounting Standards Codification (ASC) 606 issued by the Financial Accounting Standards Board (FASB). Following this accounting pronouncement, a five-step approach is applied for recognizing revenue, including (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the entity satisfies a performance obligation.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emergent BioSolutions, Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 26, 2022, the Company completed the Asset Sale to Emergent of the Company&#8217;s exclusive worldwide rights to brincidofovir, including TEMBEXA&#174; and specified related assets (the Asset Sale). Emergent paid the Company an upfront cash payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i39fee762c2014475826a3d701b15814d_D20220926-20220926" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODYzMzQz_178be9b4-c0db-4556-8e50-1b25f63e3f6d">238</ix:nonFraction>&#160;million upon the closing of the Asset Sale. In addition, pursuant to the Asset Purchase Agreement, the Company is eligible to receive from Emergent: (i) up to an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="ide975e55e26c4a95b067825a19f1af74_I20220926" decimals="-6" name="cmrx:MaximumMilestoneProceedsUponTheExerciseOfOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODYzNTI4_1b37bd57-2d9b-49ac-a603-593b573391eb">124</ix:nonFraction>&#160;million in milestone payments payable upon the exercise of the options under the BARDA Agreement for the delivery of up to <ix:nonFraction unitRef="treatment" contextRef="i4febe75fb14447a39e9fe6f7451fff6c_I20220926" decimals="INF" name="cmrx:QuantityBenchmarkGrossProfitRoyaltyRateTrigger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODYzNjQ3_2a24fcc4-38bf-44ed-b038-31daded07536">1.7</ix:nonFraction>&#160;million treatment courses of tablet and suspension formulations of TEMBEXA to the U.S. government; (ii) royalty payments equal to <ix:nonFraction unitRef="number" contextRef="i49c5bcc0f6e3428b874169048e2386a2_I20220926" decimals="INF" name="cmrx:RevenueBenchmarkGrossProfitRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODYzNzcz_0f8753af-5a90-49cf-a07c-af63714ec8a3">15</ix:nonFraction>% of all gross profits associated with the sales of TEMBEXA made outside of the United States during the exclusivity period of TEMBEXA on a market-to-market basis; (iii) royalty payments equal to <ix:nonFraction unitRef="number" contextRef="ibef35d312f6649c48ca5770e34d07f53_I20220926" decimals="INF" name="cmrx:RevenueBenchmarkGrossProfitRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODYzODkx_9c0b92e3-8e1b-4c1e-9da9-e13ffb74ca86">20</ix:nonFraction>% of future gross profits of TEMBEXA made in the United States associated with volumes above <ix:nonFraction unitRef="treatment" contextRef="i4febe75fb14447a39e9fe6f7451fff6c_I20220926" decimals="INF" name="cmrx:QuantityBenchmarkGrossProfitRoyaltyRateTrigger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODYzOTgx_2a24fcc4-38bf-44ed-b038-31daded07536">1.7</ix:nonFraction>&#160;million treatment courses of therapy during the exclusivity period of TEMBEXA; and (iv) up to an additional $<ix:nonFraction unitRef="usd" contextRef="i5668b209a8cf48ffac44b53d2385eeb5_I20220926" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODY0MDMz_39fae769-cbab-424d-9938-d21126adb426">12.5</ix:nonFraction>&#160;million upon the achievement of certain other developmental milestones. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The BARDA Agreement was novated to Emergent in December 2022. Under the Asset Purchase Agreement, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i8ae67a95e48a4514b6b62802563f5af0_D20230101-20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODY1NjM2_ebb9eea9-11e7-4e64-bb4c-68b8f3b10fa7">0.2</ix:nonFraction>&#160;million of contract revenue for expense reimbursement related to support provided to Emergent for the three months ended March&#160;31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue under cost-plus-fixed-fee grants from the federal government and private foundations is recognized as allowable costs are incurred and fees are earned. At March&#160;31, 2023, the Company has a deferred revenue balance of $<ix:nonFraction unitRef="usd" contextRef="i66e19cf7c3a84bd69adc584ad7985cb2_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTUwODc_d3cd3a4b-c84a-45bf-a12e-7d19de76b577">0.1</ix:nonFraction>&#160;million related to these grants. For the three months ended March&#160;31, 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="iec10cd07bccf4bdea2cab77c4d8be033_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTUxNjY_385e97a7-d6db-4ec3-9fa3-6861f68308df">30,000</ix:nonFraction> of grant revenue and for the three months ended March&#160;31, 2022, the Company recognized <ix:nonFraction unitRef="usd" contextRef="i3aced1df796f4e5d948dedb09bb1dc06_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTUyNDE_e112001d-9db2-4a16-8803-3b432eea7955">no</ix:nonFraction>  grant revenue related to these grants.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ohara Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Oncoceutics, Inc., a Delaware corporation (Oncoceutics) which was subsequently acquired by the Company in January 2021, entered into a license, development and commercialization agreement with Ohara Pharmaceutical Co., Ltd. for ONC201 in Japan. The Company is entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="ica04db5e597f4a148bb1cd8f8e4c8b48_I20191231" decimals="-5" name="cmrx:LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODUwNzM5_5a7f68b7-2926-46c8-8030-50415ec7de6e">2.5</ix:nonFraction>&#160;million in nonrefundable regulatory milestone payments. The Company is entitled to double-digit tiered royalties based on the aggregate annual net sales of all products, as defined in the agreement, in Japan. For the three months ended March&#160;31, 2023 and 2022, the Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="ic046decd305e415f9bdb56550cc8bda5_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODUwODAz_515d484c-b547-42ad-9921-a887d38706c8">58,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i94ca8168a35a4764b28df995a789e4a5_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjE5OTAyMzI5MzU4NA_db89c875-0452-49d5-9be8-41b16d079a39">15,000</ix:nonFraction>, respectively, of license revenue related to this agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i58244db7dae449ddbc919526438ff7c8" continuedAt="i3de6a68665a94fc5b44888335e737afa"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TEMBEXA Procurement Agreements Revenue and Royalty Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, the Company entered into the Supply Agreement and the PHAC Contract (as defined in Note 6 below), pursuant to which the Company was responsible for supplying TEMBEXA (brincidofovir) treatment courses for use outside of the United States. There are no material performance obligations outside of delivery in the agreements, therefore revenue related to these procurement agreements was recognized when the delivery performance obligation was satisfied. Revenue was recognized based on price per treatment course as outlined in the agreements.  For the three months ended September 30, 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i96d6a71fabac4ccbb276c7996d4a8257_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODU2ODA4_51bce884-cf8b-4576-b6de-91209ef4e553">32.0</ix:nonFraction>&#160;million of procurement revenue related to these agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The remaining deliveries of treatment courses related to the PHAC Contract were delivered by Emergent and were subject to the royalty terms of the Asset Purchase Agreement applicable to gross profits outside the United States. The Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i07e0fd7ae2114d36b0896130bfc39369_D20221001-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODYwOTYz_307eb884-2f5f-4bce-9456-f465bd8255d2">0.4</ix:nonFraction>&#160;million of royalty revenue in the three months ended December 31, 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0NzE_1918009a-dddf-4522-9710-1e1c8d530a2e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Prepaids and Accruals</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its research and development efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s objective is to reflect the appropriate research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of its research and development efforts. The Company determines prepaid and accrual estimates through discussion with applicable personnel and outside service providers as to the progress or state of communication of clinical trials, or other services completed. The Company adjusts its rate of research and development expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. Through March&#160;31, 2023, there had been no material adjustments to the Company&#8217;s prior period estimates of prepaid and accruals for research and development expenses. The Company&#8217;s research and development prepaids and accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA1MDI_d7ab77d7-324b-4050-bec0-33d17cd3dd20" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Net Income (Loss) Per Share of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period, excluding the dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights. Diluted net income (loss) per share of common stock is computed by dividing net income (loss) by the sum of the weighted-average number of shares of common stock outstanding during the period plus the potential dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights outstanding during the period calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during the periods of net loss, there was no difference between basic and diluted loss per share of common stock for the three months ended March&#160;31, 2023 and 2022.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0OTY_19fd9335-42ee-491a-89d4-4cebe9ca8433" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In addition to estimates discussed in other sections of this Quarterly Report on Form 10-Q, the most significant estimates in the Company&#8217;s consolidated financial statements relate to the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3de6a68665a94fc5b44888335e737afa"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0NTU_0fd0629b-dbf4-469a-9435-b748e5c8e6ce" continuedAt="ia8f481d279f74114aad1523c19cdaacc" escape="true">Segments</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia8f481d279f74114aad1523c19cdaacc">The Company operates in only <ix:nonFraction unitRef="segment" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTk1OTU_1affb8a7-9ce1-4297-b2eb-89ded2de8d28">one</ix:nonFraction> segment, pharmaceuticals.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0ODE_46235049-e065-45d4-9bd0-bc27c3386a8b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of Recently Adopted Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward-looking approach on expected losses to estimate credit losses on certain financial instruments, including trade receivables and available-for-sale debt securities. The new guidance was originally due to become effective for the Company beginning in the first quarter of 2020, however the FASB in November 2019 issued ASU 2019-10 which moved the effective date for smaller reporting companies to the first quarter of 2023. The Company adopted ASU 2016-03 as of January 1, 2023. Given the nature of the Company&#8217;s receivables and investment portfolio, adoption of this standard had no impact on the Company's financial position, results of operations or cash flows.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4446784166784bc6ab6a1471468846ff_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RleHRyZWdpb246ZmRlYWZmZTJjNDBhNDViOTlkMWViMjk2NDdiNzIyMjVfMTk2Mw_23e490c2-374b-431c-892d-ce3e128271e6" continuedAt="i70e053fc0c6c44c78184dff2fa10403f" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="i70e053fc0c6c44c78184dff2fa10403f" continuedAt="i03281895600b46c08906a4148824ef2e"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RleHRyZWdpb246ZmRlYWZmZTJjNDBhNDViOTlkMWViMjk2NDdiNzIyMjVfMTk1NA_5ac21c93-9c25-4e45-bfc6-d1897b7baaf9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following tables summarize the Company&#8217;s debt investments (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMi0yLTEtMS01NzY3OA_cf5871b3-0366-46c3-a589-a663862dfdf0">23,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMi00LTEtMS01NzY3OA_ff575937-ce0f-477c-be2a-5b961385f9b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMi02LTEtMS01NzY3OA_064ca16e-0ce4-4371-83dc-eda0c837947d">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMi04LTEtMS01NzY3OA_fc711373-d59c-4c44-b343-2c8dd177431d">23,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNC0yLTEtMS01NzY3OA_40309a37-5829-429a-b387-4700362e2df7">92,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNC00LTEtMS01NzY3OA_34f667d2-4c86-493f-af8e-67add72fc1bd">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNC02LTEtMS01NzY3OA_362dcf3d-ec61-4a6f-b814-10235b4691a6">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNC04LTEtMS01NzY3OA_ecadfd0f-e101-4f2c-9a91-740afaf19be1">92,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNS0yLTEtMS01NzY3OA_34ede36c-c0c7-44f6-8ed0-8b2c4f9a506f">115,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNS00LTEtMS01NzY3OA_8e3ee41e-16c7-4744-b89a-4929ab684765">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNS02LTEtMS01NzY3OA_637beae6-640f-4cb3-b450-5e08c38cefa9">123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNS04LTEtMS01NzY3OA_04e5bb05-d6b1-43c4-99c2-112eec156a7a">115,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNy0yLTEtMS01NzY3OA_5cd8f777-3ecf-4e7c-84c3-1241ff2b3917">230,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNy00LTEtMS01NzY3OA_2393c544-13f6-47d5-80c3-f2755c3230b6">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNy02LTEtMS01NzY3OA_a4e01361-8a7e-40f2-adf9-22dece59d63f">295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNy04LTEtMS01NzY3OA_8e756da5-298b-403e-8437-8b08f404b008">230,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTEtMi0xLTEtNTc2Nzg_f2c78a74-c404-44fc-a75e-e024108f26db">25,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTEtNC0xLTEtNTc2Nzg_cd74c9d4-e142-4e55-bf05-e4a18dff06cf">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTEtNi0xLTEtNTc2Nzg_c33bd3fc-90cc-44be-9c3b-1b4fb2a91723">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTEtOC0xLTEtNTc2Nzg_59b4b68d-98a3-4a77-95a1-9278b35ad382">25,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTItMi0xLTEtNTc2Nzg_2149e8a5-6183-4a19-988a-0c7ec9558c7d">127,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTItNC0xLTEtNTc2Nzg_a49100ea-3b3b-44fe-a5d9-e168b1648538">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTItNi0xLTEtNTc2Nzg_28b4019e-10c3-4214-bed9-4722be47783e">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTItOC0xLTEtNTc2Nzg_3cf5e8f9-e45f-487d-afee-369f288a3321">127,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b23ee2279148de946ebbc12395a903_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTQtMi0xLTEtNTc2Nzg_3c5ca7e8-7852-42a0-93eb-1470803e27e6">86,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b23ee2279148de946ebbc12395a903_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTQtNC0xLTEtNTc2Nzg_c6a90806-36b3-4187-860d-c3afc307dde7">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b23ee2279148de946ebbc12395a903_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTQtNi0xLTEtNTc2Nzg_d21842fa-f6b4-41d3-9434-69762751d879">179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b23ee2279148de946ebbc12395a903_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTQtOC0xLTEtNTc2Nzg_ec8e2ffe-3dcc-4d76-a2b7-eb4213f3e495">86,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTYtMi0xLTEtNTc2Nzg_d295f5f0-41a2-4eef-aab8-1d55f9af58ba">240,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTYtNC0xLTEtNTc2Nzg_356d3774-6188-4ba5-9d0c-5da165d18831">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTYtNi0xLTEtNTc2Nzg_cc0abbd9-519c-4600-8230-57292787616d">384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTYtOC0xLTEtNTc2Nzg_406540d6-838f-4cdc-a2e9-e39590fa6813">240,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i03281895600b46c08906a4148824ef2e" continuedAt="i2c6e5515d07d4e6ab7d4e0cf347ed0a2"><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RleHRyZWdpb246ZmRlYWZmZTJjNDBhNDViOTlkMWViMjk2NDdiNzIyMjVfMTk2Nw_5d1ad528-8a16-4e2b-b2b0-024d6e67c586" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following tables summarize the Company&#8217;s debt investments with unrealized losses, aggregated by investment type and the length of time that individual investments have been in a continuous unrealized loss position (in thousands, except number of securities):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:29.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Greater than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMy0yLTEtMS01NzY3OA_2b90816a-444d-460b-a694-7068ea8596f2">23,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMy00LTEtMS01NzY3OA_77714cb2-2ecb-4aa0-ad48-9640a67fad58">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMy02LTEtMS01NzY3OA_f57b262b-03aa-4521-9e6d-75bb6789d8a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMy04LTEtMS01NzY3OA_c7dd476b-0379-46aa-906a-225a62ccde8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMy0xMC0xLTEtNTc2Nzg_bda84256-4dcf-4e6a-8a31-51072e43c58f">23,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMy0xMi0xLTEtNTc2Nzg_aacf72bb-8675-43e1-8411-eea8ca1830fc">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNC0yLTEtMS01NzY3OA_ace6c92c-ca99-4fd9-958a-c70200ec63bc">85,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNC00LTEtMS01NzY3OA_035eca0e-0f27-4d78-9637-8780d5a77af0">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNC02LTEtMS01NzY3OA_5e703abf-4b02-4216-b532-fa98c4ec9e9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNC04LTEtMS01NzY3OA_64e92f9e-d3ad-4ef2-bcde-618dd0bc8a3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNC0xMC0xLTEtNTc2Nzg_e292271e-8308-4e83-8ab2-0b6121a7af24">85,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNC0xMi0xLTEtNTc2Nzg_8217fff6-6a19-4c49-9f22-5a58afa6c358">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNS0yLTEtMS01NzY3OA_36bd810e-5004-44f3-8715-59b267f48068">65,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNS00LTEtMS01NzY3OA_2c7a2f9d-7ce1-44b7-adc0-f89ac695b317">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNS02LTEtMS01NzY3OA_7371b00d-acb9-4074-b54d-ab09b3b69aa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNS04LTEtMS01NzY3OA_664b21b8-2cf7-4f88-bca9-b491a26f0403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNS0xMC0xLTEtNTc2Nzg_e2c80337-723c-43d7-9129-31a6c0af7f86">65,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNS0xMi0xLTEtNTc2Nzg_e222a09c-f9b4-417d-92e3-643f2b4f894a">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNy0yLTEtMS01NzY3OA_53cdaf09-fb63-4b26-afda-af304bcc34ff">173,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNy00LTEtMS01NzY3OA_ee5ab528-ba5d-4851-8c25-5d6e2aa571d2">295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNy02LTEtMS01NzY3OA_3725f329-9e64-4235-bca9-b45e3914d40c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNy04LTEtMS01NzY3OA_566bd6c1-422a-4bf6-b092-06a8f89b844b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNy0xMC0xLTEtNTc2Nzg_0bda7043-df86-4f05-8d41-cffba258a652">173,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNy0xMi0xLTEtNTc2Nzg_0ab6fd61-7de2-4cde-a7ae-56e124b42d4f">295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfOC00LTEtMS01NzY3OA_394704f5-539e-4db6-9247-a4d17751981b">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfOC04LTEtMS01NzY3OA_dd9e7a09-9612-4680-9163-d07b7b091993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfOC0xMi0xLTEtNTc2Nzg_d7948d59-6eef-49db-a3c3-f393842493d1">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Greater than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTQtMi0xLTEtNTc2Nzg_2c3ef0c1-411a-473b-b745-06194fe3fb22">22,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTQtNC0xLTEtNTc2Nzg_5b775ee8-7b57-420c-b9dc-68af71eed3c3">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTQtNi0xLTEtNTc2Nzg_ed020755-f5a0-46fc-b72f-592e54bb81d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTQtOC0xLTEtNTc2Nzg_d463f7b9-f12e-457b-a26f-0c4b12d0c283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTQtMTAtMS0xLTU3Njc4_0cfb38d5-8573-4b30-9847-d17f0f6e92b5">22,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTQtMTItMS0xLTU3Njc4_bbfd2618-ec2e-473e-94e5-e6f5ba1ecade">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTUtMi0xLTEtNTc2Nzg_50e469a0-edd0-45ab-9795-6e50394b8345">88,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTUtNC0xLTEtNTc2Nzg_f94d0c75-fbaf-4915-bf3f-7d1963a5af84">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTUtNi0xLTEtNTc2Nzg_07247d00-c763-4a72-9eaa-9071b2c025a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTUtOC0xLTEtNTc2Nzg_ad5638d7-ea80-4c75-8fec-ae0eac473798">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTUtMTAtMS0xLTU3Njc4_9efd89f1-1fa3-49bd-9df5-3c37a067bc61">88,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTUtMTItMS0xLTU3Njc4_fb2b8b73-eede-4f50-b1e4-b852b268f9c2">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b23ee2279148de946ebbc12395a903_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTYtMi0xLTEtNTc2Nzg_76d52767-cf75-4cbe-bdfb-ecd0384f91c2">67,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b23ee2279148de946ebbc12395a903_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTYtNC0xLTEtNTc2Nzg_df1579c7-eafd-47d1-8831-7bdd45e756ad">179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b23ee2279148de946ebbc12395a903_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTYtNi0xLTEtNTc2Nzg_d0ad66a0-42d7-444e-9e7c-a3d9c3029795">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b23ee2279148de946ebbc12395a903_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTYtOC0xLTEtNTc2Nzg_8fdd6a4c-3e52-477d-92dd-3829d4b4db12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b23ee2279148de946ebbc12395a903_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTYtMTAtMS0xLTU3Njc4_e9699d20-4a28-4dc8-a1f8-e4e2551304b9">67,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b23ee2279148de946ebbc12395a903_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTYtMTItMS0xLTU3Njc4_206b4b29-e095-4111-b40b-b35b1b9976f5">179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTgtMi0xLTEtNTc2Nzg_013ac1c9-c389-4850-9569-97b96a7c3cbb">179,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTgtNC0xLTEtNTc2Nzg_db25f849-2ef3-4057-8443-68405b8bf320">384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTgtNi0xLTEtNTc2Nzg_8eb18c74-365b-492b-9ce1-e15e5baff85c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTgtOC0xLTEtNTc2Nzg_0b755cd1-569d-41e6-b307-7ecc9f75cf79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTgtMTAtMS0xLTU3Njc4_3a916d0b-9405-4987-87a1-59e7656256cd">179,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTgtMTItMS0xLTU3Njc4_e38f737b-1f9e-4eb3-86be-b7b810869866">384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTktNC0xLTEtNTc2Nzg_6ecda088-2338-4b8b-87ba-feae05ebb76e">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTktOC0xLTEtNTc2Nzg_d2c9dde2-e9f6-4688-952e-23f39e8d06e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTktMTItMS0xLTU3Njc4_b05c0687-2bd0-4b75-8548-99d64f9c81e7">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, certificates of deposits, municipal and corporate notes and bonds, and commercial paper, among others. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of two years and requires an average portfolio maturity of no more than 12 months. Some of the securities in which the Company invests may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company has not realized any significant losses from its investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates, among other things, the duration and extent to which the fair value of a security is less than its cost; the financial condition of the issuer and any changes thereto; and the Company&#8217;s intent to sell, or whether it will more likely than not be required to sell, the security before recovery of its cost basis. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Unrealized gains and losses on debt investments are recorded to unrealized gain (loss) on debt investments, net in the Consolidated Statements of Operations and Comprehensive Loss. Realized gains and losses on debt investments are recorded based on specific identification to interest income and other, net in the Consolidated Statements of Operations and Comprehensive Loss. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current investments. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term investments. At March&#160;31, 2023, the Company believes that the cost of its investments is recoverable in all material </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2c6e5515d07d4e6ab7d4e0cf347ed0a2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respects. The Company recognizes interest income on an accrual basis in interest income in the Consolidated Statements of Operations and Comprehensive Loss.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RleHRyZWdpb246ZmRlYWZmZTJjNDBhNDViOTlkMWViMjk2NDdiNzIyMjVfMTk2Mg_c92db8f7-5b35-49ea-9353-b34861bcc164" escape="true"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the scheduled maturity for the Company&#8217;s debt investments at March&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOmI2NGRhYzk2OTE0NTQyZjFiN2Y5NzRhOWI2ZjE1ODEwL3RhYmxlcmFuZ2U6YjY0ZGFjOTY5MTQ1NDJmMWI3Zjk3NGE5YjZmMTU4MTBfMC0xLTEtMS01NzY3OA_b35a8cd7-a699-493d-b57a-60255381392b">198,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="cmrx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOmI2NGRhYzk2OTE0NTQyZjFiN2Y5NzRhOWI2ZjE1ODEwL3RhYmxlcmFuZ2U6YjY0ZGFjOTY5MTQ1NDJmMWI3Zjk3NGE5YjZmMTU4MTBfMS0xLTEtMS01NzY3OA_a168a4ed-f052-4dfd-8c21-af3dcad15589">31,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total debt investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOmI2NGRhYzk2OTE0NTQyZjFiN2Y5NzRhOWI2ZjE1ODEwL3RhYmxlcmFuZ2U6YjY0ZGFjOTY5MTQ1NDJmMWI3Zjk3NGE5YjZmMTU4MTBfMi0xLTEtMS01NzY3OA_aac9f060-1f2b-4cc7-8fd3-1606c202165e">230,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4446784166784bc6ab6a1471468846ff_37"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMjc1Mw_be0bfa9e-3431-4cbc-9c88-0f729e2dfa67" continuedAt="i961b3fa48ee54a8ea0ea48eebb15ed8f" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i961b3fa48ee54a8ea0ea48eebb15ed8f" continuedAt="i7bd598df2e744808bae88a9434e4e3dc"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases its facilities under long-term operating leases that expire at various dates through 2026. The Company generally has options to renew lease terms on its facilities, which may be exercised at the Company&#8217;s sole discretion. In addition, certain lease arrangements may be terminated prior to their original expiration date at the Company&#8217;s discretion. The Company evaluates renewal and termination options at the lease commencement date to determine if it is reasonably certain to exercise the option and has concluded on all operating leases that it is not reasonably certain that any options will be exercised. The weighted-average remaining lease term for the Company&#8217;s operating leases as of March&#160;31, 2023 was <ix:nonNumeric contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfNzcz_f8d2046a-b32b-4a16-a989-b327d7c543b5">3.34</ix:nonNumeric> years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense related to leases is recorded on a straight-line basis over the lease term.  Lease expense under operating leases, including common area maintenance fees, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfOTYz_8131f2ee-eb86-4347-a542-e99471aa0263">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfOTcw_021669d0-9775-4e77-b790-6d52b3a3e613">0.2</ix:nonFraction> million, respectively, for the three months ended March&#160;31, 2023 and 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The discount rate implicit within the Company&#8217;s leases is generally not determinable and therefore the Company determines the discount rate based on its incremental borrowing rate based on the information available at commencement date. As of March&#160;31, 2023, the operating lease liabilities reflect a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMTM3MA_83ff4887-3cb7-4f39-b160-e51ca1189060">7.89</ix:nonFraction>%.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="cmrx:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMjc0MQ_ea9f7e81-fe03-47a8-97e4-fed100f2166a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the operating lease right-of-use assets and liabilities as of March&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:76.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfMS0xLTEtMS01NzY3OA_38f95e61-5763-4dde-aba6-9a50e697d103">1,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfNC0wLTEtMS01NzY3OA_f81a58fa-8b97-4a63-b960-98a6f8393ce5">Operating lease short-term liabilities (recorded within Accrued liabilities)</span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfNC0xLTEtMS01NzY3OA_f785a113-b525-4212-82c2-f16b1cd7286d">590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease long-term liabilities (recorded within Lease-related obligations)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfNS0xLTEtMS01NzY3OA_d40ba0f7-fb11-4e57-979d-c3ef2054414f">1,666</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfNi0xLTEtMS01NzY3OA_b2ddeade-349d-483b-bf5e-221c365f5a6d">2,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMjc0Nw_675f4087-fccc-40c7-98a5-8e9e7c19d202" continuedAt="i551cce7eddf74f92abd422059dcde42e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease payments over the remainder of the lease terms are as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023 </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjQ3NGE3MmY1ZDMzMDQwM2I4MTYwNzVmMTgxMmFkM2I1L3RhYmxlcmFuZ2U6NDc0YTcyZjVkMzMwNDAzYjgxNjA3NWYxODEyYWQzYjVfMy0xLTEtMS01NzY3OA_ae3b58f5-0658-4495-b243-67d0e692379d">555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjQ3NGE3MmY1ZDMzMDQwM2I4MTYwNzVmMTgxMmFkM2I1L3RhYmxlcmFuZ2U6NDc0YTcyZjVkMzMwNDAzYjgxNjA3NWYxODEyYWQzYjVfNC0xLTEtMS01NzY3OA_5cc42d0b-ef47-4878-857b-7796999d0bdb">759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjQ3NGE3MmY1ZDMzMDQwM2I4MTYwNzVmMTgxMmFkM2I1L3RhYmxlcmFuZ2U6NDc0YTcyZjVkMzMwNDAzYjgxNjA3NWYxODEyYWQzYjVfNS0xLTEtMS01NzY3OA_a21dd1f8-9493-4346-be15-1c67fde8f288">781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjQ3NGE3MmY1ZDMzMDQwM2I4MTYwNzVmMTgxMmFkM2I1L3RhYmxlcmFuZ2U6NDc0YTcyZjVkMzMwNDAzYjgxNjA3NWYxODEyYWQzYjVfNi0xLTEtMS01NzY3OA_a2841872-fed9-4e11-8848-bc2bb7b2e4a9">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum rental payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjQ3NGE3MmY1ZDMzMDQwM2I4MTYwNzVmMTgxMmFkM2I1L3RhYmxlcmFuZ2U6NDc0YTcyZjVkMzMwNDAzYjgxNjA3NWYxODEyYWQzYjVfNy0xLTEtMS01NzY3OA_6c3ecce9-a39f-4843-b1a5-f9e4d9f2a55a">2,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjQ3NGE3MmY1ZDMzMDQwM2I4MTYwNzVmMTgxMmFkM2I1L3RhYmxlcmFuZ2U6NDc0YTcyZjVkMzMwNDAzYjgxNjA3NWYxODEyYWQzYjVfOC0xLTEtMS01NzY3OA_325751e6-2f34-44a0-abf0-c0434ee22b7c">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjQ3NGE3MmY1ZDMzMDQwM2I4MTYwNzVmMTgxMmFkM2I1L3RhYmxlcmFuZ2U6NDc0YTcyZjVkMzMwNDAzYjgxNjA3NWYxODEyYWQzYjVfOS0xLTEtMS01NzY3OA_f1c33146-4fa2-4d77-80c0-c3e37506159c">2,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7bd598df2e744808bae88a9434e4e3dc"><ix:continuation id="i551cce7eddf74f92abd422059dcde42e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, operating lease payments over the remainder of the lease terms were as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOmRlMTFjMjc4MzE2NzQwYjc5NTEzNWUyMjU3MWU1NzA0L3RhYmxlcmFuZ2U6ZGUxMWMyNzgzMTY3NDBiNzk1MTM1ZTIyNTcxZTU3MDRfNC0xLTEtMS01NzY3OA_ed4af7b7-b25c-4df7-a679-c77686849611">736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOmRlMTFjMjc4MzE2NzQwYjc5NTEzNWUyMjU3MWU1NzA0L3RhYmxlcmFuZ2U6ZGUxMWMyNzgzMTY3NDBiNzk1MTM1ZTIyNTcxZTU3MDRfNS0xLTEtMS01NzY3OA_57bd1e11-c96d-4d9c-ad3e-6c5d84de3ee4">759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOmRlMTFjMjc4MzE2NzQwYjc5NTEzNWUyMjU3MWU1NzA0L3RhYmxlcmFuZ2U6ZGUxMWMyNzgzMTY3NDBiNzk1MTM1ZTIyNTcxZTU3MDRfNi0xLTEtMS01NzY3OA_c7a56233-3c76-4d0b-95c9-f1579ed7a021">781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOmRlMTFjMjc4MzE2NzQwYjc5NTEzNWUyMjU3MWU1NzA0L3RhYmxlcmFuZ2U6ZGUxMWMyNzgzMTY3NDBiNzk1MTM1ZTIyNTcxZTU3MDRfNy0xLTEtMS01NzY3OA_5b17457e-bbdd-4cc1-b551-8c7e63f8afb6">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum rental payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOmRlMTFjMjc4MzE2NzQwYjc5NTEzNWUyMjU3MWU1NzA0L3RhYmxlcmFuZ2U6ZGUxMWMyNzgzMTY3NDBiNzk1MTM1ZTIyNTcxZTU3MDRfOC0xLTEtMS01NzY3OA_784120c3-ea93-4735-a11c-6bd2d0bbd259">2,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOmRlMTFjMjc4MzE2NzQwYjc5NTEzNWUyMjU3MWU1NzA0L3RhYmxlcmFuZ2U6ZGUxMWMyNzgzMTY3NDBiNzk1MTM1ZTIyNTcxZTU3MDRfOS0xLTEtMS01NzY3OA_fc91029a-044a-4792-9aff-db597c58ab01">351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOmRlMTFjMjc4MzE2NzQwYjc5NTEzNWUyMjU3MWU1NzA0L3RhYmxlcmFuZ2U6ZGUxMWMyNzgzMTY3NDBiNzk1MTM1ZTIyNTcxZTU3MDRfMTAtMS0xLTEtNTc2Nzg_d09ccd7a-eed5-46f4-b64e-9fe4f7970bd2">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, the Company made lease payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMTc2Ng_893df94c-821b-4c96-8e37-5747f716a61d">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMTc3Mw_5b9f3bba-684c-4c6d-9e0b-0f193905523f">0.1</ix:nonFraction> million, respectively.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significance of Revenue Source</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company was the recipient of federal research contract funds from BARDA, the primary source of the Company&#8217;s prior year contract and grant revenue. Periodic audits are required in connection with the Company&#8217;s receipt of such funds and certain costs may be questioned as appropriate by BARDA. Accordingly, at March&#160;31, 2023 and December&#160;31, 2022, the Company had recorded a provision for potential refundable amounts of $<ix:nonFraction unitRef="usd" contextRef="i9517f9ec839e440d95427249384ef67c_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMjczNw_3e8ac386-8c98-4503-b41a-b9e69b4c4a03"><ix:nonFraction unitRef="usd" contextRef="i342138d95ca84510be429a8206bf6d91_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMjczNw_50b8af11-d282-4da4-8be5-2fb7ccd68152">52,000</ix:nonFraction></ix:nonFraction>.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4446784166784bc6ab6a1471468846ff_40"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTU0NA_7702ccc4-6805-4f38-97e1-fa8cea8c0b94" continuedAt="idedda911cd1140e0ba917bd342b51a96" escape="true">Equity Transactions and Share-based Compensation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="idedda911cd1140e0ba917bd342b51a96" continuedAt="i9cbe79e4814542cfb6e66513dde8801e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-The-Market Equity Offering; Shelf Registration Statement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 10, 2020, we entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (the Jefferies Sales Agreement) with Jefferies LLC, as agent, pursuant to which we may offer and sell, from time to time through Jefferies, up to $<ix:nonFraction unitRef="usd" contextRef="iaf6d919a74434c88a93c3c9563ebfc77_I20200810" decimals="INF" name="cmrx:SalesOfStockAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTQ5NzU1ODIyOTQ0_9997aa8c-ab0f-4e5c-a564-bbc27af1c993">75</ix:nonFraction>&#160;million of shares of our common stock. As of March&#160;31, 2023, we have not sold any shares of our common stock under the Jefferies Sales Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 6, 2021, we filed an automatic shelf registration statement on Form S-3 with the SEC, which was subsequently amended in March 2022 to convert to a non-automatic shelf registration statement. This registration statement enables us to offer for sale, from time to time, in one or more offerings, up to $<ix:nonFraction unitRef="usd" contextRef="i8d40a540d19e49cd84414a5e1c507455_I20220331" decimals="INF" name="cmrx:SalesOfStockAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTQ5NzU1ODIyOTg1_bc978497-19b2-4e83-abfe-a08577116e04">250</ix:nonFraction>&#160;million in the aggregate, of common stock, debt securities, warrants, rights and/or units, and will remain in effect for up to <ix:nonNumeric contextRef="i8d40a540d19e49cd84414a5e1c507455_I20220331" name="cmrx:SalesOfStockAuthorizationTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTQ5NzU1ODIyOTk5_13b9aff3-5214-495b-ba9e-beb3be3ccb6a">three years</ix:nonNumeric> from the date it became effective.  As of March&#160;31, 2023, no sales have been made under the shelf registration statement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2013 Equity Incentive Plan (the 2013 Plan), which provides for the grant of incentive stock options (ISOs), non-statutory stock options (NSOs), stock appreciation rights, restricted stock awards, restricted stock unit (RSU) awards, performance-based stock awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to employees, including officers, non-employee directors and consultants of the Company and its affiliates. Additionally, the 2013 Plan provides for the grant of performance cash awards. The number of shares of common stock reserved for future issuance automatically increased on January 1, 2023, by <ix:nonFraction unitRef="number" contextRef="i2c9f154273194565a27c741f7878e0e3_D20230101-20230101" decimals="INF" name="cmrx:ShareBasedCompensationOptionProvisionEquityIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMTg4MQ_da7ae116-22e0-4f84-930a-a355aad82c35">4</ix:nonFraction>% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or <ix:nonFraction unitRef="shares" contextRef="i2c9f154273194565a27c741f7878e0e3_D20230101-20230101" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMjE3NQ_79415908-e189-4af6-a7e4-3a8307bf09d2">3.5</ix:nonFraction> million shares.&#160;As of March&#160;31, 2023, there was a total of <ix:nonFraction unitRef="shares" contextRef="i431035fe4c0e4c04baad526438084c5b_I20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMjIxNw_a195d934-839d-49e8-b705-8b16c9a418e4">3.0</ix:nonFraction> million shares reserved for future issuance under the 2013 Plan. The Company issued <ix:nonFraction unitRef="shares" contextRef="if122bfed225d4e6b9ea7dabd81e702ef_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMjMxMA_1c036c75-fde8-4340-b2b6-67205d75b05a">no</ix:nonFraction> shares of common stock pursuant to the exercise of stock options during the three months ended March&#160;31, 2023. The Company issued approximately <ix:nonFraction unitRef="shares" contextRef="i9a68a6a0ea9447b09e9381db440aee36_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMjQ1MA_afbef2e5-8f78-47ce-af23-65abc6767ed9">34,000</ix:nonFraction> shares of common stock pursuant to the exercise of stock options during the three months ended March&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2013 Employee Stock Purchase Plan (ESPP), which provides for the issuance of shares of common stock pursuant to purchase rights granted to the Company&#8217;s employees or to employees of any of its designated affiliates. The Company has reserved a total of <ix:nonFraction unitRef="shares" contextRef="ie0396b8eb64340e7b468fbedd1556a7c_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMjg3Nw_0ba98bd2-e994-4485-8e43-bb1bbc5b8e07">4.8</ix:nonFraction> million shares of common stock to be purchased under the ESPP, of which <ix:nonFraction unitRef="shares" contextRef="ie0396b8eb64340e7b468fbedd1556a7c_I20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMjk0NA_f6cc2d43-c389-42cf-a775-52d7ae16ad30">2.3</ix:nonFraction> million shares remained available for purchase as of March&#160;31, 2023. The number of shares of common stock reserved for issuance automatically increased on January 1, 2023, by an additional <ix:nonFraction unitRef="shares" contextRef="i11ef95703d59450f84bcac3c8c1fe127_D20230101-20230101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMzQ5NA_0823b5d1-31ea-49d1-b514-6c62b18c0b70">422,535</ix:nonFraction> shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP provides for an automatic reset feature to start participants on a new <ix:nonNumeric contextRef="idff0b85443fb4b408cf3cd0b099f45c4_D20230101-20230331" name="cmrx:SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTU0NQ_0eeba2b5-3e9f-4877-a9c9-aee2e7768f2b">twenty-four month</ix:nonNumeric> participation period in the event that the common stock market value on a purchase date is less than the common stock value on the first day of the <ix:nonNumeric contextRef="idff0b85443fb4b408cf3cd0b099f45c4_D20230101-20230331" name="cmrx:SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTU0OQ_c4e2c6bc-4a3e-4d5a-af2e-02ce897e9f47">twenty-four month</ix:nonNumeric> offering period. Eligible employees may authorize an amount up to <ix:nonFraction unitRef="number" contextRef="ie0396b8eb64340e7b468fbedd1556a7c_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMzgxOA_9ea37612-8011-47c9-90d2-f59ca8a72573">15</ix:nonFraction>% of their salary to purchase common </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9cbe79e4814542cfb6e66513dde8801e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock at the lower of a <ix:nonFraction unitRef="number" contextRef="idff0b85443fb4b408cf3cd0b099f45c4_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMzg4MA_e1074eb6-affc-4703-b3ea-a067d610879b">15</ix:nonFraction>% discount to the beginning price of their offering period or a <ix:nonFraction unitRef="number" contextRef="idff0b85443fb4b408cf3cd0b099f45c4_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMzk0NQ_a52bdb41-0c5a-4ec9-ac69-48ca721fa00c">15</ix:nonFraction>% discount to the ending price of each <ix:nonNumeric contextRef="idff0b85443fb4b408cf3cd0b099f45c4_D20230101-20230331" name="cmrx:SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTU0Mg_a6c3fd19-899b-47ca-9976-00cc2cfa12cd">six-month</ix:nonNumeric> purchase interval. The Company issued approximately <ix:nonFraction unitRef="shares" contextRef="idff0b85443fb4b408cf3cd0b099f45c4_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNDA0Ng_2f9af444-9a93-40e3-ba51-14ce0b9e5f9d">308,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6085f06cabc84a509e0e944fb745eeb7_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNDA1Mw_ddd340a9-ab45-4862-93a8-e25e76361308">384,000</ix:nonFraction> shares of common stock pursuant to the ESPP during the three months ended March&#160;31, 2023 and 2022, respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#8220;look-back&#8221; option and were determined using a Black-Scholes option pricing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has issued RSUs to certain employees which vest based on service criteria. When vested, the RSU represents the right to be issued the number of shares of the Company&#8217;s common stock that is equal to the number of RSUs granted. The grant date fair value for RSUs is based upon the market price of the Company&#8217;s common stock on the date of the grant. The fair value is then amortized to compensation expense over the requisite service period or vesting term. The Company issued approximately <ix:nonFraction unitRef="shares" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNDk4OQ_8b79cbdd-f697-449b-bfa7-eb7ce000036b">221,000</ix:nonFraction> shares of common stock pursuant to the vesting of RSUs during the three months ended March&#160;31, 2023. The Company issued approximately <ix:nonFraction unitRef="shares" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTExOA_e79de932-3e0e-4f97-b459-7fde68f630ca">134,000</ix:nonFraction> shares of common stock pursuant to the vesting of RSUs during the three months ended March&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For awards with only service conditions and graded-vesting features, the Company recognizes compensation expense on a straight-line basis over the requisite service period. <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTU1MQ_13a96418-243d-4ede-9495-abb312eb5687" continuedAt="i1ac4e76d20d24605b1f8231e79463d38" escape="true">Total share-based compensation expense recognized related to stock options, the ESPP and RSUs was as follows (in thousands): </ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i1ac4e76d20d24605b1f8231e79463d38"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524f8a9b49ff48159693771c90e88f29_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RhYmxlOjBkM2M2NGYwMzdiNTRhZmM5MDU4ZDJiYzIwMmFkNzk5L3RhYmxlcmFuZ2U6MGQzYzY0ZjAzN2I1NGFmYzkwNThkMmJjMjAyYWQ3OTlfMi0yLTEtMS01NzY3OA_5b678f48-5f17-485c-a472-0bef1addc181">2,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib125a1468b8f4d2e8c10c699c34bc410_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RhYmxlOjBkM2M2NGYwMzdiNTRhZmM5MDU4ZDJiYzIwMmFkNzk5L3RhYmxlcmFuZ2U6MGQzYzY0ZjAzN2I1NGFmYzkwNThkMmJjMjAyYWQ3OTlfMi00LTEtMS01NzY3OA_b7df57f7-f2c3-4446-bdc3-398edf6c8b38">1,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic212316462214f758bddf2408b982c40_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RhYmxlOjBkM2M2NGYwMzdiNTRhZmM5MDU4ZDJiYzIwMmFkNzk5L3RhYmxlcmFuZ2U6MGQzYzY0ZjAzN2I1NGFmYzkwNThkMmJjMjAyYWQ3OTlfMy0yLTEtMS01NzY3OA_bbc51c6b-c54d-4c0d-90c2-3e5a63f064ad">2,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707d882d90674ded914e0c24595f4781_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RhYmxlOjBkM2M2NGYwMzdiNTRhZmM5MDU4ZDJiYzIwMmFkNzk5L3RhYmxlcmFuZ2U6MGQzYzY0ZjAzN2I1NGFmYzkwNThkMmJjMjAyYWQ3OTlfMy00LTEtMS01NzY3OA_7f66c5aa-5af2-4987-88e4-e2afc292dabe">1,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RhYmxlOjBkM2M2NGYwMzdiNTRhZmM5MDU4ZDJiYzIwMmFkNzk5L3RhYmxlcmFuZ2U6MGQzYzY0ZjAzN2I1NGFmYzkwNThkMmJjMjAyYWQ3OTlfNC0yLTEtMS01NzY3OA_3618a2bc-22b1-4813-886d-6c73aaec3e73">4,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RhYmxlOjBkM2M2NGYwMzdiNTRhZmM5MDU4ZDJiYzIwMmFkNzk5L3RhYmxlcmFuZ2U6MGQzYzY0ZjAzN2I1NGFmYzkwNThkMmJjMjAyYWQ3OTlfNC00LTEtMS01NzY3OA_5eb60e79-0b23-4bb5-94bd-173ee50db503">3,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2022, the Company announced a reduction in workforce. As a result, certain vested stock options were modified to extend their exercise period from 90 days to 12 months.  In addition, certain outstanding stock option and RSU grants received accelerated vesting as if the service period of the terminated employee continued for up to an additional 12-month period. The Company recorded expense ratably from the announcement date through the date of termination with approximately $<ix:nonFraction unitRef="usd" contextRef="ic0ee769ecce64f21994ca9ced836dbaa_D20220101-20221231" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTQ5NzU1ODIzMDgx_92573291-588b-4008-832e-51fa95ef0cf0">0.4</ix:nonFraction>&#160;million being recognized during the twelve months ended December 31, 2022 and an additional $<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTQ5NzU1ODIzMDU0_09b67277-9355-4fb9-b53d-06bac1fe6cc5">0.6</ix:nonFraction>&#160;million being recognized during the three months ended March&#160;31, 2023.</span></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2023, the Company extended the post-termination exercise period from 90 days to three years for stock option grants made to non-employee members of our Board of Directors. This extension applies to all future grants as well as all then-outstanding grants. Related to this extension, the Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="iada28bd88d134a9886cbbb069ddd2f51_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTQ5NzU1ODI1Nzg1_56bf6bc3-554d-4946-85c7-9f01aa1827b3">0.3</ix:nonFraction>&#160;million of expense during the three months ended March 31, 2023.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4446784166784bc6ab6a1471468846ff_43"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80My9mcmFnOjg1OGU5YTk3NzAzNDRmNjQ5ODQwYTQ1MzkwMmU4ZWViL3RleHRyZWdpb246ODU4ZTlhOTc3MDM0NGY2NDk4NDBhNDUzOTAyZThlZWJfMjEzNA_78418c5e-1424-4d4b-8c58-661bcdec3c6b" continuedAt="if0fe1c0c80d64deba833b09b3091e396" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="if0fe1c0c80d64deba833b09b3091e396"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company estimates an annual effective tax rate of <ix:nonFraction unitRef="number" contextRef="i6e1bad3a6f1a46cc92694fa22413949c_D20230101-20231231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80My9mcmFnOjg1OGU5YTk3NzAzNDRmNjQ5ODQwYTQ1MzkwMmU4ZWViL3RleHRyZWdpb246ODU4ZTlhOTc3MDM0NGY2NDk4NDBhNDUzOTAyZThlZWJfMzU3_7a7eccf7-98dc-48e8-8ed8-7fa47398585b">0.0</ix:nonFraction>% for the year ending December&#160;31, 2023 as the Company incurred losses for the three month period ended March&#160;31, 2023 and is forecasting an estimated net loss for both financial statement and tax purposes for the year ending December&#160;31, 2023. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method in accordance with FASB ASC 740. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Due to the Company's history of cumulative losses since inception, there is not enough evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a full valuation allowance, since the Company cannot currently support that realization of its deferred tax assets is more likely than not. However, the Company feels its deferred tax assets may be used upon the Company becoming profitable. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the Company had <ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80My9mcmFnOjg1OGU5YTk3NzAzNDRmNjQ5ODQwYTQ1MzkwMmU4ZWViL3RleHRyZWdpb246ODU4ZTlhOTc3MDM0NGY2NDk4NDBhNDUzOTAyZThlZWJfMjAzNw_f32e30aa-f86f-4598-8999-4e47a6530dee">no</ix:nonFraction> unrecognized tax benefits that would reduce the Company&#8217;s effective tax rate if recognized.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i4446784166784bc6ab6a1471468846ff_46"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:LongTermContractsOrProgramsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTAyMTg_87225ac3-3d8a-41b7-bbb1-79f243652256" continuedAt="i5f97d5d3944c42339567f5ace7e2ca4d" escape="true">Significant Agreements </ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><ix:continuation id="i5f97d5d3944c42339567f5ace7e2ca4d" continuedAt="i76e747400cbc4ffcb86009ced6e2618c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BARDA 2022 Procurement and Development Contract</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 26, 2022, the Company entered into a procurement contract, as amended, (the BARDA Agreement) with BARDA for the delivery of up to <ix:nonFraction unitRef="treatment" contextRef="i87dd3af02ad441ce9c3886a519178bc9_I20220826" decimals="INF" name="cmrx:QuantityBenchmarkTreatmentContractualCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMjE5OTAyMzI3MzgxNw_df780295-b3e7-48ba-85d1-6b71779d57e6">1.7</ix:nonFraction>&#160;million treatment courses of tablet and suspension formulations of TEMBEXA&#174; to the U.S. government over a possible <ix:nonNumeric contextRef="i0d079805c3384255aaa8160de0eddece_D20220826-20220826" name="cmrx:SignificantAgreementsContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMjE5OTAyMzI3NzA1MA_55acb061-90a8-4d1e-9551-c12cf8e91c96">10-year</ix:nonNumeric> period. The BARDA Agreement consists of a <ix:nonNumeric contextRef="i4c153c1c04674d08b3b67fbf5f6520f6_D20220826-20220826" name="cmrx:BasePerformanceContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTAyMTk_79854ce8-2008-4814-9cc5-b1268cd66c0d">five-year</ix:nonNumeric> base period of performance and a total contract period of performance (base period plus option exercises) of up to <ix:nonNumeric contextRef="i0d079805c3384255aaa8160de0eddece_D20220826-20220826" name="cmrx:SignificantAgreementsContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNDgx_33a71cc2-64d5-4c60-8341-7e3fb433956c">ten years</ix:nonNumeric> (if necessary). Under the terms of the BARDA Agreement, the base period activities are valued at approximately $<ix:nonFraction unitRef="usd" contextRef="ia0c3ebb768e14ba1adac8fecc4608694_I20220826" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTk1_b6b4b680-cced-49a6-bdd9-f0884f3fe090">127</ix:nonFraction>&#160;million, consisting of an initial shipment of <ix:nonFraction unitRef="treatment" contextRef="ia0c3ebb768e14ba1adac8fecc4608694_I20220826" decimals="INF" name="cmrx:QuantityBenchmarkTreatmentContractualCommitment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNjM2_9f1c977e-1337-4b12-9087-50e502295371">319,000</ix:nonFraction> treatment courses of TEMBEXA to be procured and shipped to the Strategic National Stockpile for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="ibb56f621902543d18de68b58f4527963_I20220826" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNzgw_60b07c6f-f364-4162-9861-abed063189b3">115</ix:nonFraction>&#160;million, and reimbursement for certain post-marketing activities of approximately $<ix:nonFraction unitRef="usd" contextRef="ie2bf6b11e1724d84ba0bcc3f1428cc8e_I20220826" decimals="-6" name="cmrx:ReimbursableMarketingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfODU3_8bdea63f-b102-4cf6-8533-2ed1f8e37ec2">12</ix:nonFraction>&#160;million. The options under the BARDA Agreement, which are exercised at the sole discretion of BARDA, are valued at approximately $<ix:nonFraction unitRef="usd" contextRef="i1dda99b1defa4528b1254af85ee9ca46_I20220826" decimals="-6" name="cmrx:OptionToPurchaseAdditionalTreatmentCoursesGrossValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfOTgx_7cf76e90-9cd1-47cc-b731-bfe1f6ae5577">553</ix:nonFraction>&#160;million (if all such options are exercised during the <ix:nonNumeric contextRef="i0d079805c3384255aaa8160de0eddece_D20220826-20220826" name="cmrx:SignificantAgreementsContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTAyMjA_f0e51307-bbd0-407a-8759-f04f4f2c6bee">10-year</ix:nonNumeric> contract period), which consists of options to purchase up to an additional <ix:nonFraction unitRef="treatment" contextRef="i1dda99b1defa4528b1254af85ee9ca46_I20220826" decimals="INF" name="cmrx:OptionToPurchaseAdditionalTreatmentCourses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTExNA_570d0040-d90a-4927-8918-839cd641d972">1.381</ix:nonFraction>&#160;million treatment courses of TEMBEXA for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="i1dda99b1defa4528b1254af85ee9ca46_I20220826" decimals="-6" name="cmrx:OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTE5NQ_ba442ea5-8115-42aa-966e-e4ab46a7e071">551</ix:nonFraction>&#160;million and funding for certain post-marketing activities of approximately $<ix:nonFraction unitRef="usd" contextRef="i1dda99b1defa4528b1254af85ee9ca46_I20220826" decimals="-6" name="cmrx:ReimbursableMarketingCostUponTheExerciseOfOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTI2NQ_62c16c24-3908-4000-9629-a9a304fd03b8">2</ix:nonFraction>&#160;million. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the sale of the TEMBEXA franchise to Emergent, the BARDA Agreement was novated to Emergent in December 2022. In accordance with federal regulations, the terms of the novation agreement require that the Company guarantee the performance of all obligations transferred to Emergent should Emergent not have the ability to deliver on the terms of the BARDA Agreement. In this instance, BARDA may request that we perform the obligations in place of Emergent. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emergent BioSolutions, Inc. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 26, 2022, the Company completed the Asset Sale to Emergent of the Company&#8217;s exclusive worldwide rights to brincidofovir, including TEMBEXA&#174; and specified related assets (the Asset Sale). Emergent paid the Company an upfront cash payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i39fee762c2014475826a3d701b15814d_D20220926-20220926" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMjQzNw_178be9b4-c0db-4556-8e50-1b25f63e3f6d">238</ix:nonFraction>&#160;million upon the closing of the Asset Sale. In addition, pursuant to the Asset Purchase Agreement, the Company is eligible to receive from Emergent: (i) up to an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="ide975e55e26c4a95b067825a19f1af74_I20220926" decimals="-6" name="cmrx:MaximumMilestoneProceedsUponTheExerciseOfOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMjYyMQ_1b37bd57-2d9b-49ac-a603-593b573391eb">124</ix:nonFraction>&#160;million in milestone payments payable upon the exercise of the options under the BARDA Agreement for the delivery of up to <ix:nonFraction unitRef="treatment" contextRef="i4febe75fb14447a39e9fe6f7451fff6c_I20220926" decimals="INF" name="cmrx:QuantityBenchmarkGrossProfitRoyaltyRateTrigger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMjczOQ_2a24fcc4-38bf-44ed-b038-31daded07536">1.7</ix:nonFraction>&#160;million treatment courses of tablet and suspension formulations of TEMBEXA to the U.S. government; (ii) royalty payments equal to <ix:nonFraction unitRef="number" contextRef="i49c5bcc0f6e3428b874169048e2386a2_I20220926" decimals="INF" name="cmrx:RevenueBenchmarkGrossProfitRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMjg2NA_0f8753af-5a90-49cf-a07c-af63714ec8a3">15</ix:nonFraction>% of the gross profits from the sales of TEMBEXA made outside of the United States; (iii) royalty payments equal to <ix:nonFraction unitRef="number" contextRef="ibef35d312f6649c48ca5770e34d07f53_I20220926" decimals="INF" name="cmrx:RevenueBenchmarkGrossProfitRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMjk4MQ_9c0b92e3-8e1b-4c1e-9da9-e13ffb74ca86">20</ix:nonFraction>% of the gross profits from the sales of TEMBEXA made in the United States in excess of <ix:nonFraction unitRef="treatment" contextRef="i4febe75fb14447a39e9fe6f7451fff6c_I20220926" decimals="INF" name="cmrx:QuantityBenchmarkGrossProfitRoyaltyRateTrigger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMzA3MA_2a24fcc4-38bf-44ed-b038-31daded07536">1.7</ix:nonFraction>&#160;million treatment courses; and (iv) up to an additional $<ix:nonFraction unitRef="usd" contextRef="i5668b209a8cf48ffac44b53d2385eeb5_I20220926" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMzEyMQ_39fae769-cbab-424d-9938-d21126adb426">12.5</ix:nonFraction>&#160;million upon the achievement of certain other developmental milestones. The effects of recording certain adjustments associated with contingent consideration related to TEMBEXA have been excluded as the Company has made a policy election to account for these amounts when the contingency has been resolved in accordance with Accounting Standards Codification 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The period under which the Company was contracted to provide the majority of operational support services to Emergent in furtherance of its obligations under the Asset Purchase Agreement and the BARDA Agreement concluded on March 26, 2023, except for certain services which the parties agreed would continue until the occurrence of a specific event, or in some cases a predetermined end date. The BARDA Agreement was novated to Emergent in December 2022. Under the Asset Purchase Agreement, the Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i8ae67a95e48a4514b6b62802563f5af0_D20230101-20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTQ5NzU1ODI2ODc0_ebb9eea9-11e7-4e64-bb4c-68b8f3b10fa7">0.2</ix:nonFraction>&#160;million of contract revenue for support provided for the three months ended March&#160;31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The sale of TEMBEXA constitutes a significant disposition of a business, however, the Company determined the disposition did not represent a strategic shift, and accordingly, the Company did not account for the disposition as a discontinued operation. The Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i069e85b680a44fffa3ee317f7da6fae3_D20220701-20220930" decimals="-5" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNDE5Ng_6a795932-1fa1-488b-ba67-1167117a2db9">229.7</ix:nonFraction>&#160;million net gain on sale of business in other income (loss) on the Consolidated Statement of Operations and Comprehensive Income (Loss) in the third quarter of 2022.  <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="cmrx:ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTAyMjM_b733a095-5184-416c-9817-1620d59f02a6" continuedAt="i6badc1fb9c114cde888b7887d9867ccd" escape="true">The net gain consists of the following assets and liabilities transferred in accordance with the Asset Purchase Agreement (in thousands):</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><ix:continuation id="i6badc1fb9c114cde888b7887d9867ccd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.678%"><tr><td style="width:1.0%"></td><td style="width:54.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front cash payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RhYmxlOjliNzljNjMyOTEzYTRjMjA4ZDhkMDYzMWQzMWM2MTliL3RhYmxlcmFuZ2U6OWI3OWM2MzI5MTNhNGMyMDhkOGQwNjMxZDMxYzYxOWJfMS0xLTEtMS01NzY3OA_265fe916-afb0-48dd-a488-f1b489dce785">237,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed by Emergent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926" decimals="-3" name="cmrx:AssetSaleLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RhYmxlOjliNzljNjMyOTEzYTRjMjA4ZDhkMDYzMWQzMWM2MTliL3RhYmxlcmFuZ2U6OWI3OWM2MzI5MTNhNGMyMDhkOGQwNjMxZDMxYzYxOWJfMi0xLTEtMS01NzY3OA_078f016c-085d-4e8f-8cdf-a2c8034572f3">1,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory transferred to Emergent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926" decimals="-3" name="cmrx:AssetSaleInventoryTransferred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RhYmxlOjliNzljNjMyOTEzYTRjMjA4ZDhkMDYzMWQzMWM2MTliL3RhYmxlcmFuZ2U6OWI3OWM2MzI5MTNhNGMyMDhkOGQwNjMxZDMxYzYxOWJfMy0xLTEtMS01NzY3OA_d0b1d1e4-c362-4eb0-b075-735b59e51dd9">5,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids transferred to Emergent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926" decimals="-3" name="cmrx:AssetSalePrepaidsTransferred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RhYmxlOjliNzljNjMyOTEzYTRjMjA4ZDhkMDYzMWQzMWM2MTliL3RhYmxlcmFuZ2U6OWI3OWM2MzI5MTNhNGMyMDhkOGQwNjMxZDMxYzYxOWJfNC0xLTEtMS01NzY3OA_6a59508a-4c79-419b-bf89-f6656e9927ec">511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs incurred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926" decimals="-3" name="cmrx:TransactionCostsIncurredInRelationToSales" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RhYmxlOjliNzljNjMyOTEzYTRjMjA4ZDhkMDYzMWQzMWM2MTliL3RhYmxlcmFuZ2U6OWI3OWM2MzI5MTNhNGMyMDhkOGQwNjMxZDMxYzYxOWJfNS0xLTEtMS01NzY3OA_84521ea7-e095-4dd3-b536-4800af79c74d">4,002</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net gain</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926" decimals="-3" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RhYmxlOjliNzljNjMyOTEzYTRjMjA4ZDhkMDYzMWQzMWM2MTliL3RhYmxlcmFuZ2U6OWI3OWM2MzI5MTNhNGMyMDhkOGQwNjMxZDMxYzYxOWJfNi0xLTEtMS01NzY3OA_5532dae4-a56b-40a8-80f8-abd69d4be52f">229,670</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i76e747400cbc4ffcb86009ced6e2618c" continuedAt="i3d119fce705740e98310bd808a0be370"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TEMBEXA Procurement Agreements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, the Company entered into a Supply Agreement (the Supply Agreement) with a third-party outside of North America (the Purchaser), pursuant to which the Company was responsible for supplying to the Purchaser, and the Purchaser was responsible for purchasing from the Company, TEMBEXA treatment courses for use in a jurisdiction outside of the United States. Under the terms of the Supply Agreement, the Purchaser paid the Company an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="i4dc7c0b07dc840118483ece5d0ba3401_I20220731" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTAxOA_2e3081ab-6b31-4ebf-8807-7668d35725ff"><ix:nonFraction unitRef="usd" contextRef="ib85fa50450aa424aafb519800af6ba59_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTAxOA_8116ada2-f126-4a6c-bc74-0b6d64f6383c">9.3</ix:nonFraction></ix:nonFraction>&#160;million, in <ix:nonFraction unitRef="installment" contextRef="ib699e30492f44e8a804263792c19142f_D20220623-20220623" decimals="INF" name="cmrx:ContractWithCustomerLiabilityInstallmentPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTAyNQ_0bd07682-4fdd-4618-9943-2334279e82a5">two</ix:nonFraction> equal installments in June and July 2022. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i6a47e7a6ffe740b1ab49e33529826b16_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTM4Ng_e68dac71-c8da-4da0-b52a-a8f3dc16c673">9.3</ix:nonFraction>&#160;million of procurement revenue under the Supply Agreement for the three months ended September 30, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, in June 2022, the Public Health Agency of Canada (PHAC) awarded a Contract (PHAC Contract) to the Company, pursuant to which PHAC agreed to purchase up to approximately USD $<ix:nonFraction unitRef="usd" contextRef="i041e87dc76b7486fad7182d5c433de1d_I20220623" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTQ4Mjk_3b10f764-4f89-4990-abea-530d6419713c">25.3</ix:nonFraction>&#160;million (CAD $<ix:nonFraction unitRef="cad" contextRef="i041e87dc76b7486fad7182d5c433de1d_I20220623" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTYyOQ_9318c93f-3e4a-4eb7-993a-7d9344122472">33.0</ix:nonFraction>&#160;million) of TEMBEXA treatment courses for use in Canada. Substantially all of the procurement was delivered and accepted by PHAC in July 2022, completing the performance obligation for those shipments and resulting in $<ix:nonFraction unitRef="usd" contextRef="i7858fb7e8acd42509124fae89e255dca_D20220701-20220731" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTg0Ng_b30dd00a-0a0c-443f-8396-b4e16fa32e0d">22.6</ix:nonFraction>&#160;million of procurement revenue for the three months ended September 2022. Upon the assignment of the PHAC Contract to Emergent, which requires the consent of PHAC, if the remaining deliveries of treatment courses are made by Emergent, they will be subject to the royalty terms of the Asset Purchase Agreement applicable to gross profits outside the United States. PHAC assigned the PHAC Contract to Emergent in November 2022. The remaining deliveries of treatment courses were delivered by Emergent and are subject to the royalty terms of the Asset Purchase Agreement applicable to gross profits outside the United States. The Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i07e0fd7ae2114d36b0896130bfc39369_D20221001-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTQ5NzU1ODI5MjU2_52aaab60-26f2-4df0-a41a-174c7b725b02">0.4</ix:nonFraction>&#160;million of royalty revenue in the three months ended December 31, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ohara Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Oncoceutics, Inc., a Delaware corporation (Oncoceutics) which was subsequently acquired by the Company in January 2021, entered into a license, development and commercialization agreement with Ohara Pharmaceutical Co., Ltd. for ONC201 in Japan. The Company is entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="ica04db5e597f4a148bb1cd8f8e4c8b48_I20191231" decimals="-5" name="cmrx:LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfOTM3OQ_4eeeef8c-a7da-4a27-ad38-2262132efe0a">2.5</ix:nonFraction>&#160;million in nonrefundable regulatory milestone payments. The Company is entitled to double-digit tiered royalties based on the aggregate annual net sales of all products, as defined in the agreement, in Japan. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CR Sanjiu Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Oncoceutics entered into a license, development and commercialization agreement with China Resources Sanjiu Medical &amp; Pharmaceutical Co., Ltd. (CR Sanjiu). Oncoceutics granted CR Sanjiu an exclusive royalty bearing license to develop and commercialize ONC201 in China, Hong Kong, Macau and Taiwan (CR Sanjiu Territory). The Company is entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="i21532ae17c8540b2814f9047fab955e4_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfOTk4NQ_e6bcc3b8-7593-4a5f-9713-815b2c8cab17">5.0</ix:nonFraction>&#160;million in nonrefundable regulatory milestone payments. The Company is entitled to double-digit tiered royalties based on the aggregate annual net sales of all licensed products, as defined in the agreement, in the CR Sanjiu Territory. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4446784166784bc6ab6a1471468846ff_49"></div><ix:continuation id="i3d119fce705740e98310bd808a0be370" continuedAt="ia9e14a2c460c4b5da7ccad23dc972260"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. DSTAT Contract Close-out </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, the Company made the decision to discontinue the development of DSTAT for the treatment of AML. Effective July 12, 2022, the Company terminated the License and Development Agreement with Cantex. As a result, the Company recorded an accrual of expenses to close-out the DSTAT vendor contracts. As of March&#160;31, 2023, on the Consolidated Balance Sheets, the Company has recorded $<ix:nonFraction unitRef="usd" contextRef="if82f3e05482f40578ab012f41b08b052_I20230331" decimals="-5" name="cmrx:ContractCloseOutLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RleHRyZWdpb246YjM1MTZmMDdjYzFkNDY0Mzg3MGFlMmI3NTVlNTI2YTdfNDE3_7468de9a-97bf-4d29-99e0-41b5ee9aacd4">1.1</ix:nonFraction>&#160;million of contract close-out costs in accrued liabilities offset by a vendor credit of $<ix:nonFraction unitRef="usd" contextRef="i1bb99da3a7e24972a69174d9a86c03d0_I20230331" decimals="-5" name="cmrx:ContractCloseOutLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RleHRyZWdpb246YjM1MTZmMDdjYzFkNDY0Mzg3MGFlMmI3NTVlNTI2YTdfNDc1_ca3442c2-9fb8-4bc9-a585-912b853788a7">0.1</ix:nonFraction>&#160;million in accounts payable. These balances are expected to be fully paid over the first half of 2023.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="cmrx:ScheduleOfContractCloseOutCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RleHRyZWdpb246YjM1MTZmMDdjYzFkNDY0Mzg3MGFlMmI3NTVlNTI2YTdfMTIzNA_d2254281-0831-47bd-b277-492b41388668" continuedAt="i8ae454ed82464ed49a4d3e5f619a2e10" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contract close-out costs (in thousands) recorded in 2022:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.257%"><tr><td style="width:1.0%"></td><td style="width:49.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.304%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Close-out Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research &amp; development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6f299962fcf4e829643ecd56dc9183d_D20220101-20221231" decimals="-3" name="cmrx:ContractCloseOutCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjBiMWVjZjg1NjZmNjQ5YzE5MTM2NzU3MjhlZTg0OTk2L3RhYmxlcmFuZ2U6MGIxZWNmODU2NmY2NDljMTkxMzY3NTcyOGVlODQ5OTZfMS0xLTEtMS01NzY3OA_4e4220ff-11c9-469a-a451-5b7f6848493d">791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General &amp; administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5109aa96790c4d84b6c1982ac5f7ba63_D20220101-20221231" decimals="-3" name="cmrx:ContractCloseOutCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjBiMWVjZjg1NjZmNjQ5YzE5MTM2NzU3MjhlZTg0OTk2L3RhYmxlcmFuZ2U6MGIxZWNmODU2NmY2NDljMTkxMzY3NTcyOGVlODQ5OTZfMi0xLTEtMS01NzY3OA_e1248008-231d-4a43-a282-ca453a9124c0">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract close-out expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0ee769ecce64f21994ca9ced836dbaa_D20220101-20221231" decimals="-3" name="cmrx:ContractCloseOutCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjBiMWVjZjg1NjZmNjQ5YzE5MTM2NzU3MjhlZTg0OTk2L3RhYmxlcmFuZ2U6MGIxZWNmODU2NmY2NDljMTkxMzY3NTcyOGVlODQ5OTZfMy0xLTEtMS01NzY3OA_0ffb8e4e-4020-4a70-8daa-09ddfb9a1f90">799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia9e14a2c460c4b5da7ccad23dc972260" continuedAt="if071bfa321254ce6b0b5a29630854f78"><ix:continuation id="i8ae454ed82464ed49a4d3e5f619a2e10"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the accounts payable and accrual activity for contract close-out costs (in thousands) for 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"></td><td style="width:48.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Close-out Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7df4ccac55457db9fc511a4813ea18_I20220630" decimals="-3" name="cmrx:ContractCloseOutLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjQwZDdmYTk1YTdlNDQ4YjVhYjNhOGZkM2I2YzNkZWRmL3RhYmxlcmFuZ2U6NDBkN2ZhOTVhN2U0NDhiNWFiM2E4ZmQzYjZjM2RlZGZfMS0xLTEtMS01NzY3OA_3149cbcc-aa83-46c3-bed2-7263c338c253">4,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Revised estimates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80f398e930dd4c1195d38e4f087c0836_D20220701-20221231" decimals="-3" sign="-" name="cmrx:ContractCloseOutLiabilityAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjQwZDdmYTk1YTdlNDQ4YjVhYjNhOGZkM2I2YzNkZWRmL3RhYmxlcmFuZ2U6NDBkN2ZhOTVhN2U0NDhiNWFiM2E4ZmQzYjZjM2RlZGZfMi0xLTEtMS01NzY3OA_32f8365d-90fb-4c2c-9391-ca699cdaaa47">746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80f398e930dd4c1195d38e4f087c0836_D20220701-20221231" decimals="-3" name="cmrx:ContractCloseOutLiabilityPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjQwZDdmYTk1YTdlNDQ4YjVhYjNhOGZkM2I2YzNkZWRmL3RhYmxlcmFuZ2U6NDBkN2ZhOTVhN2U0NDhiNWFiM2E4ZmQzYjZjM2RlZGZfMy0xLTEtMS01NzY3OA_09c3ed18-8746-491a-93a9-91a5d583d02b">2,482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="cmrx:ContractCloseOutLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjQwZDdmYTk1YTdlNDQ4YjVhYjNhOGZkM2I2YzNkZWRmL3RhYmxlcmFuZ2U6NDBkN2ZhOTVhN2U0NDhiNWFiM2E4ZmQzYjZjM2RlZGZfNC0xLTEtMS01NzY3OA_8412e475-f14f-4323-a513-c28b5680e5d1">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the accounts payable and accrual activity for contract close-out costs (in thousands) for the three months ended March&#160;31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"></td><td style="width:48.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Close-out Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="cmrx:ContractCloseOutLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjk2OGJmYzkwM2ZiMDQ5YTY4NWMwMjcwMzc2OGE3NTM5L3RhYmxlcmFuZ2U6OTY4YmZjOTAzZmIwNDlhNjg1YzAyNzAzNzY4YTc1MzlfMS0xLTEtMS02MTM3Mg_0f31b060-cda2-4b0e-99b0-a3c96bb39e66">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Revised estimates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="cmrx:ContractCloseOutLiabilityAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjk2OGJmYzkwM2ZiMDQ5YTY4NWMwMjcwMzc2OGE3NTM5L3RhYmxlcmFuZ2U6OTY4YmZjOTAzZmIwNDlhNjg1YzAyNzAzNzY4YTc1MzlfMi0xLTEtMS02MTM3Mg_7cfe7cee-27b8-4b7f-badd-253f541a175c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="cmrx:ContractCloseOutLiabilityPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjk2OGJmYzkwM2ZiMDQ5YTY4NWMwMjcwMzc2OGE3NTM5L3RhYmxlcmFuZ2U6OTY4YmZjOTAzZmIwNDlhNjg1YzAyNzAzNzY4YTc1MzlfMy0xLTEtMS02MTM3Mg_b6e8df89-4e15-49c8-a98f-48779c2c7c20">250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="cmrx:ContractCloseOutLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjk2OGJmYzkwM2ZiMDQ5YTY4NWMwMjcwMzc2OGE3NTM5L3RhYmxlcmFuZ2U6OTY4YmZjOTAzZmIwNDlhNjg1YzAyNzAzNzY4YTc1MzlfNC0xLTEtMS02MTM3Mg_2c3ff000-aaa6-4042-9b07-c7a3cb4170e0">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="if071bfa321254ce6b0b5a29630854f78">For the three months ended March&#160;31, 2023, the revised accrual estimates resulted in an increase to research and development expenses of $<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="cmrx:ContractCloseOutLiabilityAdjustments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RleHRyZWdpb246YjM1MTZmMDdjYzFkNDY0Mzg3MGFlMmI3NTVlNTI2YTdfMTIyNw_7ecb1781-dcd8-41ce-b4da-eae2bbe775b3">10,000</ix:nonFraction>.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i4446784166784bc6ab6a1471468846ff_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RleHRyZWdpb246MjA2NmJmNWRiYWQ0NDQzNmE0MzBlYjlkNjE2NDE5OTVfMzY5Nw_d518b8e6-9a34-40ef-be25-7ab73a9a7de0" continuedAt="id6da6af09be3477ab612e9e45f980875" escape="true">Restructuring Costs</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id6da6af09be3477ab612e9e45f980875"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company made the decision to restructure its operations, which included a reduction in workforce of <ix:nonFraction unitRef="employee" contextRef="if6405e9f8e2e42febb0630cc3f4b70cf_D20221201-20221231" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RleHRyZWdpb246MjA2NmJmNWRiYWQ0NDQzNmE0MzBlYjlkNjE2NDE5OTVfNTQ5NzU1ODIyMDMw_3a81f801-d7de-4814-a347-45399f1d9c35">20</ix:nonFraction> full-time employees. During the three months ended December 31, 2022, the Company recorded expense for one-time employee termination benefits of $<ix:nonFraction unitRef="usd" contextRef="i8bc40ecede3346368c17697b995b6608_D20221001-20221231" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RleHRyZWdpb246MjA2NmJmNWRiYWQ0NDQzNmE0MzBlYjlkNjE2NDE5OTVfNTQ5NzU1ODIyMDQ3_c0d10b9f-c96d-4b2f-b03a-cf9532b9fadb">1.9</ix:nonFraction>&#160;million, which included a ratable share of the total stock compensation expense that resulted from the modifications of stock option agreements of employees. The total amount of stock compensation expense related to the reduction in workforce equals $<ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-5" name="cmrx:AnticipatedSeveranceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RleHRyZWdpb246MjA2NmJmNWRiYWQ0NDQzNmE0MzBlYjlkNjE2NDE5OTVfNTQ5NzU1ODIyMTE0_6b1b6d13-f80f-4140-8a62-76f927b5fa10">1.0</ix:nonFraction>&#160;million of which $<ix:nonFraction unitRef="usd" contextRef="ic0ee769ecce64f21994ca9ced836dbaa_D20220101-20221231" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RleHRyZWdpb246MjA2NmJmNWRiYWQ0NDQzNmE0MzBlYjlkNjE2NDE5OTVfNTQ5NzU1ODIzMDk2_92573291-588b-4008-832e-51fa95ef0cf0">0.4</ix:nonFraction>&#160;million was recorded in the fourth quarter of 2022.  </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RleHRyZWdpb246MjA2NmJmNWRiYWQ0NDQzNmE0MzBlYjlkNjE2NDE5OTVfMjE5OTAyMzI2NDI1Nw_05646e45-7c5b-41bc-af1c-d9ce29dbded5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restructuring charges (in thousands) recorded for the three months ended December 31, 2022:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Termination Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d7ce8ff73a42f8bc6ebe1f484b504b_D20221001-20221231" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RhYmxlOmVmMzA2ZjU0YjA0NzQ3OTlhYjc1NDk4NTRjOGU0NmYwL3RhYmxlcmFuZ2U6ZWYzMDZmNTRiMDQ3NDc5OWFiNzU0OTg1NGM4ZTQ2ZjBfMS0yLTEtMS02MDQyNA_5b9beff4-8ff8-46e6-8b62-3596ade57e57">1,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b15fe0b2c840688dc4fc6ff3dc199f_D20221001-20221231" decimals="-3" name="us-gaap:SeveranceCosts1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RhYmxlOmVmMzA2ZjU0YjA0NzQ3OTlhYjc1NDk4NTRjOGU0NmYwL3RhYmxlcmFuZ2U6ZWYzMDZmNTRiMDQ3NDc5OWFiNzU0OTg1NGM4ZTQ2ZjBfMi0yLTEtMS02MDQyNA_9d76c407-363f-4604-8041-2fecfced20c3">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc40ecede3346368c17697b995b6608_D20221001-20221231" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RhYmxlOmVmMzA2ZjU0YjA0NzQ3OTlhYjc1NDk4NTRjOGU0NmYwL3RhYmxlcmFuZ2U6ZWYzMDZmNTRiMDQ3NDc5OWFiNzU0OTg1NGM4ZTQ2ZjBfMy0yLTEtMS02MDQyNA_ce9a143c-06d3-4952-901d-e3156054f1bc">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RleHRyZWdpb246MjA2NmJmNWRiYWQ0NDQzNmE0MzBlYjlkNjE2NDE5OTVfMjE5OTAyMzI2NDI1OA_89e0818b-3970-49b7-8c99-bcbeb2ba9ca9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the accrual activity for employee termination benefits (in thousands) for the three months ended March&#160;31, 2023:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Termination Benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RhYmxlOjdlOGEyNWQyMzI0NTQ0NTRiNDZjMTRiYjk2Njg2ZTU4L3RhYmxlcmFuZ2U6N2U4YTI1ZDIzMjQ1NDQ1NGI0NmMxNGJiOTY2ODZlNThfMS0xLTEtMS02MDQyOQ_14ba5a95-ecf3-4593-9027-79c174251e2b">1,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Revised estimates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RhYmxlOjdlOGEyNWQyMzI0NTQ0NTRiNDZjMTRiYjk2Njg2ZTU4L3RhYmxlcmFuZ2U6N2U4YTI1ZDIzMjQ1NDQ1NGI0NmMxNGJiOTY2ODZlNThfMi0xLTEtMS02MDQyOQ_5ed9c189-ae79-4f53-83b6-00aeb60f6144">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RhYmxlOjdlOGEyNWQyMzI0NTQ0NTRiNDZjMTRiYjk2Njg2ZTU4L3RhYmxlcmFuZ2U6N2U4YTI1ZDIzMjQ1NDQ1NGI0NmMxNGJiOTY2ODZlNThfMy0xLTEtMS02MDQyOQ_edd29d23-9a1a-4edb-9963-8d39ff934cda">641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RhYmxlOjdlOGEyNWQyMzI0NTQ0NTRiNDZjMTRiYjk2Njg2ZTU4L3RhYmxlcmFuZ2U6N2U4YTI1ZDIzMjQ1NDQ1NGI0NmMxNGJiOTY2ODZlNThfNC0xLTEtMS02MDQyOQ_55a21d3e-830f-46c5-aafc-666c7ac81073">728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i4446784166784bc6ab6a1471468846ff_55"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81NS9mcmFnOjRhOWU1OTAyMGFiYjQzZWViZDQxOTBiYWVkNjU4ODVmL3RleHRyZWdpb246NGE5ZTU5MDIwYWJiNDNlZWJkNDE5MGJhZWQ2NTg4NWZfMzQ5_8e03b667-d597-4ccf-9170-ba4ac22c32bd" continuedAt="ibbe107abafd1404daa2b7d9dff8583cd" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibbe107abafd1404daa2b7d9dff8583cd">The Company has evaluated subsequent events through the issuance date of these financial statements to ensure that this filing includes appropriate disclosure of events both recognized in the financial statements as of March&#160;31, 2023, and events which occurred subsequently but were not recognized in the financial statements.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i4446784166784bc6ab6a1471468846ff_58"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. &#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December 31, 2022 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (SEC) on March 2, 2023. Past operating results are not necessarily indicative of results that may occur in future periods.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are subject to the &#8220;safe harbor&#8221; created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item IA, &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4446784166784bc6ab6a1471468846ff_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chimerix </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Chimerix, we, our, us or the Company)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company is focused on developing imipridones as a potential new class of selective cancer therapies. The most advanced imipridone is dordaviprone (ONC201) which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is currently in dose escalating clinical trials. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Dordaviprone, ONC201 </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Multiple Imipridone Datasets Presented at the American Association for Cancer Research (AACR) Annual Meeting </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the AACR annual meeting in April 2023, Chimerix and its collaborators presented multiple datasets related to the imipridone platform's potential. Key results presented by Dr. Carl Koschmann, MD, Associate Professor of Pediatrics at the University of Michigan, demonstrated that H3 K27M-mutant glioma patients treated with ONC201 experienced a statistically significant reversal of the H3 K27 trimethyl-loss (H3 K27me3-loss) epigenetic signature throughout their tumor compared to patients who did not receive ONC201. Gliomas with the H3 K27M-mutation undergo H3 K27me3-loss, which is a negative prognostic variable among gliomas and thought to be a defining characteristic of the disease. Concordant findings were also reported in preclinical models that were mechanistically linked to specific metabolic changes induced in tumors by ONC201. Other presentations at the conference highlighted preclinical oncology studies related to the imipridone platform performed by Chimerix and collaborators at the Brown University Cancer Center. The ongoing Phase 3 ACTION Study, a global Phase 3 clinical trial of ONC201 in newly diagnosed H3 K27M-mutant diffuse glioma, was also highlighted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Phase 3 ACTION Study Continues - Enrollment Expanding into Europe with European Union (EU) Study Authorization</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Phase 3 ACTION trial is authorized in nine countries including</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the United States, the United Kingdom, South Korea, Israel and certain key markets across Western Europe. The trial is still on target to report interim overall survival (OS) and progression free survival (PFS) data in 2025 with final OS data expected in 2026. The ACTION trial enrolls patients shortly after they have completed front-line radiation therapy that is the standard of care for glioma. The study is designed to enroll 450 patients randomized 1:1:1 to receive ONC201 at one of two dosing frequencies or placebo. Participants will be randomized to receive either: (i) 625mg of ONC201 once per week (the Phase 2 dosing regimen), (ii) 625mg twice per week on two consecutive days or (iii) placebo. The study is open to pediatric and adult patients &gt;10kg body weight and the dose will be scaled by body weight for patients  weighing less than 52.5kg. Primary endpoints include OS and PFS. OS will be assessed for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">efficacy at three alpha-allocated timepoints consisting of two interim assessments by the Independent Data Monitoring Committee (IDMC) at 164 events and 246 events, respectively, and a final assessment at 327 events. The final PFS analysis will be performed after 286 events, with progression assessed using response assessment in neuro-oncology-high grade glioma (RANO HGG) and response assessment in neuro-oncology-low grade glioma (RANO-LGG) criteria by blinded independent central review (BICR). Secondary endpoints include corticosteroid response, performance status response, change from baseline in quality of life (QoL) assessments and change from baseline in neurologic function as assessed by the Neurologic Assessment in Neuro-Oncology (NANO) scale.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our plan is to initiate a submission to regulators for approval upon receipt of positive overall survival data at either of the interim or the final overall survival analyses. The first submission for marketing authorization would likely be initiated in the US with submissions outside the US to follow. In addition, in the event the result of the progression free survival analysis is positive, we would discuss the potential for submission and approval of ONC201 with the regulatory authorities based on this data.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Early Pipeline Development &#8211; ONC206, ONC212 and CMX521</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ONC206</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ONC206 is a second generation, potentially differentiated imipridone DRD2 antagonist ad CLpP agonist, that has demonstrated monotherapy anti-cancer activity in pre-clinical models. ONC206 is currently being evaluated in Phase I dose escalation trials enrolling patients with advanced central nervous system tumors in partnership with the National Institutes of Health (NIH) and with the Pacific Pediatric Neuro-Oncology Consortium (PNOC). In March 2023, the Company reported a finding of an investigator-assessed response that emerged during dose escalation in the PNOC study. The responder is a recurrent glioblastoma patient without the H3K27M-mutation who received monotherapy. ONC206 dose escalation is expected to be completed by the first half of 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Preclinical work is ongoing that is designed to further elucidate the ONC206 mechanism of action, to identify potential pharmacodynamic biomarkers and assess the monotherapy efficacy profile of ONC206 in tumors that do not harbor the H3 K27M-mutation. These activities will inform data-driven clinical development plans.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ONC212</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ONC212, which targets GPR132 and ClpP, has completed IND-enabling toxicology studies. ONC212 is being explored pre-clinically in collaboration with MD Anderson Cancer Center and Brown University. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">CMX521</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. CMX521 is not mutagenic, clastogenic, or associated with mitochondrial toxicity. In addition, oral CMX521 demonstrated a favorable profile in GLP toxicology studies and was well-tolerated up to 2,400 mg in a healthy volunteer Phase 1 study for a different indication.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to a 2006 agreement between the Company and The Regents of the University of Michigan (UM), the Company obtained an exclusive, worldwide license to UM&#8217;s patent rights in certain inventions related to certain compounds originally synthesized at UM, including CMX521. Under the license agreement, the Company is permitted to research, develop, manufacture and commercialize products utilizing the UM Patent Rights, and to sublicense such rights subject to certain sublicensing fees and royalty payments.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently working with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina at Chapel Hill (UNC) for the development of CMX521 as a potential treatment for SARS-CoV-2. UNC which is the co-recipient of a grant for approximately $1.7 million from the state of North Carolina which will defray the majority of the costs on this effort. The grant will fund prodrug synthesis and animal studies to optimize delivery of CMX521 to the lungs via a convenient oral formulation. In addition, UNC will conduct COVID-19 disease mouse efficacy model studies and evaluate lung delivery of the active antiviral. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TEMBEXA (brincidofovir, BCV)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 26, 2022, we closed the Asset Sale with Emergent Biodefense Operations Lansing LLC (Emergent), upon which we received $238 million upfront and could receive additional milestones of up to $136.5 million to be paid contingent upon execution of optional future procurement awards from the Biomedical Advanced Research and Development Authority (BARDA) and other development milestones. We are also entitled to earn a 20% royalty on future gross profit of TEMBEXA in the United States associated with volumes above 1.7 million treatment courses of therapy during the exclusivity period of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TEMBEXA. The agreement also allows us to earn a 15% royalty on all gross profit associated with TEMBEXA sales outside of the United States during the exclusivity period of TEMBEXA on a market-to-market basis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The period under which the Company was contracted to provide the majority of operational support services to Emergent in furtherance of its obligations under the Asset Purchase Agreement and the BARDA Agreement concluded on March 26, 2023, except for certain services which the parties agreed would continue until the occurrence of a specific event, or in some cases a predetermined end date. The BARDA Agreement was novated to Emergent in December 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Development Review</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to our prior business development transactions, management is continuing to conduct a review and assessment of potential transaction opportunities with the goal of building our product candidate pipeline, including, but not limited to, licensing, merger or acquisition transactions, or the license, purchase or sale of specific assets, in addition to other potential actions aimed at maximizing stockholder value. There can be no assurance that this review will result in the identification or consummation of any additional transaction or action.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i4446784166784bc6ab6a1471468846ff_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL OVERVIEW</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have generated modest, non-recurring revenue from product sales. Prior to 2022, all of our revenue to date has been derived from government grants and a contract and the receipt of up-front proceeds under our collaboration and license agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emergent BioSolutions, Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 26, 2022, the Company closed the previously disclosed Asset Sale with Emergent. Emergent paid the Company an upfront cash payment of approximately $238 million upon closing. In addition, pursuant to the Asset Purchase Agreement, the Company is eligible to receive from Emergent: (i) up to an aggregate of approximately $124 million in milestone payments payable upon the exercise of the options under the BARDA Agreement; (ii) royalty payments equal to 15% of the gross profits from the sales of TEMBEXA made outside of the United States; (iii) royalty payments equal to 20% of the gross profits from the sales of TEMBEXA made in the United States in excess of 1.7 million treatment courses; and (iv) up to an additional $12.5 million upon the achievement of certain other developmental milestones.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The BARDA Agreement was novated to Emergent in December 2022. Under the Asset Purchase Agreement, the Company recognized approximately $0.2&#160;million of contract revenue for support provided for the three months ended March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TEMBEXA Procurement Agreements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, the Company entered into a Supply Agreement (the Supply Agreement) with a third-party outside of North America (the Purchaser), pursuant to which the Company was responsible for supplying to the Purchaser, and the Purchaser was responsible for purchasing from the Company, TEMBEXA treatment courses for use in a jurisdiction outside of the United States. Under the terms of the Supply Agreement, the Purchaser paid the Company an aggregate purchase price of approximately $9.3 million, in two equal installments in June 2022 and July 2022. The Company recognized $9.3 million of procurement revenue under the Supply Agreement for the three months ended September 30, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in June 2022, the Public Health Agency of Canada (PHAC) awarded a Contract (the PHAC Contract) to the Company, pursuant to which PHAC agreed to purchase up to approximately $25.3 million (CAD $33.0 million) of TEMBEXA treatment courses for use in Canada. Substantially all of the procurement was delivered and accepted by PHAC in July 2022, completing the performance obligation for those shipments and resulting in $22.6 million of procurement revenue for the three months ended September 30, 2022. PHAC assigned the PHAC Contract to Emergent in November 2022. The remaining deliveries of treatment courses were delivered by Emergent and were subject to the royalty terms of the Asset Purchase Agreement applicable to gross profits outside the United States. The Company recognized approximately $0.4&#160;million of royalty revenue in the three months ended December 31, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have focused our resources on our research and development activities, including conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for our product candidates. We recognize research and development expenses as they are incurred. Costs for certain development </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors. We cannot determine with certainty the duration and completion costs of the current or future clinical studies of any product candidates. Our research and development expenses consist primarily of:</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees paid to consultants and contract research organizations (CROs), including in connection with preclinical and clinical trials, and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work, clinical trial database management, clinical trial material management and statistical compilation and analysis;</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">salaries and related overhead expenses, which include stock option, restricted stock units and employee stock purchase program compensation and benefits, for personnel in research and development functions;</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payments to third-party manufacturers, which produce, test and package drug substance and drug product (including continued testing of process validation and stability);</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to legal and compliance with regulatory requirements; and</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">license fees for and milestone payments related to licensed products and technologies.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our research and development expenses for the periods indicated (in thousands). Our direct research and development expenses consist primarily of external costs, such as fees paid to investigators, consultants, central laboratories and CROs, in connection with our clinical trials, preclinical development, and payments to third-party manufacturers of drug substance and drug product. We typically use our employee and infrastructure resources across multiple research and development programs.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,260&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development personnel costs - excluding stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development personnel costs - stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the development of any product candidates or the period, if any, in which material net cash inflows from any product candidates may commence. This is due to the numerous risks and uncertainties associated with our business, as detailed in Part II, Item IA, &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q and in our other filings with the SEC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imipridones Program</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired Oncoceutics. As we continue to develop and prepare ONC201 for U.S. regulatory approval, we expect to incur significant research and development expense. We also plan to incur development expenses in connection with the continued development of other imipridone compounds, including ONC206 and ONC212.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TEMBEXA (Brincidofovir, BCV)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We developed TEMBEXA for the treatment of smallpox. FDA marketing approval for TEMBEXA was received on June 4, 2021. Under our February 2011 cost-plus-fixed fee development contract with BARDA, we incurred expenses in connection with the development of orthopoxvirus animal models, the demonstration of efficacy and pharmacokinetics of TEMBEXA in the animal models, the conduct of clinical studies for subjects with DNA viral infections, the manufacture and process validation of bulk drug substance and TEMBEXA 100 mg tablets and TEMBEXA 10 mg/mL oral suspension, and submission of the NDAs to the FDA. In addition, we have incurred additional supportive costs for the development of TEMBEXA for smallpox that we did not seek reimbursement for from BARDA. We have incurred costs related to the manufacturing of TEMBEXA for a procurement contract. These costs were expensed as incurred until the June 2021 FDA approval. Following the approval, costs related to the manufacturing of TEMBEXA are recorded and shown as inventories on the Consolidated Balance Sheets. With the sale of TEMBEXA to Emergent all inventory, prepaids and liabilities associated with TEMBEXA were transferred to Emergent as part of the transaction.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dociparstat Sodium (DSTAT)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given our previously announced decision to stop development of DSTAT, we are currently in the process of closing our Phase 3 DASH AML trial, and have $1.1 million of accounts payable and contract close-out accruals as of March&#160;31, 2023. We expect the close-out activities related to this program to extend through mid-2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for employees in executive, finance, commercial, investor relations, information technology, legal, human resources and administrative support functions, including share-based compensation expenses and benefits. Other significant general and administrative expenses include costs related to accounting and legal services, costs of various consultants, director and officer liability insurance, occupancy costs and information systems.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Other, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other, net consists primarily of interest earned on our cash, cash equivalents and short-term and long-term investments.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Accounting Standards Board authoritative guidance&#160;requires that share-based payment transactions with employees be recognized in the financial statements based on their fair value and recognized as compensation expense over the vesting period.&#160;Total consolidated share-based compensation expense of $4.4 million and $3.7 million was recognized in the three months ended March&#160;31, 2023 and 2022, respectively. The share-based compensation expense recognized included expense for stock options, RSUs and employee stock purchase plan purchase rights.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our share-based awards to employees and directors using the Black-Scholes pricing model. This estimate is affected by our stock price as well as assumptions including the expected volatility, expected term, risk-free interest rate, expected dividend yield, expected rate of forfeiture and the fair value of the underlying common stock on the date of grant.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance-based RSUs, we begin to recognize the expense when it is deemed probable that the performance-based goal will be achieved. We evaluate the probability of achieving performance-based goals on a quarterly basis.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our unaudited consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenues and expenses that are not readily apparent from other sources. Actual results and experiences may differ materially from these estimates. In addition, our reported financial condition and results of operations could vary if new accounting standards are enacted that are applicable to our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We discussed accounting policies and assumptions that involve a higher degree of judgment and complexity in Note 1 to our consolidated financial statements in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 filed with the SEC on March 2, 2023. There have been no material changes during the three months ended March&#160;31, 2023 to our critical accounting policies, significant judgments and estimates disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i4446784166784bc6ab6a1471468846ff_67"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March&#160;31, 2023 and 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March&#160;31, 2023 and 2022, together with the changes in those items (in thousands, except percentages):&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:34.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.321%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollar&#160;Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract and grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,672&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,218)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,771)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income and other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,050.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,372)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,767)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,395&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Not meaningful or not calculable</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract, Licensing, Procurement Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, total revenue increased to $0.3 million compared to $15,000 for the three months ended March&#160;31, 2022. The increase of $0.3 million is primarily related to the reimbursable operational support provided to Emergent under the Asset Purchase Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, our research and development expenses decreased to $18.8 million compared to $19.0 million for the three months ended March&#160;31, 2022. The decrease of $0.2 million primarily related to the following:</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">a decrease of $1.7 million in DSTAT development costs related to the discontinuation of the DSTAT program;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">a decrease of $0.4 million in compensation expenses; offset by</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">an increase of $2.1 million related to ONC201 research and development expenses, primarily in start-up expenses related to the ACTION Phase 3 study of ONC201.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, our general and administrative expenses increased to $5.7 million compared to $5.6 million for the three months ended March&#160;31, 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Other, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, our interest income and other, net increased to $2.8 million compared to $4,000 for the three months ended March&#160;31, 2022. This increase is primarily attributable to interest earned on higher cash balances.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i4446784166784bc6ab6a1471468846ff_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had capital available to fund operations of approximately $246.1 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preservation. We have incurred losses since our inception in 2000 and as of March&#160;31, 2023, we had an accumulated deficit of $734.8 million. We may continue to incur losses for the foreseeable future. The size of our losses will depend, in part, on the rate of future expenditures and our ability to generate revenues. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2020, we entered into the Jefferies Sales Agreement with Jefferies LLC, as agent, pursuant to which we may offer and sell, from time to time through Jefferies, up to $75 million of shares of our common stock. As of March 31, 2023, we have not sold any shares of our common stock under the Jefferies Sales Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2021, we filed an automatic shelf registration statement on Form S-3 with the SEC (the 2021 Shelf Registration Statement), which was subsequently amended in March 2022 to convert it to a non-automatic shelf registration statement that we are eligible to use. The amendment to the 2021 Shelf Registration Statement to convert to a non-automatic shelf registration statement. This registration statement enables us to offer for sale, from time to time, in one or more offerings, up to $250 million in the aggregate, of common stock, preferred stock, debt securities, warrants, rights and/or units, and will remain in effect for up to three years from the date it initially became effective. As of March 31, 2023, no sales have been made under the 2021 Shelf Registration Statement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022, we entered into a Loan and Security Agreement (the Loan Agreement) with Silicon Valley Bank, now a division of First-Citizens Bank &amp; Trust Company, as the lender (the Lender). The Loan Agreement provides for a four-year secured revolving loan facility (the Credit Facility) in an aggregate principal amount of up to $50.0 million. Proceeds from the Credit Facility may be used for working capital and general corporate purposes. We have no obligation to draw down any amount under the Credit Facility, and have not drawn down any amount as of December 31, 2022. In September 2022, in connection with the Asset Sale, the Lender and the Company agreed to suspend the availability of future advances under the Loan Agreement until such time the parties mutually agree to amend the Loan Agreement to, among other things, adjust the borrowing base and reset the covenants. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure that adequate funding will be available on terms acceptable to us, if at all. Any additional equity financings will be dilutive to our stockholders and any additional debt may involve operating covenants that may restrict our business. If adequate funds are not available through these means, we may be required to curtail significantly one or more of our research or development programs, and any launch and other commercialization expenses for any of our products that may receive marketing approval. We cannot assure you that we will successfully develop or commercialize our products under development or that our products, if successfully developed, will generate revenues sufficient to enable us to earn a profit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash, cash equivalents, and investments will enable us to fund our current operating expenses and capital requirements for at least the next 12 months. However, changing circumstances beyond our control may cause us to consume capital more rapidly than we currently anticipate.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the significant sources and uses of cash for the period (in thousands):&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.301%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash sources and uses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,225)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,447)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,460)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,891)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above sets forth the net decrease or increase in cash and cash equivalents alone and not the change in our total capital available to fund operations, which also includes short-term and long-term investments. Cash and cash equivalents includes cash on hand and securities with original maturities of 90 days or less. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $22.2 million for the three months ended March&#160;31, 2023 was primarily the result of our $21.4 million net loss and the change in operating assets and liabilities offset by the add-back of non-cash adjustments. The change in operating assets and liabilities includes a decrease of $4.0 million in accounts payable and accrued liabilities offset by a decrease in prepaid expenses and other assets of $0.4 million and a decrease in accounts receivable of $0.4 million. Non-cash expenses included add-backs of $4.4 million for share-based compensation and $0.1 million of amortization of deferred loan </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs offset by $2.1 million of amortization of discount/premium on investments. Net cash used in operating activities of $23.4 million for the three months ended March&#160;31, 2022 was primarily the result of our $24.8 million net loss and the change in operating assets and liabilities offset by the add-back of non-cash adjustments. The change in operating assets and liabilities includes an increase in prepaid expenses and other assets of $1.0 million, a decrease of $0.9 million in accounts payable and accrued liabilities and an increase in inventories of $0.6 million. Non-cash expenses included add-backs of $3.7 million for share-based compensation and $0.1 million of amortization of discount/premium on investments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities of $12.1 million for the three months ended March&#160;31, 2023 was primarily the result of the maturity of $19.0 million in short-term investments, partially offset by the purchase of $6.8 million in long-term investments. Net cash provided by investing activities of $53.5 million for the three months ended March&#160;31, 2022 was primarily the result of the maturity of $51.0 million in short-term investments and the sale of $7.7 million in short-term investments, offset by the purchase of $5.3 million in short-term investments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities of $0.2 million for the three months ended March&#160;31, 2023 was primarily the result of  $0.4 million in proceeds from stock purchases through our ESPP partially offset by the payment of $0.2 million of debt issuance costs. Net cash used by financing activities of $13.5 million for the three months ended March&#160;31, 2022 was primarily the result of the $14.0 million payment of the note payable related to the Oncoceutics acquisition and the payment of $0.1 million of debt issuance costs, partially offset by $0.7 million in proceeds from the exercise of stock options and stock purchases through our ESPP. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i4446784166784bc6ab6a1471468846ff_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL CASH REQUIREMENTS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion below summarizes our significant contractual obligations and commitments as of March&#160;31, 2023.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Note 3 of Notes to Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for information, including the future operating lease minimum payments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the amounts set forth above, we have payment obligations under license agreements that are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones. We will be required to make additional payments when certain milestones are achieved, and we are obligated to pay royalties based on future product sales. As of March 31, 2023, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales. In connection with the development and commercialization of ONC201, ONC206 and ONC212, in addition to royalties on product sales, we could be required to pay former Oncoceutics securityholders up to an aggregate of $340.0 million in remaining milestone payments, assuming the achievement of all remaining applicable milestone events under the merger agreement. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we enter into contracts in the normal course of business with CROs for clinical trials and clinical supply manufacturing and with vendors for preclinical research studies and other services and products for operating purposes, which generally provide for termination or cancellation within 30 days of notice. We also have agreements with our executive officers that require the funding of specific payments, if certain events occur, such as a change in control or the termination of employment without cause. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i4446784166784bc6ab6a1471468846ff_79"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. &#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. Accordingly, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our investment portfolio.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that our cash, cash equivalents and available-for-sale investments have significant risk of default or illiquidity. While we believe our cash and cash equivalents and certificates of deposit do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain certain amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations for the three months ended March&#160;31, 2023 and 2022.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4446784166784bc6ab6a1471468846ff_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. &#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of March&#160;31, 2023, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We routinely review our internal control over financial reporting and from time to time make changes intended to enhance the effectiveness of our internal control over financial reporting. We will continue to evaluate the effectiveness of our disclosure controls and procedures and internal control over financial reporting on an ongoing basis and will take action as appropriate. There have been no changes to our internal control over financial reporting, as such term is defined in Rules 13a-15(d) and 15d-15(d) under the Exchange Act, during the first quarter of 2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i4446784166784bc6ab6a1471468846ff_85"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i4446784166784bc6ab6a1471468846ff_88"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. &#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4446784166784bc6ab6a1471468846ff_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of material factors that make an investment in our common stock speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, as well as other risks that we face, can be found under the heading &#8220;Risk Factors&#8221; below. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We anticipate that we will continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All of our product candidates are still under clinical development and may not obtain regulatory approval or be successfully commercialized. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to obtain, or may be delayed in obtaining, regulatory approval for our clinical candidates, including our most advanced clinical candidate, ONC201.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to generate future revenues from product sales is uncertain and depends upon our ability to successfully develop, obtain regulatory approval for, and commercialize product candidates, and even if we generate future revenues, they may not be sufficient to lead to profitability.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we obtain regulatory approval for any of our product candidates, including ONC201, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third-party manufacturers to produce our preclinical drug supplies and clinical drug supplies, and we intend to rely on third parties to produce commercial supplies of any approved product candidates. We rely on limited sources of supply for the drug components for each of our product candidates including ONC201, and any disruption in the chain of supply for either of these product candidates may cause delays in their development and commercialization.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We routinely evaluate external assets to build our pipeline of product candidates and there can be no assurance that we will be successful in identifying or completing a transaction for a candidate, that any such transaction will result in additional value for our stockholders or that the process will not have an adverse impact on our business. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The anticipated benefits of the sale of our TEMBEXA assets to Emergent Biodefense Operations Lansing LLC, (Emergent) may not be realized fully or at all or may take longer to realize than expected. Our ability to receive future contingent consideration from the sale depends on, among other things, Emergent&#8217;s ability to successfully develop and commercialize TEMBEXA.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain or protect intellectual property rights related to our products and product candidates, we may not be able to compete effectively in our market.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, delays in the development of our product candidates, penalties and a loss of business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information contained elsewhere in this Quarterly Report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business. </span></div><div style="text-align:center;text-indent:24.75pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition and Need For Additional Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Except for the third quarter of 2022, we have incurred significant losses since our inception. We anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused primarily on developing ONC201 for the treatment of H3 K27M-mutant glioma as we also evaluate programs to advance from our earlier stage pipeline. We have incurred significant net losses in each year since our inception prior to 2022, including a net loss of $21.4 million for the three months ended March&#160;31, 2023. As of March&#160;31, 2023, we had an accumulated deficit of approximately $734.8 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, with the exception of the Asset Sale, we have financed our operations primarily through the sale of equity securities and, to a lesser extent, through government funding, licensing fees, the sales of TEMBEXA product and debt. We have devoted most of our financial resources to research and development, including our preclinical development activities and clinical trials. We may continue to incur losses and negative cash flows for the foreseeable future. The size of any loss will depend, in part, on the rate of future expenditures and our ability to generate revenues. In particular, we expect to incur substantial expenses as we seek to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue development and manufacturing activities related to imipridones, including ONC201 for the treatment of H3 K27M-mutant glioma, and other potential indications;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain regulatory approvals for ONC201 and other imipridones;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scale-up manufacturing capabilities for ONC201 and other imipridones;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identify and in-license additional product candidates to expand our research and development pipeline;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our internal research and development efforts and seek to discover additional product candidates.</span></div><div style="padding-left:58.5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must succeed in developing and eventually commercializing products with significant market potential. This will require us to be successful in a range of challenging activities, including acquiring or discovering product candidates, completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval for these product candidates, and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We are only in the preliminary stages of some of these activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained regulatory approval for and initially commercialized TEMBEXA, however, none of our other product candidates have been commercialized. We may not succeed in developing additional product candidates or commercializing any product candidate. If we do not successfully develop or commercialize any product candidate, or if revenues from any products that do receive regulatory approvals are insufficient, we will not achieve profitability and our business may fail. In addition to these risks in the United States, assuming regulatory approval in other geographies, our revenues are also dependent upon the size of markets outside of the United States, as well as our ability to obtain market approval and achieve commercial success outside of the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we achieved profitability in 2022 as a result of the closing of our Asset Sale with Emergent, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the value of our company could cause you to lose all or part of your investment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to generate future revenues from product sales is uncertain and depends upon our ability to successfully develop, obtain regulatory approval for, and commercialize product candidates, and even if we generate future revenues, they may not be sufficient to lead to profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenue and achieve profitability depends on our ability, alone or with collaborators, to successfully complete the development of, obtain the necessary regulatory approvals for and commercialize product candidates. We may not generate revenues from product sales for the foreseeable future. Our ability to generate future revenues from product sales depends heavily on our success in:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining favorable results for and advancing development of imipridones, including ONC201 for the treatment of H3 K27M-mutant glioma, and other potential indications;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining United States regulatory approval for ONC201 and other pipeline assets;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining foreign regulatory approval(s) for ONC201 and other pipeline assets;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">generating, licensing or otherwise acquiring a pipeline of product candidates which progress to clinical development, regulatory approval, and commercialization.</span></div><div style="padding-left:45pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to activate, enroll, and complete, and we may never successfully enroll a sufficient number of patients or generate the necessary data required to obtain regulatory approval and achieve product sales. Our anticipated development costs would likely increase if we do not obtain favorable results or if development of any product candidate is delayed. In particular, we would likely incur higher costs than we currently anticipate if development of any product candidate is delayed because we are required by the FDA or foreign regulatory authorities to perform studies or trials in addition to those that we currently anticipate, or we decide to conduct additional studies or trials for strategic reasons. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict with certainty the timing or amount of any increase in our anticipated development costs that will result should any additional trials be necessary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidate if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that may not be commercially available for a number of years, if at all. For any approved product candidate, we anticipate incurring significant costs in connection with commercialization. As a result, we cannot assure you that we will be able to generate revenues from sales of any approved product candidate, or that we will achieve or maintain profitability even if we do generate sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain additional financing, we could be forced to delay, reduce or eliminate our product development programs, seek corporate partners for the development of our product development programs or relinquish or license on unfavorable terms, our rights to technologies or product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete. We believe that our existing capital available to fund operations will enable us to fund our current operating expenses and capital requirements for at least the next twelve months. Changing circumstances beyond our control may cause us to consume capital more rapidly than we currently anticipate, and our clinical trials may encounter technical, enrollment or other difficulties that could increase our development costs more than we expected, or because the FDA or foreign regulatory authorities require us to perform studies or trials in addition to those that we currently anticipate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired Oncoceutics, Inc. (Oncoceutics), a privately-held, clinical-stage biotechnology company developing imipridones, a novel potential class of compounds. Oncoceutics&#8217; lead product candidate, ONC201, is currently being evaluated in multiple clinical studies including in the recently launched Phase 3 ACTION Study, a registrational study for H3 K27M-mutant glioma.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also pursuing additional external opportunities to build our pipeline of product candidates, and we may need to raise additional funds if we identify additional product candidates, which we may obtain through one or more equity offerings, debt financings, government or other third-party funding, strategic alliances and licensing or collaboration arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize our most advanced clinical compounds, or any other product candidate. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significantly delay, scale back or discontinue the development or commercialization of ONC201, or any other product candidate;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek corporate partners for ONC201, or any other product candidate at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relinquish or license on unfavorable terms, our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves.</span></div><div style="padding-left:45pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects and on our ability to develop our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we draw down on our credit facility with Silicon Valley Bank, the terms of our loan and security agreement place restrictions on our operating and financial flexibility, and failure to comply with covenants or to satisfy certain conditions may result in acceleration of our repayment obligations and foreclosure on our pledged assets, which could significantly harm our liquidity, financial condition, operating results, business and prospects and cause the price of our securities to decline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Loan and Security Agreement (the Loan Agreement) with Silicon Valley Bank, now a division of First-Citizens Bank &amp; Trust Company, effective January 31, 2022, requires us to comply with certain financial covenants, including requiring that we maintain specified liquidity and cash levels at certain times. The Loan Agreement also requires us to comply with a number of other covenants (affirmative and negative), including restrictive covenants that limit our ability to, among other things, incur additional indebtedness; merge or consolidate with or into any other organization or otherwise suffer a change in control; acquire, own or make investments; repurchase or redeem any class of stock or other equity interest; declare or pay any cash </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dividend or make a cash distribution on any class of stock or other equity interest; and transfer a material portion of our assets, in each case subject to exceptions. Our obligations under the Loan Agreement are secured by a first priority perfected security interest in substantially all of our assets other than our intellectual property, subject to certain exceptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to other specified events of default, and subject to limited exceptions, Silicon Valley Bank could declare an event of default upon our non-compliance with certain covenants or the occurrence of certain events that it may determine, in its sole discretion, to have a material adverse effect, including: a material adverse change in, or a material adverse effect on our business, property, assets or operations, taken as a whole; a material impairment of our ability to perform any of our obligations under the Loan Agreement; a material adverse effect upon the collateral for the loan or its value; or a material impairment of the enforceability or priority of the liens upon the collateral for the loan or the legality, validity, binding effect or enforceability of the Loan Agreement or related agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we default under the credit facility, Silicon Valley Bank may accelerate all of our repayment obligations, which may require us to seek additional or alternate financing and/or modify our operational plans. We cannot guarantee that we will be able to comply with all of the covenants contained in the Loan Agreement in the future, or secure waivers if or when required.  If we are unable to comply with or obtain a waiver of any noncompliance under the Loan Agreement, Silicon Valley Bank could declare an event of default or require us to further renegotiate the Loan Agreement on terms that may be significantly less favorable to us, or we may be required to seek additional or alternative financing. If we were to seek additional or alternative financing, any such financing may not be available to us on commercially reasonable terms or at all. If we are unable to access funds to meet those obligations or to renegotiate our agreement, Silicon Valley Bank could foreclose on our pledged assets and we would have to immediately cease operations. In addition, during the continuance of an event of default, the then-applicable interest rate on the then-outstanding principal balance is subject to increase. Upon an event of default, Silicon Valley Bank could also require us to repay the loan immediately, together with a prepayment penalty, and other fees. If we were to renegotiate the agreement under such circumstances, the terms may be significantly less favorable to us. If we were liquidated, Silicon Valley Bank&#8217;s right to repayment would be senior to the rights of our stockholders to receive any proceeds from the liquidation. Any declaration by Silicon Valley Bank of an event of default could significantly harm our liquidity, financial condition, operating results, business, and prospects and cause the price of our securities to decline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Silicon Valley Bank and the Company agreed to suspend the availability of future advances under the Loan Agreement until such time, if ever, the parties mutually agree to amend the Loan Agreement to, among other things, adjust the borrowing base and reset the covenants. We may never agree to such an amendment, and even if we do, recent developments regarding Silicon Valley Bank may limit the availability of such advances or our willingness to request them. Accordingly, we may not be able to rely upon the Loan Agreement as a viable source of future capital for our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may incur additional indebtedness in the future. The debt instruments governing such indebtedness may contain provisions that are as, or more, restrictive than the provisions governing our existing indebtedness. If we are unable to repay, refinance or restructure our indebtedness when payment is due, Silicon Valley Bank could proceed against the collateral or force us into bankruptcy or liquidation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We routinely evaluate external assets to build our pipeline of product candidates and there can be no assurance that we will be successful in identifying or completing a transaction for a candidate, that any such transaction&#160;will result in additional value for our stockholders or that the process will not have an adverse impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2019, we initiated a review of external assets that could be added to our pipeline of product candidates. In January 2021, we acquired Oncoceutics, a privately-held, clinical-stage biotechnology company developing imipridones, including ONC201. In connection with this transaction, we are responsible for, and bear the future costs of, development and commercialization of the acquired compounds. These costs will be substantial, and we may require additional capital in order to pursue the development and commercialization of these compounds as planned.  Moreover, the anticipated benefits of these transactions may never be realized due to the various risks and uncertainties associated with drug development detailed elsewhere in the risk factors. For example, in July 2019, we entered into a License and Development Agreement with Cantex Pharmaceuticals, Inc. pursuant to which we acquired exclusive worldwide rights to develop and commercialize Dociparstat Sodium (DSTAT) for any and all uses. In May 2022, we decided to discontinue the development of DSTAT and the License and Development Agreement was subsequently terminated.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our current assets, we may in-license or acquire additional assets, engage in a merger or acquisition transaction, issue additional shares of our common stock, or engage in other potential actions designed to maximize stockholder value. Our continuing review of these matters may not result in the identification or consummation of any transaction. The process of reviewing external opportunities may be time consuming and disruptive to our business operations and, if we are unable to effectively manage the process, our business, financial condition and results of operations could be adversely affected. We </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could incur substantial expenses associated with identifying, evaluating, negotiating, and consummating potential transactions. There can be no assurance that any potential additional transaction, if consummated, will provide greater value to our stockholders than that reflected in the current price of our common stock.  In addition, once any potential additional transaction is consummated, we are likely to incur substantial costs associated with future development and testing of any new product candidate, which may require us to raise additional capital.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;Risks Related to Clinical Development and Regulatory Approval</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">All of our product candidates are still under clinical development and may not obtain regulatory approval or be successfully commercialized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not marketed, distributed or sold any of our current product candidates. Our most advanced product candidate is ONC201, which we are developing for the treatment of H3 K27M-mutant glioma. In November 2022, we initiated a Phase 3 clinical study of ONC201 (the Phase 3 ACTION Study), and it is possible that a single trial to support regulatory approval may not be sufficient as the standard is with well-controlled Phase 3 studies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that our current or future clinical trials will be approved by regulators, and no guarantee that they will be completed or, if completed, will be successful, or if successful, will result in an approval for the sale of any of our product candidates. The success of any of our product candidates will depend on several factors, including the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">generating positive safety and efficacy data from our clinical trials of ONC201;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals from the FDA and corresponding regulatory authorities outside the United States;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing commercial manufacturing capabilities;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of the product, if approved for marketing;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety profile of the product following approval; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining, maintaining, enforcing and defending intellectual property rights and claims.</span></div><div style="padding-left:45pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, including ONC201, which would materially harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain, or may be delayed in obtaining, regulatory approval for our most advanced clinical candidate: ONC201.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2021, we acquired Oncoceutics, a privately-held, clinical-stage biotechnology company developing imipridones, a novel potential class of compounds. Oncoceutic&#8217;s lead product candidate, ONC201, is currently being evaluated in the Phase 3 ACTION Study, and multiple investigator-sponsored clinical studies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reached general agreement with the FDA on the design of the Phase 3 ACTION Study to support a potential approval for marketing. We have not yet reached agreement with foreign regulators regarding the adequacy of the planned studies, for any of our most advanced clinical candidates, with respect to a potential approval for marketing. We may be required to conduct additional clinical, nonclinical or manufacturing validation studies and submit those data before consideration of our application occurs. Depending on the extent of these or any other required studies, approval of any NDA or application that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA and/or foreign health authorities to approve our NDA or foreign application.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in obtaining, or an inability to obtain, regulatory approvals could prevent us from generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for ONC201, which would have a material adverse effect on our business and could potentially cause us to cease operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on the successful completion of clinical trials for our product candidates, including ONC201. The positive clinical results obtained for our product candidates in prior clinical studies may not be repeated in future clinical studies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approval for the sale of our product candidates, including ONC201, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more of our clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. In the case of ONC201, early </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">studies were open label studies of brain tumor patients, whereas the ongoing Phase 3 ACTION Study is a double blinded, placebo-controlled, investigational study. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience a number of unforeseen events during, or as a result of, clinical trials for our product candidates, that could adversely affect the completion of our clinical trials, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might be required to change one of our clinical research organizations (CROs) during ongoing clinical programs;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of subjects required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, or subjects may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the subjects are being exposed to unacceptable health risks, or other factors outside our control;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory or quality requirements;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may encounter agency or judicial enforcement actions which impact our clinical trials;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; or</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators to suspend or terminate the trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know whether any clinical trials we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market our most advanced product candidates, including ONC201. If later stage clinical trials do not produce favorable results, our ability to obtain regulatory approval for any of our product candidates may be adversely impacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. We may experience delays in clinical trials at any stage of development and testing of our product candidates. Our planned clinical trials may not begin on time, have an effective design, enroll a sufficient number of subjects, or be completed on schedule, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Events which may result in a delay or unsuccessful completion of clinical trials, including our currently planned or future clinical trials include:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to raise funding necessary to initiate or continue a trial; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in obtaining, or failure to obtain, regulatory approval of Investigational New Drug applications or to commence a trial; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching agreement with the FDA and foreign health authorities on final trial design;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of a clinical hold following an inspection of our clinical trial operations or trial sites by the FDA or other regulatory authorities;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays caused by disagreements with existing CROs and/or clinical trial sites; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in obtaining, or failure to obtain, required IRB or ethics committee (EC) approvals covering each site; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in recruiting suitable patients to participate in a trial; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in having subjects complete participation in a trial or return for post-treatment follow-up;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays caused by subjects dropping out of a trial due to side effects or otherwise; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical sites declining to participate or dropping out of a trial to the detriment of enrollment; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">agency or judicial enforcement actions against us;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in standard of care in specific diseases;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">time required to add new clinical sites; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If initiation or completion of any of our clinical trials for our product candidates, are delayed for any of the above reasons, our development costs may increase, our approval process could be delayed, any periods during which we may have the exclusive right to commercialize our product candidates may be reduced and our competitors may have more time to bring products to market before we do. Any of these events could impair our ability to generate revenues from product sales and impair our ability to generate regulatory and commercialization milestones and royalties, all of which could have a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adverse events (AEs) caused by our product candidates could cause us, other reviewing entities, clinical study sites or regulatory authorities to interrupt, delay or halt clinical studies and could result in the denial of regulatory approval. For example, in our Phase 2 study of ONC201, one serious adverse event, considered to be possibly ONC201-related by the investigator and unlikely to be ONC201-related by the sponsor, was identified. Full safety data collection and analysis for this cohort is ongoing. If an unacceptable frequency and/or severity of AEs are reported in our clinical trials for our product candidates, our ability to obtain regulatory approval for product candidates may be negatively impacted. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our approved products cause serious or unexpected side effects prior to or after receiving market approval, a number of potentially significant negative consequences could result, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may approve the product only with a risk evaluation and mitigation strategy (REMS), potentially with restrictions on distribution and other elements to assure safe use (ETASU);</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in a form of a modified REMS;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered or to conduct additional clinical studies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">After the completion of our clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize any of our product candidates and we cannot, therefore, predict the timing of any future revenue from any of our product candidates, including ONC201.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot commercialize our product candidates, including ONC201, until the appropriate regulatory authorities have reviewed and approved the product candidate. The regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval for any of our product candidates. Delays may occur because we may not be able to obtain accelerated approval for our product candidates and large confirmatory studies may be needed to support accelerated approval or be conducted to pursue a first full approval. For ONC201, a companion diagnostic test may be needed to identify patients with H3 K27M-mutant glioma before approval. Additional delays in the United States may result if any of our product candidates is brought before an FDA advisory committee, which could recommend restrictions on approval or recommend non-approval of the product candidate. In the EU context, an Oral Explanation during MAA review could extend approval timelines and result in a Negative Opinion. A re-examination procedure is available in the EU whereby a Negative Opinion could be over-turned and become a Positive Opinion. New rapporteurs would be selected for the product. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical studies and the review process. As a result, we cannot predict when, if at all, we will receive any future revenue from commercialization of any of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Failure by us or third-party collaborators to successfully develop, validate and obtain regulatory approval for companion diagnostics for use by oncologists could harm our ability to develop and commercialize ONC201.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For ONC201, a standard of care diagnostic test is used to identify patients with H3 K27M-mutant glioma. Currently, that test is only available as a Laboratory Developed Test, or LDT, that has not been cleared or approved by FDA. FDA may require approval of a companion diagnostic in connection with an approval of ONC201 NDA. We intend to rely on third-parties for development of companion diagnostics for commercialization of ONC201, if required. Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as medical devices. Any failure by a third-party to obtain FDA clearance or approval for an H3 K27M mutation diagnostic test may impair our ability to meet FDA requirements for ONC201 and subsequently jeopardize or delay a potential marketing authorization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA may determine that ONC201 or any of our other product candidates, even if approved for the designated rare pediatric disease prior to September 30, 2026, do not meet the eligibility criteria for a priority review voucher.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon regulatory approval of a product candidate for a designated rare pediatric disease, neglected tropical disease, or medical countermeasure, the FDA may award to the sponsor of the treatment a transferable voucher that enables the bearer to priority review of another product candidate.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has granted rare pediatric disease designation to ONC201 for treatment of H3 K27M-mutant glioma. Designation of a drug for a rare pediatric disease does not guarantee that an NDA for such drug will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Under the Federal Food, Drug, and Cosmetic Act (FDCA), we will need to request a rare pediatric disease priority review voucher in our original NDA for ONC201. The FDA may determine that an NDA for ONC201, if approved, does not meet the eligibility criteria for a priority review voucher, including for the following reasons:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">treatment of H3 K27M-mutant glioma no longer meets the definition of a rare pediatric disease;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the NDA contains an active ingredient (including any ester or salt of the active ingredient) that has been previously approved in an NDA;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the NDA is not deemed eligible for priority review;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the NDA does not rely on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population (that is, if the NDA does not contain sufficient clinical data to allow for adequate labeling for use by the full range of affected pediatric patients); or</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the NDA is approved for a different adult indication than the rare pediatric disease for which ONC201 is designated.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authority for the FDA to award rare pediatric disease priority review vouchers for drugs that have received rare pediatric disease designation prior to September 30, 2024 currently expires on September 30, 2026. Absent any legislative extension, if the NDA for ONC201 is not approved prior to September 30, 2026 for any reason, regardless of whether it meets the criteria for a rare pediatric disease priority review voucher, it will not be eligible for a priority review voucher.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Following regulatory approval for any of our product candidates, including ONC201, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval, the granting authority may still impose significant restrictions on the indicated uses, distribution or marketing of our product candidates, including ONC201, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the labeling ultimately approved for our product candidates, will likely include restrictions on use due to the specific patient population and manner of use in which the drug was evaluated and the safety and efficacy data obtained in those evaluations. In addition, the distribution of any of our product candidates may be tightly controlled through a REMS with ETASU, which are required medical interventions or other actions healthcare professionals need to execute prior to prescribing or dispensing the drug to the patient.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates will also be subject to additional ongoing regulatory requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping and reporting of safety and other post-market information. In the United States, the holder of an approved NDA is obligated to monitor and report AEs and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. If a REMS is required, the NDA holder may be required to monitor and evaluate those in the healthcare system who are responsible for implementing ETASU measures. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. Moreover, EU and member countries </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impose strict restrictions on the promotion and marketing of drug products. The off-label promotion of medicinal products is prohibited in the U.S., EU and in other territories. Physicians, on the other hand, may prescribe products for off-label uses in the U.S. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The promotion of medicinal products that are not subject to a marketing authorization is also prohibited in the EU. Violations of the rules governing the promotion of medicinal products in the EU and in other territories could be penalized by administrative measures, fines and imprisonment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, manufacturers of drug products and their facilities are subject to payment of user fees and continual review and periodic inspections by regulatory authorities for compliance with Current Good Manufacturing Practices (cGMP), and adherence to commitments made in the application. If we, or a regulatory agency, discover previously unknown problems with a product, such as quality issues or AEs of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable regulatory requirements following approval of any product candidates, a regulatory agency may:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue an untitled or warning letter asserting that we are in violation of the law;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or withdraw regulatory approval;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve a pending application or supplements to an application submitted by us;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall and/or seize product; or</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to allow us to enter into supply contracts, including government contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and inhibit our ability to generate revenues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may never obtain approval for or commercialize any of our products outside of the United States, nor does approval of any of our products outside the United States mean we will ever obtain approval for or commercialize any of our products inside the United States, all of which could limit our ability to realize their full market potential.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in any markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conversely, approval by regulatory authorities outside the United States, such as the European Commission, does not ensure approval by the FDA. Moreover, clinical trials conducted outside the United States may not be accepted by the FDA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and adequate reimbursement may not be available for ONC201, or any of our other current or future product candidates, which could make it difficult for us to sell profitably, if approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of ONC201, or any other product candidates that we commercialize, if approved, will depend in part on the extent to which coverage and adequate reimbursement will be available from third-party payers, including government health administration authorities, managed care organizations and private health insurers. Third-party payers decide which therapies they will pay for and establish reimbursement levels. Third-party payers in the United States often rely upon </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payer-by-payer basis. One payer&#8217;s determination to provide coverage for a drug does not assure that other payers will also provide coverage and adequate reimbursement for the drug. Additionally, a third-party payer&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Third-party payers are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. Even if favorable coverage and reimbursement status is attained for our products candidates for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with investigators, health care professionals, consultants, third-party payers, and customers may be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers and others play a primary role in the recommendation and prescribing of any products for which we obtain marketing approval. Our current business operations and future arrangements with investigators, healthcare professionals, consultants, third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include, but are not limited to, the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare anti-kickback statute which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the Federal Civil False Claims Act (False Claims Act) which permit private individuals to bring a civil action on behalf of the federal government to enforce certain of these laws thought civil whistleblower or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions and the Federal Civil Monetary Penalties Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent or from knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which, among other things, imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payer (e.g., public or private) and knowingly or willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), and their implementing regulations impose certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, and their business associates as well as their covered subcontractors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the General Data Protection Regulation (GDPR), which impose obligations on companies in relation to the handling of personal data of individuals within the EU, along with related national legislation;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandated healthcare professional payments reporting laws and/or requirements throughout global jurisdictions, including EU member states, in which we conduct research and development and/or other business activities;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDCA which prohibits, among other things, the adulteration or misbranding of drugs and devices;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal transparency law, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies to report to the Centers for Medicare &amp; Medicaid Services (CMS) information related to payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by state governmental and non-governmental third-party payers, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state and local laws that require the registration of pharmaceutical sales representatives; state laws and regulations that require manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities;  and state laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA.  </span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these or any other health regulatory laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and/or divert our management&#8217;s attention from the operation of our business. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they also may be subject to significant criminal, civil or administrative sanctions, including, but not limited to, exclusions from government funded healthcare programs, which could also materially affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in March 2010, the ACA was enacted to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. However, there have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. It is possible that the ACA will be subject to additional challenges in the future. It is unclear how any such challenges and other litigation, and the healthcare reform measures of the Biden administration will impact the ACA and our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries, presidential executive orders, and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, in July 2021, the Biden administration released an executive order with multiple provisions aimed at prescription drugs.  In response to this executive order, in September 2021, the U.S. Department of Health and Human Services (DHHS) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions DHHS can take to advance these principles. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law, which among other things, (1) directs the DHHS to negotiate the price of certain single-source drugs and biologics covered under </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits DHHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. DHHS has and will continue to issue and update guidance as these programs as implemented. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. While the Inflation Reduction Act of 2022 predominantly focuses on controlling spending of drugs that are covered by Medicare, and our product candidates, if approved, are not expected to target the Medicare population, other similar legislation may be implemented in the future that may be broader in scope and may adversely affect our operations, including our ability to commercialize our product candidates, if approved, successfully. Further, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, DHHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Such reform efforts are likely to continue the pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria, lower reimbursement, and additional downward pressure on the price that we receive for any future approved product. We cannot predict what healthcare reform initiatives may be adopted in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party manufacturers to produce our preclinical and clinical drug supplies, and we intend to rely on third parties to produce commercial supplies of any approved product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and we do not expect to own or operate, facilities for product manufacturing, storage and distribution, or testing with respect to our product candidates, including ONC201. In the past, we have relied on third-party manufacturers for supply of our preclinical and clinical drug supplies. We expect that in the future we will continue to rely on such manufacturers for drug supply that will be used in clinical trials and for commercialization of any of our product candidates that receive regulatory approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third-party manufacturers entails risks, including:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to meet our product specifications and quality requirements consistently;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or inability to procure or expand sufficient manufacturing capacity;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing and product quality issues related to scale-up of manufacturing;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs and validation of new equipment and facilities required for scale-up;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to comply with cGMP and similar foreign standards;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on a limited number of sources, and in some cases, single sources for product components, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell our product candidates in a timely fashion, in sufficient quantities or under acceptable terms;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier, or other factors outside our control;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">carrier disruptions or increased costs that are beyond our control; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to deliver our products under specified storage conditions and in a timely manner.</span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could lead to clinical study delays, failure to obtain regulatory approval or impact our ability to successfully commercialize our products. Some of these events could be the basis for FDA or equivalent foreign regulator action, including injunction, recall, seizure, or total or partial suspension of production. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing issues may arise that could increase product and regulatory approval costs or delay or impair commercialization of ONC201 or our other product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to validate ONC201 drug substance and drug product processes prior to approval at our selected vendors.  It is our expectation that only one supplier of drug substance and one supplier of drug product will be qualified as vendors for ONC201 with the FDA. If supply is interrupted, there could be a significant disruption in the clinical supply. An alternate vendor would need to be qualified which could result in a further delay.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more batch data is generated during both pre- and post-validation for both the drug substance and drug products, and as additional stability data is collected, issues may arise in our processes and stability programs which could require resolution in order to proceed with our planned clinical trials and obtain regulatory approval for the commercial marketing of our products and product candidates. In the future, we may identify significant impurities, which could result in increased scrutiny by the regulatory agencies, delays in clinical program and regulatory approval for our products and product candidates, increases in our operating expenses, or failure to obtain or maintain approval for ONC201.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The anticipated benefits of the sale of our TEMBEXA program and related assets may not be realized fully or at all or may take longer to realize than expected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we completed the sale of our TEMBEXA program and related assets to Emergent Biodefense Operations Lansing LLC (Emergent). Under the terms of the sale, we are entitled to contingent consideration, including milestone payments and royalties, dependent upon the further development and commercial success of TEMBEXA. Accordingly, our ability to receive the contingent consideration will depend, in part, on Emergent&#8217;s ability to successfully develop and commercialize TEMBEXA. If Emergent is unable to successfully or timely integrate TEMBEXA operations into its business, it may not be able to realize the revenue growth, milestone achievements, synergies and other anticipated benefits resulting from the Asset Sale, and consequently, we may not receive all, or any, of the contingent payments under the Purchase Agreement. The milestones set forth in the Purchase Agreement may not be achieved on a timely basis, if at all, and we may not receive any future contingent payments. Any failure to achieve such milestones, or a perception that the milestones may not be achieved, may adversely affect our business and the value of our common stock. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, in 2019, we entered into a licensing arrangement with SymBio Pharmaceuticals (SymBio), whereby SymBio is responsible for the future development and commercialization of TEMBEXA for human diseases other than orthopoxviruses, including smallpox. In connection with the sale of TEMBEXA worldwide rights to Emergent, our rights and obligations under the SymBio license agreement were assumed by Emergent. We could receive up to $12.5 million from Emergent in brincidofovir regulatory milestones related to the SymBio license agreement. Our right to receive milestone payments under the Asset Purchase Agreement depends on the achievement of certain regulatory milestones by SymBio in the licensed indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of the non-orthopox uses of TEMBEXA in humans and our ability to receive potential milestone payments under the Asset Purchase Agreement, would be adversely affected if SymBio:</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lacks or does not devote sufficient time and resource to the development of TEMBEXA;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lacks or does not devote sufficient capital to fund the development of TEMBEXA;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develops, either alone or with others, products that compete with TEMBEXA;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fails to gain the requisite regulatory approvals for TEMBEXA;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">does not conduct its activities in a timely manner;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terminates its license with Emergent;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">does not effectively pursue and enforce intellectual property rights relating to TEMBEXA; or</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">merges with a third-party that wants to terminate the collaboration.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited or no control over the occurrence of any of the foregoing. If any of these issues arise, it may delay or eliminate our ability to receive the regulatory milestones in the Asset Purchase Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emergent may not adequately perform according to the terms of the BARDA Agreement, and we might be required to guarantee performance of all obligations that Emergent assumed under novation. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by U.S. government contracting regulations, the novation agreement for the BARDA Agreement includes a clause requiring that Chimerix, as transferor, guarantee Emergent&#8217;s performance of the BARDA Agreement.  If Emergent were to fail to manufacture or deliver treatment courses of TEMBEXA, fail to properly respond to a product recall, or breach other performance obligations, BARDA may require that we perform instead, which may cause us to file claims under our insurance policies, divert the attention of our management from company priorities, expend additional resources engaging vendors, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">require  additional legal agreements with Emergent to enable Chimerix to resume title to TEMBEXA and control of supply chain vendors necessary for performance, incur additional legal fees, among other unplanned expenses which could delay or prevent our completion of our priority clinical programs, as well as result in reputational harm.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct, supervise and monitor our clinical studies and related data, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we have agreements governing their activities, we have limited influence over their actual performance. We have relied and plan to continue to rely upon CROs to monitor and manage data for our ongoing clinical programs for our product candidates, as well as the execution of nonclinical studies. We control only certain aspects of our CROs&#8217; activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on CROs does not relieve us of our regulatory responsibilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our CROs are required to comply with the FDA&#8217;s guidance for clinical trials conducted within the jurisdiction of the United States (or the foreign regulatory authority equivalent for clinical trials conducted outside the jurisdiction of the United States), which follows the International Council for Harmonization Good Clinical Practice (ICH GCP), which are regulations and guidelines enforced by the FDA for all of our product candidates in clinical development. The FDA enforces the ICH GCP through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with the ICH GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our marketing applications. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies, or other drug development activities which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize ONC201 or any other product candidates. Disagreements with our CROs over contractual issues, including performance, compliance or compensation could lead to termination of CRO agreements and/or delays in our clinical program and risks to the accuracy and usability of clinical data. As a result, our financial results and the commercial prospects for our product candidates that we develop would be harmed, our costs could increase, and our ability to generate revenues could be delayed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of ONC201, and any other product candidates, will depend upon the acceptance of these products by the medical community, including physicians, patients, pharmacists, health care payers or government agencies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following receipt of marketing approval, a product or product candidate may not gain sufficient market acceptance by physicians, patients, healthcare payers and others in the medical community. If these products do not achieve an adequate level of market acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of any of our product candidates will depend on a number of factors, including:</span></div><div style="text-align:justify;text-indent:42.75pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstration of clinical safety and efficacy in our clinical trials;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience, ease of administration and acceptance by physicians, patients, pharmacists and health care payers;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevalence and severity of any AEs;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in the FDA-approved labeling from Regulatory Authorities such as the FDA and EMA for the relevant product candidate;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability, efficacy and safety of alternative treatments;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">price and cost-effectiveness;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectiveness of our or any future collaborators&#8217; or competitor&#8217;s sales and marketing strategies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to obtain hospital formulary approval; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to ensure availability for product through appropriate channels;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to maintain adequate inventory; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to obtain and maintain sufficient third-party coverage and adequate reimbursement, which may vary from country to country.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval, the granting authority may still impose significant restrictions on the indicated uses, distribution or marketing of our other product candidates, including ONC201, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the labeling ultimately approved for our product candidates, will likely include restrictions on use due to the specific patient population and manner of use in which the drug was evaluated and the safety and efficacy data obtained in those evaluations. In addition, the distribution of ONC201 may be tightly controlled through a REMS with ETASU, which are required medical interventions or other actions healthcare professionals need to execute prior to prescribing or dispensing the drug to the patient. Some actions may also be required in order for the patient to continue on treatment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to sustainably generate revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have an organization for the sales and distribution of pharmaceutical products. The cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved we must establish our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We may enter into strategic partnerships with third parties to commercialize our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy for ONC201, is to establish a specialty sales force and/or collaborate with third parties to promote the product to healthcare professionals and third-party payers in the United States and elsewhere. We may elect to launch with a contract sales organization and utilize accompanying commercial support services provided by a contract sales organization. Our future collaboration partners, if any, may not dedicate sufficient resources to the commercialization of our product candidates or may otherwise fail in their commercialization due to factors beyond our control. If we are unable to establish effective collaborations to enable the distribution and sale of our product candidates to healthcare professionals and in geographical regions, including the United States, that are not covered by our own marketing and sales force, or if our potential future collaboration partners do not successfully commercialize our product candidates, our ability to generate revenues from product sales, including sales of ONC201, will be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Establishing an internal or contract sales force involves many challenges, including:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recruiting and retaining talented people;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">training employees that we recruit;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing compliance standards;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">setting the appropriate system of incentives;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing additional headcount;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensuring that appropriate support functions are in place to support sales force organizational needs; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integrating a new business unit into an existing corporate architecture.</span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish our own sales force or negotiate a strategic partnership for the commercialization of our product candidates in any markets, we may be forced to delay the potential commercialization of our product candidates in those markets, reduce the scope of our sales or marketing activities for our product candidates in those markets or undertake the commercialization activities for in those markets at our own expense. If we elect to increase our expenditures to fund commercialization activities ourselves, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we will not be able to bring our product candidates to market or generate product revenue. Limited or lack of funding will impede our ability to achieve successful commercialization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third-party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales, marketing and market access personnel.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are approved for commercialization, we may enter into agreements with third parties to market those product candidates outside the United States. We expect that we will be subject to additional risks related to entering into international business relationships, including:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals in the EU and other foreign countries;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers and regulatory and labor requirements;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing payer reimbursement regimes, governmental payers or patient self-pay systems and price controls;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory risks associated with cross-border transportation of animal-sourced material;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters and other events outside our control including epidemics, pandemics, earthquakes, typhoons, floods and fires; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions or its anti&#8209;bribery provisions, or similar anti&#8209;bribery or anti&#8209;corruption laws and regulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by both the EU and many of the individual countries in Europe with which we will need to comply. Many U.S.-based biopharmaceutical companies have found the process of marketing their own products outside the United States to be very challenging.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are intensely competitive. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have substantially greater financial, technical, commercial and other resources, such as larger research and development staff, stronger intellectual property portfolios and experienced marketing and manufacturing organizations and established sales forces. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, drug products that are more effective or less costly than any of our drug candidates that we are currently developing or that we may develop including ONC201.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will face competition from other drugs currently approved or that will be approved in the future for the same indications. Therefore, our ability to compete successfully will depend largely on our ability to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discover and develop medicines that are superior to other products in the market;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstrate through our clinical trials that our product candidates, including ONC201, are differentiated from existing and future therapies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract qualified scientific, product development and commercial personnel;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain and successfully defend and enforce patent and/or other proprietary protection for our medicines and technologies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain required regulatory approvals;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new medicines;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deliver a competitive value proposition compared to established competition and/or competitors who will enter the market before or after any of our product candidates, including ONC201; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negotiate competitive pricing and reimbursement with third-party payers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of our competitors&#8217; products could affect the price we are able to charge, for any product candidate we develop. The inability to compete with existing or subsequently introduced drug products would have a material adverse impact on our business, financial condition and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing medicines before we do, which would have a material adverse impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends primarily upon our ability to identify, develop and commercialize product candidates. Because we have limited financial and managerial resources, we focus on research programs and product candidates for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or other indications that later prove to have greater commercial potential.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research methodology or that of our collaboration partners may be unsuccessful in identifying potential product candidates;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our collaboration partners may change their development profiles for potential product candidates or abandon a therapeutic area.</span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our research efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or protect intellectual property rights related to our products and product candidates, we may not be able to compete effectively in our market.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our products and product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover the products in the United States or in other countries. If this were to occur, early generic competition could be expected against any product candidates we may develop. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing based on a pending patent application. Even if patents do successfully issue, third parties may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">challenge their validity, enforceability, scope or ownership, which may result in such patents, or our rights to such patents, being narrowed or invalidated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the patent applications we hold or license with respect to any of our product candidates fails to issue or if their breadth or strength of protection is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our products. We cannot offer any assurances about which, if any, patents will issue or whether any issued patents will be found not invalid and not unenforceable, will go unthreatened by third parties or will adequately protect our products and product candidates. Further, if we encounter delays in regulatory approvals, the period of time during which we could market an approved product under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to any of our product candidates. Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be provoked by a third-party or instituted by us to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license it from the prevailing party, which may not be possible. In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although we expect all of our employees to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed, that such agreements provide adequate protection and will not be breached, that our trade secrets and other confidential proprietary information will not otherwise be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the laws of some foreign countries do not protect patents and other proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property abroad. We may also fail to pursue or obtain patents and other intellectual property protection relating to our products and product candidates in all foreign countries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, certain of our activities and our licensors&#8217; activities have been funded, and may in the future be funded, by the U.S. federal government. When new technologies are developed with U.S. federal government funding, the government obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise &#8220;march-in&#8221; rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the U.S. government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, U.S. government-funded inventions must be reported to the government, U.S. government funding must be disclosed in any resulting patent applications, and our rights in such inventions may be subject to certain requirements to manufacture products in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts or otherwise affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter party reexamination proceedings before the United States Patent and Trademark Office (U.S. PTO) and its foreign counterparts. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of ONC201, or any </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our products or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors and licensees or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third-party may also cause the third-party to bring counterclaims against us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in a litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the U.S. PTO and foreign patent agencies in several stages over the lifetime of the patent. The U.S. PTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors that control the prosecution and maintenance of our licensed patents fail to maintain the patents and patent applications covering our product candidates, we may lose our rights and our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to United States Government Contracts and Grants </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable provisions in government contracts, may harm our business, financial condition and operating results. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States government contracts typically contain unfavorable provisions and are subject to audit and modification by the government at its sole discretion, which will subject us to additional risks. For example, under any contract with the U.S. government, the U.S. government has the power to unilaterally:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">audit and object to any contract-related costs and fees on grounds that they are not allowable under the FAR, and require us to reimburse all such costs and fees;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or prevent us for a set period of time from receiving new contracts or extending our existing contract based on violations or suspected violations of laws or regulations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">claim nonexclusive, nontransferable rights to product manufactured and intellectual property developed under the contract and may, under certain circumstances, such as circumstances involving public health and safety, license such inventions to third parties without our consent;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cancel, terminate or suspend any contract based on violations or suspected violations of laws or regulations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terminate any contract in whole or in part for the convenience of the government for any reason or no reason, including if funds become unavailable to the applicable governmental agency;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the scope and value of any contract;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decline to exercise an option to continue any contract;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">direct the course of a development program in a manner not chosen by the government contractor;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to perform the option segments even if doing so may cause us to forego or delay the pursuit of other opportunities with greater commercial potential;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">take actions that result in a longer development timeline than expected; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change certain terms and conditions in any contract.</span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government also has the right to terminate any contract if termination is in the government&#8217;s interest, or if we default by failing to perform in accordance with the milestones set forth in the contract. Termination-for-convenience provisions generally enable us to recover only our costs incurred or committed (plus a portion of the agreed fee) and settlement expenses on the work completed prior to termination. Except for the amount of services received by the government, termination-for-default provisions do not permit recovery of fees.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we must comply with numerous laws and regulations that affect how we conduct business with the United States government. Among the most significant government contracting regulations that affect our business are:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FAR, and agency-specific regulations supplements to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts and implement federal procurement policy in numerous areas, such as employment practices, protection of the environment, accuracy and retention periods of records, recording and charging of costs, treatment of laboratory animals and human subject research;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Act and the Foreign Corrupt Practices Act;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">export and import control laws and regulations; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we may be required to enter into agreements and subcontracts with third parties, including suppliers, consultants and other third-party contractors, in order to satisfy our contractual obligations pursuant to our agreements with the U.S. government. Negotiating and entering into such arrangements can be time-consuming and we may not be able to reach agreement with such third parties. Any such agreement must also be compliant with the terms of our government contract. Any delay or inability to enter into such arrangements or entering into such arrangements in a manner that is non-compliant with the terms of our contract, may result in violations of our contract.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these unfavorable provisions, we must undertake significant compliance activities. The diversion of resources from commercial programs to these compliance activities, as well as the exercise by the U.S. government of any rights under these provisions, could materially harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to audit by the U.S. government and a negative audit could adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States government agencies, such as the DHHS, routinely audit and investigate government contractors and recipients of federal grants. These agencies review a contractor&#8217;s performance under its contracts, cost structure and compliance with applicable laws, regulations and standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DHHS can also review the adequacy of, and a contractor&#8217;s compliance with, its internal control systems and policies, including the contractor&#8217;s purchasing, property, estimating, compensation and management information systems. Any costs found to be improperly allocated to a specific contract will not be reimbursed, while such costs already reimbursed must be refunded. If an audit uncovers improper or illegal activities, we may be subject to civil and criminal penalties and administrative sanctions, including:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of contracts;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">forfeiture of profits;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of payments;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or prohibition from conducting business with the U.S. government.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we could suffer serious reputational harm if allegations of impropriety were made against us by the U.S. government, which could adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations and Industry</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing demand for compassionate use or third-party supply of our unapproved therapies could result in losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent media attention to individual patients' expanded access requests has resulted in the introduction of legislation at the local and national level referred to as &#8220;Right to Try&#8221; laws, such as the Right to Try Act, which are intended to give patients access to unapproved therapies. New and emerging legislation regarding expanded access to unapproved drugs for life-threatening illnesses could negatively impact our business in the future. In addition, during 2014, we were the target of an active and&#160;disruptive&#160;social media campaign&#160;related&#160;to a request for access to TEMBEXA. If we experience similar social media campaigns in the future, we may experience significant disruption to our business which could result in losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A possible consequence of both activism and legislation in this area is the need for us to initiate an unanticipated expanded access program or to make our product candidates more widely available sooner than anticipated. We are a small company with limited resources and unanticipated trials or access programs could result in diversion of resources from our primary goals. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patients who receive access to unapproved drugs through compassionate use or expanded access programs have life-threatening illnesses and have exhausted all other available therapies. The risk for serious adverse events in this patient population is high which could have a negative impact on the safety profile of our product candidates, which could cause significant delays or an inability to successfully commercialize them, which could materially harm our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient demand for ONC201 or ONC206 outside of our clinical trial could impair the conduct or delay the completion of our controlled clinical trials. Currently, there are a limited number of therapeutic options available to glioma patients suffering from this severe and life-threatening disease.  In the face of a glioma diagnosis, patients will often turn to alternate means of access to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug outside the scope of our current clinical trials.  From time to time we are aware of such alternate providers that purport to supply ONC201, ONC206 or similar versions thereof and will take meaningful action when and if appropriate.  In the event that patients opt to choose alternative supplies from third-party rather than enroll in our studies, our clinical program could be negatively impacted. In the event that patients choose to access alternative supplies while enrolled in our clinical studies, we may not be able to successfully meet the study endpoints and our clinical program could be negatively impacted. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have amended the protocol of our open expanded access program to focus on patients that are not eligible for the Phase 3 ACTION Study. Therefore, the Phase 3 ACTION Study will serve as the main mechanism for a patients with newly diagnosed H3 K27M-mutant diffuse glioma following completion of radiotherapy to receive ONC201. This decision could prompt adverse publicity or other disruptions related to potential participants in such expanded access programs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition for Phase 3 ACTION Study eligible patients from Investigator Initiated Clinical Trials (IITs) could result in losses.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently provide investigational product for the Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (BIOMEDE 2) IIT, sponsored by Gustave Roussy, in Paris, France. The BIOMEDE 2 Study is a multicenter, randomized open-label phase-3 controlled trial evaluating the efficacy and safety of ONC201 and radiation in comparison with everolimus and radiation (primary objective based on internal comparison) and subsequently to historical controls. Currently, the BIOMEDE 2 Study is open in France to pre-radiotherapy newly diagnosed H3 K27M and H3 K27me3-loss glioma patients. Some of these patients may be eligible for the Phase 3 ACTION Study following radiotherapy. While we believe that the impact is likely to be small in light of the small geographic footprint and limited eligibility overlap, competing enrollment could have a negative effect on our ability to enroll the Phase 3 ACTION Study.  Patients may prefer to enroll in the BIOMEDE 2 IIT instead of the Phase 3 ACTION study because that study does not contain a placebo control arm, cross-over is allowed at progression, and treatment can be initiated with radiation. Patient preference for the BIOMEDE 2 IIT could impair the conduct or delay the initiation or completion of the Phase 3 ACTION Study. If initiation or completion of the Phase 3 ACTION Study is delayed, our development costs may increase, our approval process could be delayed, any periods during which we may have the exclusive right to commercialize ONC201 may be reduced and our competitors may have more time to bring products to market before we do. Any of these events could impair our ability to generate revenues from product sales and impair our ability to generate regulatory and commercialization milestones and royalties, all of which could have a material adverse effect on our business. We recently worked with another IIT sponsor to amend the protocol to remove potentially Phase 3 ACTION Study eligible patients. This decision could prompt adverse publicity or other disruptions related to potential participants in the IITs. While the Company has negotiated a right to obtain access to the data from the BIOMEDE 2 Study at a specified price should the Company desire to do so in support of a commercial authorization, there is no assurance that the Company will be able to enter into a definitive agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, delays in the development of our product candidates, penalties and a loss of business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities, and the activities of our collaborators, partners and third-party providers, are subject to extensive government regulation and oversight both in the United States and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. States increasingly have been placing greater restrictions on the marketing practices of healthcare companies. In addition, pharmaceutical and biotechnology companies have been the target of lawsuits and investigations alleging violations of government regulations, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of federal or state healthcare business, submission of false claims for government reimbursement, antitrust violations, violations of the Foreign Corrupt Practices Act, or violations related to environmental matters. Violations of governmental regulation may be punishable by criminal, civil and administrative sanctions, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid. In addition to penalties for violation of laws and regulations, we could be required to delay or terminate the development of our product candidates, or we could be required to repay amounts we received from government payers, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the principal members of our executive team. While we have entered into employment agreements or offer letters with each of our executive officers, any of them could leave our employment at any time, as all of our employees </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are &#8220;at will&#8221; employees. To help attract, retain, and motivate qualified employees, we use share-based incentive awards such as employee stock options and restricted stock units. As of March&#160;31, 2023, all outstanding options had an exercise price above the closing price of the stock on that date. As a result, the current situation provides a considerable challenge to maintaining employee motivation, as well as creating a serious threat to retention until a recovery commences. If our share-based compensation ceases to be viewed as a valuable benefit, our ability to attract, retain, and motivate employees could be weakened, which could harm our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share reserves under our 2013 Equity Incentive Plan (the 2013 Plan) and 2013 Employee Stock Purchase Plan (ESPP) were previously subject to automatic annual increases on January 1st of each year.  In the future, subject to limited exceptions, we will be required to seek stockholder approval of future increases to the number of shares underlying our 2013 Plan (or a successor plan) and ESPP.  In the event we are unable to obtain stockholder approval of such future increases, our ability to attract, retain and motivate employees through the use of share-based compensation would be substantially curtailed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. Recruiting and retaining other qualified employees for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of appropriately skilled executives in our industry, which is likely to continue. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. In addition, failure of any of our clinical studies may make it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of the services of any executive or key employee may adversely affect the progress of our research, development and commercialization objectives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us, which could also adversely affect the progress of our research, development and commercialization objectives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our product candidates, including ONC201, in clinical studies and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation and significant negative media attention;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of participants from our clinical studies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend the related litigation;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management&#8217;s attention from our primary business;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to commercialize our product candidates, including ONC201; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates, if approved for commercial sale.</span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently carry $15 million per occurrence, and $15 million in the aggregate in product liability insurance covering our United States clinical trials, with additional local coverage as required for the other countries in which we conduct our trials, but not yet extending coverage to commercial sales. Our current product liability insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for our product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock is likely to be volatile, and you may not be able to resell your shares at or above your purchase price.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been volatile, and is likely to continue to be volatile for the foreseeable future. Our stock price is subject to wide fluctuations in response to a variety of factors, including the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials of our product candidates or those of our competitors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in filing an application for any of our product candidates and any adverse development or perceived adverse development with respect to regulatory review of that application;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully develop and commercialize our product candidates, including ONC201;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of any of our license or collaboration agreements;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments regarding the sale of our TEMBEXA program and specified related assets to Emergent;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any agency or judicial enforcement actions against us;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain additional funding;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries applicable to our product candidates;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory decisions;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain adequate product supply for our product candidates, or the inability to do so at acceptable prices;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new products, services or technologies by our competitors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial projections we provide to the public;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed the estimates and projections of the investment community;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors, and the issuance of new or changed securities analysts&#8217; reports or recommendations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits (including patent or stockholder litigation), and disputes or other developments relating to proprietary rights (including patents, litigation matters and our ability to obtain patent protection for our technologies);</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key scientific or management personnel;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us or our stockholders in the future;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and The Nasdaq Global Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon shares of common stock outstanding as of March&#160;31, 2023, our then executive officers, directors, 5% stockholders (known to us through available information) and their affiliates beneficially owned approximately 35.8% of our voting stock. Therefore, these stockholders have the ability to substantially influence us through this ownership position. For example, these stockholders, if they choose to act together, may be able to influence the election of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholder activism could cause material disruption to our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Publicly traded companies have increasingly become subject to campaigns by activist investors advocating corporate actions such as actions related to financial restructuring, dividends, share repurchases and even sales of assets or the entire company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, our shareholder Rubric Capital Management (Rubric) issued a press release and filed a Schedule 13D in November 2022, in which Rubric expressed a lack of confidence in the Company&#8217;s strategic direction.  In response, the Company issued a press release in which we stated we do not believe a liquidation of the Company is in the best interests of all of our shareholders as it would deprive them of the significant upside potential of ONC201 and our other assets. We also stated it would be irresponsible to patients with this deadly disease as it would halt critical progress on ONC201. We stated we are confident that the continued successful execution of our strategy is the best path to maximize shareholder value, and that our Board and leadership team regularly consider all opportunities to create or enhance value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Responding to proxy contests and other actions by Rubric or other activist investors could be costly and time-consuming, disrupt our operations and divert the attention of our board of directors and senior management from the pursuit of our business strategies, which could adversely affect our results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to establish and maintain adequate finance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act of 2002, and the related rules and regulations of the Securities and Exchange Commission, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include establishing and maintaining corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compliance with Section 404 of the Sarbanes-Oxley Act has required and will continue to require that we incur substantial accounting expense and expend significant management efforts. In this or future years, our testing, or the subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls that we would be required to remediate in a timely manner so as to be able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act each year. If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner each year, we could be subject to sanctions or investigations by the Securities and Exchange Commission, The Nasdaq Stock Market or other regulatory authorities which would require additional financial and management resources and could adversely affect the market price of our common stock. Furthermore, if we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed and investors could lose confidence in our reported financial information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to review additional potential transactions to add to our pipeline of product candidates, and these transactions could involve the issuance of additional shares of common stock or other equity securities. For example, on January 7, 2021, we acquired Oncoceutics, a privately-held, clinical-stage biotechnology company developing imipridones, including ONC201. As part of the consideration for the acquisition, we paid an upfront cash payment of approximately $25.0 million and issued an aggregate of 8,723,769 shares of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our 2013 Equity Incentive Plan (the 2013 Plan), our management is authorized to grant stock options to our employees, directors and consultants. In addition, our board of directors may grant or provide for the grant of rights to purchase shares of our common stock pursuant to the terms of our 2013 Employee Stock Purchase Plan (ESPP). To the extent we seek, and our stockholders approve, future increases to the number of shares underlying our 2013 Plan (or a successor plan) and ESPP, our stockholders may experience additional dilution, which could cause our stock price to fall.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of the net proceeds from our financing transactions and may not use them effectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of the net proceeds from our financing transactions. Because of the number and variability of factors that will determine our use of the net proceeds from our financing transactions, their ultimate </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we have invested the net proceeds from our financing transactions in investment-grade, interest-bearing securities with maturities less than 24 months. These investments may not yield a favorable return to our stockholders.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Volatility in our stock price could subject us to securities class action litigation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New tax laws, statutes, rules, regulations or ordinances could be enacted at any time. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted differently, changed, or modified. Any such enactment, interpretation, change or modification could adversely affect us, possibly with retroactive effect. For example, the recently enacted IRA imposes, among other rules, a 15% minimum tax on the book income of certain large corporations and a 1% excise tax on certain corporate stock repurchases. .Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act as amended by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) or any future tax reform legislation, could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including passage of the Tax Act, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our federal net operating loss (NOL) carryforwards generated in tax years beginning before January 1, 2018, are only permitted to be carried forward for 20 years under applicable U.S. tax law. Under the Tax Act, as amended by the CARES Act, our federal NOLs generated in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited. It is uncertain if and to what extent various states will conform to the Tax Act or the CARES Act. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and certain other pre-change federal tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside our control. As a result, our ability to use our federal carryforwards and certain other pre-change federal tax attributes (such as research tax credits) to offset our post-change income or taxes could be limited. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited. As a result, we may be unable to use all or a material portion of our state NOL carryforwards and other state tax attributes, which could accelerate or permanently increase state taxes owed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, would be your sole source of gain.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain any future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common stock would be your sole source of gain on an investment in our common stock for the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make it more difficult for a third-party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management. These provisions include:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorizing the issuance of &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allowing the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting the removal of directors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">creating a staggered board of directors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring that stockholder actions must be effected at a duly called stockholder meeting and prohibiting stockholder actions by written consent;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eliminating the ability of stockholders to call a special meeting of stockholders; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at duly called stockholder meetings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require the affirmative vote of the holders of at least 66&#160;2/3 percent of the voting power of all of our then outstanding common stock.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by our board of directors. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Data Privacy</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security.  Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We process personal data and other sensitive information, which subjects us to numerous evolving data privacy and security obligations. In the ordinary course of business, we collect, receive, store, process, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, processing) personal data and other sensitive information, including proprietary and confidential business data, intellectual property, data we collect about trial participants in connection with clinical trials, sensitive third-party data, and other sensitive data. Our data processing activities may subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission Act), and other similar laws (e.g., wiretapping laws). For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. Additionally, the California Consumer Privacy Act of 2018 (CCPA) applies to personal information of consumers, business representatives, and employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for civil penalties of up to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some protected health information processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal data we may maintain about California residents. In addition, the California Privacy Rights Act of 2020 (CPRA) expands the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia and Colorado, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While these states, like the CCPA, also exempt some data processed in the context of clinical trials, these developments further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security.  For example, we are subject to the European Union&#8217;s General Data Protection Regulation (EU GDPR) and the United Kingdom&#8217;s GDPR (UK GDPR). Under the EU GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros or 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the United States or other countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (EEA), Switzerland, and the United Kingdom (UK) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA, Switzerland, and UK to the United States in compliance with law, such as the EEA, Switzerland, and UK&#8217;s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there is no lawful manner for us to transfer personal data from the EEA, Switzerland, the UK or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA, Switzerland, and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources, which may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations.  Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: interruptions or stoppages in our business operations (including our clinical trials); inability to process personal data </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Information Technology</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and the third parties upon which we rely, process proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property, trade secrets and any other sensitive data.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties upon which we rely.  Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities.  During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss of sensitive data and income, reputational harm, and diversion of funds.  Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation clinical trial data processing, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, and other functions. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our sensitive information or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps to detect and remediate vulnerabilities, but we may not be able to detect and remediate all vulnerabilities because the threats and techniques used to exploit the vulnerability change frequently and are often sophisticated in nature. Therefore, such vulnerabilities could be exploited but may not be detected until after a security incident has occurred.  These vulnerabilities pose material risks to our business. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the use of social media by us or our employees to communicate about our products or business may cause us to be found in violation of applicable laws and regulations. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our social media policy or other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image, and goodwill.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i4446784166784bc6ab6a1471468846ff_94"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. &#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4446784166784bc6ab6a1471468846ff_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. &#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4446784166784bc6ab6a1471468846ff_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. &#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4446784166784bc6ab6a1471468846ff_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. &#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i4446784166784bc6ab6a1471468846ff_106"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. &#160;&#160;&#160;&#160;EXHIBITS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this report:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000114420413022142/v340476_ex3-1.htm">Amended and Restated Certificate of Incorporation of the Registrant.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000110465922125582/tm2232316d1_ex3-2.htm">Amended and Restated Bylaws of the Registrant.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000114420413017647/v338669_ex4-1.htm">Form of Common Stock Certificate of the Registrant.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000111748023000006/a20221231cmrxex1021melemed.htm">Employment Offer Letter to Allen S. Melemed dated May 7, 2020.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20230331cmrxex-311.htm">Certification of Principal Executive Officer pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20230331cmrxex-312.htm">Certification of Principal Financial Officer pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20230331cmrxex-321.htm">Certification of Principal Executive Officer pursuant to Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20230331cmrxex-322.htm">Certification of Principal Financial Officer pursuant to Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section&#160;1350, as adopted pursuant Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+ Indicates management contract or compensation plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:15.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Incorporated by reference to the corresponding exhibit in Chimerix, Inc.&#8217;s </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000114420413022142/v340476_8k.htm">Current Report on Form 8-K (No. 001-35867), filed with the SEC on April 16, 2013.</a></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:15.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Incorporated by reference to the corresponding exhibit in Chimerix, Inc.&#8217;s </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000110465922125582/tm2232316d1_ex3-2.htm">Current Report on Form 8-K (No. 001-35867), filed with the SEC on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000110465922125582/tm2232316d1_ex3-2.htm">December</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000110465922125582/tm2232316d1_ex3-2.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000110465922125582/tm2232316d1_ex3-2.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000110465922125582/tm2232316d1_ex3-2.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000110465922125582/tm2232316d1_ex3-2.htm">22</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000110465922125582/tm2232316d1_ex3-2.htm">.</a></span></div><div style="padding-left:15.75pt;text-align:justify"><span><br/></span></div><div style="padding-left:15.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Incorporated by reference to the corresponding exhibit in Chimerix, Inc.&#8217;s </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000114420413014056/v333444_s1.htm">Registration Statement on Form S-1 (No. 333-187145), as amended</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000114420413014056/v333444_s1.htm">, filed with the SEC on March 27, 2013</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000114420413014056/v333444_s1.htm">.</a></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:15.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Incorporated by reference to Exhibit 10.21 in Chimerix, Inc.&#8217;s </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1117480/000111748023000006/a20221231cmrxex1021melemed.htm">Annual Report on Form 10-K (No. 001-35867), filed with the SEC on March 2, 2023.</a></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i4446784166784bc6ab6a1471468846ff_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHIMERIX,&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael A. Sherman</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael A. Sherman</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael T. Andriole</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael T. Andriole</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Business and Financial Officer </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a20230331cmrxex-311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i551900228c55470295d300641cfc64d4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael A. Sherman, certify that&#58;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended March&#160;31, 2023 of Chimerix, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael A. Sherman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael A. Sherman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President &#38; Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a20230331cmrxex-312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idbe262b127a74213821b56ece7c3cb5f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael T. Andriole, certify that&#58;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended March&#160;31, 2023 of Chimerix, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael T. Andriole</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael T. Andriole</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Business and Financial Officer </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a20230331cmrxex-321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia3fe099c0a294d8fa4e5d1e787b95853_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Chimerix, Inc. (the &#8220;Company&#8221;) for the period ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Michael A. Sherman, as Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael A. Sherman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael A. Sherman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President &#38; Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a20230331cmrxex-322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i22d8105a5bba43c3a74b9e1889582922_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.2</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Chimerix, Inc. (the &#8220;Company&#8221;) for the period ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Michael T. Andriole, as Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael T. Andriole</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael T. Andriole</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Business and Financial Officer </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cmrx-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:bd8f579e-4e63-4bef-9c1c-fca25009f3d7,g:bc09e6ba-bd4a-4780-8a45-ad8ddbcdd46a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cmrx="http://www.chimerix.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.chimerix.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmrx-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmrx-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmrx-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmrx-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.chimerix.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.chimerix.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityDeficit" roleURI="http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit">
        <link:definition>0000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPolicies">
        <link:definition>0000007 - Disclosure - The Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.chimerix.com/role/Investments">
        <link:definition>0000008 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.chimerix.com/role/CommitmentsandContingencies">
        <link:definition>0000009 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTransactionsandSharebasedCompensation" roleURI="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensation">
        <link:definition>0000010 - Disclosure - Equity Transactions and Share-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.chimerix.com/role/IncomeTaxes">
        <link:definition>0000011 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreements" roleURI="http://www.chimerix.com/role/SignificantAgreements">
        <link:definition>0000012 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DSTATContractCloseout" roleURI="http://www.chimerix.com/role/DSTATContractCloseout">
        <link:definition>0000013 - Disclosure - DSTAT Contract Close-out</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCosts" roleURI="http://www.chimerix.com/role/RestructuringCosts">
        <link:definition>0000014 - Disclosure - Restructuring Costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.chimerix.com/role/SubsequentEvents">
        <link:definition>0000015 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusinessandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000016 - Disclosure - The Business and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000017 - Disclosure - The Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.chimerix.com/role/InvestmentsTables">
        <link:definition>0000018 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.chimerix.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000019 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTransactionsandSharebasedCompensationTables" roleURI="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationTables">
        <link:definition>0000020 - Disclosure - Equity Transactions and Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsTables" roleURI="http://www.chimerix.com/role/SignificantAgreementsTables">
        <link:definition>0000021 - Disclosure - Significant Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DSTATContractCloseoutTables" roleURI="http://www.chimerix.com/role/DSTATContractCloseoutTables">
        <link:definition>0000022 - Disclosure - DSTAT Contract Close-out (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCostsTables" roleURI="http://www.chimerix.com/role/RestructuringCostsTables">
        <link:definition>0000023 - Disclosure - Restructuring Costs (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000024 - Disclosure - The Business and Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails" roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails">
        <link:definition>0000025 - Disclosure - The Business and Summary of Significant Accounting Policies - Employee Retention Credit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails" roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails">
        <link:definition>0000026 - Disclosure - The Business and Summary of Significant Accounting Policies - Deferred Loan Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails" roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails">
        <link:definition>0000027 - Disclosure - The Business and Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000028 - Disclosure - The Business and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofAvailableforSalesecuritiesDetails" roleURI="http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails">
        <link:definition>0000029 - Disclosure - Investments - Summary of Available-for-Sale securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" roleURI="http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails">
        <link:definition>0000030 - Disclosure - Investments - Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofInvestmentMaturityDetails" roleURI="http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails">
        <link:definition>0000031 - Disclosure - Investments - Schedule of Investment Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>0000032 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails" roleURI="http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails">
        <link:definition>0000033 - Disclosure - Commitments and Contingencies - Operating Lease Right-of-Use Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" roleURI="http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails">
        <link:definition>0000034 - Disclosure - Commitments and Contingencies - Maturity Analysis of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>0000034 - Disclosure - Commitments and Contingencies - Maturity Analysis of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTransactionsandSharebasedCompensationNarrativeDetails" roleURI="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails">
        <link:definition>0000035 - Disclosure - Equity Transactions and Share-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" roleURI="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails">
        <link:definition>0000036 - Disclosure - Equity Transactions and Share-based Compensation - Schedule of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.chimerix.com/role/IncomeTaxesDetails">
        <link:definition>0000037 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsDetails" roleURI="http://www.chimerix.com/role/SignificantAgreementsDetails">
        <link:definition>0000038 - Disclosure - Significant Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails" roleURI="http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails">
        <link:definition>0000039 - Disclosure - Significant Agreements- Schedule of Assets and Liabilities Transferred in Accordance with Asset Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DSTATContractCloseoutNarrativesDetails" roleURI="http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails">
        <link:definition>0000040 - Disclosure - DSTAT Contract Close-out - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails" roleURI="http://www.chimerix.com/role/DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails">
        <link:definition>0000041 - Disclosure - DSTAT Contract Close-out- Contract Close-out Cost Income Statement Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DSTATContractCloseoutScheduleofAccrualActivitiesforContractCloseoutCostDetails" roleURI="http://www.chimerix.com/role/DSTATContractCloseoutScheduleofAccrualActivitiesforContractCloseoutCostDetails">
        <link:definition>0000042 - Disclosure - DSTAT Contract Close-out- Schedule of Accrual Activities for Contract Close-out Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCostsDetails" roleURI="http://www.chimerix.com/role/RestructuringCostsDetails">
        <link:definition>0000043 - Disclosure - Restructuring Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCostsSummaryofRestructuringChargesDetails" roleURI="http://www.chimerix.com/role/RestructuringCostsSummaryofRestructuringChargesDetails">
        <link:definition>0000044 - Disclosure - Restructuring Costs - Summary of Restructuring Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCostsAccrualActivityforRestructuringAccrualDetails" roleURI="http://www.chimerix.com/role/RestructuringCostsAccrualActivityforRestructuringAccrualDetails">
        <link:definition>0000045 - Disclosure - Restructuring Costs - Accrual Activity for Restructuring Accrual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock" abstract="false" name="ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cmrx_ContractWithCustomerLiabilityInstallmentPeriods" abstract="false" name="ContractWithCustomerLiabilityInstallmentPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cmrx_The2013EmployeeStockPurchasePlanMember" abstract="false" name="The2013EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions" abstract="false" name="ReimbursableMarketingCostUponTheExerciseOfOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_TEMBEXAMember" abstract="true" name="TEMBEXAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_LoanFeesLiabilityNonCurrent" abstract="false" name="LoanFeesLiabilityNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_SanjiuMedicalPharmaceuticalCoLtdMember" abstract="true" name="SanjiuMedicalPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_ShareBasedCompensationOptionProvisionEquityIncrease" abstract="false" name="ShareBasedCompensationOptionProvisionEquityIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost" abstract="false" name="OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_BasePerformanceContractTerm" abstract="false" name="BasePerformanceContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cmrx_AccruedDevelopmentLiabilities" abstract="false" name="AccruedDevelopmentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_PurchaserMember" abstract="true" name="PurchaserMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_LoanFeesLiabilityCurrent" abstract="false" name="LoanFeesLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_OptionToPurchaseAdditionalTreatmentCourses" abstract="false" name="OptionToPurchaseAdditionalTreatmentCourses" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cmrx_QuantityBenchmarkTreatmentContractualCommitment" abstract="false" name="QuantityBenchmarkTreatmentContractualCommitment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cmrx_NonUnitedStatesMember" abstract="true" name="NonUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_The2013PlanMember" abstract="false" name="The2013PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived" abstract="false" name="LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_AccrualActivitiesForContractCloseOutCostRollForward" abstract="true" name="AccrualActivitiesForContractCloseOutCostRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cmrx_EmployeeRetentionCredit" abstract="false" name="EmployeeRetentionCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="BusinessAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cmrx_BasePeriodMember" abstract="true" name="BasePeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent" abstract="false" name="OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_SymBioPharmaceuticalsMember" abstract="true" name="SymBioPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_AssetSaleInventoryTransferred" abstract="false" name="AssetSaleInventoryTransferred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_PublicHealthAgencyOfCanadaMember" abstract="true" name="PublicHealthAgencyOfCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_DebtInstrumentEarlyTerminationFee" abstract="false" name="DebtInstrumentEarlyTerminationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_OncoceuticsIncMember" abstract="true" name="OncoceuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_ContractCloseOutCosts" abstract="false" name="ContractCloseOutCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue" abstract="false" name="OptionToPurchaseAdditionalTreatmentCoursesGrossValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_ContractCloseOutLiabilityAdjustments" abstract="false" name="ContractCloseOutLiabilityAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_NationalStockpileMember" abstract="true" name="NationalStockpileMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cmrx_SalesOfStockAuthorizedAmount" abstract="false" name="SalesOfStockAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_IndependentMembersOfBoardMember" abstract="true" name="IndependentMembersOfBoardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_EmergentBiodefenseOperationsLansingLLCMember" abstract="true" name="EmergentBiodefenseOperationsLansingLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_BARDAMember" abstract="true" name="BARDAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cmrx_AssetSalePrepaidsTransferred" abstract="false" name="AssetSalePrepaidsTransferred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_ContractAndGrantMember" abstract="true" name="ContractAndGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_PeriodDomain" abstract="true" name="PeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_RevenueBenchmarkGrossProfitRoyaltyRate" abstract="false" name="RevenueBenchmarkGrossProfitRoyaltyRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cmrx_PeriodAxis" abstract="true" name="PeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cmrx_ContractCloseOutLiability" abstract="false" name="ContractCloseOutLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_EmergentBioSolutionsIncMember" abstract="true" name="EmergentBioSolutionsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="BusinessAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cmrx_AssetSaleLiabilities" abstract="false" name="AssetSaleLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_ScheduleOfContractCloseOutCostsTableTextBlock" abstract="false" name="ScheduleOfContractCloseOutCostsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cmrx_DebtInstrumentNumberOfInstallmentPayments" abstract="false" name="DebtInstrumentNumberOfInstallmentPayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cmrx_RefundableAgreementsMember" abstract="true" name="RefundableAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_SalesOfStockAuthorizationTerm" abstract="false" name="SalesOfStockAuthorizationTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cmrx_ExpenseReimbursementMember" abstract="true" name="ExpenseReimbursementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_AnticipatedSeveranceCost" abstract="false" name="AnticipatedSeveranceCost" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_SignificantAgreementsContractTerm" abstract="false" name="SignificantAgreementsContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cmrx_ContractCloseOutLiabilityPayments" abstract="false" name="ContractCloseOutLiabilityPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_ReimbursableMarketingExpenses" abstract="false" name="ReimbursableMarketingExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions" abstract="false" name="MaximumMilestoneProceedsUponTheExerciseOfOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_TransactionCostsIncurredInRelationToSales" abstract="false" name="TransactionCostsIncurredInRelationToSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmrx_OharaPharmaceuticalCoLtdMember" abstract="true" name="OharaPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger" abstract="false" name="QuantityBenchmarkGrossProfitRoyaltyRateTrigger" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cmrx-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:bd8f579e-4e63-4bef-9c1c-fca25009f3d7,g:bc09e6ba-bd4a-4780-8a45-ad8ddbcdd46a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.chimerix.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cmrx-20230331.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.chimerix.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_937b76e5-cb62-48fa-806a-970246372d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d0716acd-6467-4b08-84c7-1d6a5cb544cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_937b76e5-cb62-48fa-806a-970246372d68" xlink:to="loc_us-gaap_LiabilitiesCurrent_d0716acd-6467-4b08-84c7-1d6a5cb544cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_LoanFeesLiabilityNonCurrent_7a9a88a7-cc73-41f7-acc5-c73e2e324971" xlink:href="cmrx-20230331.xsd#cmrx_LoanFeesLiabilityNonCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_937b76e5-cb62-48fa-806a-970246372d68" xlink:to="loc_cmrx_LoanFeesLiabilityNonCurrent_7a9a88a7-cc73-41f7-acc5-c73e2e324971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2b3d5eae-9d61-4b42-864f-d446d6ecfd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_937b76e5-cb62-48fa-806a-970246372d68" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2b3d5eae-9d61-4b42-864f-d446d6ecfd8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cc0ec6ab-1b6b-42c0-b0cb-1e548dedca65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e9c500fd-2754-4ab7-b240-b69426e46d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cc0ec6ab-1b6b-42c0-b0cb-1e548dedca65" xlink:to="loc_us-gaap_AssetsCurrent_e9c500fd-2754-4ab7-b240-b69426e46d3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6dffd49f-0a97-42db-8745-bb7fd971a0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cc0ec6ab-1b6b-42c0-b0cb-1e548dedca65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6dffd49f-0a97-42db-8745-bb7fd971a0b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ed4746e6-6c25-46ce-83d5-0524d5d78c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cc0ec6ab-1b6b-42c0-b0cb-1e548dedca65" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ed4746e6-6c25-46ce-83d5-0524d5d78c3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_79e484ad-1cd2-4216-88d4-edc7c75613ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cc0ec6ab-1b6b-42c0-b0cb-1e548dedca65" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_79e484ad-1cd2-4216-88d4-edc7c75613ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_4bb69814-45d8-48e4-9da1-9f73bf97ea81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cc0ec6ab-1b6b-42c0-b0cb-1e548dedca65" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_4bb69814-45d8-48e4-9da1-9f73bf97ea81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2f5db2b9-5c90-435c-9322-d63c4490c3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_0e592aeb-fe57-444f-9e73-6191ed4366ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2f5db2b9-5c90-435c-9322-d63c4490c3e7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_0e592aeb-fe57-444f-9e73-6191ed4366ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e7dccb64-3827-405d-9e41-99d85881e757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2f5db2b9-5c90-435c-9322-d63c4490c3e7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e7dccb64-3827-405d-9e41-99d85881e757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8c66f029-6eef-4d36-9621-140f32b20587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2f5db2b9-5c90-435c-9322-d63c4490c3e7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8c66f029-6eef-4d36-9621-140f32b20587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_21ec9d1b-5c61-4bbe-b55e-48d1440e86b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2f5db2b9-5c90-435c-9322-d63c4490c3e7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_21ec9d1b-5c61-4bbe-b55e-48d1440e86b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ceff5422-eaa3-45d8-a36e-8e9b97d65b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_eee5b242-cde3-49d1-8583-304682b0923f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ceff5422-eaa3-45d8-a36e-8e9b97d65b99" xlink:to="loc_us-gaap_AccountsPayableCurrent_eee5b242-cde3-49d1-8583-304682b0923f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_231eac12-83e0-46c0-a160-52b91094eca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ceff5422-eaa3-45d8-a36e-8e9b97d65b99" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_231eac12-83e0-46c0-a160-52b91094eca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_24313571-be09-4959-a65b-7b64e1faa552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_742ff2da-2e29-44f9-8e16-f5e546915bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_24313571-be09-4959-a65b-7b64e1faa552" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_742ff2da-2e29-44f9-8e16-f5e546915bd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_d1d107ee-3753-4522-a2ff-73836ea401b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_24313571-be09-4959-a65b-7b64e1faa552" xlink:to="loc_us-gaap_CommonStockValueOutstanding_d1d107ee-3753-4522-a2ff-73836ea401b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2a633a0e-0d4f-4921-ba53-92c87ac6eded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_24313571-be09-4959-a65b-7b64e1faa552" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2a633a0e-0d4f-4921-ba53-92c87ac6eded" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fce6244d-adcb-4863-a430-e3683c0af3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_24313571-be09-4959-a65b-7b64e1faa552" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fce6244d-adcb-4863-a430-e3683c0af3ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_19fece50-e74a-4000-84e9-bb8ec987d65e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_24313571-be09-4959-a65b-7b64e1faa552" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_19fece50-e74a-4000-84e9-bb8ec987d65e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a4406fdc-cc74-41d3-b54d-9315fb58b48d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_63b20f87-ce63-44a7-916e-5a0534fcaa6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a4406fdc-cc74-41d3-b54d-9315fb58b48d" xlink:to="loc_us-gaap_Liabilities_63b20f87-ce63-44a7-916e-5a0534fcaa6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a9d1ec3c-35c0-4758-94f3-ee155d672257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a4406fdc-cc74-41d3-b54d-9315fb58b48d" xlink:to="loc_us-gaap_StockholdersEquity_a9d1ec3c-35c0-4758-94f3-ee155d672257" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="cmrx-20230331.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_94de7697-82fb-4213-88ef-c4383f5b2c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_88276d51-e134-4055-9493-8998d1434e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_94de7697-82fb-4213-88ef-c4383f5b2c58" xlink:to="loc_us-gaap_OperatingExpenses_88276d51-e134-4055-9493-8998d1434e7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_fcd88df6-29fb-4ce2-9578-e6ad00295b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_94de7697-82fb-4213-88ef-c4383f5b2c58" xlink:to="loc_us-gaap_GrossProfit_fcd88df6-29fb-4ce2-9578-e6ad00295b71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_141a8335-5711-48b6-bea8-7b92b7d85819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ea26aa5a-8e0d-474d-a0d8-e64ff73b2358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_141a8335-5711-48b6-bea8-7b92b7d85819" xlink:to="loc_us-gaap_OperatingIncomeLoss_ea26aa5a-8e0d-474d-a0d8-e64ff73b2358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_e4ba68a4-81e1-48d1-a531-f188a572f85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_141a8335-5711-48b6-bea8-7b92b7d85819" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_e4ba68a4-81e1-48d1-a531-f188a572f85a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_62e03f79-a1b5-4002-af11-3b9ec46f84a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c593cf97-8f02-45a3-a0f5-c54f50e1fef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_62e03f79-a1b5-4002-af11-3b9ec46f84a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c593cf97-8f02-45a3-a0f5-c54f50e1fef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_da573005-5b0a-4c58-9e6b-06266fb18a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_62e03f79-a1b5-4002-af11-3b9ec46f84a1" xlink:to="loc_us-gaap_CostOfRevenue_da573005-5b0a-4c58-9e6b-06266fb18a59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d2ec18fa-3e82-41a2-bc0c-6ba38ead82c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_179a4025-7079-4ef0-b796-a911bd647afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d2ec18fa-3e82-41a2-bc0c-6ba38ead82c7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_179a4025-7079-4ef0-b796-a911bd647afb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_04d7929e-e9ea-43d9-b9e9-1b85ce8c699b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d2ec18fa-3e82-41a2-bc0c-6ba38ead82c7" xlink:to="loc_us-gaap_NetIncomeLoss_04d7929e-e9ea-43d9-b9e9-1b85ce8c699b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_87b94546-658a-4607-9a61-0ef275b0bf41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6c1d173b-1d51-4b9e-9867-4ffc3dea2878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_87b94546-658a-4607-9a61-0ef275b0bf41" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6c1d173b-1d51-4b9e-9867-4ffc3dea2878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c93a0bb0-6f03-4419-8fd0-c8686ddcb678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_87b94546-658a-4607-9a61-0ef275b0bf41" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c93a0bb0-6f03-4419-8fd0-c8686ddcb678" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cmrx-20230331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa81c4bf-e01f-47a2-b2e4-ce95d3c17acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ed7a8a6-a409-4424-b8b7-5beca910c86b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa81c4bf-e01f-47a2-b2e4-ce95d3c17acc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0ed7a8a6-a409-4424-b8b7-5beca910c86b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e676ecc3-b4cb-4776-ac33-a411265bf3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa81c4bf-e01f-47a2-b2e4-ce95d3c17acc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e676ecc3-b4cb-4776-ac33-a411265bf3df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38d11267-b924-4c43-8e30-b0bbf2cf2f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa81c4bf-e01f-47a2-b2e4-ce95d3c17acc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38d11267-b924-4c43-8e30-b0bbf2cf2f7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ab5046f-0d76-4d64-83c9-05664d30df03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent_be58c861-6f9f-4136-bbfe-c082a6d6ce9f" xlink:href="cmrx-20230331.xsd#cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ab5046f-0d76-4d64-83c9-05664d30df03" xlink:to="loc_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent_be58c861-6f9f-4136-bbfe-c082a6d6ce9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9a0e755d-f6e9-458d-a908-573d60854441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ab5046f-0d76-4d64-83c9-05664d30df03" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9a0e755d-f6e9-458d-a908-573d60854441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ee8eabfa-ad91-4287-880c-c948aada0be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ab5046f-0d76-4d64-83c9-05664d30df03" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ee8eabfa-ad91-4287-880c-c948aada0be3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c988b64b-91c6-41e5-a478-dcf89e8d1986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ab5046f-0d76-4d64-83c9-05664d30df03" xlink:to="loc_us-gaap_ShareBasedCompensation_c988b64b-91c6-41e5-a478-dcf89e8d1986" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d3dd4389-a25a-4aff-8c17-a8404497d085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ab5046f-0d76-4d64-83c9-05664d30df03" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d3dd4389-a25a-4aff-8c17-a8404497d085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8445f03b-73c5-4d47-bee1-ec58991b7ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ab5046f-0d76-4d64-83c9-05664d30df03" xlink:to="loc_us-gaap_NetIncomeLoss_8445f03b-73c5-4d47-bee1-ec58991b7ced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_dd2c73d0-f8e6-425b-a5d2-1bdee21034cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ab5046f-0d76-4d64-83c9-05664d30df03" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_dd2c73d0-f8e6-425b-a5d2-1bdee21034cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2fb247b2-2596-4aae-82dd-2fccf3c09c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ab5046f-0d76-4d64-83c9-05664d30df03" xlink:to="loc_us-gaap_Depreciation_2fb247b2-2596-4aae-82dd-2fccf3c09c50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7f41bc8c-1b28-436b-8503-8b53cca2e13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ab5046f-0d76-4d64-83c9-05664d30df03" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7f41bc8c-1b28-436b-8503-8b53cca2e13c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_97dea1c0-0a70-4461-9d45-277843397288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ab5046f-0d76-4d64-83c9-05664d30df03" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_97dea1c0-0a70-4461-9d45-277843397288" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6c0469ea-3a52-4dfe-8052-3c72dc6d44fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ab5046f-0d76-4d64-83c9-05664d30df03" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6c0469ea-3a52-4dfe-8052-3c72dc6d44fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0955728-7f0a-48f6-bd32-10485398cd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6f0b0546-1aea-4318-8d54-b36907345a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0955728-7f0a-48f6-bd32-10485398cd0b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6f0b0546-1aea-4318-8d54-b36907345a76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_c7280f79-e50d-4a77-8da2-e0d0ea872406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0955728-7f0a-48f6-bd32-10485398cd0b" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_c7280f79-e50d-4a77-8da2-e0d0ea872406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_ad6bc43b-13ce-457f-96fc-0b12ab7c56dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0955728-7f0a-48f6-bd32-10485398cd0b" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_ad6bc43b-13ce-457f-96fc-0b12ab7c56dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_eba14aad-10b0-4577-bbf5-fd6ad0d13029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0955728-7f0a-48f6-bd32-10485398cd0b" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_eba14aad-10b0-4577-bbf5-fd6ad0d13029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_584b28ae-3458-4586-8ad4-0f2de8fefdea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0955728-7f0a-48f6-bd32-10485398cd0b" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_584b28ae-3458-4586-8ad4-0f2de8fefdea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ffeb0f0a-53c1-42d7-80a7-9e043dbf7112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_cee867a7-a44a-49e8-9941-931c363427ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ffeb0f0a-53c1-42d7-80a7-9e043dbf7112" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_cee867a7-a44a-49e8-9941-931c363427ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_7d45e3df-d98f-4df5-b602-57e4c5817090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ffeb0f0a-53c1-42d7-80a7-9e043dbf7112" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_7d45e3df-d98f-4df5-b602-57e4c5817090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_8f7326c5-4a98-4fc3-a61a-8430ab437ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ffeb0f0a-53c1-42d7-80a7-9e043dbf7112" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_8f7326c5-4a98-4fc3-a61a-8430ab437ef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_0ac05a5d-7187-46f4-80ff-316f35ca9628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ffeb0f0a-53c1-42d7-80a7-9e043dbf7112" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_0ac05a5d-7187-46f4-80ff-316f35ca9628" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7267d245-4a44-4c1f-b690-9dabb34b65c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ba0e121b-411f-4a28-aac9-ef1e789d55e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7267d245-4a44-4c1f-b690-9dabb34b65c5" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ba0e121b-411f-4a28-aac9-ef1e789d55e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e8188416-2f58-48cd-bb77-ee2d0113a282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7267d245-4a44-4c1f-b690-9dabb34b65c5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e8188416-2f58-48cd-bb77-ee2d0113a282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_5e4b89ec-4bab-46f6-a341-f6aa63aa80d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7267d245-4a44-4c1f-b690-9dabb34b65c5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_5e4b89ec-4bab-46f6-a341-f6aa63aa80d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_da1b0fe7-9748-4bf6-a418-f31e9948a7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ef9a00e9-5dd8-40e2-830a-d9fc9aad8938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_da1b0fe7-9748-4bf6-a418-f31e9948a7eb" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ef9a00e9-5dd8-40e2-830a-d9fc9aad8938" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_54c43803-4d3a-4b15-8694-5a68714c18ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_da1b0fe7-9748-4bf6-a418-f31e9948a7eb" xlink:to="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_54c43803-4d3a-4b15-8694-5a68714c18ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AccruedDevelopmentLiabilities_90c33adc-240e-47ec-a563-30361704fc4a" xlink:href="cmrx-20230331.xsd#cmrx_AccruedDevelopmentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_da1b0fe7-9748-4bf6-a418-f31e9948a7eb" xlink:to="loc_cmrx_AccruedDevelopmentLiabilities_90c33adc-240e-47ec-a563-30361704fc4a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#InvestmentsSummaryofAvailableforSalesecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f2cce6c2-271f-4c20-ad9c-d2b3a2a6db79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_05c08707-d77b-4efe-9add-f206209b6fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f2cce6c2-271f-4c20-ad9c-d2b3a2a6db79" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_05c08707-d77b-4efe-9add-f206209b6fb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ecf8db7a-44fb-4e13-914b-23220f0eae04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f2cce6c2-271f-4c20-ad9c-d2b3a2a6db79" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ecf8db7a-44fb-4e13-914b-23220f0eae04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_832e7616-be9e-43a5-8797-4d6cf7e7616b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f2cce6c2-271f-4c20-ad9c-d2b3a2a6db79" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_832e7616-be9e-43a5-8797-4d6cf7e7616b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails"/>
  <link:calculationLink xlink:role="http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_08ca6ba2-5d54-49ea-9831-c55fe80dbfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_42c93841-0615-4d11-9a3b-46ee876b1279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_08ca6ba2-5d54-49ea-9831-c55fe80dbfe1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_42c93841-0615-4d11-9a3b-46ee876b1279" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_e18d018d-e4d8-47dc-88d1-87e4d59f911b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_08ca6ba2-5d54-49ea-9831-c55fe80dbfe1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_e18d018d-e4d8-47dc-88d1-87e4d59f911b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_240bcf44-6e88-4f64-a10e-09a07295d3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2849256d-85b6-4ca3-a6cc-b4bad817150e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_240bcf44-6e88-4f64-a10e-09a07295d3e8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2849256d-85b6-4ca3-a6cc-b4bad817150e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_ada101cb-ce77-4acc-a54e-0782c00037b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_240bcf44-6e88-4f64-a10e-09a07295d3e8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_ada101cb-ce77-4acc-a54e-0782c00037b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f48d1381-86e3-43d4-9b26-227531f4d4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_213275d7-90ad-4600-a61a-f3da12e2a6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f48d1381-86e3-43d4-9b26-227531f4d4b2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_213275d7-90ad-4600-a61a-f3da12e2a6ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1e570e44-83fd-4485-bd72-4d2643385d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f48d1381-86e3-43d4-9b26-227531f4d4b2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1e570e44-83fd-4485-bd72-4d2643385d0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#InvestmentsScheduleofInvestmentMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_7544f65a-a8a2-48d2-a9c5-fee51bb92eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo_bf83c0b2-6875-45aa-8d66-8fc9a3490ebe" xlink:href="cmrx-20230331.xsd#cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_7544f65a-a8a2-48d2-a9c5-fee51bb92eb9" xlink:to="loc_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo_bf83c0b2-6875-45aa-8d66-8fc9a3490ebe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d81e5edd-08d7-4a4d-aefc-eb5bc5b5f22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_7544f65a-a8a2-48d2-a9c5-fee51bb92eb9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d81e5edd-08d7-4a4d-aefc-eb5bc5b5f22d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e38163f7-c71e-4817-963c-aa0a60835c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4cd368cc-ae61-48e4-9a95-18fe0b616431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_e38163f7-c71e-4817-963c-aa0a60835c63" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4cd368cc-ae61-48e4-9a95-18fe0b616431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_59157c51-080e-4331-a2a2-90527718c6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_e38163f7-c71e-4817-963c-aa0a60835c63" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_59157c51-080e-4331-a2a2-90527718c6a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f33ec5e-43e2-4039-bd18-d06150ad15f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d2895346-7a2a-4076-868c-3a7a4ee26e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f33ec5e-43e2-4039-bd18-d06150ad15f1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d2895346-7a2a-4076-868c-3a7a4ee26e7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0c4b5c29-bfec-4b30-a9af-569e579e643a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f33ec5e-43e2-4039-bd18-d06150ad15f1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0c4b5c29-bfec-4b30-a9af-569e579e643a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1be8eba2-9f73-4fdf-ba7b-02bd8d86017b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f33ec5e-43e2-4039-bd18-d06150ad15f1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1be8eba2-9f73-4fdf-ba7b-02bd8d86017b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7059515f-1a13-4f5d-878e-6705149dfdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f33ec5e-43e2-4039-bd18-d06150ad15f1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7059515f-1a13-4f5d-878e-6705149dfdb0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="cmrx-20230331.xsd#CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce33b692-519f-442a-b68b-6b3dfc97cd19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9a567d2e-b0c3-4db5-a729-5741a14f241f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce33b692-519f-442a-b68b-6b3dfc97cd19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9a567d2e-b0c3-4db5-a729-5741a14f241f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0df159b3-8da1-4294-91b5-4d64f2a2433d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce33b692-519f-442a-b68b-6b3dfc97cd19" xlink:to="loc_us-gaap_OperatingLeaseLiability_0df159b3-8da1-4294-91b5-4d64f2a2433d" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cmrx-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:bd8f579e-4e63-4bef-9c1c-fca25009f3d7,g:bc09e6ba-bd4a-4780-8a45-ad8ddbcdd46a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="cmrx-20230331.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="i6106838656524acd992dfabf17c71415_ConsolidatedStatementsofOperationsandComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_91743a1b-05b6-464b-ab01-3f6351d6997b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cba4bb78-87cf-45a6-8cb0-6343ba18b96c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91743a1b-05b6-464b-ab01-3f6351d6997b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cba4bb78-87cf-45a6-8cb0-6343ba18b96c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_dbc6b9b4-3c01-45ea-8c7b-be5a1438fc90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91743a1b-05b6-464b-ab01-3f6351d6997b" xlink:to="loc_us-gaap_CostOfRevenue_dbc6b9b4-3c01-45ea-8c7b-be5a1438fc90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_ad51f0d7-e41d-4954-acf1-08053bdb7d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91743a1b-05b6-464b-ab01-3f6351d6997b" xlink:to="loc_us-gaap_GrossProfit_ad51f0d7-e41d-4954-acf1-08053bdb7d4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bf9c7dc9-bda1-4b55-9a67-68d2642b4e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_91743a1b-05b6-464b-ab01-3f6351d6997b" xlink:to="loc_us-gaap_StatementTable_bf9c7dc9-bda1-4b55-9a67-68d2642b4e67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f9b88fb2-dbce-45bf-89dc-2a5aa5270135" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bf9c7dc9-bda1-4b55-9a67-68d2642b4e67" xlink:to="loc_srt_ProductOrServiceAxis_f9b88fb2-dbce-45bf-89dc-2a5aa5270135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f9b88fb2-dbce-45bf-89dc-2a5aa5270135_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f9b88fb2-dbce-45bf-89dc-2a5aa5270135" xlink:to="loc_srt_ProductsAndServicesDomain_f9b88fb2-dbce-45bf-89dc-2a5aa5270135_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2c042e66-9a2e-4343-9902-92245f8cf80c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f9b88fb2-dbce-45bf-89dc-2a5aa5270135" xlink:to="loc_srt_ProductsAndServicesDomain_2c042e66-9a2e-4343-9902-92245f8cf80c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractAndGrantMember_4ee65815-c8a9-4c07-8542-4f6474d37192" xlink:href="cmrx-20230331.xsd#cmrx_ContractAndGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c042e66-9a2e-4343-9902-92245f8cf80c" xlink:to="loc_cmrx_ContractAndGrantMember_4ee65815-c8a9-4c07-8542-4f6474d37192" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_0e8b9eb2-8163-4fc3-bd2f-3fec906f3a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c042e66-9a2e-4343-9902-92245f8cf80c" xlink:to="loc_us-gaap_LicenseMember_0e8b9eb2-8163-4fc3-bd2f-3fec906f3a81" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="cmrx-20230331.xsd#ConsolidatedStatementsofStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="extended" id="idb5a5806ca7842b5a9fac41951bb95b4_ConsolidatedStatementsofStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_14fa0ddc-b127-468e-b04d-ecf32a82b1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_14fa0ddc-b127-468e-b04d-ecf32a82b1e7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_625d425f-4d7a-410a-9661-6faa06834a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_StockholdersEquity_625d425f-4d7a-410a-9661-6faa06834a7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_044dbe78-f6a8-492a-b1cc-29c5b9fb93ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_044dbe78-f6a8-492a-b1cc-29c5b9fb93ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d3a2094e-5e0b-41ac-a42e-038bf8a463d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d3a2094e-5e0b-41ac-a42e-038bf8a463d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_62ba2e03-f30b-4d6a-bf7d-1f0f95b1cb32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_62ba2e03-f30b-4d6a-bf7d-1f0f95b1cb32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3994c159-abb1-4846-a848-2f536975a177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3994c159-abb1-4846-a848-2f536975a177" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2dbb86bc-fb96-494a-84ca-30bac2b4cd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2dbb86bc-fb96-494a-84ca-30bac2b4cd7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3af3fb10-3012-42bd-9d45-560ccfe1f7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3af3fb10-3012-42bd-9d45-560ccfe1f7bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_da92b325-dca8-493c-9179-724e5eb14da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_da92b325-dca8-493c-9179-724e5eb14da3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7521dc9a-09d8-4d56-aa9a-8c9f0480141f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7521dc9a-09d8-4d56-aa9a-8c9f0480141f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c6bbb5c5-ef13-4fac-9b16-194ccaf1a5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7521dc9a-09d8-4d56-aa9a-8c9f0480141f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c6bbb5c5-ef13-4fac-9b16-194ccaf1a5f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_69e48d18-cd35-457b-a174-dc441d57e614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7521dc9a-09d8-4d56-aa9a-8c9f0480141f" xlink:to="loc_us-gaap_NetIncomeLoss_69e48d18-cd35-457b-a174-dc441d57e614" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_65ee65ef-505f-4564-a827-238a51ef6f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7521dc9a-09d8-4d56-aa9a-8c9f0480141f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_65ee65ef-505f-4564-a827-238a51ef6f1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_33843e40-84dc-476d-b144-b7be4eaa4a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2fe8fb1c-5157-4d4a-96b1-79825d55c548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_42442a63-9cb7-47c8-865f-bdc75dcca3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_14fa0ddc-b127-468e-b04d-ecf32a82b1e7" xlink:to="loc_us-gaap_StatementTable_42442a63-9cb7-47c8-865f-bdc75dcca3dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c5be5fb9-b6ce-4fd8-be6b-c677e5d042e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_42442a63-9cb7-47c8-865f-bdc75dcca3dc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c5be5fb9-b6ce-4fd8-be6b-c677e5d042e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c5be5fb9-b6ce-4fd8-be6b-c677e5d042e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5be5fb9-b6ce-4fd8-be6b-c677e5d042e0" xlink:to="loc_us-gaap_EquityComponentDomain_c5be5fb9-b6ce-4fd8-be6b-c677e5d042e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5474ae0d-556e-4c97-b53c-cc7a92939551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5be5fb9-b6ce-4fd8-be6b-c677e5d042e0" xlink:to="loc_us-gaap_EquityComponentDomain_5474ae0d-556e-4c97-b53c-cc7a92939551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8f720d68-0812-4b9f-a7e8-e21ce84254cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5474ae0d-556e-4c97-b53c-cc7a92939551" xlink:to="loc_us-gaap_CommonStockMember_8f720d68-0812-4b9f-a7e8-e21ce84254cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_dfddc5fb-b3ba-4a14-8c44-50c4dba854ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5474ae0d-556e-4c97-b53c-cc7a92939551" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_dfddc5fb-b3ba-4a14-8c44-50c4dba854ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5d3bb852-d199-4404-8682-55b1072dd682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5474ae0d-556e-4c97-b53c-cc7a92939551" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5d3bb852-d199-4404-8682-55b1072dd682" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_912d3b33-7707-4169-92ac-49e15c7c6fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5474ae0d-556e-4c97-b53c-cc7a92939551" xlink:to="loc_us-gaap_RetainedEarningsMember_912d3b33-7707-4169-92ac-49e15c7c6fe0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i8a9d5f38117d4975929827a7abc558c3_TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_7edb21fa-6a34-4381-bb5d-6118f94f5c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47c31147-2e8f-4972-a122-16a212f25ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_7edb21fa-6a34-4381-bb5d-6118f94f5c5c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47c31147-2e8f-4972-a122-16a212f25ca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_6e51a1a4-5494-49f3-b69b-065babb75955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_7edb21fa-6a34-4381-bb5d-6118f94f5c5c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_6e51a1a4-5494-49f3-b69b-065babb75955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_d92ad005-5286-4b8c-a34d-87f43fb48a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_7edb21fa-6a34-4381-bb5d-6118f94f5c5c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_d92ad005-5286-4b8c-a34d-87f43fb48a87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_adf207b7-1d9e-40a4-a3dc-c184fcbc492e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_7edb21fa-6a34-4381-bb5d-6118f94f5c5c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_adf207b7-1d9e-40a4-a3dc-c184fcbc492e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_e1fddb88-dc99-4258-9398-df0f3fb0dbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_7edb21fa-6a34-4381-bb5d-6118f94f5c5c" xlink:to="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_e1fddb88-dc99-4258-9398-df0f3fb0dbdf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a1582c00-b78e-494e-8d3b-f1c8c79e213e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_e1fddb88-dc99-4258-9398-df0f3fb0dbdf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a1582c00-b78e-494e-8d3b-f1c8c79e213e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a1582c00-b78e-494e-8d3b-f1c8c79e213e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a1582c00-b78e-494e-8d3b-f1c8c79e213e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a1582c00-b78e-494e-8d3b-f1c8c79e213e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_785e4cfa-8ded-4687-8c33-33fd592daa0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a1582c00-b78e-494e-8d3b-f1c8c79e213e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_785e4cfa-8ded-4687-8c33-33fd592daa0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_00dcc369-6a66-4f3f-bb13-b252b3181672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_785e4cfa-8ded-4687-8c33-33fd592daa0c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_00dcc369-6a66-4f3f-bb13-b252b3181672" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c2040d69-c303-4040-9021-2d63e23ad206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_785e4cfa-8ded-4687-8c33-33fd592daa0c" xlink:to="loc_us-gaap_CommercialPaperMember_c2040d69-c303-4040-9021-2d63e23ad206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_aa3be133-9ab0-47d5-b2d9-4921ef24155e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_e1fddb88-dc99-4258-9398-df0f3fb0dbdf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_aa3be133-9ab0-47d5-b2d9-4921ef24155e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa3be133-9ab0-47d5-b2d9-4921ef24155e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_aa3be133-9ab0-47d5-b2d9-4921ef24155e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa3be133-9ab0-47d5-b2d9-4921ef24155e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74d90516-78f2-43ca-9c88-c3ec64f860f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_aa3be133-9ab0-47d5-b2d9-4921ef24155e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74d90516-78f2-43ca-9c88-c3ec64f860f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_bb68a7d5-be32-4944-97f3-97078cd9861e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74d90516-78f2-43ca-9c88-c3ec64f860f3" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_bb68a7d5-be32-4944-97f3-97078cd9861e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f4bb57d3-b55e-452d-83ed-d2a406b35ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74d90516-78f2-43ca-9c88-c3ec64f860f3" xlink:to="loc_us-gaap_CommercialPaperMember_f4bb57d3-b55e-452d-83ed-d2a406b35ad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_0af3c140-90ca-4c40-94a0-c73bca123588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74d90516-78f2-43ca-9c88-c3ec64f860f3" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_0af3c140-90ca-4c40-94a0-c73bca123588" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_aaab7c7a-8d62-4db0-ba38-cc945df654c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_e1fddb88-dc99-4258-9398-df0f3fb0dbdf" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_aaab7c7a-8d62-4db0-ba38-cc945df654c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_aaab7c7a-8d62-4db0-ba38-cc945df654c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_aaab7c7a-8d62-4db0-ba38-cc945df654c6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_aaab7c7a-8d62-4db0-ba38-cc945df654c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9f7399d8-03ef-4c7a-b2d7-400f0efbee9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_aaab7c7a-8d62-4db0-ba38-cc945df654c6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9f7399d8-03ef-4c7a-b2d7-400f0efbee9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3bff97e8-0439-4851-be56-81b1a22ebf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9f7399d8-03ef-4c7a-b2d7-400f0efbee9e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3bff97e8-0439-4851-be56-81b1a22ebf71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbd952f4-876c-474d-a7f4-7d1151691f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_e1fddb88-dc99-4258-9398-df0f3fb0dbdf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbd952f4-876c-474d-a7f4-7d1151691f9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbd952f4-876c-474d-a7f4-7d1151691f9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbd952f4-876c-474d-a7f4-7d1151691f9a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbd952f4-876c-474d-a7f4-7d1151691f9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31ff4760-954b-4c83-b813-fdc356e53915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbd952f4-876c-474d-a7f4-7d1151691f9a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31ff4760-954b-4c83-b813-fdc356e53915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8e5b973f-f0ce-4180-8e0c-2bb945b0d93e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31ff4760-954b-4c83-b813-fdc356e53915" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8e5b973f-f0ce-4180-8e0c-2bb945b0d93e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c006f7d9-e59a-4ae8-b70a-2c3b25e1478b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31ff4760-954b-4c83-b813-fdc356e53915" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c006f7d9-e59a-4ae8-b70a-2c3b25e1478b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_64f0929c-ae72-4ba3-b4e5-4d14563dd4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31ff4760-954b-4c83-b813-fdc356e53915" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_64f0929c-ae72-4ba3-b4e5-4d14563dd4e6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails" xlink:type="extended" id="iaaaeeec88b004d40a2979651c37d30c2_TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_026b7589-aaa3-4b12-ae57-079f36db181f" xlink:href="cmrx-20230331.xsd#cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmployeeRetentionCredit_bd67b2d2-feb7-4685-a209-02f32fb16c17" xlink:href="cmrx-20230331.xsd#cmrx_EmployeeRetentionCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_026b7589-aaa3-4b12-ae57-079f36db181f" xlink:to="loc_cmrx_EmployeeRetentionCredit_bd67b2d2-feb7-4685-a209-02f32fb16c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_935ad661-7895-4c6d-bef4-7398eb613d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_026b7589-aaa3-4b12-ae57-079f36db181f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_935ad661-7895-4c6d-bef4-7398eb613d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_68431354-c135-4dab-9fd0-85f68b337151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_026b7589-aaa3-4b12-ae57-079f36db181f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_68431354-c135-4dab-9fd0-85f68b337151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_9e8407c5-c949-4143-956d-40e03a535789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_026b7589-aaa3-4b12-ae57-079f36db181f" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_9e8407c5-c949-4143-956d-40e03a535789" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_f0282ab0-a4f4-4718-9eb3-4acdabd54f36" xlink:href="cmrx-20230331.xsd#cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_026b7589-aaa3-4b12-ae57-079f36db181f" xlink:to="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_f0282ab0-a4f4-4718-9eb3-4acdabd54f36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f67143c1-83dc-4a2e-9f18-7da6514844b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_f0282ab0-a4f4-4718-9eb3-4acdabd54f36" xlink:to="loc_srt_StatementScenarioAxis_f67143c1-83dc-4a2e-9f18-7da6514844b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f67143c1-83dc-4a2e-9f18-7da6514844b9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_f67143c1-83dc-4a2e-9f18-7da6514844b9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f67143c1-83dc-4a2e-9f18-7da6514844b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fd273a97-b4a9-484c-ae41-fc1a981058f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_f67143c1-83dc-4a2e-9f18-7da6514844b9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fd273a97-b4a9-484c-ae41-fc1a981058f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_c8c2f47d-6954-4a17-92dc-cbe1b424f5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_fd273a97-b4a9-484c-ae41-fc1a981058f1" xlink:to="loc_us-gaap_ScenarioAdjustmentMember_c8c2f47d-6954-4a17-92dc-cbe1b424f5fd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails" xlink:type="extended" id="ie91fbcdd7812459c83912637e6cd6dfc_TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:href="cmrx-20230331.xsd#cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_5f8f796d-b811-4cd1-93ee-9a5119ddf91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_DebtInstrumentTerm_5f8f796d-b811-4cd1-93ee-9a5119ddf91f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_79c50176-1b1f-4276-aa0b-94ce976083af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_79c50176-1b1f-4276-aa0b-94ce976083af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9eb0e8fa-2c2d-47a8-b8d5-d62bafe0003b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9eb0e8fa-2c2d-47a8-b8d5-d62bafe0003b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_92e6c5f5-59fe-4c43-a864-2f9d7130ec34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_92e6c5f5-59fe-4c43-a864-2f9d7130ec34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_9959d1fc-8c7d-415f-9b36-3deb79c76396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_9959d1fc-8c7d-415f-9b36-3deb79c76396" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_DebtInstrumentEarlyTerminationFee_8a2d3c90-1a49-434e-9b98-7025ea31a651" xlink:href="cmrx-20230331.xsd#cmrx_DebtInstrumentEarlyTerminationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_cmrx_DebtInstrumentEarlyTerminationFee_8a2d3c90-1a49-434e-9b98-7025ea31a651" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_bd98c2a6-e685-4de8-824f-11b79e121274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_bd98c2a6-e685-4de8-824f-11b79e121274" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_DebtInstrumentNumberOfInstallmentPayments_bf494f5f-4a3e-438d-bd55-ba3e4928b0e3" xlink:href="cmrx-20230331.xsd#cmrx_DebtInstrumentNumberOfInstallmentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_cmrx_DebtInstrumentNumberOfInstallmentPayments_bf494f5f-4a3e-438d-bd55-ba3e4928b0e3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCurrent_baee03ae-ca00-4204-8ea5-96233bf56e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_DeferredCostsCurrent_baee03ae-ca00-4204-8ea5-96233bf56e3e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCosts_f4a5fcd2-b830-4084-a0c9-a1f8e2129013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_DeferredCosts_f4a5fcd2-b830-4084-a0c9-a1f8e2129013" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_LoanFeesLiabilityCurrent_db1c8cda-6fd2-4822-af00-bf34f7859906" xlink:href="cmrx-20230331.xsd#cmrx_LoanFeesLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_cmrx_LoanFeesLiabilityCurrent_db1c8cda-6fd2-4822-af00-bf34f7859906" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_LoanFeesLiabilityNonCurrent_5b8c45c9-535e-440c-8db6-000d6be0b1b9" xlink:href="cmrx-20230331.xsd#cmrx_LoanFeesLiabilityNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_cmrx_LoanFeesLiabilityNonCurrent_5b8c45c9-535e-440c-8db6-000d6be0b1b9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_3b844179-cbed-4a52-9bb0-5f721803186f" xlink:href="cmrx-20230331.xsd#cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_3b844179-cbed-4a52-9bb0-5f721803186f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f761e689-ba3c-4554-b556-9ac4ce979a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_3b844179-cbed-4a52-9bb0-5f721803186f" xlink:to="loc_us-gaap_CreditFacilityAxis_f761e689-ba3c-4554-b556-9ac4ce979a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f761e689-ba3c-4554-b556-9ac4ce979a12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f761e689-ba3c-4554-b556-9ac4ce979a12" xlink:to="loc_us-gaap_CreditFacilityDomain_f761e689-ba3c-4554-b556-9ac4ce979a12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_815b6d21-472a-4382-b41b-7ce4c492d613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f761e689-ba3c-4554-b556-9ac4ce979a12" xlink:to="loc_us-gaap_CreditFacilityDomain_815b6d21-472a-4382-b41b-7ce4c492d613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2a9f708b-4937-4ea6-a1e5-0bef79e0deae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_815b6d21-472a-4382-b41b-7ce4c492d613" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2a9f708b-4937-4ea6-a1e5-0bef79e0deae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_3d6f32e2-ed06-41a7-a38f-a943e1553564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_3b844179-cbed-4a52-9bb0-5f721803186f" xlink:to="loc_us-gaap_VariableRateAxis_3d6f32e2-ed06-41a7-a38f-a943e1553564" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3d6f32e2-ed06-41a7-a38f-a943e1553564_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_3d6f32e2-ed06-41a7-a38f-a943e1553564" xlink:to="loc_us-gaap_VariableRateDomain_3d6f32e2-ed06-41a7-a38f-a943e1553564_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ff1f711c-3ce5-4e2e-8e38-6f013eb2958a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_3d6f32e2-ed06-41a7-a38f-a943e1553564" xlink:to="loc_us-gaap_VariableRateDomain_ff1f711c-3ce5-4e2e-8e38-6f013eb2958a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_867c600a-37d5-49ac-9080-637c8c75adba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ff1f711c-3ce5-4e2e-8e38-6f013eb2958a" xlink:to="loc_us-gaap_PrimeRateMember_867c600a-37d5-49ac-9080-637c8c75adba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="ia92f47accd2c4b97b4bbfa6fecaf3808_TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:href="cmrx-20230331.xsd#cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_7c0281ff-bcec-439f-9a6f-346ec9a1590b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_7c0281ff-bcec-439f-9a6f-346ec9a1590b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions_fe78f022-31b1-4720-a0ea-c771ffc45cc3" xlink:href="cmrx-20230331.xsd#cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions_fe78f022-31b1-4720-a0ea-c771ffc45cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger_b054c562-e393-409d-bc0f-909fcb074804" xlink:href="cmrx-20230331.xsd#cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger_b054c562-e393-409d-bc0f-909fcb074804" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate_d57f036c-21da-45a2-91fb-2a33857df2e1" xlink:href="cmrx-20230331.xsd#cmrx_RevenueBenchmarkGrossProfitRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate_d57f036c-21da-45a2-91fb-2a33857df2e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_f832cf9d-6982-4715-ac6f-4b58b3a6073c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_f832cf9d-6982-4715-ac6f-4b58b3a6073c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c7bd756b-8c48-48a9-acd3-a0ba237cefe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c7bd756b-8c48-48a9-acd3-a0ba237cefe3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a4341a1f-3705-4a93-a529-91e07d311327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a4341a1f-3705-4a93-a529-91e07d311327" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived_c976c568-f21b-4b6f-8b39-b866423521db" xlink:href="cmrx-20230331.xsd#cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived_c976c568-f21b-4b6f-8b39-b866423521db" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d840e529-2f65-47ca-8894-64214d0afa8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d840e529-2f65-47ca-8894-64214d0afa8a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:href="cmrx-20230331.xsd#cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_56bd00dd-c307-4674-806a-815e7b9b3439" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_srt_ProductOrServiceAxis_56bd00dd-c307-4674-806a-815e7b9b3439" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_56bd00dd-c307-4674-806a-815e7b9b3439_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_56bd00dd-c307-4674-806a-815e7b9b3439" xlink:to="loc_srt_ProductsAndServicesDomain_56bd00dd-c307-4674-806a-815e7b9b3439_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18712b95-0072-4f1e-abf5-d915ec7a8708" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_56bd00dd-c307-4674-806a-815e7b9b3439" xlink:to="loc_srt_ProductsAndServicesDomain_18712b95-0072-4f1e-abf5-d915ec7a8708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_6d777a01-2279-45c7-9254-00200e5c03fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_18712b95-0072-4f1e-abf5-d915ec7a8708" xlink:to="loc_us-gaap_GrantMember_6d777a01-2279-45c7-9254-00200e5c03fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_d0d351d0-b945-454b-a6d6-51abfd27522a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_18712b95-0072-4f1e-abf5-d915ec7a8708" xlink:to="loc_us-gaap_LicenseMember_d0d351d0-b945-454b-a6d6-51abfd27522a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_TEMBEXAMember_84b339b2-4b2a-4d24-a636-6178c03763fc" xlink:href="cmrx-20230331.xsd#cmrx_TEMBEXAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_18712b95-0072-4f1e-abf5-d915ec7a8708" xlink:to="loc_cmrx_TEMBEXAMember_84b339b2-4b2a-4d24-a636-6178c03763fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_aaf41bba-4a50-48dc-9f65-7e52968f6b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_18712b95-0072-4f1e-abf5-d915ec7a8708" xlink:to="loc_us-gaap_RoyaltyMember_aaf41bba-4a50-48dc-9f65-7e52968f6b04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BARDAMember_f6d402c0-721e-48cf-bf9e-a88b38370d35" xlink:href="cmrx-20230331.xsd#cmrx_BARDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_18712b95-0072-4f1e-abf5-d915ec7a8708" xlink:to="loc_cmrx_BARDAMember_f6d402c0-721e-48cf-bf9e-a88b38370d35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_19df640e-f8ce-4b5e-af26-90313e27695d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_us-gaap_AssetAcquisitionAxis_19df640e-f8ce-4b5e-af26-90313e27695d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_19df640e-f8ce-4b5e-af26-90313e27695d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_19df640e-f8ce-4b5e-af26-90313e27695d" xlink:to="loc_us-gaap_AssetAcquisitionDomain_19df640e-f8ce-4b5e-af26-90313e27695d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_9d2a6179-5d15-4c8c-8739-504db09ce04e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_19df640e-f8ce-4b5e-af26-90313e27695d" xlink:to="loc_us-gaap_AssetAcquisitionDomain_9d2a6179-5d15-4c8c-8739-504db09ce04e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OncoceuticsIncMember_f60fced1-b766-4738-bc1f-6b0283fc815f" xlink:href="cmrx-20230331.xsd#cmrx_OncoceuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_9d2a6179-5d15-4c8c-8739-504db09ce04e" xlink:to="loc_cmrx_OncoceuticsIncMember_f60fced1-b766-4738-bc1f-6b0283fc815f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1a72c842-1456-4aba-92dd-b4c936dd80f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_srt_CounterpartyNameAxis_1a72c842-1456-4aba-92dd-b4c936dd80f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1a72c842-1456-4aba-92dd-b4c936dd80f6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1a72c842-1456-4aba-92dd-b4c936dd80f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1a72c842-1456-4aba-92dd-b4c936dd80f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52c041a3-e5ed-49d1-9974-a96674323b47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1a72c842-1456-4aba-92dd-b4c936dd80f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52c041a3-e5ed-49d1-9974-a96674323b47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OharaPharmaceuticalCoLtdMember_397722a2-acbd-4063-98d4-f963aa0c56b4" xlink:href="cmrx-20230331.xsd#cmrx_OharaPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52c041a3-e5ed-49d1-9974-a96674323b47" xlink:to="loc_cmrx_OharaPharmaceuticalCoLtdMember_397722a2-acbd-4063-98d4-f963aa0c56b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmergentBioSolutionsIncMember_4418c071-a6b9-48b7-89b0-fc6235236a8c" xlink:href="cmrx-20230331.xsd#cmrx_EmergentBioSolutionsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52c041a3-e5ed-49d1-9974-a96674323b47" xlink:to="loc_cmrx_EmergentBioSolutionsIncMember_4418c071-a6b9-48b7-89b0-fc6235236a8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SymBioPharmaceuticalsMember_17ca3f3e-0db5-4305-8203-9597d5ca0ec1" xlink:href="cmrx-20230331.xsd#cmrx_SymBioPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52c041a3-e5ed-49d1-9974-a96674323b47" xlink:to="loc_cmrx_SymBioPharmaceuticalsMember_17ca3f3e-0db5-4305-8203-9597d5ca0ec1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmergentBiodefenseOperationsLansingLLCMember_7fd03525-c778-42f8-bb38-44d6596459b6" xlink:href="cmrx-20230331.xsd#cmrx_EmergentBiodefenseOperationsLansingLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52c041a3-e5ed-49d1-9974-a96674323b47" xlink:to="loc_cmrx_EmergentBiodefenseOperationsLansingLLCMember_7fd03525-c778-42f8-bb38-44d6596459b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a165f0f5-5fc9-4042-bb6f-6037bfed9087" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_srt_MajorCustomersAxis_a165f0f5-5fc9-4042-bb6f-6037bfed9087" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a165f0f5-5fc9-4042-bb6f-6037bfed9087_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_a165f0f5-5fc9-4042-bb6f-6037bfed9087" xlink:to="loc_srt_NameOfMajorCustomerDomain_a165f0f5-5fc9-4042-bb6f-6037bfed9087_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fc4df9e1-6ccf-434e-9250-b6a836c2874e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_a165f0f5-5fc9-4042-bb6f-6037bfed9087" xlink:to="loc_srt_NameOfMajorCustomerDomain_fc4df9e1-6ccf-434e-9250-b6a836c2874e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PublicHealthAgencyOfCanadaMember_8864a610-8b42-4f5f-9d02-e5856c8f805d" xlink:href="cmrx-20230331.xsd#cmrx_PublicHealthAgencyOfCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fc4df9e1-6ccf-434e-9250-b6a836c2874e" xlink:to="loc_cmrx_PublicHealthAgencyOfCanadaMember_8864a610-8b42-4f5f-9d02-e5856c8f805d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PeriodAxis_d946d8f7-4c40-4fbb-8a09-7bef0b80c479" xlink:href="cmrx-20230331.xsd#cmrx_PeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_cmrx_PeriodAxis_d946d8f7-4c40-4fbb-8a09-7bef0b80c479" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PeriodDomain_d946d8f7-4c40-4fbb-8a09-7bef0b80c479_default" xlink:href="cmrx-20230331.xsd#cmrx_PeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cmrx_PeriodAxis_d946d8f7-4c40-4fbb-8a09-7bef0b80c479" xlink:to="loc_cmrx_PeriodDomain_d946d8f7-4c40-4fbb-8a09-7bef0b80c479_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PeriodDomain_7ffd7a95-ea02-4c9a-9a8b-07260032ee86" xlink:href="cmrx-20230331.xsd#cmrx_PeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cmrx_PeriodAxis_d946d8f7-4c40-4fbb-8a09-7bef0b80c479" xlink:to="loc_cmrx_PeriodDomain_7ffd7a95-ea02-4c9a-9a8b-07260032ee86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BasePeriodMember_dc83c196-1d03-4216-b6ba-f8a323a147a0" xlink:href="cmrx-20230331.xsd#cmrx_BasePeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_PeriodDomain_7ffd7a95-ea02-4c9a-9a8b-07260032ee86" xlink:to="loc_cmrx_BasePeriodMember_dc83c196-1d03-4216-b6ba-f8a323a147a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_82833262-145e-4dc6-94ea-1e6ec664a8c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_srt_StatementGeographicalAxis_82833262-145e-4dc6-94ea-1e6ec664a8c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_82833262-145e-4dc6-94ea-1e6ec664a8c8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_82833262-145e-4dc6-94ea-1e6ec664a8c8" xlink:to="loc_srt_SegmentGeographicalDomain_82833262-145e-4dc6-94ea-1e6ec664a8c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8293d029-0e6e-4bb5-8687-a9ca967bbacf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_82833262-145e-4dc6-94ea-1e6ec664a8c8" xlink:to="loc_srt_SegmentGeographicalDomain_8293d029-0e6e-4bb5-8687-a9ca967bbacf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_NonUnitedStatesMember_60ead3fb-adfe-46d3-9b72-277c62d17995" xlink:href="cmrx-20230331.xsd#cmrx_NonUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8293d029-0e6e-4bb5-8687-a9ca967bbacf" xlink:to="loc_cmrx_NonUnitedStatesMember_60ead3fb-adfe-46d3-9b72-277c62d17995" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_62d9d446-77bc-400d-b155-c04aa8bce126" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8293d029-0e6e-4bb5-8687-a9ca967bbacf" xlink:to="loc_country_US_62d9d446-77bc-400d-b155-c04aa8bce126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2c37a799-a543-48e5-a6b4-a0d88b57ea4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_srt_StatementScenarioAxis_2c37a799-a543-48e5-a6b4-a0d88b57ea4e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2c37a799-a543-48e5-a6b4-a0d88b57ea4e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_2c37a799-a543-48e5-a6b4-a0d88b57ea4e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2c37a799-a543-48e5-a6b4-a0d88b57ea4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fdc89f84-4e8f-436d-8635-904869fa9128" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_2c37a799-a543-48e5-a6b4-a0d88b57ea4e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fdc89f84-4e8f-436d-8635-904869fa9128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioPlanMember_8aa614ce-dc99-47e1-9663-e2373511dac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_fdc89f84-4e8f-436d-8635-904869fa9128" xlink:to="loc_us-gaap_ScenarioPlanMember_8aa614ce-dc99-47e1-9663-e2373511dac2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#InvestmentsSummaryofAvailableforSalesecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails" xlink:type="extended" id="i9a468936595e4286a9b23b847366a646_InvestmentsSummaryofAvailableforSalesecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e71e59f-1225-46d8-8583-39bed571648d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b491cef1-7da5-46ac-9c3e-de9ca4c3cd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e71e59f-1225-46d8-8583-39bed571648d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b491cef1-7da5-46ac-9c3e-de9ca4c3cd4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7481a0f9-5acd-4c2b-bd0c-ea1075e9490b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e71e59f-1225-46d8-8583-39bed571648d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7481a0f9-5acd-4c2b-bd0c-ea1075e9490b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a28fbe66-9f65-4ce4-bd68-864a910e2015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e71e59f-1225-46d8-8583-39bed571648d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a28fbe66-9f65-4ce4-bd68-864a910e2015" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_4d3d1095-c44a-4486-a796-2cb785335a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e71e59f-1225-46d8-8583-39bed571648d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_4d3d1095-c44a-4486-a796-2cb785335a2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_d0932e90-a01c-4bf4-929f-e2224725bcce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e71e59f-1225-46d8-8583-39bed571648d" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_d0932e90-a01c-4bf4-929f-e2224725bcce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4213565a-1082-4e0e-bbf0-076df3a59b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_d0932e90-a01c-4bf4-929f-e2224725bcce" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4213565a-1082-4e0e-bbf0-076df3a59b09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4213565a-1082-4e0e-bbf0-076df3a59b09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4213565a-1082-4e0e-bbf0-076df3a59b09" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4213565a-1082-4e0e-bbf0-076df3a59b09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c46cc592-b995-4702-b9ce-6d17d18c4a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4213565a-1082-4e0e-bbf0-076df3a59b09" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c46cc592-b995-4702-b9ce-6d17d18c4a9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_3dde4e06-c1f6-4578-955c-ffd1e02a05f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c46cc592-b995-4702-b9ce-6d17d18c4a9c" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_3dde4e06-c1f6-4578-955c-ffd1e02a05f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a638d42b-02c0-4712-b0ef-02df99576cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c46cc592-b995-4702-b9ce-6d17d18c4a9c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a638d42b-02c0-4712-b0ef-02df99576cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6f39e898-9e2b-4230-b8d9-6551a4c3668e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c46cc592-b995-4702-b9ce-6d17d18c4a9c" xlink:to="loc_us-gaap_CommercialPaperMember_6f39e898-9e2b-4230-b8d9-6551a4c3668e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" xlink:type="extended" id="i77d60dc02f6d4e25886587a42e56e1f0_InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_179326f8-f373-441c-9c43-57070dadccdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_179326f8-f373-441c-9c43-57070dadccdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_fb3184f0-1b87-4c35-948b-b318d9779f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_fb3184f0-1b87-4c35-948b-b318d9779f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_cfd54efd-2746-4bae-80fd-1143e97a8115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_cfd54efd-2746-4bae-80fd-1143e97a8115" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_81aa1b8a-53a2-425a-abfc-d6e341091d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_81aa1b8a-53a2-425a-abfc-d6e341091d6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7e51992b-cf76-46e7-ae97-c02cec3b091f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7e51992b-cf76-46e7-ae97-c02cec3b091f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_79814eac-0c70-43db-82c6-520fb2dc5d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_79814eac-0c70-43db-82c6-520fb2dc5d45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_b3e25f51-238f-4710-8ccb-2387e49b5155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_b3e25f51-238f-4710-8ccb-2387e49b5155" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_7a2d830f-233c-4521-bd7a-f8e299f9bc23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_7a2d830f-233c-4521-bd7a-f8e299f9bc23" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b240a2e4-c5c5-40bc-9adf-44630880471b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b240a2e4-c5c5-40bc-9adf-44630880471b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a139724-c995-4e7e-b21f-29a4fac50d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a139724-c995-4e7e-b21f-29a4fac50d9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fc1d4d29-f1d5-41f1-8afc-c91ee544dc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a139724-c995-4e7e-b21f-29a4fac50d9f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fc1d4d29-f1d5-41f1-8afc-c91ee544dc99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc1d4d29-f1d5-41f1-8afc-c91ee544dc99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fc1d4d29-f1d5-41f1-8afc-c91ee544dc99" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc1d4d29-f1d5-41f1-8afc-c91ee544dc99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6fb130f-db88-4092-8b1f-8269e90761da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fc1d4d29-f1d5-41f1-8afc-c91ee544dc99" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6fb130f-db88-4092-8b1f-8269e90761da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_2f1f6bc5-8ca7-48a3-9617-01a51b51d245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6fb130f-db88-4092-8b1f-8269e90761da" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_2f1f6bc5-8ca7-48a3-9617-01a51b51d245" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a027f2f7-3630-4304-89c9-05da31b68911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6fb130f-db88-4092-8b1f-8269e90761da" xlink:to="loc_us-gaap_CommercialPaperMember_a027f2f7-3630-4304-89c9-05da31b68911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4e42aea8-cb13-43dd-978d-50ccb39acfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6fb130f-db88-4092-8b1f-8269e90761da" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4e42aea8-cb13-43dd-978d-50ccb39acfc0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="ic9e050668da548f0878c140548f0dede_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b592581a-338d-4ea1-a412-ec760d818900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3d62a562-631e-49bc-962a-874993e28559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b592581a-338d-4ea1-a412-ec760d818900" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3d62a562-631e-49bc-962a-874993e28559" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4b5465a2-524c-427e-9c50-2efe2dc34769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b592581a-338d-4ea1-a412-ec760d818900" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4b5465a2-524c-427e-9c50-2efe2dc34769" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c36ed87f-086a-438b-8222-f79d44fb00bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4b5465a2-524c-427e-9c50-2efe2dc34769" xlink:to="loc_srt_CounterpartyNameAxis_c36ed87f-086a-438b-8222-f79d44fb00bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c36ed87f-086a-438b-8222-f79d44fb00bf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c36ed87f-086a-438b-8222-f79d44fb00bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c36ed87f-086a-438b-8222-f79d44fb00bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aae72e1e-4844-4d93-be87-d0ca3b1fe137" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c36ed87f-086a-438b-8222-f79d44fb00bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aae72e1e-4844-4d93-be87-d0ca3b1fe137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BARDAMember_01ff1f7f-158a-4035-8e49-f25bee64587a" xlink:href="cmrx-20230331.xsd#cmrx_BARDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aae72e1e-4844-4d93-be87-d0ca3b1fe137" xlink:to="loc_cmrx_BARDAMember_01ff1f7f-158a-4035-8e49-f25bee64587a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_146ddb8f-8e35-4104-856d-eadb34c1c460" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4b5465a2-524c-427e-9c50-2efe2dc34769" xlink:to="loc_srt_ProductOrServiceAxis_146ddb8f-8e35-4104-856d-eadb34c1c460" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_146ddb8f-8e35-4104-856d-eadb34c1c460_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_146ddb8f-8e35-4104-856d-eadb34c1c460" xlink:to="loc_srt_ProductsAndServicesDomain_146ddb8f-8e35-4104-856d-eadb34c1c460_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0b5374be-a72f-4f8c-a644-152f49e12315" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_146ddb8f-8e35-4104-856d-eadb34c1c460" xlink:to="loc_srt_ProductsAndServicesDomain_0b5374be-a72f-4f8c-a644-152f49e12315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_RefundableAgreementsMember_2b5ef530-8ed2-4030-9142-1640ec89ef45" xlink:href="cmrx-20230331.xsd#cmrx_RefundableAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0b5374be-a72f-4f8c-a644-152f49e12315" xlink:to="loc_cmrx_RefundableAgreementsMember_2b5ef530-8ed2-4030-9142-1640ec89ef45" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#EquityTransactionsandSharebasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" xlink:type="extended" id="ia52bc855e10744ce919f8ad20e82ade8_EquityTransactionsandSharebasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SalesOfStockAuthorizedAmount_b3afea45-3080-45da-860f-4fe6cd930510" xlink:href="cmrx-20230331.xsd#cmrx_SalesOfStockAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_cmrx_SalesOfStockAuthorizedAmount_b3afea45-3080-45da-860f-4fe6cd930510" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SalesOfStockAuthorizationTerm_06515faa-9b84-443a-8ce4-3c3851d70d26" xlink:href="cmrx-20230331.xsd#cmrx_SalesOfStockAuthorizationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_cmrx_SalesOfStockAuthorizationTerm_06515faa-9b84-443a-8ce4-3c3851d70d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease_63f08e54-a856-42a3-a87f-5f3e5425b20e" xlink:href="cmrx-20230331.xsd#cmrx_ShareBasedCompensationOptionProvisionEquityIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease_63f08e54-a856-42a3-a87f-5f3e5425b20e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_5d1fe679-3cab-43e9-9911-c8e4ad18e567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_5d1fe679-3cab-43e9-9911-c8e4ad18e567" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3754a908-c51b-4b33-9798-774d6dd36c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3754a908-c51b-4b33-9798-774d6dd36c52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3462079b-7cd2-4dba-a083-301889d31967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3462079b-7cd2-4dba-a083-301889d31967" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9633a21e-6da2-4dd1-9249-bb0073c44887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9633a21e-6da2-4dd1-9249-bb0073c44887" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm_bfce3466-06b2-4227-a51d-826099d0dd89" xlink:href="cmrx-20230331.xsd#cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm_bfce3466-06b2-4227-a51d-826099d0dd89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_afc17d6b-193b-490d-954e-0cdf7723b879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_afc17d6b-193b-490d-954e-0cdf7723b879" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_b856e6d3-bf0a-412a-a26f-410c1e25d9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_b856e6d3-bf0a-412a-a26f-410c1e25d9c9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_b5bfbed4-5f83-49d7-a71b-0cd738be40fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_b5bfbed4-5f83-49d7-a71b-0cd738be40fb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval_c8fcef22-f1d8-4c61-9500-9f7e479e9ed8" xlink:href="cmrx-20230331.xsd#cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval_c8fcef22-f1d8-4c61-9500-9f7e479e9ed8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1cb22beb-0741-45ae-a3e0-b962375777ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1cb22beb-0741-45ae-a3e0-b962375777ae" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_13cd7e70-d818-4f1f-8ada-854df5771eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_13cd7e70-d818-4f1f-8ada-854df5771eca" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_b5fc6ea6-76f0-4728-ab79-a8fbf3add773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_SeveranceCosts1_b5fc6ea6-76f0-4728-ab79-a8fbf3add773" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbf8b61a-14ca-4fe4-a827-c4b74d7094df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbf8b61a-14ca-4fe4-a827-c4b74d7094df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_245d7cab-a651-4951-b834-70276eb654c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbf8b61a-14ca-4fe4-a827-c4b74d7094df" xlink:to="loc_us-gaap_PlanNameAxis_245d7cab-a651-4951-b834-70276eb654c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_245d7cab-a651-4951-b834-70276eb654c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_245d7cab-a651-4951-b834-70276eb654c8" xlink:to="loc_us-gaap_PlanNameDomain_245d7cab-a651-4951-b834-70276eb654c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d151e221-1d34-4045-ba67-af1b163d36d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_245d7cab-a651-4951-b834-70276eb654c8" xlink:to="loc_us-gaap_PlanNameDomain_d151e221-1d34-4045-ba67-af1b163d36d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_The2013PlanMember_ab05f2ad-6197-4a9e-8da4-9abdc9cf42df" xlink:href="cmrx-20230331.xsd#cmrx_The2013PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d151e221-1d34-4045-ba67-af1b163d36d8" xlink:to="loc_cmrx_The2013PlanMember_ab05f2ad-6197-4a9e-8da4-9abdc9cf42df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_The2013EmployeeStockPurchasePlanMember_cb602e14-8cb5-4025-b586-b14bcec54196" xlink:href="cmrx-20230331.xsd#cmrx_The2013EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d151e221-1d34-4045-ba67-af1b163d36d8" xlink:to="loc_cmrx_The2013EmployeeStockPurchasePlanMember_cb602e14-8cb5-4025-b586-b14bcec54196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_dd53cbe9-b59b-4c21-9cd1-c51a001bc2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbf8b61a-14ca-4fe4-a827-c4b74d7094df" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_dd53cbe9-b59b-4c21-9cd1-c51a001bc2f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dd53cbe9-b59b-4c21-9cd1-c51a001bc2f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dd53cbe9-b59b-4c21-9cd1-c51a001bc2f6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dd53cbe9-b59b-4c21-9cd1-c51a001bc2f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b25fbaf9-6a9f-4629-a894-373605e1a47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dd53cbe9-b59b-4c21-9cd1-c51a001bc2f6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b25fbaf9-6a9f-4629-a894-373605e1a47b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PublicOfferingMember_7e5aeba4-b667-46e1-a42c-969864e4b152" xlink:href="cmrx-20230331.xsd#cmrx_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b25fbaf9-6a9f-4629-a894-373605e1a47b" xlink:to="loc_cmrx_PublicOfferingMember_7e5aeba4-b667-46e1-a42c-969864e4b152" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended" id="i59327a3b416c430f8b19844babbcbc5b_EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5f97f8ec-bb72-49e6-ad93-a6799532b8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6cc3e65b-2be7-4f6f-9fd5-f098ab48728b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5f97f8ec-bb72-49e6-ad93-a6799532b8a5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6cc3e65b-2be7-4f6f-9fd5-f098ab48728b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_434aff17-692b-4622-8b4f-61dc7dd8f856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5f97f8ec-bb72-49e6-ad93-a6799532b8a5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_434aff17-692b-4622-8b4f-61dc7dd8f856" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_24c2cbc8-35f6-48f2-89b7-381e992fb756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_434aff17-692b-4622-8b4f-61dc7dd8f856" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_24c2cbc8-35f6-48f2-89b7-381e992fb756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_24c2cbc8-35f6-48f2-89b7-381e992fb756_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24c2cbc8-35f6-48f2-89b7-381e992fb756" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_24c2cbc8-35f6-48f2-89b7-381e992fb756_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ccb49a47-f5d8-4938-978c-523ab2770213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24c2cbc8-35f6-48f2-89b7-381e992fb756" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ccb49a47-f5d8-4938-978c-523ab2770213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8b694932-1af3-46b7-9c15-43aa48a2f0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ccb49a47-f5d8-4938-978c-523ab2770213" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8b694932-1af3-46b7-9c15-43aa48a2f0c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7f0a0ecb-ab0a-454d-8a9b-3ff7966f87c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ccb49a47-f5d8-4938-978c-523ab2770213" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7f0a0ecb-ab0a-454d-8a9b-3ff7966f87c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_25c1c848-8eed-4179-b8dc-869a6d4ab006" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_434aff17-692b-4622-8b4f-61dc7dd8f856" xlink:to="loc_srt_TitleOfIndividualAxis_25c1c848-8eed-4179-b8dc-869a6d4ab006" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_25c1c848-8eed-4179-b8dc-869a6d4ab006_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_25c1c848-8eed-4179-b8dc-869a6d4ab006" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_25c1c848-8eed-4179-b8dc-869a6d4ab006_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41049ec0-ec51-4ce8-85c3-2d0a7cc2468c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_25c1c848-8eed-4179-b8dc-869a6d4ab006" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41049ec0-ec51-4ce8-85c3-2d0a7cc2468c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_IndependentMembersOfBoardMember_9ba82865-7cd2-470c-bd5a-b7ced4439725" xlink:href="cmrx-20230331.xsd#cmrx_IndependentMembersOfBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41049ec0-ec51-4ce8-85c3-2d0a7cc2468c" xlink:to="loc_cmrx_IndependentMembersOfBoardMember_9ba82865-7cd2-470c-bd5a-b7ced4439725" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/IncomeTaxesDetails" xlink:type="extended" id="i33d6b884231a4fe4baa5e804cc358d92_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_10890a7b-8c26-4046-9dfa-3d7316f10981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a3ed5bcb-3866-488a-939c-9cc43343d624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_10890a7b-8c26-4046-9dfa-3d7316f10981" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a3ed5bcb-3866-488a-939c-9cc43343d624" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_155b7298-1f45-4376-a545-55b3a1c4ea3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_10890a7b-8c26-4046-9dfa-3d7316f10981" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_155b7298-1f45-4376-a545-55b3a1c4ea3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_cb2ac262-aa9f-44ca-a79c-912be5475626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_10890a7b-8c26-4046-9dfa-3d7316f10981" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_cb2ac262-aa9f-44ca-a79c-912be5475626" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d28a55b0-529c-4bba-b5ce-81bff50528b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_cb2ac262-aa9f-44ca-a79c-912be5475626" xlink:to="loc_srt_StatementScenarioAxis_d28a55b0-529c-4bba-b5ce-81bff50528b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d28a55b0-529c-4bba-b5ce-81bff50528b0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_d28a55b0-529c-4bba-b5ce-81bff50528b0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d28a55b0-529c-4bba-b5ce-81bff50528b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4f32d2b9-30d6-4320-bfaf-cbbce59ca0b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_d28a55b0-529c-4bba-b5ce-81bff50528b0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4f32d2b9-30d6-4320-bfaf-cbbce59ca0b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a22390f5-f0af-4658-aa2e-d8c7112a481a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4f32d2b9-30d6-4320-bfaf-cbbce59ca0b1" xlink:to="loc_srt_ScenarioForecastMember_a22390f5-f0af-4658-aa2e-d8c7112a481a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/SignificantAgreementsDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#SignificantAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/SignificantAgreementsDetails" xlink:type="extended" id="ida911c4ecc1a4e47b6e442eecddeaf63_SignificantAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_QuantityBenchmarkTreatmentContractualCommitment_11a33621-3712-4e0b-971a-82520cb7cefc" xlink:href="cmrx-20230331.xsd#cmrx_QuantityBenchmarkTreatmentContractualCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_QuantityBenchmarkTreatmentContractualCommitment_11a33621-3712-4e0b-971a-82520cb7cefc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SignificantAgreementsContractTerm_11e5d543-7ff8-4b89-8ca5-60f3b8eb5da4" xlink:href="cmrx-20230331.xsd#cmrx_SignificantAgreementsContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_SignificantAgreementsContractTerm_11e5d543-7ff8-4b89-8ca5-60f3b8eb5da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BasePerformanceContractTerm_130aa63f-333a-4a7a-8b8d-7d0e4488d39f" xlink:href="cmrx-20230331.xsd#cmrx_BasePerformanceContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_BasePerformanceContractTerm_130aa63f-333a-4a7a-8b8d-7d0e4488d39f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4c30ada6-4e1c-4973-93df-6368c04590bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4c30ada6-4e1c-4973-93df-6368c04590bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ReimbursableMarketingExpenses_839180c5-d4c6-4d96-8c53-8e09fbfea305" xlink:href="cmrx-20230331.xsd#cmrx_ReimbursableMarketingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_ReimbursableMarketingExpenses_839180c5-d4c6-4d96-8c53-8e09fbfea305" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue_67c0638c-3979-4153-a397-c5b15c235cbe" xlink:href="cmrx-20230331.xsd#cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue_67c0638c-3979-4153-a397-c5b15c235cbe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OptionToPurchaseAdditionalTreatmentCourses_0d2b3261-094f-4c5e-a273-e852086c279a" xlink:href="cmrx-20230331.xsd#cmrx_OptionToPurchaseAdditionalTreatmentCourses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_OptionToPurchaseAdditionalTreatmentCourses_0d2b3261-094f-4c5e-a273-e852086c279a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost_a2232b5f-717d-441d-bef1-1c34e496b172" xlink:href="cmrx-20230331.xsd#cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost_a2232b5f-717d-441d-bef1-1c34e496b172" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions_1b5f1582-bacd-4cb6-a89e-a12b84c8164b" xlink:href="cmrx-20230331.xsd#cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions_1b5f1582-bacd-4cb6-a89e-a12b84c8164b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_6d14d06d-95df-45c1-adc4-ee7d3b0dac2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_6d14d06d-95df-45c1-adc4-ee7d3b0dac2f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions_652202e8-3d05-4269-8dc3-ebd5370a3a82" xlink:href="cmrx-20230331.xsd#cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions_652202e8-3d05-4269-8dc3-ebd5370a3a82" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger_e1e3855b-f948-4b17-b7cc-de9185860c11" xlink:href="cmrx-20230331.xsd#cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger_e1e3855b-f948-4b17-b7cc-de9185860c11" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate_57f864dc-b11e-45ea-89f1-9309448de2db" xlink:href="cmrx-20230331.xsd#cmrx_RevenueBenchmarkGrossProfitRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate_57f864dc-b11e-45ea-89f1-9309448de2db" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_21a6aee9-ad97-4913-a8cf-3d9663686c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_21a6aee9-ad97-4913-a8cf-3d9663686c51" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0450edb0-83c2-44d4-9ff1-6cefb05139c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0450edb0-83c2-44d4-9ff1-6cefb05139c0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_84898a36-7812-4e06-ac7a-b1cd8ae8dd87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_84898a36-7812-4e06-ac7a-b1cd8ae8dd87" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractWithCustomerLiabilityInstallmentPeriods_96e51cb9-c918-408a-bb18-67965a41f35c" xlink:href="cmrx-20230331.xsd#cmrx_ContractWithCustomerLiabilityInstallmentPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_ContractWithCustomerLiabilityInstallmentPeriods_96e51cb9-c918-408a-bb18-67965a41f35c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39523bee-1387-444a-b81c-d0060ea2a834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39523bee-1387-444a-b81c-d0060ea2a834" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived_fdec9121-9a83-4b08-bf79-05164c5d207f" xlink:href="cmrx-20230331.xsd#cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived_fdec9121-9a83-4b08-bf79-05164c5d207f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e028ff84-a518-457e-b0aa-26030cc17996" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_srt_CounterpartyNameAxis_e028ff84-a518-457e-b0aa-26030cc17996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e028ff84-a518-457e-b0aa-26030cc17996_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e028ff84-a518-457e-b0aa-26030cc17996" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e028ff84-a518-457e-b0aa-26030cc17996_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e028ff84-a518-457e-b0aa-26030cc17996" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BARDAMember_7508c4f1-4a02-4c48-9f9f-2b837d0a3667" xlink:href="cmrx-20230331.xsd#cmrx_BARDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:to="loc_cmrx_BARDAMember_7508c4f1-4a02-4c48-9f9f-2b837d0a3667" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmergentBioSolutionsIncMember_4f846163-5275-4820-8a05-b13596fc48b1" xlink:href="cmrx-20230331.xsd#cmrx_EmergentBioSolutionsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:to="loc_cmrx_EmergentBioSolutionsIncMember_4f846163-5275-4820-8a05-b13596fc48b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SymBioPharmaceuticalsMember_5889ef29-eb8d-470e-8daf-72f7d1036b11" xlink:href="cmrx-20230331.xsd#cmrx_SymBioPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:to="loc_cmrx_SymBioPharmaceuticalsMember_5889ef29-eb8d-470e-8daf-72f7d1036b11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmergentBiodefenseOperationsLansingLLCMember_67cc45ae-bb2d-4f57-8fc2-2833b2f8988a" xlink:href="cmrx-20230331.xsd#cmrx_EmergentBiodefenseOperationsLansingLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:to="loc_cmrx_EmergentBiodefenseOperationsLansingLLCMember_67cc45ae-bb2d-4f57-8fc2-2833b2f8988a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OharaPharmaceuticalCoLtdMember_ed574fee-cb53-4797-8d42-fdbd0177b2c8" xlink:href="cmrx-20230331.xsd#cmrx_OharaPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:to="loc_cmrx_OharaPharmaceuticalCoLtdMember_ed574fee-cb53-4797-8d42-fdbd0177b2c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SanjiuMedicalPharmaceuticalCoLtdMember_f6bf9922-0c09-4e0d-aa7d-fac5145cb38a" xlink:href="cmrx-20230331.xsd#cmrx_SanjiuMedicalPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:to="loc_cmrx_SanjiuMedicalPharmaceuticalCoLtdMember_f6bf9922-0c09-4e0d-aa7d-fac5145cb38a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_NationalStockpileMember_fc1db5ae-bf41-45b7-9513-2b584fea08b4" xlink:href="cmrx-20230331.xsd#cmrx_NationalStockpileMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:to="loc_cmrx_NationalStockpileMember_fc1db5ae-bf41-45b7-9513-2b584fea08b4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_126ef97b-f86b-474f-90c3-55a3d984f7ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_srt_ProductOrServiceAxis_126ef97b-f86b-474f-90c3-55a3d984f7ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_126ef97b-f86b-474f-90c3-55a3d984f7ba_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_126ef97b-f86b-474f-90c3-55a3d984f7ba" xlink:to="loc_srt_ProductsAndServicesDomain_126ef97b-f86b-474f-90c3-55a3d984f7ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1298b180-9edf-4065-9eec-912522df72af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_126ef97b-f86b-474f-90c3-55a3d984f7ba" xlink:to="loc_srt_ProductsAndServicesDomain_1298b180-9edf-4065-9eec-912522df72af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_TEMBEXAMember_53f3dd1a-8dd7-4a39-9fca-286c9970c615" xlink:href="cmrx-20230331.xsd#cmrx_TEMBEXAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1298b180-9edf-4065-9eec-912522df72af" xlink:to="loc_cmrx_TEMBEXAMember_53f3dd1a-8dd7-4a39-9fca-286c9970c615" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BARDAMember_301f6737-9250-48b6-b118-d34bdc92f43d" xlink:href="cmrx-20230331.xsd#cmrx_BARDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1298b180-9edf-4065-9eec-912522df72af" xlink:to="loc_cmrx_BARDAMember_301f6737-9250-48b6-b118-d34bdc92f43d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_371ee593-2476-4b55-9901-5c633f906920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1298b180-9edf-4065-9eec-912522df72af" xlink:to="loc_us-gaap_RoyaltyMember_371ee593-2476-4b55-9901-5c633f906920" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ExpenseReimbursementMember_f57e4780-bd4a-4c24-aa94-da2674c8f9cf" xlink:href="cmrx-20230331.xsd#cmrx_ExpenseReimbursementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1298b180-9edf-4065-9eec-912522df72af" xlink:to="loc_cmrx_ExpenseReimbursementMember_f57e4780-bd4a-4c24-aa94-da2674c8f9cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed867c34-5124-4b87-bc59-c8cd1e180842" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_srt_RangeAxis_ed867c34-5124-4b87-bc59-c8cd1e180842" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ed867c34-5124-4b87-bc59-c8cd1e180842_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ed867c34-5124-4b87-bc59-c8cd1e180842" xlink:to="loc_srt_RangeMember_ed867c34-5124-4b87-bc59-c8cd1e180842_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bbe2ec1b-c5cd-4ed0-873d-83918144069e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ed867c34-5124-4b87-bc59-c8cd1e180842" xlink:to="loc_srt_RangeMember_bbe2ec1b-c5cd-4ed0-873d-83918144069e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1e96256e-d149-45c7-992b-3e11711f9df9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bbe2ec1b-c5cd-4ed0-873d-83918144069e" xlink:to="loc_srt_MaximumMember_1e96256e-d149-45c7-992b-3e11711f9df9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PeriodAxis_d7273e78-be6f-4b8a-ab55-f45ca5149836" xlink:href="cmrx-20230331.xsd#cmrx_PeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_cmrx_PeriodAxis_d7273e78-be6f-4b8a-ab55-f45ca5149836" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PeriodDomain_d7273e78-be6f-4b8a-ab55-f45ca5149836_default" xlink:href="cmrx-20230331.xsd#cmrx_PeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cmrx_PeriodAxis_d7273e78-be6f-4b8a-ab55-f45ca5149836" xlink:to="loc_cmrx_PeriodDomain_d7273e78-be6f-4b8a-ab55-f45ca5149836_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PeriodDomain_17cac2e0-dbac-4220-8a00-ca79dd8ec393" xlink:href="cmrx-20230331.xsd#cmrx_PeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cmrx_PeriodAxis_d7273e78-be6f-4b8a-ab55-f45ca5149836" xlink:to="loc_cmrx_PeriodDomain_17cac2e0-dbac-4220-8a00-ca79dd8ec393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BasePeriodMember_7f43349d-52ae-4199-96b3-e471822f991c" xlink:href="cmrx-20230331.xsd#cmrx_BasePeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmrx_PeriodDomain_17cac2e0-dbac-4220-8a00-ca79dd8ec393" xlink:to="loc_cmrx_BasePeriodMember_7f43349d-52ae-4199-96b3-e471822f991c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_98cfb0dd-31b9-43fe-8856-606a423a5dcc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_srt_StatementScenarioAxis_98cfb0dd-31b9-43fe-8856-606a423a5dcc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_98cfb0dd-31b9-43fe-8856-606a423a5dcc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_98cfb0dd-31b9-43fe-8856-606a423a5dcc" xlink:to="loc_srt_ScenarioUnspecifiedDomain_98cfb0dd-31b9-43fe-8856-606a423a5dcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_39ad3e6e-9ec1-438a-af1f-653485326247" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_98cfb0dd-31b9-43fe-8856-606a423a5dcc" xlink:to="loc_srt_ScenarioUnspecifiedDomain_39ad3e6e-9ec1-438a-af1f-653485326247" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioPlanMember_7cea8a57-aa4a-474e-b0a5-1139b17355ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_39ad3e6e-9ec1-438a-af1f-653485326247" xlink:to="loc_us-gaap_ScenarioPlanMember_7cea8a57-aa4a-474e-b0a5-1139b17355ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_28e8c585-5970-4598-8f41-1d9fc7a7035c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_srt_StatementGeographicalAxis_28e8c585-5970-4598-8f41-1d9fc7a7035c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_28e8c585-5970-4598-8f41-1d9fc7a7035c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_28e8c585-5970-4598-8f41-1d9fc7a7035c" xlink:to="loc_srt_SegmentGeographicalDomain_28e8c585-5970-4598-8f41-1d9fc7a7035c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4ddca247-2299-49c9-b946-2e521584a722" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_28e8c585-5970-4598-8f41-1d9fc7a7035c" xlink:to="loc_srt_SegmentGeographicalDomain_4ddca247-2299-49c9-b946-2e521584a722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_NonUnitedStatesMember_b608d8ee-e7c8-4eef-a4fb-a50b2344c68e" xlink:href="cmrx-20230331.xsd#cmrx_NonUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4ddca247-2299-49c9-b946-2e521584a722" xlink:to="loc_cmrx_NonUnitedStatesMember_b608d8ee-e7c8-4eef-a4fb-a50b2344c68e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_dfe55ccf-63a9-404d-9613-7d2b7e33eb0d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4ddca247-2299-49c9-b946-2e521584a722" xlink:to="loc_country_US_dfe55ccf-63a9-404d-9613-7d2b7e33eb0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_42a4bb2b-ad6b-4f6d-a940-33dac92752e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_srt_MajorCustomersAxis_42a4bb2b-ad6b-4f6d-a940-33dac92752e1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_42a4bb2b-ad6b-4f6d-a940-33dac92752e1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_42a4bb2b-ad6b-4f6d-a940-33dac92752e1" xlink:to="loc_srt_NameOfMajorCustomerDomain_42a4bb2b-ad6b-4f6d-a940-33dac92752e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0fcafd0b-9e4c-4198-b02f-b59d92aa2e6b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_42a4bb2b-ad6b-4f6d-a940-33dac92752e1" xlink:to="loc_srt_NameOfMajorCustomerDomain_0fcafd0b-9e4c-4198-b02f-b59d92aa2e6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PurchaserMember_a0f4598d-1d9b-4caf-a205-f7b86c70f2b3" xlink:href="cmrx-20230331.xsd#cmrx_PurchaserMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0fcafd0b-9e4c-4198-b02f-b59d92aa2e6b" xlink:to="loc_cmrx_PurchaserMember_a0f4598d-1d9b-4caf-a205-f7b86c70f2b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PublicHealthAgencyOfCanadaMember_8a47b9bb-026d-4859-a501-6d37b154cd44" xlink:href="cmrx-20230331.xsd#cmrx_PublicHealthAgencyOfCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0fcafd0b-9e4c-4198-b02f-b59d92aa2e6b" xlink:to="loc_cmrx_PublicHealthAgencyOfCanadaMember_8a47b9bb-026d-4859-a501-6d37b154cd44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5b2f19e2-864b-40b8-8da3-e2f1f9972a3e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_dei_LegalEntityAxis_5b2f19e2-864b-40b8-8da3-e2f1f9972a3e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5b2f19e2-864b-40b8-8da3-e2f1f9972a3e_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5b2f19e2-864b-40b8-8da3-e2f1f9972a3e" xlink:to="loc_dei_EntityDomain_5b2f19e2-864b-40b8-8da3-e2f1f9972a3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_143eacfd-bd6d-441a-9a25-5c17a90bf69c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5b2f19e2-864b-40b8-8da3-e2f1f9972a3e" xlink:to="loc_dei_EntityDomain_143eacfd-bd6d-441a-9a25-5c17a90bf69c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OncoceuticsIncMember_b79fa22a-495d-4119-a85b-61131181b73f" xlink:href="cmrx-20230331.xsd#cmrx_OncoceuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_143eacfd-bd6d-441a-9a25-5c17a90bf69c" xlink:to="loc_cmrx_OncoceuticsIncMember_b79fa22a-495d-4119-a85b-61131181b73f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails" xlink:type="extended" id="i866b2a03945346f8bb6f740a443e2419_SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_c35d27fd-a49f-4b94-9e5f-e9284ef1752c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_c35d27fd-a49f-4b94-9e5f-e9284ef1752c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AssetSaleLiabilities_53c1a8c0-dbd7-42f4-9ae7-48256ac976b8" xlink:href="cmrx-20230331.xsd#cmrx_AssetSaleLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:to="loc_cmrx_AssetSaleLiabilities_53c1a8c0-dbd7-42f4-9ae7-48256ac976b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AssetSaleInventoryTransferred_fced3764-a4fd-46e7-a06f-a2c7576a5343" xlink:href="cmrx-20230331.xsd#cmrx_AssetSaleInventoryTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:to="loc_cmrx_AssetSaleInventoryTransferred_fced3764-a4fd-46e7-a06f-a2c7576a5343" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AssetSalePrepaidsTransferred_1f4886b0-ea0c-428a-a2fe-31de7ffa39b4" xlink:href="cmrx-20230331.xsd#cmrx_AssetSalePrepaidsTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:to="loc_cmrx_AssetSalePrepaidsTransferred_1f4886b0-ea0c-428a-a2fe-31de7ffa39b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_TransactionCostsIncurredInRelationToSales_2a3fbf8a-a5b0-43f5-a7b4-49f348c821cd" xlink:href="cmrx-20230331.xsd#cmrx_TransactionCostsIncurredInRelationToSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:to="loc_cmrx_TransactionCostsIncurredInRelationToSales_2a3fbf8a-a5b0-43f5-a7b4-49f348c821cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_2500a9ae-add6-4546-a850-a5ca73f9adb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_2500a9ae-add6-4546-a850-a5ca73f9adb2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_65913e84-e06c-42f8-834a-d90a4f88c746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_65913e84-e06c-42f8-834a-d90a4f88c746" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f12b100f-3395-4aa1-abc0-ed78ccf1fa3e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_65913e84-e06c-42f8-834a-d90a4f88c746" xlink:to="loc_srt_CounterpartyNameAxis_f12b100f-3395-4aa1-abc0-ed78ccf1fa3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f12b100f-3395-4aa1-abc0-ed78ccf1fa3e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f12b100f-3395-4aa1-abc0-ed78ccf1fa3e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f12b100f-3395-4aa1-abc0-ed78ccf1fa3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcba6c1e-c969-4332-ba33-8162aa7cc688" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f12b100f-3395-4aa1-abc0-ed78ccf1fa3e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcba6c1e-c969-4332-ba33-8162aa7cc688" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmergentBioSolutionsIncMember_2fc24dfb-ff70-4906-b6fa-45878f25d86d" xlink:href="cmrx-20230331.xsd#cmrx_EmergentBioSolutionsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcba6c1e-c969-4332-ba33-8162aa7cc688" xlink:to="loc_cmrx_EmergentBioSolutionsIncMember_2fc24dfb-ff70-4906-b6fa-45878f25d86d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#DSTATContractCloseoutNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails" xlink:type="extended" id="i8b97b1c62b44486eafd350c4a878b7a8_DSTATContractCloseoutNarrativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_eff5901a-95dc-44bb-b245-3ecae86505f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractCloseOutLiability_7f6dc192-0773-4f24-8496-785711b3e573" xlink:href="cmrx-20230331.xsd#cmrx_ContractCloseOutLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_eff5901a-95dc-44bb-b245-3ecae86505f8" xlink:to="loc_cmrx_ContractCloseOutLiability_7f6dc192-0773-4f24-8496-785711b3e573" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractCloseOutLiabilityAdjustments_4c76578b-e802-489b-8b4d-9d3b66703461" xlink:href="cmrx-20230331.xsd#cmrx_ContractCloseOutLiabilityAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_eff5901a-95dc-44bb-b245-3ecae86505f8" xlink:to="loc_cmrx_ContractCloseOutLiabilityAdjustments_4c76578b-e802-489b-8b4d-9d3b66703461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f448b88a-a683-4ed8-b567-27f30fc99b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_eff5901a-95dc-44bb-b245-3ecae86505f8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f448b88a-a683-4ed8-b567-27f30fc99b85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3af9ac4b-5a98-4222-a861-fae4e95ed9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f448b88a-a683-4ed8-b567-27f30fc99b85" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3af9ac4b-5a98-4222-a861-fae4e95ed9c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3af9ac4b-5a98-4222-a861-fae4e95ed9c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3af9ac4b-5a98-4222-a861-fae4e95ed9c7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3af9ac4b-5a98-4222-a861-fae4e95ed9c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a526c778-01e9-4e2b-a8a1-1dc967841511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3af9ac4b-5a98-4222-a861-fae4e95ed9c7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a526c778-01e9-4e2b-a8a1-1dc967841511" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_be27c5c1-b0e3-423b-b5b0-d8ba775b6b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a526c778-01e9-4e2b-a8a1-1dc967841511" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_be27c5c1-b0e3-423b-b5b0-d8ba775b6b03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_b23704e2-bf1d-4e98-b2bf-5e670f87b076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a526c778-01e9-4e2b-a8a1-1dc967841511" xlink:to="loc_us-gaap_AccountsPayableMember_b23704e2-bf1d-4e98-b2bf-5e670f87b076" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails" xlink:type="extended" id="iee7b6bef174f430ba9eef79607990136_DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_51ab4a63-6299-4452-a455-987167c22324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractCloseOutCosts_7f704a79-7091-44cb-9347-9297fd46cca0" xlink:href="cmrx-20230331.xsd#cmrx_ContractCloseOutCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_51ab4a63-6299-4452-a455-987167c22324" xlink:to="loc_cmrx_ContractCloseOutCosts_7f704a79-7091-44cb-9347-9297fd46cca0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_053cdf68-b7aa-41a2-be08-13b98b7e871d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_51ab4a63-6299-4452-a455-987167c22324" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_053cdf68-b7aa-41a2-be08-13b98b7e871d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c561ccc5-6051-457f-afdc-ab1f84668017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_053cdf68-b7aa-41a2-be08-13b98b7e871d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c561ccc5-6051-457f-afdc-ab1f84668017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c561ccc5-6051-457f-afdc-ab1f84668017_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c561ccc5-6051-457f-afdc-ab1f84668017" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c561ccc5-6051-457f-afdc-ab1f84668017_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8798739c-4b15-424c-9d77-877f33c5e41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c561ccc5-6051-457f-afdc-ab1f84668017" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8798739c-4b15-424c-9d77-877f33c5e41e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6b1b73f2-fc87-4507-aa62-69a2ecbaf0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8798739c-4b15-424c-9d77-877f33c5e41e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6b1b73f2-fc87-4507-aa62-69a2ecbaf0c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c237fc62-4e39-44b1-9073-3f7990dc7396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8798739c-4b15-424c-9d77-877f33c5e41e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c237fc62-4e39-44b1-9073-3f7990dc7396" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/RestructuringCostsSummaryofRestructuringChargesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#RestructuringCostsSummaryofRestructuringChargesDetails"/>
  <link:definitionLink xlink:role="http://www.chimerix.com/role/RestructuringCostsSummaryofRestructuringChargesDetails" xlink:type="extended" id="i4d9ef14f84aa44288a3750d79b9af78f_RestructuringCostsSummaryofRestructuringChargesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_27e7a7cc-9348-40d0-b187-cb7c26a18aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_148fff90-3c30-49e4-826e-06fff10a13f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27e7a7cc-9348-40d0-b187-cb7c26a18aef" xlink:to="loc_us-gaap_SeveranceCosts1_148fff90-3c30-49e4-826e-06fff10a13f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_77a8d3f7-d217-4b38-9acf-a32531154d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27e7a7cc-9348-40d0-b187-cb7c26a18aef" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_77a8d3f7-d217-4b38-9acf-a32531154d1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_51fbe48a-913f-4efa-935c-b8ae01f7ac45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_77a8d3f7-d217-4b38-9acf-a32531154d1d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_51fbe48a-913f-4efa-935c-b8ae01f7ac45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_51fbe48a-913f-4efa-935c-b8ae01f7ac45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_51fbe48a-913f-4efa-935c-b8ae01f7ac45" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_51fbe48a-913f-4efa-935c-b8ae01f7ac45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d03d1720-2b80-48b3-adef-61700457c859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_51fbe48a-913f-4efa-935c-b8ae01f7ac45" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d03d1720-2b80-48b3-adef-61700457c859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_89291acf-d254-4879-ae76-9ebd3dc85e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d03d1720-2b80-48b3-adef-61700457c859" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_89291acf-d254-4879-ae76-9ebd3dc85e65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d5a74d8c-cb47-4f33-b788-b271ffc3eb07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d03d1720-2b80-48b3-adef-61700457c859" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d5a74d8c-cb47-4f33-b788-b271ffc3eb07" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cmrx-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:bd8f579e-4e63-4bef-9c1c-fca25009f3d7,g:bc09e6ba-bd4a-4780-8a45-ad8ddbcdd46a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DeferredCosts_209aa1fa-2bf5-4f8d-b0a6-a239b08c1c6b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred loan costs</link:label>
    <link:label id="lab_us-gaap_DeferredCosts_label_en-US" xlink:label="lab_us-gaap_DeferredCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCosts" xlink:to="lab_us-gaap_DeferredCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5b1a84b7-fd7f-4833-b9b4-b39bc8b9176e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_OptionToPurchaseAdditionalTreatmentCourses_d63da65b-8772-4f6d-b4ba-9bd651d415b5_terseLabel_en-US" xlink:label="lab_cmrx_OptionToPurchaseAdditionalTreatmentCourses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of additional courses at the discretion of customer</link:label>
    <link:label id="lab_cmrx_OptionToPurchaseAdditionalTreatmentCourses_label_en-US" xlink:label="lab_cmrx_OptionToPurchaseAdditionalTreatmentCourses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option To Purchase Additional Treatment Courses</link:label>
    <link:label id="lab_cmrx_OptionToPurchaseAdditionalTreatmentCourses_documentation_en-US" xlink:label="lab_cmrx_OptionToPurchaseAdditionalTreatmentCourses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option To Purchase Additional Treatment Courses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OptionToPurchaseAdditionalTreatmentCourses" xlink:href="cmrx-20230331.xsd#cmrx_OptionToPurchaseAdditionalTreatmentCourses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_OptionToPurchaseAdditionalTreatmentCourses" xlink:to="lab_cmrx_OptionToPurchaseAdditionalTreatmentCourses" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate_b4fdb902-ceaa-4725-8799-6367277df572_terseLabel_en-US" xlink:label="lab_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit royalty rate (percent)</link:label>
    <link:label id="lab_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate_label_en-US" xlink:label="lab_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark, Gross Profit Royalty Rate</link:label>
    <link:label id="lab_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate_documentation_en-US" xlink:label="lab_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark, Gross Profit Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate" xlink:href="cmrx-20230331.xsd#cmrx_RevenueBenchmarkGrossProfitRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate" xlink:to="lab_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8414cb3a-6678-4c1d-9aa7-26654cdb241a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4708390f-510b-4bb1-ba36-609d28b42658_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f75ba0f2-2460-4314-87a9-80d7d97d43fa_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum rental payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3a85ad47-ee39-4757-9229-e821d38bbf7b_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a779ded-73ec-4adb-b19d-9adffba91aa8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_acb5058d-9d5e-47bc-89b8-3470037ecccd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_f3ad3a10-26ea-4ce8-9909-7e7cb9468325_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_52a4d24b-2ce7-4250-8846-5d69f2b7805e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8e3b373d-5177-4e70-9cc2-aee4b452eaeb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year four</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_53061d03-812d-41c8-9361-9fb7d67da71b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5dc7b3d7-d882-4858-b7d9-ffc560c8cc9d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2e73516d-cce2-49f0-9fc8-06fa5f4bd3c0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in&#160;Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_0274d32e-5959-4680-bcf0-279e3bf5d78a_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_10de8fc8-811a-4258-8119-32aca58d5dd0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_47e81057-069f-4115-9177-50cbc43308fd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revised estimates</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:to="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7aff6716-3270-4bea-8bf3-55da17a8d51d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_776e2755-9b39-469d-852a-353203d865b4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_266415da-4db8-4920-81d3-6d9d3d4fda9a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_04798570-eb19-4098-85b2-7d08d15f4208_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e484da81-0a17-451a-8294-cd5cc5af8bc2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_d5dd6a47-6ee4-4401-81d5-82da5450a8f9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance accrual balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_f4ab3d75-15bc-487e-9255-c2621b1020e2_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2022</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_4f645dc3-666e-4eb2-8b5a-404ab9aa2777_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at March 31, 2023</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_ContractCloseOutLiabilityPayments_504718fe-f256-4a51-ab05-4c215e8c4db7_negatedTerseLabel_en-US" xlink:label="lab_cmrx_ContractCloseOutLiabilityPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_cmrx_ContractCloseOutLiabilityPayments_label_en-US" xlink:label="lab_cmrx_ContractCloseOutLiabilityPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Close Out Liability, Payments</link:label>
    <link:label id="lab_cmrx_ContractCloseOutLiabilityPayments_documentation_en-US" xlink:label="lab_cmrx_ContractCloseOutLiabilityPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Close Out Liability, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractCloseOutLiabilityPayments" xlink:href="cmrx-20230331.xsd#cmrx_ContractCloseOutLiabilityPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_ContractCloseOutLiabilityPayments" xlink:to="lab_cmrx_ContractCloseOutLiabilityPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_98281894-e127-4981-be1d-62b1d63b5cdd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ad88ecf4-7034-44bb-992f-a19f61948cec_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_b97f726e-9e26-445c-ba47-b0a4e81c6db3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80a14d1c-dea2-4604-8d1e-876bfb494bd2_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4efafd4f-e3b9-4f55-a3c6-8463a1444894_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c1af4fb9-a1d8-418e-9acc-7374ff12d176_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8373ee62-9c14-49b5-94e8-20a6531ef0d5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_bff28aa2-1f2c-41b9-a758-491b07db2a89_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_ef3c82db-e77c-43da-9373-bb74c610c65a_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation of property and equipment</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_dba15023-62ad-4baa-8bac-0c3d0c951c12_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of investments</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f5a27d4e-40cf-40cf-a253-fca890a057bf_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a40caecc-cfdd-4fe8-a5f1-624bd78ec9d3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued pursuant to the exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_NonUnitedStatesMember_d8f0fb3c-d621-4253-ae58-65ffb4624885_terseLabel_en-US" xlink:label="lab_cmrx_NonUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- United States</link:label>
    <link:label id="lab_cmrx_NonUnitedStatesMember_label_en-US" xlink:label="lab_cmrx_NonUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- United States [Member]</link:label>
    <link:label id="lab_cmrx_NonUnitedStatesMember_documentation_en-US" xlink:label="lab_cmrx_NonUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_NonUnitedStatesMember" xlink:href="cmrx-20230331.xsd#cmrx_NonUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_NonUnitedStatesMember" xlink:to="lab_cmrx_NonUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6cb5b25f-d7bc-41f4-92c2-57c2b818c046_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Certain Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e6687be5-39e1-40a2-9219-7e3336b3a410_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_783e6ff5-efaa-4e24-8004-24668b7a58d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a7582aa4-eeb8-4b6a-928a-fb5d7644dcfd_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_60265510-19b9-4908-83b7-0c6e1b56bfe2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_TransactionCostsIncurredInRelationToSales_84639acc-8972-4aec-bb41-c2cf5bd6d2db_negatedTerseLabel_en-US" xlink:label="lab_cmrx_TransactionCostsIncurredInRelationToSales" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs incurred</link:label>
    <link:label id="lab_cmrx_TransactionCostsIncurredInRelationToSales_label_en-US" xlink:label="lab_cmrx_TransactionCostsIncurredInRelationToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Incurred In Relation To Sales</link:label>
    <link:label id="lab_cmrx_TransactionCostsIncurredInRelationToSales_documentation_en-US" xlink:label="lab_cmrx_TransactionCostsIncurredInRelationToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Incurred In Relation To Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_TransactionCostsIncurredInRelationToSales" xlink:href="cmrx-20230331.xsd#cmrx_TransactionCostsIncurredInRelationToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_TransactionCostsIncurredInRelationToSales" xlink:to="lab_cmrx_TransactionCostsIncurredInRelationToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_59f86051-2ca1-4ae2-b5e0-b8fb96cbac1e_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9fd5da03-d7ab-4b87-8636-3db73a27db1a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60e804e1-f250-4ec1-acf8-d5d9ee709642_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_SymBioPharmaceuticalsMember_366c0b9f-630b-4bad-9636-d72f6f5125b9_terseLabel_en-US" xlink:label="lab_cmrx_SymBioPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SymBio Pharmaceuticals</link:label>
    <link:label id="lab_cmrx_SymBioPharmaceuticalsMember_label_en-US" xlink:label="lab_cmrx_SymBioPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SymBio Pharmaceuticals [Member]</link:label>
    <link:label id="lab_cmrx_SymBioPharmaceuticalsMember_documentation_en-US" xlink:label="lab_cmrx_SymBioPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SymBio Pharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SymBioPharmaceuticalsMember" xlink:href="cmrx-20230331.xsd#cmrx_SymBioPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_SymBioPharmaceuticalsMember" xlink:to="lab_cmrx_SymBioPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3ddea182-3ca2-4511-858e-2b1fd06d3118_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_69a88ad5-e5e3-4ae5-9bcf-d50407dfa1b1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0ceab9d6-f16e-46a1-a048-e505d3841890_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_6f6bc882-9c35-4c6f-a48c-e79c83dc36c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d3bcfe79-08d9-4d3c-abb2-be39d373c6dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_89a5035b-da5a-4a70-a3cf-a587dd84c072_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3e35febb-ddab-4d2b-bc63-0f33d7f2fd31_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_d1f141d0-36eb-48ea-b08d-46484326dbb5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_acc96fb8-20fa-4484-b3de-531cdaf84b56_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3286bc34-e73a-47fc-9d1e-5a6bfa351244_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_LoanFeesLiabilityCurrent_cc4bf566-c5bc-4ee0-af1d-5042dadb8f80_verboseLabel_en-US" xlink:label="lab_cmrx_LoanFeesLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan fee liability</link:label>
    <link:label id="lab_cmrx_LoanFeesLiabilityCurrent_label_en-US" xlink:label="lab_cmrx_LoanFeesLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Fees Liability, Current</link:label>
    <link:label id="lab_cmrx_LoanFeesLiabilityCurrent_documentation_en-US" xlink:label="lab_cmrx_LoanFeesLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Fees Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_LoanFeesLiabilityCurrent" xlink:href="cmrx-20230331.xsd#cmrx_LoanFeesLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_LoanFeesLiabilityCurrent" xlink:to="lab_cmrx_LoanFeesLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0a36f311-5cc8-45b4-98c6-a0886efbd851_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities with unrealized losses, total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_54fb8e9e-cb11-4267-a83c-824a274b9a9b_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2b3bbdba-226a-4dc6-b537-9342bc311f33_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1cc9f3a6-8de8-4fe3-9397-d754f4aebe25_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f0e9844e-aa60-429b-88f0-0d586c85dc6e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_43376d26-4b6d-4628-b746-c908df2ec64b_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_ContractCloseOutLiabilityAdjustments_72711a5b-d341-43f0-a467-6fabd8423fb9_negatedTerseLabel_en-US" xlink:label="lab_cmrx_ContractCloseOutLiabilityAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revised estimates</link:label>
    <link:label id="lab_cmrx_ContractCloseOutLiabilityAdjustments_a8171c2d-b4d6-40bd-bb0c-ba7b1b5ff7fa_terseLabel_en-US" xlink:label="lab_cmrx_ContractCloseOutLiabilityAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revised estimates</link:label>
    <link:label id="lab_cmrx_ContractCloseOutLiabilityAdjustments_label_en-US" xlink:label="lab_cmrx_ContractCloseOutLiabilityAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Close Out Liability, Adjustments</link:label>
    <link:label id="lab_cmrx_ContractCloseOutLiabilityAdjustments_documentation_en-US" xlink:label="lab_cmrx_ContractCloseOutLiabilityAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Close Out Liability, Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractCloseOutLiabilityAdjustments" xlink:href="cmrx-20230331.xsd#cmrx_ContractCloseOutLiabilityAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_ContractCloseOutLiabilityAdjustments" xlink:to="lab_cmrx_ContractCloseOutLiabilityAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_e628fbf0-2c4b-4a03-ba15-4b6f42dbaee3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_TEMBEXAMember_ac07eaf4-e08d-4965-a1f4-ce5a548db5d3_terseLabel_en-US" xlink:label="lab_cmrx_TEMBEXAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEMBEXA</link:label>
    <link:label id="lab_cmrx_TEMBEXAMember_label_en-US" xlink:label="lab_cmrx_TEMBEXAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEMBEXA [Member]</link:label>
    <link:label id="lab_cmrx_TEMBEXAMember_documentation_en-US" xlink:label="lab_cmrx_TEMBEXAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEMBEXA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_TEMBEXAMember" xlink:href="cmrx-20230331.xsd#cmrx_TEMBEXAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_TEMBEXAMember" xlink:to="lab_cmrx_TEMBEXAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_116b728e-e0a4-4133-9063-5fc9c1c064cf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan purchases</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_81267ee9-6b86-4569-88ef-c525e598f3f4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_26ad81e4-742f-4994-96cb-ccb391da5d5c_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_acb70322-19de-4b6f-8a86-6b8059f8bc5a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f99f3b33-8df0-4d04-b4b8-6746a0a9f507_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_642f76bf-5819-4fe2-9409-973936eed640_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_b139c3cc-ff3b-43e1-8928-f33a295876aa_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_28c6148e-0b6c-4651-9d73-e0bdf4106963_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_1ff47126-5a30-460c-865b-d8f3c6d1898f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_79e81686-7400-441c-8efc-8fdb7d3de063_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_36d8bdc9-6b27-4c06-a78b-c4141bb82dc4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability, current, statement of financial position [extensible list]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_The2013PlanMember_c81fe827-b6f6-4945-af06-1feee9a1ae66_terseLabel_en-US" xlink:label="lab_cmrx_The2013PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2013 Plan</link:label>
    <link:label id="lab_cmrx_The2013PlanMember_label_en-US" xlink:label="lab_cmrx_The2013PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2013 Plan [Member]</link:label>
    <link:label id="lab_cmrx_The2013PlanMember_documentation_en-US" xlink:label="lab_cmrx_The2013PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2013 Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_The2013PlanMember" xlink:href="cmrx-20230331.xsd#cmrx_The2013PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_The2013PlanMember" xlink:to="lab_cmrx_The2013PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonrecurringIncomeExpenseAbstract_d336b5c0-d9cc-400e-ab41-539943d31a05_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonrecurringIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income:</link:label>
    <link:label id="lab_us-gaap_OtherNonrecurringIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonrecurringIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonrecurring (Income) Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonrecurringIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonrecurringIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_5ff5b804-92b2-48d6-8ddf-820c8c47e038_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_fb5beea5-2c66-432a-941c-bc4572a8cad9_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_2278ab4b-5a72-45fe-a981-39e51c68613e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5d9f0fe5-9c04-40c5-8d4a-656bc66ef163_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_9fee352f-54cc-4502-a981-da4c7e389397_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_OharaPharmaceuticalCoLtdMember_f039f00f-ecf2-468c-88a4-51a5ec20f909_terseLabel_en-US" xlink:label="lab_cmrx_OharaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ohara Pharmaceutical Co., Ltd.</link:label>
    <link:label id="lab_cmrx_OharaPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_cmrx_OharaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ohara Pharmaceutical Co., Ltd. [Member]</link:label>
    <link:label id="lab_cmrx_OharaPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_cmrx_OharaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ohara Pharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OharaPharmaceuticalCoLtdMember" xlink:href="cmrx-20230331.xsd#cmrx_OharaPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_OharaPharmaceuticalCoLtdMember" xlink:to="lab_cmrx_OharaPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_AssetSaleLiabilities_ec4ba0a9-969b-4a83-ac76-79304514911c_terseLabel_en-US" xlink:label="lab_cmrx_AssetSaleLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by Emergent</link:label>
    <link:label id="lab_cmrx_AssetSaleLiabilities_label_en-US" xlink:label="lab_cmrx_AssetSaleLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Sale, Liabilities</link:label>
    <link:label id="lab_cmrx_AssetSaleLiabilities_documentation_en-US" xlink:label="lab_cmrx_AssetSaleLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Sale, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AssetSaleLiabilities" xlink:href="cmrx-20230331.xsd#cmrx_AssetSaleLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_AssetSaleLiabilities" xlink:to="lab_cmrx_AssetSaleLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_01daec6d-fe4a-48f8-8a1d-f7c416f03571_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_752241e6-24a9-4a6b-93a7-dadb6c6938b3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_4ba4eb3c-4693-4622-b6ac-2688ae1380e6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 200,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; 88,583,567 and 88,054,127 shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_80430670-931b-4a1e-b899-051bc6c9a7c0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8ca2f750-79c3-4d84-a29d-23b64d44a2d3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Prices&#160;in Active&#160;Markets for&#160;Identical&#160;Assets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60edb914-d1a4-4207-a0fa-3c77faa47616_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan purchases (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_22747da7-98d3-422d-8974-3931c423c463_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued pursuant to employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_27d930d9-83fd-4eba-8910-1d03c01f68ca_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_6c62a0bf-eab5-4c89-b032-2f6f655a6c6d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_327ce1c1-b413-4205-8446-7e6f8a9fba98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Separate Account Investment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Separate Account Investment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xlink:to="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_e325cc48-9a19-4424-a7d1-818a9c80df56_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_AnticipatedSeveranceCost_4e258b56-1f1e-486e-bca2-e014c4d1832b_terseLabel_en-US" xlink:label="lab_cmrx_AnticipatedSeveranceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated severance cost</link:label>
    <link:label id="lab_cmrx_AnticipatedSeveranceCost_label_en-US" xlink:label="lab_cmrx_AnticipatedSeveranceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated Severance Cost</link:label>
    <link:label id="lab_cmrx_AnticipatedSeveranceCost_documentation_en-US" xlink:label="lab_cmrx_AnticipatedSeveranceCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated Severance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AnticipatedSeveranceCost" xlink:href="cmrx-20230331.xsd#cmrx_AnticipatedSeveranceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_AnticipatedSeveranceCost" xlink:to="lab_cmrx_AnticipatedSeveranceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_7e30b7ff-8688-43b0-a2f0-ee23ddd9a8fc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities with unrealized losses, less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ca875a43-39e3-48f5-b954-466ce42e064e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6e506025-e370-4fd7-a993-a45b8e374fe0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0e083a6a-7f72-483c-acb6-fa58bf85ebe8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease short-term liabilities (recorded within Accrued liabilities)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_139a4297-db18-4aa6-b375-1e4b9e560f7f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_14a85c86-c55c-4d88-ba30-8d9bb54a509f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e09f12e1-2473-44d7-972c-5173631670fd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_91510f2e-70fa-490b-85a6-63f2a6b01f8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_695eca1a-4816-47b0-9124-fa4b21e59e56_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Short-Term and Long-Term Investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_e9f9dffa-f7e3-48e2-b5ba-80610b45c9a2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0187710f-941f-4271-b91b-d5ff1e6f3a41_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_3cc13dda-af5b-4da3-9fc7-78b7457b98e3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from tax refund</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Income Tax Refunds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_QuantityBenchmarkTreatmentContractualCommitment_9d78cd7c-2fe1-4d5e-8499-565876c05ae6_terseLabel_en-US" xlink:label="lab_cmrx_QuantityBenchmarkTreatmentContractualCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual treatment commitment (treatment)</link:label>
    <link:label id="lab_cmrx_QuantityBenchmarkTreatmentContractualCommitment_label_en-US" xlink:label="lab_cmrx_QuantityBenchmarkTreatmentContractualCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quantity Benchmark, Treatment Contractual Commitment</link:label>
    <link:label id="lab_cmrx_QuantityBenchmarkTreatmentContractualCommitment_documentation_en-US" xlink:label="lab_cmrx_QuantityBenchmarkTreatmentContractualCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quantity Benchmark, Treatment Contractual Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_QuantityBenchmarkTreatmentContractualCommitment" xlink:href="cmrx-20230331.xsd#cmrx_QuantityBenchmarkTreatmentContractualCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_QuantityBenchmarkTreatmentContractualCommitment" xlink:to="lab_cmrx_QuantityBenchmarkTreatmentContractualCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_ba5be431-6e4c-470c-9832-8098c2c8128b_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_0dfd7c2b-ff88-4f28-8cdb-22ea3eeeca5a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Agreements</link:label>
    <link:label id="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_6d21e22b-e375-420c-afbf-fcae96bd80f7_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DSTAT Contract Close-out</link:label>
    <link:label id="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Contracts or Programs Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermContractsOrProgramsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:to="lab_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_ContractCloseOutLiability_fa0cafb6-4993-444e-9519-4e0f0dd75a4e_terseLabel_en-US" xlink:label="lab_cmrx_ContractCloseOutLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract close out liability</link:label>
    <link:label id="lab_cmrx_ContractCloseOutLiability_b1f405eb-bfa1-4bf1-b372-2ab9f409b6bf_periodStartLabel_en-US" xlink:label="lab_cmrx_ContractCloseOutLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at June 30, 2022</link:label>
    <link:label id="lab_cmrx_ContractCloseOutLiability_2c33da1f-483f-48a9-bbc9-7b09fab128f5_periodEndLabel_en-US" xlink:label="lab_cmrx_ContractCloseOutLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2022</link:label>
    <link:label id="lab_cmrx_ContractCloseOutLiability_label_en-US" xlink:label="lab_cmrx_ContractCloseOutLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Close Out Liability</link:label>
    <link:label id="lab_cmrx_ContractCloseOutLiability_documentation_en-US" xlink:label="lab_cmrx_ContractCloseOutLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Close Out Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractCloseOutLiability" xlink:href="cmrx-20230331.xsd#cmrx_ContractCloseOutLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_ContractCloseOutLiability" xlink:to="lab_cmrx_ContractCloseOutLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_ReimbursableMarketingExpenses_227549a7-2d32-464d-9d1b-3b684c0ca10c_terseLabel_en-US" xlink:label="lab_cmrx_ReimbursableMarketingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursable marketing expenses</link:label>
    <link:label id="lab_cmrx_ReimbursableMarketingExpenses_label_en-US" xlink:label="lab_cmrx_ReimbursableMarketingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursable Marketing Expenses</link:label>
    <link:label id="lab_cmrx_ReimbursableMarketingExpenses_documentation_en-US" xlink:label="lab_cmrx_ReimbursableMarketingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursable Marketing Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ReimbursableMarketingExpenses" xlink:href="cmrx-20230331.xsd#cmrx_ReimbursableMarketingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_ReimbursableMarketingExpenses" xlink:to="lab_cmrx_ReimbursableMarketingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cd291293-2810-4769-99b4-b3d091b8d5ef_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_2214883f-e3c1-487e-a950-c9f0eedc821c_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_9fb12352-7631-4160-9674-63f20017a6fb_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_80276138-2eec-4346-a945-0753f7de8352_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on debt investments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_421c11d4-f16a-4a20-b92b-68f8d503326c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_687c58a3-101a-46a7-8a12-070a53d0eb38_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e035c208-0ffe-417d-b12f-c73bd8c195b6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3808fc1e-6066-4f23-884b-f0bcca482c57_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_25cd82fd-ae9e-4d79-ae21-fd4a9f7eb0b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_3712aad1-4cf0-431d-a075-b99d3b0b2c5b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front cash payment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b7211785-e2cf-47de-9a36-981f8ba3d21e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_181cb198-0ad1-46ed-a227-8d1723e8bdaa_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_2f66e17e-5aed-4b87-b58b-3db40c9e7ca8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_fb72ee60-38d2-49ad-938e-bd5f8278cc58_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_589a4758-0e9f-4b8c-a907-59311398e1e9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5b5ebcdc-6615-4299-941a-a1b1b8a7ddba_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_15726431-f4ab-41b7-b95b-d0ba32eb39bd_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_SalesOfStockAuthorizationTerm_19b8385c-947e-4299-a9cd-1a3be36fbe9b_terseLabel_en-US" xlink:label="lab_cmrx_SalesOfStockAuthorizationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of stock, authorization term</link:label>
    <link:label id="lab_cmrx_SalesOfStockAuthorizationTerm_label_en-US" xlink:label="lab_cmrx_SalesOfStockAuthorizationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Of Stock, Authorization Term</link:label>
    <link:label id="lab_cmrx_SalesOfStockAuthorizationTerm_documentation_en-US" xlink:label="lab_cmrx_SalesOfStockAuthorizationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Of Stock, Authorization Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SalesOfStockAuthorizationTerm" xlink:href="cmrx-20230331.xsd#cmrx_SalesOfStockAuthorizationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_SalesOfStockAuthorizationTerm" xlink:to="lab_cmrx_SalesOfStockAuthorizationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c05145d5-5e36-4de7-acad-ab7b491ed9d3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_22b5d2bc-bb05-47ca-9b17-f0d500c3102c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_ContractAndGrantMember_db68f19a-e3cb-45aa-aaa6-0490814c43ed_terseLabel_en-US" xlink:label="lab_cmrx_ContractAndGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract and grant revenue</link:label>
    <link:label id="lab_cmrx_ContractAndGrantMember_label_en-US" xlink:label="lab_cmrx_ContractAndGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract And Grant [Member]</link:label>
    <link:label id="lab_cmrx_ContractAndGrantMember_documentation_en-US" xlink:label="lab_cmrx_ContractAndGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract And Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractAndGrantMember" xlink:href="cmrx-20230331.xsd#cmrx_ContractAndGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_ContractAndGrantMember" xlink:to="lab_cmrx_ContractAndGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_4d3c7705-170f-4383-b3fa-ad7f80630926_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_722ae500-812f-46a9-8d91-d88d27b1d095_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2c731340-fb43-4d4b-b0e6-359468f4c06b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_284005e4-f454-48f2-beb3-0eece6383825_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in workforce</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e08efb81-bcb1-41a0-ac18-365adf8b83f6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b1904b9d-29c6-45e5-b6a0-6e4234cd3366_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ea347d90-04a6-475b-be91-e983b6728a93_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8674f7a0-8f33-4f4c-a9fe-ccfde2896d83_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_a946f0b9-8d2b-40e6-aeb4-4fb7a326b953_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent_b1637f1c-18e4-4ddf-a46c-4030493ede3d_terseLabel_en-US" xlink:label="lab_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease-related amortization</link:label>
    <link:label id="lab_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent_label_en-US" xlink:label="lab_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense and Straight Line Rent</link:label>
    <link:label id="lab_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent_documentation_en-US" xlink:label="lab_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense and Straight Line Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent" xlink:href="cmrx-20230331.xsd#cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent" xlink:to="lab_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_DebtInstrumentEarlyTerminationFee_c12d8ac0-6f36-4e05-94a6-fcd303606ac5_terseLabel_en-US" xlink:label="lab_cmrx_DebtInstrumentEarlyTerminationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, early termination fee</link:label>
    <link:label id="lab_cmrx_DebtInstrumentEarlyTerminationFee_label_en-US" xlink:label="lab_cmrx_DebtInstrumentEarlyTerminationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Early Termination Fee</link:label>
    <link:label id="lab_cmrx_DebtInstrumentEarlyTerminationFee_documentation_en-US" xlink:label="lab_cmrx_DebtInstrumentEarlyTerminationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Early Termination Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_DebtInstrumentEarlyTerminationFee" xlink:href="cmrx-20230331.xsd#cmrx_DebtInstrumentEarlyTerminationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_DebtInstrumentEarlyTerminationFee" xlink:to="lab_cmrx_DebtInstrumentEarlyTerminationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_0e0139db-5492-4ea2-920e-11cfbb9af8b5_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time employee termination benefits</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_877209dd-c41d-460f-b30b-e46552b00836_verboseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restructuring expenses</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_b1bbdb80-2ed7-49d4-8582-a933d1686e31_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_a61c951d-30a8-4d5e-a15d-7c55116af735_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b0e19f11-0d7d-4656-b2f1-406ba6a67800_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_AssetSaleInventoryTransferred_3d39122f-98d3-4a21-9efc-47cda1cbda38_negatedTerseLabel_en-US" xlink:label="lab_cmrx_AssetSaleInventoryTransferred" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory transferred to Emergent</link:label>
    <link:label id="lab_cmrx_AssetSaleInventoryTransferred_label_en-US" xlink:label="lab_cmrx_AssetSaleInventoryTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Sale, Inventory Transferred</link:label>
    <link:label id="lab_cmrx_AssetSaleInventoryTransferred_documentation_en-US" xlink:label="lab_cmrx_AssetSaleInventoryTransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Sale, Inventory Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AssetSaleInventoryTransferred" xlink:href="cmrx-20230331.xsd#cmrx_AssetSaleInventoryTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_AssetSaleInventoryTransferred" xlink:to="lab_cmrx_AssetSaleInventoryTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b5c94ed2-e978-4fc5-8cd1-fcc7f0910b8e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year one</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_AccruedDevelopmentLiabilities_c6721db2-30fc-4fc1-9d45-8e7e801564b1_terseLabel_en-US" xlink:label="lab_cmrx_AccruedDevelopmentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_cmrx_AccruedDevelopmentLiabilities_label_en-US" xlink:label="lab_cmrx_AccruedDevelopmentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Development Liabilities</link:label>
    <link:label id="lab_cmrx_AccruedDevelopmentLiabilities_documentation_en-US" xlink:label="lab_cmrx_AccruedDevelopmentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued development liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AccruedDevelopmentLiabilities" xlink:href="cmrx-20230331.xsd#cmrx_AccruedDevelopmentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_AccruedDevelopmentLiabilities" xlink:to="lab_cmrx_AccruedDevelopmentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost_2194e0bf-aaa8-4ccf-a227-995b117d05ae_terseLabel_en-US" xlink:label="lab_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of additional courses at the discretion of customer, net of marketing cost</link:label>
    <link:label id="lab_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost_label_en-US" xlink:label="lab_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option To Purchase Additional Treatment Courses, Net Of Marketing Cost</link:label>
    <link:label id="lab_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost_documentation_en-US" xlink:label="lab_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option To Purchase Additional Treatment Courses, Net Of Marketing Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost" xlink:href="cmrx-20230331.xsd#cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost" xlink:to="lab_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_2586f6f1-4754-418f-a7e5-2d720d6c9dc7_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_2d22040c-cfae-455d-a89e-0f9d106377ca_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_d8aaaa84-6911-4a00-99da-1d133d3f36c3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b397c485-c09f-41ba-b814-b9725863c958_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_10c9ece1-adf5-4042-80c1-fac98cd3d254_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_The2013EmployeeStockPurchasePlanMember_f14a985a-43f0-4ea5-84ff-82df6b173b19_terseLabel_en-US" xlink:label="lab_cmrx_The2013EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2013 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_cmrx_The2013EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_cmrx_The2013EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2013 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_cmrx_The2013EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_cmrx_The2013EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2013 Employee Stock Purchase Plan Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_The2013EmployeeStockPurchasePlanMember" xlink:href="cmrx-20230331.xsd#cmrx_The2013EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_The2013EmployeeStockPurchasePlanMember" xlink:to="lab_cmrx_The2013EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2398d15e-4eb1-4f69-9709-bbfdccd8ee70_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_PublicOfferingMember_674fca68-3e75-4f7c-ac88-d2732c7feb9b_terseLabel_en-US" xlink:label="lab_cmrx_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_cmrx_PublicOfferingMember_label_en-US" xlink:label="lab_cmrx_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_cmrx_PublicOfferingMember_documentation_en-US" xlink:label="lab_cmrx_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PublicOfferingMember" xlink:href="cmrx-20230331.xsd#cmrx_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_PublicOfferingMember" xlink:to="lab_cmrx_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_5694636b-29e3-4860-a3f5-da623c1a307d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_e25a7f1b-607f-408a-aee9-1b29b18431a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_ed82e55e-7fef-4612-8a7a-f2f91acd68a4_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss, less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ce14d5e-3d52-4e02-b3ab-e4b17b2adf84_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU stock issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f271a595-14b3-455c-9b17-22e9b3840a81_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total present value of lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_954aeccf-6904-44ef-ac8e-d04bf0dc8372_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total present value of lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_02dda1cc-c826-433d-ac85-b14267c238c1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5a31cef4-f6af-4e89-a004-26a8d7daef3a_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of discount/premium on investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_75031ab4-ff17-4c69-a77e-66be699d04c0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share information:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4a7b0628-8d2b-4ce7-b07d-e6198b33b467_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_be36cb3c-bc14-44aa-85e8-611ddb93b77b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1f3d882c-65e9-4b44-9270-159a663a54ca_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss, greater than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc650152-492f-41a7-b9e8-c9579a83ec27_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c529d695-0ac5-4125-890d-b74cbb513ba2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9845a3a5-064a-4c9c-83af-cc82331fc116_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_6fd3f510-67b8-4a88-8546-b83ec4de90b7_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_415adbeb-c1a9-4cee-b54d-5f4c88d048ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_26345ee2-b9d0-4afe-8aab-4f5bace2a2e8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_e61b83aa-82e7-4b68-89bf-8610c8dc580d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_92fd514e-5763-4059-b3d4-aef60ed6f0ea_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval_e0f80a62-14ce-4e4d-9642-a9d7ccd7ec02_terseLabel_en-US" xlink:label="lab_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase interval</link:label>
    <link:label id="lab_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval_label_en-US" xlink:label="lab_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Interval</link:label>
    <link:label id="lab_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval_documentation_en-US" xlink:label="lab_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Interval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval" xlink:href="cmrx-20230331.xsd#cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval" xlink:to="lab_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6a741878-a304-43ee-b0a0-52e4f37e8ff8_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2de48f4a-93a8-436a-a2f2-3a5d2afafcaf_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_AssetsAndLiabilitiesLesseeTableTextBlock_7517953f-b873-427a-be47-827d5c035fcb_terseLabel_en-US" xlink:label="lab_cmrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Right-of-Use Assets and Liabilities</link:label>
    <link:label id="lab_cmrx_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cmrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cmrx_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cmrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cmrx-20230331.xsd#cmrx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cmrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_37d1e893-13c7-4100-bef6-d6ec9bda271f_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions_4725ea97-cd22-446d-94bc-0fab6cf8ae11_terseLabel_en-US" xlink:label="lab_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursable marketing cost upon the exercise of options</link:label>
    <link:label id="lab_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions_label_en-US" xlink:label="lab_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursable Marketing Cost Upon The Exercise Of Options</link:label>
    <link:label id="lab_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions_documentation_en-US" xlink:label="lab_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursable Marketing Cost Upon The Exercise Of Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions" xlink:href="cmrx-20230331.xsd#cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions" xlink:to="lab_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease_317d9269-cf02-4849-ab84-ab95ecdf397e_terseLabel_en-US" xlink:label="lab_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evergreen option provision, equity increase</link:label>
    <link:label id="lab_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease_label_en-US" xlink:label="lab_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation, Option Provision, Equity Increase</link:label>
    <link:label id="lab_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease_documentation_en-US" xlink:label="lab_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation, Option Provision, Equity Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease" xlink:href="cmrx-20230331.xsd#cmrx_ShareBasedCompensationOptionProvisionEquityIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease" xlink:to="lab_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_018a753c-e9d5-4284-975e-07dc83e7a999_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Scheduled Maturity of Company Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_692d1e3a-adfe-41a6-948b-2bf51d552825_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fbf92f69-c150-4e14-be75-2f9f4d9151d4_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_53e76e5e-ed2b-4ed8-a401-15c09f47d450_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_56526bcb-95d6-4fed-a553-a6633b17299a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6982176f-b6ed-4c5e-a78d-da66bdb7d3c0_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_3351b741-96ee-485e-a69f-9c0640d1d200_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss, total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_c514709f-f0ed-48d2-a858-303a46aefdd1_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_8d78e99c-23c9-4ec7-8d87-81af0c9f0468_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_AccrualActivitiesForContractCloseOutCostRollForward_2ab74c58-d3f4-422d-a706-687304723a5f_terseLabel_en-US" xlink:label="lab_cmrx_AccrualActivitiesForContractCloseOutCostRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual Activities for Contract Close-out Cost</link:label>
    <link:label id="lab_cmrx_AccrualActivitiesForContractCloseOutCostRollForward_label_en-US" xlink:label="lab_cmrx_AccrualActivitiesForContractCloseOutCostRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual Activities for Contract Close-out Cost [Roll Forward]</link:label>
    <link:label id="lab_cmrx_AccrualActivitiesForContractCloseOutCostRollForward_documentation_en-US" xlink:label="lab_cmrx_AccrualActivitiesForContractCloseOutCostRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual Activities for Contract Close-out Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AccrualActivitiesForContractCloseOutCostRollForward" xlink:href="cmrx-20230331.xsd#cmrx_AccrualActivitiesForContractCloseOutCostRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_AccrualActivitiesForContractCloseOutCostRollForward" xlink:to="lab_cmrx_AccrualActivitiesForContractCloseOutCostRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_SignificantAgreementsContractTerm_cae72c19-db20-41ff-b8ef-aea20851b454_terseLabel_en-US" xlink:label="lab_cmrx_SignificantAgreementsContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term (years)</link:label>
    <link:label id="lab_cmrx_SignificantAgreementsContractTerm_label_en-US" xlink:label="lab_cmrx_SignificantAgreementsContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Agreements, Contract Term</link:label>
    <link:label id="lab_cmrx_SignificantAgreementsContractTerm_documentation_en-US" xlink:label="lab_cmrx_SignificantAgreementsContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Agreements, Contract Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SignificantAgreementsContractTerm" xlink:href="cmrx-20230331.xsd#cmrx_SignificantAgreementsContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_SignificantAgreementsContractTerm" xlink:to="lab_cmrx_SignificantAgreementsContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3a7a0b9d-9629-4576-8307-b2edd4f7ad74_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_5cc7244e-8223-4b1e-8a00-4413a2603f60_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_68813a18-f821-4767-8459-192535cb64c4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_adcab050-ec2e-4e76-a6a0-6e42cf07be0f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_BasePeriodMember_abefd8b2-295a-409c-ac57-125cf67816ee_terseLabel_en-US" xlink:label="lab_cmrx_BasePeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Period</link:label>
    <link:label id="lab_cmrx_BasePeriodMember_label_en-US" xlink:label="lab_cmrx_BasePeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Period [Member]</link:label>
    <link:label id="lab_cmrx_BasePeriodMember_documentation_en-US" xlink:label="lab_cmrx_BasePeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BasePeriodMember" xlink:href="cmrx-20230331.xsd#cmrx_BasePeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_BasePeriodMember" xlink:to="lab_cmrx_BasePeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_803e27a6-cbbb-4958-ab26-5364a1a48300_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_f7612082-a68c-43eb-a27e-4feec2fb93fc_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock_693d6b29-326e-4868-a0b8-aba874019c01_terseLabel_en-US" xlink:label="lab_cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Net Gain From The Sales Of Assets</link:label>
    <link:label id="lab_cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock_label_en-US" xlink:label="lab_cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Net Gain From The Sales Of Assets [Table Text Block]</link:label>
    <link:label id="lab_cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock_documentation_en-US" xlink:label="lab_cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Net Gain From The Sales Of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock" xlink:href="cmrx-20230331.xsd#cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock" xlink:to="lab_cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_e9e0a698-6c42-473f-b152-226abd333a39_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_3e01bef6-8586-488f-961d-e0b670bcb88c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_5fb00c01-2897-43e7-8068-389a696527d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Separate Account Investment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Separate Account Investment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:to="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6698f6ea-eff9-4f23-beca-8a10eac8ee45_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_948de65c-6d0d-43ac-a659-2438e20c06ba_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract and grant revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_b56e40f2-c670-4e14-b0b5-aab560eb9901_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_dd13d9a2-24f0-4baf-8f67-6cf0bf48f8f0_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5b80c177-ec42-4e56-bc3e-9b1734f1dd61_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_SalesOfStockAuthorizedAmount_4cba3085-0971-4f00-abc5-939e8a685ee5_terseLabel_en-US" xlink:label="lab_cmrx_SalesOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock, amount authorized</link:label>
    <link:label id="lab_cmrx_SalesOfStockAuthorizedAmount_label_en-US" xlink:label="lab_cmrx_SalesOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Of Stock, Authorized Amount</link:label>
    <link:label id="lab_cmrx_SalesOfStockAuthorizedAmount_documentation_en-US" xlink:label="lab_cmrx_SalesOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Of Stock, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SalesOfStockAuthorizedAmount" xlink:href="cmrx-20230331.xsd#cmrx_SalesOfStockAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_SalesOfStockAuthorizedAmount" xlink:to="lab_cmrx_SalesOfStockAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7ae7c369-cd0c-4eda-a154-a7e081db5370_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_24ed0a5e-9388-4c11-b190-8d03f4114eb7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable&#160;Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_30dbd825-b0c5-4c3e-a33e-97df87711ecf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of long-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_ContractCloseOutCosts_c7fbe6ab-2027-4565-a6a1-8ba1977483c7_terseLabel_en-US" xlink:label="lab_cmrx_ContractCloseOutCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract close out cost</link:label>
    <link:label id="lab_cmrx_ContractCloseOutCosts_label_en-US" xlink:label="lab_cmrx_ContractCloseOutCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Close Out Costs</link:label>
    <link:label id="lab_cmrx_ContractCloseOutCosts_documentation_en-US" xlink:label="lab_cmrx_ContractCloseOutCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Close Out Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractCloseOutCosts" xlink:href="cmrx-20230331.xsd#cmrx_ContractCloseOutCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_ContractCloseOutCosts" xlink:to="lab_cmrx_ContractCloseOutCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo_7cc415de-c01d-48a3-bb52-12bc6c4bce00_terseLabel_en-US" xlink:label="lab_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through two years</link:label>
    <link:label id="lab_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo_label_en-US" xlink:label="lab_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year Two</link:label>
    <link:label id="lab_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo_documentation_en-US" xlink:label="lab_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:href="cmrx-20230331.xsd#cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:to="lab_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_36fdfdf2-d24c-44d0-9b0d-b7565ba96668_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8b957063-04b4-40f3-a966-b5e9c0e10af0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Transactions and Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2fc8d31d-edae-41f5-b9ee-babb98b01518_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions_2142875d-f2c6-46c2-b7f4-d8b4f8aae6fd_terseLabel_en-US" xlink:label="lab_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone proceeds upon the exercise of options</link:label>
    <link:label id="lab_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions_label_en-US" xlink:label="lab_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Milestone Proceeds Upon The Exercise Of Options</link:label>
    <link:label id="lab_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions_documentation_en-US" xlink:label="lab_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Milestone Proceeds Upon The Exercise Of Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions" xlink:href="cmrx-20230331.xsd#cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions" xlink:to="lab_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_c931b35f-794b-4258-96a8-abad0a6f194e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee and Non-Employee Share-Based Compensation Expense Recognized Related to Stock Options, the ESPP and RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_aa18b7fa-209b-4a53-b115-1923280f12f7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_84c55412-6857-4deb-a36f-4a324d8e9d58_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_bb4c8a02-eff1-476d-ab23-fa3081498fd7_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9ac30536-9370-4dc0-851a-b05a4a3bc76d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_c0a01014-5dbd-4b5a-94a9-4d38246a6654_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f8d57eba-8502-4553-a6e5-2ebae3020985_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_8ed19fa9-83ec-4332-b2d6-a24fd125c533_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income and other, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_eeee1f8c-6541-45a1-b94e-9bb9e752bb03_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8a5bbd83-b515-4898-9ae0-ecc4f8444fef_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol(s)</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_cc45edc1-6ce1-4d06-8b9f-951f74e9a58b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_81db7791-63fd-4302-89db-5a60738b4c25_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_c15e5751-08c9-47e6-9363-37ac1d6dcab6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_7d6ac532-f0c9-4ca0-aa37-de9c94f7f84b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_EmergentBiodefenseOperationsLansingLLCMember_3278944b-d6f8-41c4-95da-c38a25351f4d_terseLabel_en-US" xlink:label="lab_cmrx_EmergentBiodefenseOperationsLansingLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emergent Biodefense Operations Lansing LLC</link:label>
    <link:label id="lab_cmrx_EmergentBiodefenseOperationsLansingLLCMember_label_en-US" xlink:label="lab_cmrx_EmergentBiodefenseOperationsLansingLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emergent Biodefense Operations Lansing LLC [Member]</link:label>
    <link:label id="lab_cmrx_EmergentBiodefenseOperationsLansingLLCMember_documentation_en-US" xlink:label="lab_cmrx_EmergentBiodefenseOperationsLansingLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emergent Biodefense Operations Lansing LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmergentBiodefenseOperationsLansingLLCMember" xlink:href="cmrx-20230331.xsd#cmrx_EmergentBiodefenseOperationsLansingLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_EmergentBiodefenseOperationsLansingLLCMember" xlink:to="lab_cmrx_EmergentBiodefenseOperationsLansingLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_EmergentBioSolutionsIncMember_b3cf966b-b58a-4de8-afd6-c683b13d79fd_terseLabel_en-US" xlink:label="lab_cmrx_EmergentBioSolutionsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emergent</link:label>
    <link:label id="lab_cmrx_EmergentBioSolutionsIncMember_label_en-US" xlink:label="lab_cmrx_EmergentBioSolutionsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emergent BioSolutions, Inc. [Member]</link:label>
    <link:label id="lab_cmrx_EmergentBioSolutionsIncMember_documentation_en-US" xlink:label="lab_cmrx_EmergentBioSolutionsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emergent BioSolutions, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmergentBioSolutionsIncMember" xlink:href="cmrx-20230331.xsd#cmrx_EmergentBioSolutionsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_EmergentBioSolutionsIncMember" xlink:to="lab_cmrx_EmergentBioSolutionsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_6b233a1f-36b2-4d55-8d24-97b57140a66c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d799a7a1-08e6-4369-9800-6f6078b614c4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_eaacf74a-3ae2-4882-8e01-8e1b4240aaa9_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_814f7a69-8902-41a1-8ae3-5194f25624ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant&#160;Other Observable&#160;Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived_c69d5557-9665-445c-a9d8-e2662d8c0c3a_terseLabel_en-US" xlink:label="lab_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, nonrefundable regulatory milestone payment to be received</link:label>
    <link:label id="lab_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived_label_en-US" xlink:label="lab_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Nonrefundable Regulatory Milestone Payment To Be Received</link:label>
    <link:label id="lab_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived_documentation_en-US" xlink:label="lab_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Nonrefundable Regulatory Milestone Payment To Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived" xlink:href="cmrx-20230331.xsd#cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived" xlink:to="lab_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7ac92338-b8b3-4e64-8890-a5a7d62511b1_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_480a4c41-1520-4384-b3ae-4a17b04172ed_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable_71d64b37-3c69-4c09-8d3c-b39faa4ebe78_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of note payable related to asset acquisition</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2e606c0d-e96c-47b8-94e0-c0adda49698d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less amount of lease payments representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e19ed300-41d1-4143-a374-43040fe8c0b3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d6e79b19-806a-4297-9785-53ea9aef845a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_13d94808-e2ae-41a6-a8aa-6374bf0cfecf_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a3a490ae-a2a0-4bc1-a835-bc5542437c48_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_LoanFeesLiabilityNonCurrent_b715cf1d-588e-44de-abc8-925cb744b23d_verboseLabel_en-US" xlink:label="lab_cmrx_LoanFeesLiabilityNonCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan fees</link:label>
    <link:label id="lab_cmrx_LoanFeesLiabilityNonCurrent_800c3041-9afb-4877-a174-589535fc392b_terseLabel_en-US" xlink:label="lab_cmrx_LoanFeesLiabilityNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current loan fee liability</link:label>
    <link:label id="lab_cmrx_LoanFeesLiabilityNonCurrent_label_en-US" xlink:label="lab_cmrx_LoanFeesLiabilityNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Fees Liability, Non-Current</link:label>
    <link:label id="lab_cmrx_LoanFeesLiabilityNonCurrent_documentation_en-US" xlink:label="lab_cmrx_LoanFeesLiabilityNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Fees Liability, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_LoanFeesLiabilityNonCurrent" xlink:href="cmrx-20230331.xsd#cmrx_LoanFeesLiabilityNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_LoanFeesLiabilityNonCurrent" xlink:to="lab_cmrx_LoanFeesLiabilityNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_533bc4b9-0c0e-424e-b989-e6d33d99c578_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2ff5af8c-fc8c-434b-9f4c-7fe8c9d6f872_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_40dd7a7e-3802-41e2-8dbf-db7b3eca29df_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_d5ee0546-b1d9-49d5-9f62-759631751bf8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ae10df4e-6bd7-4fc1-a879-a7f030d46bd5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7826be6a-f1ba-46c9-8f6a-debaa5514eff_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScenarioAdjustmentMember_88aa5375-6185-403c-8ead-0239fa72adc1_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Adjustment</link:label>
    <link:label id="lab_us-gaap_ScenarioAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_ScenarioAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioAdjustmentMember" xlink:to="lab_us-gaap_ScenarioAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_608897f4-e6c3-4c8d-b77a-db1d09a4c1f2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities with unrealized losses, greater than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7a7e474b-50dc-4b02-8415-843e21a46a3b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year two</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_84ae2905-f02c-49d1-8fd7-2a3d151f3eb0_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c670d0de-ba4f-4c27-9934-ecc493186991_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_17786d3c-8f5d-4f5a-be1a-9ce95ec0a9c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a2638aa7-69c8-4cc6-87b6-863748494d6b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_01e3ecd0-0b79-4970-ab53-28d12fc7da03_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, greater than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_5d005dc8-3810-4424-a222-8fbbf77c879b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_b11f9867-bd42-4724-b61e-210f445b7f57_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_5b0c90e9-a0bf-4a74-9c9f-d78942a41a82_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; no shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_AssetSalePrepaidsTransferred_6c928cf3-f176-412a-9517-d3a7ee1ffa83_negatedTerseLabel_en-US" xlink:label="lab_cmrx_AssetSalePrepaidsTransferred" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids transferred to Emergent</link:label>
    <link:label id="lab_cmrx_AssetSalePrepaidsTransferred_label_en-US" xlink:label="lab_cmrx_AssetSalePrepaidsTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Sale, Prepaids Transferred</link:label>
    <link:label id="lab_cmrx_AssetSalePrepaidsTransferred_documentation_en-US" xlink:label="lab_cmrx_AssetSalePrepaidsTransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Sale, Prepaids Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AssetSalePrepaidsTransferred" xlink:href="cmrx-20230331.xsd#cmrx_AssetSalePrepaidsTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_AssetSalePrepaidsTransferred" xlink:to="lab_cmrx_AssetSalePrepaidsTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_PeriodAxis_314cb785-3d68-4b16-a80d-d2eb23e26cfc_terseLabel_en-US" xlink:label="lab_cmrx_PeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period [Axis]</link:label>
    <link:label id="lab_cmrx_PeriodAxis_label_en-US" xlink:label="lab_cmrx_PeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period [Axis]</link:label>
    <link:label id="lab_cmrx_PeriodAxis_documentation_en-US" xlink:label="lab_cmrx_PeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PeriodAxis" xlink:href="cmrx-20230331.xsd#cmrx_PeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_PeriodAxis" xlink:to="lab_cmrx_PeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_14e8629e-a7a2-4f5c-88b3-20af85e18ce9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_82469fe9-f33b-4fca-a015-7f4ed9a91c5c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year three</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableMember_f648ce7b-73ee-4448-ab95-7e9c2e6b578c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableMember" xlink:to="lab_us-gaap_AccountsPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_1b6d35a0-c94c-4df2-983b-62c96e024dee_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_067ff1f6-5db4-4830-b2c4-ef8f61468b93_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_cf676109-69ae-4951-82f3-66a161e92b34_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_BARDAMember_8452feaf-f67c-4047-98ae-8ec1bcd311eb_terseLabel_en-US" xlink:label="lab_cmrx_BARDAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA</link:label>
    <link:label id="lab_cmrx_BARDAMember_label_en-US" xlink:label="lab_cmrx_BARDAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA [Member]</link:label>
    <link:label id="lab_cmrx_BARDAMember_documentation_en-US" xlink:label="lab_cmrx_BARDAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BARDAMember" xlink:href="cmrx-20230331.xsd#cmrx_BARDAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_BARDAMember" xlink:to="lab_cmrx_BARDAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3999a805-04f4-4f4c-9fd5-d8194437556b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_5244cf9b-c85a-4a5c-9a75-71a4433493de_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_SanjiuMedicalPharmaceuticalCoLtdMember_6226f592-8d61-4442-9356-4c2883a7778e_terseLabel_en-US" xlink:label="lab_cmrx_SanjiuMedicalPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CR Sanjui</link:label>
    <link:label id="lab_cmrx_SanjiuMedicalPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_cmrx_SanjiuMedicalPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanjiu Medical &amp; Pharmaceutical Co., Ltd. [Member]</link:label>
    <link:label id="lab_cmrx_SanjiuMedicalPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_cmrx_SanjiuMedicalPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanjiu Medical &amp; Pharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SanjiuMedicalPharmaceuticalCoLtdMember" xlink:href="cmrx-20230331.xsd#cmrx_SanjiuMedicalPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_SanjiuMedicalPharmaceuticalCoLtdMember" xlink:to="lab_cmrx_SanjiuMedicalPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_d8b37b55-5a73-491c-9a24-5653b157b295_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ee225774-5151-4c02-9379-af061871bd1b_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_9d564f2b-8fbc-42a4-8459-1a2c7d1ea29b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for refundable amounts</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_EmployeeRetentionCredit_6489b035-04f3-4d14-8a91-94508d347888_terseLabel_en-US" xlink:label="lab_cmrx_EmployeeRetentionCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee retention credit</link:label>
    <link:label id="lab_cmrx_EmployeeRetentionCredit_label_en-US" xlink:label="lab_cmrx_EmployeeRetentionCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Retention Credit</link:label>
    <link:label id="lab_cmrx_EmployeeRetentionCredit_documentation_en-US" xlink:label="lab_cmrx_EmployeeRetentionCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Retention Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmployeeRetentionCredit" xlink:href="cmrx-20230331.xsd#cmrx_EmployeeRetentionCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_EmployeeRetentionCredit" xlink:to="lab_cmrx_EmployeeRetentionCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_89e40b54-2c25-4e5d-9a67-bb1354de974a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1bb16462-3472-4909-8bc8-b8bf20e4da74_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0d87d518-50fb-4f3b-aeaf-26c04adf3281_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm_6902081c-62a3-46d1-9257-6515cf252f64_terseLabel_en-US" xlink:label="lab_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participation term</link:label>
    <link:label id="lab_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm_label_en-US" xlink:label="lab_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Participation Term</link:label>
    <link:label id="lab_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm_documentation_en-US" xlink:label="lab_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Participation Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm" xlink:href="cmrx-20230331.xsd#cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm" xlink:to="lab_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d5b2c76e-0ef8-4704-a5b3-03121b7b2e74_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_ContractWithCustomerLiabilityInstallmentPeriods_8ffbdb17-bd7e-48e1-958e-4c768c9a1066_terseLabel_en-US" xlink:label="lab_cmrx_ContractWithCustomerLiabilityInstallmentPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of payment installments</link:label>
    <link:label id="lab_cmrx_ContractWithCustomerLiabilityInstallmentPeriods_label_en-US" xlink:label="lab_cmrx_ContractWithCustomerLiabilityInstallmentPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Installment Periods</link:label>
    <link:label id="lab_cmrx_ContractWithCustomerLiabilityInstallmentPeriods_documentation_en-US" xlink:label="lab_cmrx_ContractWithCustomerLiabilityInstallmentPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Installment Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractWithCustomerLiabilityInstallmentPeriods" xlink:href="cmrx-20230331.xsd#cmrx_ContractWithCustomerLiabilityInstallmentPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_ContractWithCustomerLiabilityInstallmentPeriods" xlink:to="lab_cmrx_ContractWithCustomerLiabilityInstallmentPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_NationalStockpileMember_cf2114e7-3d37-4013-b95e-be0667dbdb72_terseLabel_en-US" xlink:label="lab_cmrx_NationalStockpileMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Stockpile</link:label>
    <link:label id="lab_cmrx_NationalStockpileMember_label_en-US" xlink:label="lab_cmrx_NationalStockpileMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Stockpile [Member]</link:label>
    <link:label id="lab_cmrx_NationalStockpileMember_documentation_en-US" xlink:label="lab_cmrx_NationalStockpileMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Stockpile</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_NationalStockpileMember" xlink:href="cmrx-20230331.xsd#cmrx_NationalStockpileMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_NationalStockpileMember" xlink:to="lab_cmrx_NationalStockpileMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_77a958ae-5e0c-41dc-9f81-862e728d43c5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_ab1f6651-4965-4b0f-9596-54f92691e645_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f85c73b5-9b06-4fcd-b69b-40c127260cfe_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1eee59d8-37b7-4cc8-801b-39b5d00b5f56_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_b48ad388-5910-413a-bffd-34941f028ec4_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bcc606bb-7cb1-46a2-839f-78f9d61a292d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_61d5753e-d8b0-4ea7-8f12-4ea922239d0d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScenarioPlanMember_f04b77b0-5c72-43e5-a743-a565ab40e3f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Plan</link:label>
    <link:label id="lab_us-gaap_ScenarioPlanMember_label_en-US" xlink:label="lab_us-gaap_ScenarioPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioPlanMember" xlink:to="lab_us-gaap_ScenarioPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_1a587fcc-4dd4-4ce5-885b-ab1e568002c8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1178cc92-1eb6-49ff-b3ab-15cde5ea1a6a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a6b1fcf8-14ca-4ce2-80e4-14e45ee51027_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized to be granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_f64e09d6-9321-494e-9c28-63d4bf78abd4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_a2792711-47d4-499f-919c-e8bc0f0439c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted purchase price from market price, purchase date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1ad57d30-d0b7-46d3-927d-daec544ed18a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_6b759edc-8d38-4ffa-8d99-ba0420e455a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of pay that employee can contribute, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_080dea58-2895-4ce6-91e5-c7d76dd4c83d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a28d2d32-7cf7-437a-b005-03f0baa843d5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger_8e7e8de8-2847-417a-aa7b-687621f0f62e_terseLabel_en-US" xlink:label="lab_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quantity royalty rate, trigger (treatments)</link:label>
    <link:label id="lab_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger_label_en-US" xlink:label="lab_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quantity Benchmark, Gross Profit Royalty Rate Trigger</link:label>
    <link:label id="lab_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger_documentation_en-US" xlink:label="lab_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quantity Benchmark, Gross Profit Royalty Rate Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger" xlink:href="cmrx-20230331.xsd#cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger" xlink:to="lab_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_3c78ccf8-9fb1-430b-86d3-719ace239f46_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_12ab78f6-5da7-4f7d-9ad2-0afd35764cc2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_43c4bd6c-b9bd-407b-9298-54ebc60285e0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_bdaeebc3-c4e9-4a6b-ac5c-e92b5140ca29_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ab6804b0-150a-4549-b3e6-13c601d1fb22_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1921bb51-0ef9-4a32-a7c5-5b4eec2c3a69_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease-related obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9a18b295-2afe-499f-ac0b-99dad5a745d4_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease long-term liabilities (recorded within Lease-related obligations)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ec977094-0636-4d9d-b441-53a610258072_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_6e2457f4-0a90-43ae-98f2-30e41e3bdaaf_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3a721015-e697-4668-ae5b-d7c03dc65287_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_b26ec87a-3218-446b-822a-26b4ae8056e5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, unused borrowing capacity, fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_904fffee-bf6d-4c15-8c5f-ab0f532273d7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6052afc6-5023-4d43-b25b-6d953b04f710_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_98b01749-7b19-43d3-b00b-b4438aa0fa3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted purchase price from market price, offering date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_f7aea034-9998-461c-b8db-10a497de5656_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7d309286-3a7c-42f6-9057-6c4694e71179_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_DebtInstrumentNumberOfInstallmentPayments_e7e7a516-bd0b-46f6-ad11-bbc80c96f2c2_terseLabel_en-US" xlink:label="lab_cmrx_DebtInstrumentNumberOfInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of installment payments (installment)</link:label>
    <link:label id="lab_cmrx_DebtInstrumentNumberOfInstallmentPayments_label_en-US" xlink:label="lab_cmrx_DebtInstrumentNumberOfInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Installment Payments</link:label>
    <link:label id="lab_cmrx_DebtInstrumentNumberOfInstallmentPayments_documentation_en-US" xlink:label="lab_cmrx_DebtInstrumentNumberOfInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Installment Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_DebtInstrumentNumberOfInstallmentPayments" xlink:href="cmrx-20230331.xsd#cmrx_DebtInstrumentNumberOfInstallmentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_DebtInstrumentNumberOfInstallmentPayments" xlink:to="lab_cmrx_DebtInstrumentNumberOfInstallmentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_381b6baa-d9ef-493b-a803-b3d4d36dd1e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_de7943f7-a51b-4054-b437-f0b534a5d48d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2969d209-8861-4712-94d4-66781f6920f1_terseLabel_en-US" xlink:label="lab_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business and Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business and Summary of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="cmrx-20230331.xsd#cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3418a733-6a2a-46ba-b008-3408a8bbd87c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_PurchaserMember_7556e2ba-cc50-4acc-a198-5b75ebc0f5ee_terseLabel_en-US" xlink:label="lab_cmrx_PurchaserMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchaser</link:label>
    <link:label id="lab_cmrx_PurchaserMember_label_en-US" xlink:label="lab_cmrx_PurchaserMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchaser [Member]</link:label>
    <link:label id="lab_cmrx_PurchaserMember_documentation_en-US" xlink:label="lab_cmrx_PurchaserMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchaser</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PurchaserMember" xlink:href="cmrx-20230331.xsd#cmrx_PurchaserMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_PurchaserMember" xlink:to="lab_cmrx_PurchaserMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5bb142f2-64ee-4f71-8534-f10fee65f571_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_b5c82e87-de90-485d-aeb3-785935ff4b27_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_d4e10fc9-540b-44e8-aebf-721cfe49b352_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_e530eb95-5860-47d4-89fd-d61ce61731ae_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Prepaids and Accruals</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0d4549e2-1ee9-44e1-9a2d-b079adecbc2e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, measurements, recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df778610-7711-48c4-b9c0-e0c427992984_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_2f7999c6-9c3e-49c8-8024-a2097c972e2c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_a1a8a228-0682-4724-9e6d-0c57d95ee717_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_4b23927c-17af-43c6-b07c-593381b996ce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_111724f2-676f-4dca-b963-70e7c1677c24_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_5170d051-cf89-4a6c-b968-fa52917f87a5_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_PublicHealthAgencyOfCanadaMember_83dc8421-6bea-4e44-b3a4-85062d1aff8b_terseLabel_en-US" xlink:label="lab_cmrx_PublicHealthAgencyOfCanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PHAC</link:label>
    <link:label id="lab_cmrx_PublicHealthAgencyOfCanadaMember_label_en-US" xlink:label="lab_cmrx_PublicHealthAgencyOfCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Health Agency Of Canada [Member]</link:label>
    <link:label id="lab_cmrx_PublicHealthAgencyOfCanadaMember_documentation_en-US" xlink:label="lab_cmrx_PublicHealthAgencyOfCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Health Agency Of Canada</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PublicHealthAgencyOfCanadaMember" xlink:href="cmrx-20230331.xsd#cmrx_PublicHealthAgencyOfCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_PublicHealthAgencyOfCanadaMember" xlink:to="lab_cmrx_PublicHealthAgencyOfCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_ScheduleOfContractCloseOutCostsTableTextBlock_2f1d500d-7660-404e-b9df-0ee118389b47_terseLabel_en-US" xlink:label="lab_cmrx_ScheduleOfContractCloseOutCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrual Activities for Contract Close-out Cost</link:label>
    <link:label id="lab_cmrx_ScheduleOfContractCloseOutCostsTableTextBlock_label_en-US" xlink:label="lab_cmrx_ScheduleOfContractCloseOutCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Contract Close-Out Costs [Table Text Block]</link:label>
    <link:label id="lab_cmrx_ScheduleOfContractCloseOutCostsTableTextBlock_documentation_en-US" xlink:label="lab_cmrx_ScheduleOfContractCloseOutCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Contract Close-Out Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ScheduleOfContractCloseOutCostsTableTextBlock" xlink:href="cmrx-20230331.xsd#cmrx_ScheduleOfContractCloseOutCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_ScheduleOfContractCloseOutCostsTableTextBlock" xlink:to="lab_cmrx_ScheduleOfContractCloseOutCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0884eb2c-58bd-4e87-9db6-090fea8c3aeb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7a44647e-8b1c-4fc0-be84-bd9b3a18a16a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_609f4baf-fee1-411e-a7bc-c068245f27f6_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_fd92c79a-1334-4c9e-ac4c-4829eecd73e6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ac625b78-27e0-498a-9d24-cdba86f55326_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_7f34018c-d8a1-4858-ac03-f01154edbfc6_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8f1c220a-8082-440c-94f9-2ebfa5b73f6c_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_64b85f78-1729-46eb-ab9b-5f328688bc6f_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCurrent_89f48f57-fb37-490e-b369-88d37586e78c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current deferred loan costs</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCurrent" xlink:to="lab_us-gaap_DeferredCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_65592004-b469-4779-86b9-a3a4c23f2e72_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4256ba4b-b189-48c5-9674-318b481a4526_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_e497fee7-7972-4af0-a3bd-60fdd2f616be_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0540b916-c863-4e16-a0cc-b1b74e0c6ab2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_BasePerformanceContractTerm_595d5a34-0b6f-4bb9-874b-6adeb68499e6_terseLabel_en-US" xlink:label="lab_cmrx_BasePerformanceContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base performance, contract term</link:label>
    <link:label id="lab_cmrx_BasePerformanceContractTerm_label_en-US" xlink:label="lab_cmrx_BasePerformanceContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Performance, Contract Term</link:label>
    <link:label id="lab_cmrx_BasePerformanceContractTerm_documentation_en-US" xlink:label="lab_cmrx_BasePerformanceContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Performance, Contract Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BasePerformanceContractTerm" xlink:href="cmrx-20230331.xsd#cmrx_BasePerformanceContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_BasePerformanceContractTerm" xlink:to="lab_cmrx_BasePerformanceContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_48eadb56-930e-4b53-b8ad-908725c13429_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_83401e06-715c-4db5-8b8c-7d0280d69db1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_39550969-553b-449d-bb0a-25414c05481f_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_fb3faea3-edbb-4bc8-9fee-dad4a2f11a29_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_29e7ab74-6faf-44ab-8a74-f2d89512416e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_648739f1-7237-4413-9ef2-b258989402c8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated&#160;Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_IndependentMembersOfBoardMember_9ba71c59-0a11-4c14-8906-00e1375b6a2a_terseLabel_en-US" xlink:label="lab_cmrx_IndependentMembersOfBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Independent Members Of Board</link:label>
    <link:label id="lab_cmrx_IndependentMembersOfBoardMember_label_en-US" xlink:label="lab_cmrx_IndependentMembersOfBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Independent Members Of Board [Member]</link:label>
    <link:label id="lab_cmrx_IndependentMembersOfBoardMember_documentation_en-US" xlink:label="lab_cmrx_IndependentMembersOfBoardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Independent Members Of Board</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_IndependentMembersOfBoardMember" xlink:href="cmrx-20230331.xsd#cmrx_IndependentMembersOfBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_IndependentMembersOfBoardMember" xlink:to="lab_cmrx_IndependentMembersOfBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_a1bb43c8-b315-4f1c-ade9-371edc247a6c_terseLabel_en-US" xlink:label="lab_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business and Summary of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business and Summary of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business and Summary of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="cmrx-20230331.xsd#cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_44d6abcf-0b59-4000-a877-d8bc84455374_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Income (Loss) Per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_ExpenseReimbursementMember_d2792122-9baa-4d5b-84e1-450545b2f561_terseLabel_en-US" xlink:label="lab_cmrx_ExpenseReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reimbursement</link:label>
    <link:label id="lab_cmrx_ExpenseReimbursementMember_label_en-US" xlink:label="lab_cmrx_ExpenseReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Reimbursement [Member]</link:label>
    <link:label id="lab_cmrx_ExpenseReimbursementMember_documentation_en-US" xlink:label="lab_cmrx_ExpenseReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Reimbursement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ExpenseReimbursementMember" xlink:href="cmrx-20230331.xsd#cmrx_ExpenseReimbursementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_ExpenseReimbursementMember" xlink:to="lab_cmrx_ExpenseReimbursementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_90340503-d6ac-4994-b5bd-b88e96cc0e0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_0e241ed0-603b-45bc-ae3c-d787d96248e1_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_db5a8608-c101-4409-9eef-10f661a2ee56_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense under non-cancelable operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_affe2b87-4741-4a5c-b35e-8f6b95ceb09e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9c44e8cb-353e-496f-a587-6b080921be46_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue_b2bfc666-017d-4aec-8020-26cbbb02218c_terseLabel_en-US" xlink:label="lab_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of additional courses at the discretion of customer, gross value</link:label>
    <link:label id="lab_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue_label_en-US" xlink:label="lab_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option To Purchase Additional Treatment Courses, Gross Value</link:label>
    <link:label id="lab_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue_documentation_en-US" xlink:label="lab_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option To Purchase Additional Treatment Courses, Gross Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue" xlink:href="cmrx-20230331.xsd#cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue" xlink:to="lab_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_350c699a-d4c3-46af-9004-4823cadea9e4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8e57c967-40d6-4dfd-a31a-6867d2e833e3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_03685225-f2a1-4d65-b398-60258886144b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_83f76fb3-cc3f-4d27-abca-3131dee4a341_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_f8807c7c-18b1-465c-af2b-3a2d8ee572d6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ce727115-f12f-4a81-a47a-51d779475196_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_OncoceuticsIncMember_f674b958-6711-4d90-ad83-352cda75132e_terseLabel_en-US" xlink:label="lab_cmrx_OncoceuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncoceutics, Inc.</link:label>
    <link:label id="lab_cmrx_OncoceuticsIncMember_label_en-US" xlink:label="lab_cmrx_OncoceuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncoceutics, Inc. [Member]</link:label>
    <link:label id="lab_cmrx_OncoceuticsIncMember_documentation_en-US" xlink:label="lab_cmrx_OncoceuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncoceutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OncoceuticsIncMember" xlink:href="cmrx-20230331.xsd#cmrx_OncoceuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_OncoceuticsIncMember" xlink:to="lab_cmrx_OncoceuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d2cfafdb-20e6-4b8c-b183-90ac3869fc62_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_abd3dd57-6ebd-4b92-8e00-8318ab8440de_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_467c2b41-feed-4d7c-bc8f-a95e45b9aa15_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2148b17c-988c-4fa1-8c05-eb72515db895_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_PeriodDomain_0cfd6485-e232-4ba8-9248-aa6a3b3099bf_terseLabel_en-US" xlink:label="lab_cmrx_PeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period [Domain]</link:label>
    <link:label id="lab_cmrx_PeriodDomain_label_en-US" xlink:label="lab_cmrx_PeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period [Domain]</link:label>
    <link:label id="lab_cmrx_PeriodDomain_documentation_en-US" xlink:label="lab_cmrx_PeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PeriodDomain" xlink:href="cmrx-20230331.xsd#cmrx_PeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_PeriodDomain" xlink:to="lab_cmrx_PeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_61630f24-00d3-464d-abc3-7f186ba5bae8_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cmrx_RefundableAgreementsMember_3800d50e-885f-4217-a60e-d7c2a0de6a5f_terseLabel_en-US" xlink:label="lab_cmrx_RefundableAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refundable Agreements</link:label>
    <link:label id="lab_cmrx_RefundableAgreementsMember_label_en-US" xlink:label="lab_cmrx_RefundableAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refundable Agreements [Member]</link:label>
    <link:label id="lab_cmrx_RefundableAgreementsMember_documentation_en-US" xlink:label="lab_cmrx_RefundableAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refundable Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_RefundableAgreementsMember" xlink:href="cmrx-20230331.xsd#cmrx_RefundableAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmrx_RefundableAgreementsMember" xlink:to="lab_cmrx_RefundableAgreementsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cmrx-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:bd8f579e-4e63-4bef-9c1c-fca25009f3d7,g:bc09e6ba-bd4a-4780-8a45-ad8ddbcdd46a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.chimerix.com/role/CoverPage" xlink:type="simple" xlink:href="cmrx-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a9e8ae5e-1bd5-403b-9692-036b158125a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_DocumentType_a9e8ae5e-1bd5-403b-9692-036b158125a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0346446c-9a99-475f-9ea8-c93263600de1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_DocumentQuarterlyReport_0346446c-9a99-475f-9ea8-c93263600de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_35f559d2-ddda-4cc1-8fde-a6a79b2cc1a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_DocumentPeriodEndDate_35f559d2-ddda-4cc1-8fde-a6a79b2cc1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_17c46005-bab9-4f96-89de-07d32545e6fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_DocumentTransitionReport_17c46005-bab9-4f96-89de-07d32545e6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ae12ca3d-a700-47ec-8c67-774039f57b9f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityFileNumber_ae12ca3d-a700-47ec-8c67-774039f57b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fbe35867-8796-430a-a952-4422ef743400" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityRegistrantName_fbe35867-8796-430a-a952-4422ef743400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b62814d6-62f5-4606-b742-c734827f2b8e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b62814d6-62f5-4606-b742-c734827f2b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_97a7bfee-b53e-4b87-bf41-bf72227c2c09" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityTaxIdentificationNumber_97a7bfee-b53e-4b87-bf41-bf72227c2c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9b19dc42-2bcc-474c-b059-b107071159f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityAddressAddressLine1_9b19dc42-2bcc-474c-b059-b107071159f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_8f374d15-8251-4e77-8967-8446c0943d66" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityAddressAddressLine2_8f374d15-8251-4e77-8967-8446c0943d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_797b2d1b-bebb-4c24-a1da-4cdd8b3b6889" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityAddressCityOrTown_797b2d1b-bebb-4c24-a1da-4cdd8b3b6889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0b66840c-1869-46c8-927b-02fc1ec5de21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityAddressStateOrProvince_0b66840c-1869-46c8-927b-02fc1ec5de21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6b3c7eaf-8ef7-4827-ac10-2856ef09f9f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityAddressPostalZipCode_6b3c7eaf-8ef7-4827-ac10-2856ef09f9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0faa410c-ae81-423b-98cd-9ea061c93ffd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_CityAreaCode_0faa410c-ae81-423b-98cd-9ea061c93ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_13467c94-6be3-4b5d-af02-cfb4db045162" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_LocalPhoneNumber_13467c94-6be3-4b5d-af02-cfb4db045162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b7ee423f-8c58-492e-85aa-f809712f9ee9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_Security12bTitle_b7ee423f-8c58-492e-85aa-f809712f9ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5c2b28eb-6fe9-4529-8387-f1c25888aad0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_TradingSymbol_5c2b28eb-6fe9-4529-8387-f1c25888aad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_90cb015b-71eb-45c6-8035-d49f86841177" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_SecurityExchangeName_90cb015b-71eb-45c6-8035-d49f86841177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_dbe28875-0e78-4f66-b6ba-5f4bbbb488cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityCurrentReportingStatus_dbe28875-0e78-4f66-b6ba-5f4bbbb488cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fbad115c-90fe-4090-a43f-6924336ec32c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityInteractiveDataCurrent_fbad115c-90fe-4090-a43f-6924336ec32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7d36c059-159a-4fd1-971f-0e5d58f92778" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityFilerCategory_7d36c059-159a-4fd1-971f-0e5d58f92778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7859b1d2-34b4-45f3-84a3-06cda31a52a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntitySmallBusiness_7859b1d2-34b4-45f3-84a3-06cda31a52a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_54b3b164-8521-4810-b395-d0b38e0c73f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityEmergingGrowthCompany_54b3b164-8521-4810-b395-d0b38e0c73f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a116e349-47de-454f-a1ac-78ac75c82107" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityShellCompany_a116e349-47de-454f-a1ac-78ac75c82107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7c521d29-ac1a-4da0-9485-18b4a27e1f2c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7c521d29-ac1a-4da0-9485-18b4a27e1f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f4a6dcba-e6f9-4cba-b0e5-97558f13f8d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_AmendmentFlag_f4a6dcba-e6f9-4cba-b0e5-97558f13f8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0e5b0146-207a-466e-bac1-c87b480b46db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_DocumentFiscalYearFocus_0e5b0146-207a-466e-bac1-c87b480b46db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_98031fc8-941f-4a83-b867-611f3c9b8a24" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_DocumentFiscalPeriodFocus_98031fc8-941f-4a83-b867-611f3c9b8a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5591625d-5cff-4d70-9fb0-6d8f4833fae3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_EntityCentralIndexKey_5591625d-5cff-4d70-9fb0-6d8f4833fae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c5cd5e68-681a-4aef-9d68-16f96d1501f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_76a4fa82-9d26-49d9-9bf2-1be4626b0059" xlink:to="loc_dei_CurrentFiscalYearEndDate_c5cd5e68-681a-4aef-9d68-16f96d1501f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cmrx-20230331.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7a5272cf-dec8-48c2-a1e9-7b9db6375410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_718c17f0-64ce-4964-9e55-2e528cfd4b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a5272cf-dec8-48c2-a1e9-7b9db6375410" xlink:to="loc_us-gaap_AssetsAbstract_718c17f0-64ce-4964-9e55-2e528cfd4b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_361dfa23-be3f-4a54-ba95-eccb0d468ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_718c17f0-64ce-4964-9e55-2e528cfd4b37" xlink:to="loc_us-gaap_AssetsCurrentAbstract_361dfa23-be3f-4a54-ba95-eccb0d468ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_443bc2ee-5fe6-49ee-a1f6-b070d573d4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_361dfa23-be3f-4a54-ba95-eccb0d468ae2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_443bc2ee-5fe6-49ee-a1f6-b070d573d4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_d79f7503-b4c2-44b4-b88c-7216d4c84f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_361dfa23-be3f-4a54-ba95-eccb0d468ae2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_d79f7503-b4c2-44b4-b88c-7216d4c84f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e804ceb5-975c-45d4-9907-9eb00f4d4082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_361dfa23-be3f-4a54-ba95-eccb0d468ae2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e804ceb5-975c-45d4-9907-9eb00f4d4082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ae4e96fc-82fd-4dfd-b8e4-602b4741a7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_361dfa23-be3f-4a54-ba95-eccb0d468ae2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ae4e96fc-82fd-4dfd-b8e4-602b4741a7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1980dc77-707d-494f-8acf-527ec9fca0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_361dfa23-be3f-4a54-ba95-eccb0d468ae2" xlink:to="loc_us-gaap_AssetsCurrent_1980dc77-707d-494f-8acf-527ec9fca0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_0666880c-4af4-488d-a8b7-9a51df171574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_718c17f0-64ce-4964-9e55-2e528cfd4b37" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_0666880c-4af4-488d-a8b7-9a51df171574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6604f022-9751-47c2-a815-79fc47735050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_718c17f0-64ce-4964-9e55-2e528cfd4b37" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6604f022-9751-47c2-a815-79fc47735050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2531c3e0-cc1e-4881-8623-139a29955c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_718c17f0-64ce-4964-9e55-2e528cfd4b37" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2531c3e0-cc1e-4881-8623-139a29955c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a25e7973-546f-4bc8-b8dd-7348ad24b540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_718c17f0-64ce-4964-9e55-2e528cfd4b37" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a25e7973-546f-4bc8-b8dd-7348ad24b540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e803292f-32a1-4920-9f55-5331be281e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_718c17f0-64ce-4964-9e55-2e528cfd4b37" xlink:to="loc_us-gaap_Assets_e803292f-32a1-4920-9f55-5331be281e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6035e5bb-c29c-46a6-a7c8-c8afda4aac83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a5272cf-dec8-48c2-a1e9-7b9db6375410" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6035e5bb-c29c-46a6-a7c8-c8afda4aac83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a242cc81-6c1a-4bd0-87d9-bb127c03d8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6035e5bb-c29c-46a6-a7c8-c8afda4aac83" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a242cc81-6c1a-4bd0-87d9-bb127c03d8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5faf83c9-1435-4496-a0a9-d3e1cae8917f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a242cc81-6c1a-4bd0-87d9-bb127c03d8cd" xlink:to="loc_us-gaap_AccountsPayableCurrent_5faf83c9-1435-4496-a0a9-d3e1cae8917f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c7c053cf-76be-48a3-a163-bb02f8ebc273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a242cc81-6c1a-4bd0-87d9-bb127c03d8cd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c7c053cf-76be-48a3-a163-bb02f8ebc273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_271ef3c1-afb5-4afb-adbe-b951336c2305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a242cc81-6c1a-4bd0-87d9-bb127c03d8cd" xlink:to="loc_us-gaap_LiabilitiesCurrent_271ef3c1-afb5-4afb-adbe-b951336c2305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_LoanFeesLiabilityNonCurrent_a71b19db-c1c3-4557-8146-faaed4b1bed2" xlink:href="cmrx-20230331.xsd#cmrx_LoanFeesLiabilityNonCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6035e5bb-c29c-46a6-a7c8-c8afda4aac83" xlink:to="loc_cmrx_LoanFeesLiabilityNonCurrent_a71b19db-c1c3-4557-8146-faaed4b1bed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d63c8944-c6ce-435e-826a-1cd4a991eee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6035e5bb-c29c-46a6-a7c8-c8afda4aac83" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d63c8944-c6ce-435e-826a-1cd4a991eee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c2473770-0dbf-4cbb-a02c-f52e06a23924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6035e5bb-c29c-46a6-a7c8-c8afda4aac83" xlink:to="loc_us-gaap_Liabilities_c2473770-0dbf-4cbb-a02c-f52e06a23924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3ee3de55-5d56-4ae0-b895-2f91ff5b1f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6035e5bb-c29c-46a6-a7c8-c8afda4aac83" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3ee3de55-5d56-4ae0-b895-2f91ff5b1f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_a02aaecf-bbd7-4e97-b35f-44c37dc495f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3ee3de55-5d56-4ae0-b895-2f91ff5b1f3c" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_a02aaecf-bbd7-4e97-b35f-44c37dc495f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_b053f2bd-ea60-4262-8790-be5220963930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3ee3de55-5d56-4ae0-b895-2f91ff5b1f3c" xlink:to="loc_us-gaap_CommonStockValueOutstanding_b053f2bd-ea60-4262-8790-be5220963930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_34c2fe08-8e9d-49b6-8e07-f73e4bdc5d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3ee3de55-5d56-4ae0-b895-2f91ff5b1f3c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_34c2fe08-8e9d-49b6-8e07-f73e4bdc5d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36005c9f-6216-4c02-bcc3-97d4bd41375a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3ee3de55-5d56-4ae0-b895-2f91ff5b1f3c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36005c9f-6216-4c02-bcc3-97d4bd41375a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4f490f2b-6c2b-4d6f-85f8-05db582d5853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3ee3de55-5d56-4ae0-b895-2f91ff5b1f3c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4f490f2b-6c2b-4d6f-85f8-05db582d5853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_56878a7e-c166-4c12-b800-8318ba0f6c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3ee3de55-5d56-4ae0-b895-2f91ff5b1f3c" xlink:to="loc_us-gaap_StockholdersEquity_56878a7e-c166-4c12-b800-8318ba0f6c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_01838c01-0967-4f20-86d7-307330da0168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6035e5bb-c29c-46a6-a7c8-c8afda4aac83" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_01838c01-0967-4f20-86d7-307330da0168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cmrx-20230331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5e9a7b37-3ea9-4e38-94bb-926af0ced2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_cef0f9ff-c7fb-4850-b39f-0e8ecc26efab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5e9a7b37-3ea9-4e38-94bb-926af0ced2a0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_cef0f9ff-c7fb-4850-b39f-0e8ecc26efab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_405d4aa6-5b04-41f4-92d7-d60a8f8af08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5e9a7b37-3ea9-4e38-94bb-926af0ced2a0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_405d4aa6-5b04-41f4-92d7-d60a8f8af08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_331c2205-1174-494f-8e07-09141d4eeb67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5e9a7b37-3ea9-4e38-94bb-926af0ced2a0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_331c2205-1174-494f-8e07-09141d4eeb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_715c4c15-c602-45d0-abb8-ffea0db7a714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5e9a7b37-3ea9-4e38-94bb-926af0ced2a0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_715c4c15-c602-45d0-abb8-ffea0db7a714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_afd98382-d8ae-4cdf-802e-a229737aee6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5e9a7b37-3ea9-4e38-94bb-926af0ced2a0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_afd98382-d8ae-4cdf-802e-a229737aee6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_94755e46-8509-4011-95b3-d17de1a1f700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5e9a7b37-3ea9-4e38-94bb-926af0ced2a0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_94755e46-8509-4011-95b3-d17de1a1f700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_384db2fd-600e-47ef-bb4c-0084d6bafcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5e9a7b37-3ea9-4e38-94bb-926af0ced2a0" xlink:to="loc_us-gaap_CommonStockSharesIssued_384db2fd-600e-47ef-bb4c-0084d6bafcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a46f5e8b-0f84-4af8-8dfa-74fbb0b887b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5e9a7b37-3ea9-4e38-94bb-926af0ced2a0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a46f5e8b-0f84-4af8-8dfa-74fbb0b887b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="cmrx-20230331.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_cf37699d-e8a0-4cc9-86cd-3a402c39c5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bf9c7dc9-bda1-4b55-9a67-68d2642b4e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cf37699d-e8a0-4cc9-86cd-3a402c39c5cb" xlink:to="loc_us-gaap_StatementTable_bf9c7dc9-bda1-4b55-9a67-68d2642b4e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f9b88fb2-dbce-45bf-89dc-2a5aa5270135" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bf9c7dc9-bda1-4b55-9a67-68d2642b4e67" xlink:to="loc_srt_ProductOrServiceAxis_f9b88fb2-dbce-45bf-89dc-2a5aa5270135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2c042e66-9a2e-4343-9902-92245f8cf80c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f9b88fb2-dbce-45bf-89dc-2a5aa5270135" xlink:to="loc_srt_ProductsAndServicesDomain_2c042e66-9a2e-4343-9902-92245f8cf80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractAndGrantMember_4ee65815-c8a9-4c07-8542-4f6474d37192" xlink:href="cmrx-20230331.xsd#cmrx_ContractAndGrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c042e66-9a2e-4343-9902-92245f8cf80c" xlink:to="loc_cmrx_ContractAndGrantMember_4ee65815-c8a9-4c07-8542-4f6474d37192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_0e8b9eb2-8163-4fc3-bd2f-3fec906f3a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c042e66-9a2e-4343-9902-92245f8cf80c" xlink:to="loc_us-gaap_LicenseMember_0e8b9eb2-8163-4fc3-bd2f-3fec906f3a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_91743a1b-05b6-464b-ab01-3f6351d6997b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bf9c7dc9-bda1-4b55-9a67-68d2642b4e67" xlink:to="loc_us-gaap_StatementLineItems_91743a1b-05b6-464b-ab01-3f6351d6997b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cba4bb78-87cf-45a6-8cb0-6343ba18b96c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91743a1b-05b6-464b-ab01-3f6351d6997b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cba4bb78-87cf-45a6-8cb0-6343ba18b96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_dbc6b9b4-3c01-45ea-8c7b-be5a1438fc90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91743a1b-05b6-464b-ab01-3f6351d6997b" xlink:to="loc_us-gaap_CostOfRevenue_dbc6b9b4-3c01-45ea-8c7b-be5a1438fc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_ad51f0d7-e41d-4954-acf1-08053bdb7d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91743a1b-05b6-464b-ab01-3f6351d6997b" xlink:to="loc_us-gaap_GrossProfit_ad51f0d7-e41d-4954-acf1-08053bdb7d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8a0f7cf7-33c1-44da-ab50-c57d93312bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cf37699d-e8a0-4cc9-86cd-3a402c39c5cb" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8a0f7cf7-33c1-44da-ab50-c57d93312bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f1a0d55b-963b-4c54-b3e7-f2e8389f7f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8a0f7cf7-33c1-44da-ab50-c57d93312bd7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f1a0d55b-963b-4c54-b3e7-f2e8389f7f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fde4dad7-9c73-4c3d-ba30-920c935e625b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8a0f7cf7-33c1-44da-ab50-c57d93312bd7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fde4dad7-9c73-4c3d-ba30-920c935e625b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_35d4cbce-9548-4fe9-87aa-b11c1fdcf243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8a0f7cf7-33c1-44da-ab50-c57d93312bd7" xlink:to="loc_us-gaap_OperatingExpenses_35d4cbce-9548-4fe9-87aa-b11c1fdcf243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_72da5670-669d-459b-a4b1-ce304ac2fa47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cf37699d-e8a0-4cc9-86cd-3a402c39c5cb" xlink:to="loc_us-gaap_OperatingIncomeLoss_72da5670-669d-459b-a4b1-ce304ac2fa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpenseAbstract_66c686a8-9967-481b-a1ec-9382879770a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonrecurringIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cf37699d-e8a0-4cc9-86cd-3a402c39c5cb" xlink:to="loc_us-gaap_OtherNonrecurringIncomeExpenseAbstract_66c686a8-9967-481b-a1ec-9382879770a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_741709a2-a054-4e1d-ae2e-df36a8380172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonrecurringIncomeExpenseAbstract_66c686a8-9967-481b-a1ec-9382879770a3" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_741709a2-a054-4e1d-ae2e-df36a8380172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a52a8156-f629-488c-944c-eb45b0a077c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cf37699d-e8a0-4cc9-86cd-3a402c39c5cb" xlink:to="loc_us-gaap_NetIncomeLoss_a52a8156-f629-488c-944c-eb45b0a077c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_e0809cca-970d-45bb-a5bd-07f4fcea6bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cf37699d-e8a0-4cc9-86cd-3a402c39c5cb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_e0809cca-970d-45bb-a5bd-07f4fcea6bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3825eafd-7931-4b6f-8599-b9cb9c776e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_e0809cca-970d-45bb-a5bd-07f4fcea6bf4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3825eafd-7931-4b6f-8599-b9cb9c776e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_10607188-3b1f-4ce3-8968-8ed24968b0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_e0809cca-970d-45bb-a5bd-07f4fcea6bf4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_10607188-3b1f-4ce3-8968-8ed24968b0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dd825614-d39f-450c-8b67-154ca14341fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cf37699d-e8a0-4cc9-86cd-3a402c39c5cb" xlink:to="loc_us-gaap_EarningsPerShareAbstract_dd825614-d39f-450c-8b67-154ca14341fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c95bc079-62bb-4fd1-9fdd-d2e6e98fcd16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dd825614-d39f-450c-8b67-154ca14341fb" xlink:to="loc_us-gaap_EarningsPerShareBasic_c95bc079-62bb-4fd1-9fdd-d2e6e98fcd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_43dfa71a-70df-4819-87a9-a060f1960772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dd825614-d39f-450c-8b67-154ca14341fb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_43dfa71a-70df-4819-87a9-a060f1960772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fb7449d0-deef-4e78-93bf-2561474f0757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cf37699d-e8a0-4cc9-86cd-3a402c39c5cb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fb7449d0-deef-4e78-93bf-2561474f0757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_03c7c1b1-a739-433f-a618-5bc9818ce732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cf37699d-e8a0-4cc9-86cd-3a402c39c5cb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_03c7c1b1-a739-433f-a618-5bc9818ce732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="cmrx-20230331.xsd#ConsolidatedStatementsofStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d34bf345-90a5-43bb-a1c0-1850edec6809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_42442a63-9cb7-47c8-865f-bdc75dcca3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d34bf345-90a5-43bb-a1c0-1850edec6809" xlink:to="loc_us-gaap_StatementTable_42442a63-9cb7-47c8-865f-bdc75dcca3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c5be5fb9-b6ce-4fd8-be6b-c677e5d042e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42442a63-9cb7-47c8-865f-bdc75dcca3dc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c5be5fb9-b6ce-4fd8-be6b-c677e5d042e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5474ae0d-556e-4c97-b53c-cc7a92939551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5be5fb9-b6ce-4fd8-be6b-c677e5d042e0" xlink:to="loc_us-gaap_EquityComponentDomain_5474ae0d-556e-4c97-b53c-cc7a92939551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8f720d68-0812-4b9f-a7e8-e21ce84254cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5474ae0d-556e-4c97-b53c-cc7a92939551" xlink:to="loc_us-gaap_CommonStockMember_8f720d68-0812-4b9f-a7e8-e21ce84254cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_dfddc5fb-b3ba-4a14-8c44-50c4dba854ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5474ae0d-556e-4c97-b53c-cc7a92939551" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_dfddc5fb-b3ba-4a14-8c44-50c4dba854ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5d3bb852-d199-4404-8682-55b1072dd682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5474ae0d-556e-4c97-b53c-cc7a92939551" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5d3bb852-d199-4404-8682-55b1072dd682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_912d3b33-7707-4169-92ac-49e15c7c6fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5474ae0d-556e-4c97-b53c-cc7a92939551" xlink:to="loc_us-gaap_RetainedEarningsMember_912d3b33-7707-4169-92ac-49e15c7c6fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_14fa0ddc-b127-468e-b04d-ecf32a82b1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42442a63-9cb7-47c8-865f-bdc75dcca3dc" xlink:to="loc_us-gaap_StatementLineItems_14fa0ddc-b127-468e-b04d-ecf32a82b1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_14fa0ddc-b127-468e-b04d-ecf32a82b1e7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_625d425f-4d7a-410a-9661-6faa06834a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_StockholdersEquity_625d425f-4d7a-410a-9661-6faa06834a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_044dbe78-f6a8-492a-b1cc-29c5b9fb93ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_044dbe78-f6a8-492a-b1cc-29c5b9fb93ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d3a2094e-5e0b-41ac-a42e-038bf8a463d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d3a2094e-5e0b-41ac-a42e-038bf8a463d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_62ba2e03-f30b-4d6a-bf7d-1f0f95b1cb32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_62ba2e03-f30b-4d6a-bf7d-1f0f95b1cb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3994c159-abb1-4846-a848-2f536975a177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3994c159-abb1-4846-a848-2f536975a177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2dbb86bc-fb96-494a-84ca-30bac2b4cd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2dbb86bc-fb96-494a-84ca-30bac2b4cd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3af3fb10-3012-42bd-9d45-560ccfe1f7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3af3fb10-3012-42bd-9d45-560ccfe1f7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_da92b325-dca8-493c-9179-724e5eb14da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_da92b325-dca8-493c-9179-724e5eb14da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7521dc9a-09d8-4d56-aa9a-8c9f0480141f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7521dc9a-09d8-4d56-aa9a-8c9f0480141f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c6bbb5c5-ef13-4fac-9b16-194ccaf1a5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7521dc9a-09d8-4d56-aa9a-8c9f0480141f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c6bbb5c5-ef13-4fac-9b16-194ccaf1a5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_69e48d18-cd35-457b-a174-dc441d57e614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7521dc9a-09d8-4d56-aa9a-8c9f0480141f" xlink:to="loc_us-gaap_NetIncomeLoss_69e48d18-cd35-457b-a174-dc441d57e614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_65ee65ef-505f-4564-a827-238a51ef6f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7521dc9a-09d8-4d56-aa9a-8c9f0480141f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_65ee65ef-505f-4564-a827-238a51ef6f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_33843e40-84dc-476d-b144-b7be4eaa4a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_StockholdersEquity_33843e40-84dc-476d-b144-b7be4eaa4a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2fe8fb1c-5157-4d4a-96b1-79825d55c548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b117b38c-ebe5-4ce6-ab5e-6db9b13fd52d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2fe8fb1c-5157-4d4a-96b1-79825d55c548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cmrx-20230331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6c36464f-ca51-494a-b565-b61df8f8d8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_445da141-b129-43c9-848a-8a61bc4df5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6c36464f-ca51-494a-b565-b61df8f8d8ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_445da141-b129-43c9-848a-8a61bc4df5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ecc433af-88e8-47f1-8cd6-37017cb5a190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_445da141-b129-43c9-848a-8a61bc4df5ce" xlink:to="loc_us-gaap_NetIncomeLoss_ecc433af-88e8-47f1-8cd6-37017cb5a190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad373821-7641-468c-bb79-9fb643cb0ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_445da141-b129-43c9-848a-8a61bc4df5ce" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad373821-7641-468c-bb79-9fb643cb0ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_efc470ed-2586-4752-a74b-86f94d9f3283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad373821-7641-468c-bb79-9fb643cb0ed8" xlink:to="loc_us-gaap_Depreciation_efc470ed-2586-4752-a74b-86f94d9f3283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ced6d9dd-284b-4401-8d6a-bdc7f1695cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad373821-7641-468c-bb79-9fb643cb0ed8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ced6d9dd-284b-4401-8d6a-bdc7f1695cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3db81842-57c6-426e-ad70-69b06a3718de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad373821-7641-468c-bb79-9fb643cb0ed8" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3db81842-57c6-426e-ad70-69b06a3718de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_94e1a0aa-3d2c-4255-bcd9-1b5c6278be32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad373821-7641-468c-bb79-9fb643cb0ed8" xlink:to="loc_us-gaap_ShareBasedCompensation_94e1a0aa-3d2c-4255-bcd9-1b5c6278be32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_767f35ec-83a2-4823-a90b-4a64266ec07e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad373821-7641-468c-bb79-9fb643cb0ed8" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_767f35ec-83a2-4823-a90b-4a64266ec07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent_e3d9fccd-f49e-46b2-822c-76a76d617b12" xlink:href="cmrx-20230331.xsd#cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad373821-7641-468c-bb79-9fb643cb0ed8" xlink:to="loc_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent_e3d9fccd-f49e-46b2-822c-76a76d617b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d6d702-1af7-4b09-8bdb-82377040e6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad373821-7641-468c-bb79-9fb643cb0ed8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d6d702-1af7-4b09-8bdb-82377040e6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_19df4c8f-192a-4e2b-9a60-fb0a0fd8ee25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d6d702-1af7-4b09-8bdb-82377040e6b6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_19df4c8f-192a-4e2b-9a60-fb0a0fd8ee25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_23734b1c-79b8-498d-bce7-45789a3ce3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d6d702-1af7-4b09-8bdb-82377040e6b6" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_23734b1c-79b8-498d-bce7-45789a3ce3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7ddb2469-4c95-47e4-b430-a341b3332a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d6d702-1af7-4b09-8bdb-82377040e6b6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7ddb2469-4c95-47e4-b430-a341b3332a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8dfbaba1-1897-4a7d-aaba-a2bc1165e47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d6d702-1af7-4b09-8bdb-82377040e6b6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8dfbaba1-1897-4a7d-aaba-a2bc1165e47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_082a762e-4ff7-4dae-bfc2-8f46bddae6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_445da141-b129-43c9-848a-8a61bc4df5ce" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_082a762e-4ff7-4dae-bfc2-8f46bddae6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_946cd00c-8e1e-4959-a205-509fbf96f523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6c36464f-ca51-494a-b565-b61df8f8d8ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_946cd00c-8e1e-4959-a205-509fbf96f523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a9a0a424-6efc-43cc-814f-172126265c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_946cd00c-8e1e-4959-a205-509fbf96f523" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a9a0a424-6efc-43cc-814f-172126265c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7d61b043-931f-46f9-a630-f4bf3fc55d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_946cd00c-8e1e-4959-a205-509fbf96f523" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7d61b043-931f-46f9-a630-f4bf3fc55d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_10389bde-69d2-4cf7-b539-b2b768d0a1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_946cd00c-8e1e-4959-a205-509fbf96f523" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_10389bde-69d2-4cf7-b539-b2b768d0a1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_176d065d-0e0a-43ef-9f62-846e29e0e460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_946cd00c-8e1e-4959-a205-509fbf96f523" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_176d065d-0e0a-43ef-9f62-846e29e0e460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_3582990a-aba4-4004-a77a-47adff02d7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_946cd00c-8e1e-4959-a205-509fbf96f523" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_3582990a-aba4-4004-a77a-47adff02d7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ffc56a38-97aa-487d-be05-9b9eb660bf88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_946cd00c-8e1e-4959-a205-509fbf96f523" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ffc56a38-97aa-487d-be05-9b9eb660bf88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ae27ec7-111e-4188-97b9-985a7894509a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6c36464f-ca51-494a-b565-b61df8f8d8ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ae27ec7-111e-4188-97b9-985a7894509a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_fad5603d-6e1c-4bd7-b9b5-867e8e42a5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ae27ec7-111e-4188-97b9-985a7894509a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_fad5603d-6e1c-4bd7-b9b5-867e8e42a5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4fa6632c-d5a3-4b73-8ca4-1a0bbcb3054a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ae27ec7-111e-4188-97b9-985a7894509a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4fa6632c-d5a3-4b73-8ca4-1a0bbcb3054a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_9d25eb75-d78d-4b89-abb6-c260a22ae7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ae27ec7-111e-4188-97b9-985a7894509a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_9d25eb75-d78d-4b89-abb6-c260a22ae7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_3e5c13bc-2dd0-43e1-a805-d588a1e4c2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ae27ec7-111e-4188-97b9-985a7894509a" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_3e5c13bc-2dd0-43e1-a805-d588a1e4c2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4cb7f17a-29b2-416b-b0eb-8f4def883d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ae27ec7-111e-4188-97b9-985a7894509a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4cb7f17a-29b2-416b-b0eb-8f4def883d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5c27fc32-c611-45ca-b16f-36d9d5a31f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6c36464f-ca51-494a-b565-b61df8f8d8ab" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5c27fc32-c611-45ca-b16f-36d9d5a31f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0e3d07c6-dcc5-42a6-8c4e-c7ce0451cdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6c36464f-ca51-494a-b565-b61df8f8d8ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_0e3d07c6-dcc5-42a6-8c4e-c7ce0451cdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a9ae76b-2507-486d-8c6f-817102288583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0e3d07c6-dcc5-42a6-8c4e-c7ce0451cdf9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a9ae76b-2507-486d-8c6f-817102288583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62b178dc-e22a-46d5-b648-5a467ec98bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0e3d07c6-dcc5-42a6-8c4e-c7ce0451cdf9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62b178dc-e22a-46d5-b648-5a467ec98bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cmrx-20230331.xsd#TheBusinessandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7f3ac6ea-5789-4c6d-b007-60e77b5e95d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_db49644f-7445-4d8e-a99e-a916a6e775a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f3ac6ea-5789-4c6d-b007-60e77b5e95d8" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_db49644f-7445-4d8e-a99e-a916a6e775a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/Investments" xlink:type="simple" xlink:href="cmrx-20230331.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75fa97bc-4cc5-447f-8401-60f6833a8a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_49e918f8-b644-4996-81ec-d00c58972c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75fa97bc-4cc5-447f-8401-60f6833a8a3b" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_49e918f8-b644-4996-81ec-d00c58972c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cmrx-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8afa1b4a-d3ce-4b2f-a5fe-968d33fb8315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_399bb8f0-58aa-407d-b3f5-6804a72a4411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8afa1b4a-d3ce-4b2f-a5fe-968d33fb8315" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_399bb8f0-58aa-407d-b3f5-6804a72a4411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensation" xlink:type="simple" xlink:href="cmrx-20230331.xsd#EquityTransactionsandSharebasedCompensation"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f68dcea-4e68-4d03-9285-6baff2337a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_31131f9d-e02a-4609-996a-d3fc9415f3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f68dcea-4e68-4d03-9285-6baff2337a43" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_31131f9d-e02a-4609-996a-d3fc9415f3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cmrx-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_587ea59a-e330-4014-90cc-237d2d3ee6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_99490336-cdc4-4532-bb85-9d374cfae220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_587ea59a-e330-4014-90cc-237d2d3ee6f7" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_99490336-cdc4-4532-bb85-9d374cfae220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/SignificantAgreements" xlink:type="simple" xlink:href="cmrx-20230331.xsd#SignificantAgreements"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/SignificantAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_c0ebb419-02a2-4a3d-b44a-ac35e86edb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_f33b5454-92d0-47ac-8cc1-f8a4c13455fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermContractsOrProgramsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_c0ebb419-02a2-4a3d-b44a-ac35e86edb7d" xlink:to="loc_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_f33b5454-92d0-47ac-8cc1-f8a4c13455fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/DSTATContractCloseout" xlink:type="simple" xlink:href="cmrx-20230331.xsd#DSTATContractCloseout"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/DSTATContractCloseout" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_8de93497-8b6a-4e34-8586-4ca4e5aad859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_6e3287ae-a570-42d8-a4c0-f701b0108e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermContractsOrProgramsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_8de93497-8b6a-4e34-8586-4ca4e5aad859" xlink:to="loc_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_6e3287ae-a570-42d8-a4c0-f701b0108e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/RestructuringCosts" xlink:type="simple" xlink:href="cmrx-20230331.xsd#RestructuringCosts"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/RestructuringCosts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6bbea900-6ed8-403c-8a28-3349e51853ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_a996309c-7501-4651-b87e-69e0b7bca1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6bbea900-6ed8-403c-8a28-3349e51853ad" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_a996309c-7501-4651-b87e-69e0b7bca1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/SubsequentEvents" xlink:type="simple" xlink:href="cmrx-20230331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_61969811-4f14-45d0-9902-f4f89ebef62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_c59b7053-7156-4a2c-a2ea-41ced73ea2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_61969811-4f14-45d0-9902-f4f89ebef62c" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_c59b7053-7156-4a2c-a2ea-41ced73ea2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cmrx-20230331.xsd#TheBusinessandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d9b41a15-fb00-4359-80c6-d8002aa5b459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a68d2238-e7a5-4c6d-9ff7-a80bb7efc875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9b41a15-fb00-4359-80c6-d8002aa5b459" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a68d2238-e7a5-4c6d-9ff7-a80bb7efc875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_63a7012e-21d9-434d-8aac-bcaaed67c13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9b41a15-fb00-4359-80c6-d8002aa5b459" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_63a7012e-21d9-434d-8aac-bcaaed67c13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_52811d39-74c5-453b-9d5e-505bbdbac81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9b41a15-fb00-4359-80c6-d8002aa5b459" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_52811d39-74c5-453b-9d5e-505bbdbac81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ef3544a6-6558-4c2d-8a6c-8787d41a3395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9b41a15-fb00-4359-80c6-d8002aa5b459" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ef3544a6-6558-4c2d-8a6c-8787d41a3395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_66ad06ed-f69b-4041-967c-725b6f4de520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9b41a15-fb00-4359-80c6-d8002aa5b459" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_66ad06ed-f69b-4041-967c-725b6f4de520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_8fbbb107-7058-432d-bb6f-43e001810266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9b41a15-fb00-4359-80c6-d8002aa5b459" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_8fbbb107-7058-432d-bb6f-43e001810266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_bdb57652-d7f7-4865-bd09-a11d723d553c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9b41a15-fb00-4359-80c6-d8002aa5b459" xlink:to="loc_us-gaap_UseOfEstimates_bdb57652-d7f7-4865-bd09-a11d723d553c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5e11bec2-9cfe-4714-97f4-436f9398b61c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9b41a15-fb00-4359-80c6-d8002aa5b459" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5e11bec2-9cfe-4714-97f4-436f9398b61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c411b5ad-b55a-4b19-8dee-0efccc11ecf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9b41a15-fb00-4359-80c6-d8002aa5b459" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c411b5ad-b55a-4b19-8dee-0efccc11ecf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cmrx-20230331.xsd#TheBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c3878438-ff2e-4c74-8796-c1752f11a422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2eb1bd42-13a3-462a-b539-2836cde765a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3878438-ff2e-4c74-8796-c1752f11a422" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2eb1bd42-13a3-462a-b539-2836cde765a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_165598ca-9410-456b-9ad4-bd4c474f57db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3878438-ff2e-4c74-8796-c1752f11a422" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_165598ca-9410-456b-9ad4-bd4c474f57db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/InvestmentsTables" xlink:type="simple" xlink:href="cmrx-20230331.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ded132d6-80f7-48c7-820a-c8d84c406877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_9a84f130-aa05-4f26-ac02-2e7f182eea23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ded132d6-80f7-48c7-820a-c8d84c406877" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_9a84f130-aa05-4f26-ac02-2e7f182eea23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_f42be5be-93e5-4b98-8ac9-43418e6587a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ded132d6-80f7-48c7-820a-c8d84c406877" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_f42be5be-93e5-4b98-8ac9-43418e6587a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_16f7b095-54a5-4abd-b984-5c990ed8d1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ded132d6-80f7-48c7-820a-c8d84c406877" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_16f7b095-54a5-4abd-b984-5c990ed8d1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="cmrx-20230331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_84e95469-1d05-4017-ac8c-71bbf1ee3bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AssetsAndLiabilitiesLesseeTableTextBlock_976e1835-2a6a-4203-88cc-d64b39e1bc51" xlink:href="cmrx-20230331.xsd#cmrx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_84e95469-1d05-4017-ac8c-71bbf1ee3bb8" xlink:to="loc_cmrx_AssetsAndLiabilitiesLesseeTableTextBlock_976e1835-2a6a-4203-88cc-d64b39e1bc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_83d8d0c0-271d-4006-9ba3-a7d0aadf7e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_84e95469-1d05-4017-ac8c-71bbf1ee3bb8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_83d8d0c0-271d-4006-9ba3-a7d0aadf7e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationTables" xlink:type="simple" xlink:href="cmrx-20230331.xsd#EquityTransactionsandSharebasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dba8cc13-5173-4fa8-9546-d7d158d3586c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1bae2d39-2d1b-4972-81a3-cc55a37cc263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dba8cc13-5173-4fa8-9546-d7d158d3586c" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1bae2d39-2d1b-4972-81a3-cc55a37cc263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/SignificantAgreementsTables" xlink:type="simple" xlink:href="cmrx-20230331.xsd#SignificantAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/SignificantAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_87e23233-e4af-4e77-85bc-be235328afb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock_4ab3a393-9d27-4b45-9f30-90938d1b572f" xlink:href="cmrx-20230331.xsd#cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_87e23233-e4af-4e77-85bc-be235328afb2" xlink:to="loc_cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock_4ab3a393-9d27-4b45-9f30-90938d1b572f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/DSTATContractCloseoutTables" xlink:type="simple" xlink:href="cmrx-20230331.xsd#DSTATContractCloseoutTables"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/DSTATContractCloseoutTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_b439ccd2-f191-40b2-af0e-19c00c563ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ScheduleOfContractCloseOutCostsTableTextBlock_a39f2413-25f9-4620-b105-7ffdde86ea91" xlink:href="cmrx-20230331.xsd#cmrx_ScheduleOfContractCloseOutCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_b439ccd2-f191-40b2-af0e-19c00c563ad8" xlink:to="loc_cmrx_ScheduleOfContractCloseOutCostsTableTextBlock_a39f2413-25f9-4620-b105-7ffdde86ea91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/RestructuringCostsTables" xlink:type="simple" xlink:href="cmrx-20230331.xsd#RestructuringCostsTables"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/RestructuringCostsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4e9c4854-c642-495f-9680-ffa43cf31532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_4a9d56dd-6b52-4bea-87d1-2df4320d55e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4e9c4854-c642-495f-9680-ffa43cf31532" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_4a9d56dd-6b52-4bea-87d1-2df4320d55e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_4f63e8b1-6cef-4b64-b5d1-6030a1251408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4e9c4854-c642-495f-9680-ffa43cf31532" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_4f63e8b1-6cef-4b64-b5d1-6030a1251408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cceacfe2-4182-4d18-9b81-582038c27dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_e1fddb88-dc99-4258-9398-df0f3fb0dbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cceacfe2-4182-4d18-9b81-582038c27dbe" xlink:to="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_e1fddb88-dc99-4258-9398-df0f3fb0dbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a1582c00-b78e-494e-8d3b-f1c8c79e213e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_e1fddb88-dc99-4258-9398-df0f3fb0dbdf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a1582c00-b78e-494e-8d3b-f1c8c79e213e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_785e4cfa-8ded-4687-8c33-33fd592daa0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a1582c00-b78e-494e-8d3b-f1c8c79e213e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_785e4cfa-8ded-4687-8c33-33fd592daa0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_00dcc369-6a66-4f3f-bb13-b252b3181672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_785e4cfa-8ded-4687-8c33-33fd592daa0c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_00dcc369-6a66-4f3f-bb13-b252b3181672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c2040d69-c303-4040-9021-2d63e23ad206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_785e4cfa-8ded-4687-8c33-33fd592daa0c" xlink:to="loc_us-gaap_CommercialPaperMember_c2040d69-c303-4040-9021-2d63e23ad206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_aa3be133-9ab0-47d5-b2d9-4921ef24155e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_e1fddb88-dc99-4258-9398-df0f3fb0dbdf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_aa3be133-9ab0-47d5-b2d9-4921ef24155e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74d90516-78f2-43ca-9c88-c3ec64f860f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_aa3be133-9ab0-47d5-b2d9-4921ef24155e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74d90516-78f2-43ca-9c88-c3ec64f860f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_bb68a7d5-be32-4944-97f3-97078cd9861e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74d90516-78f2-43ca-9c88-c3ec64f860f3" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_bb68a7d5-be32-4944-97f3-97078cd9861e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f4bb57d3-b55e-452d-83ed-d2a406b35ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74d90516-78f2-43ca-9c88-c3ec64f860f3" xlink:to="loc_us-gaap_CommercialPaperMember_f4bb57d3-b55e-452d-83ed-d2a406b35ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_0af3c140-90ca-4c40-94a0-c73bca123588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74d90516-78f2-43ca-9c88-c3ec64f860f3" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_0af3c140-90ca-4c40-94a0-c73bca123588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_aaab7c7a-8d62-4db0-ba38-cc945df654c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_e1fddb88-dc99-4258-9398-df0f3fb0dbdf" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_aaab7c7a-8d62-4db0-ba38-cc945df654c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9f7399d8-03ef-4c7a-b2d7-400f0efbee9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_aaab7c7a-8d62-4db0-ba38-cc945df654c6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9f7399d8-03ef-4c7a-b2d7-400f0efbee9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3bff97e8-0439-4851-be56-81b1a22ebf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9f7399d8-03ef-4c7a-b2d7-400f0efbee9e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3bff97e8-0439-4851-be56-81b1a22ebf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbd952f4-876c-474d-a7f4-7d1151691f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_e1fddb88-dc99-4258-9398-df0f3fb0dbdf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbd952f4-876c-474d-a7f4-7d1151691f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31ff4760-954b-4c83-b813-fdc356e53915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbd952f4-876c-474d-a7f4-7d1151691f9a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31ff4760-954b-4c83-b813-fdc356e53915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8e5b973f-f0ce-4180-8e0c-2bb945b0d93e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31ff4760-954b-4c83-b813-fdc356e53915" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8e5b973f-f0ce-4180-8e0c-2bb945b0d93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c006f7d9-e59a-4ae8-b70a-2c3b25e1478b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31ff4760-954b-4c83-b813-fdc356e53915" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c006f7d9-e59a-4ae8-b70a-2c3b25e1478b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_64f0929c-ae72-4ba3-b4e5-4d14563dd4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31ff4760-954b-4c83-b813-fdc356e53915" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_64f0929c-ae72-4ba3-b4e5-4d14563dd4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_7edb21fa-6a34-4381-bb5d-6118f94f5c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_e1fddb88-dc99-4258-9398-df0f3fb0dbdf" xlink:to="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_7edb21fa-6a34-4381-bb5d-6118f94f5c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47c31147-2e8f-4972-a122-16a212f25ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_7edb21fa-6a34-4381-bb5d-6118f94f5c5c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47c31147-2e8f-4972-a122-16a212f25ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_6e51a1a4-5494-49f3-b69b-065babb75955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_7edb21fa-6a34-4381-bb5d-6118f94f5c5c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_6e51a1a4-5494-49f3-b69b-065babb75955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_d92ad005-5286-4b8c-a34d-87f43fb48a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_7edb21fa-6a34-4381-bb5d-6118f94f5c5c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_d92ad005-5286-4b8c-a34d-87f43fb48a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_adf207b7-1d9e-40a4-a3dc-c184fcbc492e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_7edb21fa-6a34-4381-bb5d-6118f94f5c5c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_adf207b7-1d9e-40a4-a3dc-c184fcbc492e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_432ead1e-59ed-4a0c-87b4-c6c229fbb501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_f0282ab0-a4f4-4718-9eb3-4acdabd54f36" xlink:href="cmrx-20230331.xsd#cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432ead1e-59ed-4a0c-87b4-c6c229fbb501" xlink:to="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_f0282ab0-a4f4-4718-9eb3-4acdabd54f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f67143c1-83dc-4a2e-9f18-7da6514844b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_f0282ab0-a4f4-4718-9eb3-4acdabd54f36" xlink:to="loc_srt_StatementScenarioAxis_f67143c1-83dc-4a2e-9f18-7da6514844b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fd273a97-b4a9-484c-ae41-fc1a981058f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_f67143c1-83dc-4a2e-9f18-7da6514844b9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fd273a97-b4a9-484c-ae41-fc1a981058f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_c8c2f47d-6954-4a17-92dc-cbe1b424f5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_fd273a97-b4a9-484c-ae41-fc1a981058f1" xlink:to="loc_us-gaap_ScenarioAdjustmentMember_c8c2f47d-6954-4a17-92dc-cbe1b424f5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_026b7589-aaa3-4b12-ae57-079f36db181f" xlink:href="cmrx-20230331.xsd#cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_f0282ab0-a4f4-4718-9eb3-4acdabd54f36" xlink:to="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_026b7589-aaa3-4b12-ae57-079f36db181f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmployeeRetentionCredit_bd67b2d2-feb7-4685-a209-02f32fb16c17" xlink:href="cmrx-20230331.xsd#cmrx_EmployeeRetentionCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_026b7589-aaa3-4b12-ae57-079f36db181f" xlink:to="loc_cmrx_EmployeeRetentionCredit_bd67b2d2-feb7-4685-a209-02f32fb16c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_935ad661-7895-4c6d-bef4-7398eb613d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_026b7589-aaa3-4b12-ae57-079f36db181f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_935ad661-7895-4c6d-bef4-7398eb613d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_68431354-c135-4dab-9fd0-85f68b337151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_026b7589-aaa3-4b12-ae57-079f36db181f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_68431354-c135-4dab-9fd0-85f68b337151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_9e8407c5-c949-4143-956d-40e03a535789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_026b7589-aaa3-4b12-ae57-079f36db181f" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_9e8407c5-c949-4143-956d-40e03a535789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5750ecf3-702e-4cba-a726-8b2c64e33e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_3b844179-cbed-4a52-9bb0-5f721803186f" xlink:href="cmrx-20230331.xsd#cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5750ecf3-702e-4cba-a726-8b2c64e33e51" xlink:to="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_3b844179-cbed-4a52-9bb0-5f721803186f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f761e689-ba3c-4554-b556-9ac4ce979a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_3b844179-cbed-4a52-9bb0-5f721803186f" xlink:to="loc_us-gaap_CreditFacilityAxis_f761e689-ba3c-4554-b556-9ac4ce979a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_815b6d21-472a-4382-b41b-7ce4c492d613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f761e689-ba3c-4554-b556-9ac4ce979a12" xlink:to="loc_us-gaap_CreditFacilityDomain_815b6d21-472a-4382-b41b-7ce4c492d613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2a9f708b-4937-4ea6-a1e5-0bef79e0deae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_815b6d21-472a-4382-b41b-7ce4c492d613" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2a9f708b-4937-4ea6-a1e5-0bef79e0deae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_3d6f32e2-ed06-41a7-a38f-a943e1553564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_3b844179-cbed-4a52-9bb0-5f721803186f" xlink:to="loc_us-gaap_VariableRateAxis_3d6f32e2-ed06-41a7-a38f-a943e1553564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ff1f711c-3ce5-4e2e-8e38-6f013eb2958a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_3d6f32e2-ed06-41a7-a38f-a943e1553564" xlink:to="loc_us-gaap_VariableRateDomain_ff1f711c-3ce5-4e2e-8e38-6f013eb2958a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_867c600a-37d5-49ac-9080-637c8c75adba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ff1f711c-3ce5-4e2e-8e38-6f013eb2958a" xlink:to="loc_us-gaap_PrimeRateMember_867c600a-37d5-49ac-9080-637c8c75adba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:href="cmrx-20230331.xsd#cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_3b844179-cbed-4a52-9bb0-5f721803186f" xlink:to="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_5f8f796d-b811-4cd1-93ee-9a5119ddf91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_DebtInstrumentTerm_5f8f796d-b811-4cd1-93ee-9a5119ddf91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_79c50176-1b1f-4276-aa0b-94ce976083af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_79c50176-1b1f-4276-aa0b-94ce976083af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9eb0e8fa-2c2d-47a8-b8d5-d62bafe0003b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9eb0e8fa-2c2d-47a8-b8d5-d62bafe0003b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_92e6c5f5-59fe-4c43-a864-2f9d7130ec34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_92e6c5f5-59fe-4c43-a864-2f9d7130ec34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_9959d1fc-8c7d-415f-9b36-3deb79c76396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_9959d1fc-8c7d-415f-9b36-3deb79c76396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_DebtInstrumentEarlyTerminationFee_8a2d3c90-1a49-434e-9b98-7025ea31a651" xlink:href="cmrx-20230331.xsd#cmrx_DebtInstrumentEarlyTerminationFee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_cmrx_DebtInstrumentEarlyTerminationFee_8a2d3c90-1a49-434e-9b98-7025ea31a651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_bd98c2a6-e685-4de8-824f-11b79e121274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_bd98c2a6-e685-4de8-824f-11b79e121274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_DebtInstrumentNumberOfInstallmentPayments_bf494f5f-4a3e-438d-bd55-ba3e4928b0e3" xlink:href="cmrx-20230331.xsd#cmrx_DebtInstrumentNumberOfInstallmentPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_cmrx_DebtInstrumentNumberOfInstallmentPayments_bf494f5f-4a3e-438d-bd55-ba3e4928b0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCurrent_baee03ae-ca00-4204-8ea5-96233bf56e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_DeferredCostsCurrent_baee03ae-ca00-4204-8ea5-96233bf56e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCosts_f4a5fcd2-b830-4084-a0c9-a1f8e2129013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_us-gaap_DeferredCosts_f4a5fcd2-b830-4084-a0c9-a1f8e2129013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_LoanFeesLiabilityCurrent_db1c8cda-6fd2-4822-af00-bf34f7859906" xlink:href="cmrx-20230331.xsd#cmrx_LoanFeesLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_cmrx_LoanFeesLiabilityCurrent_db1c8cda-6fd2-4822-af00-bf34f7859906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_LoanFeesLiabilityNonCurrent_5b8c45c9-535e-440c-8db6-000d6be0b1b9" xlink:href="cmrx-20230331.xsd#cmrx_LoanFeesLiabilityNonCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_5d7c5b7a-c8b0-4fd4-bf6c-6557cf21dd31" xlink:to="loc_cmrx_LoanFeesLiabilityNonCurrent_5b8c45c9-535e-440c-8db6-000d6be0b1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_42f307ae-05a4-4098-b848-a0832d4e6591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AccruedDevelopmentLiabilities_0e46837a-555c-401f-9ec5-aa9dc0d2da4d" xlink:href="cmrx-20230331.xsd#cmrx_AccruedDevelopmentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42f307ae-05a4-4098-b848-a0832d4e6591" xlink:to="loc_cmrx_AccruedDevelopmentLiabilities_0e46837a-555c-401f-9ec5-aa9dc0d2da4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_6666dd6d-5a18-4411-afc5-0c6ef6d69e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42f307ae-05a4-4098-b848-a0832d4e6591" xlink:to="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_6666dd6d-5a18-4411-afc5-0c6ef6d69e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_40dfb1ab-f653-4fb6-8a9a-232a26aa66da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42f307ae-05a4-4098-b848-a0832d4e6591" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_40dfb1ab-f653-4fb6-8a9a-232a26aa66da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8a8a97da-43e0-4173-b79e-dc90f7ddbff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42f307ae-05a4-4098-b848-a0832d4e6591" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8a8a97da-43e0-4173-b79e-dc90f7ddbff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3194adf5-ab0a-4908-9d08-1e5b6b2be62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:href="cmrx-20230331.xsd#cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3194adf5-ab0a-4908-9d08-1e5b6b2be62d" xlink:to="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_56bd00dd-c307-4674-806a-815e7b9b3439" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_srt_ProductOrServiceAxis_56bd00dd-c307-4674-806a-815e7b9b3439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18712b95-0072-4f1e-abf5-d915ec7a8708" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_56bd00dd-c307-4674-806a-815e7b9b3439" xlink:to="loc_srt_ProductsAndServicesDomain_18712b95-0072-4f1e-abf5-d915ec7a8708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_6d777a01-2279-45c7-9254-00200e5c03fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_18712b95-0072-4f1e-abf5-d915ec7a8708" xlink:to="loc_us-gaap_GrantMember_6d777a01-2279-45c7-9254-00200e5c03fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_d0d351d0-b945-454b-a6d6-51abfd27522a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_18712b95-0072-4f1e-abf5-d915ec7a8708" xlink:to="loc_us-gaap_LicenseMember_d0d351d0-b945-454b-a6d6-51abfd27522a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_TEMBEXAMember_84b339b2-4b2a-4d24-a636-6178c03763fc" xlink:href="cmrx-20230331.xsd#cmrx_TEMBEXAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_18712b95-0072-4f1e-abf5-d915ec7a8708" xlink:to="loc_cmrx_TEMBEXAMember_84b339b2-4b2a-4d24-a636-6178c03763fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_aaf41bba-4a50-48dc-9f65-7e52968f6b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_18712b95-0072-4f1e-abf5-d915ec7a8708" xlink:to="loc_us-gaap_RoyaltyMember_aaf41bba-4a50-48dc-9f65-7e52968f6b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BARDAMember_f6d402c0-721e-48cf-bf9e-a88b38370d35" xlink:href="cmrx-20230331.xsd#cmrx_BARDAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_18712b95-0072-4f1e-abf5-d915ec7a8708" xlink:to="loc_cmrx_BARDAMember_f6d402c0-721e-48cf-bf9e-a88b38370d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_19df640e-f8ce-4b5e-af26-90313e27695d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_us-gaap_AssetAcquisitionAxis_19df640e-f8ce-4b5e-af26-90313e27695d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_9d2a6179-5d15-4c8c-8739-504db09ce04e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_19df640e-f8ce-4b5e-af26-90313e27695d" xlink:to="loc_us-gaap_AssetAcquisitionDomain_9d2a6179-5d15-4c8c-8739-504db09ce04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OncoceuticsIncMember_f60fced1-b766-4738-bc1f-6b0283fc815f" xlink:href="cmrx-20230331.xsd#cmrx_OncoceuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_9d2a6179-5d15-4c8c-8739-504db09ce04e" xlink:to="loc_cmrx_OncoceuticsIncMember_f60fced1-b766-4738-bc1f-6b0283fc815f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1a72c842-1456-4aba-92dd-b4c936dd80f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_srt_CounterpartyNameAxis_1a72c842-1456-4aba-92dd-b4c936dd80f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52c041a3-e5ed-49d1-9974-a96674323b47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1a72c842-1456-4aba-92dd-b4c936dd80f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52c041a3-e5ed-49d1-9974-a96674323b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OharaPharmaceuticalCoLtdMember_397722a2-acbd-4063-98d4-f963aa0c56b4" xlink:href="cmrx-20230331.xsd#cmrx_OharaPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52c041a3-e5ed-49d1-9974-a96674323b47" xlink:to="loc_cmrx_OharaPharmaceuticalCoLtdMember_397722a2-acbd-4063-98d4-f963aa0c56b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmergentBioSolutionsIncMember_4418c071-a6b9-48b7-89b0-fc6235236a8c" xlink:href="cmrx-20230331.xsd#cmrx_EmergentBioSolutionsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52c041a3-e5ed-49d1-9974-a96674323b47" xlink:to="loc_cmrx_EmergentBioSolutionsIncMember_4418c071-a6b9-48b7-89b0-fc6235236a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SymBioPharmaceuticalsMember_17ca3f3e-0db5-4305-8203-9597d5ca0ec1" xlink:href="cmrx-20230331.xsd#cmrx_SymBioPharmaceuticalsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52c041a3-e5ed-49d1-9974-a96674323b47" xlink:to="loc_cmrx_SymBioPharmaceuticalsMember_17ca3f3e-0db5-4305-8203-9597d5ca0ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmergentBiodefenseOperationsLansingLLCMember_7fd03525-c778-42f8-bb38-44d6596459b6" xlink:href="cmrx-20230331.xsd#cmrx_EmergentBiodefenseOperationsLansingLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52c041a3-e5ed-49d1-9974-a96674323b47" xlink:to="loc_cmrx_EmergentBiodefenseOperationsLansingLLCMember_7fd03525-c778-42f8-bb38-44d6596459b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a165f0f5-5fc9-4042-bb6f-6037bfed9087" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_srt_MajorCustomersAxis_a165f0f5-5fc9-4042-bb6f-6037bfed9087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fc4df9e1-6ccf-434e-9250-b6a836c2874e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_a165f0f5-5fc9-4042-bb6f-6037bfed9087" xlink:to="loc_srt_NameOfMajorCustomerDomain_fc4df9e1-6ccf-434e-9250-b6a836c2874e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PublicHealthAgencyOfCanadaMember_8864a610-8b42-4f5f-9d02-e5856c8f805d" xlink:href="cmrx-20230331.xsd#cmrx_PublicHealthAgencyOfCanadaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fc4df9e1-6ccf-434e-9250-b6a836c2874e" xlink:to="loc_cmrx_PublicHealthAgencyOfCanadaMember_8864a610-8b42-4f5f-9d02-e5856c8f805d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PeriodAxis_d946d8f7-4c40-4fbb-8a09-7bef0b80c479" xlink:href="cmrx-20230331.xsd#cmrx_PeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_cmrx_PeriodAxis_d946d8f7-4c40-4fbb-8a09-7bef0b80c479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PeriodDomain_7ffd7a95-ea02-4c9a-9a8b-07260032ee86" xlink:href="cmrx-20230331.xsd#cmrx_PeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_PeriodAxis_d946d8f7-4c40-4fbb-8a09-7bef0b80c479" xlink:to="loc_cmrx_PeriodDomain_7ffd7a95-ea02-4c9a-9a8b-07260032ee86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BasePeriodMember_dc83c196-1d03-4216-b6ba-f8a323a147a0" xlink:href="cmrx-20230331.xsd#cmrx_BasePeriodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_PeriodDomain_7ffd7a95-ea02-4c9a-9a8b-07260032ee86" xlink:to="loc_cmrx_BasePeriodMember_dc83c196-1d03-4216-b6ba-f8a323a147a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_82833262-145e-4dc6-94ea-1e6ec664a8c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_srt_StatementGeographicalAxis_82833262-145e-4dc6-94ea-1e6ec664a8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8293d029-0e6e-4bb5-8687-a9ca967bbacf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_82833262-145e-4dc6-94ea-1e6ec664a8c8" xlink:to="loc_srt_SegmentGeographicalDomain_8293d029-0e6e-4bb5-8687-a9ca967bbacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_NonUnitedStatesMember_60ead3fb-adfe-46d3-9b72-277c62d17995" xlink:href="cmrx-20230331.xsd#cmrx_NonUnitedStatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8293d029-0e6e-4bb5-8687-a9ca967bbacf" xlink:to="loc_cmrx_NonUnitedStatesMember_60ead3fb-adfe-46d3-9b72-277c62d17995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_62d9d446-77bc-400d-b155-c04aa8bce126" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8293d029-0e6e-4bb5-8687-a9ca967bbacf" xlink:to="loc_country_US_62d9d446-77bc-400d-b155-c04aa8bce126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2c37a799-a543-48e5-a6b4-a0d88b57ea4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_srt_StatementScenarioAxis_2c37a799-a543-48e5-a6b4-a0d88b57ea4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fdc89f84-4e8f-436d-8635-904869fa9128" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_2c37a799-a543-48e5-a6b4-a0d88b57ea4e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fdc89f84-4e8f-436d-8635-904869fa9128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioPlanMember_8aa614ce-dc99-47e1-9663-e2373511dac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_fdc89f84-4e8f-436d-8635-904869fa9128" xlink:to="loc_us-gaap_ScenarioPlanMember_8aa614ce-dc99-47e1-9663-e2373511dac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:href="cmrx-20230331.xsd#cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable_c20191e8-af7d-4c12-978c-473564662ab6" xlink:to="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_7c0281ff-bcec-439f-9a6f-346ec9a1590b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_7c0281ff-bcec-439f-9a6f-346ec9a1590b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions_fe78f022-31b1-4720-a0ea-c771ffc45cc3" xlink:href="cmrx-20230331.xsd#cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions_fe78f022-31b1-4720-a0ea-c771ffc45cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger_b054c562-e393-409d-bc0f-909fcb074804" xlink:href="cmrx-20230331.xsd#cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger_b054c562-e393-409d-bc0f-909fcb074804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate_d57f036c-21da-45a2-91fb-2a33857df2e1" xlink:href="cmrx-20230331.xsd#cmrx_RevenueBenchmarkGrossProfitRoyaltyRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate_d57f036c-21da-45a2-91fb-2a33857df2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_f832cf9d-6982-4715-ac6f-4b58b3a6073c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_f832cf9d-6982-4715-ac6f-4b58b3a6073c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c7bd756b-8c48-48a9-acd3-a0ba237cefe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c7bd756b-8c48-48a9-acd3-a0ba237cefe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a4341a1f-3705-4a93-a529-91e07d311327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a4341a1f-3705-4a93-a529-91e07d311327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived_c976c568-f21b-4b6f-8b39-b866423521db" xlink:href="cmrx-20230331.xsd#cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived_c976c568-f21b-4b6f-8b39-b866423521db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d840e529-2f65-47ca-8894-64214d0afa8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems_124d91df-611a-4480-9d6e-49dbac7a46ae" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d840e529-2f65-47ca-8894-64214d0afa8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#InvestmentsSummaryofAvailableforSalesecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fd38d14e-185e-4ebb-9239-f3aa2acbf6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_d0932e90-a01c-4bf4-929f-e2224725bcce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fd38d14e-185e-4ebb-9239-f3aa2acbf6fa" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_d0932e90-a01c-4bf4-929f-e2224725bcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4213565a-1082-4e0e-bbf0-076df3a59b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_d0932e90-a01c-4bf4-929f-e2224725bcce" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4213565a-1082-4e0e-bbf0-076df3a59b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c46cc592-b995-4702-b9ce-6d17d18c4a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4213565a-1082-4e0e-bbf0-076df3a59b09" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c46cc592-b995-4702-b9ce-6d17d18c4a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_3dde4e06-c1f6-4578-955c-ffd1e02a05f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c46cc592-b995-4702-b9ce-6d17d18c4a9c" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_3dde4e06-c1f6-4578-955c-ffd1e02a05f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a638d42b-02c0-4712-b0ef-02df99576cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c46cc592-b995-4702-b9ce-6d17d18c4a9c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a638d42b-02c0-4712-b0ef-02df99576cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6f39e898-9e2b-4230-b8d9-6551a4c3668e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c46cc592-b995-4702-b9ce-6d17d18c4a9c" xlink:to="loc_us-gaap_CommercialPaperMember_6f39e898-9e2b-4230-b8d9-6551a4c3668e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e71e59f-1225-46d8-8583-39bed571648d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_d0932e90-a01c-4bf4-929f-e2224725bcce" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e71e59f-1225-46d8-8583-39bed571648d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b491cef1-7da5-46ac-9c3e-de9ca4c3cd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e71e59f-1225-46d8-8583-39bed571648d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b491cef1-7da5-46ac-9c3e-de9ca4c3cd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7481a0f9-5acd-4c2b-bd0c-ea1075e9490b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e71e59f-1225-46d8-8583-39bed571648d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7481a0f9-5acd-4c2b-bd0c-ea1075e9490b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a28fbe66-9f65-4ce4-bd68-864a910e2015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e71e59f-1225-46d8-8583-39bed571648d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a28fbe66-9f65-4ce4-bd68-864a910e2015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_4d3d1095-c44a-4486-a796-2cb785335a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3e71e59f-1225-46d8-8583-39bed571648d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_4d3d1095-c44a-4486-a796-2cb785335a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_03505fa1-96de-4c7f-9f92-5e6b43d8cfac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a139724-c995-4e7e-b21f-29a4fac50d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_03505fa1-96de-4c7f-9f92-5e6b43d8cfac" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a139724-c995-4e7e-b21f-29a4fac50d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fc1d4d29-f1d5-41f1-8afc-c91ee544dc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a139724-c995-4e7e-b21f-29a4fac50d9f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fc1d4d29-f1d5-41f1-8afc-c91ee544dc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6fb130f-db88-4092-8b1f-8269e90761da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fc1d4d29-f1d5-41f1-8afc-c91ee544dc99" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6fb130f-db88-4092-8b1f-8269e90761da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_2f1f6bc5-8ca7-48a3-9617-01a51b51d245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6fb130f-db88-4092-8b1f-8269e90761da" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_2f1f6bc5-8ca7-48a3-9617-01a51b51d245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a027f2f7-3630-4304-89c9-05da31b68911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6fb130f-db88-4092-8b1f-8269e90761da" xlink:to="loc_us-gaap_CommercialPaperMember_a027f2f7-3630-4304-89c9-05da31b68911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4e42aea8-cb13-43dd-978d-50ccb39acfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6fb130f-db88-4092-8b1f-8269e90761da" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4e42aea8-cb13-43dd-978d-50ccb39acfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a139724-c995-4e7e-b21f-29a4fac50d9f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_179326f8-f373-441c-9c43-57070dadccdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_179326f8-f373-441c-9c43-57070dadccdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_fb3184f0-1b87-4c35-948b-b318d9779f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_fb3184f0-1b87-4c35-948b-b318d9779f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_cfd54efd-2746-4bae-80fd-1143e97a8115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_cfd54efd-2746-4bae-80fd-1143e97a8115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_81aa1b8a-53a2-425a-abfc-d6e341091d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_81aa1b8a-53a2-425a-abfc-d6e341091d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7e51992b-cf76-46e7-ae97-c02cec3b091f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7e51992b-cf76-46e7-ae97-c02cec3b091f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_79814eac-0c70-43db-82c6-520fb2dc5d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_79814eac-0c70-43db-82c6-520fb2dc5d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_b3e25f51-238f-4710-8ccb-2387e49b5155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_b3e25f51-238f-4710-8ccb-2387e49b5155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_7a2d830f-233c-4521-bd7a-f8e299f9bc23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_7a2d830f-233c-4521-bd7a-f8e299f9bc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b240a2e4-c5c5-40bc-9adf-44630880471b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0c0be58-aba0-4603-8272-27baa22f4d94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b240a2e4-c5c5-40bc-9adf-44630880471b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#InvestmentsScheduleofInvestmentMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_397efc97-1ce5-4be1-8318-fd16f14ea3be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_0949723b-f5bc-4703-817f-17611c059edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_397efc97-1ce5-4be1-8318-fd16f14ea3be" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_0949723b-f5bc-4703-817f-17611c059edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_b4381322-c3d3-4fa0-9678-a8275524d4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_0949723b-f5bc-4703-817f-17611c059edd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_b4381322-c3d3-4fa0-9678-a8275524d4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo_12b1db4f-fdbf-4480-842a-c2769ea81bb3" xlink:href="cmrx-20230331.xsd#cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_0949723b-f5bc-4703-817f-17611c059edd" xlink:to="loc_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo_12b1db4f-fdbf-4480-842a-c2769ea81bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_da1722a7-acef-4315-845c-1b51f63ef8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_0949723b-f5bc-4703-817f-17611c059edd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_da1722a7-acef-4315-845c-1b51f63ef8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78e9e6b0-6820-4195-862b-9dea6bbda216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e78b4242-fbcf-4a76-b739-eade934e3862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78e9e6b0-6820-4195-862b-9dea6bbda216" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e78b4242-fbcf-4a76-b739-eade934e3862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_24600027-5c37-4ee9-a84d-907013e1543e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78e9e6b0-6820-4195-862b-9dea6bbda216" xlink:to="loc_us-gaap_OperatingLeaseExpense_24600027-5c37-4ee9-a84d-907013e1543e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7c346dba-753b-43b0-adf7-6e4cc62f9515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78e9e6b0-6820-4195-862b-9dea6bbda216" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7c346dba-753b-43b0-adf7-6e4cc62f9515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_05191d21-3b79-4f03-802a-d808ebb0ca30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78e9e6b0-6820-4195-862b-9dea6bbda216" xlink:to="loc_us-gaap_OperatingLeasePayments_05191d21-3b79-4f03-802a-d808ebb0ca30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4b5465a2-524c-427e-9c50-2efe2dc34769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78e9e6b0-6820-4195-862b-9dea6bbda216" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4b5465a2-524c-427e-9c50-2efe2dc34769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c36ed87f-086a-438b-8222-f79d44fb00bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4b5465a2-524c-427e-9c50-2efe2dc34769" xlink:to="loc_srt_CounterpartyNameAxis_c36ed87f-086a-438b-8222-f79d44fb00bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aae72e1e-4844-4d93-be87-d0ca3b1fe137" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c36ed87f-086a-438b-8222-f79d44fb00bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aae72e1e-4844-4d93-be87-d0ca3b1fe137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BARDAMember_01ff1f7f-158a-4035-8e49-f25bee64587a" xlink:href="cmrx-20230331.xsd#cmrx_BARDAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aae72e1e-4844-4d93-be87-d0ca3b1fe137" xlink:to="loc_cmrx_BARDAMember_01ff1f7f-158a-4035-8e49-f25bee64587a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_146ddb8f-8e35-4104-856d-eadb34c1c460" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4b5465a2-524c-427e-9c50-2efe2dc34769" xlink:to="loc_srt_ProductOrServiceAxis_146ddb8f-8e35-4104-856d-eadb34c1c460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0b5374be-a72f-4f8c-a644-152f49e12315" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_146ddb8f-8e35-4104-856d-eadb34c1c460" xlink:to="loc_srt_ProductsAndServicesDomain_0b5374be-a72f-4f8c-a644-152f49e12315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_RefundableAgreementsMember_2b5ef530-8ed2-4030-9142-1640ec89ef45" xlink:href="cmrx-20230331.xsd#cmrx_RefundableAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0b5374be-a72f-4f8c-a644-152f49e12315" xlink:to="loc_cmrx_RefundableAgreementsMember_2b5ef530-8ed2-4030-9142-1640ec89ef45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b592581a-338d-4ea1-a412-ec760d818900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4b5465a2-524c-427e-9c50-2efe2dc34769" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b592581a-338d-4ea1-a412-ec760d818900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3d62a562-631e-49bc-962a-874993e28559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b592581a-338d-4ea1-a412-ec760d818900" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3d62a562-631e-49bc-962a-874993e28559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7f16220-4c69-45dc-bed1-ab6c0cbe8d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3847ee9e-f7a2-4e50-83b7-91ed669923dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7f16220-4c69-45dc-bed1-ab6c0cbe8d7b" xlink:to="loc_us-gaap_AssetsAbstract_3847ee9e-f7a2-4e50-83b7-91ed669923dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_af65083c-9141-4b26-b04f-6884b2b2af12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3847ee9e-f7a2-4e50-83b7-91ed669923dc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_af65083c-9141-4b26-b04f-6884b2b2af12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_adaf966d-86e1-4cf6-ad78-11c5dbeaab3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7f16220-4c69-45dc-bed1-ab6c0cbe8d7b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_adaf966d-86e1-4cf6-ad78-11c5dbeaab3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a8e8f938-0182-4f5f-bc06-abba1f617d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_adaf966d-86e1-4cf6-ad78-11c5dbeaab3f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a8e8f938-0182-4f5f-bc06-abba1f617d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1c545407-0d63-4805-a853-a28dd6046064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_adaf966d-86e1-4cf6-ad78-11c5dbeaab3f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1c545407-0d63-4805-a853-a28dd6046064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e6d25d46-8ab0-4a8a-916d-bfe213511318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_adaf966d-86e1-4cf6-ad78-11c5dbeaab3f" xlink:to="loc_us-gaap_OperatingLeaseLiability_e6d25d46-8ab0-4a8a-916d-bfe213511318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2f8c2452-af35-42ce-ad99-c6ed76f7797d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7f16220-4c69-45dc-bed1-ab6c0cbe8d7b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2f8c2452-af35-42ce-ad99-c6ed76f7797d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fbf0d56c-8888-4e3e-b380-29456e462a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7131c706-31e7-4911-97f0-e09c2e0531a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fbf0d56c-8888-4e3e-b380-29456e462a19" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7131c706-31e7-4911-97f0-e09c2e0531a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f65f8e24-47f6-4bda-84b7-2dff4eacaa21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7131c706-31e7-4911-97f0-e09c2e0531a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f65f8e24-47f6-4bda-84b7-2dff4eacaa21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_912cc026-8cfa-463c-b88b-82c26bc2039a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7131c706-31e7-4911-97f0-e09c2e0531a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_912cc026-8cfa-463c-b88b-82c26bc2039a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_66f733c3-c0da-4647-894e-7438da7d3cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7131c706-31e7-4911-97f0-e09c2e0531a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_66f733c3-c0da-4647-894e-7438da7d3cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f5961932-6de4-4230-845d-e59b5bc027d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7131c706-31e7-4911-97f0-e09c2e0531a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f5961932-6de4-4230-845d-e59b5bc027d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e0436b9f-9359-4057-9966-c18e6c1ea660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7131c706-31e7-4911-97f0-e09c2e0531a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e0436b9f-9359-4057-9966-c18e6c1ea660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_122d7207-36e1-4d90-bd7a-2d6812627f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7131c706-31e7-4911-97f0-e09c2e0531a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_122d7207-36e1-4d90-bd7a-2d6812627f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2803e58c-5b56-4752-83bd-d499f48f798b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7131c706-31e7-4911-97f0-e09c2e0531a6" xlink:to="loc_us-gaap_OperatingLeaseLiability_2803e58c-5b56-4752-83bd-d499f48f798b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="cmrx-20230331.xsd#CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#EquityTransactionsandSharebasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6cc1f1ba-85e1-4340-b41b-ee3fa437375e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbf8b61a-14ca-4fe4-a827-c4b74d7094df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6cc1f1ba-85e1-4340-b41b-ee3fa437375e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbf8b61a-14ca-4fe4-a827-c4b74d7094df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_245d7cab-a651-4951-b834-70276eb654c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbf8b61a-14ca-4fe4-a827-c4b74d7094df" xlink:to="loc_us-gaap_PlanNameAxis_245d7cab-a651-4951-b834-70276eb654c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d151e221-1d34-4045-ba67-af1b163d36d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_245d7cab-a651-4951-b834-70276eb654c8" xlink:to="loc_us-gaap_PlanNameDomain_d151e221-1d34-4045-ba67-af1b163d36d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_The2013PlanMember_ab05f2ad-6197-4a9e-8da4-9abdc9cf42df" xlink:href="cmrx-20230331.xsd#cmrx_The2013PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d151e221-1d34-4045-ba67-af1b163d36d8" xlink:to="loc_cmrx_The2013PlanMember_ab05f2ad-6197-4a9e-8da4-9abdc9cf42df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_The2013EmployeeStockPurchasePlanMember_cb602e14-8cb5-4025-b586-b14bcec54196" xlink:href="cmrx-20230331.xsd#cmrx_The2013EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d151e221-1d34-4045-ba67-af1b163d36d8" xlink:to="loc_cmrx_The2013EmployeeStockPurchasePlanMember_cb602e14-8cb5-4025-b586-b14bcec54196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_dd53cbe9-b59b-4c21-9cd1-c51a001bc2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbf8b61a-14ca-4fe4-a827-c4b74d7094df" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_dd53cbe9-b59b-4c21-9cd1-c51a001bc2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b25fbaf9-6a9f-4629-a894-373605e1a47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dd53cbe9-b59b-4c21-9cd1-c51a001bc2f6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b25fbaf9-6a9f-4629-a894-373605e1a47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PublicOfferingMember_7e5aeba4-b667-46e1-a42c-969864e4b152" xlink:href="cmrx-20230331.xsd#cmrx_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b25fbaf9-6a9f-4629-a894-373605e1a47b" xlink:to="loc_cmrx_PublicOfferingMember_7e5aeba4-b667-46e1-a42c-969864e4b152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbf8b61a-14ca-4fe4-a827-c4b74d7094df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SalesOfStockAuthorizedAmount_b3afea45-3080-45da-860f-4fe6cd930510" xlink:href="cmrx-20230331.xsd#cmrx_SalesOfStockAuthorizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_cmrx_SalesOfStockAuthorizedAmount_b3afea45-3080-45da-860f-4fe6cd930510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SalesOfStockAuthorizationTerm_06515faa-9b84-443a-8ce4-3c3851d70d26" xlink:href="cmrx-20230331.xsd#cmrx_SalesOfStockAuthorizationTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_cmrx_SalesOfStockAuthorizationTerm_06515faa-9b84-443a-8ce4-3c3851d70d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease_63f08e54-a856-42a3-a87f-5f3e5425b20e" xlink:href="cmrx-20230331.xsd#cmrx_ShareBasedCompensationOptionProvisionEquityIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease_63f08e54-a856-42a3-a87f-5f3e5425b20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_5d1fe679-3cab-43e9-9911-c8e4ad18e567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_5d1fe679-3cab-43e9-9911-c8e4ad18e567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3754a908-c51b-4b33-9798-774d6dd36c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3754a908-c51b-4b33-9798-774d6dd36c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3462079b-7cd2-4dba-a083-301889d31967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3462079b-7cd2-4dba-a083-301889d31967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9633a21e-6da2-4dd1-9249-bb0073c44887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9633a21e-6da2-4dd1-9249-bb0073c44887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm_bfce3466-06b2-4227-a51d-826099d0dd89" xlink:href="cmrx-20230331.xsd#cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm_bfce3466-06b2-4227-a51d-826099d0dd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_afc17d6b-193b-490d-954e-0cdf7723b879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_afc17d6b-193b-490d-954e-0cdf7723b879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_b856e6d3-bf0a-412a-a26f-410c1e25d9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_b856e6d3-bf0a-412a-a26f-410c1e25d9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_b5bfbed4-5f83-49d7-a71b-0cd738be40fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_b5bfbed4-5f83-49d7-a71b-0cd738be40fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval_c8fcef22-f1d8-4c61-9500-9f7e479e9ed8" xlink:href="cmrx-20230331.xsd#cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval_c8fcef22-f1d8-4c61-9500-9f7e479e9ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1cb22beb-0741-45ae-a3e0-b962375777ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1cb22beb-0741-45ae-a3e0-b962375777ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_13cd7e70-d818-4f1f-8ada-854df5771eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_13cd7e70-d818-4f1f-8ada-854df5771eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_b5fc6ea6-76f0-4728-ab79-a8fbf3add773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0f8644b-a54b-4adf-82b9-3a4291a6383b" xlink:to="loc_us-gaap_SeveranceCosts1_b5fc6ea6-76f0-4728-ab79-a8fbf3add773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8bcd6eb9-8539-44c8-bbb3-be375d45edaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_434aff17-692b-4622-8b4f-61dc7dd8f856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8bcd6eb9-8539-44c8-bbb3-be375d45edaf" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_434aff17-692b-4622-8b4f-61dc7dd8f856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_24c2cbc8-35f6-48f2-89b7-381e992fb756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_434aff17-692b-4622-8b4f-61dc7dd8f856" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_24c2cbc8-35f6-48f2-89b7-381e992fb756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ccb49a47-f5d8-4938-978c-523ab2770213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24c2cbc8-35f6-48f2-89b7-381e992fb756" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ccb49a47-f5d8-4938-978c-523ab2770213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8b694932-1af3-46b7-9c15-43aa48a2f0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ccb49a47-f5d8-4938-978c-523ab2770213" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8b694932-1af3-46b7-9c15-43aa48a2f0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7f0a0ecb-ab0a-454d-8a9b-3ff7966f87c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ccb49a47-f5d8-4938-978c-523ab2770213" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7f0a0ecb-ab0a-454d-8a9b-3ff7966f87c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_25c1c848-8eed-4179-b8dc-869a6d4ab006" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_434aff17-692b-4622-8b4f-61dc7dd8f856" xlink:to="loc_srt_TitleOfIndividualAxis_25c1c848-8eed-4179-b8dc-869a6d4ab006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41049ec0-ec51-4ce8-85c3-2d0a7cc2468c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_25c1c848-8eed-4179-b8dc-869a6d4ab006" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41049ec0-ec51-4ce8-85c3-2d0a7cc2468c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_IndependentMembersOfBoardMember_9ba82865-7cd2-470c-bd5a-b7ced4439725" xlink:href="cmrx-20230331.xsd#cmrx_IndependentMembersOfBoardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_41049ec0-ec51-4ce8-85c3-2d0a7cc2468c" xlink:to="loc_cmrx_IndependentMembersOfBoardMember_9ba82865-7cd2-470c-bd5a-b7ced4439725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5f97f8ec-bb72-49e6-ad93-a6799532b8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_434aff17-692b-4622-8b4f-61dc7dd8f856" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5f97f8ec-bb72-49e6-ad93-a6799532b8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6cc3e65b-2be7-4f6f-9fd5-f098ab48728b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5f97f8ec-bb72-49e6-ad93-a6799532b8a5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6cc3e65b-2be7-4f6f-9fd5-f098ab48728b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4783eed4-0836-4991-8664-d173fe89878e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_cb2ac262-aa9f-44ca-a79c-912be5475626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4783eed4-0836-4991-8664-d173fe89878e" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_cb2ac262-aa9f-44ca-a79c-912be5475626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d28a55b0-529c-4bba-b5ce-81bff50528b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_cb2ac262-aa9f-44ca-a79c-912be5475626" xlink:to="loc_srt_StatementScenarioAxis_d28a55b0-529c-4bba-b5ce-81bff50528b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4f32d2b9-30d6-4320-bfaf-cbbce59ca0b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_d28a55b0-529c-4bba-b5ce-81bff50528b0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4f32d2b9-30d6-4320-bfaf-cbbce59ca0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a22390f5-f0af-4658-aa2e-d8c7112a481a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4f32d2b9-30d6-4320-bfaf-cbbce59ca0b1" xlink:to="loc_srt_ScenarioForecastMember_a22390f5-f0af-4658-aa2e-d8c7112a481a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_10890a7b-8c26-4046-9dfa-3d7316f10981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_cb2ac262-aa9f-44ca-a79c-912be5475626" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_10890a7b-8c26-4046-9dfa-3d7316f10981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a3ed5bcb-3866-488a-939c-9cc43343d624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_10890a7b-8c26-4046-9dfa-3d7316f10981" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a3ed5bcb-3866-488a-939c-9cc43343d624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_155b7298-1f45-4376-a545-55b3a1c4ea3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_10890a7b-8c26-4046-9dfa-3d7316f10981" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_155b7298-1f45-4376-a545-55b3a1c4ea3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/SignificantAgreementsDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#SignificantAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/SignificantAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_2f68b2fc-4b97-4adf-a636-5afa604ee9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_2f68b2fc-4b97-4adf-a636-5afa604ee9cc" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e028ff84-a518-457e-b0aa-26030cc17996" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_srt_CounterpartyNameAxis_e028ff84-a518-457e-b0aa-26030cc17996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e028ff84-a518-457e-b0aa-26030cc17996" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BARDAMember_7508c4f1-4a02-4c48-9f9f-2b837d0a3667" xlink:href="cmrx-20230331.xsd#cmrx_BARDAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:to="loc_cmrx_BARDAMember_7508c4f1-4a02-4c48-9f9f-2b837d0a3667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmergentBioSolutionsIncMember_4f846163-5275-4820-8a05-b13596fc48b1" xlink:href="cmrx-20230331.xsd#cmrx_EmergentBioSolutionsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:to="loc_cmrx_EmergentBioSolutionsIncMember_4f846163-5275-4820-8a05-b13596fc48b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SymBioPharmaceuticalsMember_5889ef29-eb8d-470e-8daf-72f7d1036b11" xlink:href="cmrx-20230331.xsd#cmrx_SymBioPharmaceuticalsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:to="loc_cmrx_SymBioPharmaceuticalsMember_5889ef29-eb8d-470e-8daf-72f7d1036b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmergentBiodefenseOperationsLansingLLCMember_67cc45ae-bb2d-4f57-8fc2-2833b2f8988a" xlink:href="cmrx-20230331.xsd#cmrx_EmergentBiodefenseOperationsLansingLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:to="loc_cmrx_EmergentBiodefenseOperationsLansingLLCMember_67cc45ae-bb2d-4f57-8fc2-2833b2f8988a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OharaPharmaceuticalCoLtdMember_ed574fee-cb53-4797-8d42-fdbd0177b2c8" xlink:href="cmrx-20230331.xsd#cmrx_OharaPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:to="loc_cmrx_OharaPharmaceuticalCoLtdMember_ed574fee-cb53-4797-8d42-fdbd0177b2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SanjiuMedicalPharmaceuticalCoLtdMember_f6bf9922-0c09-4e0d-aa7d-fac5145cb38a" xlink:href="cmrx-20230331.xsd#cmrx_SanjiuMedicalPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:to="loc_cmrx_SanjiuMedicalPharmaceuticalCoLtdMember_f6bf9922-0c09-4e0d-aa7d-fac5145cb38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_NationalStockpileMember_fc1db5ae-bf41-45b7-9513-2b584fea08b4" xlink:href="cmrx-20230331.xsd#cmrx_NationalStockpileMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6340da9-93a4-40f1-bc87-2a8f2f45d48d" xlink:to="loc_cmrx_NationalStockpileMember_fc1db5ae-bf41-45b7-9513-2b584fea08b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_126ef97b-f86b-474f-90c3-55a3d984f7ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_srt_ProductOrServiceAxis_126ef97b-f86b-474f-90c3-55a3d984f7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1298b180-9edf-4065-9eec-912522df72af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_126ef97b-f86b-474f-90c3-55a3d984f7ba" xlink:to="loc_srt_ProductsAndServicesDomain_1298b180-9edf-4065-9eec-912522df72af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_TEMBEXAMember_53f3dd1a-8dd7-4a39-9fca-286c9970c615" xlink:href="cmrx-20230331.xsd#cmrx_TEMBEXAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1298b180-9edf-4065-9eec-912522df72af" xlink:to="loc_cmrx_TEMBEXAMember_53f3dd1a-8dd7-4a39-9fca-286c9970c615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BARDAMember_301f6737-9250-48b6-b118-d34bdc92f43d" xlink:href="cmrx-20230331.xsd#cmrx_BARDAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1298b180-9edf-4065-9eec-912522df72af" xlink:to="loc_cmrx_BARDAMember_301f6737-9250-48b6-b118-d34bdc92f43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_371ee593-2476-4b55-9901-5c633f906920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1298b180-9edf-4065-9eec-912522df72af" xlink:to="loc_us-gaap_RoyaltyMember_371ee593-2476-4b55-9901-5c633f906920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ExpenseReimbursementMember_f57e4780-bd4a-4c24-aa94-da2674c8f9cf" xlink:href="cmrx-20230331.xsd#cmrx_ExpenseReimbursementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1298b180-9edf-4065-9eec-912522df72af" xlink:to="loc_cmrx_ExpenseReimbursementMember_f57e4780-bd4a-4c24-aa94-da2674c8f9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed867c34-5124-4b87-bc59-c8cd1e180842" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_srt_RangeAxis_ed867c34-5124-4b87-bc59-c8cd1e180842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bbe2ec1b-c5cd-4ed0-873d-83918144069e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ed867c34-5124-4b87-bc59-c8cd1e180842" xlink:to="loc_srt_RangeMember_bbe2ec1b-c5cd-4ed0-873d-83918144069e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1e96256e-d149-45c7-992b-3e11711f9df9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bbe2ec1b-c5cd-4ed0-873d-83918144069e" xlink:to="loc_srt_MaximumMember_1e96256e-d149-45c7-992b-3e11711f9df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PeriodAxis_d7273e78-be6f-4b8a-ab55-f45ca5149836" xlink:href="cmrx-20230331.xsd#cmrx_PeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_cmrx_PeriodAxis_d7273e78-be6f-4b8a-ab55-f45ca5149836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PeriodDomain_17cac2e0-dbac-4220-8a00-ca79dd8ec393" xlink:href="cmrx-20230331.xsd#cmrx_PeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_PeriodAxis_d7273e78-be6f-4b8a-ab55-f45ca5149836" xlink:to="loc_cmrx_PeriodDomain_17cac2e0-dbac-4220-8a00-ca79dd8ec393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BasePeriodMember_7f43349d-52ae-4199-96b3-e471822f991c" xlink:href="cmrx-20230331.xsd#cmrx_BasePeriodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_PeriodDomain_17cac2e0-dbac-4220-8a00-ca79dd8ec393" xlink:to="loc_cmrx_BasePeriodMember_7f43349d-52ae-4199-96b3-e471822f991c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_98cfb0dd-31b9-43fe-8856-606a423a5dcc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_srt_StatementScenarioAxis_98cfb0dd-31b9-43fe-8856-606a423a5dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_39ad3e6e-9ec1-438a-af1f-653485326247" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_98cfb0dd-31b9-43fe-8856-606a423a5dcc" xlink:to="loc_srt_ScenarioUnspecifiedDomain_39ad3e6e-9ec1-438a-af1f-653485326247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioPlanMember_7cea8a57-aa4a-474e-b0a5-1139b17355ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_39ad3e6e-9ec1-438a-af1f-653485326247" xlink:to="loc_us-gaap_ScenarioPlanMember_7cea8a57-aa4a-474e-b0a5-1139b17355ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_28e8c585-5970-4598-8f41-1d9fc7a7035c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_srt_StatementGeographicalAxis_28e8c585-5970-4598-8f41-1d9fc7a7035c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4ddca247-2299-49c9-b946-2e521584a722" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_28e8c585-5970-4598-8f41-1d9fc7a7035c" xlink:to="loc_srt_SegmentGeographicalDomain_4ddca247-2299-49c9-b946-2e521584a722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_NonUnitedStatesMember_b608d8ee-e7c8-4eef-a4fb-a50b2344c68e" xlink:href="cmrx-20230331.xsd#cmrx_NonUnitedStatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4ddca247-2299-49c9-b946-2e521584a722" xlink:to="loc_cmrx_NonUnitedStatesMember_b608d8ee-e7c8-4eef-a4fb-a50b2344c68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_dfe55ccf-63a9-404d-9613-7d2b7e33eb0d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4ddca247-2299-49c9-b946-2e521584a722" xlink:to="loc_country_US_dfe55ccf-63a9-404d-9613-7d2b7e33eb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_42a4bb2b-ad6b-4f6d-a940-33dac92752e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_srt_MajorCustomersAxis_42a4bb2b-ad6b-4f6d-a940-33dac92752e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0fcafd0b-9e4c-4198-b02f-b59d92aa2e6b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_42a4bb2b-ad6b-4f6d-a940-33dac92752e1" xlink:to="loc_srt_NameOfMajorCustomerDomain_0fcafd0b-9e4c-4198-b02f-b59d92aa2e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PurchaserMember_a0f4598d-1d9b-4caf-a205-f7b86c70f2b3" xlink:href="cmrx-20230331.xsd#cmrx_PurchaserMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0fcafd0b-9e4c-4198-b02f-b59d92aa2e6b" xlink:to="loc_cmrx_PurchaserMember_a0f4598d-1d9b-4caf-a205-f7b86c70f2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_PublicHealthAgencyOfCanadaMember_8a47b9bb-026d-4859-a501-6d37b154cd44" xlink:href="cmrx-20230331.xsd#cmrx_PublicHealthAgencyOfCanadaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0fcafd0b-9e4c-4198-b02f-b59d92aa2e6b" xlink:to="loc_cmrx_PublicHealthAgencyOfCanadaMember_8a47b9bb-026d-4859-a501-6d37b154cd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5b2f19e2-864b-40b8-8da3-e2f1f9972a3e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_dei_LegalEntityAxis_5b2f19e2-864b-40b8-8da3-e2f1f9972a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_143eacfd-bd6d-441a-9a25-5c17a90bf69c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5b2f19e2-864b-40b8-8da3-e2f1f9972a3e" xlink:to="loc_dei_EntityDomain_143eacfd-bd6d-441a-9a25-5c17a90bf69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OncoceuticsIncMember_b79fa22a-495d-4119-a85b-61131181b73f" xlink:href="cmrx-20230331.xsd#cmrx_OncoceuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_143eacfd-bd6d-441a-9a25-5c17a90bf69c" xlink:to="loc_cmrx_OncoceuticsIncMember_b79fa22a-495d-4119-a85b-61131181b73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_23da95b3-022a-492e-a584-6a3c8f6429b2" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_QuantityBenchmarkTreatmentContractualCommitment_11a33621-3712-4e0b-971a-82520cb7cefc" xlink:href="cmrx-20230331.xsd#cmrx_QuantityBenchmarkTreatmentContractualCommitment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_QuantityBenchmarkTreatmentContractualCommitment_11a33621-3712-4e0b-971a-82520cb7cefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_SignificantAgreementsContractTerm_11e5d543-7ff8-4b89-8ca5-60f3b8eb5da4" xlink:href="cmrx-20230331.xsd#cmrx_SignificantAgreementsContractTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_SignificantAgreementsContractTerm_11e5d543-7ff8-4b89-8ca5-60f3b8eb5da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_BasePerformanceContractTerm_130aa63f-333a-4a7a-8b8d-7d0e4488d39f" xlink:href="cmrx-20230331.xsd#cmrx_BasePerformanceContractTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_BasePerformanceContractTerm_130aa63f-333a-4a7a-8b8d-7d0e4488d39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4c30ada6-4e1c-4973-93df-6368c04590bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4c30ada6-4e1c-4973-93df-6368c04590bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ReimbursableMarketingExpenses_839180c5-d4c6-4d96-8c53-8e09fbfea305" xlink:href="cmrx-20230331.xsd#cmrx_ReimbursableMarketingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_ReimbursableMarketingExpenses_839180c5-d4c6-4d96-8c53-8e09fbfea305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue_67c0638c-3979-4153-a397-c5b15c235cbe" xlink:href="cmrx-20230331.xsd#cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue_67c0638c-3979-4153-a397-c5b15c235cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OptionToPurchaseAdditionalTreatmentCourses_0d2b3261-094f-4c5e-a273-e852086c279a" xlink:href="cmrx-20230331.xsd#cmrx_OptionToPurchaseAdditionalTreatmentCourses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_OptionToPurchaseAdditionalTreatmentCourses_0d2b3261-094f-4c5e-a273-e852086c279a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost_a2232b5f-717d-441d-bef1-1c34e496b172" xlink:href="cmrx-20230331.xsd#cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost_a2232b5f-717d-441d-bef1-1c34e496b172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions_1b5f1582-bacd-4cb6-a89e-a12b84c8164b" xlink:href="cmrx-20230331.xsd#cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions_1b5f1582-bacd-4cb6-a89e-a12b84c8164b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_6d14d06d-95df-45c1-adc4-ee7d3b0dac2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_6d14d06d-95df-45c1-adc4-ee7d3b0dac2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions_652202e8-3d05-4269-8dc3-ebd5370a3a82" xlink:href="cmrx-20230331.xsd#cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions_652202e8-3d05-4269-8dc3-ebd5370a3a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger_e1e3855b-f948-4b17-b7cc-de9185860c11" xlink:href="cmrx-20230331.xsd#cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger_e1e3855b-f948-4b17-b7cc-de9185860c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate_57f864dc-b11e-45ea-89f1-9309448de2db" xlink:href="cmrx-20230331.xsd#cmrx_RevenueBenchmarkGrossProfitRoyaltyRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate_57f864dc-b11e-45ea-89f1-9309448de2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_21a6aee9-ad97-4913-a8cf-3d9663686c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_21a6aee9-ad97-4913-a8cf-3d9663686c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0450edb0-83c2-44d4-9ff1-6cefb05139c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0450edb0-83c2-44d4-9ff1-6cefb05139c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_84898a36-7812-4e06-ac7a-b1cd8ae8dd87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_84898a36-7812-4e06-ac7a-b1cd8ae8dd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractWithCustomerLiabilityInstallmentPeriods_96e51cb9-c918-408a-bb18-67965a41f35c" xlink:href="cmrx-20230331.xsd#cmrx_ContractWithCustomerLiabilityInstallmentPeriods"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_ContractWithCustomerLiabilityInstallmentPeriods_96e51cb9-c918-408a-bb18-67965a41f35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39523bee-1387-444a-b81c-d0060ea2a834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39523bee-1387-444a-b81c-d0060ea2a834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived_fdec9121-9a83-4b08-bf79-05164c5d207f" xlink:href="cmrx-20230331.xsd#cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f9a157d3-9e86-47fb-81d3-669c7a5902d5" xlink:to="loc_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived_fdec9121-9a83-4b08-bf79-05164c5d207f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_ac312503-e268-4055-bf43-4c5c7fee93d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_65913e84-e06c-42f8-834a-d90a4f88c746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_ac312503-e268-4055-bf43-4c5c7fee93d4" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_65913e84-e06c-42f8-834a-d90a4f88c746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f12b100f-3395-4aa1-abc0-ed78ccf1fa3e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_65913e84-e06c-42f8-834a-d90a4f88c746" xlink:to="loc_srt_CounterpartyNameAxis_f12b100f-3395-4aa1-abc0-ed78ccf1fa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcba6c1e-c969-4332-ba33-8162aa7cc688" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f12b100f-3395-4aa1-abc0-ed78ccf1fa3e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcba6c1e-c969-4332-ba33-8162aa7cc688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_EmergentBioSolutionsIncMember_2fc24dfb-ff70-4906-b6fa-45878f25d86d" xlink:href="cmrx-20230331.xsd#cmrx_EmergentBioSolutionsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcba6c1e-c969-4332-ba33-8162aa7cc688" xlink:to="loc_cmrx_EmergentBioSolutionsIncMember_2fc24dfb-ff70-4906-b6fa-45878f25d86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_65913e84-e06c-42f8-834a-d90a4f88c746" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_c35d27fd-a49f-4b94-9e5f-e9284ef1752c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_c35d27fd-a49f-4b94-9e5f-e9284ef1752c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AssetSaleLiabilities_53c1a8c0-dbd7-42f4-9ae7-48256ac976b8" xlink:href="cmrx-20230331.xsd#cmrx_AssetSaleLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:to="loc_cmrx_AssetSaleLiabilities_53c1a8c0-dbd7-42f4-9ae7-48256ac976b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AssetSaleInventoryTransferred_fced3764-a4fd-46e7-a06f-a2c7576a5343" xlink:href="cmrx-20230331.xsd#cmrx_AssetSaleInventoryTransferred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:to="loc_cmrx_AssetSaleInventoryTransferred_fced3764-a4fd-46e7-a06f-a2c7576a5343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AssetSalePrepaidsTransferred_1f4886b0-ea0c-428a-a2fe-31de7ffa39b4" xlink:href="cmrx-20230331.xsd#cmrx_AssetSalePrepaidsTransferred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:to="loc_cmrx_AssetSalePrepaidsTransferred_1f4886b0-ea0c-428a-a2fe-31de7ffa39b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_TransactionCostsIncurredInRelationToSales_2a3fbf8a-a5b0-43f5-a7b4-49f348c821cd" xlink:href="cmrx-20230331.xsd#cmrx_TransactionCostsIncurredInRelationToSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:to="loc_cmrx_TransactionCostsIncurredInRelationToSales_2a3fbf8a-a5b0-43f5-a7b4-49f348c821cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_2500a9ae-add6-4546-a850-a5ca73f9adb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b648cd04-0d8b-43da-a5fc-c0b040def6d7" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_2500a9ae-add6-4546-a850-a5ca73f9adb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#DSTATContractCloseoutNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_a3c3ca5e-34a0-4c64-aeac-ba3df5df489a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f448b88a-a683-4ed8-b567-27f30fc99b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_a3c3ca5e-34a0-4c64-aeac-ba3df5df489a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f448b88a-a683-4ed8-b567-27f30fc99b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3af9ac4b-5a98-4222-a861-fae4e95ed9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f448b88a-a683-4ed8-b567-27f30fc99b85" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3af9ac4b-5a98-4222-a861-fae4e95ed9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a526c778-01e9-4e2b-a8a1-1dc967841511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3af9ac4b-5a98-4222-a861-fae4e95ed9c7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a526c778-01e9-4e2b-a8a1-1dc967841511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_be27c5c1-b0e3-423b-b5b0-d8ba775b6b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a526c778-01e9-4e2b-a8a1-1dc967841511" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_be27c5c1-b0e3-423b-b5b0-d8ba775b6b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_b23704e2-bf1d-4e98-b2bf-5e670f87b076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a526c778-01e9-4e2b-a8a1-1dc967841511" xlink:to="loc_us-gaap_AccountsPayableMember_b23704e2-bf1d-4e98-b2bf-5e670f87b076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_eff5901a-95dc-44bb-b245-3ecae86505f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f448b88a-a683-4ed8-b567-27f30fc99b85" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_eff5901a-95dc-44bb-b245-3ecae86505f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractCloseOutLiability_7f6dc192-0773-4f24-8496-785711b3e573" xlink:href="cmrx-20230331.xsd#cmrx_ContractCloseOutLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_eff5901a-95dc-44bb-b245-3ecae86505f8" xlink:to="loc_cmrx_ContractCloseOutLiability_7f6dc192-0773-4f24-8496-785711b3e573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractCloseOutLiabilityAdjustments_4c76578b-e802-489b-8b4d-9d3b66703461" xlink:href="cmrx-20230331.xsd#cmrx_ContractCloseOutLiabilityAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_eff5901a-95dc-44bb-b245-3ecae86505f8" xlink:to="loc_cmrx_ContractCloseOutLiabilityAdjustments_4c76578b-e802-489b-8b4d-9d3b66703461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_4f1635dc-95b7-42e3-852c-ff5c1ce9d764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_053cdf68-b7aa-41a2-be08-13b98b7e871d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_4f1635dc-95b7-42e3-852c-ff5c1ce9d764" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_053cdf68-b7aa-41a2-be08-13b98b7e871d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c561ccc5-6051-457f-afdc-ab1f84668017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_053cdf68-b7aa-41a2-be08-13b98b7e871d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c561ccc5-6051-457f-afdc-ab1f84668017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8798739c-4b15-424c-9d77-877f33c5e41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c561ccc5-6051-457f-afdc-ab1f84668017" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8798739c-4b15-424c-9d77-877f33c5e41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6b1b73f2-fc87-4507-aa62-69a2ecbaf0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8798739c-4b15-424c-9d77-877f33c5e41e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6b1b73f2-fc87-4507-aa62-69a2ecbaf0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c237fc62-4e39-44b1-9073-3f7990dc7396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8798739c-4b15-424c-9d77-877f33c5e41e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c237fc62-4e39-44b1-9073-3f7990dc7396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_51ab4a63-6299-4452-a455-987167c22324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_053cdf68-b7aa-41a2-be08-13b98b7e871d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_51ab4a63-6299-4452-a455-987167c22324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractCloseOutCosts_7f704a79-7091-44cb-9347-9297fd46cca0" xlink:href="cmrx-20230331.xsd#cmrx_ContractCloseOutCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_51ab4a63-6299-4452-a455-987167c22324" xlink:to="loc_cmrx_ContractCloseOutCosts_7f704a79-7091-44cb-9347-9297fd46cca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/DSTATContractCloseoutScheduleofAccrualActivitiesforContractCloseoutCostDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#DSTATContractCloseoutScheduleofAccrualActivitiesforContractCloseoutCostDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/DSTATContractCloseoutScheduleofAccrualActivitiesforContractCloseoutCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_05f07b75-456f-4d8f-9da9-1e237b00d2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AccrualActivitiesForContractCloseOutCostRollForward_e7235610-f58d-447e-870d-57ffcd269dca" xlink:href="cmrx-20230331.xsd#cmrx_AccrualActivitiesForContractCloseOutCostRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_05f07b75-456f-4d8f-9da9-1e237b00d2bd" xlink:to="loc_cmrx_AccrualActivitiesForContractCloseOutCostRollForward_e7235610-f58d-447e-870d-57ffcd269dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractCloseOutLiability_7ea82efe-d5e7-4655-a6a7-54310a2a53b4" xlink:href="cmrx-20230331.xsd#cmrx_ContractCloseOutLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_AccrualActivitiesForContractCloseOutCostRollForward_e7235610-f58d-447e-870d-57ffcd269dca" xlink:to="loc_cmrx_ContractCloseOutLiability_7ea82efe-d5e7-4655-a6a7-54310a2a53b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractCloseOutLiabilityAdjustments_ea84e845-672d-4de0-ad00-fa7d6460f45c" xlink:href="cmrx-20230331.xsd#cmrx_ContractCloseOutLiabilityAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_AccrualActivitiesForContractCloseOutCostRollForward_e7235610-f58d-447e-870d-57ffcd269dca" xlink:to="loc_cmrx_ContractCloseOutLiabilityAdjustments_ea84e845-672d-4de0-ad00-fa7d6460f45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractCloseOutLiabilityPayments_b2351691-f3d5-4d71-883c-b878f48924ca" xlink:href="cmrx-20230331.xsd#cmrx_ContractCloseOutLiabilityPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_AccrualActivitiesForContractCloseOutCostRollForward_e7235610-f58d-447e-870d-57ffcd269dca" xlink:to="loc_cmrx_ContractCloseOutLiabilityPayments_b2351691-f3d5-4d71-883c-b878f48924ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_ContractCloseOutLiability_548866bb-1755-4fb5-932a-685e3c68f4e6" xlink:href="cmrx-20230331.xsd#cmrx_ContractCloseOutLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmrx_AccrualActivitiesForContractCloseOutCostRollForward_e7235610-f58d-447e-870d-57ffcd269dca" xlink:to="loc_cmrx_ContractCloseOutLiability_548866bb-1755-4fb5-932a-685e3c68f4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/RestructuringCostsDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#RestructuringCostsDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/RestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_faef5b40-8251-4531-b110-a071fe42e2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_e8b5417e-fc91-41bd-8dc9-9324bf390ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_faef5b40-8251-4531-b110-a071fe42e2b4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_e8b5417e-fc91-41bd-8dc9-9324bf390ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_7fd9b265-af28-422a-a66b-d161add2137d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_faef5b40-8251-4531-b110-a071fe42e2b4" xlink:to="loc_us-gaap_SeveranceCosts1_7fd9b265-af28-422a-a66b-d161add2137d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmrx_AnticipatedSeveranceCost_f5424761-55b1-4030-943b-203114d5882e" xlink:href="cmrx-20230331.xsd#cmrx_AnticipatedSeveranceCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_faef5b40-8251-4531-b110-a071fe42e2b4" xlink:to="loc_cmrx_AnticipatedSeveranceCost_f5424761-55b1-4030-943b-203114d5882e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_dee9a710-36b4-474b-ba55-cfb91707e64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_faef5b40-8251-4531-b110-a071fe42e2b4" xlink:to="loc_us-gaap_RestructuringReserve_dee9a710-36b4-474b-ba55-cfb91707e64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/RestructuringCostsSummaryofRestructuringChargesDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#RestructuringCostsSummaryofRestructuringChargesDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/RestructuringCostsSummaryofRestructuringChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_db481801-883b-478a-b5ff-7c1962a9cb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_77a8d3f7-d217-4b38-9acf-a32531154d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_db481801-883b-478a-b5ff-7c1962a9cb5b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_77a8d3f7-d217-4b38-9acf-a32531154d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_51fbe48a-913f-4efa-935c-b8ae01f7ac45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_77a8d3f7-d217-4b38-9acf-a32531154d1d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_51fbe48a-913f-4efa-935c-b8ae01f7ac45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d03d1720-2b80-48b3-adef-61700457c859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_51fbe48a-913f-4efa-935c-b8ae01f7ac45" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d03d1720-2b80-48b3-adef-61700457c859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_89291acf-d254-4879-ae76-9ebd3dc85e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d03d1720-2b80-48b3-adef-61700457c859" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_89291acf-d254-4879-ae76-9ebd3dc85e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d5a74d8c-cb47-4f33-b788-b271ffc3eb07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d03d1720-2b80-48b3-adef-61700457c859" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d5a74d8c-cb47-4f33-b788-b271ffc3eb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_27e7a7cc-9348-40d0-b187-cb7c26a18aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_77a8d3f7-d217-4b38-9acf-a32531154d1d" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_27e7a7cc-9348-40d0-b187-cb7c26a18aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_148fff90-3c30-49e4-826e-06fff10a13f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27e7a7cc-9348-40d0-b187-cb7c26a18aef" xlink:to="loc_us-gaap_SeveranceCosts1_148fff90-3c30-49e4-826e-06fff10a13f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.chimerix.com/role/RestructuringCostsAccrualActivityforRestructuringAccrualDetails" xlink:type="simple" xlink:href="cmrx-20230331.xsd#RestructuringCostsAccrualActivityforRestructuringAccrualDetails"/>
  <link:presentationLink xlink:role="http://www.chimerix.com/role/RestructuringCostsAccrualActivityforRestructuringAccrualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_47a53992-1512-48a5-bb4f-be1bb54db365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_6a11c2e2-f616-4211-a40b-551abc3e5db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_47a53992-1512-48a5-bb4f-be1bb54db365" xlink:to="loc_us-gaap_RestructuringReserveRollForward_6a11c2e2-f616-4211-a40b-551abc3e5db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_98a5f1eb-0665-4521-af2b-a98777f29f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_6a11c2e2-f616-4211-a40b-551abc3e5db7" xlink:to="loc_us-gaap_RestructuringReserve_98a5f1eb-0665-4521-af2b-a98777f29f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_e14514b8-ad11-489e-b8fe-0ae81c7567d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_6a11c2e2-f616-4211-a40b-551abc3e5db7" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_e14514b8-ad11-489e-b8fe-0ae81c7567d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_be880b24-8612-401c-8334-1fae05e0f01a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_6a11c2e2-f616-4211-a40b-551abc3e5db7" xlink:to="loc_us-gaap_PaymentsForRestructuring_be880b24-8612-401c-8334-1fae05e0f01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_3b9cb32b-fc1a-4d58-bacf-aa47a557435a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_6a11c2e2-f616-4211-a40b-551abc3e5db7" xlink:to="loc_us-gaap_RestructuringReserve_3b9cb32b-fc1a-4d58-bacf-aa47a557435a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829192820192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CHIMERIX,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0903395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2505 Meridian Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">806-1074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">CMRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,583,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001117480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829191119728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,951<span></span>
</td>
<td class="nump">$ 25,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">198,801<span></span>
</td>
<td class="nump">191,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,330<span></span>
</td>
<td class="nump">9,764<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">224,750<span></span>
</td>
<td class="nump">228,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent', window );">Total long-term investments</a></td>
<td class="nump">31,322<span></span>
</td>
<td class="nump">48,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,848<span></span>
</td>
<td class="nump">1,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">258,533<span></span>
</td>
<td class="nump">279,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,847<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">13,584<span></span>
</td>
<td class="nump">17,381<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,431<span></span>
</td>
<td class="nump">20,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_LoanFeesLiabilityNonCurrent', window );">Loan fees</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease-related obligations</a></td>
<td class="nump">1,666<span></span>
</td>
<td class="nump">1,819<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">18,222<span></span>
</td>
<td class="nump">22,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; no shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, 200,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; 88,583,567 and 88,054,127 shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">975,254<span></span>
</td>
<td class="nump">970,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss, net</a></td>
<td class="num">(231)<span></span>
</td>
<td class="num">(337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(734,801)<span></span>
</td>
<td class="num">(713,429)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">240,311<span></span>
</td>
<td class="nump">256,857<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 258,533<span></span>
</td>
<td class="nump">$ 279,341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_LoanFeesLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Fees Liability, Non-Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_LoanFeesLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829192789584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">88,583,567<span></span>
</td>
<td class="nump">88,054,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">88,583,567<span></span>
</td>
<td class="nump">88,054,127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829190511632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Contract and grant revenue</a></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">283<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">18,822<span></span>
</td>
<td class="nump">19,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,679<span></span>
</td>
<td class="nump">5,632<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">24,501<span></span>
</td>
<td class="nump">24,672<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(24,218)<span></span>
</td>
<td class="num">(24,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonrecurringIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income and other, net</a></td>
<td class="nump">2,846<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,372)<span></span>
</td>
<td class="num">(24,767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on debt investments, net</a></td>
<td class="nump">106<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (21,266)<span></span>
</td>
<td class="num">$ (24,819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss, basic (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss, diluted (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic (in shares)</a></td>
<td class="nump">88,294,624<span></span>
</td>
<td class="nump">87,088,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted (in shares)</a></td>
<td class="nump">88,294,624<span></span>
</td>
<td class="nump">87,088,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cmrx_ContractAndGrantMember', window );">Contract and grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Contract and grant revenue</a></td>
<td class="nump">$ 234<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Contract and grant revenue</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cmrx_ContractAndGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cmrx_ContractAndGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829188583760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in&#160;Capital</div></th>
<th class="th"><div>Accumulated&#160;Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 68,252<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 953,782<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
<td class="num">$ (885,596)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,884,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">3,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan purchases</a></td>
<td class="nump">555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">RSU stock issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on investments, net</a></td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">(24,819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">47,798<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">958,147<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(910,363)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,436,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 256,857<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">970,535<span></span>
</td>
<td class="num">(337)<span></span>
</td>
<td class="num">(713,429)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">88,054,127<span></span>
</td>
<td class="nump">88,054,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 4,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan purchases</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">RSU stock issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on investments, net</a></td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,372)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">(21,266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 240,311<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 975,254<span></span>
</td>
<td class="num">$ (231)<span></span>
</td>
<td class="num">$ (734,801)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">88,583,567<span></span>
</td>
<td class="nump">88,583,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829188243904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (21,372)<span></span>
</td>
<td class="num">$ (24,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount/premium on investments</a></td>
<td class="num">(2,096)<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">4,363<span></span>
</td>
<td class="nump">3,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gain on sale of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent', window );">Lease-related amortization</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">441<span></span>
</td>
<td class="num">(1,002)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued liabilities and deferred revenue</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(912)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,225)<span></span>
</td>
<td class="num">(23,447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(62)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchases of long-term investments</a></td>
<td class="num">(6,803)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sales of short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Proceeds from maturities of short-term investments</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">51,026<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">12,135<span></span>
</td>
<td class="nump">53,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="num">(157)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Payment of note payable related to asset acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">199<span></span>
</td>
<td class="num">(13,460)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(9,891)<span></span>
</td>
<td class="nump">16,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning of period</a></td>
<td class="nump">25,842<span></span>
</td>
<td class="nump">15,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">End of period</a></td>
<td class="nump">$ 15,951<span></span>
</td>
<td class="nump">$ 31,957<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-of-Use Asset, Amortization Expense and Straight Line Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829194037152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">The Business and Summary of Significant Accounting Policies</a></td>
<td class="text">The Business and Summary of Significant Accounting Policies<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chimerix is a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December&#160;31, 2022.&#160;In the opinion of the Company&#8217;s management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of its financial position, operating results and cash flows for the periods presented have been included.&#160;Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the full year, for any other interim period or for any future year.&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of certain financial instruments, including accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of such instruments.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For assets and liabilities recorded at fair value, it is the Company&#8217;s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates and are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, fair value measurements cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the calculated current or future fair values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The determination of where an asset or liability falls in the hierarchy requires significant judgment. These levels are:</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.</span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and models for which all significant inputs are observable, either directly or indirectly.</span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There was no material re-measurement to fair value of financial assets and liabilities that are not measured at fair value on a recurring basis. For additional information regarding the Company&#8217;s investments, please refer to Note 2, &#8220;Investments.&#8221;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below are tables that present information about certain assets measured at fair value on a recurring basis (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:33.599%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets<br/>for&#160;Identical&#160;Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="18" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,801&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,463&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,338&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total long-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,395&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,013&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,382&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets<br/>for&#160;Identical&#160;Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,826&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total long-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,626&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,941&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. The Company begins capitalization of these inventory related costs once regulatory approval is obtained. The Company primarily uses actual costs to determine its cost basis for inventories. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 15, 2022, we entered into an Asset Purchase Agreement (the Asset Purchase Agreement) with an affiliate of Emergent BioSolutions Inc. (Emergent BioSolutions) for the sale of our exclusive worldwide rights to brincidofovir, including </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TEMBEXA&#174; and specified related assets (the Asset Sale). On September 26, 2022, we closed the Asset Sale with Emergent Biodefense Operations Lansing LLC (Emergent), an affiliate of Emergent BioSolutions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale of TEMBEXA to Emergent, the Company&#8217;s inventory consisted of TEMBEXA, which was being manufactured for the treatment of smallpox for potential delivery to the Strategic National Stockpile (SNS) for the U.S. government and to other government agencies. TEMBEXA was approved by the FDA on June 4, 2021, at which time the Company began to capitalize inventory costs associated with TEMBEXA. Prior to FDA approval of TEMBEXA, all costs related to the manufacturing of TEMBEXA were charged to research and development expense in the period incurred as there was no alternative future use.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company valued its inventories at the lower of cost or estimated net realizable value. The Company determined the cost of its inventories, which included amounts related to materials, manufacturing costs, shipping and handling costs on a first-in, first-out (FIFO) basis. Work-in-process included all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods included packaged and labelled products. Title to all inventory was transferred to Emergent upon the close of the Asset Sale.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Retention Credit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) passed by the United States Congress and signed by the President, the Company was eligible for a refundable employee retention credit subject to certain criteria. The Company recognized a $2.0&#160;million employee retention credit during the three months ended September 30, 2022 related to labor costs recognized during 2020 and 2021, which is recorded in prepaid expenses and other current assets. For the three months ended September 30, 2022, $1.5&#160;million was recorded as a reduction to research and development expenses and $0.5&#160;million was recorded as a reduction to general and administrative expenses. The Company has filed for refunds of the employee retention credits and as of the date of this Quarterly Report on Form 10-Q, it has received $27,000 of refunds and cannot reasonably estimate when it will receive any or all of the remaining refunds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Loan Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022 (the Effective Date), the Company entered into a Loan and Security Agreement (the Loan Agreement), by and between the Company, as borrower, and Silicon Valley Bank, now a division of First-Citizens Bank &amp; Trust Company, as the lender (the Lender). The Loan Agreement provides for a four-year secured revolving loan facility (the Credit Facility) in an aggregate principal amount of up to $50.0&#160;million. Proceeds from the Credit Facility may be used for working capital and general corporate purposes. The Company has no obligation to draw down any amount under the Credit Facility, and has not drawn down any amount as of March&#160;31, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, in connection with the Asset Sale, the Lender and the Company agreed to suspend the availability of future advances under the Loan Agreement until such time the parties mutually agree to amend the Loan Agreement to, among other things, adjust the borrowing base and reset the covenants. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Facility accrue interest at a floating per annum rate of the greater of (i) 1.50% above the Prime Rate (as defined below) and (ii) 4.75%. Prime Rate is defined as the rate of interest per annum published in The Wall Street Journal or any successor publication thereto as the &#8220;Prime Rate&#8221;. If such rate of interest from The Wall Street Journal becomes unavailable, the &#8220;Prime Rate&#8221; shall mean the rate of interest per annum announced by the Lender as its prime rate in effect. In each case, in the event such prime rate is less than zero, such rate shall be deemed to be zero for purposes of the Loan Agreement. The Company must also pay an unused line fee equal to 0.25% per annum on the unused portion of the Credit Facility, payable quarterly in arrears. Upon the termination of the Loan Agreement for any reason prior to the Maturity Date, the Company will be required to pay to the Lender an early termination fee of $0.5&#160;million. The Loan Agreement also requires the Company to pay the Lender a non-refundable commitment fee of $0.5&#160;million, payable in four equal installments beginning on the Effective Date and each anniversary of the Effective Date thereafter until January 31, 2025. As of March&#160;31, 2023, the Company has recorded current deferred loan costs of $0.1&#160;million in prepaid expenses and other current assets and non-current deferred loan costs of $0.3&#160;million in other long-term assets on the Consolidated Balance Sheets. As of March&#160;31, 2023, the Company has recorded a current loan fee liability of $0.2&#160;million in accrued liabilities and a non-current loan fee liability of $0.1&#160;million in loan fees on the Consolidated Balance Sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,381&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Policy</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s revenues generally consist of  (i) contract and grant revenue&#8212;revenue generated under federal and private foundation grants and contracts, (ii) licensing revenue&#8212;revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements (iii) royalty revenue&#8212;revenue related to sales of TEMBEXA made by Emergent after the Asset Sale, and (iv) procurement revenue&#8212;revenue related to sales of TEMBEXA prior to the Asset Sale. Revenue is recognized in accordance with the criteria outlined in Accounting Standards Codification (ASC) 606 issued by the Financial Accounting Standards Board (FASB). Following this accounting pronouncement, a five-step approach is applied for recognizing revenue, including (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the entity satisfies a performance obligation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emergent BioSolutions, Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 26, 2022, the Company completed the Asset Sale to Emergent of the Company&#8217;s exclusive worldwide rights to brincidofovir, including TEMBEXA&#174; and specified related assets (the Asset Sale). Emergent paid the Company an upfront cash payment of approximately $238&#160;million upon the closing of the Asset Sale. In addition, pursuant to the Asset Purchase Agreement, the Company is eligible to receive from Emergent: (i) up to an aggregate of approximately $124&#160;million in milestone payments payable upon the exercise of the options under the BARDA Agreement for the delivery of up to 1.7&#160;million treatment courses of tablet and suspension formulations of TEMBEXA to the U.S. government; (ii) royalty payments equal to 15% of all gross profits associated with the sales of TEMBEXA made outside of the United States during the exclusivity period of TEMBEXA on a market-to-market basis; (iii) royalty payments equal to 20% of future gross profits of TEMBEXA made in the United States associated with volumes above 1.7&#160;million treatment courses of therapy during the exclusivity period of TEMBEXA; and (iv) up to an additional $12.5&#160;million upon the achievement of certain other developmental milestones. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The BARDA Agreement was novated to Emergent in December 2022. Under the Asset Purchase Agreement, the Company recognized $0.2&#160;million of contract revenue for expense reimbursement related to support provided to Emergent for the three months ended March&#160;31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue under cost-plus-fixed-fee grants from the federal government and private foundations is recognized as allowable costs are incurred and fees are earned. At March&#160;31, 2023, the Company has a deferred revenue balance of $0.1&#160;million related to these grants. For the three months ended March&#160;31, 2023, the Company recognized $30,000 of grant revenue and for the three months ended March&#160;31, 2022, the Company recognized no  grant revenue related to these grants.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ohara Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Oncoceutics, Inc., a Delaware corporation (Oncoceutics) which was subsequently acquired by the Company in January 2021, entered into a license, development and commercialization agreement with Ohara Pharmaceutical Co., Ltd. for ONC201 in Japan. The Company is entitled to receive up to $2.5&#160;million in nonrefundable regulatory milestone payments. The Company is entitled to double-digit tiered royalties based on the aggregate annual net sales of all products, as defined in the agreement, in Japan. For the three months ended March&#160;31, 2023 and 2022, the Company recognized approximately $58,000 and $15,000, respectively, of license revenue related to this agreement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TEMBEXA Procurement Agreements Revenue and Royalty Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, the Company entered into the Supply Agreement and the PHAC Contract (as defined in Note 6 below), pursuant to which the Company was responsible for supplying TEMBEXA (brincidofovir) treatment courses for use outside of the United States. There are no material performance obligations outside of delivery in the agreements, therefore revenue related to these procurement agreements was recognized when the delivery performance obligation was satisfied. Revenue was recognized based on price per treatment course as outlined in the agreements.  For the three months ended September 30, 2022, the Company recognized $32.0&#160;million of procurement revenue related to these agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The remaining deliveries of treatment courses related to the PHAC Contract were delivered by Emergent and were subject to the royalty terms of the Asset Purchase Agreement applicable to gross profits outside the United States. The Company recognized approximately $0.4&#160;million of royalty revenue in the three months ended December 31, 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Prepaids and Accruals</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its research and development efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s objective is to reflect the appropriate research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of its research and development efforts. The Company determines prepaid and accrual estimates through discussion with applicable personnel and outside service providers as to the progress or state of communication of clinical trials, or other services completed. The Company adjusts its rate of research and development expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. Through March&#160;31, 2023, there had been no material adjustments to the Company&#8217;s prior period estimates of prepaid and accruals for research and development expenses. The Company&#8217;s research and development prepaids and accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Net Income (Loss) Per Share of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period, excluding the dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights. Diluted net income (loss) per share of common stock is computed by dividing net income (loss) by the sum of the weighted-average number of shares of common stock outstanding during the period plus the potential dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights outstanding during the period calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during the periods of net loss, there was no difference between basic and diluted loss per share of common stock for the three months ended March&#160;31, 2023 and 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In addition to estimates discussed in other sections of this Quarterly Report on Form 10-Q, the most significant estimates in the Company&#8217;s consolidated financial statements relate to the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in only one segment, pharmaceuticals. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of Recently Adopted Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward-looking approach on expected losses to estimate credit losses on certain financial instruments, including trade receivables and available-for-sale debt securities. The new guidance was originally due to become effective for the Company beginning in the first quarter of 2020, however the FASB in November 2019 issued ASU 2019-10 which moved the effective date for smaller reporting companies to the first quarter of 2023. The Company adopted ASU 2016-03 as of January 1, 2023. Given the nature of the Company&#8217;s receivables and investment portfolio, adoption of this standard had no impact on the Company's financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829196968640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following tables summarize the Company&#8217;s debt investments (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,354&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,123&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,118&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following tables summarize the Company&#8217;s debt investments with unrealized losses, aggregated by investment type and the length of time that individual investments have been in a continuous unrealized loss position (in thousands, except number of securities):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:29.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Greater than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,832&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,832&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Greater than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, certificates of deposits, municipal and corporate notes and bonds, and commercial paper, among others. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of two years and requires an average portfolio maturity of no more than 12 months. Some of the securities in which the Company invests may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company has not realized any significant losses from its investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates, among other things, the duration and extent to which the fair value of a security is less than its cost; the financial condition of the issuer and any changes thereto; and the Company&#8217;s intent to sell, or whether it will more likely than not be required to sell, the security before recovery of its cost basis. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Unrealized gains and losses on debt investments are recorded to unrealized gain (loss) on debt investments, net in the Consolidated Statements of Operations and Comprehensive Loss. Realized gains and losses on debt investments are recorded based on specific identification to interest income and other, net in the Consolidated Statements of Operations and Comprehensive Loss. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current investments. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term investments. At March&#160;31, 2023, the Company believes that the cost of its investments is recoverable in all material </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respects. The Company recognizes interest income on an accrual basis in interest income in the Consolidated Statements of Operations and Comprehensive Loss.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the scheduled maturity for the Company&#8217;s debt investments at March&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.158%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total debt investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829192717728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases its facilities under long-term operating leases that expire at various dates through 2026. The Company generally has options to renew lease terms on its facilities, which may be exercised at the Company&#8217;s sole discretion. In addition, certain lease arrangements may be terminated prior to their original expiration date at the Company&#8217;s discretion. The Company evaluates renewal and termination options at the lease commencement date to determine if it is reasonably certain to exercise the option and has concluded on all operating leases that it is not reasonably certain that any options will be exercised. The weighted-average remaining lease term for the Company&#8217;s operating leases as of March&#160;31, 2023 was 3.34 years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense related to leases is recorded on a straight-line basis over the lease term.  Lease expense under operating leases, including common area maintenance fees, totaled approximately $0.2 million and $0.2 million, respectively, for the three months ended March&#160;31, 2023 and 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The discount rate implicit within the Company&#8217;s leases is generally not determinable and therefore the Company determines the discount rate based on its incremental borrowing rate based on the information available at commencement date. As of March&#160;31, 2023, the operating lease liabilities reflect a weighted-average discount rate of 7.89%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the operating lease right-of-use assets and liabilities as of March&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:76.179%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfNC0wLTEtMS01NzY3OA_f81a58fa-8b97-4a63-b960-98a6f8393ce5">Operating lease short-term liabilities (recorded within Accrued liabilities)</span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease long-term liabilities (recorded within Lease-related obligations)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,666)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,256)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease payments over the remainder of the lease terms are as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023 </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum rental payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, operating lease payments over the remainder of the lease terms were as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum rental payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, the Company made lease payments of approximately $0.2 million and $0.1 million, respectively.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significance of Revenue Source</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company was the recipient of federal research contract funds from BARDA, the primary source of the Company&#8217;s prior year contract and grant revenue. Periodic audits are required in connection with the Company&#8217;s receipt of such funds and certain costs may be questioned as appropriate by BARDA. Accordingly, at March&#160;31, 2023 and December&#160;31, 2022, the Company had recorded a provision for potential refundable amounts of $52,000.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829190593344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions and Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Transactions and Share-based Compensation</a></td>
<td class="text">Equity Transactions and Share-based Compensation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-The-Market Equity Offering; Shelf Registration Statement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 10, 2020, we entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (the Jefferies Sales Agreement) with Jefferies LLC, as agent, pursuant to which we may offer and sell, from time to time through Jefferies, up to $75&#160;million of shares of our common stock. As of March&#160;31, 2023, we have not sold any shares of our common stock under the Jefferies Sales Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 6, 2021, we filed an automatic shelf registration statement on Form S-3 with the SEC, which was subsequently amended in March 2022 to convert to a non-automatic shelf registration statement. This registration statement enables us to offer for sale, from time to time, in one or more offerings, up to $250&#160;million in the aggregate, of common stock, debt securities, warrants, rights and/or units, and will remain in effect for up to three years from the date it became effective.  As of March&#160;31, 2023, no sales have been made under the shelf registration statement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2013 Equity Incentive Plan (the 2013 Plan), which provides for the grant of incentive stock options (ISOs), non-statutory stock options (NSOs), stock appreciation rights, restricted stock awards, restricted stock unit (RSU) awards, performance-based stock awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to employees, including officers, non-employee directors and consultants of the Company and its affiliates. Additionally, the 2013 Plan provides for the grant of performance cash awards. The number of shares of common stock reserved for future issuance automatically increased on January 1, 2023, by 4% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or 3.5 million shares.&#160;As of March&#160;31, 2023, there was a total of 3.0 million shares reserved for future issuance under the 2013 Plan. The Company issued no shares of common stock pursuant to the exercise of stock options during the three months ended March&#160;31, 2023. The Company issued approximately 34,000 shares of common stock pursuant to the exercise of stock options during the three months ended March&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2013 Employee Stock Purchase Plan (ESPP), which provides for the issuance of shares of common stock pursuant to purchase rights granted to the Company&#8217;s employees or to employees of any of its designated affiliates. The Company has reserved a total of 4.8 million shares of common stock to be purchased under the ESPP, of which 2.3 million shares remained available for purchase as of March&#160;31, 2023. The number of shares of common stock reserved for issuance automatically increased on January 1, 2023, by an additional 422,535 shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP provides for an automatic reset feature to start participants on a new twenty-four month participation period in the event that the common stock market value on a purchase date is less than the common stock value on the first day of the twenty-four month offering period. Eligible employees may authorize an amount up to 15% of their salary to purchase common </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock at the lower of a 15% discount to the beginning price of their offering period or a 15% discount to the ending price of each six-month purchase interval. The Company issued approximately 308,000 and 384,000 shares of common stock pursuant to the ESPP during the three months ended March&#160;31, 2023 and 2022, respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#8220;look-back&#8221; option and were determined using a Black-Scholes option pricing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has issued RSUs to certain employees which vest based on service criteria. When vested, the RSU represents the right to be issued the number of shares of the Company&#8217;s common stock that is equal to the number of RSUs granted. The grant date fair value for RSUs is based upon the market price of the Company&#8217;s common stock on the date of the grant. The fair value is then amortized to compensation expense over the requisite service period or vesting term. The Company issued approximately 221,000 shares of common stock pursuant to the vesting of RSUs during the three months ended March&#160;31, 2023. The Company issued approximately 134,000 shares of common stock pursuant to the vesting of RSUs during the three months ended March&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For awards with only service conditions and graded-vesting features, the Company recognizes compensation expense on a straight-line basis over the requisite service period. Total share-based compensation expense recognized related to stock options, the ESPP and RSUs was as follows (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,708&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2022, the Company announced a reduction in workforce. As a result, certain vested stock options were modified to extend their exercise period from 90 days to 12 months.  In addition, certain outstanding stock option and RSU grants received accelerated vesting as if the service period of the terminated employee continued for up to an additional 12-month period. The Company recorded expense ratably from the announcement date through the date of termination with approximately $0.4&#160;million being recognized during the twelve months ended December 31, 2022 and an additional $0.6&#160;million being recognized during the three months ended March&#160;31, 2023.</span></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2023, the Company extended the post-termination exercise period from 90 days to three years for stock option grants made to non-employee members of our Board of Directors. This extension applies to all future grants as well as all then-outstanding grants. Related to this extension, the Company recorded approximately $0.3&#160;million of expense during the three months ended March 31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829192722160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company estimates an annual effective tax rate of 0.0% for the year ending December&#160;31, 2023 as the Company incurred losses for the three month period ended March&#160;31, 2023 and is forecasting an estimated net loss for both financial statement and tax purposes for the year ending December&#160;31, 2023. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method in accordance with FASB ASC 740. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Due to the Company's history of cumulative losses since inception, there is not enough evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a full valuation allowance, since the Company cannot currently support that realization of its deferred tax assets is more likely than not. However, the Company feels its deferred tax assets may be used upon the Company becoming profitable. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the Company had no unrecognized tax benefits that would reduce the Company&#8217;s effective tax rate if recognized.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829196062704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock', window );">Significant Agreements</a></td>
<td class="text">Significant Agreements <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BARDA 2022 Procurement and Development Contract</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 26, 2022, the Company entered into a procurement contract, as amended, (the BARDA Agreement) with BARDA for the delivery of up to 1.7&#160;million treatment courses of tablet and suspension formulations of TEMBEXA&#174; to the U.S. government over a possible 10-year period. The BARDA Agreement consists of a five-year base period of performance and a total contract period of performance (base period plus option exercises) of up to ten years (if necessary). Under the terms of the BARDA Agreement, the base period activities are valued at approximately $127&#160;million, consisting of an initial shipment of 319,000 treatment courses of TEMBEXA to be procured and shipped to the Strategic National Stockpile for an aggregate purchase price of approximately $115&#160;million, and reimbursement for certain post-marketing activities of approximately $12&#160;million. The options under the BARDA Agreement, which are exercised at the sole discretion of BARDA, are valued at approximately $553&#160;million (if all such options are exercised during the 10-year contract period), which consists of options to purchase up to an additional 1.381&#160;million treatment courses of TEMBEXA for an aggregate purchase price of approximately $551&#160;million and funding for certain post-marketing activities of approximately $2&#160;million. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the sale of the TEMBEXA franchise to Emergent, the BARDA Agreement was novated to Emergent in December 2022. In accordance with federal regulations, the terms of the novation agreement require that the Company guarantee the performance of all obligations transferred to Emergent should Emergent not have the ability to deliver on the terms of the BARDA Agreement. In this instance, BARDA may request that we perform the obligations in place of Emergent. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emergent BioSolutions, Inc. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 26, 2022, the Company completed the Asset Sale to Emergent of the Company&#8217;s exclusive worldwide rights to brincidofovir, including TEMBEXA&#174; and specified related assets (the Asset Sale). Emergent paid the Company an upfront cash payment of approximately $238&#160;million upon the closing of the Asset Sale. In addition, pursuant to the Asset Purchase Agreement, the Company is eligible to receive from Emergent: (i) up to an aggregate of approximately $124&#160;million in milestone payments payable upon the exercise of the options under the BARDA Agreement for the delivery of up to 1.7&#160;million treatment courses of tablet and suspension formulations of TEMBEXA to the U.S. government; (ii) royalty payments equal to 15% of the gross profits from the sales of TEMBEXA made outside of the United States; (iii) royalty payments equal to 20% of the gross profits from the sales of TEMBEXA made in the United States in excess of 1.7&#160;million treatment courses; and (iv) up to an additional $12.5&#160;million upon the achievement of certain other developmental milestones. The effects of recording certain adjustments associated with contingent consideration related to TEMBEXA have been excluded as the Company has made a policy election to account for these amounts when the contingency has been resolved in accordance with Accounting Standards Codification 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The period under which the Company was contracted to provide the majority of operational support services to Emergent in furtherance of its obligations under the Asset Purchase Agreement and the BARDA Agreement concluded on March 26, 2023, except for certain services which the parties agreed would continue until the occurrence of a specific event, or in some cases a predetermined end date. The BARDA Agreement was novated to Emergent in December 2022. Under the Asset Purchase Agreement, the Company recognized approximately $0.2&#160;million of contract revenue for support provided for the three months ended March&#160;31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The sale of TEMBEXA constitutes a significant disposition of a business, however, the Company determined the disposition did not represent a strategic shift, and accordingly, the Company did not account for the disposition as a discontinued operation. The Company recorded a $229.7&#160;million net gain on sale of business in other income (loss) on the Consolidated Statement of Operations and Comprehensive Income (Loss) in the third quarter of 2022.  The net gain consists of the following assets and liabilities transferred in accordance with the Asset Purchase Agreement (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.678%"><tr><td style="width:1.0%"/><td style="width:54.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front cash payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed by Emergent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory transferred to Emergent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids transferred to Emergent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs incurred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,002)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net gain</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,670</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TEMBEXA Procurement Agreements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, the Company entered into a Supply Agreement (the Supply Agreement) with a third-party outside of North America (the Purchaser), pursuant to which the Company was responsible for supplying to the Purchaser, and the Purchaser was responsible for purchasing from the Company, TEMBEXA treatment courses for use in a jurisdiction outside of the United States. Under the terms of the Supply Agreement, the Purchaser paid the Company an aggregate purchase price of approximately $9.3&#160;million, in two equal installments in June and July 2022. The Company recognized $9.3&#160;million of procurement revenue under the Supply Agreement for the three months ended September 30, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, in June 2022, the Public Health Agency of Canada (PHAC) awarded a Contract (PHAC Contract) to the Company, pursuant to which PHAC agreed to purchase up to approximately USD $25.3&#160;million (CAD $33.0&#160;million) of TEMBEXA treatment courses for use in Canada. Substantially all of the procurement was delivered and accepted by PHAC in July 2022, completing the performance obligation for those shipments and resulting in $22.6&#160;million of procurement revenue for the three months ended September 2022. Upon the assignment of the PHAC Contract to Emergent, which requires the consent of PHAC, if the remaining deliveries of treatment courses are made by Emergent, they will be subject to the royalty terms of the Asset Purchase Agreement applicable to gross profits outside the United States. PHAC assigned the PHAC Contract to Emergent in November 2022. The remaining deliveries of treatment courses were delivered by Emergent and are subject to the royalty terms of the Asset Purchase Agreement applicable to gross profits outside the United States. The Company recognized approximately $0.4&#160;million of royalty revenue in the three months ended December 31, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ohara Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Oncoceutics, Inc., a Delaware corporation (Oncoceutics) which was subsequently acquired by the Company in January 2021, entered into a license, development and commercialization agreement with Ohara Pharmaceutical Co., Ltd. for ONC201 in Japan. The Company is entitled to receive up to $2.5&#160;million in nonrefundable regulatory milestone payments. The Company is entitled to double-digit tiered royalties based on the aggregate annual net sales of all products, as defined in the agreement, in Japan. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CR Sanjiu Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Oncoceutics entered into a license, development and commercialization agreement with China Resources Sanjiu Medical &amp; Pharmaceutical Co., Ltd. (CR Sanjiu). Oncoceutics granted CR Sanjiu an exclusive royalty bearing license to develop and commercialize ONC201 in China, Hong Kong, Macau and Taiwan (CR Sanjiu Territory). The Company is entitled to receive up to $5.0&#160;million in nonrefundable regulatory milestone payments. The Company is entitled to double-digit tiered royalties based on the aggregate annual net sales of all licensed products, as defined in the agreement, in the CR Sanjiu Territory. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. DSTAT Contract Close-out </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, the Company made the decision to discontinue the development of DSTAT for the treatment of AML. Effective July 12, 2022, the Company terminated the License and Development Agreement with Cantex. As a result, the Company recorded an accrual of expenses to close-out the DSTAT vendor contracts. As of March&#160;31, 2023, on the Consolidated Balance Sheets, the Company has recorded $1.1&#160;million of contract close-out costs in accrued liabilities offset by a vendor credit of $0.1&#160;million in accounts payable. These balances are expected to be fully paid over the first half of 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contract close-out costs (in thousands) recorded in 2022:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.257%"><tr><td style="width:1.0%"/><td style="width:49.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.304%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Close-out Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research &amp; development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General &amp; administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract close-out expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the accounts payable and accrual activity for contract close-out costs (in thousands) for 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"/><td style="width:48.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Close-out Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Revised estimates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the accounts payable and accrual activity for contract close-out costs (in thousands) for the three months ended March&#160;31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"/><td style="width:48.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Close-out Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Revised estimates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>For the three months ended March&#160;31, 2023, the revised accrual estimates resulted in an increase to research and development expenses of $10,000.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84167097&amp;loc=d3e55538-109407<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 405<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126938335&amp;loc=d3e56417-109416<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54658-109401<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(d)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54711-109401<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54672-109401<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 35<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197326<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6471471&amp;loc=d3e48698-109348<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(c)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126937589&amp;loc=SL119991590-234733<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126937589&amp;loc=SL119991585-234733<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -URI https://asc.fasb.org/topic&amp;trid=2145070<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(c)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 405<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126938292&amp;loc=d3e56288-109415<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54708-109401<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84167097&amp;loc=d3e55562-109407<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 405<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938335&amp;loc=d3e56414-109416<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermContractsOrProgramsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829192800112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DSTAT Contract Close-out<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock', window );">DSTAT Contract Close-out</a></td>
<td class="text">Significant Agreements <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BARDA 2022 Procurement and Development Contract</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 26, 2022, the Company entered into a procurement contract, as amended, (the BARDA Agreement) with BARDA for the delivery of up to 1.7&#160;million treatment courses of tablet and suspension formulations of TEMBEXA&#174; to the U.S. government over a possible 10-year period. The BARDA Agreement consists of a five-year base period of performance and a total contract period of performance (base period plus option exercises) of up to ten years (if necessary). Under the terms of the BARDA Agreement, the base period activities are valued at approximately $127&#160;million, consisting of an initial shipment of 319,000 treatment courses of TEMBEXA to be procured and shipped to the Strategic National Stockpile for an aggregate purchase price of approximately $115&#160;million, and reimbursement for certain post-marketing activities of approximately $12&#160;million. The options under the BARDA Agreement, which are exercised at the sole discretion of BARDA, are valued at approximately $553&#160;million (if all such options are exercised during the 10-year contract period), which consists of options to purchase up to an additional 1.381&#160;million treatment courses of TEMBEXA for an aggregate purchase price of approximately $551&#160;million and funding for certain post-marketing activities of approximately $2&#160;million. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the sale of the TEMBEXA franchise to Emergent, the BARDA Agreement was novated to Emergent in December 2022. In accordance with federal regulations, the terms of the novation agreement require that the Company guarantee the performance of all obligations transferred to Emergent should Emergent not have the ability to deliver on the terms of the BARDA Agreement. In this instance, BARDA may request that we perform the obligations in place of Emergent. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emergent BioSolutions, Inc. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 26, 2022, the Company completed the Asset Sale to Emergent of the Company&#8217;s exclusive worldwide rights to brincidofovir, including TEMBEXA&#174; and specified related assets (the Asset Sale). Emergent paid the Company an upfront cash payment of approximately $238&#160;million upon the closing of the Asset Sale. In addition, pursuant to the Asset Purchase Agreement, the Company is eligible to receive from Emergent: (i) up to an aggregate of approximately $124&#160;million in milestone payments payable upon the exercise of the options under the BARDA Agreement for the delivery of up to 1.7&#160;million treatment courses of tablet and suspension formulations of TEMBEXA to the U.S. government; (ii) royalty payments equal to 15% of the gross profits from the sales of TEMBEXA made outside of the United States; (iii) royalty payments equal to 20% of the gross profits from the sales of TEMBEXA made in the United States in excess of 1.7&#160;million treatment courses; and (iv) up to an additional $12.5&#160;million upon the achievement of certain other developmental milestones. The effects of recording certain adjustments associated with contingent consideration related to TEMBEXA have been excluded as the Company has made a policy election to account for these amounts when the contingency has been resolved in accordance with Accounting Standards Codification 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The period under which the Company was contracted to provide the majority of operational support services to Emergent in furtherance of its obligations under the Asset Purchase Agreement and the BARDA Agreement concluded on March 26, 2023, except for certain services which the parties agreed would continue until the occurrence of a specific event, or in some cases a predetermined end date. The BARDA Agreement was novated to Emergent in December 2022. Under the Asset Purchase Agreement, the Company recognized approximately $0.2&#160;million of contract revenue for support provided for the three months ended March&#160;31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The sale of TEMBEXA constitutes a significant disposition of a business, however, the Company determined the disposition did not represent a strategic shift, and accordingly, the Company did not account for the disposition as a discontinued operation. The Company recorded a $229.7&#160;million net gain on sale of business in other income (loss) on the Consolidated Statement of Operations and Comprehensive Income (Loss) in the third quarter of 2022.  The net gain consists of the following assets and liabilities transferred in accordance with the Asset Purchase Agreement (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.678%"><tr><td style="width:1.0%"/><td style="width:54.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front cash payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed by Emergent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory transferred to Emergent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids transferred to Emergent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs incurred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,002)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net gain</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,670</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TEMBEXA Procurement Agreements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, the Company entered into a Supply Agreement (the Supply Agreement) with a third-party outside of North America (the Purchaser), pursuant to which the Company was responsible for supplying to the Purchaser, and the Purchaser was responsible for purchasing from the Company, TEMBEXA treatment courses for use in a jurisdiction outside of the United States. Under the terms of the Supply Agreement, the Purchaser paid the Company an aggregate purchase price of approximately $9.3&#160;million, in two equal installments in June and July 2022. The Company recognized $9.3&#160;million of procurement revenue under the Supply Agreement for the three months ended September 30, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, in June 2022, the Public Health Agency of Canada (PHAC) awarded a Contract (PHAC Contract) to the Company, pursuant to which PHAC agreed to purchase up to approximately USD $25.3&#160;million (CAD $33.0&#160;million) of TEMBEXA treatment courses for use in Canada. Substantially all of the procurement was delivered and accepted by PHAC in July 2022, completing the performance obligation for those shipments and resulting in $22.6&#160;million of procurement revenue for the three months ended September 2022. Upon the assignment of the PHAC Contract to Emergent, which requires the consent of PHAC, if the remaining deliveries of treatment courses are made by Emergent, they will be subject to the royalty terms of the Asset Purchase Agreement applicable to gross profits outside the United States. PHAC assigned the PHAC Contract to Emergent in November 2022. The remaining deliveries of treatment courses were delivered by Emergent and are subject to the royalty terms of the Asset Purchase Agreement applicable to gross profits outside the United States. The Company recognized approximately $0.4&#160;million of royalty revenue in the three months ended December 31, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ohara Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Oncoceutics, Inc., a Delaware corporation (Oncoceutics) which was subsequently acquired by the Company in January 2021, entered into a license, development and commercialization agreement with Ohara Pharmaceutical Co., Ltd. for ONC201 in Japan. The Company is entitled to receive up to $2.5&#160;million in nonrefundable regulatory milestone payments. The Company is entitled to double-digit tiered royalties based on the aggregate annual net sales of all products, as defined in the agreement, in Japan. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CR Sanjiu Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Oncoceutics entered into a license, development and commercialization agreement with China Resources Sanjiu Medical &amp; Pharmaceutical Co., Ltd. (CR Sanjiu). Oncoceutics granted CR Sanjiu an exclusive royalty bearing license to develop and commercialize ONC201 in China, Hong Kong, Macau and Taiwan (CR Sanjiu Territory). The Company is entitled to receive up to $5.0&#160;million in nonrefundable regulatory milestone payments. The Company is entitled to double-digit tiered royalties based on the aggregate annual net sales of all licensed products, as defined in the agreement, in the CR Sanjiu Territory. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. DSTAT Contract Close-out </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, the Company made the decision to discontinue the development of DSTAT for the treatment of AML. Effective July 12, 2022, the Company terminated the License and Development Agreement with Cantex. As a result, the Company recorded an accrual of expenses to close-out the DSTAT vendor contracts. As of March&#160;31, 2023, on the Consolidated Balance Sheets, the Company has recorded $1.1&#160;million of contract close-out costs in accrued liabilities offset by a vendor credit of $0.1&#160;million in accounts payable. These balances are expected to be fully paid over the first half of 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contract close-out costs (in thousands) recorded in 2022:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.257%"><tr><td style="width:1.0%"/><td style="width:49.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.304%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Close-out Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research &amp; development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General &amp; administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract close-out expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the accounts payable and accrual activity for contract close-out costs (in thousands) for 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"/><td style="width:48.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Close-out Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Revised estimates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the accounts payable and accrual activity for contract close-out costs (in thousands) for the three months ended March&#160;31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"/><td style="width:48.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Close-out Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Revised estimates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>For the three months ended March&#160;31, 2023, the revised accrual estimates resulted in an increase to research and development expenses of $10,000.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84167097&amp;loc=d3e55538-109407<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 405<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126938335&amp;loc=d3e56417-109416<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54658-109401<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(d)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54711-109401<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54672-109401<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 35<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197326<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6471471&amp;loc=d3e48698-109348<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(c)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126937589&amp;loc=SL119991590-234733<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126937589&amp;loc=SL119991585-234733<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -URI https://asc.fasb.org/topic&amp;trid=2145070<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(c)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 405<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126938292&amp;loc=d3e56288-109415<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54708-109401<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84167097&amp;loc=d3e55562-109407<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 405<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938335&amp;loc=d3e56414-109416<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermContractsOrProgramsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829196902320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Costs</a></td>
<td class="text">Restructuring Costs<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company made the decision to restructure its operations, which included a reduction in workforce of 20 full-time employees. During the three months ended December 31, 2022, the Company recorded expense for one-time employee termination benefits of $1.9&#160;million, which included a ratable share of the total stock compensation expense that resulted from the modifications of stock option agreements of employees. The total amount of stock compensation expense related to the reduction in workforce equals $1.0&#160;million of which $0.4&#160;million was recorded in the fourth quarter of 2022.  </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restructuring charges (in thousands) recorded for the three months ended December 31, 2022:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Termination Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the accrual activity for employee termination benefits (in thousands) for the three months ended March&#160;31, 2023:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Termination Benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Revised estimates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829194228096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsThe Company has evaluated subsequent events through the issuance date of these financial statements to ensure that this filing includes appropriate disclosure of events both recognized in the financial statements as of March&#160;31, 2023, and events which occurred subsequently but were not recognized in the financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829192742064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Business and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December&#160;31, 2022.&#160;In the opinion of the Company&#8217;s management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of its financial position, operating results and cash flows for the periods presented have been included.&#160;Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the full year, for any other interim period or for any future year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of certain financial instruments, including accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of such instruments.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For assets and liabilities recorded at fair value, it is the Company&#8217;s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates and are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, fair value measurements cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the calculated current or future fair values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The determination of where an asset or liability falls in the hierarchy requires significant judgment. These levels are:</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.</span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and models for which all significant inputs are observable, either directly or indirectly.</span></div><div style="margin-bottom:3pt;padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There was no material re-measurement to fair value of financial assets and liabilities that are not measured at fair value on a recurring basis. For additional information regarding the Company&#8217;s investments, please refer to Note 2, &#8220;Investments.&#8221;</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. The Company begins capitalization of these inventory related costs once regulatory approval is obtained. The Company primarily uses actual costs to determine its cost basis for inventories. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 15, 2022, we entered into an Asset Purchase Agreement (the Asset Purchase Agreement) with an affiliate of Emergent BioSolutions Inc. (Emergent BioSolutions) for the sale of our exclusive worldwide rights to brincidofovir, including </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TEMBEXA&#174; and specified related assets (the Asset Sale). On September 26, 2022, we closed the Asset Sale with Emergent Biodefense Operations Lansing LLC (Emergent), an affiliate of Emergent BioSolutions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale of TEMBEXA to Emergent, the Company&#8217;s inventory consisted of TEMBEXA, which was being manufactured for the treatment of smallpox for potential delivery to the Strategic National Stockpile (SNS) for the U.S. government and to other government agencies. TEMBEXA was approved by the FDA on June 4, 2021, at which time the Company began to capitalize inventory costs associated with TEMBEXA. Prior to FDA approval of TEMBEXA, all costs related to the manufacturing of TEMBEXA were charged to research and development expense in the period incurred as there was no alternative future use.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company valued its inventories at the lower of cost or estimated net realizable value. The Company determined the cost of its inventories, which included amounts related to materials, manufacturing costs, shipping and handling costs on a first-in, first-out (FIFO) basis. Work-in-process included all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods included packaged and labelled products. Title to all inventory was transferred to Emergent upon the close of the Asset Sale.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Policy</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s revenues generally consist of  (i) contract and grant revenue&#8212;revenue generated under federal and private foundation grants and contracts, (ii) licensing revenue&#8212;revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements (iii) royalty revenue&#8212;revenue related to sales of TEMBEXA made by Emergent after the Asset Sale, and (iv) procurement revenue&#8212;revenue related to sales of TEMBEXA prior to the Asset Sale. Revenue is recognized in accordance with the criteria outlined in Accounting Standards Codification (ASC) 606 issued by the Financial Accounting Standards Board (FASB). Following this accounting pronouncement, a five-step approach is applied for recognizing revenue, including (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the entity satisfies a performance obligation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Prepaids and Accruals</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Prepaids and Accruals</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its research and development efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s objective is to reflect the appropriate research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of its research and development efforts. The Company determines prepaid and accrual estimates through discussion with applicable personnel and outside service providers as to the progress or state of communication of clinical trials, or other services completed. The Company adjusts its rate of research and development expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. Through March&#160;31, 2023, there had been no material adjustments to the Company&#8217;s prior period estimates of prepaid and accruals for research and development expenses. The Company&#8217;s research and development prepaids and accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Income (Loss) Per Share of Common Stock</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Net Income (Loss) Per Share of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period, excluding the dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights. Diluted net income (loss) per share of common stock is computed by dividing net income (loss) by the sum of the weighted-average number of shares of common stock outstanding during the period plus the potential dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights outstanding during the period calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during the periods of net loss, there was no difference between basic and diluted loss per share of common stock for the three months ended March&#160;31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In addition to estimates discussed in other sections of this Quarterly Report on Form 10-Q, the most significant estimates in the Company&#8217;s consolidated financial statements relate to the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text">SegmentsThe Company operates in only one segment, pharmaceuticals.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Impact of Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of Recently Adopted Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward-looking approach on expected losses to estimate credit losses on certain financial instruments, including trade receivables and available-for-sale debt securities. The new guidance was originally due to become effective for the Company beginning in the first quarter of 2020, however the FASB in November 2019 issued ASU 2019-10 which moved the effective date for smaller reporting companies to the first quarter of 2023. The Company adopted ASU 2016-03 as of January 1, 2023. Given the nature of the Company&#8217;s receivables and investment portfolio, adoption of this standard had no impact on the Company's financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829364022528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Certain Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below are tables that present information about certain assets measured at fair value on a recurring basis (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:33.599%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets<br/>for&#160;Identical&#160;Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="18" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,801&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,463&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,338&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total long-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,395&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,013&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,382&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets<br/>for&#160;Identical&#160;Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,826&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total long-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,626&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,941&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,381&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829192777536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Short-Term and Long-Term Investments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following tables summarize the Company&#8217;s debt investments (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,354&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,123&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,118&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following tables summarize the Company&#8217;s debt investments with unrealized losses, aggregated by investment type and the length of time that individual investments have been in a continuous unrealized loss position (in thousands, except number of securities):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:29.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Greater than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,832&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,832&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Greater than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of securities with unrealized losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of the Scheduled Maturity of Company Investments</a></td>
<td class="text"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the scheduled maturity for the Company&#8217;s debt investments at March&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.158%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total debt investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829194866512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Operating Lease Right-of-Use Assets and Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the operating lease right-of-use assets and liabilities as of March&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:76.179%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfNC0wLTEtMS01NzY3OA_f81a58fa-8b97-4a63-b960-98a6f8393ce5">Operating lease short-term liabilities (recorded within Accrued liabilities)</span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease long-term liabilities (recorded within Lease-related obligations)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,666)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,256)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Maturity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease payments over the remainder of the lease terms are as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023 </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum rental payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, operating lease payments over the remainder of the lease terms were as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum rental payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829197097792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions and Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Employee and Non-Employee Share-Based Compensation Expense Recognized Related to Stock Options, the ESPP and RSUs</a></td>
<td class="text">Total share-based compensation expense recognized related to stock options, the ESPP and RSUs was as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,708&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829192752960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock', window );">Schedule Of Net Gain From The Sales Of Assets</a></td>
<td class="text">The net gain consists of the following assets and liabilities transferred in accordance with the Asset Purchase Agreement (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.678%"><tr><td style="width:1.0%"/><td style="width:54.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front cash payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed by Emergent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory transferred to Emergent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids transferred to Emergent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs incurred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,002)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net gain</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,670</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Net Gain From The Sales Of Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829297164960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DSTAT Contract Close-out (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ScheduleOfContractCloseOutCostsTableTextBlock', window );">Schedule of Accrual Activities for Contract Close-out Cost</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contract close-out costs (in thousands) recorded in 2022:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.257%"><tr><td style="width:1.0%"/><td style="width:49.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.304%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Close-out Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research &amp; development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General &amp; administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract close-out expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the accounts payable and accrual activity for contract close-out costs (in thousands) for 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"/><td style="width:48.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Close-out Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Revised estimates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the accounts payable and accrual activity for contract close-out costs (in thousands) for the three months ended March&#160;31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"/><td style="width:48.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Close-out Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Revised estimates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_ScheduleOfContractCloseOutCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Contract Close-Out Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_ScheduleOfContractCloseOutCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829194113776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Restructuring and Related Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restructuring charges (in thousands) recorded for the three months ended December 31, 2022:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Termination Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the accrual activity for employee termination benefits (in thousands) for the three months ended March&#160;31, 2023:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Termination Benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Revised estimates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829187968496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The Business and Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">$ 198,801<span></span>
</td>
<td class="nump">$ 191,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent', window );">Total long-term investments</a></td>
<td class="nump">31,322<span></span>
</td>
<td class="nump">48,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">13,272<span></span>
</td>
<td class="nump">22,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">198,801<span></span>
</td>
<td class="nump">191,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent', window );">Total long-term investments</a></td>
<td class="nump">31,322<span></span>
</td>
<td class="nump">48,626<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">243,395<span></span>
</td>
<td class="nump">262,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring | Quoted&#160;Prices&#160;in Active&#160;Markets for&#160;Identical&#160;Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">13,272<span></span>
</td>
<td class="nump">17,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">26,463<span></span>
</td>
<td class="nump">25,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent', window );">Total long-term investments</a></td>
<td class="nump">10,278<span></span>
</td>
<td class="nump">11,685<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">50,013<span></span>
</td>
<td class="nump">54,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring | Significant&#160;Other Observable&#160;Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">172,338<span></span>
</td>
<td class="nump">166,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent', window );">Total long-term investments</a></td>
<td class="nump">21,044<span></span>
</td>
<td class="nump">36,941<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">193,382<span></span>
</td>
<td class="nump">208,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring | Significant Unobservable&#160;Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent', window );">Total long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">60,747<span></span>
</td>
<td class="nump">38,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent', window );">Total long-term investments</a></td>
<td class="nump">31,322<span></span>
</td>
<td class="nump">48,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Fair value, measurements, recurring | Quoted&#160;Prices&#160;in Active&#160;Markets for&#160;Identical&#160;Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">26,463<span></span>
</td>
<td class="nump">25,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent', window );">Total long-term investments</a></td>
<td class="nump">10,278<span></span>
</td>
<td class="nump">11,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Fair value, measurements, recurring | Significant&#160;Other Observable&#160;Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">34,284<span></span>
</td>
<td class="nump">12,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent', window );">Total long-term investments</a></td>
<td class="nump">21,044<span></span>
</td>
<td class="nump">36,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Fair value, measurements, recurring | Significant Unobservable&#160;Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent', window );">Total long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">115,016<span></span>
</td>
<td class="nump">127,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair value, measurements, recurring | Quoted&#160;Prices&#160;in Active&#160;Markets for&#160;Identical&#160;Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair value, measurements, recurring | Significant&#160;Other Observable&#160;Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">115,016<span></span>
</td>
<td class="nump">127,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair value, measurements, recurring | Significant Unobservable&#160;Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">23,038<span></span>
</td>
<td class="nump">25,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Fair value, measurements, recurring | Quoted&#160;Prices&#160;in Active&#160;Markets for&#160;Identical&#160;Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Fair value, measurements, recurring | Significant&#160;Other Observable&#160;Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">23,038<span></span>
</td>
<td class="nump">25,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Fair value, measurements, recurring | Significant Unobservable&#160;Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Short-term investments, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">13,272<span></span>
</td>
<td class="nump">17,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair value, measurements, recurring | Quoted&#160;Prices&#160;in Active&#160;Markets for&#160;Identical&#160;Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">13,272<span></span>
</td>
<td class="nump">17,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair value, measurements, recurring | Significant&#160;Other Observable&#160;Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair value, measurements, recurring | Significant Unobservable&#160;Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair value, measurements, recurring | Quoted&#160;Prices&#160;in Active&#160;Markets for&#160;Identical&#160;Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair value, measurements, recurring | Significant&#160;Other Observable&#160;Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair value, measurements, recurring | Significant Unobservable&#160;Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829192825616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Business and Summary of Significant Accounting Policies - Employee Retention Credit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_EmployeeRetentionCredit', window );">Employee retention credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 18,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Proceeds from tax refund</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember', window );">Scenario, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business and Summary of Significant Accounting Policies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_EmployeeRetentionCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Retention Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_EmployeeRetentionCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829188514160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The Business and Summary of Significant Accounting Policies - Deferred Loan Costs (Details)<br></strong></div></th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_LoanFeesLiabilityNonCurrent', window );">Non-current loan fee liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit facility, unused capacity, commitment fee percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_DebtInstrumentEarlyTerminationFee', window );">Debt instrument, early termination fee</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Debt instrument, unused borrowing capacity, fee</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_DebtInstrumentNumberOfInstallmentPayments', window );">Number of installment payments (installment) | installment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Current deferred loan costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Noncurrent deferred loan costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_LoanFeesLiabilityCurrent', window );">Loan fee liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_LoanFeesLiabilityNonCurrent', window );">Non-current loan fee liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business and Summary of Significant Accounting Policies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_DebtInstrumentEarlyTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Early Termination Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_DebtInstrumentEarlyTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_DebtInstrumentNumberOfInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Installment Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_DebtInstrumentNumberOfInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_LoanFeesLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Fees Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_LoanFeesLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_LoanFeesLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Fees Liability, Non-Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_LoanFeesLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829195216272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The Business and Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_AccruedDevelopmentLiabilities', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 7,936<span></span>
</td>
<td class="nump">$ 6,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrentAndNoncurrent', window );">Accrued compensation</a></td>
<td class="nump">3,348<span></span>
</td>
<td class="nump">6,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">4,252<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 13,584<span></span>
</td>
<td class="nump">$ 17,381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_AccruedDevelopmentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued development liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_AccruedDevelopmentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829188199584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Business and Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 26, 2022 </div>
<div>USD ($) </div>
<div>treatment</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Contract and grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_OharaPharmaceuticalCoLtdMember', window );">Ohara Pharmaceutical Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived', window );">License agreement, nonrefundable regulatory milestone payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_EmergentBioSolutionsIncMember', window );">Emergent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Up-front cash payment</a></td>
<td class="nump">$ 237,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_SymBioPharmaceuticalsMember', window );">SymBio Pharmaceuticals | Scenario, Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Deferred revenue</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_EmergentBiodefenseOperationsLansingLLCMember', window );">Emergent Biodefense Operations Lansing LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant | Oncoceutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Contract and grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Contract and grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing | Ohara Pharmaceutical Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Contract and grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cmrx_TEMBEXAMember', window );">TEMBEXA | PHAC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Contract and grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cmrx_TEMBEXAMember', window );">TEMBEXA | Emergent | Base Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Up-front cash payment</a></td>
<td class="nump">$ 238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger', window );">Quantity royalty rate, trigger (treatments) | treatment</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cmrx_TEMBEXAMember', window );">TEMBEXA | Emergent | Base Period | Non- United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate', window );">Gross profit royalty rate (percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cmrx_TEMBEXAMember', window );">TEMBEXA | Emergent | Base Period | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate', window );">Gross profit royalty rate (percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Contract and grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cmrx_BARDAMember', window );">BARDA | Emergent | Base Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Business and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions', window );">Maximum milestone proceeds upon the exercise of options</a></td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business and Summary of Significant Accounting Policies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Nonrefundable Regulatory Milestone Payment To Be Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Milestone Proceeds Upon The Exercise Of Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Quantity Benchmark, Gross Profit Royalty Rate Trigger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Benchmark, Gross Profit Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_RevenueBenchmarkGrossProfitRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmrx_OharaPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmrx_OharaPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmrx_EmergentBioSolutionsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmrx_EmergentBioSolutionsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmrx_SymBioPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmrx_SymBioPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmrx_EmergentBiodefenseOperationsLansingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmrx_EmergentBiodefenseOperationsLansingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=cmrx_OncoceuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=cmrx_OncoceuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cmrx_TEMBEXAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cmrx_TEMBEXAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cmrx_PublicHealthAgencyOfCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cmrx_PublicHealthAgencyOfCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_PeriodAxis=cmrx_BasePeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_PeriodAxis=cmrx_BasePeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cmrx_NonUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cmrx_NonUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cmrx_BARDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cmrx_BARDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829193338704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Available-for-Sale securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 230,354<span></span>
</td>
<td class="nump">$ 240,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(384)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">230,123<span></span>
</td>
<td class="nump">240,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">23,072<span></span>
</td>
<td class="nump">25,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">23,038<span></span>
</td>
<td class="nump">25,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">92,152<span></span>
</td>
<td class="nump">86,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">92,069<span></span>
</td>
<td class="nump">86,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">115,130<span></span>
</td>
<td class="nump">127,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">$ 115,016<span></span>
</td>
<td class="nump">$ 127,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829188101104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value, less than 12 months</a></td>
<td class="nump">$ 173,832<span></span>
</td>
<td class="nump">$ 179,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized loss, less than 12 months</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair value, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized loss, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value, total</a></td>
<td class="nump">173,832<span></span>
</td>
<td class="nump">179,254<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized loss, total</a></td>
<td class="num">$ (295)<span></span>
</td>
<td class="num">$ (384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of securities with unrealized losses, less than 12 months | security</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities with unrealized losses, greater than 12 months | security</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities with unrealized losses, total | security</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value, less than 12 months</a></td>
<td class="nump">$ 23,038<span></span>
</td>
<td class="nump">$ 22,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized loss, less than 12 months</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair value, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized loss, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value, total</a></td>
<td class="nump">23,038<span></span>
</td>
<td class="nump">22,905<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized loss, total</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value, less than 12 months</a></td>
<td class="nump">85,101<span></span>
</td>
<td class="nump">88,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized loss, less than 12 months</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair value, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized loss, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value, total</a></td>
<td class="nump">85,101<span></span>
</td>
<td class="nump">88,860<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized loss, total</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value, less than 12 months</a></td>
<td class="nump">65,693<span></span>
</td>
<td class="nump">67,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized loss, less than 12 months</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair value, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized loss, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value, total</a></td>
<td class="nump">65,693<span></span>
</td>
<td class="nump">67,489<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized loss, total</a></td>
<td class="num">$ (138)<span></span>
</td>
<td class="num">$ (179)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829190549888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Investment Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 198,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo', window );">Maturing after one year through two years</a></td>
<td class="nump">31,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total debt investments</a></td>
<td class="nump">$ 230,123<span></span>
</td>
<td class="nump">$ 240,118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829192907952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">3 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense under non-cancelable operating leases</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">7.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_BARDAMember', window );">BARDA | Refundable Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Provision for refundable amounts</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmrx_BARDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmrx_BARDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cmrx_RefundableAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cmrx_RefundableAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829188594352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease Right-of-Use Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,848<span></span>
</td>
<td class="nump">$ 1,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease short-term liabilities (recorded within Accrued liabilities)</a></td>
<td class="num">(590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease long-term liabilities (recorded within Lease-related obligations)</a></td>
<td class="num">(1,666)<span></span>
</td>
<td class="num">(1,819)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total present value of lease payments</a></td>
<td class="num">$ (2,256)<span></span>
</td>
<td class="num">$ (2,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, liability, current, statement of financial position [extensible list]</a></td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829191128192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturity Analysis of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year one</a></td>
<td class="nump">$ 555<span></span>
</td>
<td class="nump">$ 736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year two</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year three</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year four</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum rental payments</a></td>
<td class="nump">2,562<span></span>
</td>
<td class="nump">2,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amount of lease payments representing interest</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total present value of lease payments</a></td>
<td class="nump">$ 2,256<span></span>
</td>
<td class="nump">$ 2,392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829188200848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions and Share-based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">One-time employee termination benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 1,854,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmrx_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_SalesOfStockAuthorizedAmount', window );">Sale of common stock, amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_SalesOfStockAuthorizationTerm', window );">Sales of stock, authorization term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmrx_The2013PlanMember', window );">The 2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease', window );">Evergreen option provision, equity increase</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued pursuant to the exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmrx_The2013EmployeeStockPurchasePlanMember', window );">The 2013 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="nump">422,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized to be granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm', window );">Participation term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of pay that employee can contribute, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Discounted purchase price from market price, offering date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discounted purchase price from market price, purchase date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval', window );">Purchase interval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued pursuant to employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_SalesOfStockAuthorizationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Of Stock, Authorization Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_SalesOfStockAuthorizationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_SalesOfStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Of Stock, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_SalesOfStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_ShareBasedCompensationOptionProvisionEquityIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation, Option Provision, Equity Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_ShareBasedCompensationOptionProvisionEquityIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Participation Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Purchase Interval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmrx_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmrx_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmrx_The2013PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmrx_The2013PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmrx_The2013EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmrx_The2013EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829187744112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions and Share-based Compensation - Schedule of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 4,363<span></span>
</td>
<td class="nump">$ 3,708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cmrx_IndependentMembersOfBoardMember', window );">Independent Members Of Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">2,312<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 2,051<span></span>
</td>
<td class="nump">$ 1,805<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cmrx_IndependentMembersOfBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cmrx_IndependentMembersOfBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829195166816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Estimated annual effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829184975104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements (Details)<br> $ in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 26, 2022 </div>
<div>USD ($) </div>
<div>treatment</div>
</th>
<th class="th">
<div>Aug. 26, 2022 </div>
<div>USD ($) </div>
<div>treatment</div>
</th>
<th class="th">
<div>Jun. 23, 2022 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 23, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Contract and grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cmrx_TEMBEXAMember', window );">TEMBEXA | Purchaser</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ContractWithCustomerLiabilityInstallmentPeriods', window );">Number of payment installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Contract and grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cmrx_TEMBEXAMember', window );">TEMBEXA | PHAC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Contract and grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cmrx_TEMBEXAMember', window );">TEMBEXA | Scenario, Plan | Purchaser</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cmrx_TEMBEXAMember', window );">TEMBEXA | Scenario, Plan | PHAC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Contract and grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_BARDAMember', window );">BARDA | TEMBEXA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_BasePerformanceContractTerm', window );">Base performance, contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue', window );">Amount of additional courses at the discretion of customer, gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 553,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_OptionToPurchaseAdditionalTreatmentCourses', window );">Amount of additional courses at the discretion of customer | treatment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost', window );">Amount of additional courses at the discretion of customer, net of marketing cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions', window );">Reimbursable marketing cost upon the exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_BARDAMember', window );">BARDA | TEMBEXA | Base Period | Scenario, Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_QuantityBenchmarkTreatmentContractualCommitment', window );">Contractual treatment commitment (treatment) | treatment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_BARDAMember', window );">BARDA | TEMBEXA | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_QuantityBenchmarkTreatmentContractualCommitment', window );">Contractual treatment commitment (treatment) | treatment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_SignificantAgreementsContractTerm', window );">Contract term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_EmergentBioSolutionsIncMember', window );">Emergent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Up-front cash payment</a></td>
<td class="nump">$ 237,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Gain (loss) on sale of assets</a></td>
<td class="nump">229,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_EmergentBioSolutionsIncMember', window );">Emergent | TEMBEXA | Base Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Up-front cash payment</a></td>
<td class="nump">$ 238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger', window );">Quantity royalty rate, trigger (treatments) | treatment</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_EmergentBioSolutionsIncMember', window );">Emergent | TEMBEXA | Base Period | Non- United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate', window );">Gross profit royalty rate (percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_EmergentBioSolutionsIncMember', window );">Emergent | TEMBEXA | Base Period | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate', window );">Gross profit royalty rate (percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_EmergentBioSolutionsIncMember', window );">Emergent | BARDA | Base Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions', window );">Maximum milestone proceeds upon the exercise of options</a></td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_SymBioPharmaceuticalsMember', window );">SymBio Pharmaceuticals | Scenario, Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Deferred revenue</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_EmergentBiodefenseOperationsLansingLLCMember', window );">Emergent Biodefense Operations Lansing LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_OharaPharmaceuticalCoLtdMember', window );">Ohara Pharmaceutical Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived', window );">License agreement, nonrefundable regulatory milestone payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_SanjiuMedicalPharmaceuticalCoLtdMember', window );">CR Sanjui | Scenario, Plan | Oncoceutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_NationalStockpileMember', window );">National Stockpile | TEMBEXA | Base Period | Scenario, Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmrx_NationalStockpileMember', window );">National Stockpile | Expense reimbursement | Base Period | Scenario, Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ReimbursableMarketingExpenses', window );">Reimbursable marketing expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_BasePerformanceContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base Performance, Contract Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_BasePerformanceContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_ContractWithCustomerLiabilityInstallmentPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Installment Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_ContractWithCustomerLiabilityInstallmentPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Nonrefundable Regulatory Milestone Payment To Be Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Milestone Proceeds Upon The Exercise Of Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_OptionToPurchaseAdditionalTreatmentCourses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option To Purchase Additional Treatment Courses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_OptionToPurchaseAdditionalTreatmentCourses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option To Purchase Additional Treatment Courses, Gross Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option To Purchase Additional Treatment Courses, Net Of Marketing Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Quantity Benchmark, Gross Profit Royalty Rate Trigger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_QuantityBenchmarkTreatmentContractualCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Quantity Benchmark, Treatment Contractual Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_QuantityBenchmarkTreatmentContractualCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursable Marketing Cost Upon The Exercise Of Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_ReimbursableMarketingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursable Marketing Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_ReimbursableMarketingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_RevenueBenchmarkGrossProfitRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Benchmark, Gross Profit Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_RevenueBenchmarkGrossProfitRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_SignificantAgreementsContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Agreements, Contract Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_SignificantAgreementsContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cmrx_TEMBEXAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cmrx_TEMBEXAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cmrx_PurchaserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cmrx_PurchaserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cmrx_PublicHealthAgencyOfCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cmrx_PublicHealthAgencyOfCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmrx_BARDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmrx_BARDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_PeriodAxis=cmrx_BasePeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_PeriodAxis=cmrx_BasePeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmrx_EmergentBioSolutionsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmrx_EmergentBioSolutionsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cmrx_NonUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cmrx_NonUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cmrx_BARDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cmrx_BARDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmrx_SymBioPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmrx_SymBioPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmrx_EmergentBiodefenseOperationsLansingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmrx_EmergentBiodefenseOperationsLansingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmrx_OharaPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmrx_OharaPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmrx_SanjiuMedicalPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmrx_SanjiuMedicalPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cmrx_OncoceuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cmrx_OncoceuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmrx_NationalStockpileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmrx_NationalStockpileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cmrx_ExpenseReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cmrx_ExpenseReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829188269536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements- Schedule of Assets and Liabilities Transferred in Accordance with Asset Purchase Agreement (Details) - Emergent - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Up-front cash payment</a></td>
<td class="nump">$ 237,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_AssetSaleLiabilities', window );">Liabilities assumed by Emergent</a></td>
<td class="nump">1,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_AssetSaleInventoryTransferred', window );">Inventory transferred to Emergent</a></td>
<td class="num">(5,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_AssetSalePrepaidsTransferred', window );">Prepaids transferred to Emergent</a></td>
<td class="num">(511)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_TransactionCostsIncurredInRelationToSales', window );">Transaction costs incurred</a></td>
<td class="num">(4,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Net gain</a></td>
<td class="nump">$ 229,670<span></span>
</td>
<td class="nump">$ 229,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_AssetSaleInventoryTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Sale, Inventory Transferred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_AssetSaleInventoryTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_AssetSaleLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Sale, Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_AssetSaleLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_AssetSalePrepaidsTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Sale, Prepaids Transferred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_AssetSalePrepaidsTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_TransactionCostsIncurredInRelationToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs Incurred In Relation To Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_TransactionCostsIncurredInRelationToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmrx_EmergentBioSolutionsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmrx_EmergentBioSolutionsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829187744000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DSTAT Contract Close-out - Narratives (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ContractCloseOutLiability', window );">Contract close out liability</a></td>
<td class="nump">$ 1,071<span></span>
</td>
<td class="nump">$ 1,311<span></span>
</td>
<td class="nump">$ 4,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ContractCloseOutLiabilityAdjustments', window );">Revised estimates</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">$ 746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ContractCloseOutLiability', window );">Contract close out liability</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ContractCloseOutLiability', window );">Contract close out liability</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_ContractCloseOutLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Close Out Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_ContractCloseOutLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_ContractCloseOutLiabilityAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Close Out Liability, Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_ContractCloseOutLiabilityAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829193330688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DSTAT Contract Close-out- Contract Close-out Cost Income Statement Location (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ContractCloseOutCosts', window );">Contract close out cost</a></td>
<td class="nump">$ 799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ContractCloseOutCosts', window );">Contract close out cost</a></td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ContractCloseOutCosts', window );">Contract close out cost</a></td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_ContractCloseOutCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Close Out Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_ContractCloseOutCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829193327760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DSTAT Contract Close-out- Schedule of Accrual Activities for Contract Close-out Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_AccrualActivitiesForContractCloseOutCostRollForward', window );"><strong>Accrual Activities for Contract Close-out Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ContractCloseOutLiability', window );">Balance at June 30, 2022</a></td>
<td class="nump">$ 1,311<span></span>
</td>
<td class="nump">$ 4,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ContractCloseOutLiabilityAdjustments', window );">Revised estimates</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ContractCloseOutLiabilityPayments', window );">Payments</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(2,482)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_ContractCloseOutLiability', window );">Balance at December 31, 2022</a></td>
<td class="nump">$ 1,071<span></span>
</td>
<td class="nump">$ 1,311<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_AccrualActivitiesForContractCloseOutCostRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrual Activities for Contract Close-out Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_AccrualActivitiesForContractCloseOutCostRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_ContractCloseOutLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Close Out Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_ContractCloseOutLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_ContractCloseOutLiabilityAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Close Out Liability, Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_ContractCloseOutLiabilityAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_ContractCloseOutLiabilityPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Close Out Liability, Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_ContractCloseOutLiabilityPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829191126912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Reduction in workforce | employee</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">One-time employee termination benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 1,854<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmrx_AnticipatedSeveranceCost', window );">Anticipated severance cost</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Severance accrual balance</a></td>
<td class="nump">$ 1,442<span></span>
</td>
<td class="nump">$ 728<span></span>
</td>
<td class="nump">$ 1,442<span></span>
</td>
<td class="nump">$ 1,442<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmrx_AnticipatedSeveranceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Anticipated Severance Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmrx_AnticipatedSeveranceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829188571600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs - Summary of Restructuring Charges (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Total restructuring expenses</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 1,854<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Total restructuring expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Total restructuring expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139829193304976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs - Accrual Activity for Restructuring Accrual (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at December 31, 2022</a></td>
<td class="nump">$ 1,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Revised estimates</a></td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at March 31, 2023</a></td>
<td class="nump">$ 728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>cmrx-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cmrx="http://www.chimerix.com/20230331"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cmrx-20230331.xsd" xlink:type="simple"/>
    <context id="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i00ca283eef774858b67f6475ece947f1_I20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i040b1a26f397449cbae5cbdc11f92d47_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd4275020e18400eb3bcc3b3b804d073_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:ContractAndGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1946ece09c904951861cbc7bb236f26e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:ContractAndGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id2cbb7f16c184e0ca3be6befb0a3c161_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6258f7ba70a2429d893b0989f0d4e545_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia4f4cba41ac745a2873593ff4a0af42c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i78825b0461dd42a184dfa832830bb172_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee7e43b8df1e40e2838c78908a8c90a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea3aca87c515473fb5fb58cb32a3ecaf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88f8447d733347d58c5c02338a641fca_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i16d995cc04da4cafbe2ba9be78b1c72b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaea1f9ee2956448baa9ee91273abae28_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3dab6564bb614134994df6db247ed37a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icd0a1f31f73c41a7a5ec947966979961_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i03f11fe9d82e47fd898e0f573563fa9b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id1f10aa7207a45ec828484d3d85f7316_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i03c8e1a7f33e40d49435c773a7314a83_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i84561bae0aa74e99990371324cca219c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d07e6b250054a5da85d70f2553d7020_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28c9d91d02cb4b33936d8547b6f48fc3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i796ee983b1a3444ba7cc01d9c90293e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6de410df18e74128ab476b930f4658bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if412d998e56846989f5ae6842d1e08f4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i44a6ce80a0054a1c81b01150954b377c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic5a7585076314ed6a713d0ca7be1cc36_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if5551887562a49f8bc19f22a00cfe692_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5542e921d03d486d97066d5da0dd33dd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icd9e7194f06647efb45e1a08985ba180_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6877193126b044118b28af082201f8d3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8e69b868007a4b97aafa93214a71b658_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3c9fa7eab31843dd898750d8c76cfcf9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1192c9f83b36465e8f80e3685ed58c8b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2ffd7159be8e43f19e53d050ecbf41ae_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i20743e8f7f174eeeadbd88e1c7f0cc12_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i20f3f186e36448f5b3a63b9e3b863269_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i804d7d03889847d5ae48e5ad93dbb50f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i887daef78c58443e893277334452edbc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8ade65735c9545f2a12dec9f4312f6cd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id7c60bf2d7ba4e96bf4498b8f2014d16_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib107a3ac2180405c9d10f438e8b18db3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id189accf19a84607a3af2777ead773ad_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic51cb125601349b8b451af99cb1a781a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i39e8a7b56d01472097cdbcd15bfb49c6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib0c0f4bcdd5c402e9040e2f3d650afb7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic5037b9b3c73466389a40771e5177e59_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifedf03aebe3b4bc78bfbfef940377a97_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8ff2067d964e4f6eb5c4572c7df44ff5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib5a617b479c5421ab4085ecb7805f41b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3b72ea3730984bc299a26ec655d2be77_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i550880ea43424204a2167a6dad7fc32f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic9aa19420d064b6ea99c0aef9e593870_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i15168c3e9c9e45d884e1da247a40b7ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e929ebf603643be9d50f1d1c81d5553_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia11f96247a744891aedb33da4b10f863_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i826e3ed6eed14f59899dfce3d3fb5ed5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41d1ac0e92874f2ab60e2efbc7472cb3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff7a494199b34fe38f094bf02e43219e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id99c937daad4485a99236d4462f4fe95_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie06e373167d2401d87352019c0070854_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if67b2ed977af4ca5be169e787fd04e24_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic01dbb19691142bcaf240d5503fa85ce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i216aa5360f47421dad09d1e2fe063cd9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfbc49f108964d9586b1fe78301cede3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i65078142e8c646429535c348eb43e549_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i73233ee3c3004e849b476b2a2bdd672d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea8cb0da69264659b6fb1593ca7975a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i95a0ab613b064db9811414440e1df09c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i830e14896ae3418090aea88e6361ccff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2bb926ac6f54414ab15657d5d02f6bef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff79739385f045859d1ea7c0fd2a699e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i70b68c3a79434ad59d870f352df7ab52_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic9612d95ff6e485ab93759b9c6a1bc22_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5cdfd50074bb4f2780f387ee055c71f1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i229430736baa458696f8be14caad07c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i843f7d4691c94406bd8946f2730515ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18d0bbe7e74a49d99423e480deb74908_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic0b110316ee84c4196d882c915b7f130_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3fff5d25cf6449308bcbf75364001e45_D20220131-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i5f1afc1bd8bb425d867be35c0e46ed08_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="i80ced39ca26c4f13818bb6d006095818_D20220131-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="id5258aa58e96454ba7f47be820e18166_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i39fee762c2014475826a3d701b15814d_D20220926-20220926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBioSolutionsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-26</startDate>
            <endDate>2022-09-26</endDate>
        </period>
    </context>
    <context id="ide975e55e26c4a95b067825a19f1af74_I20220926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBioSolutionsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="i4febe75fb14447a39e9fe6f7451fff6c_I20220926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBioSolutionsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="i49c5bcc0f6e3428b874169048e2386a2_I20220926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBioSolutionsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cmrx:NonUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="ibef35d312f6649c48ca5770e34d07f53_I20220926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBioSolutionsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="i5668b209a8cf48ffac44b53d2385eeb5_I20220926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:SymBioPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="i8ae67a95e48a4514b6b62802563f5af0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBiodefenseOperationsLansingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i66e19cf7c3a84bd69adc584ad7985cb2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cmrx:OncoceuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iec10cd07bccf4bdea2cab77c4d8be033_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cmrx:OncoceuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3aced1df796f4e5d948dedb09bb1dc06_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cmrx:OncoceuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ica04db5e597f4a148bb1cd8f8e4c8b48_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:OharaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic046decd305e415f9bdb56550cc8bda5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:OharaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i94ca8168a35a4764b28df995a789e4a5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:OharaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i96d6a71fabac4ccbb276c7996d4a8257_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cmrx:PublicHealthAgencyOfCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i07e0fd7ae2114d36b0896130bfc39369_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i81f288735d374f28b4bc08d750b772c0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i60cc7c18a97a43f2bc365519b6490b77_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i26c7e37b1d0940819ffe67431c0d8379_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icb7c6239239c4da7a999932e68f2b1d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5b23ee2279148de946ebbc12395a903_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9517f9ec839e440d95427249384ef67c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:RefundableAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i342138d95ca84510be429a8206bf6d91_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:RefundableAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaf6d919a74434c88a93c3c9563ebfc77_I20200810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmrx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-10</instant>
        </period>
    </context>
    <context id="i8d40a540d19e49cd84414a5e1c507455_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmrx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2c9f154273194565a27c741f7878e0e3_D20230101-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i431035fe4c0e4c04baad526438084c5b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if122bfed225d4e6b9ea7dabd81e702ef_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9a68a6a0ea9447b09e9381db440aee36_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie0396b8eb64340e7b468fbedd1556a7c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i11ef95703d59450f84bcac3c8c1fe127_D20230101-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="idff0b85443fb4b408cf3cd0b099f45c4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6085f06cabc84a509e0e944fb745eeb7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmrx:The2013EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i524f8a9b49ff48159693771c90e88f29_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib125a1468b8f4d2e8c10c699c34bc410_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic212316462214f758bddf2408b982c40_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i707d882d90674ded914e0c24595f4781_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic0ee769ecce64f21994ca9ced836dbaa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iada28bd88d134a9886cbbb069ddd2f51_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cmrx:IndependentMembersOfBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6e1bad3a6f1a46cc92694fa22413949c_D20230101-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i87dd3af02ad441ce9c3886a519178bc9_I20220826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-26</instant>
        </period>
    </context>
    <context id="i0d079805c3384255aaa8160de0eddece_D20220826-20220826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-26</startDate>
            <endDate>2022-08-26</endDate>
        </period>
    </context>
    <context id="i4c153c1c04674d08b3b67fbf5f6520f6_D20220826-20220826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-26</startDate>
            <endDate>2022-08-26</endDate>
        </period>
    </context>
    <context id="ia0c3ebb768e14ba1adac8fecc4608694_I20220826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-26</instant>
        </period>
    </context>
    <context id="ibb56f621902543d18de68b58f4527963_I20220826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:NationalStockpileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-26</instant>
        </period>
    </context>
    <context id="ie2bf6b11e1724d84ba0bcc3f1428cc8e_I20220826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:NationalStockpileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:ExpenseReimbursementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cmrx:PeriodAxis">cmrx:BasePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-26</instant>
        </period>
    </context>
    <context id="i1dda99b1defa4528b1254af85ee9ca46_I20220826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-26</instant>
        </period>
    </context>
    <context id="i069e85b680a44fffa3ee317f7da6fae3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBioSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:EmergentBioSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-26</startDate>
            <endDate>2022-09-26</endDate>
        </period>
    </context>
    <context id="i4dc7c0b07dc840118483ece5d0ba3401_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cmrx:PurchaserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="ib85fa50450aa424aafb519800af6ba59_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cmrx:PurchaserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib699e30492f44e8a804263792c19142f_D20220623-20220623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cmrx:PurchaserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-23</startDate>
            <endDate>2022-06-23</endDate>
        </period>
    </context>
    <context id="i6a47e7a6ffe740b1ab49e33529826b16_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cmrx:PurchaserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i041e87dc76b7486fad7182d5c433de1d_I20220623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cmrx:PublicHealthAgencyOfCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-23</instant>
        </period>
    </context>
    <context id="i7858fb7e8acd42509124fae89e255dca_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cmrx:PublicHealthAgencyOfCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmrx:TEMBEXAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i21532ae17c8540b2814f9047fab955e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmrx:SanjiuMedicalPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cmrx:OncoceuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if82f3e05482f40578ab012f41b08b052_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1bb99da3a7e24972a69174d9a86c03d0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic6f299962fcf4e829643ecd56dc9183d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5109aa96790c4d84b6c1982ac5f7ba63_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5d7df4ccac55457db9fc511a4813ea18_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i80f398e930dd4c1195d38e4f087c0836_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if6405e9f8e2e42febb0630cc3f4b70cf_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8bc40ecede3346368c17697b995b6608_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i01d7ce8ff73a42f8bc6ebe1f484b504b_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic3b15fe0b2c840688dc4fc6ff3dc199f_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001117480</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="installment">
        <measure>cmrx:installment</measure>
    </unit>
    <unit id="treatment">
        <measure>cmrx:treatment</measure>
    </unit>
    <unit id="segment">
        <measure>cmrx:segment</measure>
    </unit>
    <unit id="security">
        <measure>cmrx:security</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="employee">
        <measure>cmrx:employee</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80L2ZyYWc6M2ZiMDYxNmY0ZTM1NDFhZjg4YTUyMTkwYzg1N2UxYzYvdGFibGU6MDQ2NDcxYWI5MmRjNDJkNTgyZmRmYmQyMjIxYzRmMzcvdGFibGVyYW5nZTowNDY0NzFhYjkyZGM0MmQ1ODJmZGZiZDIyMjFjNGYzN180LTEtMS0xLTU3Njc4_34b040f1-3e5a-43d5-b048-815a472cd286">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80L2ZyYWc6M2ZiMDYxNmY0ZTM1NDFhZjg4YTUyMTkwYzg1N2UxYzYvdGFibGU6MDQ2NDcxYWI5MmRjNDJkNTgyZmRmYmQyMjIxYzRmMzcvdGFibGVyYW5nZTowNDY0NzFhYjkyZGM0MmQ1ODJmZGZiZDIyMjFjNGYzN181LTEtMS0xLTU3Njc4_7e37088d-418c-4107-a76c-e5546cd4a952">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80L2ZyYWc6M2ZiMDYxNmY0ZTM1NDFhZjg4YTUyMTkwYzg1N2UxYzYvdGFibGU6MDQ2NDcxYWI5MmRjNDJkNTgyZmRmYmQyMjIxYzRmMzcvdGFibGVyYW5nZTowNDY0NzFhYjkyZGM0MmQ1ODJmZGZiZDIyMjFjNGYzN182LTEtMS0xLTU3Njc4_820f624a-8f79-4241-a116-75e8ba53e8bd">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80L2ZyYWc6M2ZiMDYxNmY0ZTM1NDFhZjg4YTUyMTkwYzg1N2UxYzYvdGFibGU6MDQ2NDcxYWI5MmRjNDJkNTgyZmRmYmQyMjIxYzRmMzcvdGFibGVyYW5nZTowNDY0NzFhYjkyZGM0MmQ1ODJmZGZiZDIyMjFjNGYzN183LTEtMS0xLTU3Njc4_d09b8a3d-46b4-442b-ae8f-eab4808c4952">0001117480</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80L2ZyYWc6M2ZiMDYxNmY0ZTM1NDFhZjg4YTUyMTkwYzg1N2UxYzYvdGFibGU6MDQ2NDcxYWI5MmRjNDJkNTgyZmRmYmQyMjIxYzRmMzcvdGFibGVyYW5nZTowNDY0NzFhYjkyZGM0MmQ1ODJmZGZiZDIyMjFjNGYzN184LTEtMS0xLTU3Njc4_fb079328-d44c-40e9-bdc4-0b486cffb23d">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfNC0wLTEtMS01NzY3OA_f81a58fa-8b97-4a63-b960-98a6f8393ce5">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTkw_1fc814f2-cd8f-4987-943b-84510501c587">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6ZDIyMmU0YTI4MTEwNDRiZWEzY2M4MTIwMThlMGIxMTEvdGFibGVyYW5nZTpkMjIyZTRhMjgxMTA0NGJlYTNjYzgxMjAxOGUwYjExMV8wLTAtMS0xLTU3Njc4_cb315ad8-c3b3-4fe8-86f6-2e34805fb8b0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xMzc_93e73736-3a09-4567-918d-1d54322dc702">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6ZTRmMzI3NThiNDVlNGQ2N2I4NzU0YTMzNWYwY2MxMGIvdGFibGVyYW5nZTplNGYzMjc1OGI0NWU0ZDY3Yjg3NTRhMzM1ZjBjYzEwYl8wLTAtMS0xLTU3Njc4_bea201b3-60b0-4873-81e6-7f6907244bb9">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTkx_accc56a2-6bef-4958-b823-5160bc6607bd">001-35867</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTky_d75c3963-c46b-4af3-bad6-3e0c6c62713c">CHIMERIX,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NzRiMjgwOWI2NTVhNGNjNWFjMmFlMjM2MWJjM2NmODYvdGFibGVyYW5nZTo3NGIyODA5YjY1NWE0Y2M1YWMyYWUyMzYxYmMzY2Y4Nl8wLTAtMS0xLTU3Njc4_f3bddd9b-9385-4650-8cf8-73cba6a860fa">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NzRiMjgwOWI2NTVhNGNjNWFjMmFlMjM2MWJjM2NmODYvdGFibGVyYW5nZTo3NGIyODA5YjY1NWE0Y2M1YWMyYWUyMzYxYmMzY2Y4Nl8wLTItMS0xLTU3Njc4_500caf85-73eb-4a2b-8c6a-384e8df52185">33-0903395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NzRiMjgwOWI2NTVhNGNjNWFjMmFlMjM2MWJjM2NmODYvdGFibGVyYW5nZTo3NGIyODA5YjY1NWE0Y2M1YWMyYWUyMzYxYmMzY2Y4Nl8zLTAtMS0xLTU3Njc4L3RleHRyZWdpb246OGQwNzk1MTIwMDVmNDcxNmE2ZjA3ZDljNTQ3ZGFlZjFfNA_1438394c-77ea-4a05-942c-8b3b7ada2f65">2505 Meridian Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NzRiMjgwOWI2NTVhNGNjNWFjMmFlMjM2MWJjM2NmODYvdGFibGVyYW5nZTo3NGIyODA5YjY1NWE0Y2M1YWMyYWUyMzYxYmMzY2Y4Nl8zLTAtMS0xLTU3Njc4L3RleHRyZWdpb246OGQwNzk1MTIwMDVmNDcxNmE2ZjA3ZDljNTQ3ZGFlZjFfOA_9c867475-b8ec-4469-a7b6-ad635a60ca98">Suite&#160;100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NzRiMjgwOWI2NTVhNGNjNWFjMmFlMjM2MWJjM2NmODYvdGFibGVyYW5nZTo3NGIyODA5YjY1NWE0Y2M1YWMyYWUyMzYxYmMzY2Y4Nl80LTAtMS0xLTU3Njc4L3RleHRyZWdpb246ZjE1ZTYyMDlkMTJlNDdkNDlkY2E3YWYzMmRiYWIxMWZfNA_5e4ef440-b859-4d77-9845-22720d5ef526">Durham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NzRiMjgwOWI2NTVhNGNjNWFjMmFlMjM2MWJjM2NmODYvdGFibGVyYW5nZTo3NGIyODA5YjY1NWE0Y2M1YWMyYWUyMzYxYmMzY2Y4Nl80LTAtMS0xLTU3Njc4L3RleHRyZWdpb246ZjE1ZTYyMDlkMTJlNDdkNDlkY2E3YWYzMmRiYWIxMWZfOA_a7d1eb6d-b947-4508-80e7-18a3679610fe">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NzRiMjgwOWI2NTVhNGNjNWFjMmFlMjM2MWJjM2NmODYvdGFibGVyYW5nZTo3NGIyODA5YjY1NWE0Y2M1YWMyYWUyMzYxYmMzY2Y4Nl80LTItMS0xLTU3Njc4_a5034790-4d75-40bb-ad7c-3dfab2a42fb0">27713</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8zMzI_34a236cb-f717-4417-9eb2-8bfba5a256ac">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTk0_3969d143-28d3-46a2-b00c-5a36a92d28fa">806-1074</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NWQ4YzJhYjU5N2YyNDExMzg2MWQwNjliNmNjMDI3MDEvdGFibGVyYW5nZTo1ZDhjMmFiNTk3ZjI0MTEzODYxZDA2OWI2Y2MwMjcwMV8xLTAtMS0xLTU3Njc4_629b4ea5-740e-4ffb-811d-e4121133a97b">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NWQ4YzJhYjU5N2YyNDExMzg2MWQwNjliNmNjMDI3MDEvdGFibGVyYW5nZTo1ZDhjMmFiNTk3ZjI0MTEzODYxZDA2OWI2Y2MwMjcwMV8xLTEtMS0xLTU3Njc4_6cda7983-e2fa-4a81-8c3b-c9c526a38641">CMRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6NWQ4YzJhYjU5N2YyNDExMzg2MWQwNjliNmNjMDI3MDEvdGFibGVyYW5nZTo1ZDhjMmFiNTk3ZjI0MTEzODYxZDA2OWI2Y2MwMjcwMV8xLTItMS0xLTU3Njc4_0859f25b-172d-4789-a5e1-18f4a3699bcc">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTk1_20341a07-9331-48a8-9b9b-0b19371468cb">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTg4_33304586-3a45-4e3e-a422-2ed397cc9f26">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6OTI3ODlhMTk4NzlmNDQ4ZDljNGMwYmFjMzIyMWM4ODUvdGFibGVyYW5nZTo5Mjc4OWExOTg3OWY0NDhkOWM0YzBiYWMzMjIxYzg4NV8xLTAtMS0xLTU3Njc4L3RleHRyZWdpb246NTljZTE4NGNlMzdhNGI0NThkN2VkMTc5MmE2ZDVkNmVfNA_9730d6fc-63cb-4a1d-8125-b5454980a537">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6OTI3ODlhMTk4NzlmNDQ4ZDljNGMwYmFjMzIyMWM4ODUvdGFibGVyYW5nZTo5Mjc4OWExOTg3OWY0NDhkOWM0YzBiYWMzMjIxYzg4NV8xLTItMS0xLTU3Njc4L3RleHRyZWdpb246MTk4YjQwZjUxMzZmNGZiZmEwODI4ZDBjODAzNDBmNzJfMzA_5719366f-5ebb-42ec-875b-a7f0307d795b">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGFibGU6OTI3ODlhMTk4NzlmNDQ4ZDljNGMwYmFjMzIyMWM4ODUvdGFibGVyYW5nZTo5Mjc4OWExOTg3OWY0NDhkOWM0YzBiYWMzMjIxYzg4NV8yLTItMS0xLTU3Njc4L3RleHRyZWdpb246NGFkMWEwOGFhN2VlNGUxNTkxM2UxMDliZDQ3YmY2ZmVfMjg_224aff02-12ff-4fa8-95d2-a576ff98d114">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTg5_e95e35b6-1c2e-4503-904b-53be34aecb16">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i00ca283eef774858b67f6475ece947f1_I20230428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xL2ZyYWc6ZWM1NjM2Yzk5M2I2NDVlMDlkOTZmOGE3N2EzZWE4MzEvdGV4dHJlZ2lvbjplYzU2MzZjOTkzYjY0NWUwOWQ5NmY4YTc3YTNlYTgzMV8xOTg2_f434ad56-172e-45f8-abfe-92311de5f7ba"
      unitRef="shares">88583567</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMy0yLTEtMS01NzY3OA_2ca9d13b-8a62-41ca-8c02-456a6d76da22"
      unitRef="usd">15951000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMy00LTEtMS01NzY3OA_42f61638-12c8-4f37-925c-b638af0b4104"
      unitRef="usd">25842000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfNC0yLTEtMS01NzY3OA_850acd71-6ef7-424f-92ca-b8e913c6e4a8"
      unitRef="usd">198801000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfNC00LTEtMS01NzY3OA_b37c8ade-e5a3-4211-9ec6-89746a80efed"
      unitRef="usd">191492000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfNS0yLTEtMS01NzY3OA_aba5b69b-e7c7-4dea-b6cf-10d96a0c0201"
      unitRef="usd">668000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfNS00LTEtMS01NzY3OA_87245bcd-65af-4d22-8d4a-1c758f39dff4"
      unitRef="usd">1040000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfNy0yLTEtMS01NzY3OA_17cc5839-ac4a-4430-aae6-03f4b2756696"
      unitRef="usd">9330000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfNy00LTEtMS01NzY3OA_05b06319-8a82-4c8c-8f8d-a19315d0e563"
      unitRef="usd">9764000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfOC0yLTEtMS01NzY3OA_5f501abe-0a70-42e3-8ed1-0773150fc085"
      unitRef="usd">224750000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfOC00LTEtMS01NzY3OA_dacf0b5b-ed32-407b-900b-ceac5ea5054e"
      unitRef="usd">228138000</us-gaap:AssetsCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfOS0yLTEtMS01NzY3OA_d5de335b-5fc8-4ef7-a93c-1ae8e776d1c4"
      unitRef="usd">31322000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfOS00LTEtMS01NzY3OA_4c3dee56-7f93-44c5-b977-8efb9160b705"
      unitRef="usd">48626000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTAtMi0xLTEtNTc2Nzg_158fbdc7-a731-438b-bd8b-394bf9cf6a47"
      unitRef="usd">267000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTAtNC0xLTEtNTc2Nzg_518d8828-81c7-40ec-8e5f-12483422e741"
      unitRef="usd">227000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTEtMi0xLTEtNTc2Nzg_c08be86d-007b-46fa-b801-bc13fdb721e7"
      unitRef="usd">1848000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTEtNC0xLTEtNTc2Nzg_ca239b36-74d9-4c2e-92db-200b840d2546"
      unitRef="usd">1964000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTItMi0xLTEtNTc2Nzg_bd720ea7-5382-46c5-9667-39c81d3b72ab"
      unitRef="usd">346000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTItNC0xLTEtNTc2Nzg_f3aeb6ba-fe26-4221-9453-5e2ee8b87606"
      unitRef="usd">386000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTMtMi0xLTEtNTc2Nzg_2733e723-62dd-49ef-a0ec-42792a168757"
      unitRef="usd">258533000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTMtNC0xLTEtNTc2Nzg_75338131-3a5c-4a0e-9765-68538a11895d"
      unitRef="usd">279341000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTctMi0xLTEtNTc2Nzg_8b1ebc9e-851b-453a-980d-62ee86e8b9d4"
      unitRef="usd">2847000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTctNC0xLTEtNTc2Nzg_60bfbcbe-a273-42e7-8186-8c4b530f42f2"
      unitRef="usd">3034000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTgtMi0xLTEtNTc2Nzg_002b9155-1bc3-4197-8340-589241685598"
      unitRef="usd">13584000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMTgtNC0xLTEtNTc2Nzg_7eda4f01-87d3-4d6c-ae17-dafc3d0740dd"
      unitRef="usd">17381000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjEtMi0xLTEtNTc2Nzg_fee88dd9-c125-4377-86d0-5e68308bb385"
      unitRef="usd">16431000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjEtNC0xLTEtNTc2Nzg_fe2b9d4a-b9a5-4f1b-97f6-e986f7ca402a"
      unitRef="usd">20415000</us-gaap:LiabilitiesCurrent>
    <cmrx:LoanFeesLiabilityNonCurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjItMi0xLTEtNTc2Nzg_a42f6a02-2472-4038-9176-68a635c44b14"
      unitRef="usd">125000</cmrx:LoanFeesLiabilityNonCurrent>
    <cmrx:LoanFeesLiabilityNonCurrent
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjItNC0xLTEtNTc2Nzg_8061af71-920f-4345-9d09-c27ba888ac81"
      unitRef="usd">250000</cmrx:LoanFeesLiabilityNonCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjMtMi0xLTEtNTc2Nzg_ba4a5038-3f39-45e4-b16a-0decbc78d615"
      unitRef="usd">1666000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjMtNC0xLTEtNTc2Nzg_6f7fcc1b-8c9a-4e7c-bf71-0f1506babdcf"
      unitRef="usd">1819000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjQtMi0xLTEtNTc2Nzg_93e13c97-0722-48e5-b4e1-fc0a11d93e05"
      unitRef="usd">18222000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjQtNC0xLTEtNTc2Nzg_8dcae06f-d9bb-4014-b14f-729114f8e971"
      unitRef="usd">22484000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF8yMQ_6e35e955-e389-4d12-a49a-d5e559ffc31d"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF8yMQ_9d9ed04e-24c8-4210-9543-d071cb65d552"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF8zNQ_55384b2e-e33c-4cdc-946f-516b0760d6e4"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF8zNQ_b1810015-4975-493c-b28b-2cff5ab81b41"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF83MA_5d25123f-4c75-413f-820e-d340bd8297c6"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF83MA_d8b3a860-c091-459b-812b-55dbd0d9f621"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF83MA_da847bdc-1c31-4880-94c8-863fa1bcd9a8"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjoxZjYyNDM2NDUwMWQ0OGUzODJlMjcxNGVhNGRhZTM2OF83MA_e8f84e54-87ca-461b-989c-a6889bb665c3"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctMi0xLTEtNTc2Nzg_590e5c4e-20a9-408f-a1fe-1895cdeacb5a"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjctNC0xLTEtNTc2Nzg_35b37d23-6577-4ea5-bab6-709a184d312d"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV8xOA_a416b9e3-e118-4550-a25c-d47c1bb2abca"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV8xOA_fd181bea-8123-4eb1-abfb-34331a59c142"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV8zMg_07809c3a-ba58-4984-bb25-d74cc993a64b"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV8zMg_cfdb7c13-2d91-4857-a3de-dd0efff1c583"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV82Nw_01571cb4-16f8-4a13-9228-e8e4b202af62"
      unitRef="shares">88583567</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV82Nw_8141010e-23b6-4c91-831f-1fd4928e785d"
      unitRef="shares">88583567</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV83NA_3bb2d28e-8b7d-46af-946e-c446afee037f"
      unitRef="shares">88054127</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMC0xLTEtNTc2NzgvdGV4dHJlZ2lvbjo2NTJkMGE2MGIzOWQ0OGU1OTdlYzU5MDEwMjczNmFjZV83NA_e75ca9e7-9eab-4655-b2b0-49f663ca84ed"
      unitRef="shares">88054127</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtMi0xLTEtNTc2Nzg_91565acd-a684-46dc-bbde-2913285b5d53"
      unitRef="usd">89000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjgtNC0xLTEtNTc2Nzg_adb8039e-bc8f-481e-a9bb-a5bdf5886b91"
      unitRef="usd">88000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjktMi0xLTEtNTc2Nzg_e07c46ca-5106-4944-a6bc-8a9f7b2e80a0"
      unitRef="usd">975254000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMjktNC0xLTEtNTc2Nzg_7cc33eaf-4c0a-496f-8489-5bd59dd94cae"
      unitRef="usd">970535000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzAtMi0xLTEtNTc2Nzg_7a97e458-98d4-400e-9905-f1dcb0c4fc9d"
      unitRef="usd">-231000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzAtNC0xLTEtNTc2Nzg_75396688-9b3e-422d-8d08-0bdd1b0cfc08"
      unitRef="usd">-337000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzEtMi0xLTEtNTc2Nzg_23852491-88ce-4b00-bb8c-ca599c0ee989"
      unitRef="usd">-734801000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzEtNC0xLTEtNTc2Nzg_98d89fae-08cc-44d0-ab4a-c714f4896352"
      unitRef="usd">-713429000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzItMi0xLTEtNTc2Nzg_0a9cee6d-6b2a-41ca-8b16-50d016eb809c"
      unitRef="usd">240311000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzItNC0xLTEtNTc2Nzg_ecd7d169-7a36-4861-b99a-d7f5c2b69551"
      unitRef="usd">256857000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzMtMi0xLTEtNTc2Nzg_d94b3314-e50e-470c-a8e3-df4f69c99987"
      unitRef="usd">258533000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xMy9mcmFnOjgyNDNjZWEzNzc2NjQ5MjY5OTNiNzRjNmZkYjE0OTBkL3RhYmxlOjMwOWM1MTkyMWQ0YTQ5MjJiYjk3ZTA2YTBmYWZhMDIxL3RhYmxlcmFuZ2U6MzA5YzUxOTIxZDRhNDkyMmJiOTdlMDZhMGZhZmEwMjFfMzMtNC0xLTEtNTc2Nzg_b20c4423-dc93-40b1-8f8b-3017af2f2d1d"
      unitRef="usd">279341000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd4275020e18400eb3bcc3b3b804d073_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNC0yLTEtMS01NzY3OA_2a659d38-64b1-449e-8411-a4a42fb2d258"
      unitRef="usd">234000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1946ece09c904951861cbc7bb236f26e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNC00LTEtMS01NzY3OA_8c34b56b-f0b4-4f0f-aaaa-86d4fca1a144"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2cbb7f16c184e0ca3be6befb0a3c161_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNS0yLTEtMS01NzY3OA_62506264-5c2a-4722-bf98-21a2b4ae6500"
      unitRef="usd">49000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6258f7ba70a2429d893b0989f0d4e545_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNS00LTEtMS01NzY3OA_d4e27c88-7b54-43cd-8b6c-bacdcde65731"
      unitRef="usd">15000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNi0yLTEtMS01NzY3OA_de5542db-a71f-46d8-a533-45049a6c48f0"
      unitRef="usd">283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNi00LTEtMS01NzY3OA_2c18373d-b730-46f1-becb-067ecdbab652"
      unitRef="usd">15000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNy0yLTEtMS01NzY3OA_838a4fa4-b337-4a67-903a-0ceeb2aac652"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfNy00LTEtMS01NzY3OA_5242fba7-790c-4ae6-8298-bea3582bf3a2"
      unitRef="usd">114000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfOC0yLTEtMS01NzY3OA_1dff1ebb-b719-4ea5-93a9-03551dcfd218"
      unitRef="usd">283000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfOC00LTEtMS01NzY3OA_9d110c12-fb12-41a2-8d93-35ad00f0d3c4"
      unitRef="usd">-99000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTAtMi0xLTEtNTc2Nzg_592f7ead-0d0f-4c01-8ed9-8d7d921e3e7d"
      unitRef="usd">18822000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTAtNC0xLTEtNTc2Nzg_9713037b-266f-452f-ba63-31ecd37a1cf2"
      unitRef="usd">19040000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTEtMi0xLTEtNTc2Nzg_582c0643-f255-4353-b9b7-689aed7d264a"
      unitRef="usd">5679000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTEtNC0xLTEtNTc2Nzg_b8f1d565-1a1a-493b-acfd-c7b0a47e4b76"
      unitRef="usd">5632000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTMtMi0xLTEtNTc2Nzg_eda00beb-665f-46a2-b163-ce903768eeed"
      unitRef="usd">24501000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTMtNC0xLTEtNTc2Nzg_f7e2b21a-7631-4779-b57b-49dfc9141554"
      unitRef="usd">24672000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTQtMi0xLTEtNTc2Nzg_f9a0e62a-98de-488b-898e-006de9aaa64a"
      unitRef="usd">-24218000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTQtNC0xLTEtNTc2Nzg_bd6d98d0-5ea3-4187-b741-ed8619a2a906"
      unitRef="usd">-24771000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTctMi0xLTEtNTc2Nzg_d7641584-ba34-4706-84db-c2f14204cef8"
      unitRef="usd">2846000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMTctNC0xLTEtNTc2Nzg_8baa6131-2571-434e-9de8-29d0b561958b"
      unitRef="usd">4000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjEtMi0xLTEtNTc2Nzg_28a1a8c8-8db1-4657-a527-9aa4416ab8a9"
      unitRef="usd">-21372000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjEtNC0xLTEtNTc2Nzg_28764e30-c18c-4ed5-8003-b6a4322917b3"
      unitRef="usd">-24767000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjMtMi0xLTEtNTc2Nzg_649ae1aa-d6e0-4ea5-8736-daddc130dbc8"
      unitRef="usd">106000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjMtNC0xLTEtNTc2Nzg_b45249e5-e4fa-4ea0-9e46-571f6f7e167a"
      unitRef="usd">-52000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjQtMi0xLTEtNTc2Nzg_ce920f90-f350-4070-9352-380089f61404"
      unitRef="usd">-21266000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjQtNC0xLTEtNTc2Nzg_d810b5e7-a40d-4a24-9b25-b7c297718d90"
      unitRef="usd">-24819000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjYtMi0xLTEtNTc2Nzg_3f5d9fda-5cb3-448f-a224-3ce4fb1a5f4c"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjYtMi0xLTEtNTc2Nzg_63a4d5eb-d4e9-418f-b5c5-9cc1baf9158f"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjYtNC0xLTEtNTc2Nzg_bb123421-bafb-46d6-99cd-513ba05ce289"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjYtNC0xLTEtNTc2Nzg_eab7f8ef-1e4b-466e-9f6b-c54f790d1a16"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjktMi0xLTEtNTc2Nzg_524127b3-b663-4c63-987a-e816fdc1c01d"
      unitRef="shares">88294624</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjktMi0xLTEtNTc2Nzg_cd817d03-2a27-4c5e-a06b-af7ef99d93d2"
      unitRef="shares">88294624</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjktNC0xLTEtNTc2Nzg_dbc9ac26-f965-41ce-97c1-5c9a5469f964"
      unitRef="shares">87088804</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xNi9mcmFnOjA2ZjVkODJlODE1MDQwYzViYjcxODFjMWI1NzExNmYzL3RhYmxlOjEwMzEyN2JlN2JhZDQxNjQ5Mzc0MDgxNWY5ZGY5MGNmL3RhYmxlcmFuZ2U6MTAzMTI3YmU3YmFkNDE2NDkzNzQwODE1ZjlkZjkwY2ZfMjktNC0xLTEtNTc2Nzg_fcdd3845-9199-445c-8726-c629a9067b34"
      unitRef="shares">87088804</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia4f4cba41ac745a2873593ff4a0af42c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMi0xLTEtMS01NzY3OA_6153deea-3331-4821-a991-79e174ada623"
      unitRef="shares">88054127</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia4f4cba41ac745a2873593ff4a0af42c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMi0zLTEtMS01NzY3OA_f470e7c1-7ce8-455a-951c-fe8ec359933b"
      unitRef="usd">88000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i78825b0461dd42a184dfa832830bb172_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMi01LTEtMS01NzY3OA_b84211e7-a3ac-4dc7-aafd-bd352338e89b"
      unitRef="usd">970535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iee7e43b8df1e40e2838c78908a8c90a6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMi03LTEtMS01NzY3OA_e9275a49-2dfd-4a26-b065-b44e2947630a"
      unitRef="usd">-337000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iea3aca87c515473fb5fb58cb32a3ecaf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMi05LTEtMS01NzY3OA_b53271a2-5450-4c41-8c3d-bad877483a3a"
      unitRef="usd">-713429000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMi0xMS0xLTEtNTc2Nzg_5e931020-224f-43e8-9a48-07b5aa13743f"
      unitRef="usd">256857000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i88f8447d733347d58c5c02338a641fca_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMy01LTEtMS01NzY3OA_765503c2-c012-4004-bb76-bba188271a6e"
      unitRef="usd">4363000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMy0xMS0xLTEtNTc2Nzg_9d551830-0104-4397-9f8e-fc9911b1c334"
      unitRef="usd">4363000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i16d995cc04da4cafbe2ba9be78b1c72b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfNS0xLTEtMS01NzY3OA_b314f70a-28d3-4a10-b742-9c6b8f13eae3"
      unitRef="shares">308000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i16d995cc04da4cafbe2ba9be78b1c72b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfNS0zLTEtMS01NzY3OA_cd2df34a-cf30-46a7-a4ec-23da68b981fd"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i88f8447d733347d58c5c02338a641fca_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfNS01LTEtMS01NzY3OA_70847b51-f5dc-4bbc-ba6b-b454c114ce77"
      unitRef="usd">356000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfNS0xMS0xLTEtNTc2Nzg_d8945224-8fea-49d0-a906-854cdfcf5e11"
      unitRef="usd">357000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i16d995cc04da4cafbe2ba9be78b1c72b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfNi0xLTEtMS01NzY3OA_28963a02-a4fb-4b11-ae6a-423423775097"
      unitRef="shares">221440</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iaea1f9ee2956448baa9ee91273abae28_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTAtNy0xLTEtNTc2Nzg_33462300-7186-4499-9d0b-a5d7391382ad"
      unitRef="usd">106000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTAtMTEtMS0xLTU3Njc4_7c4dcd72-e73e-4f86-9f09-e6f01f6c4db5"
      unitRef="usd">106000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i3dab6564bb614134994df6db247ed37a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTEtOS0xLTEtNTc2Nzg_03cf1fab-88b4-4127-b2d7-245e5a99ff4b"
      unitRef="usd">-21372000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTEtMTEtMS0xLTU3Njc4_068f66f9-311c-42c3-a520-44fd67c907fd"
      unitRef="usd">-21372000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTItMTEtMS0xLTU3Njc4_ac506b4d-954d-40e3-bed3-67017e78edbf"
      unitRef="usd">-21266000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icd0a1f31f73c41a7a5ec947966979961_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTMtMS0xLTEtNTc2Nzg_51f49506-2e29-4882-a215-5f0708ee535f"
      unitRef="shares">88583567</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icd0a1f31f73c41a7a5ec947966979961_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTMtMy0xLTEtNTc2Nzg_a7c290be-48d4-4dcd-af62-4108bd3dff2c"
      unitRef="usd">89000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i03f11fe9d82e47fd898e0f573563fa9b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTMtNS0xLTEtNTc2Nzg_5008a90b-dab3-4c18-a503-f986483fc1c1"
      unitRef="usd">975254000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id1f10aa7207a45ec828484d3d85f7316_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTMtNy0xLTEtNTc2Nzg_2ac9ae7b-c17c-4cdd-8b7d-13a77effc094"
      unitRef="usd">-231000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i03c8e1a7f33e40d49435c773a7314a83_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTMtOS0xLTEtNTc2Nzg_718da81f-b532-4ba9-bfc3-a42923d0eaa6"
      unitRef="usd">-734801000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8xOS9mcmFnOmI3ZTMzNDBmMjkwNTQ3NDg5OGRjMGY3YjNiYjU1ZTU2L3RhYmxlOmRlYjk0ZWNhMTMwMjRkYTg5ZGEzZTI0ZGFlOTJjMjRhL3RhYmxlcmFuZ2U6ZGViOTRlY2ExMzAyNGRhODlkYTNlMjRkYWU5MmMyNGFfMTMtMTEtMS0xLTU3Njc4_a94e436f-8237-4ca5-a903-be343cf69477"
      unitRef="usd">240311000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i84561bae0aa74e99990371324cca219c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMi0xLTEtMS01NzY3OA_aad25472-93be-442c-bf69-cb217a37de51"
      unitRef="shares">86884266</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i84561bae0aa74e99990371324cca219c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMi0zLTEtMS01NzY3OA_c865a15f-2cd1-40aa-a006-641ed7a8def5"
      unitRef="usd">87000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1d07e6b250054a5da85d70f2553d7020_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMi01LTEtMS01NzY3OA_a3150805-0fa3-44e9-8c87-262ca1a07bbd"
      unitRef="usd">953782000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i28c9d91d02cb4b33936d8547b6f48fc3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMi03LTEtMS01NzY3OA_9abd0546-61f5-41f6-8f8e-1d002a592ba8"
      unitRef="usd">-21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i796ee983b1a3444ba7cc01d9c90293e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMi05LTEtMS01NzY3OA_5045cecc-52d6-46f2-a97d-0891d8863b14"
      unitRef="usd">-885596000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6de410df18e74128ab476b930f4658bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMi0xMS0xLTEtNTc2Nzg_9e6b8334-c56a-4c06-84e1-367007db0221"
      unitRef="usd">68252000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if412d998e56846989f5ae6842d1e08f4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMy01LTEtMS01NzY3OA_fb863cd8-9446-4625-8c47-41aec82be020"
      unitRef="usd">3708000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMy0xMS0xLTEtNTc2Nzg_38180e6d-531e-4746-9552-aa38ceb3bd12"
      unitRef="usd">3708000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i44a6ce80a0054a1c81b01150954b377c_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfNC0xLTEtMS01NzY3OA_a8fa2591-1a6a-47d8-a72e-873d6261e1bc"
      unitRef="shares">34406</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if412d998e56846989f5ae6842d1e08f4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfNC01LTEtMS01NzY3OA_835ffbd7-3b5a-4769-aff5-9427fb155d43"
      unitRef="usd">102000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfNC0xMS0xLTEtNTc2Nzg_5a8dfd7e-b8bc-4d11-8534-3a69867b009c"
      unitRef="usd">102000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i44a6ce80a0054a1c81b01150954b377c_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfNS0xLTEtMS01NzY3OA_c597a0c7-fe6b-4763-bc78-5616ad9a7835"
      unitRef="shares">383981</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if412d998e56846989f5ae6842d1e08f4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfNS01LTEtMS01NzY3OA_9ba0dd17-00ee-46ea-a053-f7b93e4a20e6"
      unitRef="usd">555000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfNS0xMS0xLTEtNTc2Nzg_0aeb2bb9-e15c-4e9b-83ef-005a271ec9f4"
      unitRef="usd">555000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i44a6ce80a0054a1c81b01150954b377c_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfNi0xLTEtMS01NzY3OA_18d25386-edb8-4c15-a85e-47b04865f66b"
      unitRef="shares">133527</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic5a7585076314ed6a713d0ca7be1cc36_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTAtNy0xLTEtNTc2Nzg_b78e5116-f395-4de5-b502-e9ff6c932560"
      unitRef="usd">-52000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTAtMTEtMS0xLTU3Njc4_908dc25a-097e-4650-9d82-8fb161b6a83c"
      unitRef="usd">-52000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="if5551887562a49f8bc19f22a00cfe692_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTEtOS0xLTEtNTc2Nzg_2b619cae-fd7b-4824-9e1d-da5f6e57d368"
      unitRef="usd">-24767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTEtMTEtMS0xLTU3Njc4_c3ea1be8-1b49-455b-b4e0-77d61b7ac6bf"
      unitRef="usd">-24767000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTItMTEtMS0xLTU3Njc4_cebd7dc4-7a72-4b3f-9b44-0c83ea1917d8"
      unitRef="usd">-24819000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5542e921d03d486d97066d5da0dd33dd_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTMtMS0xLTEtNTc2Nzg_d0ce03c8-88d8-41c8-9b41-6063a8f68552"
      unitRef="shares">87436180</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5542e921d03d486d97066d5da0dd33dd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTMtMy0xLTEtNTc2Nzg_6a055bfb-c2dd-4def-8ea7-c7a9b9e1441f"
      unitRef="usd">87000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icd9e7194f06647efb45e1a08985ba180_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTMtNS0xLTEtNTc2Nzg_88169bd4-634b-447d-8452-38151c5a3aed"
      unitRef="usd">958147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6877193126b044118b28af082201f8d3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTMtNy0xLTEtNTc2Nzg_8a0b019f-d1a0-45f9-9881-90cd10a02c29"
      unitRef="usd">-73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8e69b868007a4b97aafa93214a71b658_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTMtOS0xLTEtNTc2Nzg_b3bc7520-c4b7-4881-8bab-9d59d2594f4f"
      unitRef="usd">-910363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c9fa7eab31843dd898750d8c76cfcf9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yMi9mcmFnOjgzMDRiMGMxOGE2NTQ2MzE4ODExZmIxYjZjMDA4MWE5L3RhYmxlOjJhYmQyNDk0NzA0ZjQ3NGM5ZTE2YTA2YjRiNDM4ODcxL3RhYmxlcmFuZ2U6MmFiZDI0OTQ3MDRmNDc0YzllMTZhMDZiNGI0Mzg4NzFfMTMtMTEtMS0xLTU3Njc4_63996401-b5c2-4ec0-ab83-4bdf922e86c6"
      unitRef="usd">47798000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMy0yLTEtMS01NzY3OA_c341df24-2822-48bd-9d9a-b2009cf3b06a"
      unitRef="usd">-21372000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMy00LTEtMS01NzY3OA_21cd03cc-9b09-4f21-8d8d-49f6a6c2bf42"
      unitRef="usd">-24767000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNS0yLTEtMS01NzY3OA_cd67d46c-209b-4297-98df-cfc82d3720bc"
      unitRef="usd">22000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNS00LTEtMS01NzY3OA_ebbbf163-20ce-46c8-80dd-bb77ef8a1146"
      unitRef="usd">24000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNi0yLTEtMS01NzY3OA_a8e02682-993b-4b76-90a1-6efc1d450b64"
      unitRef="usd">66000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNi00LTEtMS01NzY3OA_8f8fdc8b-1b10-4b35-90db-5a24c2ac0bc7"
      unitRef="usd">33000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNy0yLTEtMS01NzY3OA_7c8000f6-59ce-42a6-a6b3-cf106bdf1c12"
      unitRef="usd">2096000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNy00LTEtMS01NzY3OA_cb66138b-cb43-49b3-aee7-f7071eb33e9a"
      unitRef="usd">-53000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfOC0yLTEtMS01NzY3OA_ae9ff67c-6c41-4835-b175-d2224c16054c"
      unitRef="usd">4363000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfOC00LTEtMS01NzY3OA_2075a33f-0b1c-40a9-b70e-342147b5bebf"
      unitRef="usd">3708000</us-gaap:ShareBasedCompensation>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTMtMi0xLTEtNTc2Nzg_404780c5-150c-4f5a-a60c-113a223725c8"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTMtNC0xLTEtNTc2Nzg_b0e97684-3004-4e13-833e-d75b0af65d71"
      unitRef="usd">1000</us-gaap:RealizedInvestmentGainsLosses>
    <cmrx:OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTUtMi0xLTEtNTc2Nzg_cd6662e8-a74a-495d-ba12-a00ee35b4960"
      unitRef="usd">-20000</cmrx:OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent>
    <cmrx:OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTUtNC0xLTEtNTc2Nzg_36c95fb7-948a-49c5-9b43-47f83c12e8dc"
      unitRef="usd">63000</cmrx:OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTctMi0xLTEtNTc2Nzg_b2f13f7d-9fbb-41fa-9a59-467a0162f371"
      unitRef="usd">-371000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTctNC0xLTEtNTc2Nzg_d0b74482-130b-4791-91fa-6535138322c2"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTgtMi0xLTEtNTc2Nzg_affe98cb-2a50-4a28-90ad-62e0177918e1"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTgtNC0xLTEtNTc2Nzg_258c685d-da57-44ee-aeaf-38c10341dba9"
      unitRef="usd">646000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTktMi0xLTEtNTc2Nzg_1f54fe58-b728-42be-939e-ff59486b58fb"
      unitRef="usd">-441000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMTktNC0xLTEtNTc2Nzg_c481b8a0-43b6-4424-88a1-3bc1c5f5c015"
      unitRef="usd">1002000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjAtMi0xLTEtNTc2Nzg_933644de-e238-4c98-a596-c0d061b4d409"
      unitRef="usd">-4000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjAtNC0xLTEtNTc2Nzg_5e0374ed-5da7-4014-92d3-433c1deb2ee3"
      unitRef="usd">-912000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjItMi0xLTEtNTc2Nzg_ef685d28-f713-4b36-bf29-59d606c6f5bb"
      unitRef="usd">-22225000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjItNC0xLTEtNTc2Nzg_351bf248-c94c-4118-8fc4-0f91d0354d5e"
      unitRef="usd">-23447000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjUtMi0xLTEtNTc2Nzg_cd215f5d-5a3a-461c-bb2a-76793d11a054"
      unitRef="usd">62000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjUtNC0xLTEtNTc2Nzg_0134532e-a222-48f3-a24e-f23bacfe1c7d"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjctMi0xLTEtNTc2Nzg_b4cf8b84-653d-4f73-b008-652a53091ee6"
      unitRef="usd">0</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjctNC0xLTEtNTc2Nzg_c0791c65-a922-48f6-a151-82273fd408a3"
      unitRef="usd">5258000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjgtMi0xLTEtNTc2Nzg_2062f754-3353-4f08-891f-052b61445c34"
      unitRef="usd">6803000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjgtNC0xLTEtNTc2Nzg_4b3bb545-8164-41dd-9f1d-e4adbae427c3"
      unitRef="usd">0</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjktMi0xLTEtNTc2Nzg_90ea7ff2-d2dd-4243-aa7f-3bd28958283c"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMjktNC0xLTEtNTc2Nzg_2e32ba86-8980-479b-88fc-0635a69a7c01"
      unitRef="usd">7699000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzAtMi0xLTEtNTc2Nzg_2fab5c3b-6521-4fb9-ac81-4e3703e425f4"
      unitRef="usd">19000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzAtNC0xLTEtNTc2Nzg_8128142d-4851-42c4-be18-ba5ee0981386"
      unitRef="usd">51026000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzMtMi0xLTEtNTc2Nzg_988045c4-9f37-44b3-ab7e-790f0e1ddad9"
      unitRef="usd">12135000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzMtNC0xLTEtNTc2Nzg_16316b57-e741-48bb-b729-a7d2791a8793"
      unitRef="usd">53467000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzYtMi0xLTEtNTc2Nzg_01e22f0b-52c4-421f-ba86-6c96ddff49b0"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzYtNC0xLTEtNTc2Nzg_8db70fcd-35cd-4e5b-9f1c-299a8279c4b0"
      unitRef="usd">102000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzctMi0xLTEtNTc2Nzg_01ece5ec-3edb-4d42-8c68-c97e1353f6e8"
      unitRef="usd">356000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzctNC0xLTEtNTc2Nzg_033b0ab3-d3fc-426c-947c-06aab7afa30d"
      unitRef="usd">556000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzktMi0xLTEtNTc2Nzg_a4ad8542-d497-4d54-9f99-2b694eb395ee"
      unitRef="usd">157000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfMzktNC0xLTEtNTc2Nzg_e8ac67b6-92a1-4d51-9da9-8d506e30d9af"
      unitRef="usd">118000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDAtMi0xLTEtNTc2Nzg_874d8e45-46da-4ed5-8a6d-3183850293ea"
      unitRef="usd">0</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDAtNC0xLTEtNTc2Nzg_a21aa608-7a46-4b6e-8fec-14726f86c531"
      unitRef="usd">-14000000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDEtMi0xLTEtNTc2Nzg_11760136-cb87-41c5-a2a6-1073fea1aac5"
      unitRef="usd">199000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDEtNC0xLTEtNTc2Nzg_2c6982d2-fa1a-4eb5-8346-0b746afeb4b4"
      unitRef="usd">-13460000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDItMi0xLTEtNTc2Nzg_621ac78e-104b-44b9-b86b-f96a7c288e09"
      unitRef="usd">-9891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDItNC0xLTEtNTc2Nzg_b24e218d-3b89-431f-a308-1945f91f4564"
      unitRef="usd">16560000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDQtMi0xLTEtNTc2Nzg_ed95d22a-3901-4935-ae9c-728fe535c69a"
      unitRef="usd">25842000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6de410df18e74128ab476b930f4658bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDQtNC0xLTEtNTc2Nzg_80203605-4f7d-4759-ab75-63e1470ea5f6"
      unitRef="usd">15397000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDUtMi0xLTEtNTc2Nzg_fa8b7473-5c23-45da-94f5-4f97bada81fc"
      unitRef="usd">15951000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3c9fa7eab31843dd898750d8c76cfcf9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8yNS9mcmFnOjg2ZmIyN2RhZGZkYjQzZTZiZGZkNmI2NmFhN2E0MjJiL3RhYmxlOjM4NDRmMzgyMTUxNDQ1ZmY4MmUyNzIyNzJkMzZiODczL3RhYmxlcmFuZ2U6Mzg0NGYzODIxNTE0NDVmZjgyZTI3MjI3MmQzNmI4NzNfNDUtNC0xLTEtNTc2Nzg_baec640d-bd0a-4360-866a-180bbdb65f8e"
      unitRef="usd">31957000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0Nzc_39212364-e523-43ea-9e6b-c7a1f311345d">The Business and Summary of Significant Accounting Policies&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Chimerix is a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company&#x2019;s audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December&#160;31, 2022.&#160;In the opinion of the Company&#x2019;s management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of its financial position, operating results and cash flows for the periods presented have been included.&#160;Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the full year, for any other interim period or for any future year.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of certain financial instruments, including accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of such instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For assets and liabilities recorded at fair value, it is the Company&#x2019;s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates and are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, fair value measurements cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the calculated current or future fair values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The determination of where an asset or liability falls in the hierarchy requires significant judgment. These levels are:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and models for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:24.75pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There was no material re-measurement to fair value of financial assets and liabilities that are not measured at fair value on a recurring basis. For additional information regarding the Company&#x2019;s investments, please refer to Note 2, &#x201c;Investments.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below are tables that present information about certain assets measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active&#160;Markets&lt;br/&gt;for&#160;Identical&#160;Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="18" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active&#160;Markets&lt;br/&gt;for&#160;Identical&#160;Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. The Company begins capitalization of these inventory related costs once regulatory approval is obtained. The Company primarily uses actual costs to determine its cost basis for inventories. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On May 15, 2022, we entered into an Asset Purchase Agreement (the Asset Purchase Agreement) with an affiliate of Emergent BioSolutions Inc. (Emergent BioSolutions) for the sale of our exclusive worldwide rights to brincidofovir, including &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;TEMBEXA&#xae; and specified related assets (the Asset Sale). On September 26, 2022, we closed the Asset Sale with Emergent Biodefense Operations Lansing LLC (Emergent), an affiliate of Emergent BioSolutions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the sale of TEMBEXA to Emergent, the Company&#x2019;s inventory consisted of TEMBEXA, which was being manufactured for the treatment of smallpox for potential delivery to the Strategic National Stockpile (SNS) for the U.S. government and to other government agencies. TEMBEXA was approved by the FDA on June 4, 2021, at which time the Company began to capitalize inventory costs associated with TEMBEXA. Prior to FDA approval of TEMBEXA, all costs related to the manufacturing of TEMBEXA were charged to research and development expense in the period incurred as there was no alternative future use.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company valued its inventories at the lower of cost or estimated net realizable value. The Company determined the cost of its inventories, which included amounts related to materials, manufacturing costs, shipping and handling costs on a first-in, first-out (FIFO) basis. Work-in-process included all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods included packaged and labelled products. Title to all inventory was transferred to Emergent upon the close of the Asset Sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Retention Credit&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) passed by the United States Congress and signed by the President, the Company was eligible for a refundable employee retention credit subject to certain criteria. The Company recognized a $2.0&#160;million employee retention credit during the three months ended September 30, 2022 related to labor costs recognized during 2020 and 2021, which is recorded in prepaid expenses and other current assets. For the three months ended September 30, 2022, $1.5&#160;million was recorded as a reduction to research and development expenses and $0.5&#160;million was recorded as a reduction to general and administrative expenses. The Company has filed for refunds of the employee retention credits and as of the date of this Quarterly Report on Form 10-Q, it has received $27,000 of refunds and cannot reasonably estimate when it will receive any or all of the remaining refunds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Loan Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 31, 2022 (the Effective Date), the Company entered into a Loan and Security Agreement (the Loan Agreement), by and between the Company, as borrower, and Silicon Valley Bank, now a division of First-Citizens Bank &amp;amp; Trust Company, as the lender (the Lender). The Loan Agreement provides for a four-year secured revolving loan facility (the Credit Facility) in an aggregate principal amount of up to $50.0&#160;million. Proceeds from the Credit Facility may be used for working capital and general corporate purposes. The Company has no obligation to draw down any amount under the Credit Facility, and has not drawn down any amount as of March&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, in connection with the Asset Sale, the Lender and the Company agreed to suspend the availability of future advances under the Loan Agreement until such time the parties mutually agree to amend the Loan Agreement to, among other things, adjust the borrowing base and reset the covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Credit Facility accrue interest at a floating per annum rate of the greater of (i) 1.50% above the Prime Rate (as defined below) and (ii) 4.75%. Prime Rate is defined as the rate of interest per annum published in The Wall Street Journal or any successor publication thereto as the &#x201c;Prime Rate&#x201d;. If such rate of interest from The Wall Street Journal becomes unavailable, the &#x201c;Prime Rate&#x201d; shall mean the rate of interest per annum announced by the Lender as its prime rate in effect. In each case, in the event such prime rate is less than zero, such rate shall be deemed to be zero for purposes of the Loan Agreement. The Company must also pay an unused line fee equal to 0.25% per annum on the unused portion of the Credit Facility, payable quarterly in arrears. Upon the termination of the Loan Agreement for any reason prior to the Maturity Date, the Company will be required to pay to the Lender an early termination fee of $0.5&#160;million. The Loan Agreement also requires the Company to pay the Lender a non-refundable commitment fee of $0.5&#160;million, payable in four equal installments beginning on the Effective Date and each anniversary of the Effective Date thereafter until January 31, 2025. As of March&#160;31, 2023, the Company has recorded current deferred loan costs of $0.1&#160;million in prepaid expenses and other current assets and non-current deferred loan costs of $0.3&#160;million in other long-term assets on the Consolidated Balance Sheets. As of March&#160;31, 2023, the Company has recorded a current loan fee liability of $0.2&#160;million in accrued liabilities and a non-current loan fee liability of $0.1&#160;million in loan fees on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Policy&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s revenues generally consist of  (i) contract and grant revenue&#x2014;revenue generated under federal and private foundation grants and contracts, (ii) licensing revenue&#x2014;revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements (iii) royalty revenue&#x2014;revenue related to sales of TEMBEXA made by Emergent after the Asset Sale, and (iv) procurement revenue&#x2014;revenue related to sales of TEMBEXA prior to the Asset Sale. Revenue is recognized in accordance with the criteria outlined in Accounting Standards Codification (ASC) 606 issued by the Financial Accounting Standards Board (FASB). Following this accounting pronouncement, a five-step approach is applied for recognizing revenue, including (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Emergent BioSolutions, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On September 26, 2022, the Company completed the Asset Sale to Emergent of the Company&#x2019;s exclusive worldwide rights to brincidofovir, including TEMBEXA&#xae; and specified related assets (the Asset Sale). Emergent paid the Company an upfront cash payment of approximately $238&#160;million upon the closing of the Asset Sale. In addition, pursuant to the Asset Purchase Agreement, the Company is eligible to receive from Emergent: (i) up to an aggregate of approximately $124&#160;million in milestone payments payable upon the exercise of the options under the BARDA Agreement for the delivery of up to 1.7&#160;million treatment courses of tablet and suspension formulations of TEMBEXA to the U.S. government; (ii) royalty payments equal to 15% of all gross profits associated with the sales of TEMBEXA made outside of the United States during the exclusivity period of TEMBEXA on a market-to-market basis; (iii) royalty payments equal to 20% of future gross profits of TEMBEXA made in the United States associated with volumes above 1.7&#160;million treatment courses of therapy during the exclusivity period of TEMBEXA; and (iv) up to an additional $12.5&#160;million upon the achievement of certain other developmental milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The BARDA Agreement was novated to Emergent in December 2022. Under the Asset Purchase Agreement, the Company recognized $0.2&#160;million of contract revenue for expense reimbursement related to support provided to Emergent for the three months ended March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grant Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant revenue under cost-plus-fixed-fee grants from the federal government and private foundations is recognized as allowable costs are incurred and fees are earned. At March&#160;31, 2023, the Company has a deferred revenue balance of $0.1&#160;million related to these grants. For the three months ended March&#160;31, 2023, the Company recognized $30,000 of grant revenue and for the three months ended March&#160;31, 2022, the Company recognized no  grant revenue related to these grants.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ohara Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, Oncoceutics, Inc., a Delaware corporation (Oncoceutics) which was subsequently acquired by the Company in January 2021, entered into a license, development and commercialization agreement with Ohara Pharmaceutical Co., Ltd. for ONC201 in Japan. The Company is entitled to receive up to $2.5&#160;million in nonrefundable regulatory milestone payments. The Company is entitled to double-digit tiered royalties based on the aggregate annual net sales of all products, as defined in the agreement, in Japan. For the three months ended March&#160;31, 2023 and 2022, the Company recognized approximately $58,000 and $15,000, respectively, of license revenue related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TEMBEXA Procurement Agreements Revenue and Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2022, the Company entered into the Supply Agreement and the PHAC Contract (as defined in Note 6 below), pursuant to which the Company was responsible for supplying TEMBEXA (brincidofovir) treatment courses for use outside of the United States. There are no material performance obligations outside of delivery in the agreements, therefore revenue related to these procurement agreements was recognized when the delivery performance obligation was satisfied. Revenue was recognized based on price per treatment course as outlined in the agreements.  For the three months ended September 30, 2022, the Company recognized $32.0&#160;million of procurement revenue related to these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The remaining deliveries of treatment courses related to the PHAC Contract were delivered by Emergent and were subject to the royalty terms of the Asset Purchase Agreement applicable to gross profits outside the United States. The Company recognized approximately $0.4&#160;million of royalty revenue in the three months ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Prepaids and Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its research and development efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s objective is to reflect the appropriate research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of its research and development efforts. The Company determines prepaid and accrual estimates through discussion with applicable personnel and outside service providers as to the progress or state of communication of clinical trials, or other services completed. The Company adjusts its rate of research and development expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. Through March&#160;31, 2023, there had been no material adjustments to the Company&#x2019;s prior period estimates of prepaid and accruals for research and development expenses. The Company&#x2019;s research and development prepaids and accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Net Income (Loss) Per Share of Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period, excluding the dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights. Diluted net income (loss) per share of common stock is computed by dividing net income (loss) by the sum of the weighted-average number of shares of common stock outstanding during the period plus the potential dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights outstanding during the period calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during the periods of net loss, there was no difference between basic and diluted loss per share of common stock for the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In addition to estimates discussed in other sections of this Quarterly Report on Form 10-Q, the most significant estimates in the Company&#x2019;s consolidated financial statements relate to the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in only one segment, pharmaceuticals. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impact of Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the impairment model by requiring entities to use a forward-looking approach on expected losses to estimate credit losses on certain financial instruments, including trade receivables and available-for-sale debt securities. The new guidance was originally due to become effective for the Company beginning in the first quarter of 2020, however the FASB in November 2019 issued ASU 2019-10 which moved the effective date for smaller reporting companies to the first quarter of 2023. The Company adopted ASU 2016-03 as of January 1, 2023. Given the nature of the Company&#x2019;s receivables and investment portfolio, adoption of this standard had no impact on the Company's financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0OTI_aaf58cc5-514d-4308-850b-69bd04203442">Basis of PresentationThe accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company&#x2019;s audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December&#160;31, 2022.&#160;In the opinion of the Company&#x2019;s management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of its financial position, operating results and cash flows for the periods presented have been included.&#160;Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the full year, for any other interim period or for any future year.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0NDg_6d75765a-cd12-4359-a505-d6b3b1d43bfc">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of certain financial instruments, including accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of such instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For assets and liabilities recorded at fair value, it is the Company&#x2019;s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates and are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, fair value measurements cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the calculated current or future fair values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The determination of where an asset or liability falls in the hierarchy requires significant judgment. These levels are:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and models for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:24.75pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There was no material re-measurement to fair value of financial assets and liabilities that are not measured at fair value on a recurring basis. For additional information regarding the Company&#x2019;s investments, please refer to Note 2, &#x201c;Investments.&#x201d;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0ODM_15e3250e-a530-4ec3-b107-119aaace8043">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below are tables that present information about certain assets measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active&#160;Markets&lt;br/&gt;for&#160;Identical&#160;Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="18" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active&#160;Markets&lt;br/&gt;for&#160;Identical&#160;Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1192c9f83b36465e8f80e3685ed58c8b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNC0xLTEtMS01NzY3OA_ad9e26ec-a91b-4d86-8b2b-a56bf1550910"
      unitRef="usd">13272000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2ffd7159be8e43f19e53d050ecbf41ae_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNC0zLTEtMS01NzY3OA_912c1422-915b-436c-aae3-31d895751890"
      unitRef="usd">13272000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i20743e8f7f174eeeadbd88e1c7f0cc12_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNC01LTEtMS01NzY3OA_ce551013-36fb-402b-b5c2-72468c1b9baa"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i20f3f186e36448f5b3a63b9e3b863269_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNC03LTEtMS01NzY3OA_5b692765-2d93-4572-9003-e58d960ef9f5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i804d7d03889847d5ae48e5ad93dbb50f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfOS0xLTEtMS01NzY3OA_b723e719-b9d1-42c3-868d-d00b2d232c3e"
      unitRef="usd">13272000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i887daef78c58443e893277334452edbc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfOS0zLTEtMS01NzY3OA_a5efc4d8-ee3d-404e-a972-203507a60ffc"
      unitRef="usd">13272000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8ade65735c9545f2a12dec9f4312f6cd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfOS01LTEtMS01NzY3OA_21aceab3-f714-454b-930f-528b0c54977f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id7c60bf2d7ba4e96bf4498b8f2014d16_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfOS03LTEtMS01NzY3OA_b4a3b552-33ec-4bfb-bd8d-f327f91609a9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ib107a3ac2180405c9d10f438e8b18db3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTItMS0xLTEtNTc2Nzg_998ccc8c-95f1-43ad-b0a5-bcf98e31f3be"
      unitRef="usd">60747000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="id189accf19a84607a3af2777ead773ad_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTItMy0xLTEtNTc2Nzg_368d88ec-257f-4ed0-90da-13de65ed19a3"
      unitRef="usd">26463000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ic51cb125601349b8b451af99cb1a781a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTItNS0xLTEtNTc2Nzg_e86f5ddf-0dd9-415b-ae45-1ce3c28f1b13"
      unitRef="usd">34284000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i39e8a7b56d01472097cdbcd15bfb49c6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTItNy0xLTEtNTc2Nzg_c305d262-09b2-4158-91e9-625810c4fb56"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ib0c0f4bcdd5c402e9040e2f3d650afb7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTQtMS0xLTEtNTc2Nzg_7d8c9c09-5570-4c64-ab2c-33c437810983"
      unitRef="usd">115016000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ic5037b9b3c73466389a40771e5177e59_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTQtMy0xLTEtNTc2Nzg_40abfcb8-b285-4d4d-a20a-dcc4cbe30613"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ifedf03aebe3b4bc78bfbfef940377a97_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTQtNS0xLTEtNTc2Nzg_a9df39eb-72a7-47ee-be4f-bb4d39fe817f"
      unitRef="usd">115016000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i8ff2067d964e4f6eb5c4572c7df44ff5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTQtNy0xLTEtNTc2Nzg_4c46c8c0-f21e-45fe-9027-d58368a63aba"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ib5a617b479c5421ab4085ecb7805f41b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTUtMS0xLTEtNTc2Nzg_58399088-d21c-4554-891b-9beadebd5b9f"
      unitRef="usd">23038000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i3b72ea3730984bc299a26ec655d2be77_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTUtMy0xLTEtNTc2Nzg_9340258d-b6ec-4db7-a7d6-094f5d68c264"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i550880ea43424204a2167a6dad7fc32f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTUtNS0xLTEtNTc2Nzg_59254bcf-5bb6-428d-9e4d-56e5e6b8d4ff"
      unitRef="usd">23038000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ic9aa19420d064b6ea99c0aef9e593870_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTUtNy0xLTEtNTc2Nzg_3b1a0fdc-e684-431c-b99b-284aeba33347"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i804d7d03889847d5ae48e5ad93dbb50f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTYtMS0xLTEtNTc2Nzg_28c4764d-f7aa-47ab-9027-79b4bce6ac47"
      unitRef="usd">198801000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i887daef78c58443e893277334452edbc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTYtMy0xLTEtNTc2Nzg_2ab7ad89-0250-4950-8f3c-d345b5420ae3"
      unitRef="usd">26463000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i8ade65735c9545f2a12dec9f4312f6cd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTYtNS0xLTEtNTc2Nzg_cdb722a6-95ae-4746-9557-ca955d9e0a96"
      unitRef="usd">172338000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="id7c60bf2d7ba4e96bf4498b8f2014d16_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTYtNy0xLTEtNTc2Nzg_a49fdd9a-e537-4f06-aa48-2b54ef456ca2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="ib107a3ac2180405c9d10f438e8b18db3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTktMS0xLTEtNTc2Nzg_9a624034-a6dd-4f25-99b9-f04215807187"
      unitRef="usd">31322000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="id189accf19a84607a3af2777ead773ad_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTktMy0xLTEtNTc2Nzg_2c186d77-cee5-41fa-8688-6efef448fced"
      unitRef="usd">10278000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="ic51cb125601349b8b451af99cb1a781a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTktNS0xLTEtNTc2Nzg_ff98b07f-098d-4671-852c-924dd4e43be6"
      unitRef="usd">21044000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="i39e8a7b56d01472097cdbcd15bfb49c6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMTktNy0xLTEtNTc2Nzg_6eabfd3a-4c74-4ec9-85cb-11c77e4e4d20"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="i804d7d03889847d5ae48e5ad93dbb50f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjAtMS0xLTEtNTc2Nzg_ede7f3b7-e17d-409f-8d39-ecad718a86f4"
      unitRef="usd">31322000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="i887daef78c58443e893277334452edbc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjAtMy0xLTEtNTc2Nzg_d5106be5-c438-4d2c-b712-20fc80279b1f"
      unitRef="usd">10278000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="i8ade65735c9545f2a12dec9f4312f6cd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjAtNS0xLTEtNTc2Nzg_5550e16b-a276-43ef-acbc-750d01bf24d6"
      unitRef="usd">21044000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="id7c60bf2d7ba4e96bf4498b8f2014d16_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjAtNy0xLTEtNTc2Nzg_8953f10e-e864-4e6f-89f1-b3a6ff1bb63e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i804d7d03889847d5ae48e5ad93dbb50f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjEtMS0xLTEtNTc2Nzg_98be16c7-a528-4530-88dd-a9744d5777eb"
      unitRef="usd">243395000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i887daef78c58443e893277334452edbc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjEtMy0xLTEtNTc2Nzg_42159dff-3ac1-4c48-92bc-025b7bbd5427"
      unitRef="usd">50013000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8ade65735c9545f2a12dec9f4312f6cd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjEtNS0xLTEtNTc2Nzg_e9ad6493-31aa-4f42-91ae-f9f74e725ebe"
      unitRef="usd">193382000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id7c60bf2d7ba4e96bf4498b8f2014d16_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjEtNy0xLTEtNTc2Nzg_b85b345c-27a3-43fb-a123-6852756b4381"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i15168c3e9c9e45d884e1da247a40b7ec_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjctMS0xLTEtNTc2Nzg_dd24e4c9-8bfd-43e5-b4c8-af0f3862c504"
      unitRef="usd">17826000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6e929ebf603643be9d50f1d1c81d5553_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjctMy0xLTEtNTc2Nzg_d53cd4dc-cc09-4ebe-b305-dc81e4d85ad0"
      unitRef="usd">17826000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia11f96247a744891aedb33da4b10f863_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjctNS0xLTEtNTc2Nzg_fac9eee5-cf95-4b9e-a825-979934038885"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i826e3ed6eed14f59899dfce3d3fb5ed5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjctNy0xLTEtNTc2Nzg_fe5b0b23-028b-454e-b681-7ebee92def29"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i41d1ac0e92874f2ab60e2efbc7472cb3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjktMS0xLTEtNTc2Nzg_84abfcaa-eb49-4b7c-a1aa-e19b9ef8bb00"
      unitRef="usd">4998000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iff7a494199b34fe38f094bf02e43219e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjktMy0xLTEtNTc2Nzg_0d79ace5-9abd-4fc0-9670-67fca89e3df2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id99c937daad4485a99236d4462f4fe95_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjktNS0xLTEtNTc2Nzg_1f9d16d5-2215-49ce-a118-2716915c9d68"
      unitRef="usd">4998000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie06e373167d2401d87352019c0070854_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMjktNy0xLTEtNTc2Nzg_6833cf19-5e2f-4035-8267-73d9b7d8e3cd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if67b2ed977af4ca5be169e787fd04e24_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzEtMS0xLTEtNTc2Nzg_0186dda4-421d-472f-84e0-39f04ce049a0"
      unitRef="usd">22824000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic01dbb19691142bcaf240d5503fa85ce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzEtMy0xLTEtNTc2Nzg_f81772cc-dbb1-4894-8e8b-46be01471839"
      unitRef="usd">17826000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i216aa5360f47421dad09d1e2fe063cd9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzEtNS0xLTEtNTc2Nzg_9c3b4198-15ab-4dcd-859a-d0afdf587d2c"
      unitRef="usd">4998000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icfbc49f108964d9586b1fe78301cede3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzEtNy0xLTEtNTc2Nzg_d1be3403-e02a-4317-8fd5-1215e9296be0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i65078142e8c646429535c348eb43e549_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzQtMS0xLTEtNTc2Nzg_f42e1ab2-e60a-49f9-94c5-e8f2f5ab387c"
      unitRef="usd">38094000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i73233ee3c3004e849b476b2a2bdd672d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzQtMy0xLTEtNTc2Nzg_33629e72-4a8e-4ba4-82a1-4f11264d92dd"
      unitRef="usd">25271000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="iea8cb0da69264659b6fb1593ca7975a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzQtNS0xLTEtNTc2Nzg_0da34720-3390-4304-986a-ec9da0832e2a"
      unitRef="usd">12823000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i95a0ab613b064db9811414440e1df09c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzQtNy0xLTEtNTc2Nzg_d0b69d22-0e07-4764-a0c4-bca4dbd077e3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i830e14896ae3418090aea88e6361ccff_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzYtMS0xLTEtNTc2Nzg_1ff8a5aa-24e6-44e6-a76d-299bc25750f1"
      unitRef="usd">127517000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i2bb926ac6f54414ab15657d5d02f6bef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzYtMy0xLTEtNTc2Nzg_f50073ae-4b6f-41df-a164-e5696064ea6f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="iff79739385f045859d1ea7c0fd2a699e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzYtNS0xLTEtNTc2Nzg_3f253d3c-4a2d-4d7f-a8d2-ff0a843f25a5"
      unitRef="usd">127517000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i70b68c3a79434ad59d870f352df7ab52_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzYtNy0xLTEtNTc2Nzg_ad0bc65c-cb30-416d-95e0-6eb973a20ed8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ic9612d95ff6e485ab93759b9c6a1bc22_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzctMS0xLTEtNTc2Nzg_561eacd9-8bf4-4b34-8856-86e37aba49a4"
      unitRef="usd">25881000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i5cdfd50074bb4f2780f387ee055c71f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzctMy0xLTEtNTc2Nzg_9f3fcba5-5f5d-435e-bf7d-e343799586cd"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i229430736baa458696f8be14caad07c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzctNS0xLTEtNTc2Nzg_575f6b46-e9f2-4d83-8929-e35a98a2b9ed"
      unitRef="usd">25881000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i843f7d4691c94406bd8946f2730515ba_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzctNy0xLTEtNTc2Nzg_16d011e8-75c7-4bcb-a54d-aee9323edc71"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="if67b2ed977af4ca5be169e787fd04e24_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzgtMS0xLTEtNTc2Nzg_58daa351-9e8c-42ee-8749-49cb60a7949d"
      unitRef="usd">191492000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ic01dbb19691142bcaf240d5503fa85ce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzgtMy0xLTEtNTc2Nzg_f0a37326-3d65-433f-bf81-471b97f64c9a"
      unitRef="usd">25271000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i216aa5360f47421dad09d1e2fe063cd9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzgtNS0xLTEtNTc2Nzg_30385fce-e73d-4a58-a907-079700802a52"
      unitRef="usd">166221000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="icfbc49f108964d9586b1fe78301cede3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfMzgtNy0xLTEtNTc2Nzg_5317e767-941b-4be8-be33-7fad0b1c719b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="i65078142e8c646429535c348eb43e549_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDEtMS0xLTEtNTc2Nzg_4fae78c6-5a84-4e11-a456-47a2def97b9c"
      unitRef="usd">48626000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="i73233ee3c3004e849b476b2a2bdd672d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDEtMy0xLTEtNTc2Nzg_a61c86a7-fd9e-42e4-b3a7-39ab53f08017"
      unitRef="usd">11685000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="iea8cb0da69264659b6fb1593ca7975a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDEtNS0xLTEtNTc2Nzg_5410e054-1dee-4a27-b28f-2032ca59c7f8"
      unitRef="usd">36941000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="i95a0ab613b064db9811414440e1df09c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDEtNy0xLTEtNTc2Nzg_65bc9ebc-46d6-49ad-ae14-cb3d9e3b38a2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="if67b2ed977af4ca5be169e787fd04e24_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDMtMS0xLTEtNTc2Nzg_e372736c-6070-435e-9d76-6295b1b90fc0"
      unitRef="usd">48626000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="ic01dbb19691142bcaf240d5503fa85ce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDMtMy0xLTEtNTc2Nzg_662ca35c-dc57-4fca-a5a2-22c82d947101"
      unitRef="usd">11685000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="i216aa5360f47421dad09d1e2fe063cd9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDMtNS0xLTEtNTc2Nzg_8452b90d-336c-42f6-a748-2584bf7d176b"
      unitRef="usd">36941000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
      contextRef="icfbc49f108964d9586b1fe78301cede3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDMtNy0xLTEtNTc2Nzg_4975c97e-7dba-492e-ba9c-b90a2704054f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if67b2ed977af4ca5be169e787fd04e24_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDQtMS0xLTEtNTc2Nzg_3bab8ea1-ed95-4fd7-9cf4-1b98db8e65d8"
      unitRef="usd">262942000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic01dbb19691142bcaf240d5503fa85ce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDQtMy0xLTEtNTc2Nzg_557a434b-4adc-4a51-9d36-35674d4a54cb"
      unitRef="usd">54782000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i216aa5360f47421dad09d1e2fe063cd9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDQtNS0xLTEtNTc2Nzg_df56169c-c441-4e0b-a76d-24d56102f5e9"
      unitRef="usd">208160000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icfbc49f108964d9586b1fe78301cede3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjUxYWQ5YzRkMGQ4YjRhODE5ZjNjZjk2N2VkMjIwMzZlL3RhYmxlcmFuZ2U6NTFhZDljNGQwZDhiNGE4MTlmM2NmOTY3ZWQyMjAzNmVfNDQtNy0xLTEtNTc2Nzg_9be4aefd-82f0-41f6-b8b7-ec97d9c12030"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0NTk_0843c488-5f2e-4e02-9668-8c944f19e155">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. The Company begins capitalization of these inventory related costs once regulatory approval is obtained. The Company primarily uses actual costs to determine its cost basis for inventories. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On May 15, 2022, we entered into an Asset Purchase Agreement (the Asset Purchase Agreement) with an affiliate of Emergent BioSolutions Inc. (Emergent BioSolutions) for the sale of our exclusive worldwide rights to brincidofovir, including &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;TEMBEXA&#xae; and specified related assets (the Asset Sale). On September 26, 2022, we closed the Asset Sale with Emergent Biodefense Operations Lansing LLC (Emergent), an affiliate of Emergent BioSolutions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the sale of TEMBEXA to Emergent, the Company&#x2019;s inventory consisted of TEMBEXA, which was being manufactured for the treatment of smallpox for potential delivery to the Strategic National Stockpile (SNS) for the U.S. government and to other government agencies. TEMBEXA was approved by the FDA on June 4, 2021, at which time the Company began to capitalize inventory costs associated with TEMBEXA. Prior to FDA approval of TEMBEXA, all costs related to the manufacturing of TEMBEXA were charged to research and development expense in the period incurred as there was no alternative future use.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company valued its inventories at the lower of cost or estimated net realizable value. The Company determined the cost of its inventories, which included amounts related to materials, manufacturing costs, shipping and handling costs on a first-in, first-out (FIFO) basis. Work-in-process included all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods included packaged and labelled products. Title to all inventory was transferred to Emergent upon the close of the Asset Sale.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <cmrx:EmployeeRetentionCredit
      contextRef="i18d0bbe7e74a49d99423e480deb74908_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNzc3Ng_59755d32-14af-4c70-a945-838b5b1f9a42"
      unitRef="usd">2000000</cmrx:EmployeeRetentionCredit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic0b110316ee84c4196d882c915b7f130_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfODAwNw_3b2d0ece-67f4-48e1-8dc1-d433269281ee"
      unitRef="usd">-1500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic0b110316ee84c4196d882c915b7f130_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfODA3OA_846b560a-7837-4ae9-ba3f-f7d8d19c3e6c"
      unitRef="usd">-500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODQzMjcy_60c8dac1-5fa2-4122-9535-af0df8ad5a90"
      unitRef="usd">27000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:DebtInstrumentTerm
      contextRef="i3fff5d25cf6449308bcbf75364001e45_D20220131-20220131"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0NTE_14f52841-3987-4e40-96f5-1c59a0bc0a78">P4Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5f1afc1bd8bb425d867be35c0e46ed08_I20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfODc2MA_089e9d6d-ccb8-4dce-ad9f-1d030e28cae7"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i80ced39ca26c4f13818bb6d006095818_D20220131-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfOTA5Mw_5a2b4b4a-36df-4dc4-87d2-d7f3403f7572"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5f1afc1bd8bb425d867be35c0e46ed08_I20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfOTE0NQ_ee578b71-f364-41bf-95fb-916f0edc9db0"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i3fff5d25cf6449308bcbf75364001e45_D20220131-20220131"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfOTY3Ng_dfa36a2c-60d7-4a21-82f9-1ff6744e01dc"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <cmrx:DebtInstrumentEarlyTerminationFee
      contextRef="i3fff5d25cf6449308bcbf75364001e45_D20220131-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfOTkyOQ_6b62163b-b959-483d-84c9-a2a32cd5d128"
      unitRef="usd">500000</cmrx:DebtInstrumentEarlyTerminationFee>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="i3fff5d25cf6449308bcbf75364001e45_D20220131-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTAwMzE_93092901-2ef6-4294-8511-21a0175cd567"
      unitRef="usd">500000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <cmrx:DebtInstrumentNumberOfInstallmentPayments
      contextRef="i5f1afc1bd8bb425d867be35c0e46ed08_I20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTAwNDY_7d4a94ad-54d4-493c-847a-41800c54bbde"
      unitRef="installment">4</cmrx:DebtInstrumentNumberOfInstallmentPayments>
    <us-gaap:DeferredCostsCurrent
      contextRef="id5258aa58e96454ba7f47be820e18166_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTAyNDQ_3e62fb3c-245b-4c26-a688-bc4f18c9e6e2"
      unitRef="usd">100000</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCosts
      contextRef="id5258aa58e96454ba7f47be820e18166_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTAzMzE_6a105043-b069-47ba-af9a-59871d013ed6"
      unitRef="usd">300000</us-gaap:DeferredCosts>
    <cmrx:LoanFeesLiabilityCurrent
      contextRef="id5258aa58e96454ba7f47be820e18166_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTA0NjM_87135ace-77ff-4c1c-87ec-142e17e8cb77"
      unitRef="usd">200000</cmrx:LoanFeesLiabilityCurrent>
    <cmrx:LoanFeesLiabilityNonCurrent
      contextRef="id5258aa58e96454ba7f47be820e18166_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTA1Mjk_aeae8149-a7de-4139-ab97-8dbf7c9b4d9f"
      unitRef="usd">100000</cmrx:LoanFeesLiabilityNonCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0ODA_66e8e767-0aaf-4564-9989-9d4d20955dff">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cmrx:AccruedDevelopmentLiabilities
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfMS0xLTEtMS01NzY3OA_d6d17dd9-dce2-4fa5-94b7-86156f009cb2"
      unitRef="usd">7936000</cmrx:AccruedDevelopmentLiabilities>
    <cmrx:AccruedDevelopmentLiabilities
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfMS0zLTEtMS01NzY3OA_a6a812a2-e2f1-4376-a8cc-4f129fa433f1"
      unitRef="usd">6691000</cmrx:AccruedDevelopmentLiabilities>
    <us-gaap:AccruedSalariesCurrentAndNoncurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfMi0xLTEtMS01NzY3OA_686d92a5-9bc3-4722-99f6-4df01318bd07"
      unitRef="usd">3348000</us-gaap:AccruedSalariesCurrentAndNoncurrent>
    <us-gaap:AccruedSalariesCurrentAndNoncurrent
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfMi0zLTEtMS01NzY3OA_57332938-7a7e-485e-96b2-dc34a88b977a"
      unitRef="usd">6438000</us-gaap:AccruedSalariesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfNS0xLTEtMS01NzY3OA_f2986dbc-647e-4078-914c-9343162d83f9"
      unitRef="usd">2300000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfNS0zLTEtMS01NzY3OA_74cfbdde-4aff-4c05-b5ae-8861e1bb3efe"
      unitRef="usd">4252000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfNi0xLTEtMS01NzY3OA_f332bcdb-2f41-4b35-9af7-d14717adf604"
      unitRef="usd">13584000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RhYmxlOjgzMGRiM2U5MDRhNDRhNTJiYjI0NzY2ZWJjZWE1YzUyL3RhYmxlcmFuZ2U6ODMwZGIzZTkwNGE0NGE1MmJiMjQ3NjZlYmNlYTVjNTJfNi0zLTEtMS01NzY3OA_0cae9acd-0ebb-485a-b02a-d2b76c75954d"
      unitRef="usd">17381000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0ODQ_7e05a350-674a-49a6-a5b0-5c45c883f7fe">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Policy&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s revenues generally consist of  (i) contract and grant revenue&#x2014;revenue generated under federal and private foundation grants and contracts, (ii) licensing revenue&#x2014;revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements (iii) royalty revenue&#x2014;revenue related to sales of TEMBEXA made by Emergent after the Asset Sale, and (iv) procurement revenue&#x2014;revenue related to sales of TEMBEXA prior to the Asset Sale. Revenue is recognized in accordance with the criteria outlined in Accounting Standards Codification (ASC) 606 issued by the Financial Accounting Standards Board (FASB). Following this accounting pronouncement, a five-step approach is applied for recognizing revenue, including (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i39fee762c2014475826a3d701b15814d_D20220926-20220926"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODYzMzQz_178be9b4-c0db-4556-8e50-1b25f63e3f6d"
      unitRef="usd">238000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <cmrx:MaximumMilestoneProceedsUponTheExerciseOfOptions
      contextRef="ide975e55e26c4a95b067825a19f1af74_I20220926"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODYzNTI4_1b37bd57-2d9b-49ac-a603-593b573391eb"
      unitRef="usd">124000000</cmrx:MaximumMilestoneProceedsUponTheExerciseOfOptions>
    <cmrx:QuantityBenchmarkGrossProfitRoyaltyRateTrigger
      contextRef="i4febe75fb14447a39e9fe6f7451fff6c_I20220926"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODYzNjQ3_2a24fcc4-38bf-44ed-b038-31daded07536"
      unitRef="treatment">1700000</cmrx:QuantityBenchmarkGrossProfitRoyaltyRateTrigger>
    <cmrx:RevenueBenchmarkGrossProfitRoyaltyRate
      contextRef="i49c5bcc0f6e3428b874169048e2386a2_I20220926"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODYzNzcz_0f8753af-5a90-49cf-a07c-af63714ec8a3"
      unitRef="number">0.15</cmrx:RevenueBenchmarkGrossProfitRoyaltyRate>
    <cmrx:RevenueBenchmarkGrossProfitRoyaltyRate
      contextRef="ibef35d312f6649c48ca5770e34d07f53_I20220926"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODYzODkx_9c0b92e3-8e1b-4c1e-9da9-e13ffb74ca86"
      unitRef="number">0.20</cmrx:RevenueBenchmarkGrossProfitRoyaltyRate>
    <cmrx:QuantityBenchmarkGrossProfitRoyaltyRateTrigger
      contextRef="i4febe75fb14447a39e9fe6f7451fff6c_I20220926"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODYzOTgx_2a24fcc4-38bf-44ed-b038-31daded07536"
      unitRef="treatment">1700000</cmrx:QuantityBenchmarkGrossProfitRoyaltyRateTrigger>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i5668b209a8cf48ffac44b53d2385eeb5_I20220926"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODY0MDMz_39fae769-cbab-424d-9938-d21126adb426"
      unitRef="usd">12500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i8ae67a95e48a4514b6b62802563f5af0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODY1NjM2_ebb9eea9-11e7-4e64-bb4c-68b8f3b10fa7"
      unitRef="usd">200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i66e19cf7c3a84bd69adc584ad7985cb2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTUwODc_d3cd3a4b-c84a-45bf-a12e-7d19de76b577"
      unitRef="usd">100000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec10cd07bccf4bdea2cab77c4d8be033_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTUxNjY_385e97a7-d6db-4ec3-9fa3-6861f68308df"
      unitRef="usd">30000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3aced1df796f4e5d948dedb09bb1dc06_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTUyNDE_e112001d-9db2-4a16-8803-3b432eea7955"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <cmrx:LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived
      contextRef="ica04db5e597f4a148bb1cd8f8e4c8b48_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODUwNzM5_5a7f68b7-2926-46c8-8030-50415ec7de6e"
      unitRef="usd">2500000</cmrx:LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic046decd305e415f9bdb56550cc8bda5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODUwODAz_515d484c-b547-42ad-9921-a887d38706c8"
      unitRef="usd">58000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94ca8168a35a4764b28df995a789e4a5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjE5OTAyMzI5MzU4NA_db89c875-0452-49d5-9be8-41b16d079a39"
      unitRef="usd">15000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96d6a71fabac4ccbb276c7996d4a8257_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODU2ODA4_51bce884-cf8b-4576-b6de-91209ef4e553"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07e0fd7ae2114d36b0896130bfc39369_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfNTQ5NzU1ODYwOTYz_307eb884-2f5f-4bce-9456-f465bd8255d2"
      unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0NzE_1918009a-dddf-4522-9710-1e1c8d530a2e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Prepaids and Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with its research and development efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s objective is to reflect the appropriate research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of its research and development efforts. The Company determines prepaid and accrual estimates through discussion with applicable personnel and outside service providers as to the progress or state of communication of clinical trials, or other services completed. The Company adjusts its rate of research and development expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. Through March&#160;31, 2023, there had been no material adjustments to the Company&#x2019;s prior period estimates of prepaid and accruals for research and development expenses. The Company&#x2019;s research and development prepaids and accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA1MDI_d7ab77d7-324b-4050-bec0-33d17cd3dd20">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Net Income (Loss) Per Share of Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period, excluding the dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights. Diluted net income (loss) per share of common stock is computed by dividing net income (loss) by the sum of the weighted-average number of shares of common stock outstanding during the period plus the potential dilutive effects of non-vested restricted stock, stock options, and employee stock purchase plan purchase rights outstanding during the period calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during the periods of net loss, there was no difference between basic and diluted loss per share of common stock for the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0OTY_19fd9335-42ee-491a-89d4-4cebe9ca8433">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In addition to estimates discussed in other sections of this Quarterly Report on Form 10-Q, the most significant estimates in the Company&#x2019;s consolidated financial statements relate to the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0NTU_0fd0629b-dbf4-469a-9435-b748e5c8e6ce">SegmentsThe Company operates in only one segment, pharmaceuticals.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMTk1OTU_1affb8a7-9ce1-4297-b2eb-89ded2de8d28"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zMS9mcmFnOmNkOTM2MGNiZjhjYjRiNjhhNTM1NjUxM2QzMWFkYWVjL3RleHRyZWdpb246Y2Q5MzYwY2JmOGNiNGI2OGE1MzU2NTEzZDMxYWRhZWNfMjA0ODE_46235049-e065-45d4-9bd0-bc27c3386a8b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impact of Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the impairment model by requiring entities to use a forward-looking approach on expected losses to estimate credit losses on certain financial instruments, including trade receivables and available-for-sale debt securities. The new guidance was originally due to become effective for the Company beginning in the first quarter of 2020, however the FASB in November 2019 issued ASU 2019-10 which moved the effective date for smaller reporting companies to the first quarter of 2023. The Company adopted ASU 2016-03 as of January 1, 2023. Given the nature of the Company&#x2019;s receivables and investment portfolio, adoption of this standard had no impact on the Company's financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RleHRyZWdpb246ZmRlYWZmZTJjNDBhNDViOTlkMWViMjk2NDdiNzIyMjVfMTk2Mw_23e490c2-374b-431c-892d-ce3e128271e6">Investments&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following tables summarize the Company&#x2019;s debt investments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following tables summarize the Company&#x2019;s debt investments with unrealized losses, aggregated by investment type and the length of time that individual investments have been in a continuous unrealized loss position (in thousands, except number of securities):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Greater than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of securities with unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Greater than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of securities with unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, certificates of deposits, municipal and corporate notes and bonds, and commercial paper, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of two years and requires an average portfolio maturity of no more than 12 months. Some of the securities in which the Company invests may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates, among other things, the duration and extent to which the fair value of a security is less than its cost; the financial condition of the issuer and any changes thereto; and the Company&#x2019;s intent to sell, or whether it will more likely than not be required to sell, the security before recovery of its cost basis. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Unrealized gains and losses on debt investments are recorded to unrealized gain (loss) on debt investments, net in the Consolidated Statements of Operations and Comprehensive Loss. Realized gains and losses on debt investments are recorded based on specific identification to interest income and other, net in the Consolidated Statements of Operations and Comprehensive Loss. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current investments. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term investments. At March&#160;31, 2023, the Company believes that the cost of its investments is recoverable in all material &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respects. The Company recognizes interest income on an accrual basis in interest income in the Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes the scheduled maturity for the Company&#x2019;s debt investments at March&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total debt investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RleHRyZWdpb246ZmRlYWZmZTJjNDBhNDViOTlkMWViMjk2NDdiNzIyMjVfMTk1NA_5ac21c93-9c25-4e45-bfc6-d1897b7baaf9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following tables summarize the Company&#x2019;s debt investments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMi0yLTEtMS01NzY3OA_cf5871b3-0366-46c3-a589-a663862dfdf0"
      unitRef="usd">23072000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMi00LTEtMS01NzY3OA_ff575937-ce0f-477c-be2a-5b961385f9b2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMi02LTEtMS01NzY3OA_064ca16e-0ce4-4371-83dc-eda0c837947d"
      unitRef="usd">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMi04LTEtMS01NzY3OA_fc711373-d59c-4c44-b343-2c8dd177431d"
      unitRef="usd">23038000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNC0yLTEtMS01NzY3OA_40309a37-5829-429a-b387-4700362e2df7"
      unitRef="usd">92152000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNC00LTEtMS01NzY3OA_34f667d2-4c86-493f-af8e-67add72fc1bd"
      unitRef="usd">55000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNC02LTEtMS01NzY3OA_362dcf3d-ec61-4a6f-b814-10235b4691a6"
      unitRef="usd">138000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNC04LTEtMS01NzY3OA_ecadfd0f-e101-4f2c-9a91-740afaf19be1"
      unitRef="usd">92069000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNS0yLTEtMS01NzY3OA_34ede36c-c0c7-44f6-8ed0-8b2c4f9a506f"
      unitRef="usd">115130000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNS00LTEtMS01NzY3OA_8e3ee41e-16c7-4744-b89a-4929ab684765"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNS02LTEtMS01NzY3OA_637beae6-640f-4cb3-b450-5e08c38cefa9"
      unitRef="usd">123000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNS04LTEtMS01NzY3OA_04e5bb05-d6b1-43c4-99c2-112eec156a7a"
      unitRef="usd">115016000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNy0yLTEtMS01NzY3OA_5cd8f777-3ecf-4e7c-84c3-1241ff2b3917"
      unitRef="usd">230354000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNy00LTEtMS01NzY3OA_2393c544-13f6-47d5-80c3-f2755c3230b6"
      unitRef="usd">64000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNy02LTEtMS01NzY3OA_a4e01361-8a7e-40f2-adf9-22dece59d63f"
      unitRef="usd">295000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfNy04LTEtMS01NzY3OA_8e756da5-298b-403e-8437-8b08f404b008"
      unitRef="usd">230123000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTEtMi0xLTEtNTc2Nzg_f2c78a74-c404-44fc-a75e-e024108f26db"
      unitRef="usd">25906000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTEtNC0xLTEtNTc2Nzg_cd74c9d4-e142-4e55-bf05-e4a18dff06cf"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTEtNi0xLTEtNTc2Nzg_c33bd3fc-90cc-44be-9c3b-1b4fb2a91723"
      unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTEtOC0xLTEtNTc2Nzg_59b4b68d-98a3-4a77-95a1-9278b35ad382"
      unitRef="usd">25881000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTItMi0xLTEtNTc2Nzg_2149e8a5-6183-4a19-988a-0c7ec9558c7d"
      unitRef="usd">127657000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTItNC0xLTEtNTc2Nzg_a49100ea-3b3b-44fe-a5d9-e168b1648538"
      unitRef="usd">36000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTItNi0xLTEtNTc2Nzg_28b4019e-10c3-4214-bed9-4722be47783e"
      unitRef="usd">176000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTItOC0xLTEtNTc2Nzg_3cf5e8f9-e45f-487d-afee-369f288a3321"
      unitRef="usd">127517000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="id5b23ee2279148de946ebbc12395a903_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTQtMi0xLTEtNTc2Nzg_3c5ca7e8-7852-42a0-93eb-1470803e27e6"
      unitRef="usd">86892000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id5b23ee2279148de946ebbc12395a903_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTQtNC0xLTEtNTc2Nzg_c6a90806-36b3-4187-860d-c3afc307dde7"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id5b23ee2279148de946ebbc12395a903_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTQtNi0xLTEtNTc2Nzg_d21842fa-f6b4-41d3-9434-69762751d879"
      unitRef="usd">179000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id5b23ee2279148de946ebbc12395a903_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTQtOC0xLTEtNTc2Nzg_ec8e2ffe-3dcc-4d76-a2b7-eb4213f3e495"
      unitRef="usd">86720000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTYtMi0xLTEtNTc2Nzg_d295f5f0-41a2-4eef-aab8-1d55f9af58ba"
      unitRef="usd">240455000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTYtNC0xLTEtNTc2Nzg_356d3774-6188-4ba5-9d0c-5da165d18831"
      unitRef="usd">47000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTYtNi0xLTEtNTc2Nzg_cc0abbd9-519c-4600-8230-57292787616d"
      unitRef="usd">384000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjcwMTdiMThkMWFiZDQwZjdiYTExOWQ3NmE1NTBlZTgwL3RhYmxlcmFuZ2U6NzAxN2IxOGQxYWJkNDBmN2JhMTE5ZDc2YTU1MGVlODBfMTYtOC0xLTEtNTc2Nzg_406540d6-838f-4cdc-a2e9-e39590fa6813"
      unitRef="usd">240118000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RleHRyZWdpb246ZmRlYWZmZTJjNDBhNDViOTlkMWViMjk2NDdiNzIyMjVfMTk2Nw_5d1ad528-8a16-4e2b-b2b0-024d6e67c586">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following tables summarize the Company&#x2019;s debt investments with unrealized losses, aggregated by investment type and the length of time that individual investments have been in a continuous unrealized loss position (in thousands, except number of securities):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Greater than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of securities with unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Greater than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of securities with unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMy0yLTEtMS01NzY3OA_2b90816a-444d-460b-a694-7068ea8596f2"
      unitRef="usd">23038000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMy00LTEtMS01NzY3OA_77714cb2-2ecb-4aa0-ad48-9640a67fad58"
      unitRef="usd">34000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMy02LTEtMS01NzY3OA_f57b262b-03aa-4521-9e6d-75bb6789d8a1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMy04LTEtMS01NzY3OA_c7dd476b-0379-46aa-906a-225a62ccde8e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMy0xMC0xLTEtNTc2Nzg_bda84256-4dcf-4e6a-8a31-51072e43c58f"
      unitRef="usd">23038000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i81f288735d374f28b4bc08d750b772c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMy0xMi0xLTEtNTc2Nzg_aacf72bb-8675-43e1-8411-eea8ca1830fc"
      unitRef="usd">34000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNC0yLTEtMS01NzY3OA_ace6c92c-ca99-4fd9-958a-c70200ec63bc"
      unitRef="usd">85101000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNC00LTEtMS01NzY3OA_035eca0e-0f27-4d78-9637-8780d5a77af0"
      unitRef="usd">123000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNC02LTEtMS01NzY3OA_5e703abf-4b02-4216-b532-fa98c4ec9e9a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNC04LTEtMS01NzY3OA_64e92f9e-d3ad-4ef2-bcde-618dd0bc8a3b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNC0xMC0xLTEtNTc2Nzg_e292271e-8308-4e83-8ab2-0b6121a7af24"
      unitRef="usd">85101000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i26c7e37b1d0940819ffe67431c0d8379_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNC0xMi0xLTEtNTc2Nzg_8217fff6-6a19-4c49-9f22-5a58afa6c358"
      unitRef="usd">123000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNS0yLTEtMS01NzY3OA_36bd810e-5004-44f3-8715-59b267f48068"
      unitRef="usd">65693000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNS00LTEtMS01NzY3OA_2c7a2f9d-7ce1-44b7-adc0-f89ac695b317"
      unitRef="usd">138000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNS02LTEtMS01NzY3OA_7371b00d-acb9-4074-b54d-ab09b3b69aa1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNS04LTEtMS01NzY3OA_664b21b8-2cf7-4f88-bca9-b491a26f0403"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNS0xMC0xLTEtNTc2Nzg_e2c80337-723c-43d7-9129-31a6c0af7f86"
      unitRef="usd">65693000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i60cc7c18a97a43f2bc365519b6490b77_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNS0xMi0xLTEtNTc2Nzg_e222a09c-f9b4-417d-92e3-643f2b4f894a"
      unitRef="usd">138000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNy0yLTEtMS01NzY3OA_53cdaf09-fb63-4b26-afda-af304bcc34ff"
      unitRef="usd">173832000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNy00LTEtMS01NzY3OA_ee5ab528-ba5d-4851-8c25-5d6e2aa571d2"
      unitRef="usd">295000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNy02LTEtMS01NzY3OA_3725f329-9e64-4235-bca9-b45e3914d40c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNy04LTEtMS01NzY3OA_566bd6c1-422a-4bf6-b092-06a8f89b844b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNy0xMC0xLTEtNTc2Nzg_0bda7043-df86-4f05-8d41-cffba258a652"
      unitRef="usd">173832000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfNy0xMi0xLTEtNTc2Nzg_0ab6fd61-7de2-4cde-a7ae-56e124b42d4f"
      unitRef="usd">295000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfOC00LTEtMS01NzY3OA_394704f5-539e-4db6-9247-a4d17751981b"
      unitRef="security">51</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfOC04LTEtMS01NzY3OA_dd9e7a09-9612-4680-9163-d07b7b091993"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfOC0xMi0xLTEtNTc2Nzg_d7948d59-6eef-49db-a3c3-f393842493d1"
      unitRef="security">51</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTQtMi0xLTEtNTc2Nzg_2c3ef0c1-411a-473b-b745-06194fe3fb22"
      unitRef="usd">22905000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTQtNC0xLTEtNTc2Nzg_5b775ee8-7b57-420c-b9dc-68af71eed3c3"
      unitRef="usd">29000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTQtNi0xLTEtNTc2Nzg_ed020755-f5a0-46fc-b72f-592e54bb81d9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTQtOC0xLTEtNTc2Nzg_d463f7b9-f12e-457b-a26f-0c4b12d0c283"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTQtMTAtMS0xLTU3Njc4_0cfb38d5-8573-4b30-9847-d17f0f6e92b5"
      unitRef="usd">22905000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="icb7c6239239c4da7a999932e68f2b1d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTQtMTItMS0xLTU3Njc4_bbfd2618-ec2e-473e-94e5-e6f5ba1ecade"
      unitRef="usd">29000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTUtMi0xLTEtNTc2Nzg_50e469a0-edd0-45ab-9795-6e50394b8345"
      unitRef="usd">88860000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTUtNC0xLTEtNTc2Nzg_f94d0c75-fbaf-4915-bf3f-7d1963a5af84"
      unitRef="usd">176000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTUtNi0xLTEtNTc2Nzg_07247d00-c763-4a72-9eaa-9071b2c025a6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTUtOC0xLTEtNTc2Nzg_ad5638d7-ea80-4c75-8fec-ae0eac473798"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTUtMTAtMS0xLTU3Njc4_9efd89f1-1fa3-49bd-9df5-3c37a067bc61"
      unitRef="usd">88860000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i3dba971c47cd49a9bf038e8de0cfe03e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTUtMTItMS0xLTU3Njc4_fb2b8b73-eede-4f50-b1e4-b852b268f9c2"
      unitRef="usd">176000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="id5b23ee2279148de946ebbc12395a903_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTYtMi0xLTEtNTc2Nzg_76d52767-cf75-4cbe-bdfb-ecd0384f91c2"
      unitRef="usd">67489000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="id5b23ee2279148de946ebbc12395a903_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTYtNC0xLTEtNTc2Nzg_df1579c7-eafd-47d1-8831-7bdd45e756ad"
      unitRef="usd">179000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="id5b23ee2279148de946ebbc12395a903_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTYtNi0xLTEtNTc2Nzg_d0ad66a0-42d7-444e-9e7c-a3d9c3029795"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="id5b23ee2279148de946ebbc12395a903_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTYtOC0xLTEtNTc2Nzg_8fdd6a4c-3e52-477d-92dd-3829d4b4db12"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="id5b23ee2279148de946ebbc12395a903_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTYtMTAtMS0xLTU3Njc4_e9699d20-4a28-4dc8-a1f8-e4e2551304b9"
      unitRef="usd">67489000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="id5b23ee2279148de946ebbc12395a903_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTYtMTItMS0xLTU3Njc4_206b4b29-e095-4111-b40b-b35b1b9976f5"
      unitRef="usd">179000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTgtMi0xLTEtNTc2Nzg_013ac1c9-c389-4850-9569-97b96a7c3cbb"
      unitRef="usd">179254000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTgtNC0xLTEtNTc2Nzg_db25f849-2ef3-4057-8443-68405b8bf320"
      unitRef="usd">384000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTgtNi0xLTEtNTc2Nzg_8eb18c74-365b-492b-9ce1-e15e5baff85c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTgtOC0xLTEtNTc2Nzg_0b755cd1-569d-41e6-b307-7ecc9f75cf79"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTgtMTAtMS0xLTU3Njc4_3a916d0b-9405-4987-87a1-59e7656256cd"
      unitRef="usd">179254000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTgtMTItMS0xLTU3Njc4_e38f737b-1f9e-4eb3-86be-b7b810869866"
      unitRef="usd">384000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTktNC0xLTEtNTc2Nzg_6ecda088-2338-4b8b-87ba-feae05ebb76e"
      unitRef="security">55</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTktOC0xLTEtNTc2Nzg_d2c9dde2-e9f6-4688-952e-23f39e8d06e2"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOjE2MGFjZGFjNmM5ZTQwNDQ5NjQ1N2JlZmNhN2IzMzgwL3RhYmxlcmFuZ2U6MTYwYWNkYWM2YzllNDA0NDk2NDU3YmVmY2E3YjMzODBfMTktMTItMS0xLTU3Njc4_b05c0687-2bd0-4b75-8548-99d64f9c81e7"
      unitRef="security">55</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RleHRyZWdpb246ZmRlYWZmZTJjNDBhNDViOTlkMWViMjk2NDdiNzIyMjVfMTk2Mg_c92db8f7-5b35-49ea-9353-b34861bcc164">&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes the scheduled maturity for the Company&#x2019;s debt investments at March&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total debt investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOmI2NGRhYzk2OTE0NTQyZjFiN2Y5NzRhOWI2ZjE1ODEwL3RhYmxlcmFuZ2U6YjY0ZGFjOTY5MTQ1NDJmMWI3Zjk3NGE5YjZmMTU4MTBfMC0xLTEtMS01NzY3OA_b35a8cd7-a699-493d-b57a-60255381392b"
      unitRef="usd">198801000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <cmrx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOmI2NGRhYzk2OTE0NTQyZjFiN2Y5NzRhOWI2ZjE1ODEwL3RhYmxlcmFuZ2U6YjY0ZGFjOTY5MTQ1NDJmMWI3Zjk3NGE5YjZmMTU4MTBfMS0xLTEtMS01NzY3OA_a168a4ed-f052-4dfd-8c21-af3dcad15589"
      unitRef="usd">31322000</cmrx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNC9mcmFnOmZkZWFmZmUyYzQwYTQ1Yjk5ZDFlYjI5NjQ3YjcyMjI1L3RhYmxlOmI2NGRhYzk2OTE0NTQyZjFiN2Y5NzRhOWI2ZjE1ODEwL3RhYmxlcmFuZ2U6YjY0ZGFjOTY5MTQ1NDJmMWI3Zjk3NGE5YjZmMTU4MTBfMi0xLTEtMS01NzY3OA_aac9f060-1f2b-4cc7-8fd3-1606c202165e"
      unitRef="usd">230123000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMjc1Mw_be0bfa9e-3431-4cbc-9c88-0f729e2dfa67">Commitments and Contingencies &lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases its facilities under long-term operating leases that expire at various dates through 2026. The Company generally has options to renew lease terms on its facilities, which may be exercised at the Company&#x2019;s sole discretion. In addition, certain lease arrangements may be terminated prior to their original expiration date at the Company&#x2019;s discretion. The Company evaluates renewal and termination options at the lease commencement date to determine if it is reasonably certain to exercise the option and has concluded on all operating leases that it is not reasonably certain that any options will be exercised. The weighted-average remaining lease term for the Company&#x2019;s operating leases as of March&#160;31, 2023 was 3.34 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense related to leases is recorded on a straight-line basis over the lease term.  Lease expense under operating leases, including common area maintenance fees, totaled approximately $0.2 million and $0.2 million, respectively, for the three months ended March&#160;31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The discount rate implicit within the Company&#x2019;s leases is generally not determinable and therefore the Company determines the discount rate based on its incremental borrowing rate based on the information available at commencement date. As of March&#160;31, 2023, the operating lease liabilities reflect a weighted-average discount rate of 7.89%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the operating lease right-of-use assets and liabilities as of March&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfNC0wLTEtMS01NzY3OA_f81a58fa-8b97-4a63-b960-98a6f8393ce5"&gt;Operating lease short-term liabilities (recorded within Accrued liabilities)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease long-term liabilities (recorded within Lease-related obligations)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease payments over the remainder of the lease terms are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum rental payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Less amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total present value of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, operating lease payments over the remainder of the lease terms were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum rental payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Less amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total present value of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023 and 2022, the Company made lease payments of approximately $0.2 million and $0.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significance of Revenue Source&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company was the recipient of federal research contract funds from BARDA, the primary source of the Company&#x2019;s prior year contract and grant revenue. Periodic audits are required in connection with the Company&#x2019;s receipt of such funds and certain costs may be questioned as appropriate by BARDA. Accordingly, at March&#160;31, 2023 and December&#160;31, 2022, the Company had recorded a provision for potential refundable amounts of $52,000.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfNzcz_f8d2046a-b32b-4a16-a989-b327d7c543b5">P3Y4M2D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseExpense
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfOTYz_8131f2ee-eb86-4347-a542-e99471aa0263"
      unitRef="usd">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfOTcw_021669d0-9775-4e77-b790-6d52b3a3e613"
      unitRef="usd">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMTM3MA_83ff4887-3cb7-4f39-b160-e51ca1189060"
      unitRef="number">0.0789</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <cmrx:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMjc0MQ_ea9f7e81-fe03-47a8-97e4-fed100f2166a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the operating lease right-of-use assets and liabilities as of March&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfNC0wLTEtMS01NzY3OA_f81a58fa-8b97-4a63-b960-98a6f8393ce5"&gt;Operating lease short-term liabilities (recorded within Accrued liabilities)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease long-term liabilities (recorded within Lease-related obligations)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cmrx:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfMS0xLTEtMS01NzY3OA_38f95e61-5763-4dde-aba6-9a50e697d103"
      unitRef="usd">1848000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfNC0xLTEtMS01NzY3OA_f785a113-b525-4212-82c2-f16b1cd7286d"
      unitRef="usd">590000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfNS0xLTEtMS01NzY3OA_d40ba0f7-fb11-4e57-979d-c3ef2054414f"
      unitRef="usd">1666000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjA2YzYwZDUxYmRkMTRiMmViMTUxM2ZjYzE1NmZhZWExL3RhYmxlcmFuZ2U6MDZjNjBkNTFiZGQxNGIyZWIxNTEzZmNjMTU2ZmFlYTFfNi0xLTEtMS01NzY3OA_b2ddeade-349d-483b-bf5e-221c365f5a6d"
      unitRef="usd">2256000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMjc0Nw_675f4087-fccc-40c7-98a5-8e9e7c19d202">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease payments over the remainder of the lease terms are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum rental payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Less amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total present value of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, operating lease payments over the remainder of the lease terms were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum rental payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Less amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total present value of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjQ3NGE3MmY1ZDMzMDQwM2I4MTYwNzVmMTgxMmFkM2I1L3RhYmxlcmFuZ2U6NDc0YTcyZjVkMzMwNDAzYjgxNjA3NWYxODEyYWQzYjVfMy0xLTEtMS01NzY3OA_ae3b58f5-0658-4495-b243-67d0e692379d"
      unitRef="usd">555000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjQ3NGE3MmY1ZDMzMDQwM2I4MTYwNzVmMTgxMmFkM2I1L3RhYmxlcmFuZ2U6NDc0YTcyZjVkMzMwNDAzYjgxNjA3NWYxODEyYWQzYjVfNC0xLTEtMS01NzY3OA_5cc42d0b-ef47-4878-857b-7796999d0bdb"
      unitRef="usd">759000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjQ3NGE3MmY1ZDMzMDQwM2I4MTYwNzVmMTgxMmFkM2I1L3RhYmxlcmFuZ2U6NDc0YTcyZjVkMzMwNDAzYjgxNjA3NWYxODEyYWQzYjVfNS0xLTEtMS01NzY3OA_a21dd1f8-9493-4346-be15-1c67fde8f288"
      unitRef="usd">781000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjQ3NGE3MmY1ZDMzMDQwM2I4MTYwNzVmMTgxMmFkM2I1L3RhYmxlcmFuZ2U6NDc0YTcyZjVkMzMwNDAzYjgxNjA3NWYxODEyYWQzYjVfNi0xLTEtMS01NzY3OA_a2841872-fed9-4e11-8848-bc2bb7b2e4a9"
      unitRef="usd">467000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjQ3NGE3MmY1ZDMzMDQwM2I4MTYwNzVmMTgxMmFkM2I1L3RhYmxlcmFuZ2U6NDc0YTcyZjVkMzMwNDAzYjgxNjA3NWYxODEyYWQzYjVfNy0xLTEtMS01NzY3OA_6c3ecce9-a39f-4843-b1a5-f9e4d9f2a55a"
      unitRef="usd">2562000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjQ3NGE3MmY1ZDMzMDQwM2I4MTYwNzVmMTgxMmFkM2I1L3RhYmxlcmFuZ2U6NDc0YTcyZjVkMzMwNDAzYjgxNjA3NWYxODEyYWQzYjVfOC0xLTEtMS01NzY3OA_325751e6-2f34-44a0-abf0-c0434ee22b7c"
      unitRef="usd">306000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOjQ3NGE3MmY1ZDMzMDQwM2I4MTYwNzVmMTgxMmFkM2I1L3RhYmxlcmFuZ2U6NDc0YTcyZjVkMzMwNDAzYjgxNjA3NWYxODEyYWQzYjVfOS0xLTEtMS01NzY3OA_f1c33146-4fa2-4d77-80c0-c3e37506159c"
      unitRef="usd">2256000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOmRlMTFjMjc4MzE2NzQwYjc5NTEzNWUyMjU3MWU1NzA0L3RhYmxlcmFuZ2U6ZGUxMWMyNzgzMTY3NDBiNzk1MTM1ZTIyNTcxZTU3MDRfNC0xLTEtMS01NzY3OA_ed4af7b7-b25c-4df7-a679-c77686849611"
      unitRef="usd">736000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOmRlMTFjMjc4MzE2NzQwYjc5NTEzNWUyMjU3MWU1NzA0L3RhYmxlcmFuZ2U6ZGUxMWMyNzgzMTY3NDBiNzk1MTM1ZTIyNTcxZTU3MDRfNS0xLTEtMS01NzY3OA_57bd1e11-c96d-4d9c-ad3e-6c5d84de3ee4"
      unitRef="usd">759000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOmRlMTFjMjc4MzE2NzQwYjc5NTEzNWUyMjU3MWU1NzA0L3RhYmxlcmFuZ2U6ZGUxMWMyNzgzMTY3NDBiNzk1MTM1ZTIyNTcxZTU3MDRfNi0xLTEtMS01NzY3OA_c7a56233-3c76-4d0b-95c9-f1579ed7a021"
      unitRef="usd">781000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOmRlMTFjMjc4MzE2NzQwYjc5NTEzNWUyMjU3MWU1NzA0L3RhYmxlcmFuZ2U6ZGUxMWMyNzgzMTY3NDBiNzk1MTM1ZTIyNTcxZTU3MDRfNy0xLTEtMS01NzY3OA_5b17457e-bbdd-4cc1-b551-8c7e63f8afb6"
      unitRef="usd">467000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOmRlMTFjMjc4MzE2NzQwYjc5NTEzNWUyMjU3MWU1NzA0L3RhYmxlcmFuZ2U6ZGUxMWMyNzgzMTY3NDBiNzk1MTM1ZTIyNTcxZTU3MDRfOC0xLTEtMS01NzY3OA_784120c3-ea93-4735-a11c-6bd2d0bbd259"
      unitRef="usd">2743000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOmRlMTFjMjc4MzE2NzQwYjc5NTEzNWUyMjU3MWU1NzA0L3RhYmxlcmFuZ2U6ZGUxMWMyNzgzMTY3NDBiNzk1MTM1ZTIyNTcxZTU3MDRfOS0xLTEtMS01NzY3OA_fc91029a-044a-4792-9aff-db597c58ab01"
      unitRef="usd">351000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RhYmxlOmRlMTFjMjc4MzE2NzQwYjc5NTEzNWUyMjU3MWU1NzA0L3RhYmxlcmFuZ2U6ZGUxMWMyNzgzMTY3NDBiNzk1MTM1ZTIyNTcxZTU3MDRfMTAtMS0xLTEtNTc2Nzg_d09ccd7a-eed5-46f4-b64e-9fe4f7970bd2"
      unitRef="usd">2392000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMTc2Ng_893df94c-821b-4c96-8e37-5747f716a61d"
      unitRef="usd">200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMTc3Mw_5b9f3bba-684c-4c6d-9e0b-0f193905523f"
      unitRef="usd">100000</us-gaap:OperatingLeasePayments>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i9517f9ec839e440d95427249384ef67c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMjczNw_3e8ac386-8c98-4503-b41a-b9e69b4c4a03"
      unitRef="usd">52000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i342138d95ca84510be429a8206bf6d91_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl8zNy9mcmFnOmZmNjkwZDUzZDYyMTRjYjJhZjQ1NmZiZGFmNTcyOTkwL3RleHRyZWdpb246ZmY2OTBkNTNkNjIxNGNiMmFmNDU2ZmJkYWY1NzI5OTBfMjczNw_50b8af11-d282-4da4-8be5-2fb7ccd68152"
      unitRef="usd">52000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTU0NA_7702ccc4-6805-4f38-97e1-fa8cea8c0b94">Equity Transactions and Share-based Compensation&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-The-Market Equity Offering; Shelf Registration Statement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 10, 2020, we entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (the Jefferies Sales Agreement) with Jefferies LLC, as agent, pursuant to which we may offer and sell, from time to time through Jefferies, up to $75&#160;million of shares of our common stock. As of March&#160;31, 2023, we have not sold any shares of our common stock under the Jefferies Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 6, 2021, we filed an automatic shelf registration statement on Form S-3 with the SEC, which was subsequently amended in March 2022 to convert to a non-automatic shelf registration statement. This registration statement enables us to offer for sale, from time to time, in one or more offerings, up to $250&#160;million in the aggregate, of common stock, debt securities, warrants, rights and/or units, and will remain in effect for up to three years from the date it became effective.  As of March&#160;31, 2023, no sales have been made under the shelf registration statement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 2013 Equity Incentive Plan (the 2013 Plan), which provides for the grant of incentive stock options (ISOs), non-statutory stock options (NSOs), stock appreciation rights, restricted stock awards, restricted stock unit (RSU) awards, performance-based stock awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to employees, including officers, non-employee directors and consultants of the Company and its affiliates. Additionally, the 2013 Plan provides for the grant of performance cash awards. The number of shares of common stock reserved for future issuance automatically increased on January 1, 2023, by 4% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or 3.5 million shares.&#160;As of March&#160;31, 2023, there was a total of 3.0 million shares reserved for future issuance under the 2013 Plan. The Company issued no shares of common stock pursuant to the exercise of stock options during the three months ended March&#160;31, 2023. The Company issued approximately 34,000 shares of common stock pursuant to the exercise of stock options during the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 2013 Employee Stock Purchase Plan (ESPP), which provides for the issuance of shares of common stock pursuant to purchase rights granted to the Company&#x2019;s employees or to employees of any of its designated affiliates. The Company has reserved a total of 4.8 million shares of common stock to be purchased under the ESPP, of which 2.3 million shares remained available for purchase as of March&#160;31, 2023. The number of shares of common stock reserved for issuance automatically increased on January 1, 2023, by an additional 422,535 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP provides for an automatic reset feature to start participants on a new twenty-four month participation period in the event that the common stock market value on a purchase date is less than the common stock value on the first day of the twenty-four month offering period. Eligible employees may authorize an amount up to 15% of their salary to purchase common &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock at the lower of a 15% discount to the beginning price of their offering period or a 15% discount to the ending price of each six-month purchase interval. The Company issued approximately 308,000 and 384,000 shares of common stock pursuant to the ESPP during the three months ended March&#160;31, 2023 and 2022, respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#x201c;look-back&#x201d; option and were determined using a Black-Scholes option pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has issued RSUs to certain employees which vest based on service criteria. When vested, the RSU represents the right to be issued the number of shares of the Company&#x2019;s common stock that is equal to the number of RSUs granted. The grant date fair value for RSUs is based upon the market price of the Company&#x2019;s common stock on the date of the grant. The fair value is then amortized to compensation expense over the requisite service period or vesting term. The Company issued approximately 221,000 shares of common stock pursuant to the vesting of RSUs during the three months ended March&#160;31, 2023. The Company issued approximately 134,000 shares of common stock pursuant to the vesting of RSUs during the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For awards with only service conditions and graded-vesting features, the Company recognizes compensation expense on a straight-line basis over the requisite service period. Total share-based compensation expense recognized related to stock options, the ESPP and RSUs was as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2022, the Company announced a reduction in workforce. As a result, certain vested stock options were modified to extend their exercise period from 90 days to 12 months.  In addition, certain outstanding stock option and RSU grants received accelerated vesting as if the service period of the terminated employee continued for up to an additional 12-month period. The Company recorded expense ratably from the announcement date through the date of termination with approximately $0.4&#160;million being recognized during the twelve months ended December 31, 2022 and an additional $0.6&#160;million being recognized during the three months ended March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2023, the Company extended the post-termination exercise period from 90 days to three years for stock option grants made to non-employee members of our Board of Directors. This extension applies to all future grants as well as all then-outstanding grants. Related to this extension, the Company recorded approximately $0.3&#160;million of expense during the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <cmrx:SalesOfStockAuthorizedAmount
      contextRef="iaf6d919a74434c88a93c3c9563ebfc77_I20200810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTQ5NzU1ODIyOTQ0_9997aa8c-ab0f-4e5c-a564-bbc27af1c993"
      unitRef="usd">75000000</cmrx:SalesOfStockAuthorizedAmount>
    <cmrx:SalesOfStockAuthorizedAmount
      contextRef="i8d40a540d19e49cd84414a5e1c507455_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTQ5NzU1ODIyOTg1_bc978497-19b2-4e83-abfe-a08577116e04"
      unitRef="usd">250000000</cmrx:SalesOfStockAuthorizedAmount>
    <cmrx:SalesOfStockAuthorizationTerm
      contextRef="i8d40a540d19e49cd84414a5e1c507455_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTQ5NzU1ODIyOTk5_13b9aff3-5214-495b-ba9e-beb3be3ccb6a">P3Y</cmrx:SalesOfStockAuthorizationTerm>
    <cmrx:ShareBasedCompensationOptionProvisionEquityIncrease
      contextRef="i2c9f154273194565a27c741f7878e0e3_D20230101-20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMTg4MQ_da7ae116-22e0-4f84-930a-a355aad82c35"
      unitRef="number">0.04</cmrx:ShareBasedCompensationOptionProvisionEquityIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i2c9f154273194565a27c741f7878e0e3_D20230101-20230101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMjE3NQ_79415908-e189-4af6-a7e4-3a8307bf09d2"
      unitRef="shares">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i431035fe4c0e4c04baad526438084c5b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMjIxNw_a195d934-839d-49e8-b705-8b16c9a418e4"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if122bfed225d4e6b9ea7dabd81e702ef_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMjMxMA_1c036c75-fde8-4340-b2b6-67205d75b05a"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9a68a6a0ea9447b09e9381db440aee36_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMjQ1MA_afbef2e5-8f78-47ce-af23-65abc6767ed9"
      unitRef="shares">34000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ie0396b8eb64340e7b468fbedd1556a7c_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMjg3Nw_0ba98bd2-e994-4485-8e43-bb1bbc5b8e07"
      unitRef="shares">4800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ie0396b8eb64340e7b468fbedd1556a7c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMjk0NA_f6cc2d43-c389-42cf-a775-52d7ae16ad30"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i11ef95703d59450f84bcac3c8c1fe127_D20230101-20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMzQ5NA_0823b5d1-31ea-49d1-b514-6c62b18c0b70"
      unitRef="shares">422535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <cmrx:SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm
      contextRef="idff0b85443fb4b408cf3cd0b099f45c4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTU0NQ_0eeba2b5-3e9f-4877-a9c9-aee2e7768f2b">P24M</cmrx:SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm>
    <cmrx:SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm
      contextRef="idff0b85443fb4b408cf3cd0b099f45c4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTU0OQ_c4e2c6bc-4a3e-4d5a-af2e-02ce897e9f47">P24M</cmrx:SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="ie0396b8eb64340e7b468fbedd1556a7c_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMzgxOA_9ea37612-8011-47c9-90d2-f59ca8a72573"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="idff0b85443fb4b408cf3cd0b099f45c4_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMzg4MA_e1074eb6-affc-4703-b3ea-a067d610879b"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="idff0b85443fb4b408cf3cd0b099f45c4_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfMzk0NQ_a52bdb41-0c5a-4ec9-ac69-48ca721fa00c"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <cmrx:SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval
      contextRef="idff0b85443fb4b408cf3cd0b099f45c4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTU0Mg_a6c3fd19-899b-47ca-9976-00cc2cfa12cd">P6M</cmrx:SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="idff0b85443fb4b408cf3cd0b099f45c4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNDA0Ng_2f9af444-9a93-40e3-ba51-14ce0b9e5f9d"
      unitRef="shares">308000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i6085f06cabc84a509e0e944fb745eeb7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNDA1Mw_ddd340a9-ab45-4862-93a8-e25e76361308"
      unitRef="shares">384000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNDk4OQ_8b79cbdd-f697-449b-bfa7-eb7ce000036b"
      unitRef="shares">221000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTExOA_e79de932-3e0e-4f97-b459-7fde68f630ca"
      unitRef="shares">134000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTU1MQ_13a96418-243d-4ede-9495-abb312eb5687">Total share-based compensation expense recognized related to stock options, the ESPP and RSUs was as follows (in thousands): &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i524f8a9b49ff48159693771c90e88f29_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RhYmxlOjBkM2M2NGYwMzdiNTRhZmM5MDU4ZDJiYzIwMmFkNzk5L3RhYmxlcmFuZ2U6MGQzYzY0ZjAzN2I1NGFmYzkwNThkMmJjMjAyYWQ3OTlfMi0yLTEtMS01NzY3OA_5b678f48-5f17-485c-a472-0bef1addc181"
      unitRef="usd">2312000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib125a1468b8f4d2e8c10c699c34bc410_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RhYmxlOjBkM2M2NGYwMzdiNTRhZmM5MDU4ZDJiYzIwMmFkNzk5L3RhYmxlcmFuZ2U6MGQzYzY0ZjAzN2I1NGFmYzkwNThkMmJjMjAyYWQ3OTlfMi00LTEtMS01NzY3OA_b7df57f7-f2c3-4446-bdc3-398edf6c8b38"
      unitRef="usd">1903000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic212316462214f758bddf2408b982c40_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RhYmxlOjBkM2M2NGYwMzdiNTRhZmM5MDU4ZDJiYzIwMmFkNzk5L3RhYmxlcmFuZ2U6MGQzYzY0ZjAzN2I1NGFmYzkwNThkMmJjMjAyYWQ3OTlfMy0yLTEtMS01NzY3OA_bbc51c6b-c54d-4c0d-90c2-3e5a63f064ad"
      unitRef="usd">2051000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i707d882d90674ded914e0c24595f4781_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RhYmxlOjBkM2M2NGYwMzdiNTRhZmM5MDU4ZDJiYzIwMmFkNzk5L3RhYmxlcmFuZ2U6MGQzYzY0ZjAzN2I1NGFmYzkwNThkMmJjMjAyYWQ3OTlfMy00LTEtMS01NzY3OA_7f66c5aa-5af2-4987-88e4-e2afc292dabe"
      unitRef="usd">1805000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RhYmxlOjBkM2M2NGYwMzdiNTRhZmM5MDU4ZDJiYzIwMmFkNzk5L3RhYmxlcmFuZ2U6MGQzYzY0ZjAzN2I1NGFmYzkwNThkMmJjMjAyYWQ3OTlfNC0yLTEtMS01NzY3OA_3618a2bc-22b1-4813-886d-6c73aaec3e73"
      unitRef="usd">4363000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic50d2a170ad04ba08755a9363936c41c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RhYmxlOjBkM2M2NGYwMzdiNTRhZmM5MDU4ZDJiYzIwMmFkNzk5L3RhYmxlcmFuZ2U6MGQzYzY0ZjAzN2I1NGFmYzkwNThkMmJjMjAyYWQ3OTlfNC00LTEtMS01NzY3OA_5eb60e79-0b23-4bb5-94bd-173ee50db503"
      unitRef="usd">3708000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SeveranceCosts1
      contextRef="ic0ee769ecce64f21994ca9ced836dbaa_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTQ5NzU1ODIzMDgx_92573291-588b-4008-832e-51fa95ef0cf0"
      unitRef="usd">400000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTQ5NzU1ODIzMDU0_09b67277-9355-4fb9-b53d-06bac1fe6cc5"
      unitRef="usd">600000</us-gaap:SeveranceCosts1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iada28bd88d134a9886cbbb069ddd2f51_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80MC9mcmFnOmYzMTg1ZTE3MzhlNjRmZWI4Njg0MzU4MzgwZTBjYjQxL3RleHRyZWdpb246ZjMxODVlMTczOGU2NGZlYjg2ODQzNTgzODBlMGNiNDFfNTQ5NzU1ODI1Nzg1_56bf6bc3-554d-4946-85c7-9f01aa1827b3"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80My9mcmFnOjg1OGU5YTk3NzAzNDRmNjQ5ODQwYTQ1MzkwMmU4ZWViL3RleHRyZWdpb246ODU4ZTlhOTc3MDM0NGY2NDk4NDBhNDUzOTAyZThlZWJfMjEzNA_78418c5e-1424-4d4b-8c58-661bcdec3c6b">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company estimates an annual effective tax rate of 0.0% for the year ending December&#160;31, 2023 as the Company incurred losses for the three month period ended March&#160;31, 2023 and is forecasting an estimated net loss for both financial statement and tax purposes for the year ending December&#160;31, 2023. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method in accordance with FASB ASC 740. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Due to the Company's history of cumulative losses since inception, there is not enough evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a full valuation allowance, since the Company cannot currently support that realization of its deferred tax assets is more likely than not. However, the Company feels its deferred tax assets may be used upon the Company becoming profitable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, the Company had no unrecognized tax benefits that would reduce the Company&#x2019;s effective tax rate if recognized.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6e1bad3a6f1a46cc92694fa22413949c_D20230101-20231231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80My9mcmFnOjg1OGU5YTk3NzAzNDRmNjQ5ODQwYTQ1MzkwMmU4ZWViL3RleHRyZWdpb246ODU4ZTlhOTc3MDM0NGY2NDk4NDBhNDUzOTAyZThlZWJfMzU3_7a7eccf7-98dc-48e8-8ed8-7fa47398585b"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80My9mcmFnOjg1OGU5YTk3NzAzNDRmNjQ5ODQwYTQ1MzkwMmU4ZWViL3RleHRyZWdpb246ODU4ZTlhOTc3MDM0NGY2NDk4NDBhNDUzOTAyZThlZWJfMjAzNw_f32e30aa-f86f-4598-8999-4e47a6530dee"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:LongTermContractsOrProgramsDisclosureTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTAyMTg_87225ac3-3d8a-41b7-bbb1-79f243652256">Significant Agreements &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BARDA 2022 Procurement and Development Contract&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On August 26, 2022, the Company entered into a procurement contract, as amended, (the BARDA Agreement) with BARDA for the delivery of up to 1.7&#160;million treatment courses of tablet and suspension formulations of TEMBEXA&#xae; to the U.S. government over a possible 10-year period. The BARDA Agreement consists of a five-year base period of performance and a total contract period of performance (base period plus option exercises) of up to ten years (if necessary). Under the terms of the BARDA Agreement, the base period activities are valued at approximately $127&#160;million, consisting of an initial shipment of 319,000 treatment courses of TEMBEXA to be procured and shipped to the Strategic National Stockpile for an aggregate purchase price of approximately $115&#160;million, and reimbursement for certain post-marketing activities of approximately $12&#160;million. The options under the BARDA Agreement, which are exercised at the sole discretion of BARDA, are valued at approximately $553&#160;million (if all such options are exercised during the 10-year contract period), which consists of options to purchase up to an additional 1.381&#160;million treatment courses of TEMBEXA for an aggregate purchase price of approximately $551&#160;million and funding for certain post-marketing activities of approximately $2&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the sale of the TEMBEXA franchise to Emergent, the BARDA Agreement was novated to Emergent in December 2022. In accordance with federal regulations, the terms of the novation agreement require that the Company guarantee the performance of all obligations transferred to Emergent should Emergent not have the ability to deliver on the terms of the BARDA Agreement. In this instance, BARDA may request that we perform the obligations in place of Emergent. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Emergent BioSolutions, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On September 26, 2022, the Company completed the Asset Sale to Emergent of the Company&#x2019;s exclusive worldwide rights to brincidofovir, including TEMBEXA&#xae; and specified related assets (the Asset Sale). Emergent paid the Company an upfront cash payment of approximately $238&#160;million upon the closing of the Asset Sale. In addition, pursuant to the Asset Purchase Agreement, the Company is eligible to receive from Emergent: (i) up to an aggregate of approximately $124&#160;million in milestone payments payable upon the exercise of the options under the BARDA Agreement for the delivery of up to 1.7&#160;million treatment courses of tablet and suspension formulations of TEMBEXA to the U.S. government; (ii) royalty payments equal to 15% of the gross profits from the sales of TEMBEXA made outside of the United States; (iii) royalty payments equal to 20% of the gross profits from the sales of TEMBEXA made in the United States in excess of 1.7&#160;million treatment courses; and (iv) up to an additional $12.5&#160;million upon the achievement of certain other developmental milestones. The effects of recording certain adjustments associated with contingent consideration related to TEMBEXA have been excluded as the Company has made a policy election to account for these amounts when the contingency has been resolved in accordance with Accounting Standards Codification 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The period under which the Company was contracted to provide the majority of operational support services to Emergent in furtherance of its obligations under the Asset Purchase Agreement and the BARDA Agreement concluded on March 26, 2023, except for certain services which the parties agreed would continue until the occurrence of a specific event, or in some cases a predetermined end date. The BARDA Agreement was novated to Emergent in December 2022. Under the Asset Purchase Agreement, the Company recognized approximately $0.2&#160;million of contract revenue for support provided for the three months ended March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The sale of TEMBEXA constitutes a significant disposition of a business, however, the Company determined the disposition did not represent a strategic shift, and accordingly, the Company did not account for the disposition as a discontinued operation. The Company recorded a $229.7&#160;million net gain on sale of business in other income (loss) on the Consolidated Statement of Operations and Comprehensive Income (Loss) in the third quarter of 2022.  The net gain consists of the following assets and liabilities transferred in accordance with the Asset Purchase Agreement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.678%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 26, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up-front cash payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed by Emergent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory transferred to Emergent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaids transferred to Emergent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction costs incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net gain&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,670&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;TEMBEXA Procurement Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2022, the Company entered into a Supply Agreement (the Supply Agreement) with a third-party outside of North America (the Purchaser), pursuant to which the Company was responsible for supplying to the Purchaser, and the Purchaser was responsible for purchasing from the Company, TEMBEXA treatment courses for use in a jurisdiction outside of the United States. Under the terms of the Supply Agreement, the Purchaser paid the Company an aggregate purchase price of approximately $9.3&#160;million, in two equal installments in June and July 2022. The Company recognized $9.3&#160;million of procurement revenue under the Supply Agreement for the three months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Additionally, in June 2022, the Public Health Agency of Canada (PHAC) awarded a Contract (PHAC Contract) to the Company, pursuant to which PHAC agreed to purchase up to approximately USD $25.3&#160;million (CAD $33.0&#160;million) of TEMBEXA treatment courses for use in Canada. Substantially all of the procurement was delivered and accepted by PHAC in July 2022, completing the performance obligation for those shipments and resulting in $22.6&#160;million of procurement revenue for the three months ended September 2022. Upon the assignment of the PHAC Contract to Emergent, which requires the consent of PHAC, if the remaining deliveries of treatment courses are made by Emergent, they will be subject to the royalty terms of the Asset Purchase Agreement applicable to gross profits outside the United States. PHAC assigned the PHAC Contract to Emergent in November 2022. The remaining deliveries of treatment courses were delivered by Emergent and are subject to the royalty terms of the Asset Purchase Agreement applicable to gross profits outside the United States. The Company recognized approximately $0.4&#160;million of royalty revenue in the three months ended December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ohara Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, Oncoceutics, Inc., a Delaware corporation (Oncoceutics) which was subsequently acquired by the Company in January 2021, entered into a license, development and commercialization agreement with Ohara Pharmaceutical Co., Ltd. for ONC201 in Japan. The Company is entitled to receive up to $2.5&#160;million in nonrefundable regulatory milestone payments. The Company is entitled to double-digit tiered royalties based on the aggregate annual net sales of all products, as defined in the agreement, in Japan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CR Sanjiu Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, Oncoceutics entered into a license, development and commercialization agreement with China Resources Sanjiu Medical &amp;amp; Pharmaceutical Co., Ltd. (CR Sanjiu). Oncoceutics granted CR Sanjiu an exclusive royalty bearing license to develop and commercialize ONC201 in China, Hong Kong, Macau and Taiwan (CR Sanjiu Territory). The Company is entitled to receive up to $5.0&#160;million in nonrefundable regulatory milestone payments. The Company is entitled to double-digit tiered royalties based on the aggregate annual net sales of all licensed products, as defined in the agreement, in the CR Sanjiu Territory. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 7. DSTAT Contract Close-out &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, the Company made the decision to discontinue the development of DSTAT for the treatment of AML. Effective July 12, 2022, the Company terminated the License and Development Agreement with Cantex. As a result, the Company recorded an accrual of expenses to close-out the DSTAT vendor contracts. As of March&#160;31, 2023, on the Consolidated Balance Sheets, the Company has recorded $1.1&#160;million of contract close-out costs in accrued liabilities offset by a vendor credit of $0.1&#160;million in accounts payable. These balances are expected to be fully paid over the first half of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contract close-out costs (in thousands) recorded in 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contract Close-out Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research &amp;amp; development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General &amp;amp; administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract close-out expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table sets forth the accounts payable and accrual activity for contract close-out costs (in thousands) for 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contract Close-out Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Revised estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table sets forth the accounts payable and accrual activity for contract close-out costs (in thousands) for the three months ended March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contract Close-out Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Revised estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;For the three months ended March&#160;31, 2023, the revised accrual estimates resulted in an increase to research and development expenses of $10,000.</us-gaap:LongTermContractsOrProgramsDisclosureTextBlock>
    <cmrx:QuantityBenchmarkTreatmentContractualCommitment
      contextRef="i87dd3af02ad441ce9c3886a519178bc9_I20220826"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMjE5OTAyMzI3MzgxNw_df780295-b3e7-48ba-85d1-6b71779d57e6"
      unitRef="treatment">1700000</cmrx:QuantityBenchmarkTreatmentContractualCommitment>
    <cmrx:SignificantAgreementsContractTerm
      contextRef="i0d079805c3384255aaa8160de0eddece_D20220826-20220826"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMjE5OTAyMzI3NzA1MA_55acb061-90a8-4d1e-9551-c12cf8e91c96">P10Y</cmrx:SignificantAgreementsContractTerm>
    <cmrx:BasePerformanceContractTerm
      contextRef="i4c153c1c04674d08b3b67fbf5f6520f6_D20220826-20220826"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTAyMTk_79854ce8-2008-4814-9cc5-b1268cd66c0d">P5Y</cmrx:BasePerformanceContractTerm>
    <cmrx:SignificantAgreementsContractTerm
      contextRef="i0d079805c3384255aaa8160de0eddece_D20220826-20220826"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNDgx_33a71cc2-64d5-4c60-8341-7e3fb433956c">P10Y</cmrx:SignificantAgreementsContractTerm>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia0c3ebb768e14ba1adac8fecc4608694_I20220826"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTk1_b6b4b680-cced-49a6-bdd9-f0884f3fe090"
      unitRef="usd">127000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <cmrx:QuantityBenchmarkTreatmentContractualCommitment
      contextRef="ia0c3ebb768e14ba1adac8fecc4608694_I20220826"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNjM2_9f1c977e-1337-4b12-9087-50e502295371"
      unitRef="treatment">319000</cmrx:QuantityBenchmarkTreatmentContractualCommitment>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibb56f621902543d18de68b58f4527963_I20220826"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNzgw_60b07c6f-f364-4162-9861-abed063189b3"
      unitRef="usd">115000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <cmrx:ReimbursableMarketingExpenses
      contextRef="ie2bf6b11e1724d84ba0bcc3f1428cc8e_I20220826"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfODU3_8bdea63f-b102-4cf6-8533-2ed1f8e37ec2"
      unitRef="usd">12000000</cmrx:ReimbursableMarketingExpenses>
    <cmrx:OptionToPurchaseAdditionalTreatmentCoursesGrossValue
      contextRef="i1dda99b1defa4528b1254af85ee9ca46_I20220826"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfOTgx_7cf76e90-9cd1-47cc-b731-bfe1f6ae5577"
      unitRef="usd">553000000</cmrx:OptionToPurchaseAdditionalTreatmentCoursesGrossValue>
    <cmrx:SignificantAgreementsContractTerm
      contextRef="i0d079805c3384255aaa8160de0eddece_D20220826-20220826"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTAyMjA_f0e51307-bbd0-407a-8759-f04f4f2c6bee">P10Y</cmrx:SignificantAgreementsContractTerm>
    <cmrx:OptionToPurchaseAdditionalTreatmentCourses
      contextRef="i1dda99b1defa4528b1254af85ee9ca46_I20220826"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTExNA_570d0040-d90a-4927-8918-839cd641d972"
      unitRef="treatment">1381000</cmrx:OptionToPurchaseAdditionalTreatmentCourses>
    <cmrx:OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost
      contextRef="i1dda99b1defa4528b1254af85ee9ca46_I20220826"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTE5NQ_ba442ea5-8115-42aa-966e-e4ab46a7e071"
      unitRef="usd">551000000</cmrx:OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost>
    <cmrx:ReimbursableMarketingCostUponTheExerciseOfOptions
      contextRef="i1dda99b1defa4528b1254af85ee9ca46_I20220826"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTI2NQ_62c16c24-3908-4000-9629-a9a304fd03b8"
      unitRef="usd">2000000</cmrx:ReimbursableMarketingCostUponTheExerciseOfOptions>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i39fee762c2014475826a3d701b15814d_D20220926-20220926"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMjQzNw_178be9b4-c0db-4556-8e50-1b25f63e3f6d"
      unitRef="usd">238000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <cmrx:MaximumMilestoneProceedsUponTheExerciseOfOptions
      contextRef="ide975e55e26c4a95b067825a19f1af74_I20220926"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMjYyMQ_1b37bd57-2d9b-49ac-a603-593b573391eb"
      unitRef="usd">124000000</cmrx:MaximumMilestoneProceedsUponTheExerciseOfOptions>
    <cmrx:QuantityBenchmarkGrossProfitRoyaltyRateTrigger
      contextRef="i4febe75fb14447a39e9fe6f7451fff6c_I20220926"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMjczOQ_2a24fcc4-38bf-44ed-b038-31daded07536"
      unitRef="treatment">1700000</cmrx:QuantityBenchmarkGrossProfitRoyaltyRateTrigger>
    <cmrx:RevenueBenchmarkGrossProfitRoyaltyRate
      contextRef="i49c5bcc0f6e3428b874169048e2386a2_I20220926"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMjg2NA_0f8753af-5a90-49cf-a07c-af63714ec8a3"
      unitRef="number">0.15</cmrx:RevenueBenchmarkGrossProfitRoyaltyRate>
    <cmrx:RevenueBenchmarkGrossProfitRoyaltyRate
      contextRef="ibef35d312f6649c48ca5770e34d07f53_I20220926"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMjk4MQ_9c0b92e3-8e1b-4c1e-9da9-e13ffb74ca86"
      unitRef="number">0.20</cmrx:RevenueBenchmarkGrossProfitRoyaltyRate>
    <cmrx:QuantityBenchmarkGrossProfitRoyaltyRateTrigger
      contextRef="i4febe75fb14447a39e9fe6f7451fff6c_I20220926"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMzA3MA_2a24fcc4-38bf-44ed-b038-31daded07536"
      unitRef="treatment">1700000</cmrx:QuantityBenchmarkGrossProfitRoyaltyRateTrigger>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i5668b209a8cf48ffac44b53d2385eeb5_I20220926"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMzEyMQ_39fae769-cbab-424d-9938-d21126adb426"
      unitRef="usd">12500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i8ae67a95e48a4514b6b62802563f5af0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTQ5NzU1ODI2ODc0_ebb9eea9-11e7-4e64-bb4c-68b8f3b10fa7"
      unitRef="usd">200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i069e85b680a44fffa3ee317f7da6fae3_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNDE5Ng_6a795932-1fa1-488b-ba67-1167117a2db9"
      unitRef="usd">229700000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <cmrx:ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTAyMjM_b733a095-5184-416c-9817-1620d59f02a6">The net gain consists of the following assets and liabilities transferred in accordance with the Asset Purchase Agreement (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.678%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 26, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up-front cash payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed by Emergent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory transferred to Emergent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaids transferred to Emergent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction costs incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net gain&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,670&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cmrx:ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RhYmxlOjliNzljNjMyOTEzYTRjMjA4ZDhkMDYzMWQzMWM2MTliL3RhYmxlcmFuZ2U6OWI3OWM2MzI5MTNhNGMyMDhkOGQwNjMxZDMxYzYxOWJfMS0xLTEtMS01NzY3OA_265fe916-afb0-48dd-a488-f1b489dce785"
      unitRef="usd">237987000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <cmrx:AssetSaleLiabilities
      contextRef="i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RhYmxlOjliNzljNjMyOTEzYTRjMjA4ZDhkMDYzMWQzMWM2MTliL3RhYmxlcmFuZ2U6OWI3OWM2MzI5MTNhNGMyMDhkOGQwNjMxZDMxYzYxOWJfMi0xLTEtMS01NzY3OA_078f016c-085d-4e8f-8cdf-a2c8034572f3"
      unitRef="usd">1423000</cmrx:AssetSaleLiabilities>
    <cmrx:AssetSaleInventoryTransferred
      contextRef="i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RhYmxlOjliNzljNjMyOTEzYTRjMjA4ZDhkMDYzMWQzMWM2MTliL3RhYmxlcmFuZ2U6OWI3OWM2MzI5MTNhNGMyMDhkOGQwNjMxZDMxYzYxOWJfMy0xLTEtMS01NzY3OA_d0b1d1e4-c362-4eb0-b075-735b59e51dd9"
      unitRef="usd">5227000</cmrx:AssetSaleInventoryTransferred>
    <cmrx:AssetSalePrepaidsTransferred
      contextRef="i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RhYmxlOjliNzljNjMyOTEzYTRjMjA4ZDhkMDYzMWQzMWM2MTliL3RhYmxlcmFuZ2U6OWI3OWM2MzI5MTNhNGMyMDhkOGQwNjMxZDMxYzYxOWJfNC0xLTEtMS01NzY3OA_6a59508a-4c79-419b-bf89-f6656e9927ec"
      unitRef="usd">511000</cmrx:AssetSalePrepaidsTransferred>
    <cmrx:TransactionCostsIncurredInRelationToSales
      contextRef="i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RhYmxlOjliNzljNjMyOTEzYTRjMjA4ZDhkMDYzMWQzMWM2MTliL3RhYmxlcmFuZ2U6OWI3OWM2MzI5MTNhNGMyMDhkOGQwNjMxZDMxYzYxOWJfNS0xLTEtMS01NzY3OA_84521ea7-e095-4dd3-b536-4800af79c74d"
      unitRef="usd">4002000</cmrx:TransactionCostsIncurredInRelationToSales>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RhYmxlOjliNzljNjMyOTEzYTRjMjA4ZDhkMDYzMWQzMWM2MTliL3RhYmxlcmFuZ2U6OWI3OWM2MzI5MTNhNGMyMDhkOGQwNjMxZDMxYzYxOWJfNi0xLTEtMS01NzY3OA_5532dae4-a56b-40a8-80f8-abd69d4be52f"
      unitRef="usd">229670000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i4dc7c0b07dc840118483ece5d0ba3401_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTAxOA_2e3081ab-6b31-4ebf-8807-7668d35725ff"
      unitRef="usd">9300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib85fa50450aa424aafb519800af6ba59_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTAxOA_8116ada2-f126-4a6c-bc74-0b6d64f6383c"
      unitRef="usd">9300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <cmrx:ContractWithCustomerLiabilityInstallmentPeriods
      contextRef="ib699e30492f44e8a804263792c19142f_D20220623-20220623"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTAyNQ_0bd07682-4fdd-4618-9943-2334279e82a5"
      unitRef="installment">2</cmrx:ContractWithCustomerLiabilityInstallmentPeriods>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a47e7a6ffe740b1ab49e33529826b16_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTM4Ng_e68dac71-c8da-4da0-b52a-a8f3dc16c673"
      unitRef="usd">9300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i041e87dc76b7486fad7182d5c433de1d_I20220623"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfMTQ4Mjk_3b10f764-4f89-4990-abea-530d6419713c"
      unitRef="usd">25300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i041e87dc76b7486fad7182d5c433de1d_I20220623"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTYyOQ_9318c93f-3e4a-4eb7-993a-7d9344122472"
      unitRef="cad">33000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7858fb7e8acd42509124fae89e255dca_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTg0Ng_b30dd00a-0a0c-443f-8396-b4e16fa32e0d"
      unitRef="usd">22600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07e0fd7ae2114d36b0896130bfc39369_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfNTQ5NzU1ODI5MjU2_52aaab60-26f2-4df0-a41a-174c7b725b02"
      unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <cmrx:LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived
      contextRef="ica04db5e597f4a148bb1cd8f8e4c8b48_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfOTM3OQ_4eeeef8c-a7da-4a27-ad38-2262132efe0a"
      unitRef="usd">2500000</cmrx:LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i21532ae17c8540b2814f9047fab955e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80Ni9mcmFnOmRkM2JiZmJlMzVmNDRmYjE5YmRiZjUxN2E3MDQ0MTgxL3RleHRyZWdpb246ZGQzYmJmYmUzNWY0NGZiMTliZGJmNTE3YTcwNDQxODFfOTk4NQ_e6bcc3b8-7593-4a5f-9713-815b2c8cab17"
      unitRef="usd">5000000</us-gaap:ContractWithCustomerAssetNet>
    <cmrx:ContractCloseOutLiability
      contextRef="if82f3e05482f40578ab012f41b08b052_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RleHRyZWdpb246YjM1MTZmMDdjYzFkNDY0Mzg3MGFlMmI3NTVlNTI2YTdfNDE3_7468de9a-97bf-4d29-99e0-41b5ee9aacd4"
      unitRef="usd">1100000</cmrx:ContractCloseOutLiability>
    <cmrx:ContractCloseOutLiability
      contextRef="i1bb99da3a7e24972a69174d9a86c03d0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RleHRyZWdpb246YjM1MTZmMDdjYzFkNDY0Mzg3MGFlMmI3NTVlNTI2YTdfNDc1_ca3442c2-9fb8-4bc9-a585-912b853788a7"
      unitRef="usd">100000</cmrx:ContractCloseOutLiability>
    <cmrx:ScheduleOfContractCloseOutCostsTableTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RleHRyZWdpb246YjM1MTZmMDdjYzFkNDY0Mzg3MGFlMmI3NTVlNTI2YTdfMTIzNA_d2254281-0831-47bd-b277-492b41388668">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contract close-out costs (in thousands) recorded in 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contract Close-out Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research &amp;amp; development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General &amp;amp; administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract close-out expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table sets forth the accounts payable and accrual activity for contract close-out costs (in thousands) for 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contract Close-out Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Revised estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table sets forth the accounts payable and accrual activity for contract close-out costs (in thousands) for the three months ended March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contract Close-out Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Revised estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cmrx:ScheduleOfContractCloseOutCostsTableTextBlock>
    <cmrx:ContractCloseOutCosts
      contextRef="ic6f299962fcf4e829643ecd56dc9183d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjBiMWVjZjg1NjZmNjQ5YzE5MTM2NzU3MjhlZTg0OTk2L3RhYmxlcmFuZ2U6MGIxZWNmODU2NmY2NDljMTkxMzY3NTcyOGVlODQ5OTZfMS0xLTEtMS01NzY3OA_4e4220ff-11c9-469a-a451-5b7f6848493d"
      unitRef="usd">791000</cmrx:ContractCloseOutCosts>
    <cmrx:ContractCloseOutCosts
      contextRef="i5109aa96790c4d84b6c1982ac5f7ba63_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjBiMWVjZjg1NjZmNjQ5YzE5MTM2NzU3MjhlZTg0OTk2L3RhYmxlcmFuZ2U6MGIxZWNmODU2NmY2NDljMTkxMzY3NTcyOGVlODQ5OTZfMi0xLTEtMS01NzY3OA_e1248008-231d-4a43-a282-ca453a9124c0"
      unitRef="usd">8000</cmrx:ContractCloseOutCosts>
    <cmrx:ContractCloseOutCosts
      contextRef="ic0ee769ecce64f21994ca9ced836dbaa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjBiMWVjZjg1NjZmNjQ5YzE5MTM2NzU3MjhlZTg0OTk2L3RhYmxlcmFuZ2U6MGIxZWNmODU2NmY2NDljMTkxMzY3NTcyOGVlODQ5OTZfMy0xLTEtMS01NzY3OA_0ffb8e4e-4020-4a70-8daa-09ddfb9a1f90"
      unitRef="usd">799000</cmrx:ContractCloseOutCosts>
    <cmrx:ContractCloseOutLiability
      contextRef="i5d7df4ccac55457db9fc511a4813ea18_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjQwZDdmYTk1YTdlNDQ4YjVhYjNhOGZkM2I2YzNkZWRmL3RhYmxlcmFuZ2U6NDBkN2ZhOTVhN2U0NDhiNWFiM2E4ZmQzYjZjM2RlZGZfMS0xLTEtMS01NzY3OA_3149cbcc-aa83-46c3-bed2-7263c338c253"
      unitRef="usd">4539000</cmrx:ContractCloseOutLiability>
    <cmrx:ContractCloseOutLiabilityAdjustments
      contextRef="i80f398e930dd4c1195d38e4f087c0836_D20220701-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjQwZDdmYTk1YTdlNDQ4YjVhYjNhOGZkM2I2YzNkZWRmL3RhYmxlcmFuZ2U6NDBkN2ZhOTVhN2U0NDhiNWFiM2E4ZmQzYjZjM2RlZGZfMi0xLTEtMS01NzY3OA_32f8365d-90fb-4c2c-9391-ca699cdaaa47"
      unitRef="usd">-746000</cmrx:ContractCloseOutLiabilityAdjustments>
    <cmrx:ContractCloseOutLiabilityPayments
      contextRef="i80f398e930dd4c1195d38e4f087c0836_D20220701-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjQwZDdmYTk1YTdlNDQ4YjVhYjNhOGZkM2I2YzNkZWRmL3RhYmxlcmFuZ2U6NDBkN2ZhOTVhN2U0NDhiNWFiM2E4ZmQzYjZjM2RlZGZfMy0xLTEtMS01NzY3OA_09c3ed18-8746-491a-93a9-91a5d583d02b"
      unitRef="usd">2482000</cmrx:ContractCloseOutLiabilityPayments>
    <cmrx:ContractCloseOutLiability
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjQwZDdmYTk1YTdlNDQ4YjVhYjNhOGZkM2I2YzNkZWRmL3RhYmxlcmFuZ2U6NDBkN2ZhOTVhN2U0NDhiNWFiM2E4ZmQzYjZjM2RlZGZfNC0xLTEtMS01NzY3OA_8412e475-f14f-4323-a513-c28b5680e5d1"
      unitRef="usd">1311000</cmrx:ContractCloseOutLiability>
    <cmrx:ContractCloseOutLiability
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjk2OGJmYzkwM2ZiMDQ5YTY4NWMwMjcwMzc2OGE3NTM5L3RhYmxlcmFuZ2U6OTY4YmZjOTAzZmIwNDlhNjg1YzAyNzAzNzY4YTc1MzlfMS0xLTEtMS02MTM3Mg_0f31b060-cda2-4b0e-99b0-a3c96bb39e66"
      unitRef="usd">1311000</cmrx:ContractCloseOutLiability>
    <cmrx:ContractCloseOutLiabilityAdjustments
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjk2OGJmYzkwM2ZiMDQ5YTY4NWMwMjcwMzc2OGE3NTM5L3RhYmxlcmFuZ2U6OTY4YmZjOTAzZmIwNDlhNjg1YzAyNzAzNzY4YTc1MzlfMi0xLTEtMS02MTM3Mg_7cfe7cee-27b8-4b7f-badd-253f541a175c"
      unitRef="usd">10000</cmrx:ContractCloseOutLiabilityAdjustments>
    <cmrx:ContractCloseOutLiabilityPayments
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjk2OGJmYzkwM2ZiMDQ5YTY4NWMwMjcwMzc2OGE3NTM5L3RhYmxlcmFuZ2U6OTY4YmZjOTAzZmIwNDlhNjg1YzAyNzAzNzY4YTc1MzlfMy0xLTEtMS02MTM3Mg_b6e8df89-4e15-49c8-a98f-48779c2c7c20"
      unitRef="usd">250000</cmrx:ContractCloseOutLiabilityPayments>
    <cmrx:ContractCloseOutLiability
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RhYmxlOjk2OGJmYzkwM2ZiMDQ5YTY4NWMwMjcwMzc2OGE3NTM5L3RhYmxlcmFuZ2U6OTY4YmZjOTAzZmIwNDlhNjg1YzAyNzAzNzY4YTc1MzlfNC0xLTEtMS02MTM3Mg_2c3ff000-aaa6-4042-9b07-c7a3cb4170e0"
      unitRef="usd">1071000</cmrx:ContractCloseOutLiability>
    <cmrx:ContractCloseOutLiabilityAdjustments
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl80OS9mcmFnOmIzNTE2ZjA3Y2MxZDQ2NDM4NzBhZTJiNzU1ZTUyNmE3L3RleHRyZWdpb246YjM1MTZmMDdjYzFkNDY0Mzg3MGFlMmI3NTVlNTI2YTdfMTIyNw_7ecb1781-dcd8-41ce-b4da-eae2bbe775b3"
      unitRef="usd">10000</cmrx:ContractCloseOutLiabilityAdjustments>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RleHRyZWdpb246MjA2NmJmNWRiYWQ0NDQzNmE0MzBlYjlkNjE2NDE5OTVfMzY5Nw_d518b8e6-9a34-40ef-be25-7ab73a9a7de0">Restructuring Costs&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company made the decision to restructure its operations, which included a reduction in workforce of 20 full-time employees. During the three months ended December 31, 2022, the Company recorded expense for one-time employee termination benefits of $1.9&#160;million, which included a ratable share of the total stock compensation expense that resulted from the modifications of stock option agreements of employees. The total amount of stock compensation expense related to the reduction in workforce equals $1.0&#160;million of which $0.4&#160;million was recorded in the fourth quarter of 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the restructuring charges (in thousands) recorded for the three months ended December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee Termination Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restructuring expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the accrual activity for employee termination benefits (in thousands) for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee Termination Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Revised estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="if6405e9f8e2e42febb0630cc3f4b70cf_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RleHRyZWdpb246MjA2NmJmNWRiYWQ0NDQzNmE0MzBlYjlkNjE2NDE5OTVfNTQ5NzU1ODIyMDMw_3a81f801-d7de-4814-a347-45399f1d9c35"
      unitRef="employee">20</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:SeveranceCosts1
      contextRef="i8bc40ecede3346368c17697b995b6608_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RleHRyZWdpb246MjA2NmJmNWRiYWQ0NDQzNmE0MzBlYjlkNjE2NDE5OTVfNTQ5NzU1ODIyMDQ3_c0d10b9f-c96d-4b2f-b03a-cf9532b9fadb"
      unitRef="usd">1900000</us-gaap:SeveranceCosts1>
    <cmrx:AnticipatedSeveranceCost
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RleHRyZWdpb246MjA2NmJmNWRiYWQ0NDQzNmE0MzBlYjlkNjE2NDE5OTVfNTQ5NzU1ODIyMTE0_6b1b6d13-f80f-4140-8a62-76f927b5fa10"
      unitRef="usd">1000000</cmrx:AnticipatedSeveranceCost>
    <us-gaap:SeveranceCosts1
      contextRef="ic0ee769ecce64f21994ca9ced836dbaa_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RleHRyZWdpb246MjA2NmJmNWRiYWQ0NDQzNmE0MzBlYjlkNjE2NDE5OTVfNTQ5NzU1ODIzMDk2_92573291-588b-4008-832e-51fa95ef0cf0"
      unitRef="usd">400000</us-gaap:SeveranceCosts1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RleHRyZWdpb246MjA2NmJmNWRiYWQ0NDQzNmE0MzBlYjlkNjE2NDE5OTVfMjE5OTAyMzI2NDI1Nw_05646e45-7c5b-41bc-af1c-d9ce29dbded5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the restructuring charges (in thousands) recorded for the three months ended December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee Termination Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restructuring expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i01d7ce8ff73a42f8bc6ebe1f484b504b_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RhYmxlOmVmMzA2ZjU0YjA0NzQ3OTlhYjc1NDk4NTRjOGU0NmYwL3RhYmxlcmFuZ2U6ZWYzMDZmNTRiMDQ3NDc5OWFiNzU0OTg1NGM4ZTQ2ZjBfMS0yLTEtMS02MDQyNA_5b9beff4-8ff8-46e6-8b62-3596ade57e57"
      unitRef="usd">1768000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ic3b15fe0b2c840688dc4fc6ff3dc199f_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RhYmxlOmVmMzA2ZjU0YjA0NzQ3OTlhYjc1NDk4NTRjOGU0NmYwL3RhYmxlcmFuZ2U6ZWYzMDZmNTRiMDQ3NDc5OWFiNzU0OTg1NGM4ZTQ2ZjBfMi0yLTEtMS02MDQyNA_9d76c407-363f-4604-8041-2fecfced20c3"
      unitRef="usd">86000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i8bc40ecede3346368c17697b995b6608_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RhYmxlOmVmMzA2ZjU0YjA0NzQ3OTlhYjc1NDk4NTRjOGU0NmYwL3RhYmxlcmFuZ2U6ZWYzMDZmNTRiMDQ3NDc5OWFiNzU0OTg1NGM4ZTQ2ZjBfMy0yLTEtMS02MDQyNA_ce9a143c-06d3-4952-901d-e3156054f1bc"
      unitRef="usd">1854000</us-gaap:SeveranceCosts1>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RleHRyZWdpb246MjA2NmJmNWRiYWQ0NDQzNmE0MzBlYjlkNjE2NDE5OTVfMjE5OTAyMzI2NDI1OA_89e0818b-3970-49b7-8c99-bcbeb2ba9ca9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the accrual activity for employee termination benefits (in thousands) for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee Termination Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Revised estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i040b1a26f397449cbae5cbdc11f92d47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RhYmxlOjdlOGEyNWQyMzI0NTQ0NTRiNDZjMTRiYjk2Njg2ZTU4L3RhYmxlcmFuZ2U6N2U4YTI1ZDIzMjQ1NDQ1NGI0NmMxNGJiOTY2ODZlNThfMS0xLTEtMS02MDQyOQ_14ba5a95-ecf3-4593-9027-79c174251e2b"
      unitRef="usd">1442000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RhYmxlOjdlOGEyNWQyMzI0NTQ0NTRiNDZjMTRiYjk2Njg2ZTU4L3RhYmxlcmFuZ2U6N2U4YTI1ZDIzMjQ1NDQ1NGI0NmMxNGJiOTY2ODZlNThfMi0xLTEtMS02MDQyOQ_5ed9c189-ae79-4f53-83b6-00aeb60f6144"
      unitRef="usd">-73000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:PaymentsForRestructuring
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RhYmxlOjdlOGEyNWQyMzI0NTQ0NTRiNDZjMTRiYjk2Njg2ZTU4L3RhYmxlcmFuZ2U6N2U4YTI1ZDIzMjQ1NDQ1NGI0NmMxNGJiOTY2ODZlNThfMy0xLTEtMS02MDQyOQ_edd29d23-9a1a-4edb-9963-8d39ff934cda"
      unitRef="usd">641000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i1ea283aae3314b6683e2cb4a1614f1d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81Mi9mcmFnOjIwNjZiZjVkYmFkNDQ0MzZhNDMwZWI5ZDYxNjQxOTk1L3RhYmxlOjdlOGEyNWQyMzI0NTQ0NTRiNDZjMTRiYjk2Njg2ZTU4L3RhYmxlcmFuZ2U6N2U4YTI1ZDIzMjQ1NDQ1NGI0NmMxNGJiOTY2ODZlNThfNC0xLTEtMS02MDQyOQ_55a21d3e-830f-46c5-aafc-666c7ac81073"
      unitRef="usd">728000</us-gaap:RestructuringReserve>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ0NDY3ODQxNjY3ODRiYzZhYjZhMTQ3MTQ2ODg0NmZmL3NlYzo0NDQ2Nzg0MTY2Nzg0YmM2YWI2YTE0NzE0Njg4NDZmZl81NS9mcmFnOjRhOWU1OTAyMGFiYjQzZWViZDQxOTBiYWVkNjU4ODVmL3RleHRyZWdpb246NGE5ZTU5MDIwYWJiNDNlZWJkNDE5MGJhZWQ2NTg4NWZfMzQ5_8e03b667-d597-4ccf-9170-ba4ac22c32bd">Subsequent EventsThe Company has evaluated subsequent events through the issuance date of these financial statements to ensure that this filing includes appropriate disclosure of events both recognized in the financial statements as of March&#160;31, 2023, and events which occurred subsequently but were not recognized in the financial statements.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M0U553-4QLB@+@3MIL*PHFQE6?J!L ,XOI#2/'5M;-+5D_ =02P,$%     @
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M931A0AO ^P7G:G>C/]"<K4[_ U!+ P04    " #10Z16ZW,-2. &  ">,@
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MH=!$6H=*GY@K_?$RJ1EP-(5J[4P(=AR%0M#Z'Q0MAD(3*1Q4 F(^&W&F3$I
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M\70UPJ/7"]_X:JW-A<GB<D-7[('I[YM["6>36DO",Y8K+G(DV?)J=(TO;OW
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MO0$LQ7]<+6U= ??\YQ#"O-YB>#V4J.]L*5/UPQ&(C%75O3IZ_>U?IF>35X]
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MC3L^*%D)A5H7A#%5VZ6JO-Z<C<5[/CU3ZL*)Z!"46UF F4:@$B*BS'X'^T1
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M%\D9T&HZ3<XN3L7\++E<].$8YM1G3&PY]6P&/R-;GBZ2<^+/V>0BF9Y-(@9
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MSDY@A;4L-\G5(]PGMP*2G!V)E<I"4 4J\!Z%%O0"*!,"BI9R08O; CP8,OH
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MH[<4#A0"VTMPM-E6@18'UF@O3?E7@HB$NG*(41D.4!YYA$%^5"HQ2L55-2B
MM&[=1O!-MW9OSC[ 3"^%70761Y_^.H,W#JD*C:'+(+*98Z6<(I*#W/,5S_*X
M),A8?.(2Q]N@(7\C5P/#@N!3''BA"U42&@W,>Q/%Z16HT)G3OH7$MQP^J_Y[
M*-'[#&P\VF<R6/5%%R8P,41%KB1N'DC:XC^_7L:*.G&]@LP;[>,57H_"L?1:
M6Z(U.P6L.-*QWI]C?O->51H*-,_I@4;DMGA9)+[?W^[0M;+!QCS]6!DCZZWA
MO7]Q@!V'2 A#(J@=PLEJY#QDH)!CKN473Z%>5(<LW+XQA4SI;*/M''%X%0?V
M ,K@C1AT3/&0*DV<3C:K0'=#&U V3-%]ML"%\"+%?>C!"[WA*BK(=;RXQ+$1
M.Z+TG <&%\BO]$M[N1 X$]'PSW18]R0 K>B?@G*/, 4F?/R-!'S8#"\Z@KLO
M6W_/\8L!%:>H"ZCC*O.S,;'#[.*EUF6^4^OVE2KOA_$Y,.>8 M^D*#",6'."
MM/M8(+)V4%T?5<KY[:O,T/MT@[T-;<IQ>L8DQ38'WQ]Q=?>)?AE-P5\;?%%K
MY#H4/Q"3B./?3 DZ;3X[PZ:EZ%4*=#@Z(U%J!I_H\M<ZJ+'8!GVL*UJ'7O9
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MGPS#5(X%,G\I,VXMJW?VK(: JHD])09'*%L*M$X=.#%=-O4R6/>]^C*0R7.
MGW<UWOJC5QC=*MQ*G0/!&>?[BA+U'PVI\=DIRYI:#:=3-W&4F74-<B>1P?Q&
MC;JE5*WH61<GTWY(Q/2\T6I>:%6T<>BDTL8A5&W^HY==\ACCGC>R)),[1&Q<
M<9=;AQE.PI<XE(_&S32YHE<0]4Q$K"EQQFH:9&B:Q'$X<)\8U+SI['O_/6Q]
MJ\"Q8,U?9(A=4<^JSQ;U:/W1Y[;ZUM%,K[X88=MKHI%,K;!T=#Z?#M";\5>8
MZL:;+7_Y6!KO3<Z7&R715M $/%\9G%?"#2FH/X7=_!M02P,$%     @ T4.D
M5I:8^CQ9!@  ]A   !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6RM6%EO
MVS@0_BL#-ULD@.-#OI(T"9"C10NTV"#I[F*QV =:&EE$*5$E*3O^]SM#2CYB
M)VC:?4DDBOQFYIN3/E]H\\UFB X><U78BU;F7'G6[=HXPUS8CBZQH"^I-KEP
M]&IF75L:%(D_E*MNU.N-N[F01>ORW*_=F<MS73DE"[PS8*L\%V9YC4HO+EK]
M5K-P+V>9XX7NY7DI9OB [H_RSM!;=X62R!P+*W4!!M.+UE7_['K(^_V&/R4N
M[,8SL"53K;_QRZ?DHM5CA5!A[!A!T+\YWJ!2#$1J?*\Q6RN1?'#SN4'_X&TG
M6Z;"XHU6?\G$91>MDQ8DF(I*N7N]^(BU/2/&B[6R_B\LPMY1U(*XLD[G]6'2
M()=%^"\>:QXV#ISTGCD0U0<BKW<0Y+6\%4Y<GAN] ,.["8T?O*G^-"DG"W;*
M@S/T5=(Y=WFC\UPZ8ME9$$4"-[IPLIAA$4NTYUU'(GAC-Z[AK@-<] S< +X0
M0&;A?9%@LGV^2ZJM](L:_:ZC%P&_"-.!0;\-42\:O( W6-D[\'B#G[$7;J6-
ME;:50?CG:FJ=H:#Y=Q\+0<APOQ!.I#-;BA@O6I0I%LT<6Y=OW_3'O7<OF#!<
MF3!\"?WU+OL%./B,%/(6OF9('_)2%$M084G2_E3$4DG'&RMRN &EB]FQ0Y,#
ME0TC&*C9[S+A !]+2>32TUP8J2L+B7#^H]'5+&,OCSM;TD@1 E)J"9FPA,JY
M3/LU582"<MZ# TNDC\43I=JPR&2<4;XL88HD'$TL+28LWZUEO'US$O4G[RQ8
MK1 2B@&#+*8#GZAL)(GDES;$:!Q5N5JD,$802X&W6@"K(0LR*(&2K#.L)LF1
M!K21,_JB @'"%R2V_#E--I789 /G0E6>,6\^ ;++&KF,VC!4 P=E8_(Q.=1K
M&^229@F&<P@R)>) ,JBPNA!38KNQEC8VO'G @._%LD-B7<2JHEQG]LE-S_@]
MP!?:[17!.]BZ1O>%)*!-AP42%K[$8G(LYB1CAH3%;6<ER_, *?.^A](=Q3B<
M4J "0Q'25!A8T.J@,QC"$H6Q'7C_2.W/LBCE_4IT-/'/=,7:-+8#EPM6\)@S
MC%L%[="DZ88?6,%.R"F.!(\<$N>I=FV0GEA>8>^Q!*(.V&"'A2!G0HJ\SVDG
M%,=T61K]**E1(7%[T.M$U"^4:IRUN= FS6V)OB&J97M%&64A(N2A@B-7\*?T
M,!(]1,$A'*6ZHI R'%(R+Y6,R=,+Z3+OUETGK+E;YS5'11.+%!<80CI#:L_:
MX";,.F2M7]Z6S\TY:8H L6=\N%.*3+6A$LM,;N]C"%F$P<;3-!=2!0W<;LIT
MX&I/P+3KI-CR'B@IIDUA)#-X!*$ V8G?;?T)>](Y.?TM<)MJI8+2SJMDD4N;
M-B[;*]'XR-/I<<6UR?K=S..F)GL#_M![BBHQ[;9'9V2D/_O[#^ ?0+]],CR!
MSQLRGIZS&:D<.L*F*H>KU*F#Y2J.385;^AZ1@,/1:>]H!W3=95[$]'EVW&2N
MGBHY\XXFY,-^>SP>'\%73IX7W4<Z1.UH--[5HA3+4/U721[JD4_G]$G66TY?
M]D#PJ]WA_6^N-SPVL8!;I,";$@Z[:5_8A3^CT8@?AC 9G?+#""8G?=]#83B>
MU,:EE>-YAK)&YE7.?8-75\H?0-0>C2,BRY*.N0]'$O?$1(-^D/&3 7 %HC<'
M@]ZX%E)_!6Y/N.<\2R$2:UNVS.-RTMYQP2O)7>"OL;NC42!X,AC_+P1/AH.?
M(WC4?P7!@],(/KRZE+>W*FPN$MQQ0?H#S:6_O[ETX$'."IG*V+<L@KK'.19D
MPX.N#*UL3C?<?(.K8UE*#$2EF'"C8%3T%M#(X0=S(IZ<"ZG1.5Q?W=]>!4MH
M\N+K)0US'K\.EJ>-*,QGW.37>&S)C*8Z'E*\CAVX0]J7R!@$M6(7DMC@]XJ&
MV(3<Q&>+^G[)16>O*+(&9>EML17I']1F8<T %&N['B*_5^1Y N26;@/QI*QO
M7,M@9X>K)54Z"A7NWM2L]KAV3XYM^CD3R7I\$42'GDM_T>99H-2.(]&3SMJ&
MGNA#UT?#P2AJ]WJ]SK[+3'?C+IJCF?D;-\^)=#A<2U>KJTO]5;C+KK>'7P3(
M*AJ:>6A(Z6BO,QFU0A]J7IPN_<UVJAW=D_UCAA3 AC?0]U23(?4+"UC]U''Y
M'U!+ P04    " #10Z16KX%D.0<*  "]'   &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6R]66MOVS@6_2N$ISMH ;_MM&F;!$@ZG=T.IMN@;G<^+/8#
M+=$V$4ET2<J.Y]?ON9>4+"6VV\X6^R&Q'N1]GGMX25ULC;US*Z6\N,^SPEUV
M5MZO7PT&+EFI7+J^6:L";Q;&YM+CUBX';FV53'E2G@W&P^'S02YUT;FZX&>W
M]NK"E#[3A;JUPI5Y+NWN1F5F>]D9=:H''_5RY>G!X.IB+9=JIOSG]:W%W:"6
MDNI<%4Z;0EBUN.Q<CU[=3&D\#_B75EO7N!;DR=R8.[IYEUYVAF20RE3B28+$
MST:]45E&@F#&ERBS4ZNDB<WK2OJO[#M\F4NGWICL#YWZU67GO"-2M9!EYC^:
M[3]4].>,Y"4F<_Q?;,/8Z<N.2$KG31XGPX)<%^%7WL<X-":<#X],&,<)8[8[
M*&(K?Y%>7EU8LQ661D,:7;"K/!O&Z8*2,O,6;S7F^:NW7TKM=^*3E863'"@G
M9)&*V4I:U2-_4_'&Y," D_3V8N"AE>8.DJCA)F@8']$P$>]-X5=.O"U2E;;G
M#V!M;?*X,OEF?%+@>VG[8C+JBO%P/#DA;U*'8,+R)D?D!5=OV-5;N0/BO+BV
M",A2\?6_K^?.6P3G/X><#[*GAV532;UR:YFHRPYJQBF[49VKGW\:/1^^/F'Y
MM+9\>DKZ#TG>C]4@KGWOTTKUD*,[,$J<_F&Q4%87R]>8I[*%^*B6FD+*,V9>
M^A#H#YA>+H%Y,1IR=O%_JP1>*0L]NO &RL4':!-1P4QF2EPOK0H29N_%4[]2
MXC?%&I7C 6X_XAG*RZ\:[W___4U72#BUQ-NN6)?6E1*2H&J[TLF*#,CE3AB:
MP*Z#4;*N6%B3"P]ZHI'A=V5-N6S([HIR36^?O#A#Y689.6L6PE'H'%V9THK$
MY#F>H\Z3N[ZXYN?P#8HKA',,5G*C1&&\<"9+8<;NA!A1HM"L.!F'/@7[/?QZ
MSDI&K&2A,T7"A2Q!.\A. BV4+]O,EZOSA1MB1C'K34)82>7L+0(:0X>XNG+N
MU)<2P[.=D)B6<B:CCU ]IA EIM@HRU&7<+/H?9L%??%II=TQ\U0AY^1TZ4AN
M2"!6,>$0B@,)[))9IE "0W)C59@!U.X3.3X;UIG$8')7+A'2)51V*17--'2Q
M.,R1,)645GO&PU82K7A<65HLN)0&4%<6FAX2NK80#X=H.245E+_$L]G!!J!,
M*;%3TKKH HQ(H5]H+^8J08CC)"QVQP!5& Z""[":*]13+E/5 ,[IJ,\89A_6
M@0]0[\P!A$JRV^,/KD'7:%(QP+LBP4R8)&XS (R+E-_3[;,*,&MK-CJ%7>0O
M#5E2N,@#7<\/$#=1]]-WLP_N69<Q0P8"-G;W<,P_PYCP5*Y!Q(D./H4T(!T*
M;NK$ YMQ%%*5'GI!J1)//\X^/ZO'K)7EY@@F1D9LRZ"T&GC#Z,LY(2I$)6DR
MYU,LY5G(6[;KMF3 > E88&*($Q'2/$8'Z@ +E:\SLU,$,H0J*U/@E@"L$V5=
M"$\U1*0: 4"< I.C]!PZ&((E*?"-9-)K32B%G P14PZ 2E--YL(>&-E*XXGT
M-4(D$NE6T:\^8Z<H\SF"TZ+&%I_%A3-EN8O2ERA.[8BG(:YF"K*(G$=K2CG
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M];>YZ_!):C\\?-B#MB7MFS.UP-1A_\59)S1&U8TW:_Y -3<>^R.^7"FDR-(
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MV[@5_2L8;[ICS3"R'E9LYS4C.VF3;1Z>V&D[T^D'B(0D9"F""Y!6M+^^YUX
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M+W=O<FMS:&5E=',O<VAE970Q-"YX;6R-5DUOXS80_2L#-2@V0-:R9<5Q4]M
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MHH\<-%Z [DNM7??B#?2?38O_ %!+ P04    " #10Z163"I92(L"  #H!0
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M/_>A!U(ZM=0.%%8$S2;O3A.P0U\9-MZTL9;IIJ@SQ*6@5HPV.-!Y98S?;4*
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M>9%H>T$^^\B7J72+$1>+L14//@A. <%BSAA:* DF9>BRQ>@M*W!YP[V;4!P
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M/CW6UT@TG_WA_7>1265^,5P5"/6>:U-[]NUL<09&.6<?0=OX"&/)&GMD%(Z
MQB2, PA"0I.P578IBX*K5"",+=NBH[X?$<^/VP/'\TNIME(QPV$IK:,T(%Z0
MM-M'T]I!W8_8'R<D\?P],G]$2="1_2K+S4^XB7<:4 R:AT%+@/K$"\,C''FO
MQE<(-H1\"S0,2#".<!1Y&); 7N\8EY+N_;[$O4\\Y<428]S0C_ZO]!N1A,;=
MP7/Z/;O\D(S'APMX.GN!JY2B^G!OY:G(SS(U2(@W#H%&>!,^^%9S<(*I=$0B
M?W1@ZM'\&5,CDB3^@:E/I__"5)^$8]HBBV-"J?]?F1HF),98^3Z)DPB"F(S#
M8QS]3'V%X(&I,<5M2\LH)"/'3^HE!,M,AP G"D[4%ISHU04'2Z6JD,E?!5N*
MW#G;5TE.*NRO)'O-^4$SI!+[06TS!TUCEL!:YEAO;$TXK@9'K_[S1-SKMP;=
M6=O_K/@]%K"MC3WP!^Q]-;>1'9%Q8/,I)O'8;R536=@3=3G#%R%,\$"(SUF=
MP*S' 7SN/ ]3AD;[EZ#OE"L@$3[9+I4#I&S?K0T[?1^FR<9UMS9&V+K4+6"[
MVC;0%W7?>#A>=]\8K(TH->1\C:+>V0CO2]4=;3TQ<NNZR*4TV).Z889_ KBR
M!W!_+?$]:R;60/NW8O8/4$L#!!0    ( -%#I%8,;D  XP0  ,8.   9
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M%9H!SY><J^U&&ZB?KN._ %!+ P04    " #10Z16%2\_+Y$#  "V"0  &0
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MC<ZG6$>Z?26T':MJ?S.OE<5[WC<K?%B!=@MPOE3*[CK.0?]46_X'4$L#!!0
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M&M(K-\WH!X'*&M#Y2DJS6]@ [2\G_@]02P,$%     @ T4.D5OP>KX/R @
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M96%>?G8H&Y+EYD7\DDG)4G.X5;PPUQW4]35C\J6AW^W7'W^B?P%02P,$%
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M5&-0C4,U@=+,M%5U2/=D=4@76H= -1^J4:C&H!J':@*EF>FLZI"NO0YI>!D
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M0EDHNYQN71J"YN4!T98*0=/R\DCPGC 5()\?*!6O#77F5)\QKOX#4$L#!!0
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M@4@R&7%V #Q!*[;D1YJ;=+2*)HB3QSB37%T-U#@Y^1SOJ9#JN4@!.F!V?)B
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MC*M:[+78RO%JDX7X+;H,:/7NUCFX$ELY!]JXH=VY+^@T,L;BHH>PAP>G)6J
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M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6RM55U/VS 4_2M7&9I
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M-3VJ>/[6!_J\#/\YJR2-8G=?=\STA VB.!YU88W,<*M?N7\%M8 EEX8J94'
MZ/0;\>BF_S83JU:^A<V5I8;HAR7]LE"[ -I?*&5?)ZXK=C_!["]02P,$%
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MI_[UK+I9_*:I+CI8 6:,*SRFEDCI70SP-)'5W:%ZT6)MJ^F%T%B;V\<5WK=
MF@[X?2F$WK^8 /4-+OH?4$L#!!0    ( -%#I%99T)]Z+@,  .<)   9
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M$U(@MJT5M>7L@59?#IPATOBYM$@Y49(R:JBA5_\>W9W3.7=&^KUZ9A_$R>*
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M5 M1+4*U&-4$JDE*TWM $[6SC3&>JYND5-92%9M+5V<3=6I-'M?[E2H6K;V
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M,E7%^@?J[]_G>?7XR7J"[WGQ=7/85_\'4$L#!!0    ( -%#I%:0&WMS+0,
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M!NU"^GRX%#D.8&ZI T  WX#E?_S0'SE?VBC_D]@;YD'-/.A2]Y_R7L35KJ(
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MQ5A5F)<=1SF1+#>7]II)U0*88:*:-.#:0#V/&)/[B0Y0MWW^'U!+ P04
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #10Z16JPJ\U[L#  !;'@
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MX^_+Q\G."W7'V<'OL<4O4$L#!!0    ( -%#I%93V2LIL@$  %,;   3
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -%#I%:[;ZJZ]04  ,\?   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #10Z16U'%3-;L%   S%P  &               @($Y#@  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ T4.D5@(BQV3W @  5PH
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M965T-RYX;6Q02P$"% ,4    " #10Z166"W%VX\)   6&P  &
M    @($82   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
MT4.D5I:8^CQ9!@  ]A   !@              ("!W5$  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( -%#I%:O@60Y!PH  +T<   9
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M970Q-"YX;6Q02P$"% ,4    " #10Z163"I92(L"  #H!0  &0
M    @('FA@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M -%#I%:&>X"Q21,  -8X   9              " @:B)  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ T4.D5LK24NR5!   8@P  !D
M             ("!*)T  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " #10Z16#&Y  .,$  #&#@  &0              @('TH0  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( -%#I%85+S\OD0,
M +8)   9              " @0ZG  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ T4.D5ND@64+C @  ?@8  !D              ("!
MUJH  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #10Z16
M_!ZO@_("   ]!@  &0              @('PK0  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -%#I%:QN41L,P,  .4'   9
M      " @1FQ  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ T4.D5EX&J%P? P  H@<  !D              ("!@[0  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #10Z16DMR- ZH)  !W60
M&0              @('9MP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( -%#I%96M1ZF>P,  !@/   9              " @;K!  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ T4.D5@E>0]BI
M!   "!H  !D              ("!;,4  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " #10Z16;T?MO+T"  !-!P  &0
M@(%,R@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( -%#
MI%;#X-P#G0D  'ES   9              " @4#-  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ T4.D5EMB)/$\!   ;Q0  !D
M         ("!%-<  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    " #10Z16A#,)Q"L%  !C'0  &0              @(&'VP  >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( -%#I%9XZH]]J0(  ! '
M   9              " @>G@  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ T4.D5EA.HRZ0 P  S0T  !D              ("!R>,
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #10Z166="?
M>BX#  #G"0  &0              @(&0YP  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( -%#I%;(F5RY# ,  !T)   9
M  " @?7J  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
MT4.D5LONBE+_!@  ;SD  !D              ("!..X  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " #10Z16Z0W2XG0#  #$#@  &0
M            @(%N]0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( -%#I%:OQ/^IDP(  % (   9              " @1GY  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ T4.D5DHXB.P=$0
M.!L! !D              ("!X_L  'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " #10Z16D!M[<RT#   ""@  &0              @($W
M#0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( -%#I%;_
MB'!B@P,  /,/   9              " @9L0 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ T4.D5H_BSS[+ @  "@D  !D
M     ("!510! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -%#I%:\A2X*)0,  $H2   -              "
M =XC 0!X;"]S='EL97,N>&UL4$L! A0#%     @ T4.D5I>*NQS     $P(
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9>&UL4$L%!@     U #4 :@X  ,,O 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>151</ContextCount>
  <ElementCount>229</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - The Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>The Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Equity Transactions and Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensation</Role>
      <ShortName>Equity Transactions and Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/SignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - DSTAT Contract Close-out</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/DSTATContractCloseout</Role>
      <ShortName>DSTAT Contract Close-out</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Restructuring Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/RestructuringCosts</Role>
      <ShortName>Restructuring Costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - The Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>The Business and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - The Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>The Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chimerix.com/role/Investments</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chimerix.com/role/CommitmentsandContingencies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Equity Transactions and Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationTables</Role>
      <ShortName>Equity Transactions and Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Significant Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/SignificantAgreementsTables</Role>
      <ShortName>Significant Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chimerix.com/role/SignificantAgreements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - DSTAT Contract Close-out (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/DSTATContractCloseoutTables</Role>
      <ShortName>DSTAT Contract Close-out (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chimerix.com/role/DSTATContractCloseout</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Restructuring Costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/RestructuringCostsTables</Role>
      <ShortName>Restructuring Costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chimerix.com/role/RestructuringCosts</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - The Business and Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>The Business and Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - The Business and Summary of Significant Accounting Policies - Employee Retention Credit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails</Role>
      <ShortName>The Business and Summary of Significant Accounting Policies - Employee Retention Credit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - The Business and Summary of Significant Accounting Policies - Deferred Loan Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails</Role>
      <ShortName>The Business and Summary of Significant Accounting Policies - Deferred Loan Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - The Business and Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails</Role>
      <ShortName>The Business and Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - The Business and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>The Business and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Investments - Summary of Available-for-Sale securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails</Role>
      <ShortName>Investments - Summary of Available-for-Sale securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Investments - Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails</Role>
      <ShortName>Investments - Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Investments - Schedule of Investment Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails</Role>
      <ShortName>Investments - Schedule of Investment Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Commitments and Contingencies - Operating Lease Right-of-Use Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease Right-of-Use Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Commitments and Contingencies - Maturity Analysis of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Maturity Analysis of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Equity Transactions and Share-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails</Role>
      <ShortName>Equity Transactions and Share-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Equity Transactions and Share-based Compensation - Schedule of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails</Role>
      <ShortName>Equity Transactions and Share-based Compensation - Schedule of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chimerix.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Significant Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/SignificantAgreementsDetails</Role>
      <ShortName>Significant Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chimerix.com/role/SignificantAgreementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Significant Agreements- Schedule of Assets and Liabilities Transferred in Accordance with Asset Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails</Role>
      <ShortName>Significant Agreements- Schedule of Assets and Liabilities Transferred in Accordance with Asset Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - DSTAT Contract Close-out - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails</Role>
      <ShortName>DSTAT Contract Close-out - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - DSTAT Contract Close-out- Contract Close-out Cost Income Statement Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails</Role>
      <ShortName>DSTAT Contract Close-out- Contract Close-out Cost Income Statement Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - DSTAT Contract Close-out- Schedule of Accrual Activities for Contract Close-out Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/DSTATContractCloseoutScheduleofAccrualActivitiesforContractCloseoutCostDetails</Role>
      <ShortName>DSTAT Contract Close-out- Schedule of Accrual Activities for Contract Close-out Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Restructuring Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/RestructuringCostsDetails</Role>
      <ShortName>Restructuring Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chimerix.com/role/RestructuringCostsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Restructuring Costs - Summary of Restructuring Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/RestructuringCostsSummaryofRestructuringChargesDetails</Role>
      <ShortName>Restructuring Costs - Summary of Restructuring Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cmrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Restructuring Costs - Accrual Activity for Restructuring Accrual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chimerix.com/role/RestructuringCostsAccrualActivityforRestructuringAccrualDetails</Role>
      <ShortName>Restructuring Costs - Accrual Activity for Restructuring Accrual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cmrx-20230331.htm">cmrx-20230331.htm</File>
    <File>a20230331cmrxex-311.htm</File>
    <File>a20230331cmrxex-312.htm</File>
    <File>a20230331cmrxex-321.htm</File>
    <File>a20230331cmrxex-322.htm</File>
    <File>cmrx-20230331.xsd</File>
    <File>cmrx-20230331_cal.xml</File>
    <File>cmrx-20230331_def.xml</File>
    <File>cmrx-20230331_lab.xml</File>
    <File>cmrx-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="490">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cmrx-20230331.htm": {
   "axisCustom": 1,
   "axisStandard": 20,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 490,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 151,
   "dts": {
    "calculationLink": {
     "local": [
      "cmrx-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cmrx-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cmrx-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cmrx-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cmrx-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cmrx-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 376,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 38,
   "keyStandard": 191,
   "memberCustom": 20,
   "memberStandard": 26,
   "nsprefix": "cmrx",
   "nsuri": "http://www.chimerix.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.chimerix.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Equity Transactions and Share-based Compensation",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensation",
     "shortName": "Equity Transactions and Share-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.chimerix.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermContractsOrProgramsDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Significant Agreements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.chimerix.com/role/SignificantAgreements",
     "shortName": "Significant Agreements",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermContractsOrProgramsDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - DSTAT Contract Close-out",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.chimerix.com/role/DSTATContractCloseout",
     "shortName": "DSTAT Contract Close-out",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Restructuring Costs",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.chimerix.com/role/RestructuringCosts",
     "shortName": "Restructuring Costs",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.chimerix.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - The Business and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "16",
     "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "The Business and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - The Business and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "The Business and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Investments (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.chimerix.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmrx:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.chimerix.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmrx:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.chimerix.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Equity Transactions and Share-based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationTables",
     "shortName": "Equity Transactions and Share-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmrx:ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Significant Agreements (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.chimerix.com/role/SignificantAgreementsTables",
     "shortName": "Significant Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmrx:ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmrx:ScheduleOfContractCloseOutCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - DSTAT Contract Close-out (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.chimerix.com/role/DSTATContractCloseoutTables",
     "shortName": "DSTAT Contract Close-out (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmrx:ScheduleOfContractCloseOutCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Restructuring Costs (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.chimerix.com/role/RestructuringCostsTables",
     "shortName": "Restructuring Costs (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - The Business and Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "The Business and Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i804d7d03889847d5ae48e5ad93dbb50f_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i18d0bbe7e74a49d99423e480deb74908_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cmrx:EmployeeRetentionCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - The Business and Summary of Significant Accounting Policies - Employee Retention Credit (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails",
     "shortName": "The Business and Summary of Significant Accounting Policies - Employee Retention Credit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i18d0bbe7e74a49d99423e480deb74908_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cmrx:EmployeeRetentionCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmrx:LoanFeesLiabilityNonCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - The Business and Summary of Significant Accounting Policies - Deferred Loan Costs (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails",
     "shortName": "The Business and Summary of Significant Accounting Policies - Deferred Loan Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i3fff5d25cf6449308bcbf75364001e45_D20220131-20220131",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmrx:AccruedDevelopmentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - The Business and Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails",
     "shortName": "The Business and Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmrx:AccruedDevelopmentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - The Business and Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "The Business and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Investments - Summary of Available-for-Sale securities (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails",
     "shortName": "Investments - Summary of Available-for-Sale securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Investments - Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails",
     "shortName": "Investments - Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Investments - Schedule of Investment Maturity (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails",
     "shortName": "Investments - Schedule of Investment Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Commitments and Contingencies - Operating Lease Right-of-Use Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Operating Lease Right-of-Use Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cmrx:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Commitments and Contingencies - Maturity Analysis of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Maturity Analysis of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Equity Transactions and Share-based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails",
     "shortName": "Equity Transactions and Share-based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Equity Transactions and Share-based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails",
     "shortName": "Equity Transactions and Share-based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.chimerix.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Significant Agreements (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.chimerix.com/role/SignificantAgreementsDetails",
     "shortName": "Significant Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4dc7c0b07dc840118483ece5d0ba3401_I20220731",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Significant Agreements- Schedule of Assets and Liabilities Transferred in Accordance with Asset Purchase Agreement (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails",
     "shortName": "Significant Agreements- Schedule of Assets and Liabilities Transferred in Accordance with Asset Purchase Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4961cde06b594dbda19a2c2e104299b5_D20220926-20220926",
      "decimals": "-3",
      "lang": "en-US",
      "name": "cmrx:AssetSaleLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i1ea283aae3314b6683e2cb4a1614f1d9_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmrx:ContractCloseOutLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - DSTAT Contract Close-out - Narratives (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails",
     "shortName": "DSTAT Contract Close-out - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "if82f3e05482f40578ab012f41b08b052_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "cmrx:ContractCloseOutLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cmrx:ScheduleOfContractCloseOutCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "ic0ee769ecce64f21994ca9ced836dbaa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmrx:ContractCloseOutCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - DSTAT Contract Close-out- Contract Close-out Cost Income Statement Location (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.chimerix.com/role/DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails",
     "shortName": "DSTAT Contract Close-out- Contract Close-out Cost Income Statement Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cmrx:ScheduleOfContractCloseOutCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "ic0ee769ecce64f21994ca9ced836dbaa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmrx:ContractCloseOutCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i040b1a26f397449cbae5cbdc11f92d47_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cmrx:ContractCloseOutLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - DSTAT Contract Close-out- Schedule of Accrual Activities for Contract Close-out Cost (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.chimerix.com/role/DSTATContractCloseoutScheduleofAccrualActivitiesforContractCloseoutCostDetails",
     "shortName": "DSTAT Contract Close-out- Schedule of Accrual Activities for Contract Close-out Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "cmrx:ContractCloseOutLiabilityPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "if6405e9f8e2e42febb0630cc3f4b70cf_D20221201-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Restructuring Costs (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.chimerix.com/role/RestructuringCostsDetails",
     "shortName": "Restructuring Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "if6405e9f8e2e42febb0630cc3f4b70cf_D20221201-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Restructuring Costs - Summary of Restructuring Charges (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.chimerix.com/role/RestructuringCostsSummaryofRestructuringChargesDetails",
     "shortName": "Restructuring Costs - Summary of Restructuring Charges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i01d7ce8ff73a42f8bc6ebe1f484b504b_D20221001-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i040b1a26f397449cbae5cbdc11f92d47_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Restructuring Costs - Accrual Activity for Restructuring Accrual (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.chimerix.com/role/RestructuringCostsAccrualActivityforRestructuringAccrualDetails",
     "shortName": "Restructuring Costs - Accrual Activity for Restructuring Accrual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserveAccrualAdjustment1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i6de410df18e74128ab476b930f4658bc_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i6de410df18e74128ab476b930f4658bc_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - The Business and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPolicies",
     "shortName": "The Business and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Investments",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.chimerix.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.chimerix.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cmrx-20230331.htm",
      "contextRef": "i4e2757f9f59a4bb8be609320d7f0e9b4_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "cmrx_AccrualActivitiesForContractCloseOutCostRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrual Activities for Contract Close-out Cost",
        "label": "Accrual Activities for Contract Close-out Cost [Roll Forward]",
        "terseLabel": "Accrual Activities for Contract Close-out Cost"
       }
      }
     },
     "localname": "AccrualActivitiesForContractCloseOutCostRollForward",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutScheduleofAccrualActivitiesforContractCloseoutCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmrx_AccruedDevelopmentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued development liabilities.",
        "label": "Accrued Development Liabilities",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedDevelopmentLiabilities",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_AnticipatedSeveranceCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anticipated Severance Cost",
        "label": "Anticipated Severance Cost",
        "terseLabel": "Anticipated severance cost"
       }
      }
     },
     "localname": "AnticipatedSeveranceCost",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/RestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_AssetSaleInventoryTransferred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Sale, Inventory Transferred",
        "label": "Asset Sale, Inventory Transferred",
        "negatedTerseLabel": "Inventory transferred to Emergent"
       }
      }
     },
     "localname": "AssetSaleInventoryTransferred",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_AssetSaleLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Sale, Liabilities",
        "label": "Asset Sale, Liabilities",
        "terseLabel": "Liabilities assumed by Emergent"
       }
      }
     },
     "localname": "AssetSaleLiabilities",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_AssetSalePrepaidsTransferred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Sale, Prepaids Transferred",
        "label": "Asset Sale, Prepaids Transferred",
        "negatedTerseLabel": "Prepaids transferred to Emergent"
       }
      }
     },
     "localname": "AssetSalePrepaidsTransferred",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Operating Lease Right-of-Use Assets and Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmrx_BARDAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BARDA [Member]",
        "label": "BARDA [Member]",
        "terseLabel": "BARDA"
       }
      }
     },
     "localname": "BARDAMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_BasePerformanceContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Performance, Contract Term",
        "label": "Base Performance, Contract Term",
        "terseLabel": "Base performance, contract term"
       }
      }
     },
     "localname": "BasePerformanceContractTerm",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmrx_BasePeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Period",
        "label": "Base Period [Member]",
        "terseLabel": "Base Period"
       }
      }
     },
     "localname": "BasePeriodMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business and Summary of Significant Accounting Policies",
        "label": "Business and Summary of Significant Accounting Policies [Line Items]",
        "terseLabel": "Business and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmrx_BusinessAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business and Summary of Significant Accounting Policies",
        "label": "Business and Summary of Significant Accounting Policies [Table]",
        "terseLabel": "Business and Summary of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "BusinessAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmrx_ContractAndGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract And Grant",
        "label": "Contract And Grant [Member]",
        "terseLabel": "Contract and grant revenue"
       }
      }
     },
     "localname": "ContractAndGrantMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_ContractCloseOutCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Close Out Costs",
        "label": "Contract Close Out Costs",
        "terseLabel": "Contract close out cost"
       }
      }
     },
     "localname": "ContractCloseOutCosts",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_ContractCloseOutLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Close Out Liability",
        "label": "Contract Close Out Liability",
        "periodEndLabel": "Balance at December 31, 2022",
        "periodStartLabel": "Balance at June 30, 2022",
        "terseLabel": "Contract close out liability"
       }
      }
     },
     "localname": "ContractCloseOutLiability",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails",
      "http://www.chimerix.com/role/DSTATContractCloseoutScheduleofAccrualActivitiesforContractCloseoutCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_ContractCloseOutLiabilityAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Close Out Liability, Adjustments",
        "label": "Contract Close Out Liability, Adjustments",
        "negatedTerseLabel": "Revised estimates",
        "terseLabel": "Revised estimates"
       }
      }
     },
     "localname": "ContractCloseOutLiabilityAdjustments",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails",
      "http://www.chimerix.com/role/DSTATContractCloseoutScheduleofAccrualActivitiesforContractCloseoutCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_ContractCloseOutLiabilityPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Close Out Liability, Payments",
        "label": "Contract Close Out Liability, Payments",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "ContractCloseOutLiabilityPayments",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutScheduleofAccrualActivitiesforContractCloseoutCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_ContractWithCustomerLiabilityInstallmentPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Installment Periods",
        "label": "Contract With Customer, Liability, Installment Periods",
        "terseLabel": "Number of payment installments"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityInstallmentPeriods",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cmrx_DebtInstrumentEarlyTerminationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Early Termination Fee",
        "label": "Debt Instrument, Early Termination Fee",
        "terseLabel": "Debt instrument, early termination fee"
       }
      }
     },
     "localname": "DebtInstrumentEarlyTerminationFee",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_DebtInstrumentNumberOfInstallmentPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Installment Payments",
        "label": "Debt Instrument, Number Of Installment Payments",
        "terseLabel": "Number of installment payments (installment)"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfInstallmentPayments",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cmrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year Two",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year Two",
        "terseLabel": "Maturing after one year through two years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_EmergentBioSolutionsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emergent BioSolutions, Inc.",
        "label": "Emergent BioSolutions, Inc. [Member]",
        "terseLabel": "Emergent"
       }
      }
     },
     "localname": "EmergentBioSolutionsIncMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_EmergentBiodefenseOperationsLansingLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emergent Biodefense Operations Lansing LLC",
        "label": "Emergent Biodefense Operations Lansing LLC [Member]",
        "terseLabel": "Emergent Biodefense Operations Lansing LLC"
       }
      }
     },
     "localname": "EmergentBiodefenseOperationsLansingLLCMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_EmployeeRetentionCredit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Retention Credit",
        "label": "Employee Retention Credit",
        "terseLabel": "Employee retention credit"
       }
      }
     },
     "localname": "EmployeeRetentionCredit",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_ExpenseReimbursementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense Reimbursement [Member]",
        "label": "Expense Reimbursement [Member]",
        "terseLabel": "Expense reimbursement"
       }
      }
     },
     "localname": "ExpenseReimbursementMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_IndependentMembersOfBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Independent Members Of Board",
        "label": "Independent Members Of Board [Member]",
        "terseLabel": "Independent Members Of Board"
       }
      }
     },
     "localname": "IndependentMembersOfBoardMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Nonrefundable Regulatory Milestone Payment To Be Received",
        "label": "License Agreement, Nonrefundable Regulatory Milestone Payment To Be Received",
        "terseLabel": "License agreement, nonrefundable regulatory milestone payment to be received"
       }
      }
     },
     "localname": "LicenseAgreementNonrefundableRegulatoryMilestonePaymentToBeReceived",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_LoanFeesLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Fees Liability, Current",
        "label": "Loan Fees Liability, Current",
        "verboseLabel": "Loan fee liability"
       }
      }
     },
     "localname": "LoanFeesLiabilityCurrent",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_LoanFeesLiabilityNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Fees Liability, Non-Current",
        "label": "Loan Fees Liability, Non-Current",
        "terseLabel": "Non-current loan fee liability",
        "verboseLabel": "Loan fees"
       }
      }
     },
     "localname": "LoanFeesLiabilityNonCurrent",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_MaximumMilestoneProceedsUponTheExerciseOfOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Milestone Proceeds Upon The Exercise Of Options",
        "label": "Maximum Milestone Proceeds Upon The Exercise Of Options",
        "terseLabel": "Maximum milestone proceeds upon the exercise of options"
       }
      }
     },
     "localname": "MaximumMilestoneProceedsUponTheExerciseOfOptions",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_NationalStockpileMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "National Stockpile",
        "label": "National Stockpile [Member]",
        "terseLabel": "National Stockpile"
       }
      }
     },
     "localname": "NationalStockpileMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_NonUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non- United States",
        "label": "Non- United States [Member]",
        "terseLabel": "Non- United States"
       }
      }
     },
     "localname": "NonUnitedStatesMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_OharaPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ohara Pharmaceutical Co., Ltd.",
        "label": "Ohara Pharmaceutical Co., Ltd. [Member]",
        "terseLabel": "Ohara Pharmaceutical Co., Ltd."
       }
      }
     },
     "localname": "OharaPharmaceuticalCoLtdMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_OncoceuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncoceutics, Inc.",
        "label": "Oncoceutics, Inc. [Member]",
        "terseLabel": "Oncoceutics, Inc."
       }
      }
     },
     "localname": "OncoceuticsIncMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent": {
     "auth_ref": [],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right-of-Use Asset, Amortization Expense and Straight Line Rent",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense and Straight Line Rent",
        "terseLabel": "Lease-related amortization"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_OptionToPurchaseAdditionalTreatmentCourses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option To Purchase Additional Treatment Courses",
        "label": "Option To Purchase Additional Treatment Courses",
        "terseLabel": "Amount of additional courses at the discretion of customer"
       }
      }
     },
     "localname": "OptionToPurchaseAdditionalTreatmentCourses",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cmrx_OptionToPurchaseAdditionalTreatmentCoursesGrossValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option To Purchase Additional Treatment Courses, Gross Value",
        "label": "Option To Purchase Additional Treatment Courses, Gross Value",
        "terseLabel": "Amount of additional courses at the discretion of customer, gross value"
       }
      }
     },
     "localname": "OptionToPurchaseAdditionalTreatmentCoursesGrossValue",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option To Purchase Additional Treatment Courses, Net Of Marketing Cost",
        "label": "Option To Purchase Additional Treatment Courses, Net Of Marketing Cost",
        "terseLabel": "Amount of additional courses at the discretion of customer, net of marketing cost"
       }
      }
     },
     "localname": "OptionToPurchaseAdditionalTreatmentCoursesNetOfMarketingCost",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_PeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period",
        "label": "Period [Axis]",
        "terseLabel": "Period [Axis]"
       }
      }
     },
     "localname": "PeriodAxis",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmrx_PeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period [Domain]",
        "label": "Period [Domain]",
        "terseLabel": "Period [Domain]"
       }
      }
     },
     "localname": "PeriodDomain",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_PublicHealthAgencyOfCanadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Health Agency Of Canada",
        "label": "Public Health Agency Of Canada [Member]",
        "terseLabel": "PHAC"
       }
      }
     },
     "localname": "PublicHealthAgencyOfCanadaMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_PurchaserMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchaser",
        "label": "Purchaser [Member]",
        "terseLabel": "Purchaser"
       }
      }
     },
     "localname": "PurchaserMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_QuantityBenchmarkGrossProfitRoyaltyRateTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quantity Benchmark, Gross Profit Royalty Rate Trigger",
        "label": "Quantity Benchmark, Gross Profit Royalty Rate Trigger",
        "terseLabel": "Quantity royalty rate, trigger (treatments)"
       }
      }
     },
     "localname": "QuantityBenchmarkGrossProfitRoyaltyRateTrigger",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cmrx_QuantityBenchmarkTreatmentContractualCommitment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quantity Benchmark, Treatment Contractual Commitment",
        "label": "Quantity Benchmark, Treatment Contractual Commitment",
        "terseLabel": "Contractual treatment commitment (treatment)"
       }
      }
     },
     "localname": "QuantityBenchmarkTreatmentContractualCommitment",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cmrx_RefundableAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refundable Agreements [Member]",
        "label": "Refundable Agreements [Member]",
        "terseLabel": "Refundable Agreements"
       }
      }
     },
     "localname": "RefundableAgreementsMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_ReimbursableMarketingCostUponTheExerciseOfOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursable Marketing Cost Upon The Exercise Of Options",
        "label": "Reimbursable Marketing Cost Upon The Exercise Of Options",
        "terseLabel": "Reimbursable marketing cost upon the exercise of options"
       }
      }
     },
     "localname": "ReimbursableMarketingCostUponTheExerciseOfOptions",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_ReimbursableMarketingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursable Marketing Expenses",
        "label": "Reimbursable Marketing Expenses",
        "terseLabel": "Reimbursable marketing expenses"
       }
      }
     },
     "localname": "ReimbursableMarketingExpenses",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_RevenueBenchmarkGrossProfitRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Benchmark, Gross Profit Royalty Rate",
        "label": "Revenue Benchmark, Gross Profit Royalty Rate",
        "terseLabel": "Gross profit royalty rate (percent)"
       }
      }
     },
     "localname": "RevenueBenchmarkGrossProfitRoyaltyRate",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmrx_SalesOfStockAuthorizationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Of Stock, Authorization Term",
        "label": "Sales Of Stock, Authorization Term",
        "terseLabel": "Sales of stock, authorization term"
       }
      }
     },
     "localname": "SalesOfStockAuthorizationTerm",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmrx_SalesOfStockAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Of Stock, Authorized Amount",
        "label": "Sales Of Stock, Authorized Amount",
        "terseLabel": "Sale of common stock, amount authorized"
       }
      }
     },
     "localname": "SalesOfStockAuthorizedAmount",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmrx_SanjiuMedicalPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanjiu Medical &amp; Pharmaceutical Co., Ltd.",
        "label": "Sanjiu Medical &amp; Pharmaceutical Co., Ltd. [Member]",
        "terseLabel": "CR Sanjui"
       }
      }
     },
     "localname": "SanjiuMedicalPharmaceuticalCoLtdMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_ScheduleOfContractCloseOutCostsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Contract Close-Out Costs",
        "label": "Schedule Of Contract Close-Out Costs [Table Text Block]",
        "terseLabel": "Schedule of Accrual Activities for Contract Close-out Cost"
       }
      }
     },
     "localname": "ScheduleOfContractCloseOutCostsTableTextBlock",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmrx_ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Net Gain From The Sales Of Assets",
        "label": "Schedule Of Net Gain From The Sales Of Assets [Table Text Block]",
        "terseLabel": "Schedule Of Net Gain From The Sales Of Assets"
       }
      }
     },
     "localname": "ScheduleOfNetGainFromTheSalesOfAssetsTableTextBlock",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmrx_ShareBasedCompensationOptionProvisionEquityIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation, Option Provision, Equity Increase",
        "label": "Share-Based Compensation, Option Provision, Equity Increase",
        "terseLabel": "Evergreen option provision, equity increase"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionProvisionEquityIncrease",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Participation Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Participation Term",
        "terseLabel": "Participation term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardParticipationTerm",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmrx_SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Interval",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Interval",
        "terseLabel": "Purchase interval"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardPurchaseInterval",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmrx_SignificantAgreementsContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Agreements, Contract Term",
        "label": "Significant Agreements, Contract Term",
        "terseLabel": "Contract term (years)"
       }
      }
     },
     "localname": "SignificantAgreementsContractTerm",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmrx_SymBioPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SymBio Pharmaceuticals [Member]",
        "label": "SymBio Pharmaceuticals [Member]",
        "terseLabel": "SymBio Pharmaceuticals"
       }
      }
     },
     "localname": "SymBioPharmaceuticalsMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_TEMBEXAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TEMBEXA",
        "label": "TEMBEXA [Member]",
        "terseLabel": "TEMBEXA"
       }
      }
     },
     "localname": "TEMBEXAMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_The2013EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The 2013 Employee Stock Purchase Plan Member.",
        "label": "The 2013 Employee Stock Purchase Plan [Member]",
        "terseLabel": "The 2013 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "The2013EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_The2013PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The 2013 Plan [Member]",
        "label": "The 2013 Plan [Member]",
        "terseLabel": "The 2013 Plan"
       }
      }
     },
     "localname": "The2013PlanMember",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmrx_TransactionCostsIncurredInRelationToSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Costs Incurred In Relation To Sales",
        "label": "Transaction Costs Incurred In Relation To Sales",
        "negatedTerseLabel": "Transaction costs incurred"
       }
      }
     },
     "localname": "TransactionCostsIncurredInRelationToSales",
     "nsuri": "http://www.chimerix.com/20230331",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.chimerix.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r143",
      "r144",
      "r251",
      "r256",
      "r441",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r193",
      "r456",
      "r513",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r282",
      "r398",
      "r420",
      "r438",
      "r439",
      "r453",
      "r464",
      "r472",
      "r512",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r193",
      "r456",
      "r513",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r190",
      "r412",
      "r454",
      "r470",
      "r507",
      "r508",
      "r513",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r190",
      "r412",
      "r454",
      "r470",
      "r507",
      "r508",
      "r513",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r275",
      "r282",
      "r310",
      "r311",
      "r312",
      "r374",
      "r398",
      "r420",
      "r438",
      "r439",
      "r453",
      "r464",
      "r472",
      "r506",
      "r512",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r275",
      "r282",
      "r310",
      "r311",
      "r312",
      "r374",
      "r398",
      "r420",
      "r438",
      "r439",
      "r453",
      "r464",
      "r472",
      "r506",
      "r512",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r143",
      "r144",
      "r251",
      "r256",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r283",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r158",
      "r283",
      "r480",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/IncomeTaxesDetails",
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r191",
      "r192",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r455",
      "r471",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r191",
      "r192",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r455",
      "r471",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r158",
      "r283",
      "r480",
      "r481",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/IncomeTaxesDetails",
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r497",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r19",
      "r468"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r194",
      "r195"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of discount/premium on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedSalariesCurrentAndNoncurrent": {
     "auth_ref": [
      "r98",
      "r107"
     ],
     "calculation": {
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.",
        "label": "Accrued Salaries",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedSalariesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r124",
      "r417",
      "r425",
      "r426"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss, net"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r26",
      "r29",
      "r87",
      "r365",
      "r421",
      "r422",
      "r485",
      "r486",
      "r487",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated\u00a0Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r14",
      "r468"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r492",
      "r493",
      "r494",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in\u00a0Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r80",
      "r81",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r33",
      "r253",
      "r356",
      "r490"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r103",
      "r121",
      "r141",
      "r175",
      "r184",
      "r188",
      "r205",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r335",
      "r337",
      "r349",
      "r468",
      "r510",
      "r511",
      "r549"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails",
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r116",
      "r127",
      "r141",
      "r205",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r335",
      "r337",
      "r349",
      "r468",
      "r510",
      "r511",
      "r549"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r60",
      "r196",
      "r415"
     ],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "The Business and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r43",
      "r48",
      "r50"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets",
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r43",
      "r93"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails",
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r235",
      "r236",
      "r428",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r492",
      "r493",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, 200,000,000 shares authorized at March\u00a031, 2023 and December\u00a031, 2022; 88,583,567 and 88,054,127 shares issued and outstanding as of March\u00a031, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r30",
      "r132",
      "r134",
      "r138",
      "r413",
      "r418"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "verboseLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r259",
      "r261",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r259",
      "r260",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Provision for refundable amounts"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r259",
      "r260",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails",
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r35",
      "r141",
      "r205",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r349",
      "r510"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r24",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r203",
      "r216",
      "r450"
     ],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Fair value, greater than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r203",
      "r216"
     ],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "Unrealized loss, greater than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of securities with unrealized losses, greater than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r203",
      "r216",
      "r450"
     ],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Fair value, less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r203",
      "r216"
     ],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Unrealized loss, less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Number of securities with unrealized losses, less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Total debt investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsScheduleofInvestmentMaturityDetails",
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current",
        "terseLabel": "Short-term investments, available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Noncurrent",
        "terseLabel": "Total long-term investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "verboseLabel": "Summary of Short-Term and Long-Term Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r200",
      "r212",
      "r450"
     ],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Fair value, total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r201",
      "r213"
     ],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Unrealized loss, total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r199",
      "r450",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Investments with Unrealized Losses, Aggregated by Investment Type and the Length of Time"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r202",
      "r214"
     ],
     "calculation": {
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "totalLabel": "Number of securities with unrealized losses, total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r95",
      "r102",
      "r482"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Noncurrent deferred loan costs"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred Costs, Current",
        "terseLabel": "Current deferred loan costs"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r46",
      "r62"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation of property and equipment"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r271",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r287",
      "r315",
      "r316",
      "r317",
      "r321",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Transactions and Share-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Per share information:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r139",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r159",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r341",
      "r342",
      "r414",
      "r419",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r139",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r341",
      "r342",
      "r414",
      "r419",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Net Income (Loss) Per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "verboseLabel": "Estimated annual effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r73",
      "r114",
      "r135",
      "r136",
      "r137",
      "r145",
      "r146",
      "r147",
      "r149",
      "r155",
      "r157",
      "r168",
      "r206",
      "r258",
      "r318",
      "r319",
      "r320",
      "r328",
      "r329",
      "r340",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r365",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r252",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r344",
      "r371",
      "r372",
      "r373",
      "r451",
      "r452",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r252",
      "r276",
      "r281",
      "r344",
      "r371",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0Prices\u00a0in Active\u00a0Markets for\u00a0Identical\u00a0Assets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r252",
      "r276",
      "r281",
      "r344",
      "r372",
      "r451",
      "r452",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant\u00a0Other Observable\u00a0Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r252",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r344",
      "r373",
      "r451",
      "r452",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable\u00a0Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r252",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r371",
      "r372",
      "r373",
      "r451",
      "r452",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value, measurements, recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r197",
      "r198",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r215",
      "r217",
      "r218",
      "r254",
      "r257",
      "r339",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r450",
      "r499",
      "r500",
      "r501",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]",
        "verboseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails",
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "terseLabel": "Gain (loss) on sale of assets",
        "verboseLabel": "Net gain"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails",
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.chimerix.com/role/RestructuringCostsSummaryofRestructuringChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r34",
      "r141",
      "r175",
      "r183",
      "r187",
      "r189",
      "r205",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r349",
      "r449",
      "r510"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "verboseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "verboseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r222",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails",
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.chimerix.com/role/RestructuringCostsSummaryofRestructuringChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails",
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.chimerix.com/role/RestructuringCostsSummaryofRestructuringChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r324",
      "r326",
      "r327",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable, accrued liabilities and deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income and other, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r125",
      "r167",
      "r219",
      "r220",
      "r221",
      "r407",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of the Scheduled Maturity of Company Investments"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r94",
      "r101",
      "r111",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum rental payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Year one"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Year four"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Year three"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Year two"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less amount of lease payments representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r21",
      "r141",
      "r205",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r336",
      "r337",
      "r338",
      "r349",
      "r448",
      "r510",
      "r549",
      "r550"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r18",
      "r97",
      "r105",
      "r468",
      "r491",
      "r502",
      "r545"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r117",
      "r141",
      "r205",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r336",
      "r337",
      "r338",
      "r349",
      "r468",
      "r510",
      "r549",
      "r550"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Licensing",
        "verboseLabel": "Licensing revenue"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Commitment Fee Amount",
        "terseLabel": "Debt instrument, unused borrowing capacity, fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit facility, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermContractsOrProgramsDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r112",
      "r113",
      "r122",
      "r123",
      "r126",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term contracts or programs.",
        "label": "Long-Term Contracts or Programs Disclosure [Text Block]",
        "terseLabel": "Significant Agreements",
        "verboseLabel": "DSTAT Contract Close-out"
       }
      }
     },
     "localname": "LongTermContractsOrProgramsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseout",
      "http://www.chimerix.com/role/SignificantAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r43",
      "r44",
      "r47"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r31",
      "r47",
      "r99",
      "r108",
      "r115",
      "r131",
      "r133",
      "r137",
      "r141",
      "r148",
      "r150",
      "r151",
      "r152",
      "r153",
      "r156",
      "r157",
      "r162",
      "r175",
      "r183",
      "r187",
      "r189",
      "r205",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r342",
      "r349",
      "r449",
      "r510"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Impact of Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r175",
      "r183",
      "r187",
      "r189",
      "r449"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense under non-cancelable operating leases"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "negatedTotalLabel": "Total present value of lease payments",
        "terseLabel": "Total present value of lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseLiabilitiesDetails",
      "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Operating lease short-term liabilities (recorded within Accrued liabilities)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease, liability, current, statement of financial position [extensible list]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "negatedLabel": "Operating lease long-term liabilities (recorded within Lease-related obligations)",
        "terseLabel": "Lease-related obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails",
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r360",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesOperatingLeaseRightofUseAssetsandLiabilitiesDetails",
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r363",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r362",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r128",
      "r129",
      "r130"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on debt investments, net",
        "verboseLabel": "Unrealized loss on investments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonrecurringIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonrecurring (Income) Expense [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "OtherNonrecurringIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r225",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/RestructuringCostsAccrualActivityforRestructuringAccrualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "auth_ref": [
      "r488"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.",
        "label": "Payments to Acquire Long-Term Investments",
        "negatedTerseLabel": "Purchases of long-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r12",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "verboseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized at March\u00a031, 2023 and December\u00a031, 2022; no shares issued and outstanding as of March\u00a031, 2023 and December\u00a031, 2022"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r484"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "auth_ref": [
      "r44",
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.",
        "label": "Proceeds from Income Tax Refunds",
        "terseLabel": "Proceeds from tax refund"
       }
      }
     },
     "localname": "ProceedsFromIncomeTaxRefunds",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r41",
      "r78"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "auth_ref": [
      "r38",
      "r40"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments",
        "verboseLabel": "Proceeds from maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfNotesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.",
        "label": "Proceeds from (Repayments of) Notes Payable",
        "terseLabel": "Payment of note payable related to asset acquisition"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Up-front cash payment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-Term Investments",
        "terseLabel": "Proceeds from sales of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r78"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r63",
      "r106",
      "r416",
      "r468"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "negatedTerseLabel": "Gain on sale of investments"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails",
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.chimerix.com/role/RestructuringCostsSummaryofRestructuringChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Prepaids and Accruals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r223",
      "r225",
      "r228",
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/RestructuringCosts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Reduction in workforce"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/RestructuringCostsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/RestructuringCostsSummaryofRestructuringChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r225",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Balance at March 31, 2023",
        "periodStartLabel": "Balance at December 31, 2022",
        "terseLabel": "Severance accrual balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/RestructuringCostsAccrualActivityforRestructuringAccrualDetails",
      "http://www.chimerix.com/role/RestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAccrualAdjustment1": {
     "auth_ref": [
      "r225",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.",
        "label": "Restructuring Reserve, Accrual Adjustment",
        "terseLabel": "Revised estimates"
       }
      }
     },
     "localname": "RestructuringReserveAccrualAdjustment1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/RestructuringCostsAccrualActivityforRestructuringAccrualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/RestructuringCostsAccrualActivityforRestructuringAccrualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r74",
      "r104",
      "r424",
      "r426",
      "r468"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r114",
      "r145",
      "r146",
      "r147",
      "r149",
      "r155",
      "r157",
      "r206",
      "r318",
      "r319",
      "r320",
      "r328",
      "r329",
      "r340",
      "r421",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r173",
      "r174",
      "r182",
      "r185",
      "r186",
      "r190",
      "r191",
      "r193",
      "r270",
      "r271",
      "r412"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Contract and grant revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r274",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition [Abstract]",
        "terseLabel": "Revenue Recognition [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domain member used to indicate figures that are adjustments during a period or as of a point in time. This domain member would never be expected to appear in a relationship group without the \"Scenario, Previously Reported\" Member with the same parent.",
        "label": "Scenario, Adjustment [Member]",
        "terseLabel": "Scenario, Adjustment"
       }
      }
     },
     "localname": "ScenarioAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesEmployeeRetentionCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The scenario under which facts represent plans as distinct from actual.",
        "label": "Scenario, Plan [Member]",
        "terseLabel": "Scenario, Plan"
       }
      }
     },
     "localname": "ScenarioPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/DSTATContractCloseoutContractCloseoutCostIncomeStatementLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Employee and Non-Employee Share-Based Compensation Expense Recognized Related to Stock Options, the ESPP and RSUs"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r76",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Certain Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Separate Account Investment [Line Items]",
        "terseLabel": "Fair Value, Separate Account Investment"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable": {
     "auth_ref": [
      "r469",
      "r473",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about fair value of asset supporting separate account.",
        "label": "Fair Value, Separate Account Investment [Table]",
        "terseLabel": "Fair Value, Separate Account Investment [Table]"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails",
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails",
      "http://www.chimerix.com/role/SignificantAgreementsDetails",
      "http://www.chimerix.com/role/SignificantAgreementsScheduleofAssetsandLiabilitiesTransferredinAccordancewithAssetPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/RestructuringCostsSummaryofRestructuringChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r67",
      "r68",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Restructuring and Related Costs"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/RestructuringCostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r66",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/RestructuringCostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r284",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "One-time employee termination benefits",
        "verboseLabel": "Total restructuring expenses"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails",
      "http://www.chimerix.com/role/RestructuringCostsDetails",
      "http://www.chimerix.com/role/RestructuringCostsSummaryofRestructuringChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date",
        "terseLabel": "Discounted purchase price from market price, offering date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Discounted purchase price from market price, purchase date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of pay that employee can contribute, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "verboseLabel": "Additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Number of shares authorized to be granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r25",
      "r73",
      "r114",
      "r135",
      "r136",
      "r137",
      "r145",
      "r146",
      "r147",
      "r149",
      "r155",
      "r157",
      "r168",
      "r206",
      "r258",
      "r318",
      "r319",
      "r320",
      "r328",
      "r329",
      "r340",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r365",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r168",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r12",
      "r13",
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued pursuant to employee stock purchase plan (in shares)",
        "verboseLabel": "Employee stock purchase plan purchases (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r12",
      "r13",
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "RSU stock issuance (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r73",
      "r74",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Shares issued pursuant to the exercise of stock options (in shares)",
        "verboseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r12",
      "r13",
      "r73",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Employee stock purchase plan purchases"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r73",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r16",
      "r17",
      "r57",
      "r468",
      "r491",
      "r502",
      "r545"
     ],
     "calculation": {
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets",
      "http://www.chimerix.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/EquityTransactionsandSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r197",
      "r198",
      "r254",
      "r257",
      "r339",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r499",
      "r500",
      "r501",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]",
        "verboseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails",
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r446",
      "r461",
      "r463",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/InvestmentsSummaryofAvailableforSalesecuritiesDetails",
      "http://www.chimerix.com/role/InvestmentsSummaryofInvestmentswithUnrealizedLossesAggregatedbyInvestmentTypeandtheLengthofTimeDetails",
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r322",
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r169",
      "r170",
      "r171",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/TheBusinessandSummaryofSignificantAccountingPoliciesDeferredLoanCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r160",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r159",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.chimerix.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991585-234733",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991590-234733",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(c)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(c)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(d)(ii))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=6471471&loc=d3e48698-109348",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938061&loc=d3e54658-109401",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938061&loc=d3e54672-109401",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938061&loc=d3e54681-109401",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938061&loc=d3e54708-109401",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938061&loc=d3e54711-109401",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=84167097&loc=d3e55538-109407",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=84167097&loc=d3e55562-109407",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938292&loc=d3e56288-109415",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938335&loc=d3e56414-109416",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938335&loc=d3e56417-109416",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "912",
   "URI": "https://asc.fasb.org/topic&trid=2145070",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124504833&loc=d3e7104-158389",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124505678&loc=SL117422397-158474",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r475": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r476": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r477": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r478": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r479": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "35",
   "Topic": "605",
   "URI": "https://asc.fasb.org/subtopic&trid=2197326",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001117480-23-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001117480-23-000018-xbrl.zip
M4$L#!!0    ( -%#I%8BA+PW+P@  #DE   7    83(P,C,P,S,Q8VUR>&5X
M+3,Q,2YH=&WM6FUOVS@2_GZ_@NO@N@E@R^]-XJ0!4L=%#;1)-W&ONY\.M$A9
MO$BBEJ3L^'[]/23EE\1.ZVY[UR:X G$M<3@<SCSSS%#RZ2\75_W1'Q\&)#9I
M0CY\?/UNV">56KW^J=VOUR]&%^3MZ/T[T@D:33)2--/"")G1I%X?7%9()38F
M[]7KL]DLF+4#J2;UT77=JNK4$RDU#YAAE;-3>P>?G+*SOYW^4JN1"QD6*<\,
M"16GAC-2:)%-R"?&]2VIU4JIOLSG2DQB0UJ-5IM\DNI63*D?-\(D_&RAY[3N
MKT_K;I'3L63SLU,FID2P5Q71[3:/&XU6ZRCL=CN'C=9QE[4;C9>=9AB%+SNL
M\\\FC*Q#W,_19I[P5Y549+68V_5[G59PV,W-R4PP$_>:C<;?*T[T[#22F<%Z
M"O/]5Z]F0YGA=Z9&$S')>FY+%3]U,1S*1*K>7L/].[$CM8BF(IGW?AV)E&MR
MR6?D6J8T^[6J$8::YDI$7E"+?W/8!//<Y<R;? @]B<CX8@O-EC5Z<!>+L3 O
M]IHO&R?M9M"\;_9V@T-XF*L3=T=D#%>]]LO\O[^%SM8M>-MWM_L'>;H_N!X-
MWPS[YZ/AU26Y>D/Z;X>#-V3P^Z#_<33\QP"W,#JX1M)=WWP\OQR1T16Y&?2=
M>+O1LE-&;P?DYOSZ]?GEX*9V]?N[P1_DO#^R(RW ^=F%+J5J@IPS,N\=0]_:
M-OY5:".B^0\R>U@E[T484YZ0\X#<Q%Q!996$7%FCB(DI$JI[]/0VU@S(D,1T
MRHGB4\%G(&(3"TU^*Z@";)(YN>:Y5(;(C+R1*B7-1NTW$DD%,8X_Q3E)L4JL
M"0>X&'E/51@OR*7J:5M&I!_#:B7NJF28A0%\=?ST?-4*R&NJL4?X(IV3VTS.
M$LXFO.I=IKRCF,2*F41A@T(J,D*S.2DRHPH.@U'J7-6#2RA)<:4$34A$0]Q2
M1*;"$".]W(9 QD.N-55S*Y+26^YBL-2I<8_!&"R9N)*)-:Q *!1*),0R3(<E
MC"LRBX%FH@O[L9H_XXJ72NP&4J$3U%);EF?"Q-B@SGGH#+1Z<Y@F&;8YQ31&
MQO-U-SS-"+<_$V%.(I'!AS8<*Y]5$5Z(8UBMC8L,&8+@H5'"]S I;&8@+FL.
MJB*FPN97#K=:1%BD),DJY*6W]8.E@2KF.K"JE2@2""#.$L%PRVEG3TAU3*)$
MSO0"!(I/A#9HWPRA]J:W&U96UV*I%\9L6/LTP]D)R.C>WE_L';6:AR>Z#%A)
MWQ;@,HH$+IU7AH0J[OP/?XIQPAW?<01]G @=6W$KEB*Y;8+;:R9TF$A=8)Y-
M>R43'XA<R9 SW-9D'WYG'('TSAW<H9QD$T[.D5'710*)9IO6FMU]?N"F-KO,
M7_E+8:MXY@%@]1.;=FNX\'&RMNR\4'1OH0@++7A]'2V0L/7A&\O;O?ZCU0JZ
M/ZP#H0?D@FN8!O<X OQR[*J6FT-:Z-VG6)(<<\2A7,G3KBP4%"#9ID*[%(84
MSYP>VT*LDG^=0!1/J MLR;NKX%1+<K&# D0 6[1,!'/G*5V,M6""*F$W('QU
M<)2664V%MHSM\D [>G<)CP,;#,))RDW*T0.(L$BHY2ELRQFQ8G[,\'5DO?SA
MVYA;05 )YG/VC=3Q\P!G_! X.Z?D!GYV3^:=803H306SZ* :QW/+6E0#6;;J
M6\A0Q1;A Z $'8M$F+DM#]N6M6!VD79!]#B\)[K6-3ARO"LWE!<J!XBT*V=A
M*!5S!KC^8<(S5*D$6,((SRU(K0AZ(X\7@%GDX*=G@YCP@ RF-"E</EIW\BA"
M21=3.$)O*<W+\K0#O_C+[=7: 003P0W:]P1C69C'+=B% >E2FMN&)_IR"TC&
MBU;*89Y[3\ >%U^[P'.(,0,K>/=MAL%V_F7Q=2-;8_T57&!+A S#0EEGK_'Q
M%JVIU ;W[>$?NG0(17_Z(QW9?V1*!-0@2Q](EX:CH^3NT&+/,UFQM.O 6Q53
MO2Q>-K\=RCASQ.?\49+2'$>36YZ4)Y@'\M5O=M%W0-8/@E'WK[:J[NS.%@BL
MKI+.<L Z"E;Y9^/X%;5KH^U8FD;1>ABI]+)<N!M0F>(<:SC_#,.-)0J2'6<"
M]CDE^\ *"$5;PL+_M@%: )S_60B8[\!<9*$[Z!P\IX[T'"<_6^(%0FN[;MN_
MAX(C%B75+SO#&:>WEKM]B77L[9H#]_A@<0K\J@B739P_\VS)4\HP4?-EFCZ*
MAK*EP!2$%)6_Z@N(1O7018J P"=N,R4];CTO/ZOB@);Q'#4@4DB,*OS,72XC
M4N[Q2AG2JJ=0D4UE,N661S,Z*9\2J3+]>9HG<LXQ.HNESWEZ#S (\'<I,L&&
MV\].C>LF2]>-$5BN:O!@0G/->XLO)^"@/*'SGLB<']RDDS)68VF,3'OV_<G4
M$AD*3!DR%RH_7+Y:.3X.CKIM^W;%*/RQQ<+EBY? O7BI&[8YU@F.&ZU'1QM!
M\]&QSVGMMH.C1N>[JVT?!L?'NZFM.T=X9\#=.J?9JTJ[LIB04V9;^UXKOR/-
M[0GQP.G>W__[G' OS2X ^_O47>[_Z6_M/9V3CG_F_6V;*]_9_$Q[>['7 9&X
MSRVO0NYM]WGA]<$;JR_'LV%W5?FL:$FBMH1!EKB'-F2QE:>%B_]CX1NQ\+3"
M_4&AV[2-%7FQUSXZL>_U>$0&=SPL[%,%<N4/)W\% U_AJZ?H5J>Q)PQ6"W=P
M]/X'_SP,S=F&=P\VW5MW_=:]MNV1WZ4LQWZR5_\/?F>32_]#HYY__#WE&[^\
M69&I:RX;JRET#$8MS.-3'ON%R*,_XRD__8^*W,^;SOX#4$L#!!0    ( -%#
MI%8WO2D\+@@  /XE   7    83(P,C,P,S,Q8VUR>&5X+3,Q,BYH=&WM6FUO
MVS@2_GZ_@NOBN@G@]Y>F<=( KN.@!MJDFWK1VT\'2J0L7B112U)V?+_^'I+R
M2V*G=;>]2Q-<@;B6.!P.9YYY9BCK])?SJ^'DCX\C$ILT(1]_?_M^/"256J/Q
MN3-L-,XGY^3=Y,-[TJTW6V2B:*:%$3*C2:,QNJR02FQ,WF\TYO-Y?=ZI2S5M
M3*X;5E6WD4BI>9T95CD[M7?PR2D[^]OI+[4:.9=AD?+,D%!Q:C@CA1;9E'QF
M7-^06JV4&LI\H<0T-J3=;'?(9ZENQ(SZ<2-,PL^6>DX;_OJTX18Y#21;G)TR
M,2."O:D(%O#VJW;0:A_1HVZ[U7G=;@6]5SSD1V$G#'K1/ULPL@%Q/T>;1<+?
M5%*1U6)NU^]WV_6C7FY.YH*9N-]J-O]><:)GIY',#-93F.^_>C5;R@R_-36:
MB&G6=UNJ^*G+X5 F4O5?--V_$SM2BV@JDD7_UXE(N2:7?$ZN94JS7ZL:8:AI
MKD3D!;7X-X=-,,]=SKW)1]"3B(POM]!J6Z-'M[$(A'GYHO6J>=)IU=MWS=YM
M< @/<W7B[HB,X:K?>97_][?0W;D%;_O^=C^2IX>CZ\GX8CP<3,97E^3J@DS>
MC<CPW7AT02[&EX/+X7CP'K<A,;I&XEU_^GUP.2&3*_)I-'13.LWV<MJGP?7;
MP>7H4^WJ'^]'?Y#!<&)'VLWF\PM?2M44>6=DWC^&OHUM_*O01D2+1S)[7"4?
M1!A3GI!)G0PRIH1,>)6$7%FKB(DILJKW^NGMK%4G8Q+3&2>*SP2?@XU-+#3Y
MK: *N$D6Y)KG4ADB,W(A54I:S=IO))(*8AQ_BG.28I58$PYT,?*!JC!>,DS5
M<[>,R#"&U4K<5LDX"^OPU?'3\U6[3MY2C3W"%^F"W&1RGG V!0Z<RY1W%)-8
M,9.H;E!(149HMB!%9E3!83#JG2M]< DE*:Z4H F):(A;BLA4&&*DE]L2R%"S
MM*9J8452>L-=#%8Z->XQ&(,E$U<WL885"(5"G818ANFPA'%%YC'@3'1A/];S
MYUSQ4HG=0"IT@H)J:_-<F!@;U#D/G8%6;P[3),,V9YC&2+#8=,/3C'#G"Q'F
M)!(9?&C#L?99%>&%.(;5QKC(D"$('KHE? ^3PF8&XK+AH"IB*FQ^Y7"K181%
M2I*L0UYZ6]];&JABK@VK6HDB@0#B+!$,MYQV]H14QR1*Y%PO0:#X5&B#'LX0
M:F]ZNV%E=2.6>FG,EK5/,YS=.IG<V?O+%VC^CDYT&;"2OBW 910)7#JOC E5
MW/D?_A1!PAW?<00]2(2.K;@52Y'<-L'M-1,Z3*0N,,^FO9*)#T2N9,@9;FMR
M +\SCD!ZYXYN44^R*2<#9-1UD4"BU:&U5N^ '[JIK1[S5_Y2V#*>>0!8_<2F
MW08N?)RL+7LO%-U9*,)"2U[?1 LD;'WXSO)VIP%IM^N]1VM!Z"$YYQJFP3V.
M +\>NZKEYI 6>O\IEB0#CCB4*WG:E86" B3;3&B7PI#BF=-C6XAU\F\2B.()
M=8$M>7<=G&I)+G90@ A@BY:)8.Y0I8M "R:H$G8#PE<'1VF9U51HR]@N#[2C
M=Y?P.+7!(!RGW*0</8 (BX1:GL*VG!%KYL<,7T<VRQ^^!=P*@DHPG[/OI(Z?
M!SC!?>#LG9);^-D_F?>&$: W$\RB@VJ<T2UK40UDV:IO(4,56X8/@!(T$(DP
M"UL>=BUKP>PB[8+H<7A'=*-K<.1X6VXH+U0.$&E7SL)0*N8,</W#E&>H4@FP
MA!&>6Y!:$?1&'B\ L\C!3\\&,>$A&<UH4KA\M.[D4822+F9PA-Y1FE?E:0]^
M\9>[J[4#"":"&[3O"0)9F(<MV(<!Z4J:VX8G^GH+2()E*^4PS[TG8(^+KUW@
M.<28@16\^[;#8#O_LOBZD9VQ_@8NL"5"AF&AK+,W^'B'UE1J@_OV] ]=.H2B
M/_V1CAP\,"4":I"E]Z1+P]%1<G=HL>>9K%C9=>BMBJE>%2^;WPYEG#GB<_XH
M26F!H\D-3\H3S#WYZG>[Z <@ZY%@U/NKK:H[N[,E JOKI+,<L(F"=?[9.'Y#
M[=IJ.U:F4;0>1BJ]*A?N!E2F.,<:SK_ <(%$0;+C3, ^I^0 6 &A:$M8^-\V
M0$N \S\+ ?,=F(LL= >=P^?4D0YP\K,E7B"TMNNV_7LH.&)14OVJ,YQS>F.Y
MVY=8Q]ZN.7"/#Y:GP&^*<-G$^3//CCRE#!,U7Z7I@V@H6PI,04A1^:N^@&A4
M#UVD" A\XC93TN/.\_*S*@YH&0>H 9%"8E3A9^YR&9%RCU?*D%8]A8IL)I,9
MMSR:T6GYE$B5Z<_3/)$+CM%Y+'W.TSN 08!_2)&I[_-,^7&I<O]GR#[PQC7#
MY6@ 7')5@ZT)S37O+[^<@$+SA"[Z(G,KNDDGI:Y &B-3J^YD9GD8];'TA'.*
M'RY_'CH^KK_N=>PO1$;ACRT7+G\\JKL?CQJ&;8]UZ\?-]H.CS7KKP;$O:>UU
MZJ^;W1^NMG-4/S[>3VW#.<([ ^[6.<W>5#J5Y82<,GLRZ;?S6]+:G<_WG.[]
M_;]'G_OA[QQ9ZRH/62&P=,#3W]L'NB!=_\S^^S97_NCT,^WMY8LNB-!][OHM
MY\Y^GQ=B[_'EUP/:M+NJ?%&TI%%+LI E[JD366[E:0'C_V#X7C \K7@/8\$C
M\M:^<V(?@=A^]&+5!UV59ZN_@H!O\-13=*K3V!<&JX5[N/G@HW^>!Z=NN?=P
MV[T-UW!MM',/OERS&OO)^LY[+POETK\MU?>/[V=\Z_6A-9>Z[K*YGD(#$&IA
M'I[RT&LN#[Z+5'[Z-Z/<.UIG_P%02P,$%     @ T4.D5G"GZZSU!0  %QL
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MPYTBU]M5MMWH;OU(4_X6GXSLQZOC/P%02P,$%     @ T4.D5O+*5VGU!0
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M2]F8TL(33H>K'K[)N_#8P]R;6@6^JP+LA@I$BR2(1>6>,0!P$ VX18[E"#1
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MDKM+D<Q,BA[&+PM<0#BPQ0"$@0*[L@'\$T,=#&L+;8M3Y^8-?-,;A*=HA8*
MWR"MD<@01K17FEJDE8[(L\ 97V@K?%SYS<7^'$>>& SB\XA9@Y3DW&@JP.<3
MCF$W!_DM1+\9%AD01H:-DXP#*Y>4:QHC,\A$1MSC<<?[JOM4J2]B*IO_&:5(
M2[][W._!Q\%5W8?ON_W>[K#O/LU>_V=%:J^(1BI%N$5,8 ]$S\"XXJ-1%!PG
M9"V6Y,F(9LW[,@)F.F]-VV_UULUQ>V@Z"R*F$&1@P+E]Q(&A .)13BJ-E%'
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MJ7Q*I%YP9**5"Z"]WU.8E-D4BK+*LX&>J77EQ\=I1*75ECI)F1 4."=#4N+
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M4T#.DS>MM6%C%YV^:;VGS2/'/CI+,3=>Y>#^T9S%H'(EHLA)H."4\0@R0PD
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M/L1VKZP]5>9+I:EA B_YE?:5A_%OT].^>\+7VS<],9'GR<E?:>OTS';OTKB
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MDI#:BA_!BF]L>>4<I<&D%3K(@!6+F"NF= [DA&OO-7,F)"M&RYS.:F>!"B5
M+0Y%<6[4'4UJ  \/0P%OW3TNPF'H#=J?0];I#P;+62\,YUUN;P&Q[I='H2P#
M>$_XZY:M_J:"W4YR7;\LUJT>2#F\ =DVPW [MLQI#7CW ;SSM1NT11HM ^,J
MU\JS'!0BY%HCGH/PG$6.1:?]TDMRR]9)O]8ADZ=@P3].5VH+GHL%WZ LG&H
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MW(O+VI)FTX%<T!1'C5%D/'%/+-.6Q#A%3&&L=!0$,%1G"U3,TL]5R0(HX%?
MK\;\O(#?3P*_:3[N%<&6!XD,8(_ 4$#:4HZL=%1+2937N#I;4>0AO1%*"M3F
MI4"]#KU&_]3T0J/5&:EP6C-/G@MU;0FRM,A\=Y@L_[O68+VA^P$G+V5"-_U<
M9L53HR9A=<V&-?V6&S59:+6'@_ H#7\?G#U1NPE<F/"N"Z=-V])QWI66:]C3
M.ZGMGNEUTKSU)]^[.UJEE\P5%^8Z!W-]-V.VL\B]CMX@[BQ# "HB0Q-]92Y
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M-OS*L@ V_,JR #;\RK( -OS*L@ V_,JR #;\RK( -OS*L@ V_,JR #;\RK(
M-OS*L@ V_,JR #;\RK( -OS*L@ V_,JR #;\RK( -OS*L@ V_,JR #;\RK(
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M.>UU@KI<+LHRIIGP*MDY5D10T;&[06[EBI&N"J"Q*4#3QOJT R6"1B)'0*)
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M=9(DT_2]R*(L@+8(H+5F&(=1 5.A*-*:)<9AI4 :&X)$B(YXX-@*V-H6XJ&
M]AU0>2S&413VJ1A'4=CE*>PT U%11>^41<02G+LK\J2PWB)N*#AJ7+(0Y-8V
MFRWI^W0*NVENCAD&TNJ[]'B#WQ(//VL-SQKIY5;G<QC[4(N_H^X'V%/HYEPO
MY&^]"7.[8RGW=SK^]4C0_?TK*9>3I*6!XNP!MW0J+;@H$-?9+*-&(",L0RX2
M+*R/Q)%\DM3$>I;(K/+Y]IJK>2W.@^^K[D6C%]'H:9KCK!"$)9KC+# $.BFS
M"4&B*+$DP3(6M-G:Y@^F.<71<F_MK-H.(VORL:[KGIV'3G]$>8I[9:7<*Y4<
M_\AB?'%-BH6O+ O=CE[,>EV"CE%(A_+>A$ E(\X2R9&G-%EQ"< XN*UMN+4U
M2W&\K(TJ+]WQ4E3YT55Y)H@-2VX8BPA;XA!@HY&5." &E("TW 8;M[994^('
M-PWY>2Z9^A6G*'5,RJ/5:L!+>[2U<W^^,CG(,WUMVE:R^[.X.E?5,G@3T@1\
M"_[*KY%EV\^!\6'*H1E;7X-'WT*O6PC%(E'QN1%9ZV;G1L @%78<$8X3HXC<
M("/2;X0P0RF3E#N5PTD5)?3W&OD_BC[7,,EE(84NBKN0XAZ^F&JYFE!6"@6(
M80P( F%(,1:0E]QB$P7WDFQMDWJ<0!3"M3:.V#]#LOA156LO^(:Y=DQ1/+%U
M/UJ>.G1R9[VOSX\F"5*58-_DP1W%M_VPDU!Z</T4:N]K]O&$G8X_'O1,ON[/
M]#QO$JP7+%\(R]_.D##GA1 T*&0D& 2:>V0-H<A@' +C%K3 N1+, \"\>&;K
M:THMC7D5A7XBA9XF9TENFD<KD0:5%3K95[HZ6I91,4>2JGNWM5VK\Y9-*U#S
MXM1T/J3;W<P1SCK2KS($VRUC6^T'5)J:U_)<?([K#7P/R-8M4[;L*F\K8U;L
MN%& 4T[P#ZW/N:)LL2=J[K^](X9MO^-ZF7KLAM&_^YV)<-]<RK8PC(48AILQ
M&2R-A$7ID8[6(B#1(&VX1B"DP430R++[)_VH$<4H.EQ7PV$QU2U',4M1Z6FC
MP6,K 11%A.&DTE(3I+->"\XX88I1ZNC2CF)J:CFL E7)YQF=0;=WK9)0.9*J
M*47Y$;Q=DV7!M:7@VH<9JF)B#%HYBZCA&(&A*F?]>B1HP$0FF%.!E"/F5=7G
M)SUB_H%"%\5=2'&G"0GER@G%/?*&2P00 C+!1,24(SA7>;5&;VT+J$F:VZ:Y
M3%[WPKEI^488^?%';LONX#3TQG[,XD"I.3N9VX$R%O5NB*'7"_[JY.8HB[LZ
MV2EPMQC<?9KA*21RB($K9&6B*$!M0)KI@&*2,"AAN8IV:QN@N%163:MKQE'F
MT^:21K,\59]F-@X4L<HD:X19D9@-!:24(8A91QR/W&'"M[9)$^.'E*@O/I:'
M'P>=FXOL=&PVC'.]8;AQ+EL1'C_6HD8O).8_O-^I43'AZLAZ)HO@]6@-)(#<
M&2V"/Z_60,')I>'DQYT92J09$P ^H$!9HD1.*V2X%LAACP6QX 'KG#J<UF<]
M;,"B\#7D0TM6^*+3"^GT-/?A 3,)P2/NC42 "2!-/4M4B#GB@Z4AL*UM36K2
MG*>D#LQ%*)FL.:,[7*0SQU/9MG>V(%QWE'_4QFNYF^?K7O=SRP?_Q\7;?DX)
MNXQ2WKD4?J%RRX/]_1DJ%V)VY5.%HB0LE_(4R$:J$==>8.%$Y-;F:O]-2OG#
M;=[Y%&F%O%X;BPR/VONL(,,3(,-,L@(G"0E (:?!(2!$(14=(!PU\9AQ\#Q1
M%LJ:  _IC/93D&%,J2:CF*QZJ/3^"</0U_8>F]B-?%1CI&;=R%<]X:%,6>GH
M]J. AV'/G9H<Z5#:N:VLF7B3 [XV%U6MII/NCDLR[(778[&^;IO.8*?C]R:2
M+31O(9IW6Y(Y)3QRC[AA!H$@#EE+#9)":N8),9CGYBLU<?L5W:U[KL@BJELB
MJY>BTM.6&R8,.*,!&4HI A59^@T"BI2E51X#<=+7,;*Z^/37)PCU.B?KGW9[
M S0(O;,'UV'<[("U6E&RXRS5DR34.QO,%$B_)Z3?DM<++BJK(&?]>011,F0Q
M5NE/:CC#FH0@ZI@$6/2ZAH[W!RMV<;4_3+MGXDZQU,0)CHP>$3:!#.$$*4HE
MBQZP,FQKFS<IGZW?7N).?S:=:7<['Y;#9C;;2JV7A^G/)-5! ;W' KW9_%^*
M!8V2 V*,LT1I$IM1FD2$.;6" '#'LN.IJ?!L/;3B>ZJM5M>*ROQ0J8N)<F]]
MGB8Q8)FU'#A21  "XG,1(N)1 ..M"4"E8ROH=5H_UTROFQ[ CP^M<X.,XJ19
M&R?-6+8ODVB/DV2/8O'2/!H$SJ8*:QR,C)$B3Q/Z 06&3'H!,>NITEQ1Q5SQ
MTFR 8B^?V=Q#L8O!\C#MGJE[$ABU1HEDIBB<"[%9I%1T" O&C=!&.DRVMF53
M:%TCW=XX5\T->I.48=@;904OE^,4(Z\.'.?@4KQ5\821];?3\2],N]T?8V1Q
MZCP61GZ;S0RFT5CNF,T'4P1!M!H9I])O@4G,DA'((VQM$WUK:G"IZ;8V6O^H
M!*AH_1-K_30S4H0J C29/(HG7:<.D U$(6MX"%@KPI38VN:DB>EL4;C:>G[J
M%T546MEN;'KT^3@=KF$O;DTT>6I'W5HE0CXEO;TC_7%_(O.2_O@8>]IL!URM
M% :>=C(=6:YR:ADR5@8D-4Z2)=X;KQ.3I4W"9A.C[V?NE^SH-0&%I;/? @I/
M PK31)<(1H3E$@4)B>@J:W-5T&3C2D^E)D9)G0.U6!/$;$YT'4&A)$:7Q.A'
M3XR.K8[IN)(871*C2V+TTQV%A*^AYUK]4!V$#+KN4Z-[GO>E<OZQ6@;BC:/@
M+,>CD1CWQO+U);QC*>SOW8Q)B$F@-&*+>/9P B415>?!PFGA?8R@+:YCA%O1
MZ;K;=W/H=-'=A71WYHC"6XFC\XCQ] ,"MSDZU2&JM5')=G.0=9?<4MB]MN<3
M:QZ9&L[.V]V+$,9DY7R<@M,X;YO.4WN[UQO>'I6R[/?[PV0-5A%LIA?Z;SL^
M]/;3"YUD&N;:SM7+?R1)^Q?=L]P"P^3QYNH1I<CS8B@XFT:<&(P+/#C$@K<(
M/%"4>WDAIV4@C+,H@MK:9OS!I[0E.+6^ZOVH[*6H]T]4[YG"+XQ9;"Q#GD67
M#!3AD :9(U2-L=)$P[#?VN:U4N\2J; ^_J9Q*%;V,/E@!XW6& S2T_=+G.VJ
MID@G*,\,?(+L+[(L"U0O!-6SJ4(&C%<\\2\/6B8FQG.@@=:(6J$A6*9Y2#A"
M^$-**Q<74HW5]=&2GXNZ+D%=IYE54,8):072269970G2WFBD/,<B)%JE34SJ
M2AY2GZ5XCA[*/#+QZ'0'8=(>L-$+;3,(OC'HCGH?-TRN"]!O9<D4']+*^I#>
M7$;]'\7#).])9[!R\K4$^#O<G4WK41*\"L 1"&\0!,^1,L(C1A13'%/-@BF)
MS:NJUO7H^[*X@I?HQH=I^33),908([!"TH! 8$5 *@:'"$@JHA*.)V%NDX?V
M]:QI<O-JYH+\,NZ;]^NM479/[7*Y,WAU_6/ ?U9BR,N)V*_'@!<@7  (]V;H
M#B%28,($<E9)E'8UC@PU A$L60PFH:3+?> ?7N=A4359(??-NJE^/4C2(B!0
MJ-+R$&*F%HP36E%/TUHCV2"RR2!BB31A*T&8&"S87.<@)X(LH07ZH^/#>F4E
MW$V??O'CIN*_)LHT^BWW'*Y856X85?V2NT9]3MI1@_)WFPRBC]=[."-H_F_O
M2M!O0G_0:[E!\/F-G8Z_^<*U*U^G)^_ZV2;UKCW,TMC[ZDY-YT-X8P9A+R;K
M:5" >'E /-N_6"2;U4D5$C<#F]-T-;)*6!2U,-)1I0+66]NZJ31YQ":EZYBC
MNZ(0\Y1'< 585A=8IAF>I6D#(LHC9I5&P$A$AF&%B 8>-8G 169XHLEO87A+
M3O5],IJWX@%)+^[B=??+/EV%_.(:Y2BOAE?UC_"AU>EDMVGN'EMA\%.S_O7>
M=3%@2PP5D6D)H)TU@3OK'2%14P_RG_V\V1+ZJ)MMV3N7MW?^-4/*@]?<4VH0
MTXD[@68<F: =DE3%P!EW0INM;<J;"AZ<;U5.B^NKZL('(-A'HG*]%*J,!2FL
M9CB"X,JZ2M5)4?454O69O$J<["*!>>Y)Z!%(KG.9+(X$"P0D#H9'D>-8FPGM
M:Z3J&W5PO)<8\,/(S0\8YYS^Z]$D/&=IWGQWF./S)L_^,"=$[2;\_]S3P;^,
M"5J;S8,$0Q4S)C!&P JA6*#.@B&"0"1>5YO''.?F9?.HR>;Q=H8G1J.L!,D0
M=Y0AX-X@#3'O)5I:XXTBT56;A^:SWML'';4O0=.>^"R^8&[!W*5C+G,Z&AF,
M940!\UYI)3GVRDGAHHLCS'UL1WC!W&5B[HQ?VP0G 'MD/38($G='2@B#B,+6
M>BMX5&%KFY&$N0\F[+7!W(KN_S;((<3I7]_ZO/VO]&,R\&OWRGGJH3>Z>ZOC
MTU_/F:AP]R=K+KVEAMT/Q_U$PSPY#0WC7/<L??=%]J3F')Q^P_32RYU&*XWL
M0\^T&^>F5V7H#$YS0G"GDG*5G3..7$V7] ?IA2KN^]FBS[XB,AM?"W1T>G+>
M'24C/:\RE5J?P^]?6GYP.D'N:Q\<:P^^^HBQ:0J'@[L_4I?U(19>P=O_LKW?
MMF]^[/K/?(L*_0% 2 5$Y)_6"6.%(2 )"*5 Q/@/55N3#YU>EKD]-Q\"LKU@
M/B$3T[<^-^TOYJ*_]=N-P9VU.I/GH-G$GY[F'PWU224Q4YFUDL2+?^\?[+W9
M_]]F8__PQ;,: <OMPST\.MD[;IP<-5X<'1X?_;F_NW.RM]MXN7^X<_AB?^?/
MQO%)>N%@[_#DN/:/\LNP8X:^E>#NU_7!M/E4,">-7'WHB592S@HESQIC+GPX
M/$OW<4L(.+O)>_\P_5;_*+[NA7X26579)I>\21)MQ41..H.=M$T..[ED^^NT
M_;E6Z)^D[_^CW76?GI;/?CN8\-FSPT]')P?TX-5AZ_W'TX_O/KYI'7X\/3T\
M.2"'']]^/:!_?3OX^^6G=W__YV/BINWP[S<7[__VYY:">$?_X@??WGUY1__G
M["A]_O#5/CUZM4<.OKVEB:M^>[][\/7=WXDG_YT[+.ZD,;A_F,YG?0)0X-D'
MP()!.@B+G#0D,D(8\+&5TNH,@]_)9H'66G##0C).'!CM##.0+!6)J3%*1;S5
M",E*.,\JU1N&$4'Y8]A/JZ+?K^(!CH=G9Z9WD=G(->$TKJ33F(AG0H''*V8*
MZ--[XY%5LAY)\,>CN_DT/@;ML%,\F@B*!\,PMN"%<\$Z 'O+IEY;2'BTP51W
M?-X:)'AT<^C[;EH O5951#,+>2+\>:#WX[ _:,6+[S"1>3[W$^5!:-[93UMY
M@7YMM-(*;]A6]_S4)"/:A6%E%37&[+SQY;3;#XVS5K]?K==<HR=GQ_OP.;2[
MYXVSX-.R3U.56+H9I#]-#HV(PW;[HM$ZRXEGH5*@]-@A_9.I?#NQUJKDSWG2
M@:K\3S15&IH/QJ>/^58_![+U$_@N:_;KLLI^SFXRM6=<C'YN\KYQ=++_CS&1
M*^<XX@1\VC>P0HICBX2V'@/%#(!.(ZTR--I(N-:)FEB<<-DX"-[XO,EP'*;W
MC4H >6E?W]"_OR-\URZH&7!<KN'9/>R',S5K]%\2W!\;]SGYHCWTH<(/,UK>
M_8EKX,48J3+,M-++";$R^G2_=-+=^D/;;_F6Z;4RH#QH#*<F89D-H=,XSUTD
M>U4:;76[GJ^*EGUI#4XGH\LW/^^E8;?.VVGN/X1.Z)D\K/1^.!^,/IM'_[93
M??UQ_I[JD7:J56(:O[S:V7G]:W9M5AZ17NOLVK!:G9'+,\U_L[I-J]-/2[!R
MNE7X_#*]W2 8_55-RTYV=;43H<7Y&]Z$#\/V2';'Z'^?52RFEUUF[8OJ9@F"
MN]DE<SGK:>"3R;[VQ=6=8[<[&'EO>CE<LC=*,LY#KT:>I[H=$I6^=4;S#?JG
MW6$[?2C77C'5K"1)?!QV1J[G:DJO";FJ&"%_3Q\=B^W.^XX&E3[:"VDZQD]2
MW3^OD9U.6KWM-!/GW>QCZES.U_^MAIV_\2*87B/M6>E#N\&%,QMZ(P[#2+.1
MO=ICC]/^2([=\U9G3!YN&V]2._.A&EZSFD[CLQ97PVU6:Z\U:M!7%:1)$]Q.
MT^&&O5Z5GGW]VDX:2[^?N6@>J$E[9ZN7%^0EW.1;Y$>\FIF) ZB9!IE68?4]
MZ0/#]GBJW+7V*^.''QW]]R<W3G-PM?HG<SE^_J.9>TYN,CCMA40=$E:<]L<S
M>6!Z[O3&-++*[9=7V^3)6IDZ=!*MJ/Q;DPF=W'Q$,\Q%7C'AZWEPU2H8?V/F
M'97@FJ/92:C0S4O@4H-&S]5([TW>C\/!L#>2]K,*J:]CV_=9ZVV(_;@;_,LD
M[/^8]C <Q9<3\>Y7FE^MCM%&OX'[^^'NAW^$3[.;["CD/*%I?\^!11QSY(5E
MEGA@-KKI_;I.W##+ME$)-R_Y2_$VKLEWQ9E#WGV=Z?6JG=><76[B+O0&)@'S
M]>WM\IF;8[P9U:D8[_P)&T/K<SZ=:5Z].*GAE2$MO9@$["N$Z/3SV<)YLD6^
MMM+.59&(--45<'[.\]UO^#3I:9?($-+/S:!1[@:==*^"AMS^9NA.KP]J+D_H
M>++K[I.KVRIYF8$YUUX;;4[MEK&M=I6AGL6>#_Z2> ?7Q-><6*6W;+OG%2)F
MV9Z9)/TTC.JRX:BK4=>F,5;+* GW?#C^QK.TD4]?.>S,7OOE-&V&8SLXK\ZK
M$64SN)^6SN4"GF&)U69U=?UI*^VA:6>\>-9X>?M=1OO5[=/R)9.<$=5)"SX1
MB7YZ^ZRB1^E#G>[UYSPSO4]AT$@TUU0;K\V%M3-3/1MMO,/SQ"!RC\BSBH]6
MNE3I0#+?D_*VW7!4(&_TN>Z(^R2Q=+IG:;^KV$2NTCUH57MWZ'QN];J=$>VI
MCO%.33X:3BLC?86[I/"C6GMIL)/'&K'YT=X=TP>ZO1%[[X4T#TGB=\QU&F$G
M4XG$#7S(.MS*-D UXXG)N%9_0ELS@1A?F&AG.TE[1.:SI :9&?9-FJQ,O<^R
MAR.C1AKAH!TF50-O'W7BTMY77"MS_>98)F.VTNKDO]+'OP3S*3N70G_TG1>7
M$YN'-PCNM-/Z[W $9*,<OO[$6ACFZNCM$8#V^\.S4=>7O$K]=:#TK7X%BHW>
MI12O9)I&/R8]5\0O<]!,P_M7SLULJU1I@R/!78D^T])J%GJ3^UR#TI&--3')
MAH-6GMO^G?)*BCE2ZNM77..[^8+)]G#'ZL]_5PZIL;ROWRG/0[N;OZY ]B-O
M[!.1YX".\_Z=PKH.W*-%G6V$=D;1M AOH,H(JJJE_^6TY4ZO=.Z6^V8 [)EJ
M;QB[&7OA"DRN%/:&RMRU;D:+>/+.I54UPEG3N0VN8E+X2RV]A/.)4=R_KEB-
MCT/_(:_NZFOZDZ?/S_!\_19IDN*'5N=:+,\D/@?EB,#G%&:R0F][/D34$SZ@
MHE1</N'/MA9N&]3-.23PC.?9^3.OHP9YY(%^=ZX:XY*>E2%C1IIVJ=3#S@C9
MTU__'78'(][AQKN@JPC#1.<KKU>6?'46,5;Z:PK7FAPX7'< GIH1"9SH9"[B
MZ[)/X6[L+ZOS)Z].6MO5>7-)Y@783R2Z;7IW++^91=N\Y197:WB>^TU6?[6R
M)VZQT9<T1[2UZ_-.D>\\VA*S*_'ZUC(Q8S)EOR3]S49H54S:IZW(96)7^90G
M?RU'.XHJ+*H*K+:J,%Y%E\OPAO5;.>VO+;FQWZ3[N3K@N(/IKQ'[?IKC^LKV
M;7Q).UPG^S*R!5V=$:!KDYQ%<6WZLYUWZ5&[@S??0)KQK:;<*WE!F&NG$3:?
M<3YK5&Z:2V/WQKE0+WPPU7G2K2Z95N=SN#S-.&]7)=6269_@*0V_"KNBS6IU
MTGRV<GGML^HE,B6/Z:/5E5U8,R</M\4 ;TP L%QZ /#/CN6]]9#\AX%;4^$'
M1#DLE;8T*1I84!8K1K$4.?)-8BD?/:#DV)T&/VSGXZ;)R=-.!20['?_G%8P<
MC('CJ/-F A-5),1)WC V.NYD]^ ?P@.C' =D.,,(@F/($BP1(=H8XX+"P&X[
MEZJ=E^>/T.Y^&7E:LES'F\?XA/AF8(#M#@?3?KL%=I?&+Y4CI3M,P_7]7]?7
M*Y(3F"I&^*]J2J^0NTIO2F-MF_-^>#[YY?=)T\!6I_K&ZD._WV3I>8^82FVJ
MIF3T]AC'M'ZF.,M0-BYI,/[B,<H]JU!N*EMK]!YCS[C6=[Z-GY$[W_O>;3,S
M%N)>M_W^>YS1Y0]6/ -QOSDH@_W^8,DSBN<;T \*<ORXU@Z9N?:6K.5Q6L73
M9.?.Q G@29S "%VJ_7CTZ\&U0Y4;V98;.TU5I%%C$F1TGSEYTB1V/==#WIY>
M>UNU@ 429I]*L/,]\DEW8-K+>N)Y*B'>R$6>O=7ZS.Q?E?=RM*1>5R[,T>^M
M3F7E5)T")G S<E16KR?:-PZ$G/@Z1W^.#(7JDE\JA]?H93)31/FQ)KT(]YIP
MKV4MC<,VLT>XDL[1I6]O$M":O7\S@J-%<$\LN$HD;Z_Y8K\K+_;K(IO>6G1L
M>+'$;@P/6ZE$W;,<Y)+JS-5:3*/U>=?/@VXG7$SBU&)ZTADQ+C(7:UJ+:#VK
M"1&BJ=-1,<L$"!Y45#@PH7CP7#EE%ZG@MM.9+A-TZ<+<O8P*6XG*0??U7(XK
M![W]^N[OO_B[;V\^';SZ"])G3H]V]_C[CX<?WW_\1 _I?SX=?-S_<O#M?7NZ
M<M#AR<O3][OMCX>O_OKR?O>T=?AJ#PY.VFFDAV=')^_8^[__NCCXN//M\.P_
M<5(UZ. 8D\-O:0YV_C%>!RJ"0T83B\ K@92E%ADN<J88QYK@JN41E0\NZEN_
MSO4%I-84I&B,7A*N;5 !6"0Z<.8QQ\'9",2$ E)U!JEO4R"E"74$*$6:<)NK
MFR6X,H$A1KS27'*B= &I E*U>+9%0 I+8(D_R4@DA!",MUZI0)R,V#E"'QFD
M8NMK\.A;Z'4+/BV&3V0*GUS@G&"2 $G$A$\X\2?+'462@E".6&V-&46^$?I[
M :@"4"L#4#%Q)R62>0>@(K?,"&9U8%8)1L5"Q;H+0/U$@&)3 ,6MT%0*CJC7
MN22W3%0*8X8"5UX+''+\41T!Z@>.MDFD11IL^#ZFE2MO7EDFMDSL:EU9)O9I
M)G8MSIR^?YCQ_9]5+,/\/<0?TIQWS1N'*0Q>>LR4T@JDYR: "MPD2N*MY3@6
MIUQM.>71\<S)@964!4DTLMH3!-0QI(3RR&-LJ:<LO1"6Y91;2'%6J%'@QB*!
MDMZ$*)7C"K(/3#,J)6, G 8_;B%8D*"F2##MGC<\1 =>H1"81X A(*.3B4DQ
MXU@:@6/5\*D@04&"620P/@@N&7>: X_4$)JT4D=@A$;A?'$QU10$IGW@E!B7
M6TRA* D@X&!1;@F+.%46.PY:RK@T%U-!@?5" 2^=P#92+ZV!H(6- %I9%2DF
MX(DH*%!3%)AV-%LPS').$6/!(;#1(NN341 3OXLZZ;@V>K508!-B/8^ORFE>
M2_Q_C)["Y1XUO$=QK1;7ZB.Y5M\^.W[6&/2JQ,>+1C]GD%?%"![B/EUO*I3+
M#AAF'"4* TYFD2<X64,J*$N4MVQ>*K0;[.#X<KYW/IM6.V>CO.SVCA/!V?LZ
MKD*Z,ZK!O)\S:A+POQB5#2WNDF5QI(.3_<R/;C1KU5HYYY1#FD>"@!F/+#8<
M61>U"HQ$9A.$"-R4\.!FK;<CRJK80^NMZIXH;9R+1!L%HE+[2*64P7@ITZHH
MJKYZJGYQ4]694#FDTR'*9400/$8:>X,(RVZOX)/HV=8V%4T0K*CZ^JJZX\19
M0KG A(&VR@(G)FJ=7C12$5-4?>54_7!J5P]*1.Y]1-A[C2!G*I@ '!$7F*,J
M$DN2JC-H4@5%U==7U9D.RDC+A<<$),5:.F^=3^LA6M!N;E_F$E6]^#?OK^53
M&[ICF'LJ*,+:TJSE"FD2-!*4*X(=Q"3X93LX2R1MC:_<!/_P]WT\+[IG9Z$W
M:F)GSD/O7KZ=>5-%5GIKL-CA"&DS\-P!ID%CP(%&Y@7')EI96."*[0]_S?AV
MI%=..ZP1YQ(C< *0L=0AQARPQ/2Q5HD%$L*;F(@:95HL^RQBXW7=<<RDU98Y
MR4 (IK0!+"4)G$@9^-RY4X4&UD+-IV@@8&.CLPI9JC@"#QX9B@WRSH&S@6&1
MC;WZ)505-5^RFL?@(V8F))G;M+-+E:R\&**&I/W2Z+*EKYZN3SMVC/8Q&?46
M26HD AD"L@$BLA8\TS$HDB/;RI:^]KJN8J182*\%)/F+8!.+YY(ZZ2- C+QL
MZ2NEYM-;N@/AE,,H4A(0\!B0QE0BSQ43R@AF;"V+.)0@DQ?=WGDW-U%MV.XM
ME0B+:_K2_\"-(-*"U(X#)<8"5CPX*Q7F$<C<I?L*6:D)BKV=\3\DL-(:*X4\
M)2ZA& >D<F4_;8/QP7IN=2(KE#4Q4S5R3Y=3J&6?0EE)@V&28:V274*U-KG,
MH^#<4QOD4]@EA:O<7\NGN(IF@"E7'ME<NA.\E<A(+Q#6$+D7RE$!=3R%*FJ^
M9#7G/&$]#@884* 8#"5"&N&-E]$Q.G=*?=G1:Z/KT^X'KBE/"!X1MU8@H$GK
M=0"/N @\"*M\,CW+CK[^JNZT,40G)?=80,)]H[7#)D0=N&9*XK*CKY263P>*
M6F)P] X%H0 !2^3=:FT156""-8PQD'7<T4OXPSS5@_J+)=C-X6F=NW?*^@'A
MLLH(%<Y3$S1\-^/%H,J!%(GD1&D, FGLR!<K=3YD"\*XC(9$JZ;"9$F^V$6Z
M$:W*><PFH\222@P5E*@/2DQQ)FJL-%YIA"G'"'3ZH2)SR#/@EB>F;,+2DFLV
M$236'2&65'JH($1M$&+:=^*\E90:@71BB8E'0/Z-2^1,^L?K@(T6B4=(VF0/
M=YXLI$X%'VJ/#\LJ2E0<+K6 ABGR8$!'[[5!@3.)(&*!C &%:&(.(0(7SM!E
MAWO4K%+1"@:"_-GM?%A.H:*E=!!=AF-[[0>YJB,L*7,E96X5RB)M1.SMTY9%
M.NQV7+'7EDW*/LU61C*" F: C/ ^D3+*D=96HXB!$JZP)$IN;3/29'0-&ST6
M;:]'9:2B[8^D[=/^6T>42 )%B9YQ!"2:W$%"(1%BLL! 11?\UC;!32J7Y9PI
MVEY#;7_:XDA%VQ]'VZ=]L3%J9;&,"&N5]G8A"5*<.J0I> \!F UB:YN2)H8'
MUT<JVEY?;7_:^DAW:7OQK-Y?T:>V=1&,C9X9!$X"@N!T4G1G$2$N,;BDZ9[B
MDDA71[?$/*%L[84\L _I>;'^)TQ/&\E6B,\CX.''G1FG1O!!1F8E"D3F]E@Z
M(N691L$E:Y8HHT2$93DU%M6I%8KNWV2<>-)8MH(3CX034[S)<X*%#1PY8 HE
MEN20E22WT8M.82JU)7%9[I""$VN)$T\:T59PXG%P8B8AD',<B+#(4"E0V@XB
M,LXZ)#E.)K6-%/S2'"D%)]81)YXVLJVX8)8/$5-40FG.(L$!!26R"T8DDT-'
M@BPS(D9BK<B]N7]2&[XGBV];N["1AWMO3+\?9MTUCYM&5+M)_C^/]_QKLT4L
MRS6U4RVXTI']43> O=E &F431702&4Z3+<D91DIYG_NR WB>0RELXHC FDSS
M#<N-*FA7T.Z1'&P%[7X.VDV7[J2$:Q\C8L81! X4TC19Q)AR*ZWU'*C<VN:X
MB<FF)8(6L"M@]TA>P@)V/P7L9OK,:>,%:(88R;4Q(E"DB0DHZB@A2,I#[AY+
M=*)V:EE!TG5#NWLE1!4H+%#X2([0.:&P>#COCX)3E,\J;AEPAZ@T# &+%J5]
MC"&A.)5<6&"*_+3TW25[."<#F:QJ7L'8[1"Y2%[DU?!9&J#O#FT[W">-M'SG
M,K[S!^[L'Q]QD9EK;]F67,BG+D^$S_)6?,XP.5+ "BQ'OQY4N9!A-IIP8Z=I
M-[AP9D.OP4BSD;8A>I]IJ1=1N?U!;P?C[RO9#_'WJ82KYWKDZC!F64^\&#RM
M^,S]->P.@A\MF=>]E@O]T>^MSK]L[[?MG;2_?YY BNE]RH==^?7$PD8O[OOT
M2/E91G^.B%MUR2]_AL]A_#+YM0CG'L(Y3@-HQ328SF TCT>#T]"K9O?(IEM^
MSM$!8SETSH>W3#PM$__ B:^F]&VG.]]\LU\7V576(@7BA>F?-L)_AZW/R0 K
MU6/*(!]SD"5FY:#;"1>-LVHO;L3A+?VY'IP.6;L96=CUMI[>-<*)4(X%[70
M[I6"0+RA( U@*\/H5)42^B/O6D;LG8[/_^Q=X78Y>'A4EYN;B2GQGD* G,UI
MH\]QQQQ9< J9B"-3@CJ.(1?3;"JZAFU0"TJM*4J)H*D.-@K,1"Y"H#W'D7CB
M%/&<<U90JMXH-9-%Q9P'[Y!S6",(-B#+,$<^R3. 5]QX7%"JH%0=GFT!E#*$
M1"TR=Y( *A_X>\N8-V )CDH\-DJ5D\M[ ]1,'1R3Z' N>.6BY@BL#LBH7.A.
MZMS6D2FE>!W+8Q2$*@CUW; R*@(+7H3@"42NE=8^NL \BY8'SPM"U1:AIBA4
M#-QB2QG"5%D$'!*%$HH@F<A4(LL^1*KKB%"E8'-="C:OX+' ][V8+[IG9Z'G
M6J;=.#?GH?>0@D?KG5L,R70V#B><4!(B-5;@0$.T3H*DSA9SNLY[P6Q%9@7&
M1F<,"A:2.6VE0R;''0>B$W.-REJ<S&EH:EV:#Z^Q5L<H#6@@6EL&,3 5L08;
M,0W *-&AD+O:*O04N<->:N.2^:F-S276'49:2(R$3&JN=.+K<7E];XI*UU>E
MO=9.,^F-\0"*&ZTI$^E706/2</W8]EK9J!^FU]-N)1*U)\)SE&3&$6@7TD9-
M%**2"$URPPRARD:]]EH=L A,,B*DIX")5Y)QBHEV&$NL.)2-NK8*/5U&63&6
M.V @'FA$@!E'B@J))//:2J\"<[Z.&W7QPM3%"[-VL63S5#AR\X9WELZG=UM[
M0EH:O);21'"&YUHR.D@EH\<0Z&-O(H4:/F G^39;# CG-CO>  )*DLDGTW:B
M(&#$=,3@ @9M\-8VI4U%E]5YHS1!7A,H<(E#6DMTLB$(4.M,3+32<XY9-(J[
MQW;\%"AX(!1,'^TI(B5U#F6A(E :4&ZAB$#8D-NQ$,7TDJ.C"A2L"110(HSA
M3. (,N\DQF/M23).DLV9;!%=H*#64##M,-*.62!:(<)- @#O/%)<&^2QB3YR
M)3UU2W(8%218+R1PT3K0D6"E!7C-E; D)ON 8>*"#R48L;X@,!TM36S(08<H
M8&H0,"*1BIXC0@G/<?&9%ORT,BJEB]><JGI\VNT-YF_"]9.R(\L]?M(]BH>U
M>%@?R</Z]MGQL\:@5Q7CN6CT+WL[/,2+NMY<2' L%0$:E!,@@&K.N&.@@LT9
MDC"W572_7AHO2L.=99.DOV;\IS%)EQA+41 XD20=-=+@. HJTIB,)Z9DLI28
M:F)=.A>OL:I+1AD+@3F&,00%VH(4EAIJO1>2^J+JJZ?J4_808X+J("D"HP("
M:P I:@B"2 C-MB[U?FN;\B:5I*CZ^JIZ,,I9[(W02>J":RNB)5PS9Z26W,SM
MX2BJ7AM5G_9_)NFRW'\>,:8Q H8!:24,"DY[@Q6C@9JM;9)/19?5-*"H>@U5
M77.#C16$69P WFI%"!  P('XB/7<56J6J.K%P7E_+9]V<&(KM*<4X8 E2GP-
MD,$.D'4F"=MC*0,KN8P;=.4F^(=++N.24MI9V@1 :6$" Z*PQB810Q4$$\2Y
M& L+7+']X=V,;X?$J PW!E$( D'^8:3PB&IM'>4RUX+*+% V.9$UBK(NB1/+
MCFZQ-MEZQHG((?$_D\P]P:7G'M,H;'@*72\T\/YJ/AWWQC&6S&27CH@($K-'
MAB0N&+C0(O'^8$2L8S)%4?/E)S)KR313/&+@BN<(-B,=CIX:H>=/9"Y;>FUT
M?=JQPR+ES#.'P%"/P,NDZ\I3%",V"O*[AI<M?0-T72;;7SEFI 8&QB==5Q)'
MQJF/TEA.RY:^4FH^M:4;CZT3W"%G&4Y;>B+MF@>,1+ )X0W%P:LZ;NDER.1%
MMW?>[9E!:-CN+?7@BVOZ,LY6"T*]YC&*D$LT6,TDUU8[84BR3I\"P I9>0B*
MS195YR+Q3^>KHNJ0K!,&2"DND,II_,8:T :J V>ERH'S&JLZ=S[Z;*2"M1"I
M5+FFO@P!<^XDB:1PE972\BFNHB.+SAJ.>.2Y=0(/R$;I46# I,X)%$NLY5#4
MO+YJ3FFR1;!DPAH#2>Q:1&4# 6<2G96N[.BKI^O3[@<N>106! HZ4@1>,:0T
MU4G7N='*4*N#+SOZ^JMZ=C5)#T(3IP&PL%YI$&EK9Y@3;DW9T5=*RZ=V="(\
M)B0H)!,_2[S=660X>&1"T(RRX!-KJ^..7L(?YBDBU%\LP6X.3^O<O4;7#PB7
M54VH<)Z:H.&'62^&\L8P3I .RB&@(2 E<[UH[:S V0&O$^<AFC1!TR7Y8A?I
MWKLJYS$;C!++*C144*(^*#$=A($-DXP*Q+S@"!B+R$9%$$ABM8P"G#;+2JXI
M(+&.(+&L$D0%)&H#$C/1&SC'YKB @F0>@>'J_V?OS9OB.)J]T:_2H7O>]UH1
M%$^M7572"45@2?:1PX M(?M*_Q"UPDBS<&810I_^9E5WSXX  6* ?N(Q@IE>
M:LG\Y5J9R&@L$99:8JPP-8*"*E&66[#1+4JT*'%[Y8E:S\M& ,22%B$8D4&6
M$FE.+.(V*&0#8TC&E!%"G"3:WG3>QZT#Q&-("OEST#^ZF:)%E_5!M\_8G&>T
M!]K: VWWH6C1H\B,O=NB17N#OFM-J9O5E/9>K=9]Y]& UNM*)(SBB ="D.&B
M1%R:U,152ZM3A5>U55Z_V'.;![^YW'ZW=8M:;K\E;E_.AR^)4Z61*'H=4@R&
M(\O@3Z:-%2QBA8E\\H*0K5*)EML?+K??;>FBEMMOA]M7LLPXP0$+CH@/(9UT
MD\A2%1'%C#HCM)-1/7G!RBW-;\I+VG+[!G+[W58O.H_;6W?GCS/Z<AM 89T.
MUB%>>E#=M4DY9H2G4V\@YYEERFQDO][6W[,I_IY[Z"J^?@9?]TK.YNOT^GCX
M\;2[3>!K-<K;$#2[*]ZBP"25K'2HQ!)79Y2TER4JJ1:66(VCPS?E+;HJ3]VC
M0PV/&"?N-H6OQ8E;PHEEA;0$ Y,)A[P3$O'H##+"4$2I4]1K+@DF-^5G:G'B
M(>+$W6;QM3AQ.SBQ[*%27%#0&CQB2:G@-*;*BEPA*A1/AY^)+.U->:A:G'B(
M.'&W>7RM;^OF(6))E>!:"J=E0-+;U%B'!F2-=@A@PU").1;\YJHR_BR,:/-Q
MKN^],:-16'777#)+LUJ99PSVSP\FP.C3[;T>EF[<+OS7'2[0@Q$R-^7<VLDD
MVW:QOE41LMJ;C5EC53 $P18*L$:]1-I%CHC5RL,WI4A5 &E)0<V\X9.G-\!&
M=QQ&;0&U!=2-]0*V@/IS '7Y>(V0AC-N$3<^E5!.A_H]*Q$3I>0>_N8.S';!
MMZ1J\;3%TQ9/[XNWM,73GX*GRVY0'T4)%H5#CG.">,"V;C##/7R!:11!@X**
MU19 9PNH+:"V@'I/W,J7!-367_SC6+I<1M<&;D+T2-&82O['$EEE96K9*KUV
MA&*&;^GH]QUB:78H_V><0A;PK^]\>=%,;6_2 VYQ+_X[?_B3V8XN.X*G*YM'
MLS#"10;D@4HAHXY"&VYA!T.)-:/8RXB#MOSP%3 @<",F*/_"$B<N\MZ;_I?0
M'P^&9W_!<KNS WCVK]V!^WP_&:L;_N?MV<=__8FEO/Q _Q:[WSZ<?J!_]/;A
M_KW?W]#]WU^3W6_OZ=[!ZV\?7^T" [X]_OCO7@1FP7L'GP^QXLQQI9"(-"0E
M@R)=E@JI5'HT$AV($!4*=OJ3X'<2-.F2,!=T */<<NV8XAP+:JFG4GK/\9,B
M %R=P**/AY.4?0K;VI#7' %_FHS&G7AV>["?G_BL,X;7N06*E&LILJ&,^?._
MF2"G//+BO^WP/R]6OKR+N7V7MPZ.0_%RT(,WGZ6M&W4 9D;%,!Q-NB:1?F%.
M3H:#+Z9;#&(!O_F)&Q?.]'W'FS$,8SPH; !!Z !<3*=?P#?3RV!PDPBX"-(J
M?=@9#-/EZY[=,V=%?S!.CP)H\_"\;ABM'T9G5 QL>E7PV\7.J!A-W/%6,89I
MS%X'8 B3&8U'24:N&W6GBKI>,"HS#'E40*"9,K[!#6:4<WTS+!1V,LX7A:\G
MH3^JOAV&43!#=YQ7PH<OH3LX27G!U8"VB_D%M^&HTQ_-GF^R5@$+#=,9A;D7
M#0.,+?AZ4@-8[8O79OY%,,V>&0+U%),13#\M$EQ>/0TF[T-*8H;;B@Y\D#XN
MK!EUJN7KS&A]N[@Z0=\#1B 4&&&_7^P"%1*Q523-;*LXA7W-47H/2P"+!$/*
MRECQUP2VU\#^[!P-0\A[^TNBO_.^?5J<=L:)'@H38Z?;23UI8(]?@] Z2C?_
MVAF\&W0G:>]'Q9N^VRY^6?O=T[P=Z4TC4/#2(P:3(=">ZTY&G2^A.!T,N_X4
M&+C(\K[B3> %U_&#./C2&6XENJ_2$)8V<EG4I[]K(,\TN;!E];)Q >MZ,AAU
MT@7/,H7"*)[# ,;'C;X\=U>MV^#9+<:.TM3.OV6.-ES>BCO"2'49ZET8X3JB
MG_]Y/&R><&*. K+#8#XC$^$!STSWU)R-GOQGX3W F\V0J(0Q+Z_816]=VLY*
M?R'*8:FTI: ^<LN5Q0KT(UD&09G$4B[+<N)+KP0A6A#%B:>6$<\C,YH+^".&
M)^>\YT(=8#,!X>#U[J^O_[\=4#LE?Y[1?'0"AEKL " T>%RE$,RS?TKV>;I=
M )J\"R?CT+-A6-!R#E.2^09W+MY1(<0\U_L0DT@I]D_"T%30\"=,)K'NGW^^
MG"'$TZW+ <L#A>[,GW\U0GP>&^OM2Q\W"U*I";5,S :<?#XOSK/^,TK[.KL?
M]NRX ]+\%$2[#6GY%[2:!I%389A\_"?=.@)COGLR^%II'X,Q?)SZH/O0!8"$
M]]0C?3=.[<F.P'#9RSL,E[P;@WEQTH$9_/)N[]T,\'/QF:,!W-W/+TG4"$\9
MP'?#A<]AFBX+ZF;Z:=R5?@"CM6?Y:;^]V@$=HOAC @*?9](D0$7C>J9CV)KY
MA4I:"NPIO&ZF!RTL6E(B@!$&KI-Y(I-R_?KM8KHWZ:7SNN1T?6&MZH<T7%6O
MSZ(^-[>EIR"4"Q"RL*F^TMW.4;EJO0Q&FQ\(K 2,-5/^8&G2 H:\2'V0\%T
MX'X68T6<I U.ZM)V\8!99UY)_)(<3#ZK@',Z7R*,M'C= 2Q[VH6L'L*>!AAW
M+^]7'U ,Z#\IL,EGD9^SJ'].%<P*^*I'Q.57-;Q6:2EI@WJ#27^1,-(;A\!-
M</$:?7^K&!UW3D[2WXD6CN%'=V8, ,V;(G:&HS'J]+?JWP:@P__RVYO?]I]6
M.N]V\>]@^!DN0$"K+EDAL^$ I2X3_M2 .#'NLSEJWMPU-G33J^=UKJ$YG8Y_
M*RGAB= :ZP0N )KL9)C*=#R<'#5?;A>_=?J=T3&,X6@P\'-#JMZ:QC9]:9@:
M8 D&.F/8D:2]+HP]$3R@3W\40^:$.9 L)B>#BEVRI*JMD3E9M;VJ.IZK*MX'
M_KBBZ?^Z=](=G(50O T9V&&Q7J:-&]]S1\#[/EC^%4P"1G=&6>6H-Q_&"#@Z
MLTV!KX<@K\"DF(R*G8[?@L7H=D*L*/<UD,.@!V*M3H<^*W9<;2*]W'G[^EWZ
M\RE0[F@T$TGO^YW$X._&V3Q_.4C, *R7M2Y8F]F%?\'G8.(L"?-,T#"$HTX"
MH"0U#8!&G/1]1J30[-EPNF<N[UDQFMA/ 4:7I%OMP7 PY,2BBP@V#&YPU*]<
M ,5_72$00)3'U@89)#=<>ZTY98$K[(.57&.5_9"@=E=^2(HUPPL1 =%X)5UO
M^/590WU3XJMH[W+1U?*1.2[WOCFV=W0HM!3",XH(-Q%Q)S%*-@M23%EA2=2&
MTR<OZ/9Y@5%@MF[:Y/.IR%<B*"N"QV#U%SV@@&.@R'["Z)DAP'!E",P+- !M
M(-=& 9H26?U(N!IG+JB4M%H^5E<.?79- +^&$]/QC;93<4VE&M9G"VH[!<1(
MHZY>9I1;5Z)SARTAF)$R!,4=)QJ,146=)L+*2!B^!)TG3H??EMWP;VOU;J?O
M7\V4N]?5;.<.5OSOI#-,)RO^JN3V2UC2EB_6\<7^JYW3O=-#!B8X#BZ@4J:N
ML"H0I+PCR'/&:*FI(@%L>K)]W@'+AB].S1P])G,#_DKJ1_KN$MIY1:^;06J_
MASZ8VUV@M!W?2RI7,M% 2ZN)K26G<\B)[>\<*EY:46*#I&(2<1,TLH9%%*57
MGFC'0NF>O,#7):>C:HLRT9B%39H2U*+D/H9GQ$ZW-M8KK6"FV9R'Z155FNF%
MOG:NC(\!??^>F"'H"-TST'M.!L-QLBP 6GL%P>AOT/C'^:4PB=!)9O=5:/N'
MPI;?2R#(:!C\Z+?AH/>F[P:]<&"^OJU6X7+TC!\9/>\=_"WVOKTG,)]ONY_<
MV6&)G?(&D%%$0Q$GE*)4RQ:9B'U4Q@NC,2@0<@LT]!7B3D33$%TB*6?Z*::4
M"@F#"FV!AAI#&J1[Z"?B.05.:*BG2"2<]-ENMR'%8>B!GIH-RNJYV_?:/W%%
M^^M5J&W6/P<PG"3D5T.P]VGZWS7*]OO%'P8,:S#9&:EUQVQ(O8XQ5/Z#5T Y
M3Q>-H<6P5;50B?1F]MABX"I?, M7;25;*UUOP_@TA/[\L[<2)(+".DS>H,K<
M>]>!C0-0^P=(-)P5OYK^YZVB/SB%-\.2=AJS\;?L;7G9&</TP;),EQ7_U_1.
MGA<'8$6.%UZ0_4TA&Z35 //O3RM<7QQM9:WZ,*JMON^EA+ 8H_!4N%AR#DJ!
MLLY&*5@)BT\"%[7>0%BM-Y#5E)!TRO=-'R3.)+W\( Q["Q@*^^R>@>I^"M)K
M%/J/##BK1)'7AX1'014GB&D%FD#@&.DR"D0<"#5L'392/7D1!Y,A.@/5<#GZ
M6!57SU&6+X/NEP1TW;3GT3@@-2#?RI50F5Z_U1\^+7+R06&.@#*.$IJ>Y-#G
M25(5LALQ$>'D)*D05Y''(A(3';%>6<NI\*J4-C#A<.!E\&"^OYF1RDP,O]G[
M;9ER_@3FWH_5J)M![YJOG=ZD]VOF)YCG2W,"WXS/6CUSO9[IZ.[.(58Z:%]Z
MY)Q5B'LP8(S7$1&/&0Y4.1/DDQ<"7V3/I]A$I1H5$72C8@U1Y;P4FZ, E?8(
M?/TY^Y.K2$C&OT8A!8T5=,%,>1/X;:T>VA\4 PMRQ33:K$\^83\X[6<Y7Q/J
M9.J*6QK/5NW5'N6TE'1O?^7F2F7=3197-=U:<+"'' %\LQ!NS;Z+Y,D;]/NA
MXO <E%KT8U<RLQ(M54!M;K-,DB_9/S.:C,"JJ+XU556'BC9@E>L@D?%?3-_!
M;&8;MR2D8&,ZW9RJ- NOG8 -D>(KO4E*QNG6[\R^^E[SPJ7'C =;:9M3-"R[
M=\ 8Z1^-X#.?EC_?81LL2=&,D.>5#/!Q'7?Y$OJF/W[0T> IFH[.9Z3"Y#(<
M24/*93A2D,L4$<3,."W=2:8(P-UB.#7[0G&48KQ5#.R7SM/B7"$"]P$9+C=J
MQRYXIIVAI>.1,$5 H)0>8S#O!/RQ5O?XKD!95$5^3;&K=R<P1+_?_\<,.\GQ
M_1;&2Z;R M'')C .=L3NZ:$PU'++#6*ECTE@<*2DIPA,:L8Q PU0TNSG6A48
M_Z<P%GBFCCPDSDU+6OP"(.M#S/%,&[J#TZ>9T7[I7)DL;DR]6*2&IKQ,&FV.
MJ?B_PC!E*)FC\)CI =[_]V$(0BHK"8J@^8,Y;R.8\]$B3<J(@W?:VU2#<ENN
M>JK^S_8\&71F5% ;+0U<3'%EAB0G$Q#\.80+DBGI!?\FD_[=&+!]7/P!NG#*
M_T@F#$@?$!3)@YVR1])=KE874JY"$@_5NU(""\7/9^/)'Y#GV\6;6(F:E=%D
M/>>\=]N0G$,)-$U3O&CKNR\J1L?I,;U@^A=-/OD\4H[P-(S7B-U1S@$XR8_.
M]\/BA&S;PC3@5P/3<"#(MIH<CI!"V-7TYN\:%3EA>'P,8TFG8+;F5J :)JAQ
M/HE17Z<LIZNJ!)U:6VM@?E'F+NIPO21F@053N#_9R+!863=,4JB((+W#_Z;$
M6GC#U6#@ARS3&1[PRQ@;[_-0&Q,#9M3KY(REWT)HP2&!PX<4+/31L-+05*#6
M)R\V)>D<D$8DQE)R'C#QV8M-UX##','7*10U>20?\7ST?%FK!V+*<>K_G?J5
MDS$[!&$^!%7M?9.04>70S">)+RN(L0:0RKLX2TY)E^Z:<>7]21ZCI>AYIV*0
M8:AB:%4^RS11;:HC S^FP<V/(Q$]C.4J)O4UB7TI(KXH^%ZG 1[,Q@?$W1K3
MZ\G]\]G^WX>E+2DIF456"XVX8AXI[C0RU##JO/"$JDL$;=9ZYC).UB0U6J"W
MAKSF: LLVCZ:2]EP4WRZ4Q+['J N0.A.MKY;6EOK%SS8.=W]]OH0-D)3G2)7
M(9:(4PV*N"#P)S&82 'D5LI+$-L,+P$ESR6*#F "R/U>+JUXLSKW&MS9RU)]
M/[Z9O?4O<Y;[ :PZB($NI@[B1QIC2R0!\SF4GAO-C4>">]#%-7. /]* 5JXP
M=H);ZT/E*EX-K%6ZUMP^CZH#53DT5HO,Q3A)MM*R3@E2.N5BCU)DI1:E2Y=F
M;3L?R:B]-TN!&)%/GZUWM2U*U^/Y@':3D>.;,%9V;=?YJ5<#.2^H4,8(%73)
M8:F,C!PH65$<B")EF>EX-4*\@FU-1"W'TM8V%F^!;$JU9S"^0Q9*&BW0*N7"
M(NYHB4RI%++)M:.<#F6@"<C.*SG<I#I<)7DK?Y&$Y*934$LZYY#.MR0#2T.P
MP)PABTM0N*0UR$1MD-!*$@]")_@RD0Z[F'0J*IGUH*GI9- $;/NY2D#.,_S5
M=).'NGAW''(>X(\@EYD29!6- ZVLVYESAO],PLL2.*F;H'F-_FQ&T6+7]PD0
MWK]["&3&A'$!21E3-BP!B2N#0ZE1,Y%!.2NS$G9>W;4Y JR<Z'Y*!IT:OLP"
M3FTJM>P-^BW!?)]@R.ZGSX<FF* (!YM0^@"*&8/?K)9(>3"IG+;<ZWA)8=>0
MPN5 ZB[/F5QPWZ,[ JT?Z!'HBXXT+QV!%HIR[JWT)G"NO;=.P[VTY$Q%8 9U
M;PJ8U&T(BC]GT'TS3'*[%7G>N>/@)]VP'^L)S(W_(+D$'G.-GOU7.X=E&520
MI438I+,NHN1(:Z61]MQ3K(7P,6Y*S9WO L[.&MUBX7QV$A]QT.U6R0Z_Y/#0
M8 *O]*.GS\ZEY9X9'@&0I#I:8K$,WQ2\<@VL&63GNELPZZXY&85GS2_/FZ:9
MG7X>>[[I>?WT&N?3"Y9J;N7W55_7 *;UMA(L85C=S:%^<0UOVQG>ELJ(5=\)
MO4TI/?=K$,CG?O>]QQ*US>2//?;[WPEV2X/EEWKL!1TS+NRBLWKIFEJ.%1'=
M4<W"%:3/LC$;>8W3BIW;G/01K,2KX.H#;G4J]<)B/(:.*@VH7G@DZP?K%S[V
M"JB/J< I"88J9DP -8W;LE0L4&>Y(27AD=05H[]S/BD;Y35!SAWKG%/H'D/)
MZ*-ON[^_[>S2]V+WU=OCO?3?P1^=#Y_>P'L^T(___O'IX[^OR8=O[\^6RYSN
MO]H]_?C[FV\?#SZ?[OT.8TJ:8>^/SNZGO]G>IX_=#SV8R\$_G^!YL>EG O\2
M>&XZK0>&#Y'>:^1=H(A'(Y#F%JSZDH@R8JR=I4]>R"W-KMV']ZH\<C_*0;=8
M]WBP#G-LB:%E9%J"W>^L"<)9[PB)FGHN+RKFW&+=3\6Z;TM89TJC"#44!1H)
MXDR6R"CG /4(U=%PQB)Y\J+<*O6U>X3^+*R[LK:ZU"ST/B!3HZVZ02]II=EM
M=Z[]<HDFIP^[C^EU];%IP?EJU=^9KDDUN>H0R4[?/ZZ6QC\)K#HKBEFI2J]I
M4L>L8XC+=-A<IW0I'U-*DK(>RR<OV!;CZH::E=[3GL4/FYVOJW*T['PW[+RL
M>PC)&-5,(6ED0%R)@'1I*9A=C!NE;&H)FG0/SC:)G2]0+QKG-PPV?!\!?M:5
M#VW #\+=N)\3E-9DB?R0%K=F 1X>[-^4%I>7?C5&>J6$EQ;Q+T;\O57/6J0:
M5#CK4,D3XF.ID";<(<TX(R7UBL74BVV+K2D6]&/6Y@8YSUI.OFD%KN7DG\;)
MR[J;Y"Y:GY+>3$Z5Q )980)2JB2!6,M":GK MZBXJ2:U&^0:JAB2;E.QX5K&
MP2!78KE8R[AH ;[;A.U\E]Z#]OG?Y-(\&&B_85=;B^JWB.JK#K8(!KEUWB(:
M4Z]<RP32)DKD"9=$&A]+S)^\(&Q+*'Y#)OE-L,\=>^9:\&S!<Z/TXA8\?P9X
M+JO$V)F@C?,(!VN3.],@BZE!GEI9.BFTX![ 4VXQ=>U8Z@: Y^6ZXFY@HOS;
M5"=G$E+1YY?PZ+0#_W;&QR]A6 -X8]O0%N9R* ,6A@F,2LD-XMJ4R B+D7!<
M.*58E.D$R&8DRU_Q?$>]_\7;JJ-$!N4;.P7U\R=Y3M^W3,7WM^].U69P34NZ
M8;5[HZ:V:'?:FRZ=?,C5!UW-U54)TJ'ICYN[ZL[D]5_U(]*AB:H:8@Q^6C__
M9-CYDFH=Q 2[U;&H_*BZ4GG]BM%65=D.%CM4'0C7OVFNJ<E2,9?)21P.JDHN
M\+#AX,QTIX=%84D#@%(_%<2L"F:D*D/]Z7BKMX:J.F;U/8P&AE,]YNSBP:2.
M@*/Y_G$]XT,J1#9M>565>5@N#UJ5]/OR-)683@6)<X;TU=^V4(1IKHU6T?!H
M9Z'Q2W6N%J1:/@LYK5O:="4J!I-Q-Y><@PM!!TI59]*6O!O#<,W0I^9)OA.;
MFG&_[+Q[^;0H<0EO&4WF6@!V^O#\U)5P[3-^'< _Q2^_[;S[]6GJ&M,<L\G=
M#\SL#EB9JK!;K^I;5L3.EP!L'$ZJ7G^FZE8#OW<[TP8,U53GZ&B^1]HOY&F1
M^SL!1]8U2VM"KYKH%JX68<^+7^C2I2=AF%6_M'"S,KNCIG1<\R2XDSV=ZWE<
M]6\$%JZ55]@P%^ B_C15W1^XNAK(ZC7-IE[ZO9FBQ-/9=C<KD$O_;^7R?Z/J
M"'Z:%A!WRGH:Q<PKY[QF33NVFU!/-DW,K9< :UN=;N4FRO=<+)S30':^.D/*
MB^N&\6HSV?EN?M.&;8L2Y@>[1E^K)^YT3+G@R4*UY?Y41#@S.FXD01I\AI&O
MN3\&2,$KU0#3(&YD21W%A',I%"T-\Q(32X0BW-<UP#0M4?/+@L59?J^32IK2
M?ORKZK,(RY@GVI8^N:"?RH=ON]_^_G9())@T8,<@AST8D4*42 50PXFE(I8L
ML%B"$4G/S8AI*@HL=*JL>\0N"]DW($[!#AQ7=<,FP]'$Y$+:<Q>N=FQ?Y+/.
M7&O!W,^J:LR2BZDV-/TL*V55>X&%+@37(F$?M!1!B)"*1AL-MDDI%16&Z%3"
M3/*Z4MFYE)OSSNLF [N-GM60<2HK"<KGZZ]AZ#HCH.;]DPR?+1%?1,1[!V_X
M(;%,6B\DHE[;9#PZ9$K,D-#,IJ0O38)]\H+0\WS(<V4QUJC 386[*8F'>IL:
M&A]4FS57XOS7G;>O=I9J@>;.54W;Z6G_BW,I<-K%>KDI50PV2!$M "F7AND
MV%H" 0H28RS=>CI<KICW=V(]4&I^#7UWW#/#S[\/!Z,1D&.$UU?*?*HN? !R
MZ"A5R&W)\ (R_/0W.Z2&\N@<1TS9B#@/'EG,%&+$@Y7C<2IZF8J;RPO(<-;
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MCX]36[D>O. 8=-I^NFQ==\![S?%7#!O\GN.E-=G?ZXE?8IH-156>HE0G')V
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M.%DXD)E4@V7I?T.EFVX7B(&[9GT'_IIO(C!J,;EI4//ZD)>4"<PU"K@$*UF
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MYB@@"UK>9V22E_*9Z9Z:L]&3_RR\I]?I-V.B$@:]O&07O75I/RN$PXPJHK0
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M=0W(P)BH#=:]@>>%A4Y456O "$Q\- *M=KN8:<'%$<BKBOWK]1ST5[9J&-P
MUCU=#NR7I,@P'(.T3#(VW;4%VGTW22C37XXH),#/T TRI2)H&RH4K,!C''H)
M1X= -%.4<*9FX'7/.C;#H^I! \#5+)67!2<L[, G3:V;(/1+)YRN<BNLQ=IA
M)-LB+7H&K6@ZP^*+Z4Y"XAG@5C< ?K!FU*E6[!06 1AI6,"/]%!X9H52^6[7
M&;I);S1.0G&4$3A)E0H7TNR<&0[/$CO-T"D!+VQ")?$J5LV+G\#8IHV;GV=(
M(TNPMR!<$G#UCT85#_I)M4)YM$#!->3-P'ANANGU#6AG.9UW-*].%OHP]>?5
M/5-% S;6=QJ]*"/K:#2!(:2W9?JL%R.-*XP'S_,7Z[&A&=H(5*FMM)"PMGDZ
M %*G'2#N+&^ZG<\!-C4/:KH\66CYV<USPN<,KHB#X701SZ8JS'0C%]>TAL91
M+2>F0G,E3@9/S(IA&O4J[0 ^@S3K9/H;3;KC&6@N@&J]/A?R8U:*UC$E:&IY
MXI/%^XM?TKU/U]VZ!8(EZUS5-O1S-#6%Q8MW8_BG>CPLTOZ4N?)87B[P_)]9
MUW[[XT.&E8>?<-D(!&+"<S"RX:I*\4KT-"]_0((FM2(]/U/X#4[AS;+\'H"I
M!^3=G1?DP*[I\>F14PW,AK-!IN5A"+7V4R-"XJQ\<T@W B'/V&BJ*%6TD(9O
M33?KS*/C9!;DUZ2%F@*[3P@.I#Q,A+8@;5>&;F:*0#VZ'WU?%\ $P>+W%M^X
M,RYV#<R_,M 9V2HHIFQ1QYCCGP;E!J/Q.LF4M*L9LF7+L-N=:2*+@CB9TJ[R
M<><=71#-M7CDZ?CZ2>W >38,H%C 1C\_[?CQ<>.3FKNK]A3@V2W& B5-QN??
M,J<#N)"H\XY4 ,(NHZ8L#'&==C/_\WC8/.$$M'YD 4X^(Q/A <],]]2<C9[\
M9^$]H"8W8Z(2!KV\9!>]=6D_*Q\;=640@@B/I>>A-#;]@UUD7 :/#3UW-^Y6
M(P.02FK]DB29ZDRC%23+\CA9S,,D6BIUHM-?N>PF$&Z%4,[?F 5OU:)OE@<J
MA8PZ"FVXM<J&$FM&L9<1!VWYX:N$!)A@@O(O+#EI%[VR<W#U<@HVOYZEP%5R
M_,%"[-;H]0IF>) PX0#>_VMWX#[?3Q=L-_S/V[./__H32WGYL?>V^^%?>-[!
M'Y_V7OUZO/?JG\[^0??S[K__='8_);>J[^Q]>P/W_I/<J73WZ-!IZJV*$@G+
M4E9I,$@SP9!E7)7$.D=*_J0((V=.$C<,)V&>]2[,JOH)W$%H;:]$,/,&I]FR
MK?P4DUY2C[[5>E9C4_N9!$OJ^3I%<56M6"N4BE\R\PPF,'(_>OKL2GA9C[$1
M$]EMG W5DU%XUOSRO"G(TNGG.>>;GL.L0'UHO-!)("TYC?/[JJ]GF+F-*]RL
ML]#J-]=?;^>OEMS@U7=*;I><GOLUWB;G?O>]QQ*X4:A+/?8Q),]5N)1]38#<
M(?O+&KWN6O72'EA:\_TK"7>%W&42#%7,F "BC=NR5"Q09[DA)>&1>)VCD[7@
M^U[N\G(X<A:H3&'+W:G1\6\GF?'[_? !J.TW,-+_23;Z(SC'T7M#]WZ'W[]]
MIOOIV0=_GWW\]%MGCWX0>]_>'N_#.S]^>DWV7[U>"5E^^/0!IU#G_L$' 7,@
M>Z_^Z.W^^X9]_/29[?W^6L#\>KL'[_GNP:]QMT[3V'V'R=XW6(.=0Y"R1CDO
MD2FU!GG+/+)"&E1B*@13A&F::L!HM:4PV:!JEC=4!6RC46B*P=DDF<$PV-^#
MR='Q+(YQ;OKRPVPE^!,1S/6&7R_(K9CB5*/*[X#:EWR>?J?OWZ6(1)A7\A.T
M'9P.6E"[,5![MP)JL+W*\.!1Q*FHN(\>*4<)F/;,.^.)$$H_>0%J,Z-T@QJ)
M/@:]LEK=\W[F6H<KYLZ-9L4\TN-W-[DTK72X4O+=ZZ^N.TFKMY-\7\&_J3U>
MK0BX,1'0614!QNF(2XQ(I!9QYR12T3,$*%,ZV%52BO#D!6SN%J'L9V3CW>V!
MOELMN7L##_]^#N':0,C=N+V7*&/J6<L\RCDOI>*D3#^M*XTM#>&2I 1X7L9X
MR.23S<BRD&LGMS<8AX)M%[?L%7\YZ/4ZE6@'%;DZQ5%GXKWJC%PW)^-LC!_\
M;(I_O;U/GT\_OGK_[>.K#V>[!V\_??CTQ_''E%;<^]@!K.KM';BS_8//IZM^
M\ ^ ?[]^WCO8^[SWZ<W7O=_W.KL]N/[5>_JQ]\?G#_]^ -QZ(_83EGUR9/?T
MT 9LH]$!,<Y(ZK3JD'9*(1PEU8'Z:$I923-@"C UDA31);$L&JY"$-RH8'#(
M?UA+1/ J+OO-Y_:ACJ3,[42QRH5+<9/54-;% U@<L+1>:.4C#9)SA94U02FC
M.>.!!U#5+PI]51C9Z:<H^C-6YD,*M\0W^8G/.J">=MPE..D\F+@#CK_BR/\,
M9OY ]$/*))M&9IIH93?/-0?IHW$IJ3H1/@CV,)Q+!Z@SKE)V<W5]CO*'KR>=
M*MOABQEV!I-1SBL839TS '[E8FSTJ,D4S$E^@Y,JA)F3'?LPM_SP(KVQRD9;
M&-36-,<B91O RU.:;<HFJ?,-EB-&H%V$ J2M&X;TFBI9V5=I2U6Z;TJ8J5YI
MAL.4D%/A0/V"-(Q./P=?IUF7\)[.<)8KDA>@8OXJHV+]2.8'L3:/JYI^G6#<
MO#=G5]4K5#^X&FQ.,>Z[/-KJO3 R'ZK[0M%)*1=5EH49#?J@5)Q-9YMRW>MU
MRP^LGI]?FS8$H"GIZ56&3DXL7+OOU>/K%,V55^2D79A=,_:<Q#6_8=4B5!0:
M/&H2CH>AUV303\G@W'#@RL!,CHNOBPB>PE??D^97L8 6A?A^,X@,&/_6$]JI
MYO.VF4[^\@ F0Q:L'6!>]\Q/ALE[^<CD^]XW]^TP*D\Q+PVR+%DGL-S(:*73
MG])+)SBSXLD+MLWXLA2N'+X/.-/W]=>3T!\ECLAU:_*)C!JF1[-4NL2B,+*A
M27>B])0ZHR2E5LW!1>*C[:+(9)@3T=.C*X!?YJ*4BEL;ZAEETBN Q:OC+:&?
M$\AB2->-DY<J8>_)R7#PM9.RMP #_NL*CH<?4J+G/!#B^]Q8K^'E' SE(V/
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M88K KQE)$JHT\)%8)VJZK#4/<TMUJ+/0),Q8);,X5B#EXU!0&XMDNJS5KWH
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M1)0S9C.9@8&5Q*F(-!6417EE:"513.H?KJM&OY8^-D>S^.9*],I9@&0@ER%
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M?9,?KA_ \[=_;NV=T6FJ;IRN1<WV7^WF=YC;=YSO]A50/]S_J75PVCIKGF[
M"=G@6WO_Y(VK PY4;3C-5&83(F3,0/K:G"@;<9)*E<92R-38F;)(DQB9R#P4
MRL8LA2L3&EEA&<]%%F8IGP9;G-B-.IXW7? [1=/7@G/.RH$;I_3BA-J\-@NW
M0;'N#1?3!JY9V+GUS7+*NAD<"*76P+=Z[5D$;*]@5R^ZO3/@[]CR,%_<[-NV
MSUO=2VNG09L3%G(K\LQ&ED6Y50J+<33H;DREH:XZ?<-;S4\L'>OT?<,91?(
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M!*Z&(_I?=<(!G3(@F;T&600QA.NCX3 O8I2^X":IKF13X=_)#)CFH+-FOA%
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M3 8:*3;>-K]U07O!\SX3_AYE=53,=-(.Y@^%*/B0HP* Y;O@U9YYAP+M:[K
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MK7M4D;.<.X-ET3NJJ,Z N?[]SN4E=SEM=^Z=M_ZP!D"C^GZO*>(WD-!RB^!
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M1<7PJD$L6P8[)^>?RUTE-5*;RMZU7<Z'6,Z*._&*12$43Z5;V5'>"75<HB9
M+M*(*B(U7NSWR?/:WG'BJ)P/ \A3X%1RD5\$QZ?YS8*GYH4;.FF=@ACMO<!Z
M^QUTYDBC<0DVM!^[%;Q[!6K4S<9=Y!D)G "74%NF^IQ\7ERJT1820RQ,YH9^
M@3X)$1T^L1NSR,U#%4*'5=@N^7T?'=',$M\I*14Z=%J(OH:N0<UDR0F("K 1
M?41&XRRVU/ <[1(5@:ZSI+&_3?.2#[ Z\Y!=DDXBTH/043@KWD4!PUXST:WH
M/!U_14U+VRJGRUU9+G[69KE%S)IDH&TM!??^JR9>W(;"VLK*?9LT6'/;E7VZ
MU731NN.M.? H9X-KE1R-X6?:07_"3J.Z &&/YHI3X<'@%*^R1,U'HK:K=M];
M#7%':4/5+=YD]B#5-'QI,T8S/PBP]K9M^PJ@S0F:5&V;W3V$(;]@8<C2P[)Q
M;5](1A,C+CQAJ#-M6HY1!#3=870E0R01<8'G[)*@8^=!SB7-*#S/.ST@>=>O
MV*+IYHIYDKD)2:M:URA=)2V4%+"Z7+MN%Y=E)^@.9]^)95)K;+O  41"A*F:
M#I3?:D"/,\U <_J[/7SY3 U!.N)E&W-L=6!8PD+0PB0N5BHN]\'GRZ;S$ZR)
M\7G'L'SL_]$.GA#FD>A44$IHFW,N$?%1$@".+/2,,TE.@I0]/!9J%';,\9X_
M33Y%>.F_R6;GNU=?6$O&AJ:X+BOB59ZS#KAWQ$MX*^1E/DL9+Q:=%LAE"?_-
M(HS/9R+69Z#Q8K3+.*&&3,Q4K:RBKAL=3X7&(Y%CPMD/\_'04*A+/,("6&B$
M3->I\5M^/U\Y.^4,L\\\9%D7=*?B4;XJ$- _!#S""<0-R=HNII[@.\WBU/)?
MLNNVZ>=[MQD;P&,FK<*V'!10\?T!Y9:1]#$S848L!F^WA93WN41.A3=AXU[/
MV26(<=SP9RU\$P[V';+#>M![;;?B 0>VB_N0BTN5/Q0O[RY!TD:_"VHL\DS@
MG8("I5-U&W.Y5]TY43!K"XB+Q(A^T3D:V@RI6833\CE-<1]:V$WI5]I8/[V;
M/66[V@^P4\FQHO*M."E=5SS>J[99! (JM#"JM=*TJENM^GA:-<]\Y@CN+$6K
MYP/?= &[5V^[>$_%WA%PS-GYK\3678%35)(-DU3(=+=S>K+;*)Z[-H1QHO:]
M!&O<;L2'VHC#HDXJ[M^3\-Y33#\U8<"N59S?$V3(UOI\P.6YBJYY:0288:NL
MW+H0Z;)=&<:15G7!O6K $JKV'',I&S][]72K*A_4)K'KA[B[*4=T*K9.Q2]@
M#N_.],\->/_;#?<P.&^V[;EA(D&CFAH08^X+5E"ZP<0&_JDLP0[+N63]?KS"
MO1?/J7!ON_V^ WO<:E 6;;!7;RW]^]6&5*E ]H?E \?\1,2=J= 90V8R]+0Q
M2[E=C?N%$&'G'[^0!"ZBMA?-0XNH$[<+<?]6W6#F4,V(J7/,2-)H6C$8S*.8
M)M?40-LF3Q4.UD[X.<C7,TZ2GHTT967[9?DI4+^SPQKEN-RQ@0F<// *$7 -
M<J838UQRFQ2'\172"9<P%Z%R4W&:1EMUV8Y6\IZ0N^' +.2QEA6[%A(.Q4\4
M5K;^C^K"-)MS"U.C8^Q":6(J*&G3@S2WM@Z$P25(H$&: CNF%D(E1-7?'O9(
MV+B(NY*[G-OR'ZF/EKY)DVF4%&U@B9 9&4=E1!Q'#1R)0B>6W^ZBY)V]'$'N
M3%DA91^W&,MG45HQO1=W8N%Y'MZ!MFBSM]::^*3/B^6*>9J:<T4>)TVG]-1C
MLE=+?,#S;9$,RG7%-44+NMFX)N#E$)ZF>]Q293.WA"6K"QS#]F:OU%+^RV.=
M=MYS.\>GY:X7+%B@#GCZE6 KM"DGVS\PJQ+>):WF,NS3YHO24PPC@-V#S01#
MM[Y7L.GF.:$<[5>S$R(8#0EGM3LD8;YW*7XCDX,<!*T6."&5R.+48D5)Y,]5
MZ+/>H:(SRJ<WDYOW"FEG)>DY'PLKO5E=)S*XO?LNH=X,J2&H]GC$UH7O:U!
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MPD0TKE:/.L'QS(HY PA#+A2#'2>CAH71R.VS7442I>:&Q7$W(Z=-S4S@6XE
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M.\S3;<X3E,DHE9NV@,W_^M,;+J1*7EB!E&@2680X_QZP 'S.TY*<0[$..S*
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M]^$994R.23>).%Q("3&-ZQ2RQM9R^KG9A^#GR:*^8/A !RER7>V(&.6))_B
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M#@5:_3@*P#BNLA2$DW :7?D4_*A*K:KLVHF"6V5 D7NLX//:&P?BFD0#29C
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M2X@KN:L$HDFIKYOUX/3<5>UF23\,$\JKWN@Z+_-NADS1P+QUM?+<;:=F"0?
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MD#L:_T:034P&L<(PV0SV!4D-Q%*$N^OQ3'7-]>D638J#HKG-1NR;&*P#J-!
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M)7 &IPP8K(C,1NO$"?9Z^S=GU!R3S$OZ6,U8#TQQ,REQ ^S.!6EF;[$U<?D
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M-$P^A(&5PNZ"2FXTS-)IYVZ7$[I-N"E#T-X64D%E4U%22SI?=I JJ2G$(U>
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M(?$JPFM2?*+M9F_.PQ$T>SH[>?[^U>N?9^\P1T(!OR1HX*XO"15=T5X4F@
MTV:8;C1G(LIAPBEW<*'!JH"TAYQKX07^]G3V'T^^_>EH-?0<4BY)%$7.OV4#
MSC$1YW1G?)LORH;/YXVT]9$SS : M+T[DFWI(G<TR/##_E2_DWL,2M9M9.<U
MQK.=E\JVWFN1I0C1C'BL9)]V.=)W?*'>,#6H^D*4V \C.KEB;/'9FB!S^,IP
M->&'KR3.7<R>JUEXSW'C@U>OWG</KYU4^.Q&]*JM[W2J17PM HXX1:<1C.[=
M'TK2@<88_00Q0#2BX[,7LHM>032E[H+_^J9!3TLQ^ROOJP<O7KWYZ\/92^PC
M(:)\\,.KUS^]?/%R]N3A+ QT-@-+<-<(N?-?P^# ,KT-H5NW(6CN&RB49N$4
M!RB&@SR[A,PWZ5>L0*C,3E46-FZ]:%8D\P1#=A1\Z2*\%Q;+T5/OMK/_7X!0
M)JJZ%N KUGXP"?),L9ZQ5^&%+*5"<6]X2)7=@"O>!#]_Z$;??:#Y!&9+A"4Q
M5BJ'\=&K/50(-"=X,&/!3 23$]8O38:\QU:P,35 9,_#P_(XBK#.46+@=MA,
M>@K^[U7Q](B8J4<AR?'L76,T[)W;=P*KN=9IX*RP?ZSC&5.%!P_@% *J%X5Q
M1FHX'EZO*C\4/#Y \5#>B'0?D2E6)17ZZUD!L[D.87.X7].'&1$THP9F_*P<
M@:-N5>7K3.F6D?\E5T4 >5,I@I1&.4%"D]>U^S"<O?'#MJ84N?NAY$SCW(;M
M,T.YK<@7^HZC"[,GI(HR+.Y"?S(M(268#7-9A:CPM#&,6=ZNPGNW8;:/J)4=
MFPSS@Q-(>&4*D6:@?@;K>Q3D>FD&EE42=1<<ZVO*&U+FTBQ-\G+7"\N]^E8[
M.L!W#_:KY>_ZX8P._'!K0-0PP9ZE@W%J+'M'%:R"O\/Y,NEE322@[%)(<&J_
MJ:3WA8C7B]42"EJX%2.W0IH7$BME;18L8S')&Z[7I?RL1D@L/V:]*I3:!8EX
MN-J2\K@0-F7@G^UW2:XE\S5:_4R4T..)PI<'#5'TJ"'53.VGVO]SPI5R2VVJ
M5<I3Z>@=R/JJS&;&Z</E5'[ONESH2$VW5%%#(W\3AD56=UZS:X=5*P<:13YP
ML%/WFKS(58/*E/I[X5K7<V,^F<.))X87I+87_WXN:7A4 FMI9B&=>%N'JF)K
M*2'\#-U-&HUN'TRD="B84":N0.WGG-[+WQ32QTS\OVA @41.,3$:B>)>;"]0
MA<>QPE7=1('9>((\M^)"6!Q;%/K<D@2:$;(5%T5LFKG;U:6;%N2IO*="!Y[(
MHE>!>S)) JV-W8]-5"B3IB[6.Q='2ZA6YURY9:"#PZ50GE)-Z4([["5;+LO4
MV]\]"?@1=-?T-;Z O@2@2Y*V&C%)KJ/<TMF5,1:(.F)=M-K7Z,28-4&6C=GG
MXU)PC0NQ%8"/(4J2P690L7)*,5':($ROQ^N<2*'GQQ<GUHB0<Q.3EPQBPY?\
M;L9T>9[$8B6*VZ0^B":'.13AX%I'MA,W<EL >W9& %XM++E$#[65O]IF.V;Y
M5Y*^*3OM[8,M;Z0*)[\@B<3R=%!J#5?. E(+G$'QQ_0+JH%%X/ZQ#FIIL)I*
M#O[3(@0%</QP":6#LR99@GK5LZ@CPHZ!<@2P#%_8O[1]N4I+=;BTF(A25-C'
M0V^C<UHV3B#6?N@>*<4RF-)SVAS#A1+ TO!<:5_?Y.I+9E"%54-0SR,8M<:X
M 7C>M,2NB#.)^Q,=PTEP4H 9EQI\LUQJA*GS1ZLB?75UJ3(#WB9HE7#]BLOX
M1)Q%^)B\\JT]R#-C)OVP1W&-]/F7>87&.GY)>-?)B$@#A;"?!!^@;]%)$<<P
M&XWGE6P11,KE?N/<#$>U B0(0$AM6"7_N6/"("\1#8:XL>NA+KMSVN6G&VO(
MR%R3QC6Z,68$Q>4-2K];!2\1LEVCTT%<;(6.FG.D\;X;2DW"^;M0BB278AS_
MHUPDNX))RO262S]R1CT]HA!PI^*H>=K:;B/%V@W.1<CI[KAP,"[0*B::,'1B
M1GHP&A8_"B&&:?EB]!,G%%*<.GLNK"G,W881LIXA#D/*+NR3^2 K1\0R1WL/
M/Z5OL]:3K+&4K0QN:\&LE\QVJK_A[BIUVGM6]\VXZN[,BOA],"W$-Q^^A)*-
M&GP)<\0O$;$")F0+WDF^RL]$LLEPM!DC37K?3D7Q%JU<0^7Q.KZWW9._HS65
M 6):Y_$ZDJ/XL"TH]OA0;"+K@S@N#4:86\'E6ZR.$[Z"S?*/(3P/1Q]AX*&@
M6WU)5'4"M@+R!<D_&F"R&2976\/V <('P(+YBI%;HR_RE4O2,6:']OJ"-Y+C
MY')4"8A."79>%70B2.X4+ 9;MR !.?8W+>V@Y;NJP WI^^X^/7T3>XSZR"7T
MC]^""LT!L6"(A<<'Q,(M#"LVEB";<VYT55!S5#6?O0^G7U&MQT8JVV6E')_8
M):/L@F/4AA&F&#GL5APF%XQN6'0C8KP"U?%F_B$"C<C-8(>_6,B'8(E&;R]M
M]I_ 3<=(X*>/L]F31T^>2BIMZ*FIFYC*Y'+G.5*-D:J!$SHAII3L):3!.8HH
MHV:#/%'-69D%P1\<8P67-!3?81J=&H5VW$@-5 B'@?-SG-R@[76BC)2ZUR&0
M4>6 *I),X#SG8,K0@PRCD@-&3NG@#L'GC 2GE'R"E@QEE0E2X68D::F>%Z1G
MRF4*M(8C@X8WH (4N;=%72S+/AL?</N71S1JYLI=A@T7KK7(1@E/ 08Z,?7&
M.D[NMG]Q96\^30OQ+;;P#ICK (/QY-'CI[.7P?4-8_W*=M";*CSF RP^^AS_
MY)(<?UU7TSM:OF^XMUY_]?+=FS</&9@/:2PLIFJ3LFN$PR+O6>L>31CJ3Y)W
M\[_R\+>PM!YWY+W3J;@I\M9A^ 0Z[RYI%2PB^K6H05.;WK?OBN(#[[OSIB+=
M/BU1('9DIRL^D#C8$;)( RD#6&U4L<M&:?: )<#8:T-48$.'<1F#FR08&&I-
MODHB>=?SD4D;/^15&V;7?E'PLM*!Z=M-[=Y+W5NHR0)'PLG[8)K"':IB<8^W
MSZ^%TCN;S*V<;'"YV7/6PZVL-<VN$CQCAZZ+M0EW$KXMYBU8,"6=Q?-&BXN^
M.7$$T@U2C5%'"#9'T83()E+"-?/S,]X;QGRER3_I,I'U*R@EU! B=")'E:+M
M*=1+D'O8Y1]*PA:XUQ5<F\MQDTU."M<JH,(-$'@FUP\S'^%>4M;1T:M&H)N^
M*8?LX5RGW*ME.I1ZELK(X6"5_&IR^([OK&\7KUU*(DO(]"AY-[0U58VI9B<5
M8<08]'(32#[9K6[BW0T:+BJM>_XVT7RAN4LYV^,#YD1Y;>3 -T@^+AV*,P:"
M:2Y3]:>%:6J,)9=D+[T>M<.4/9=6U2,1?OJ6U[E_UZD@E-+<23> _A#M95*_
M(/])^=OEN3SM(4?$YOA0=F:48)#R))7S]9UT861)'FFZX&I@EOOL/HP;IUL,
M()5@4ZK!,+IE)ZR".PQ1K!38=ZD)LBNY<YKK'BO*_,G):ON4R"JOG!'*@A9G
MFV/J+-[UB ;.X=5!^"OY;X3Y$2XL.":#"[!R 4?Q(KC(MZ#';?4&D6518GLQ
M^$@WEX7@14GC''X+EF%IC3VVY(=1\PS9Q<,2_F,R;&\B $!2PU6I8Q^++K&G
MW_<O:;?@G Y*<X?L"F5,O_'\3HPZFZL(-<&"$+R+S-F7E(E['SW07=GZ:%.T
M!0'PP_'YHX<P,#5;@XQSSI!%XFC'ZIZYV:"PA>L_F/=/544FZADM%:XR'<_>
M[/ADMN)J;PANR=?N1SP13&]*Z3T/"'!5YM$Y'D]M=2/1 %558G_H+Y<E$TL:
MM2@AW524W UP>/#782W.YSF#V2K4'6>_#0N1WXI52<JH<),"<0)K#X=M%0-S
M:E]DWE-&)&U/33%&G39/AWF&3Y2T-"R*)>F8RG#M&GI7'-J](14OU?7C$BTW
MMU=B.\-$L(M!P1EQWPX]E#&SG?=/*58/4NV?(S\.P^I\.= @#K%.Q8!CUYEJ
MJ-81@<2!,NHVYPHF:M$&<U,Q39<#YUEK^MCJ'V;D5MFE$@;DCG&Q8IT9KL%%
M:S@^7$,^S,?M*I]V+%K%;F0LJQO7::RJ;[$YJ.$[3-'M$K)%'\2 -E*4 O[%
MFEDU$TB^1'[@([QM1\!GE-+6@>N&'0<VPT^@MBV@9T=JL7-Z) %]41A1FH+A
M$0)^28*D27MCB"*#R?FWQU^C)Z0213=$>O2-><$U5/^Y8)'SLS/$1#W2KQ-!
M3ZQO4 %8DW0I@GG$0Y!)GTB$QC$U&ET!582\BP4Z3?"+700 KQ5<LX7NACX.
M=]9;G X]Y=4W1<](;$:ZZBV2_<X=-Y(AE-KZE:^*J[CD/8A(2DIN<G9:8*4(
MZ[7R$Y5*6^F@U0P/LY@<SWYJV@+7SJ9N5G;H7M,HWL&7^;K";Y;2B>W@"K"Z
MU<1MJ T%%V^X!DF$]Z1DXM]1H9#4.TF"@I0:E>!<WFXQ%)SSDB$42O(%,SWL
MS;GLV^.72FW'*/NU]G--O RGY8+!+I(L4*K 09F/[Z$N6M#81PKTK3+LOE5!
M&7"]+B'K;0Q%C84&D;GO>Q6=18G))3IVY15F0N/$E0U)-4RDD'Q:D@DM4)!G
MB FYZ7.2S@Y#1K8RIG90*"]VC:-*A4P",B?1$UQ?NC6HYI>'2GMR3U%IGQ_[
M[/.PB<->9BC+_<JYW[ F\MZZ72)(31IG5XU@4K8:SB\(O5^)1[%IAFF%+N2H
M\6FK )J<3AF&Q]'?UXHBHGM_:=6/'DWB'AVX-?!H/J5<?#KBDSB*T=R85X6F
MLJXH:%J47O7UZ-A(E9! 73E;5I"_$4M?@A*6&GT9O3"[R)D+FUIO3%?.MXL9
MN\$A/_XY1ESN1!^Y[KL+<DQ W71^K6IW_2&)<9NSE9O>(- 29<68,56A,JR2
M0^E,S!Z!(6I#Q*0M4X0"DGZGJ2\PJ46!WG6)?ES#,XD^$3H'D45\J,.BN%6E
M#8%GC8GA9-JVL!\W2'@=YNW3R2^Y35N!T(EYA&-O.M4IK8_H,#6WFX<TB]<Y
M$GR?5\ \"0^\\0-2&=E8/;0XAEYK3I^\!,=^N.9A\F[[D"1.!&H/_FT <QN@
M/6BFG7,3:BYM_C&;<IB23U9\4;Z<F!.&BF'XS6$.;M?3-T\-26FBK$GLW$Y&
MDG$^WHF>2LO MC-QF,M;-7'BF;LY57:LP\C?ZLB#?/>LL,T2U8%36ABA.E'!
MV,.<?/K314HOQK3''.;[BDV2*$LNQ[QK"&=C)P[ER@YS>LMSFHILU>%6D4DH
MMOZT,VMKPM%TNCDDI/Y%N0?BH2?E&ZHN+L,VJK7L2FTF<+@O#=^N^'KF;3S,
MTK]FEJ@;F870Q=GSLR6-=DP2)%2OJQ5H$C:'"?N$7H84YH2M6V9&NS:M*^0P
M);<Y)3('P!^55@PC W95LVU72&%,&Y3*KAMR$:[#N88T'TWX M\=6NTBRZO@
M/78"[1720SKR0,$![HT%KX;#Q-]N.JD.D>]<Z9N62:-(/O_'4#+ !&X)-Z"6
M<^,0/2_7X>^_09!E1GU%+3LM\WR-TGS24QI\EX%QP0</YE_3XF =;0]B)03-
M:UP8\[P<L>'A(>_K1=FMA]XS/(QRR-+6S" Z4I &,)Q(I"?N%Q9-O(621QJ;
M^7:X(T\I^#RM Q)(TKG'#P]+Z7:S,GHT$%$_; #O]R71$;A^^/"YHT0T[H/#
M]-SJ3B>N_2EX36)YW38?"?8>IN=6RZ&"@KIHJF$U"8,ZC/]MCC]+352SX%O6
MS:J<9T;;(S08(__WT USZSO">B$$6P<]B'E;GJH6?>D4Y+L/LQ_Y6\I'U;$G
M<+>I/:[/3A,I%66I@K*:US2[:(!:_IQWB_P?L[]6S2E4O>R+W&P\A'@Z4_5E
MY: "H54/'0=E=0R7$AN58".%]H!H6Z$>2WC-H5840$-Z)/#]0%W/6M&2 A,H
M/9R_HB7&YWKN5*4<Q?P/;9/;5N0.$-FBND((@!ME'1U1S%7HWC$A0L/Z"<2$
M,/6 ]PRE>T.\]&MNK!62X,1G8&MIWEUS"9DI'V80PJY6$K78NF&BJ5Z0Y2/X
ML],^;!:J(IXQC0P<:G>*/O">S=5>H_ #]0\.:ZQKAIM+%Y"Y>Y[!-=]-]DK1
MTSG)@6X3,K.H!J5UOO[W=/X??*@QY\3B9#R+4=G:D;H_U)00&*"6P'-2&I:Y
M4*6U*%P*&"),Y$=*TX:_/?WZ^+M_U[5ST;". QYAK"S:%>FCF9Q6HK7N21VC
M',/@22*AI'<I"8V9MM0<0QLAC$X.!;&I^U'?4?CS)E'%Q2H](Y[Z3)NO=+6G
M8A!%55C]QXTWJ4M9-H9$6]NS8"#_6W4<%\U\6'$0W:04FH &$08KW-IH@@B>
ME<7 ?97_1L [R!^3E6[#:F3$D"A1A2V(#=P:=D_F8-U<,E"B6D1]@G7+=)_
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M_[Q0#V+2I[M.7>IX]N/0X@E7E-4N/6NX8LGW6#>7@27CE:7NI\C!3'B5-A?
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M)8\CN0G"ZZ.%D'L%O^?TCC_::&!<[LL]'RI=B;57ABV<@.#DXN>CCRP'0G+
MV[&$EQU.>(!1R,HOI<;!OH=88E,JO,=;[IHI'RPQS>>,YH32Y;PEW()*>4-D
MXR1[.G*#$]-"2VQG5UPGB4_IB(F %7H8QM;164&3&^Z1P+KL';:6EOD7[FG
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M7H8#1[Y+3:GNRB.B;^%T6)!1E5J!F-MPZ(4K8F4]1+:VQF,WRR-9'/&I]0%
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M!?%WBZD?3FW8Z69,S>M>U1205$^NWQO Z73K#_B=,'_M7>>D<P+WGW:2'^Q
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M7C(6K"3"&8TZU9]@RD\#-OF)B"MHI*#YEC)9==^3?1V@ELZ'">Q/8J%-*X^
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MWP0. ;@<=0."-EBHPCD#7*JMW4C6!JN_\@D';TB"A^L05[GSRP]C#L =5&'
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M8E.I/,-X*U=[0_=PPHPFU+Q4_'?OUNZMPN1<JBKC^2$X?XX7A^/IJ^D2[9F
M(\K^46/.P%RNB93*$+ DP*ACTE$7(5K'SKLA?CCQ0%/6WH.Y>[Y^^NAHO'*'
M89I7H<L'G-:.E377ILW.KDV[T@B]0PS0&$&;BZW[4TJC&.(RCM.7?ATAA;1&
M%@O)<B1.<\JIC$P0 @N&.:F3:7TKUS50=F[I6?^U%]H!5,K2N+KDA(:3K$@A
M?/ :N"O(HN$4+;?>Y[\5U)"<>0N.?-/6T]0JS;SO-;!.FQ.TY]HFS6FZK5T$
M-/5 $#3G>Z:%M=PE$_;$E %V9^^1)MO8X[[<WUG,.0V3K]VXFY7U0O7F_;8
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MWLQ71!!*RM:)[T8+X@\DS=B%/2U,LJ&S/?F\_A'I7;_\\!]02P,$%     @
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M]P,,)\CK9CJ<E%.]9M /)>@]'J=)^?K[/OC^8!8(_S7!>#I*$28_0W\TRV[
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M-1B2\LZ(3#(M!3R8I<0F&@CW'HU(7+1=]03.+7">AME429&;*'.@%KJTF^Y
MX\L\"$IU-M&1I%RIRH#&G3<4" _"<Y68--8?@2#\91)D'RT<:041"VA:9NJX
M"P22*55< *<L2[7BR*32(D:9.@LG/H3ST@BRCQ8VQIU/7@]A65#_4YJ@%!'
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MZXZCRXK7#V;"NO^NO(71X+H8B/TA% TASIX%'D5PE# H!SM"HI7HG26&<I5
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MC>,*:8-AC(.TK%5QDI:JOC_Z<<,2E=2R1M$'R/0X88?/?;1-<S_ <'+;J.R
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M*^S4/4,Z4LGW$"=2+/LD+1"'O,<M/N-/0@7B46"490-!=IQ)^+3B1)49L$,
M:!=-'-VO;P/NKP#0SFK<R<'?1P=')TJD(C+#*>'>XNYJO2" F(AFAE*I3+"J
M55OCITV0 P) W?%C%]&?* !D'7>L+):1*XD0C2.0C"8N^2@B DRZ]F[S'0:
M=E+D'@&@7;1PL@!05&!DM $M.(G;;!:">&-+>H]A.8?2!*3V =9W&0 ZA"SU
M-5$[ /1 C3/!I10O?WI;HAOC/IID;X?3RT56^OM^2=IX--*S U7*@.-;KI2A
M=XOO5)C"32#GL!?O3NKDZU*,:3@Y\^-9FD?E%VG+0-4S;A<#=)Y-NQSGZ*__
MXUI[/%-V14B[OJ6+C\L?'L;I/_[M_P=02P,$%     @ T4.D5ICOX[J3L
MKBX' !4   !C;7)X+3(P,C,P,S,Q7VQA8BYX;6S<O>MRXSB6+OI_G@*G^L1,
M581119 @"?9<=CAOO7/OK'1.VCD]<RI.*'"UV25+;E)RI??3'X 4=1<%4"#-
M.3^Z.FV+6&M]$#\L .OR+__C^^,4/,NBS.>S?_T!_1S\ .2,ST4^N__7'[[=
M?8#DA__Q;__P#__R?T'XGV^^?@+OYGSY*&<+\+:0="$%^"-?/("_"EG^#E0Q
M?P1_G1>_Y\\4PG^K'GH[?WHI\ON'!0B#,-K_:_%G)HB*TTQ"+),(8B85S#CB
M4'$:QD&0J4BD5_=_9CS(9,(H9 )3B%,20$)Q#*D@0C N!$[J0:?Y[/<_F_\P
M6DJ@C9N5U8__^L/#8O'TYU]^^>.//W[^SHKIS_/B_I<P"*)?FD__L/KX]X//
M_Q%5GT99EOU2_77]T3(_]D$]+/KE/W_]=,L?Y".%^:Q<T!DW LK\SV7URT]S
M3A<5YF?U B<_87Z"S<>@^15$(8S0S]]+\<.__0, -1S%?"J_2@7,_W_[^O&D
MR.P7\XE?9O+>S.P76>1S<;N@Q>(397*JM:]&6[P\R7_]H<P?GZ:R^=U#(=7Q
M8:=%L3.JT3(S6J+$:/FG4\)^N4!]3_HN#G7UH%QE[F=?.K9A^MF;NG>:'V3_
M"F^)N5CE^@OU?B:&^NZN15VL>O\:^_I:S!=T.L#78B-F2^6I^<4G_:^5&#-0
M"YE6<E;4O:6J_+Z0,R%KMMP9&N3B7W_0_YHL2WA/Z=/DG52R**1X.R\7Y20,
M,DJ1HC!D*H98$0%90!-(PRAC =%+6,(FB_47>B)G\-MM([L2T#+Z#PXV+4Z\
MFX4LY\N";U:UQ^FQI4JO4F9=([_,Z*,LG^CJ :VB<0!JK?_M\WS&EUH[O>R+
ME9Y@.J<SP(VV__++QBA7&*?]@C/M%Y=&+U I=@4V.)W$9,YWM)D:-V!>[-L^
MY^VV;]ZI4JM=&:YHR2K-5P]J%,+P%SE=E,UOH/E-]6(='_N7@\F[+AIM:<'/
MX+WZQ"]<8R"?%G '>N,96IBUF%O,>PV<%O<#F!="%MIK/:+ZP??N^IGF^N>I
M_# O;NE4WDH]5?DBE^4[R1:_TL7JI[]J?S:?W<SD?TE:?*!Y\1]TNI23F"%*
M,$NA$JF"F$019!G#D.G7G1.6H321+N_[9>J,C2!J?6?W()^!^4R"%ZVLGATP
ME:4C/5PX379\,ASXO1,06X"-]E=@;1E4\P(:VZZ 41Q4FE^!E6TO^I/3BGLT
M>=&9 +=Z\J9R_6?P3O_E"ABS@3;?'YOY0=X3_5VHS*!\Z0>X?8+U-*H;(_/'
MXOODYLGL?N_F7_2K\*!WK]="Y.8W='IG#A;,$<-;_9J4LIR()!(TB1DD:1IJ
M5RO1KA9F%&9,)#$2&,4LMJ%>1[ECX]CKQ_E2.V!S!>A:9^V 5;H"N@"+!PE$
M7O)"FK^9S_%EN9@_RL*.@5VGI9UJ>P2[9TZME09W<]"H#39Z@[7B8*5Y/^"*
MU3%;=4;T&B#O*#!^L*T7HHZ0U2N.>=@L(U$0U8=L?W(=;I UHZ.-S>+0]?$.
MJ\!7^2QG2_E&SOC#(RU^_TLQ+\LOQ5SEBZ_S%SI=O'S5CLB$8258%H202VI.
M?\-8KP59!I,H2<,T%2I.0^L5P$[FV-B_TA(\56J"HM83%%I1\..3U#)FBY\<
MF,@2=PN*]X]FS_2^4ABL-;X"-;:UTF"E-3!J^T?4@=?](SL0IWM!V(W0W;!J
M)7/+H88C<C?;=DC<\=&.!ROB;]K/--^K\F[^51J3\JG\+!<?9UQ[GY^TR+OY
M6UH^:,'/N9#BS<NW4HJ/LQM-7/JK.+N_YHO\N=IG7+-R45"^F!",,&<1A4F2
M$H@Y$C"C-(5ADL28"Q9B1)V.6WI0<FQ+Q):-8#$'16,EF,D%R"L[P8]3;>E/
MYL_FEUP;#);:SNK<IK$4T+6I?W8\O.GCJV!YI//*$]SSJK4WMVL#@;80?%S-
M[:=F;HV=H#$4L!?PX[=ZDG\":W/!QE[P6V/Q_^OQI*?'"?%U_M.'BL.>"O4(
M\L%949^RNBT]6K+>C)3RG:S__^/L=C'GOS_,IWJ,\OW?E[E>X>;3Z8=Y\0<M
MQ 2G 8FR0,$8!0QBQA!D-$I@$F0B) R'24Q<5A5'^6-;,!KUP8^- 3^9A6#;
MAG\"M15NZX#KO-A1?(]H]\S>#D"#WXP)8&6#1S[NB)XGJG65/BB+=H1FGR"[
M#M.-^S[)LI1RS:V?C,1/.67Y5(OY0E\JHGZWE!.5QHP&*H0A3@*((X0A26D&
M22!2D:4"1TJ[TNL8B[.OH:U@)[8[$4GB\R6LPDB 6BZ6A02/^2Q_7#X"<U>O
M?_NT4MN-YJRGP([?^@"V9V*K5;[:\BHKK:_ 6N\KXX\R";[07/@C,U>H/+&8
MM=A!Z<L5C'W><G[>C;#*8C&YE?=FE+_(^7U!GQYR3J?OYH\TGTTB2F(J< JE
MC#*(TSB%61AF4)(0B8@PIE*K.*I6*6-SO+8U!+_5.IY>ZAW0;"<:;QCUS"IN
M\%B3AY7Y;4RA!]AB"?W3AB':QQZ$#JS,:]Y]NP]W\TQ,U+M83N6->JN]'<KF
MAE>>Y751Z$F6%9M<SX2)E3OQYSO]K](<0LUGY9V)3I@0FJ:9WE+"-)(<8BH8
M9"@S9X)"*48S1*G3QLV_BF.CF!V[P);F5;C/]L\WBP=9@,4#G8'=AWZK#+/D
MI1XGW\Y[>MTI[9D1!YA-9Q^L/\ ]>6L]*#BH7]<?P/L>8(^2NBTA)OIL$XNV
M'Z7V;:;WU]/\_TAA#AV_S,LJ,F$=EE8I<">_+]YH-'^?4,[B("9ZL1"QU!XF
MXY!DC, (IWI24LDY%VZ1^MYT&]NB<;M\?*3%BXD=^SA[ELV%0Y7BMS$,&,NJ
M8-/[^Z).T3!W#)LGP)W6K&(F$Y/V2<[N]?-ZS+O\T?)*O8_O@=TR\DJSV_/Z
M814GO#?#H#%O.X)XM8P 8R2HK/2XHO2 O;=$"7^:#9QFX1W2PR0-_R*ZK1I?
MBCF74I0?- R;V.4OA6R.]_0B]I9.I^6-NGV8%PM-J8];/#=1$14110$,$TDA
MYI+ + LRF,J4LPPG) KCR;,LV-QVK;A0(Q<&V=:K/R)I#*ISO1_7)AEZ+XT%
MT)@ \HT-;H1_Z13:D?R T](SL>_.Q\:6*[!E3;445_:8::HL@G=FFCY:3),S
MBWL"UQ-S7ZK-H&SM";I]AO8U;%=67F7Q5;=A7VAQ4]PNC--8+0!?9''[0 LY
MB4.*18@9#+E,(0[C !*"$QB+)%,A2TD0.R78V8D=FP>^UAJ41NTK\$0+\%QY
M7C_F,R#,_JLHP9/>XY=&?\N@7\>YL&51WPCW3I8-N+<UN%_J+,5:ZY6#J_4&
ME>(^&=$%*&_$9R5T8'YS >*0QIR>[O=:O4J$T]_,"9$1B])(P!BEFK=D&L",
M\Q!2*3'#<2BI="H$X*K V!BLRAE5>KA^[M+7N-MQ5)]H]LQ6;G?KJV3=#VW
M]W;-OH_>P-?M:_&CO';?!Z?K]?O!.)UC)N>/LB).,_(ZS#J.@@2)((($A0)B
MQ/7F-TH0S!1+19(*FB(G'CLA9VQTM8J=7NMI$POMA*L=3WE JV<ZZ@)4ER#%
M-AC\!2,>E3)TT&&;J4>""UL_[D8&0N:3][.%)IAK(?2WQ!S,+>CT_\F?WLZ%
MWHL)GK)(I% 0$D),8@(U"610*1XG 2><9U97)NUBQD8%M:9@I>H5J)4%6EM@
MU+6C@S/(MK.!/[QZ)H.N4%D3@AT21_B@E/SG^_GS+WJ F@KT/S8,<&;800C
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M2SBC'$D7/_,B;<;FAAKUJAM:;OXA-XJZ>9R7S5"F1"QH$$&14@8Q(RDD293
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MK_+9Y%P#0Z*/CNV^K?"F!*6(AP(R+#2#!DS_BP4<,IHRQ&*E4D6MZP)Z WI
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MQ(,$<^5R*=])B['Q5Z/HJ@K@TTI5\*0_M?[)T9?I-CUV?D[OH/=]Q%?!7!L
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M3[0 SW4U>:W-55#_#Y1ZOVGV0\O%P[RH"O71!?A5S\3#/_X))<$_1\A\/HR
M-A6\D[S:B^[\*?QG0,A53**K.$FKC^D?@QA?H3!MAL_KXO;FC_,-;GH79EY4
M-VE70 _X)$W/53E]<2X@??+[8D>$GKX%/?/@Z@MP6W\!5CT$ME3U6B'Z'![^
M*D2?E#1TA>AS)A^I$'WVD:XU#:^%T%^=LF+9FZ)J4JS-F)  1T&2!MIM0N9T
M!TG(2);!($:,)SRC*7>L:7A<T-BX;U6D;Z7L*F=10PH:A5VK&I[ MYTN?*+6
M,U=T!ZQ#7<-V-"ZH:WABX('K&K:;=UC7\,SGNSE%ZRYN'V=/FF<^2;U.HM45
M!>$T5&D<P#3CVBD2!$,:9@*&$4NPP)B&=DW8+&2-C1C^?3E?2%'[$E^*G,NR
M_G<^ U4#=UG_J)V1WV5=%J+^Q4>A75=S%E__6)>0 C]6IM:_0C^Y>2%M$V3G
MA7B"O6=FV<3)7(%:T2M0J0J0Q_1"!TP\>2)MD@;U1"Q,WO=$;![QVH#MMMH
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MW\ZV+?+'T-/V/#R6W6PM!G*O>_E)WM-I?8]1M[ -$29F2RTCCO2^.I609G$
M>:8"*04G(;+R&8^,/3:VJM0#JV*,+ETMC^'6SD 7HM'W*;,#$$YU)T^8W*G&
MY/Y8@]63/&'$=NW(4Q_I6HNG.MRY?9!R\6F5MEA]QS+%4!C%(4R32+^;* E@
MEJ2XRC$/ I321#GEF)\2-+87M3GMJA0%C::=&M&>Q-;.@_"!6,\O<S>P.E32
M:4?"6^V<$V(&KI;3;NQA?9PSG^^8*V/JRIFTYD(^Z!U/_BSK^%I3ZG\_XV\K
M%U#\;5EGS7Z6BQMU1[]/2!"F"8H(#*7D$$<XT8L\CF&0QI%*A22:9)RR:SPI
M-C;BV>KY<4_S&?C1='OY">C729@\VGR3CUQ5WW%,V/$UFUB[9 @)#!5**,0T
M#"#+0@83HO065&_]PX2[A2*\QGP.$Z3P;;=SCYG*D<RBW0+T&C/3\X)U\_;C
M%;#JQO.7ZATTIOYT!:C2#  VEE7IH]HRCPEAGK'VE4+F2ZUAD\X\@WF0IN9[
M_&Y+]%=-)<62+ZIM^_5,5/&"4FQ:5!R-)2,ICPF-( I,09"$II!0%.KE.*!Q
M) +)(J<^\%V4&-O2NV-#U;C0\1"QTTS8D7#?^/9^T[,-K:'-E0%;#7'ZCRR[
M!$1/3-I)A4%9\Q*0]AGRHK&Z5IE_?#1M-/1(55VF\GJY>)@7QOV:R""*>1@0
M&"@E(4:I@ R%"O(T8H)PE,7,J8]ZBZRQ<5NM:GU#<@7*2EM U^J"'[6;4__6
ML7E%&]YVU.8)Q9X9; 7@;0U@K2C8:.JSM/I9.+Q52C\M:>#"YV=-/JQC?OZ1
MCED1FSXNDX@$1'$D81(DB4EYB" AF$$5,,XI)B&/4Y?.@5MC.Q'$ *T![XR,
M[28VCC'T6ZC9O?8=L>C[7L(" />(]D-3?86K;XT\;"SZH4D'@>9'/N*C8,]?
M97[_8+P(TQ7[7GZ5)A6J^:.);$>3,.:"A$I *C.]T(LTT_\*$50"TTRED@5N
M"[VK F-;_1N- :U5!D6C\ZK9E6ES=4GM'XLYL3QLZA'IO@^5]NL%K5%?J0_6
M^M>? '=MJ%]83,@>NE[*#%F(?\4"1/;@M)<F<ACG\J)%YACI1NG?B"6OVK.4
MI5QH'R5%(:4"0<Q5 '&$-.L%J6EQG(E($YWV49QN:,^+'!N[?7N">L)GJ];&
MJU)FW:L7G<#9CK_\HM<S8^U6,JH*L58=9AJ%0:UQ/P6-VM'IH:S1"8&O5MRH
M'8"V$D=GGNP8BWJ\BO6FCOJ;E\U'5C79KO^@A?BT[M7&TA"AE,10AEQ!G H)
M,QHE,".F%0&-3/ZR4W#JQ2J-C:JVNP]LV[33RXV]@*-="HQECE&ME\^I'>T-
M.U,]T^)V/X'SD_3F<))Z:KKG#V1?P;&7*S1LM*PW  _"9_V-[%YRJ.H9;4;\
MBS1YW$\/.:?3*L(,$<09R@@,*@<QD=HW#,,4$H'2,)*$"6I5LJ-5RM@X=EL_
MIX"]=BS;B= ;0CUSFPLX3H6 SAI_0<F?TV,/5MSGK'G;97S.?_C"<[!-NJ5*
M$HE2"6.JWVW,2 I93!B,!,,!SV3**7$YH#Z0,,YCZOGZJ,4MO?(TD(ZG4R-,
MIMP</_E+_CMKM^^SHV$S L^:=_+TY\+\/T,2O]+O^>/R\=>JDL)$Z;V3E$D
M(R)"B#,J8!81O040L2)A2CB/K>)Q#D8>V^J\4LY^1=[%Z?PJW-GZGM_/E5[@
MMUHS3\ON46LO6&IWQQML>3UJQO:2>OP#W9;1SW)A&DM\*>;/N9#BS<LW[91_
MG-6MGDR@RCH\9=W[)"89Q6FL'6F9*;/.<DBS((5Q%B$4940BF;F<;+BK,+;W
MN.J:HJ;S/U:GAWFC.J!KW1W[SW28%[MENU^T>^8-K7S=HJ91WQP]_&@LT)C_
M!-9&;$?2]='!ICN(GIR$#@H,ZD5T!VC?S;A@I&Z,>+WIW]P6U+Q.'(A9+!D7
M'"8),I4HL\PTS:&0(H88H:D0S*D4J*/\L7'AEOI@;O0W9>XW!E1I'QWR/%QG
MQ8X,>\2Z9R;<AKE2'>SHWK3B:+(U/M>]R;WF9W0$SQ,#NDH?E/XZ0K//?5V'
MZ49\?RGH;+':6J X#1-3B5UARB!&+(4LBQD4 :-1*%F4,>%":EMCCXVP*M7<
MR&@;*3NBZ6A_WP>@1BN/F[ 6:SV]]=LC#_I&'S%I_VT]]I$.->7,A79YHZIP
MWB:0M[I!,3$T$Y0Q$I&8:Q\CE;6W03,N(*(1DU&BF,RL(ES.BQK;>UHINZYL
M=+4.V*^O(^V#]BQ ;G^G_4+7]_UMA=J-:H+U=W1M#[IS1<VALIPW] :J+'<!
MBF[%Y:R :2TNUS["<,7EK"S9*2YG]X1[B:6Z,,Q!DL3-<E$NZ$SH/>2$!S'"
ML8AAK#D48B%32#D5D+*4X0Q)D0FKEH=VXL;&K*O*0T>S>K;4MB_.9(%X.\7Z
MQ[%GFKT40J>R3O;(=*KT9#'\8,6?[$W=K@?E\%2WK=('FA=5.;A?)34)FU7U
MBO4O_V<N"SWD0]-5*0Q9+$+&(6-!#''**<P82J$*1!P$/$)!:%73K9/TL9&-
MT;.IF+BM_Q78_ 6L;7#L>=5M?NRV<+VAWC,U'8759)U_OOX/CPVP+H+)T^[0
M3?:@^\=.L.SO,+L-<D&WDNN9V#[K$"PA"F74%*=D$,>40DII @.<!01ACB-I
M=2K4(F-L=+6NQ&_>F/OJO*20SW*VE!WZ%^S!:;'-O!RDGMEEC8_6$%B>)]E_
MW]R[.W0':NC6#FO /#=T.(Z 53>'O4>';^5P7/>C?1Q.?+1KV:#G^?19^X5O
M"RGRQ0?*J]80JZ\A%A%/4^VZH310$$<D@BQ2FOM$JDB01$$6.F70MDH;&P&N
ME06UMJ!1U[4<4!O"=AZ8-]QZYL23D/5PU&Z%B;=Z/6VR!B[,8V'V804>FX<Z
M1@U4:6=OET5AFG^G84BEWMM!8DKJX(1FD(@,04&("%.&1)#%+J'(.Z,[,<1@
M8<B\5@[0]C1)"_#LR* S)#V__+5>5V"EF<?K]F,&^[I,WQE[V*OR8V8=7(0?
M_5#GM=ZX[R9WM/$E3&?AM\MR,7^4Q9?Y-.<OFY)T(4\C%.$ *H8CB 5FD 4R
M@5&<8;T;PCQ(G%+*W<2/T!LPVH.ODL_O9[EQE9W] !?TK1V#GC#MWU.HX*RB
M1M<[@S^T[J!1'OQ6JP]ZJ@+8!3E__H2+\*$=C [ '/$XNHSBM?:IJ=WY>6E<
MG!OU95[F=>N2:?Z8S\R?)R'!01!+#!6.,<1$A9!)%L% 2BX3O=DA8>RA^ND9
M-<9'=%4]@:H^-?AC7ORNYGID+R50STV(+>?U#7/OW'>J#*JQX0K45E1%.!H[
MP,:0W@NA6@+9;RG4<TJ,H1BJ)5"6Y5!M1^M:0D@JJ9U(L74K6#=ZFLB 2,4(
M@HPST]R%!I!R1&"4Q%0HPDBDG YY3HL:&]6M-=VKB)K7S<XZ5T-M =N.XOQ
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MU#(_2#GA*!2$\@ FRJ3QRB"&F3D75%SH"4V"A'*K4 8[<6-;W=[5/=$;C:^
M-#I7E1%62@,E7=)6S@-NL8YYA;'ODW^#X,<M!"MUP9:^X(-G!!U6%J](#K1N
M7(BHVVI@#5 KUY\?93@FM[9HAZ?MG^K8'46:%D]:^ZHM-)H$,D!1)AB,<19J
MVJ4AS,) 0H2X8BRCBC"G"+*]\<?&LS<S"1?YHP3R\6DZ?Y%RAV*9G$F5NT;
M[T-*TC0,,B$@QTA G 0*LBA@4.(DCD,6!"1*)OH1-A\ U&TY_<%:IQ$4.U%A
MW2J:[X-I=V9T 4 ]+TMKS<[T87=OHG+<9%\=4?9&'[:]R7'3#GJ5G/C8!4E
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M^4)_\UF4I1R3&/(@4Z83-X6,( Q9EAK'+^)93&S#B_8''YO;42EESA0DY0^
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MRU6_\7&X2AD2]8&7C!;PK>R@%1Y8Z:N,R*W\-K[DV_" >UQI# G\2-<5H0?
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MH%)BHI5$,)7:+.0J2B$5+(>,H#S#FG%"A9];PZ[QJ<V^YG[>"@AJ"7W]%_:
MNSP#KX%CX$GH@40/[X1CE:]P2=AK;&0_A&,UCIT/3CS3,V^'%L:(MSE"JOKJ
MNGB:V5(D6<;,U$QR6U@XBB%E2D#"TRA+J, R]CI>/.YB:A.TRC$VWXIX VPR
M6\\4&L<XNAG+UZ$S\'RM@/F\!\Q]%S#^&2W.ZAXJ2<5Q!^/FG3BKX%$JB?-/
M]LSLWD0QV<J]G\MR8Z-K&S?K\A]+TX[9NIN>YC^UM;%/>E];M^MR)A'1)",(
M1E0RB#-M?1O2!"89ETBE2G*1^M!!*,&F1B+;.+^J.K9NHW^JO3EX;A+&@V?S
MCF=N^% #Z<9';S$\ [-8J](-:!6ROM>U2C?@8O3-KJ!Y'8RUC=\\7_O//R=]
M8-1#Y:T/)=:XN>T#@WF4_SYT^_T8_O9I5:SG_Z<)H&G\TI</=1[S3*5<DB2&
M>6196_((<IYD4&DF&<ZSG&*G_95+9U-CXGU9[4Q7E7G73GWIGB?>"6DW6@V%
MW\!4^1JZV@!LH0N4-MX'DT!$UMG5J.3DHO1KPG%ZIT=RD\J%W29?F:^4SNT5
MSE[V%$-0IH\O7SXT7E%)G%&&L8 JS2G$2&+(B.)0)I3')"$HQ^Z)37QZGAJ]
MM+*#G?#[290:\8&1WR.MAM=0=%/.H  /?4#DC.UES[8K0?;(6S(4V"/E+ GP
M0?NE*>F#5V>*$J\&QTM/TD?/@]0DO1JX;B'XL5ILJO:-$=O&(24R9VDJH""4
MVQ!$"GFN4BA3F@B4J(QYI+3J[&JJ5-^/8TY Z<?<UP$T(E5O!:VR#/[U2FX^
M@5L_,KX.OS=@WU<XAJ?;\XBX\NN)%MZ$4,]K<HY!.]X(5#SSQZ.QT^]?E6U,
M19PD'.4P,3\9]B0$4A4;XSD3)$,XXFDJV^J9CB>H+OTZ?>F'E3.'/B#=+YI9
M6I%#5\T\B;_CL6<P3-^N;F8E\IB%,[LP&JIRYLD^W[9T9A<,%VMG=K[<CY?:
MS&,_=/%S;G.JGCJ!W$^^LTM =J<+8VI6!PM?MCF:C8''>,;M#9!.(4Y2!AF-
M(ICF:911D2(LG8+*!I)O:D;C?DV&,Q<*E;ML79;J W^>K_G"*G<#;I]6&U=K
M<ZC1=N/+-QS#@9G5X3ZH>_@&2J,]$.*!>#JT=*,R^D#0ON;^H;KQCQZ^GZ]M
MPK;/2S7_.5<;OKC]8U[.-.<RSS"'"=?&4J4TAE1'R/P'"1P;2Y5SYAH\?+*'
MJ3%U):2U1G=B@M^LH(X;U_-0=I-H$( &IL$>V'B%$G?J?T4D\>EV1PLD[E1K
M/XZX^\%^AM^V?.'GY?/&,(7^J1=Q<X)"$<XS;DPWRFS0,+*5T[E.($$,YS%)
M8\R]$I-T]#6U:?YC;D@TGTN^7/_Y3RB-_O;-!M>!;Z(T1&S32M:_K14![RI5
MZE_%GNE)N@; S:X*!.O Y+!?;[46] 94HH)X@/Q%#I@$LF*Z>AK5(G%0^;5U
MX?)*CZN!+\92,=;N[4.A*_OWZVIIL-XLE9TXW_7#9F%'[V67/;TVF>]7[\V_
M2CW_J=5,IDP10C+(TI1 C(F$G"D*=9RFL:(RD@EWOD ((-#4"*I1"?!6IQNP
MW-<*%%NU]DMI-)N3]0H(^TBMF\>1>XBA=;C0&'G !J:^=JQN=V-UH!#8:;1?
M!*(9J_L5>%\E?'^+L?*X1!EYS$:Z:AEE[/SN9@("W7F#$Z*?\>YY J)R<!L4
MLMV>9[-YKFWM75U'SM_S/[[SM:X3;FSFRX?=_?XLXY+%24*AH"*!6*<84F.\
M0TYXIM*8("207\U%]\Y])N\X)1,_E>OY4Y7OCB^7=C.J6V7 FO\!C-SG,]]=
M.Q*.1Z*#H#OT+?X6Q2:=AA$;6+FKJB1+.5_,*YEO;()!V>4*X7^@Z8U7J+-*
M]X['/8;T!N3HA-&_!?]8W@^;HC ?PB_S4O+%?VA>?%JJCZ:;&:81QQ(CB$@<
M09Q0#$5BR\5RE(D(HRS63D<,79U,S71OY 2UH,!*"HRHX*,S'W5"VLT\H8 :
MF&-Z8>05_WL)A%YQP&<;'2T>^)):^W'!%Y^]/HSPNVZVG.6W_.MJK4MC'EG#
M:98AE6*19# Q.WV(9<0@58DTLY_EG&,M=.94H\"GTZD10;M+6.5F[[ZN=N?-
MUGU;T8N7I:W::^_]Z](1_0,!SPZ%FZD2&N"!">0PM/+=3F*#]E] )31HI!XF
M).\21@.$VYWM\LU"Z2Z!T!4F=_'=GOG"M)E2K4_T\N&+YF:>-]F#7OZQ5+8N
M\&9IIM^G/Z1YM+Z?G\4ZC5(9*:A9*B'.!(4,ZPC*B"O%,4L9];H*Z27%U/C+
M*@%X[<!@.&RAJVCE=IX5^METIJNTD&#>)'_S3"[6:ZS<^&SP$1CZ4+&2_P9L
M-0"5"C=@J\0-V%<#U'I<\A?R3U=V#8ZA<ICUDF'<Q&;7P'24[>RJQGJ>0O%B
M:?HJVT3T'^>+C>EAIA'3*HG,Y@TI9/Z#$\B3#-LD,#C*-961\,K >J:?J7'?
M5V.6+59E>0-4+6"06A7G0'8\3;H>NJ&/CAH)=Z4G;D C9<!#HFX80IT(G>EE
MW..?;E6/SGHN/-ZS,B:W7BE5SL6O9NR_Y?<%7Y9<VNW*Q]43GR]G*M49$\CL
M\:*40QRS#+*,$D@2S1G7.<7$Z3;7O<NI\865N$HA4N5V^:T6TK<"YF6@W8@B
M+'P#<X8G<OZ5+IW!"%7G\G*'XU:Y= ;@J,:E^YO]J.4?I6FTO<8I9RA1#-/(
M>H'8,V+$4\@IYS U!H?((YEKZ91\]73S4Z,,(UU5);Z5SX\L7D'G1@S] 1F8
M!%YC<0/N5HNY? &_-7\.4MO\-!R!:.!5XZ-.^=.*O9[>9Y[J6:^&EX^V3H3Y
MPZ9D_FFH8[DNMQYHNY(1,YYPS"(SP7G,S;9"2&1F>4*@L%5M8YQD$GL=#3OW
M/#4"L!)72=D;D3V+T#@#[L8-@\ X]#621;".N3$_[(E] W;^J'M%: )6GO%%
M*U35&>=^QZTXXPO'4;49[P;Z.*ZN^/(7K<OM6<K7U;*Y))N)#!&9(P4)I<;V
MP,KPDY 4LIA(D6$LXD2YN=9<ZFIZCC166)!K5Q/D(I8TBF028009SP7$-,L@
M1QDVT#*2D%PF+';*-!<2R5$.C59+*)N;[46#Z;8RAV/AC8O@=K-Y2,B&/N&V
M"%DQ]X^T+82-J('P\G%Q#8/;6*ZK??'S=$>]#$JWFVG'^R.ZCU[6XM MU.'Y
MZU*$-!OK-I-BG3F2)(F06# 8R<BL0C'64##*H$Y58C;'3)*,MIE![CV\)SKZ
M=/JR#[."W(_G/%$&R=;9B;F;>7PUA",G =F>J V5JM,%D, 9/TYV]2:)/KJ4
M/I??H_.=GOE^U7]NF@0A]ZM;I2H7(KZXXW/U>=GD(:AN L3KF/+ONG8Y:B//
MZVCR)KK</E"9W;,XSPFWQ=5R26W]12P@R[&$F;WY8S;M9Q9[Y0P>6."I683[
MB3_DGC:>R8:''F8W"IS2X U,H[=WGS\XY('_O)1%Y163KXJ*7\&>3@&S(H\$
M?*C,RD.+.VYVYI' /\KP/%:_?;V YT_:AA(TL>PX4BKCF88)K9()Z!A2)7*H
M1"82+7G,E-?=S:OVIT;LE7A55(ROQ^XA;([&9W\PAK8WMS@,$.5_1NU@KK6'
MK8_L17M2M6.'V=./]?3DV(C2<(.AE$\_+:]L2]0KHG5$< H%4@QBIH@Q\](8
M9H2E"<H($KG7E<RYCJ8VBW=R@EI0ERKU?M"Z3? 0@ T\TWMAY>^M<0&(4#X:
MY[H9US/C@K)'_AB7GN])"Z>SCNT,W?<ONT<:._CV=UZHNMS@MWQGG=05;VXW
MZ\=589.4S;A&D<JQAJE0&<1Y==F;,<BS/$HBA<VOB5_$\H#23N]F9B=K[6]:
M KZ5MO)(K7_KZ88ZY( [\MTT!G%HRMS;/^[KN;^)!.+E]#[3:GO3E$2UIWE[
MGT*M,MCI')!_AQ^84!0^H*3CK@+#0WZTD(S09<_PK5VA]_8"+Z-Q*G3*88X$
MASB5#-+<_%69G2\G!&&=FYWERFR'W1:0XRZ\S-)M1\/QQKWM VQODG?R>H97
M'6/IQL[7(33TM?%.N!L0[*KSLNJA8IF..Q@W4.FL@D=12.>?[&EG2KWDQ7RU
M.]EJ$U%2,Y&3C, 440)QE$A(-5<PBFVT>!9S)9'7]O-,1Y/;?C9RWH"=I)Z6
MW#E('<VP $ -;4.=P&B HZ9+2(0R6LYU,Z[%<4'9(W/ATO/]"\W_T&:9JSCF
M]B>?+VP ^"^KP@8>-"EJ5IOR'\M"U_G4OZS*\FY59TI \:_FB<?R6_%E9:R6
MHC5-VG\O9VE$*<MR#'4J$X@E55!DF3$<!%(1XUBBW.OR<F!YI\9.NZU'N54:
M_#Y?/X+-5L$J1M(NQ _F-T8HL'[D2X!B\%3IZD=F0W\/;IPXH5$>F%JK2JX[
M50W#MLK"?%5 JZZQL+8*@YW&P*H,6IUN[(#7:IOY#VK%][>N6^7#\?5(HQ2(
M]H>6=M358R3H7R]"8W4[0-J1U@/HXT;;-$SWOZ]F]JH49UA $BD)L8AB2#$B
MYC^)CA''*4^\BG%[]C^UM:9* +;^?14P?\@)T!UWO\-!.?36V"%G2)T:VGH1
MW-1IU^X[4 ^;+>0\=F/D"3G1^W0RA)R'QBLW2$<S_6AMKP+9YZ5EX-NE^I47
M_Z77EGMMI,[Z98^4E^J#+M9\OKPON#+2W=KT9N4N>,=&<59!G#.*N8Y91& >
MQ=+>."-(<Y7!F"<*$90G6D1^]T)#B3J]2R&72G[CCJ8;L4YAA 9FX#T5P7P)
M*@O;QB?NU 2UGGMV-WA713#6NH)&65!K^Y>]X$7PVR!!T$./2B!N'TS,41>!
MH<%^O5H,WE_?9:7VF_VHZS\_+V]EE=*J30)H)#&_*3;&B-^=0L]DFD4J4M:A
M&N<0RSB#C"48:BDQ2Q!-&?-,?]Y/D.DM":W4;8[1&\!KJ?=OCRHFLD7CB\+\
M0Z%_ZN7&TWVQY\"YK@]##\;@[-^X@[]K5?B+706V@].H48U#HPCXXG"[UX/3
MKT$R&&/W$F)D/KX&J&.VO:JUWEQ:YW4_99BA+*.IS;M,<Z(@S@F'0B,.F=2,
M:!EQ)KVR]W5U-K4SA5WU M^+\TY(G;DL"%##,U9;X6$$0_,R).&HYWQ78Q/,
M1:5/T,CE=WHFW%H6VP*RIH/W>JGS^;J<\3A-*.<93)FDQK*2*:29,/^QJ;<H
M9EBE7L>19_J9&D7LBUG5C!&-H)ZYN,Z@ZD85 ; :F"4.8+)<\?X23/ZIN+I!
M")63ZTPOXR;GZE;U*$O7A<>G</<^BY!.M%01C$1F TBR"')!$AA3A>)<9HI'
M7G9&6/&F1CM5;JJ?=:W4Z5V<O\D]^838;M!K\:G>@$_ZPON_\_WV.-?95ZX&
M'PJMYNM?N*QND9I<PT1%$5'&'$PHBB#&,88\CF.SE10BSS)),^9E$Y[J9&K,
M7,L(6B%[)G(^":<;JUX+TL#<Z(V/?V+%#@!"Y5 \U<6XZ1([E#S*C-CU;+_I
M_EV7ZV(CUX9\E@\V;<7M4IG?Z>*G_C)?ZL]K_53.!$(YHVD&A<(QQ)F9_B)%
M&L8HRC$F(LM)YC/]73J=&AT<R%PG^+!GMXW8?J3@!+H;282&<F#2Z$81_&9E
M!I70 7G$!Z- O.+4Y:@\XP/":][Q>K=O#I'F,JI*C%5E)?FV69=K\W68/F=$
M1))%FD$>B1QBGF'(),NARBC#,<>(T]CONJ^[P^E=ZVWE!:45^ ;\W]%?HPB!
M9[[=/Z+H)HJJ_S\1(<S7UO- /O[Y3RB-_I:@&V#S,U:S[Z.6E0__P3_%?P/+
M5=N.3;A7U5968+4#"? JMYQ?L[XY4CH_"S>.##?4 [/C;HQ_U&/\SWI@]Z0-
MF5'%!95@"58Z.QLYWXJ+XL?I5YS>ZI&*NO*LL#L]T\4SGZNR*JU1=S9+)8NI
MS!.8HRR%&,4<,H(RJ!*>:8WRG-/$(POHQ0Z=9L,;I !M) 7KG:C6?_73DRX>
M_!($=\+=32AAT!LI;5U53K8^H=JBMR=J*,0\<BJ'0FZDI,J]$?1+JNR"2F=6
MY<X&QDNK[*+'05YEIQ=Z\&F=X^[VCWDY2Q"6PE8?2U1*(1;(5A&*%%2Q%G&B
MXU3FTCG[_*[=J>U-:\G ;U8VQ_.IUT@Y$%\__8<VF:Y7W8/!^D$P$E_5P@5B
MI6--.SEH[_'Q&.=8Q@-^.?'/8>JAON?E7,X0UC2-F88\X['UIY*04I$8<'A.
MB494:G9--=2JEZDQS:X6JK#B#5()M8;7;6MW-6@#T].I*JB5C,/50#V 8* *
MJ'4?;UK_]$#-2]5/#Q\>(:S3X*YG-,8IRS6#>9((F_".0QXA K,<:\4X0Y(X
M61^])9@:>]2AG5:R 8,[*^C=V&-00 =FEGX!GIW8#QOBN8_?6P1Y5OU/-\QS
M'YZK CT/&NI92^+05;W)(Y2GV-@TF8!9HFU9-$PA%\S0F68RUJD@&?6BLY.]
M3(VR7@=L>%9K. FD&SE=#<_0!TRO0UG"9V+JA"!4A8*3?8Q;5J!+S:-: )T/
M#^$!>ONT*M;V#LG>_'WZ0RXV53Q@';SR>6EFH2[7M[GY\W:Q6/UN"]J8-VM?
M!>NH-$,B50GA$90,2XA5'D-&C464QI*E.HJQ,BNV1];&8<7U8J 1,D!N]:FN
MRT-Z@UX]L&Y$-IWA&I@1G;Q%#X?S!FQ5WH8!MDK? &[5!EN]Z](RM=N557TL
M!])00S2*0^G5PD[(P304\'X.I\%Z'6"?_2NW3BCKEWLK[RX0+TJS/$=Y"HD2
M&&*:1%#$$D.=TSQ%.*6"><4<])!A:H;KJWTA:*4.N/,^,Q@!]M[70SR!W7>K
M!/BM4@,,$DEY!8QC;,+/2#"=;7@W1%X;\0M-^;&ATO/9I^7:-'>KE/ERR^:/
M+_.ECF<R3[,410RFC)NM.",(TCA/8)IRE"+-8I%@%[[K[&5JC%8+"AH1;]H?
M@!6V,W69![#=W!4,KJ%O'?HBY4P_3DB<()A2R[\^K'[^/^;]FEO,#SM*Z6YU
M%-)P4JRE!;>'>[@PO+_]_O&VS8B.29QKGD,SY\WN.<*9V3V;64^U1$*J!"'M
M%'OSNN&I3>]*-(\;_'V,NJ?M-9H//%,KJ2Z?G'5K[^' T!.%D3P8'-'P\V0X
MH7*G*\/^\^/Y,IR0\L"9X=2_A[,HT"QAC'$:$1CAW.R@;&%GEBL"%44,XR0C
MQ"WK0V<O4Z.<SG7RV]+QL+\;V/X6A1=<;VE1="$5Q*) _]<0%L6IV3*R18%>
MSW6WA_LG<%T:\%_N5HNY?-EMV$F,L<R9@)(2#C$G9N[SC, ,<3/U$\P2I?TR
M0YWN:&K3OY73NYK2623=CCY"X#/P?-^*> -J(<%OS9^#)1[M0B1@XM"3W8R>
M^+-+V5.).SN?[['!^,&7_SG?_*K57/+%W2,OGLQWL%G;OWU8?5FKQK),XSC-
M";/UNU-DK_QCR!*2VGR;E"8\RS+JQ P>?4Z-)#Y\!U;PS=S#.'=$UV'7$AZS
M@8FC%A@T$H,_\Z?GOX%#P<&'U5]O@!'^KWTV/H[8>NR)PF,\TG;)"^M NRD_
ML#HW6HY-C;<'\]/M8'OF^6K/U"RK<OTM_UXGZYTI*I),$ ()SQ*(&;)66XPA
M24DB$,E$S(A73I;]UB?'PC93P"H'#ZN5*D&Y6CC&KYV&SLU,ZPW(P!3;8O']
M0M9F_WPKIQ0.E6CEH.UQ,ZR<4NLHM<K)A_SF:5FL9]_ULQGG1U[JVX="5P5T
M/UA_+5T\\V+]\M6,:Y,$2.LX)EEF)BPBQK:2D;6M;#GT/$H1S9!0R.G$Q:O7
MZ<WKG93 BNF99LD/\NYY/QB0@_.!-X;.U- +DR[*, WNT87YVXXJ_/H:A4)Z
MJ=]22[^7^YH&RW7!Y?K?Y^O'#YMRO7K2Q?9B>L8427$>"YNO34*;+P523!A$
M/):90IK'GNG;NGJ;&L7<%:N?\](8XI7[G/DT-TM5I]Y_JAQI?0V)+J!=#8M
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M9VL%W!7ZF<]5?;M0I2'@"\] &)<A<".@P, .3$"7ZB_<U'<QAI.:/P<)??'
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MD?DK88D-$&8LE5Y'<&'%FQI3[1_6+6QPPMH("U ,GBIQ_?@J\$BZ\=O;C<_
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M^*WYTZ60AO<)A2-"@<XE+O4VZFF$H^JOSR!<7^MA'#?)5+_K^9/8F.G\M#7
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MP,OA#*0O"@-/\4  >!QT] 5BI ,.5T#\CC=.*=UYK''PPGC'&:?D/#C&./F
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M]$LR81O!?R#YXXO%Z7R]_/YBD7$2C7!<90-&%'*&#3,0K1*0K%1.V"*BPP;
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MFI?3V>FZ#L60N03+ Y!%+C68WN1V/87!AA7NR:XV3S[<0\JX1]BC(.<0H7>
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MPKE,7YK4>F+T[M2-:T$?O]QC"*5U\(3>/9R=I<GN%J17)F56GV]"3FSZ.G]
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M@5[-SYTCC@XW/P]]W' CF<8Q/U%)GU(64+CG%*!$ :$P!.Y3'4YO9!A@XL?
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M2]F/#9XMW;_/5U\P;1X V::82Q96!F\AJE!K2%1-"BL.)?'@'6?:E9U,\8\
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M/ 1>')*U]:QY4<\U G;+(K,_+8CV4L#8!UXM"Z:CFN00XMD)?C[B*-87FW,
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M]AZ_XOP4?\#9)&M;F#0)!*^#UG0@1X67"")(Z;3-1>!N!9N[K?>4:J8:X&L
M)73@N;U8S#?3L/X^77\^+Q39^ &_X7I2G!2IT,XPW@FRR9PB\D2>@(K:11D,
MLS(U]MD>HN<I556T\=::::=3I%W,A-]NKO>8%B34_\(\239FJTT$EY0#Y8(G
M[K(DIR &"LH3,='Z$9#]*'Q*U[S#H;&1!CO YY:!&AC=Q>BK;VEVFDFF=?_1
M?_/'\&T2E%0\<(J-+-.@ GD200M/%A^9S9)S*7:J5]YG-,G^9#ZEVX(V2!U:
MEV,[A-M!3A<M![\MYD3&Z3QO7C?&3Z>S^J^_7T9?9R^-?5P\KQL4*=:G[>FM
M(0?801$\TJ%!)P<=&QZB,T;51B6>XT[>8@-BGE)2L($K^=CJZ\"ZGC]_MVU=
MF7_:7BRO)MDI5F<-@:ACAY1- 9SS"H@+KC(+);C60][N)>9IOAYWC*5LHY=>
MW^;Y9?Z5=M"&GXMAU<^^ANFL;K2R6-8,Z K3Z?+8EW<.6ZC)3.X&/#8:PGV%
MDOKV)2'YU7^>DFOXX6+UB]G+)4N7N4+@KI:188S@!5FO(D,0(<5B2NM-OSMU
MQ]_CGKU:5!_[O%CS["XI,R\%^IK;Y(FL=E'$MR^ 0@AEA8XIM1XZ=#\UXPZ=
M&0@MMR][FRBC@R/T]70>YFD:9I>/RF[J)L@>2VUT ,YJ'@ 90HR% ;,FDX2T
MCVRGN=Q[8.H>4L8%5"M-+]J+O0/T?%R&^:K4!L'S$8-TV+\M=W"W^D@?N;K[
M1]OJBZ1,2MH+B-Y7WX#5OR4$D[G-G.+]X%LG!EO2/RY.FP!JT8EV.T#VB\7R
MRX*<5WR^J,R?GQ[G@UMR1I*E@<2+ :6M U_?7BLE4V O M-%-X;J@P2-B[WQ
M<'(KE]A*:1T@\/</'Y<85J?+[[<X"89<%R4B;,:O*LM)1@P+?9D+28UB^-RZ
M@.]^:L9]%*\;[#525P? >[$X.:F%%&'V+E  ?]Y.4:1'YVG/('&B*$R%Z+*O
M3_7RH)(TQK4.,NXD9-RW\KJ!V_%*Z@!I=SK7ERDHB9:C)H^:"Z%K!X\#IYT$
MZ2-F;;E1KO5PYH<I&M?4#12*-%1"!Y"J4?^58/\\9?7Z+&7U[&2Q7-=[Q!>+
MU?KRPN;L@<%?ZH E$L"S0O__;#9;_$$;M_[+%\3&=/UFL5I-HO(\8>%@<ZC2
M" E\D@@9?:H;+&6U4_?F'I <EJ,.H^L#L;?H%@C-GIX\8ESY#?YO2">ETY-Z
M/X1Y4X#T^YQ<F5D5S]_HG'I>$[Y8;S.M<CRPXD&'5(O6Z8R)F27 P)G5Z%7[
M<NLFA'=HM]N _/'5VH&)/Y3INF\OF0["E8C&G#U,HA(J8MJ0[ VY79RA8+QU
M"-^$\'']WPZQ?+A:]\>R/\/R'#]50A[!8;GO:)JH+#-G%#8DI3;7LP:"]09$
MBM9I*740C^N(W$?IN$]2C^9@-%'<4[H!O_*]/Z;KS]?W)\GGTZ?EV:Z)WR]_
MM<;(89[7G_$-SC^M/R_*1UJK\97Y )0-=L<^M!0?_U*>2<UT";7U-2,99%O(
M-'L!&DU4,KM40NM;G<>[E'_8!IS%YBYPZ:U0D#99'K0(4? "P@=%O&N6_>-:
MZJ=U3;\/?O8ST?NKIP/G][Y[OI)X5EEX*#P3&YPB4Q=*(JXXHE:JMJ#_GW!?
MWUSE.U[<[R/_#F#4-(\=3(E<L@(Y.E>[W@2X2/)TPGCTS!J>6]==_?DO[O<"
MU) 7]_MHMP-D/WP'+ HO)B8-+@5;VT<DG2O< N-!\ZAY%NK_O[A_!)SL=7&_
MC]*Z0.!=5W.!"5M$L2"-9/5M#@7.)P],YR!Y-,YSWAQYA]Z?/HWK^N,0=ZR2
M.D#: S4'"I4(&!PD$A%QDG.=+Y-!LY2B]"&5Q!K#[<@2D:=Q9W\,YAJIJP/@
M7:;5;GK8EYQ=9MD*2RRB=A!BH%UEF"1Q;29QQA"$*"K[UF^M[T7@N"9QZ(AE
M.%UU ,2'A5?;-*?ST\7IC>N"=XNS)VG?X&KU\7.8<_$K_>;GU81;+X4I#HJT
MM T5K[>Z2H*VS+(<<DHWVQ<'SM7LRT$OU_G-H;979F=0O?_I4'_E:FU3VE"B
MY$X5!CRZ^L1#'8"H7(3Z[>RM]47O-$)TM$UP@Z%>;O^?UIXX!A5/X&+U1^(X
M%\/;Y9O%O(YV2B5KA263*I0!%0."8_0EYTJBM\'QYO4";3GHI7"@[VUPE-Z?
M_-%PD_N;1L#Q$&C_!] R"%!"!])029 -2L69Y]FTSO0.RE OQ0E/:T\<@XHG
M<#3<+82)1<V]%Q%2L60(#%H(9  @,9$PR4A\/NX][MUTCC//K#=(-]!A!U6[
MA_!X<W-:[[C"D( E6U.:.9*,DP$M6(DB)YV;WW@T('N<.6A/ \7':/A8\_OQ
MD;"];[1R/G'F_.>K290H=-$<A*RS_&U]032E6+^TJ'S47/?EK_^0I7$FKO6V
M)QX7&7\ZC_ZV.&P0V=4;#2%E J4%AYAM?9X1A??%QR1:S\0<F*5Q!K\]M8W2
M%AG=;Y2[A7"'=1"*!8$*DDX:%(L)?,AD)Y21S#E&]N)QKP!V)'R<*7.]@7X(
M+3<+! :LPM^*_VH!^:]A787TO5$U_0XK-*^*WY>KQZ]NE]YB211!\H2$HX@<
MG.0.2N:F5*]<QM93$1ZONOW^K5P7WFJ"OOHPG7^:X85F*$ZXK-[VRELA(Q1=
M'V2T=:=S6X!;PWEBVF-NW<)_/-5/IC9^'_3]J-UN8.5VX!_LRG$=ZCR=OYWC
M_\*P?!VFRW\/LU.<1"4=ET) DEF"*G1R>6/I#*.C2VNAL@JMQW(?1_&X,'YL
M?!T([P;*'GMN]\,>T05/YR*N PU2S>74<KA;PJ]B^/C'8L)%Y#FJ0K8DEK/Q
MOTZ) $E8XS$X'N-N3UH-0=VX-_HC(;L/77=@QP]LO,V!6R&"A9"P/N[)-7&I
M$]0*\F(D4E3;VE4;L&-ZL(OZD>WV(RBWUWBNEJ1/SQR_,,]GZ9M/.*]CV7\+
MRSI(_>LQK='[?'R32.Y@?AJ%<5?6?W9C_9?359HM5J?+2]!:AQY-9&"<8*"X
MKR_/BP@^8S QYB"X:6P>]B+P6*MY,8O_#885_AVGGS[7<^$K??<3@;06MY__
M\",N3_@$K8M** $E)MI2P1J(5GK D-%+A9+$TU@@^](XKH<['+YN&L5!==?!
MB7Z=OU??OM2'3"9"&<:8L*"3M* 0/;G?*H-GEG&)7"O9^L"^DY!QO<VQ4':(
M%KJ#THVM4@56'SRI;RJ^PV4BH4YLDLKD&,!J\EB4)-F%7"P85"D94;QN7M>Y
M+XWC.H2=F+EC==<=-K?O+ZTF3'//L^ @H_6@2G67&85?V3&',;(49.M6O;LI
M&;<:<BR<':2'#M!$0@G;<4"DH;=E^SS=6<.8BEJ9^DRL%HI",&$1?-(,!-$J
M,FT;BNQ;![L/T#-N4>+C(:N93D;$UVJY)HF=ULB:Q+O^_ELXP<U$BB0-9D=Q
M/',FD+5UM<Y,D(]I?5:J1,;B3@6PM, 5/-%7EUBZ;^V19\HTT^JBH8A'ALA[
M_'*Z3)_#E1<';[)TWC(=T KD",HI!2I["1&=A5PM:N0%N=SIXN0'N-F9H''
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MK(!-P$[Y838;@QQ*GP-)-#BG&"CK6 K>91)J9P:-V%:7X#H$!#]THJ@KD0Y
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M,2YH=&U02P$"% ,4    " #10Z16-[TI/"X(  #^)0  %P
M@ %D"   83(P,C,P,S,Q8VUR>&5X+3,Q,BYH=&U02P$"% ,4    " #10Z16
M<*?KK/4%   7&P  %P              @ ''$   83(P,C,P,S,Q8VUR>&5X
M+3,R,2YH=&U02P$"% ,4    " #10Z16\LI7:?4%  !1&@  %P
M    @ 'Q%@  83(P,C,P,S,Q8VUR>&5X+3,R,BYH=&U02P$"% ,4    " #1
M0Z16K@YT%60^ @#FZQ0 $0              @ $;'0  8VUR>"TR,#(S,#,S
M,2YH=&U02P$"% ,4    " #10Z16E\\%%!,/  #SFP  $0
M@ &N6P( 8VUR>"TR,#(S,#,S,2YX<V102P$"% ,4    " #10Z16,$5 D*@7
M  #VY   %0              @ 'P:@( 8VUR>"TR,#(S,#,S,5]C86PN>&UL
M4$L! A0#%     @ T4.D5D_.H,<#10  _=4" !4              ( !RX("
M &-M<G@M,C R,S S,S%?9&5F+GAM;%!+ 0(4 Q0    ( -%#I%:8[^.ZD[
M *XN!P 5              "  0'( @!C;7)X+3(P,C,P,S,Q7VQA8BYX;6Q0
M2P$"% ,4    " #10Z16%0C^X6!P  !-X@0 %0              @ ''> ,
K8VUR>"TR,#(S,#,S,5]P<F4N>&UL4$L%!@     *  H G@(  %KI P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
